

The 34th Annual Meeting of
the Asian Pacific Association for the Study of the Liver

APASL 2025 BEIJING


Multidisciplinary Collaboration For Elimination & Cure

26–30 March 2025

China National Convention Center | Beijing · China

PROGRAM BOOK

www.apasl2025beijing.com



Ahead Together



Innovation in
hepatology
is our priority

See how we are getting ahead
of liver disease together.

.....

Visit the GSK booth
to learn more

.....

本资料并非广告。本资料基于科学信息制作且仅供医疗保健专业人士阅读。请勿传播本资料

GSK

Trademarks are owned by or licensed
to the GSK group of companies.

©2025 GSK or licensor.
PM-GBL-HP-DPB-250002 2025年2月批准/有效期至2027年2月



Global Liver Health Forum

Reducing the burden of liver disease - New evidence revealed

Friday, March 28th, 2025, 12:00-13:00 CST

1st floor of CNCC in Function Hall A

MASLD:

Early Screening, Treatment Strategies, and Quality of Life

Insights from New Clinical Evidence

CHAIRMAN PROF. ZOBAIR M. YOUNOSSI - VIRGINIA, USA



DR. JIAN-GAO FAN - SHANGHAI, CHINA



PROF. NORBERT STEFAN - TÜBINGEN, GERMANY



PROF. JOSE D. SOLLANO - MANILA, PHILIPPINES



Visit us at our Opella booth in the Function Hall

Scan the QR code to register for this FREE forum and to watch content after the event



MAT-GLB-2500110-1 01/2025

Opella.

A Sanofi company.

APASL 2025 BEIJING

26-30 March 2025



APASL 2026 Istanbul



35TH ANNUAL MEETING OF THE ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER

25-28 March 2026

Istanbul Lutfi Kırdar International Convention and Exhibition Centre
Istanbul / Türkiye

We are thrilled to invite you to the **35th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2026)**, taking place from **March 25–28, 2026**, at the **Istanbul Lutfi Kırdar International Convention and Exhibition Centre**. This event will bring together renowned experts, professionals, and researchers from across the globe to explore the latest developments and breakthroughs in hepatology.

We are eagerly looking forward to welcoming you to **Istanbul**, where world-class science, collaboration, and a rich cultural experience await.



Prof. Dr. Necati Örmeci
President



Prof. Dr. A. Kadir Dökmeci
Honorary President



Prof. Dr. Hakan Şentürk
Scientific Committee
Chair



Prof. Dr. Mehmet Demir
Secretary General



Prof. Dr. Gülseren Seven
Deputy Secretary
General



Prof. Dr. Mehmet Asil
Deputy Secretary
General



Prof. Dr. Murat Kekilli
Deputy Secretary
General

Table of Contents

01

Welcome Message	06
About APASL	10
About CFHPC	10
APASL Steering Committee	11
APASL Executive Council	12
Organizing Committee	13
Invited Faculty	17

02

Conference Information	23
Transportation Map	25
Beijing Rail Transit Lines	26
Venue	28
Instructions for Attendees	30
Instructions for Speakers	30
Instructions for Moderators	30
Instructions for Oral Presentation	31
Instructions for Poster Presentation	31
Instructions for E-Poster Presentation	31
Awards	32

03

Program at a Glance	37
Scientific Program	46
Poster	142
E-Poster	236

Welcome Message

Dear Distinguished Colleagues, Esteemed Guests, and Friends,

It is with immense pride and joy that we welcome you to the 34th Annual Meeting of the Asia-Pacific Association for the Study of the Liver (APASL) in Beijing, China. This marks the fourth time China has had the privilege of hosting this prestigious event, following successful conferences in Hong Kong SAR (2009), Beijing (2010), and Shanghai (2017). As Honorary Presidents and members of the APASL Steering Committee, we extend our heartfelt gratitude for your participation in this pivotal gathering, where science, collaboration, and innovation converge to shape the future of hepatology.

Over the decades, the Asia-Pacific region has made remarkable strides in combating liver diseases. Countries like China have set global benchmarks in hepatitis B prevention through robust vaccination programs and public health policies. Yet, significant challenges persist. Chronic hepatitis B remains a formidable adversary, with gaps in diagnosis, treatment rates, and the elusive goal of functional cure. Concurrently, emerging threats—such as fatty liver disease fueled by lifestyle changes, autoimmune and genetic metabolic liver disorders, and the relentless toll of hepatocellular carcinoma—demand urgent multidisciplinary action. These challenges remind us that no single discipline or nation can triumph alone; collaboration is our greatest strength.

This year's theme, "Multidisciplinary Collaboration for Elimination and Cure," reflects our collective resolve. The APASL 2025 conference is structured around four pillars: the APASL Hepatology/Oncology Consortium (A-HOC), pioneering liver cancer care; APASL-ACLF Research Consortium (AARC), dedicated to advancing liver failure management; the Viral Elimination Task Force, accelerating hepatitis eradication; and the Metabolic fatty Liver Disease coNsortium (MAIDEN), addressing metabolic liver disease. These initiatives, bolstered by artificial intelligence and big data, aim to deliver personalized, cost-effective solutions for patients worldwide.

As we gather in Beijing, a city where ancient heritage harmonizes with modernity, we invite you to explore its cultural tapestry—from the awe-inspiring Great Wall to the bustling hutongs. Let this vibrant backdrop inspire not only scientific discourse but also the human connections that fuel progress.

To our colleagues from across the world: Your expertise, dedication, and shared vision are the lifeblood of this conference. We extend special thanks to Prof. Shiv Kumar Sarin, Prof. Masao Omata, the APASL Secretariat, and countless contributors whose tireless efforts have made this event possible. Let APASL 2025 be a catalyst for transformative collaborations, driving us closer to a world where liver diseases are preventable, curable, and consigned to history.



Hui ZHUANG
Honorary President
APASL 2025



George K. K. LAU
Honorary President
APASL 2025



Jidong JIA
Honorary President
APASL 2025



JinLin HOU
Honorary President
APASL 2025

Welcome Message

Dear Distinguished Colleagues, Esteemed Guests, and Friends,

On the occasion of the grand opening of the 34th Annual Meeting of the Asia Pacific Association for the Study of the Liver (APASL 2025 BEIJING), I extend my warmest welcome to all distinguished scholars and experts from around the globe on behalf of my colleagues in hepatobiliary surgery. As a physician deeply committed to the fields of hepatobiliary surgery and liver transplantation, I am truly honored to join you in this remarkable gathering of minds and ideas.

Liver diseases pose a significant health burden in the Asia-Pacific region. Confronting this transnational threat to human life, I firmly believe that only by breaking down disciplinary barriers and building a comprehensive, multidisciplinary prevention and treatment system can we pave the way to saving lives.

In this spirit, we pioneered the Precision Surgery Paradigm, offering patients optimized diagnostic and therapeutic pathways and bringing new hope to countless individuals with liver diseases. It is gratifying to see this innovative concept transcend the boundaries of hepatobiliary surgery and drive transformative changes in modern surgical practices worldwide. I am confident that this aligns with your shared commitment to innovation and the relentless pursuit of medical excellence.

I sincerely hope that through the vibrant exchange of ideas at this conference, we can collectively chart the future of liver disease prevention and treatment, advance liver research, and write a new chapter in the fight against liver diseases for the Asia-Pacific region and beyond.



Jia-Hong DONG

Chairman of Scientific Committee
APASL 2025

Welcome Message

Dear Distinguished Guests, Experts and Colleagues,

It is my great honor to welcome you to the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL). On behalf of the Chinese Foundation for Hepatitis Prevention and Control (CFHPC), I extend my warmest greeting and heartfelt gratitude to all experts, scholars and colleagues from the Asian-Pacific region and around the world. I also express sincere appreciation to all partners who have long supported the fight against liver diseases.


Viral hepatitis and related liver diseases remain critical global public health challenges. Through hepatitis B vaccination and safe blood screening, we have dramatically reduced new infections. Advances in medical science have further accelerated development in prevention, diagnosis, treatment and management, equipping us with effective tools to control viral hepatitis. With the above background, the World Health Organization has raised the strategic target to eliminate viral hepatitis as a public health threat by 2030.

As a driving force in liver disease prevention and control, the CFHPC has always adhered to its mission of "Combating Hepatitis for the Benefit of Humanity". We are committed to advancing scientific research, fostering academic collaboration, and promoting health education. In recent years, we have actively supported hepatitis elimination initiatives, advocating for a government-led, multi-sectoral and socially inclusive approach to build a comprehensive health service system including prevention, screening, diagnosis, treatment and management.

The Asian-Pacific region bears a disproportionate burden of viral hepatitis globally. As the premier academic event in hepatology for the region, APASL 2025 Beijing will convene leading experts, healthcare professionals and industry representatives under the theme "Multidisciplinary Collaboration For Elimination & Cure." This meeting will allow in-depth discussion for cutting-edge researches, clinical innovations and optimized public health strategies.

We believe this platform will ignite intellectual exchange, catalyze partnerships and inspire novel approaches to liver disease prevention and treatment. Together, we can inject new vitality into the field of liver disease and bring hope to millions of patients worldwide. Let us unite in driving towards a future free from the burden of liver diseases.

Welcome to Beijing and may this conference be both unforgettable and fruitful!



Yu WANG

Chairman of Scientific Committee
APASL 2025

Welcome Message

Dear Friends and Colleagues,

On behalf of APASL and CFHPC, we are delighted to welcoming you to join us in Beijing from 26-30 March 2025 for the 34th Annual Meeting of APASL (APASL 2025 BEIJING).

Under the theme “Multidisciplinary Collaboration For Elimination & Cure”, the five-day scientific programme will embrace diverse topics, ranging from basic research to clinical management including drug discovery, interventional and surgical procedures, covering viral hepatitis to liver cancer.

With five years left to meet the WHO's 2030 goal of eliminating viral hepatitis as a public health threat, the Asia-Pacific region, home to 60% of global hepatitis B cases, has launched a Viral Hepatitis Elimination Forum. In partnership with the WHO, this forum will share strategies and experiences to accelerate progress toward elimination.

We've established a Multidisciplinary Collaboration Forum, bringing together experts to provide comprehensive patient care. Additionally, we've invited industry leaders to build a Liver Health Community, focusing on patient-centered care and advancing new therapies for liver diseases.

Achieving a functional cure for hepatitis B is vital to eliminating viral hepatitis, reducing stigma, and easing the disease burden. Cure Forum and various sessions will focus on strategies and innovations for this goal, and an Expert Consensus on Functional Cure will be released during the conference. Additionally, there are three pivotal APASL Consensus documents, focusing on Acute Variceal Bleeding, Acute-on-Chronic Liver Failure (ACLF), and Nutrition in Liver Diseases, further enriching the discourse and shaping future clinical practices.

We've established a Women's Leadership in Hepatology Forum to empower women in the Asia-Pacific region, where traditional gender roles persist. Discussions will focus on advancing women's roles in research, clinical practice, and improving care for female patients.

APASL 2025 Beijing will feature invited lectures and selected abstracts for oral, poster, and award presentations, offering researchers and industry professionals a platform to showcase their work. Beyond academics, join us at Culture Night to reconnect and build new connections.

Since APASL's first China meeting in 2010, which gathered over 4,600 participants, we've built valuable connections and advanced liver disease care. Breakthroughs like DAAs for hepatitis C, liver cancer immunotherapy, and advanced interventions have transformed the field. With the recent FDA approval of the first MASH drug and hepatitis B functional cure on the horizon, we're confident progress will continue through our collective efforts.

Please enjoy the stay in Beijing for an unforgettable and productive meeting. Together, let us collaborate, innovate, and strive towards the elimination and cure.



Lai WEI
President
APASL 2025



Xiaoyuan XU
Executive President
APASL 2025



Huiying RAO
Secretary General
APASL 2025



About APASL

The Asian Pacific Association for the Study of the Liver, is one of the leading associations based on investigation and treatment of liver diseases in the world and the largest scientific body that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.

APASL's Main Objectives

Promote the latest scientific advancement and education of hepatology science, exchange of information and the development of consensus, encourage the practice of medicine in liver diseases and also coordinate scientific studies between various scientists and clinicians throughout the region.

APASL's Event

Hold scientific educational symposium/ conferences developed by leading hepatologists periodically. Feature expert speakers presenting the finest data in the most happening topics of liver diseases with high quality scientific technical presentations, followed by varied supporting program. Each of the events intended to meet the growing demands of hepatology as core medical specialty and offers participants the right platform to exchange research, discuss outcomes, and interact with colleagues, focused on liver diseases.

APASL's Members

APASL members include all medical professionals dedicated to hepatology — its research, practice and care. APASL members are elected on their documented scientific publications. Mentoring, sharing of knowledge and dedication to professional growth and development are among the core values of APASL and its members.



About CFHPC

Chinese Foundation for Hepatitis Prevention and Control (CFHPC) was founded in Jun, 1996. Following approval from the Ministry of Civil Affairs of the People's Republic of China, and the leadership of National Health Committee and National Disease Control and Prevention Administration. CFHPC's mission is to actively raise fund and materials for public benefit activities pushing hepatitis prevention, control and treatment in China and promoting the whole nation's health. It is a national level public welfare foundation with independent legal status.

CFHPC is one of the key roles in the field of hepatitis. Over the years, CFHPC upholds the spirit of charity dedication, and has raised 1 billion yuan to carry out more than 600 different types of public welfare projects, such as hepatitis prevention, scientific research funds, grass-roots training, academic exchanges, health education, and patient management.

APASL Steering Committee



Shiv K SARIN
Chairman



Lai WEI
President



Shuichiro SHIINA
Immediate Past
President



Necati ORMECI
President Elect



Manoj K SHARMA
Secretary General
-cum-Treasurer



Laurentius A. LESMANA
Past President



Jose SOLLANO
Past President



Masao OMATA
Past President



Dong Jin SUH
Past President



George LAU
Past President



Ji-Dong JIA
Past President



Teerha PIRATVISUTH
Past President



Jia-Horng KAO
Past President



Darrell CRAWFORD
Past President



A. Kadir DOKMECI
Past President



Osamu YOKOSUKA
Past President



Jinlin HOU
Past President



Barjesh C. SHARMA
Past President



Diana A. PAYAWAL
Past President



Rino GANI
Past President



Tawesak TANWANDEE
Past President



Jin Mo YANG
Past President



Han-Chieh LIN
Past President



Barjesh C. SHARMA
Ethics and Guidelines
Committee



A. Kadir DOKMECI
Finance Committee



Shiv K SARIN
International
Liaison



Osamu YOKOSUKA
Scientific Program
Committee

APASL Executive Council



Lai WEI
President



Shuichiro SHIINA
Immediate Past
President



Necati ORMECI
President Elect



Manoj K SHARMA
Secretary General
-cum-Treasurer



Gulnara AGHAYEVA
Executive Councillor



Chun-Jen LIU
Executive Councillor



Mamun-AI-MAHTAB
Executive Councillor



Rakhi MAIWALL
Executive Councillor




Yoshiyuki UENO
Executive Councillor



Sang Hoon AHN
Executive Councillor



Elizabeth POWELL
Executive Councillor



Jian ZHOU
Executive Councillor

Organizing Committee

Host

The Asian Pacific Association for the Study of the Liver (APASL)

Organizer

Chinese Foundation for Hepatitis Prevention and Control (CFHPC)

Scientific Support

Chinese Society of Hepatology, Chinese Medical Association

Co-organizer

Beijing Tsinghua Changgung Hospital, Tsinghua University

Chinese Center for Disease Control and Prevention

Peking University People's Hospital, Peking University Hepatology Institute

Chinese Society of Infectious Diseases, Chinese Medical Association

Chinese Society of Gastroenterology, Chinese Medical Association

Chinese Society of Digestive Endoscopy, Chinese Medical Association

The Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases, Chinese Preventive Medicine Association

Specialty Society of Vaccines and Immunization, Chinese Preventive Medicine Association

Infectious Diseases Branch of Chinese Preventive Medicine Association

Working Committee on Promoting Elimination of Viral Hepatitis, Chinese Preventive Medicine Association

Liver-gallbladder Diseases Society of China Association of Chinese Medicine

Hepatology Committee of China Medicine Education Association

Professional Committee of Integrated Traditional Chinese and Western Medicine Chinese Research Hospital Association

For the China Liver Health

Asia-Pacific Alliance of Liver Diseases, Beijing

Media Partner

Chinese Journal of Hepatology

Chinese Journal of Viral Diseases

Journal of Clinical Hepatology

Chinese Hepatology

Journal of Practical Hepatology

Advisory Board

Lanjuan LI Fu-Sheng WANG Ningshao XIA Xizhong YANG

Honorary President

Hui ZHUANG George K. K LAU Jidong JIA Jinlin HOU

Chairman of Scientific Committee

Jia-Hong DONG Yu WANG

President

Lai WEI

Executive President

Gang CUI Xiaoyuan XU Yuemin NAN Zhongping DUAN
Hong YOU

Chairman of Organizing Committee

Xiaoyuan XU Yuemin NAN Zhongping DUAN

Chairman of Management Committee

Zengde LI

Vice President

Jian SUN Jie LI Xiong MA

Secretary General

Huiying RAO

Deputy Secretary General

Jiaqi KANG

Scientific Committee

Deputy Chairman of Scientific Committee *(In alphabetical order)*

Fuqiang CUI	Xiaoguang DOU	Zijian FENG	Zhiliang GAO
Ying HAN	Taisheng LI	Xiaofeng LIANG	Enqiang LINGHU
Zhongfu LIU	Shichun LU	Lungen LU	Chengwei TANG
Guiqiang WANG	Huaqing WANG	Chunjun XU	Yongping YANG
Zundong YIN	Zhenghong YUAN		

Secretary General *(In alphabetical order)*

Hongsong CHEN	Yu CHEN	Mingyang LI	Xinxin ZHANG
---------------	---------	-------------	--------------

Committee Members *(In alphabetical order)*

Jihong AN	Ping AN	Chengwei CHEN	Hong CHEN
Yuanwen CHEN	Shuangsoo DANG	Guohong DENG	Huiguo DING
Jian DOU	Jiangao Fan	Chunfang GAO	Yanhang GAO

Jiawei GENG	Tao HAN	Jianfeng HE	Bijie HU
Heping HU	Peng HU	Yan HUANG	Yuan HUANG
Yingan JIANG	Yongfang JIANG	Yabin LI	Jia LI
Jun LI	Jun LI	Rongkuan LI	Shulan LI
Shuchen LI	Wengang LI	Yufang LI	Zhiwei LI
Shumei LIN	Jingfeng LIU	Shuang LIU	Xiaoqing LIU
Zhenwen LIU	Zhengyin LIU	Fengmin LU	Xiaobo LU
Huiming LUO	Xinhua LUO	Qing MAO	Yimin MAO
Qinghua MENG	Yuqiang MI	Qin NING	Junqi NIU
Qishui OU	Xiaojuan OU	Jie PENG	Hong REN
Wanhua REN	Jia SHANG	Huiping SHENG	Li SHI
Minghua SU	Hong TANG	Xiaoping TANG	Yu TIAN
Ailing WANG	Hui WANG	Jianshe WANG	Lei WANG
Mingguai WANG	Rongqi WANG	Zhili WEN	Cheng WENG
Biao WU	Bin WU	Chao WU	Hong WU
Yonghong XIAO	Qing XIE	Wen XIE	Yao XIE
Shaojie XIN	Huichun XING	Jinghang XU	Ming YAN
Dongliang YANG	Hui YANG	Jiming YANG	Jinhui YANG
Li YANG	Ruifeng YANG	Yongfeng YANG	Changqing YANG
Dapeng YIN	Shaoli YOU	Yanyan YU	Zujiang YU
Yunsong YU	Chaohui YU	Yongyi ZENG	Dazhi ZHANG
Hongfei ZHANG	Liaoyun ZHANG	Lingyi ZHANG	Wenhong ZHANG
Yuexin ZHANG	Caiyan ZHAO	Hong ZHAO	Jingmin ZHAO
Shousong ZHAO	Yingren ZHAO	Jianping ZHONG	Xinmin ZHOU
Yongjian ZHOU	Ying ZHU	Yueyong ZHU	Ma ZHUO
Guizhou ZOU	Hongmei ZU	Weize ZUO	

Organizing Committee

Committee Members (In alphabetical order)

Lang BAI	Jianqiang CAI	Wei CAO	Zhanjie CHANG
Baiyi CHEN	Guofeng CHEN	Minhu CHEN	Suoxian CHEN
Yongping CHEN	Zhenhuai CHEN	Zhihai CHEN	Jun CHENG
Xiaoliang CHI	Cunliang DENG	Xiangchun DING	Xiaoping DONG
Jingyuan FANG	Qingchun FU	Jianhe GAN	Hainv GAO
Yan GAO	Yueiu GAO	Yufeng GAO	Ye GU
Jianchun GUO	Yan HE	Jianhua HU	Jinhua HU

Xiaoyu HU	Wenxiang HUANG	Ming JI	Jianwei JIA
Jianning JIANG	Zhendong JIN	Chengzhong LI	Fei LI
Jin LI	Bimin LI	Jingnan LI	Qin LI
Wenhui LI	Xiaodong LI	Xiuhui LI	Jianqi LIAN
Baiming LIAO	Bingliang LIN	Feng LIN	Bo LIU
Fuquan LIU	Lianxin LIU	Yingxia LIU	Zhihua LIU
Bingjiu LU	Hongzhou LU	Jun LYU	Xiaoju LYU
Xiaorong MAO	Yongzhan NIE	Wei QI	Yiming SHAO
Junping SHI	Ning SONG	SiYu SUN	Xiaodong SUN
Mobin WAN	Xicheng WANG	Fuzhen WANG	Mingmin WANG
Qinying WANG	Wentao WANG	Xianbo WANG	Xiaoping WU
Yong XIONG	Aiqiang XU	Jie XU	Wenbo XU
Aiming YANG	Wenjie YANG	Xiaoming YANG	Xingxiang YANG
Shukun YAO	Hanhui YE	Yongxiang YI	Mei ZENG
Haojun ZHANG	Hongguang ZHANG	Kaiyu ZHANG	Shaobai ZHANG
Shutian ZHANG	Wei ZHANG	Ying ZHANG	Zhenhua ZHANG
Zheng ZHANG	Jie ZHAO	Min ZHAO	Wenxia ZHAO
Xueke ZHAO	Bo ZHENG	Xin ZHENG	Haiyang ZHOU
Jian ZHOU	Liya ZHOU	Pinghong ZHOU	Yihua ZHOU
Chuanlong ZHU	Duowu ZOU	Xiaoping ZOU	Zhiqiang ZOU

Management Committee

Committee Members

Huiying RAO	Jiaqi KANG	Liqun WU	Chao LIU
-------------	------------	----------	----------

Invited Faculty

Zaigham ABBAS
Karachi

Leon ADAMS
Perth

Gulnara AGHAYEVA
Baku

Sang Hoon AHN
Seoul

Seema ALAM
New Delhi

Jihong AN
Hohhot

Zhijie AN
Beijing

Paolo ANGELI
Padova

Tarik ASSELAH
Paris

Oidov BAATARKHUU
Ulaanbaatar

Han BAI
Shenyang

Jasmohan S. BAJAJ
Richmond

Shiyun BAO
Shenzhen

Antonio BERTOLETTI
Singapore

Robert N. BRIERLEY
London

Jinzhen CAI
Qingdao

Zhenhuan CAO
Beijing

Laurent CASTERA
Paris

Albert C.Y. CHAN
Hong Kong

Henry L.Y. CHAN
Hong Kong

Po-Lin CHAN
WHO

Stephen L. CHAN
Hong Kong

Wah Kheong CHAN
Kuala Lumpur

Ming-Ling CHANG
Taoyuan

Yogesh K. CHAWLA
Chandigarh

Chao-Long CHEN
Kaohsiung

Chengwei CHEN
Shanghai

Hong CHEN
Beijing

Hongsong CHEN
Beijing

Jinjun CHEN
Guangzhou

Li CHEN
Shanghai

Pei-Jer CHEN
Taipei

Xiangmei CHEN
Beijing

Yu CHEN
Beijing

Yuanwen CHEN
Shanghai

Zhongdan CHEN
WHO

Jason C.H. CHENG
Taipei

Yongqian CHENG
Beijing

Valerie CHEW
Singapore

Ashok CHOUDHURY
New Delhi

Pierce K.H. CHOW
Singapore

Wan-Long CHUANG
Kaohsiung

Min CONG
Beijing

Markus CORNBERG
Hannover

Darrell H.G. CRAWFORD
Brisbane

Ian H. CUA
Manila

Fuqiang CUI
Beijing

Gang CUI
Beijing

Chia-Yen DAI
Kaohsiung

Yun DAI
Beijing

Yock Young DAN
Singapore

Guohong DENG
Chongqing

Huiguo DING
Beijing

A. Kadir DOKMECI
Ankara

Jia-Hong DONG
Beijing

Xiaoguang DOU
Shenyang

Xuefei DUAN
Beijing

Xuezhong DUAN
Beijing

Cumali EFE
Sanliurfa

Jiangao FAN
Shanghai

Jinghua FAN
Kunming

Rong FAN
Guangzhou

Bo FENG
Beijing

Xiaobin FENG
Beijing

Zijian FENG
Beijing

Robert FONTANA
Ann Arbor

Graham FOSTER
London

Carrie FRENETTE
Foster City

Junliang FU
Beijing

Edward J. GANE
Auckland

Rino A. GANI
Jakarta

Bin GAO
Bethesda

Fengli GAO
Beijing

Jie GAO
Beijing

Yan GAO
Beijing

Yanhang GAO
Changchun

Zhiliang GAO
Guangzhou

Juan Carlos GARCIA-PAGAN
Barcelona

Guadalupe GARCIA-TSAO
Milford

Jacob GEORGE
Sydney

Marc G. GHANY
Bethesda

Hasmik GHAZINYAN
Yerevan

George B.B. GOH
Singapore

Jordi GRACIA-SANCHO
Barcelona

Ju-Tao GUO
Doylestown

Saeed HAMID
Karachi

Meifang HAN
Wuhan

Tao HAN
Tianjin

Ying HAN
Xi'an

Kiyoshi HASEGAWA
Tokyo

Nelia HERNANDEZ
Montevideo

Gideon M. HIRSCHFIELD
Toronto

Jinlin HOU
Guangzhou

Wei HOU
Zibo

Heping HU
Shanghai

Jinhua HU
Beijing

Keqin HU
Irvine

Peng HU
Chongqing

Zhongjie HU
Beijing

Ailong HUANG
Chongqing

Daniel Q. HUANG
Singapore

Rui HUANG
Beijing

Yan HUANG
Changsha

Yuan HUANG
Beijing

Hiroyuki ISAYAMA
Tokyo

Kiyohiko IZUMI
WHO

Rajiv JALAN
London

Amarsanaa JAZAG
Ulaanbaatar

Sook-Hyang JEONG
Seoul

Jidong JIA
Beijing

Jianning JIANG
Nanning

Yingan JIANG
Wuhan

Yongfang JIANG
Changsha

Shuo JIN
Beijing

Charles J. KAHL
Indianapolis

Saul KARPEN
Richmond

Norifumi KAWADA
Osaka

Patrick KENNEDY
London

Dong Joon KIM
Chuncheon

Seung Up KIM
Seoul

W. Ray KIM
Palo Alto

Won KIM
Seoul

Yuanyuan KONG
Beijing

Yan KOU
Jinan

Aleksander KRAG
Odense

Masatoshi KUDO
Osaka

Paul Y. KWO
Redwood City

George K.K. LAU
Hong Kong

Jeong Min LEE
Seoul

Cosmas R.A. LESMANA
Jakarta

Hai LI
Shanghai

Hai LI
Tianjin

Jia LI
Tianjin

Jiabin LI
Hefei

Jian LI
Beijing

Jie LI
Beijing

Jie LI
Nanjing

Jingtao LI
Xi'an

Jun LI
Hangzhou

Jun LI
Nanjing

Lanjuan LI
Hangzhou

Minghui LI
Beijing

Qun LI
Beijing

Rongkuan LI
Dalian

Shuchen LI
Harbin

Taisheng LI
Beijing

Wenhui LI
Beijing

Xiaojaoyang LI
Beijing

Yan LI
Guangzhou

Yufang LI
Yinchuan

Zengde LI
Beijing

Zhao LI
Beijing

Hongxia LIANG
Zhengzhou

Ping LIANG
Beijing

Wenyan LIANG
Beijing

Xiaofeng LIANG
Beijing

Seng Gee LIM
Singapore

Young-Suk LIM
Seoul

Biaoyang LIN
Hangzhou

Bingliang LIN
Guangzhou

Han-Chieh LIN
Taipei

Shumei LIN
Xi'an

Enqiang LINGHU
Beijing

Chenghai LIU
Shanghai

Chun-Jen LIU
Taipei

Feng LIU
Beijing

Feng LIU
Jinan

Jianxiang LIU
Beijing

Jingfeng LIU
Fuzhou

Ruyu LIU
Beijing

Yali LIU
Beijing

Yannan LIU
Beijing

Yingdi LIU
Beijing

Zhongfu LIU
Beijing

Ana LLEO
Milan

Anna S.F. LOK
Ann Arbor

Rohit LOOMBA
La Jolla

Daniel LOW-BEER
WHO

Gaofeng LU
Zhengzhou

Haiying LU
Beijing

Lungen LU
Shanghai

Mengji LU
Essen

Qian LU
Beijing

Shichun LU
Beijing

Xiaobo LU
Urumqi

Yinying LU
Beijing

Xinhua LUO
Guiyang

Yingying LUO
Beijing

Anlin MA
Beijing

Xiong MA
Shanghai

Rakhi MAIWALL
New Delhi

Loey L.Y. MAK
Hong Kong

Kwan MAN
Hong Kong

Yimin MAO
Shanghai

Fanping MENG
Beijing

Zhongji MENG
Shiyan

Yuqiang MI
Tianjin

Rosmawati MOHAMED
Kuala Lumpur

Erkin MUSABAEV
Tashkent

Mark MUTHIAH
Singapore

Yuemin NAN
Shijiazhuang

Alexander V. NERSESOV
Almaty

Irene O.L. NG
Hong Kong

Mindie H. NGUYEN
Palo Alto

Natalia NIETO
Chicago

Qin NING
Wuhan

Junqi NIU
Changchun

Mazen NOUREDDIN
Houston

Masao OMATA
Kofu

Necati ORMECI
Istanbul

Qishui OU
Fuzhou

Calvin Q. PAN
New York

Qin PAN
Shanghai

Diana A. PAYAWAL
Manila

Mario G. PESSOA
Sao Paulo

Teerha PIRATVISUTH
Hat Yai

Kittiyod POOVORAWAN
Bangkok

Elizabeth E. POWELL
Brisbane

Ulrike PROTZER
Munich

Xiaolong QI
Nanjing

Lunxiu QIN
Shanghai

Huiying RAO
Beijing

K. Rajender REDDY
Philadelphia

Hong REN
Chongqing

Wanhua REN
Jinan

Peter REVILL
Melbourne

Shiv K. SARIN
New Delhi

Jinsil SEONG
Seoul

Wai-Kay SETO
Hong Kong

Jia SHANG
Zhengzhou

Barjesh C. SHARMA
New Delhi

Manoj K. SHARMA
New Delhi

Debbie SHAWCROSS
London

Feng SHEN
Shanghai

Fei SHI
Shenzhen

Junping SHI
Hangzhou

Li SHI
Lhasa

Gamal SHIHA
Mansoura

Shuichiro SHIINA
Tokyo

Samuel SO
Palo Alto

Jose D. SOLLANO
Manila

Milan J. SONNEVELD
Rotterdam

Norbert STEFAN
Tübingen

Grace L. SU
Ann Arbor

Minghua SU
Nanning

Mark SULKOWSKI
Baltimore

Jian SUN
Guangzhou

Xuehua SUN
Shanghai

Soek-Siam TAN
Kuala Lumpur

Atsushi TANAKA
Tokyo

Yasuhito TANAKA
Kumamoto

Hong TANG
Chengdu

Xiaoping TANG
Guangzhou

Tawesak TANWANDEE
Bangkok

Olga TARASOVA
Moscow

Ryosuke TATEISHI
Tokyo

Norah TERRAULT
Los Angeles

Alexander J. THOMPSON
Melbourne

Guangdong TONG
Shenzhen

Sombat TREEPRASERTSUK
Bangkok

Emmanuel TSOCHATZIS
London

Thomas TU
Sydney

Yoshiyuki UENO
Yamagata

Nipun VERMA
Chandigarh

Ailing WANG
Beijing

Cunchuan WANG
Guangzhou

Fu-Sheng WANG
Beijing

Guangyu WANG
Beijing

Guiqiang WANG
Beijing

Huaqing WANG
Beijing

Jianshe WANG
Shanghai

Jie WANG
Beijing

Kun WANG
Beijing

Lei WANG
Jinan

Ping WANG
Beijing

Qi WANG
Beijing

Rongqi WANG
Shijiazhuang

Shaoyang WANG
Fuzhou

Shuai WANG
Beijing

Yajie WANG
Beijing

Yan WANG
Beijing

Yu WANG
BFH, Beijing

Yu WANG
CFHPC, Beijing

John W. WARD
Decatur

Aileen WEE
Singapore

Lai WEI
Beijing

Martin WELTMAN
Penrith

Zhili WEN
Nanchang

Khin Maung WIN
Yangon

Carmen C.L. WONG
Hong Kong

Grace L.H. WONG
Hong Kong

Vincent W.S. WONG
Hong Kong

Biao WU
Haikou

Chao WU
Nanjing

Liqun WU
Qingdao

Canhong XIANG
Beijing

Qing XIE
Shanghai

Wen XIE
Beijing

Yandi XIE
Beijing

Shaojie XIN
Beijing

Yongning XIN
Qingdao

Huichun XING
Beijing

Chunjun XU
Beijing

Jinghang XU
Beijing

Xiaoyuan XU
Beijing

Youqing XU
Beijing

Jun YAN
Beijing

Weijuan YAN
Beijing

Xuebing YAN
Xuzhou

Changqing YANG
Shanghai

Dongliang YANG
Wuhan

Hui YANG
Guangzhou

Hui YANG
Taiyuan

Jiming YANG
Tianjin

Jinhui YANG
Kunming

Ju Dong YANG
Los Angeles

Li YANG
Chengdu

Ming YANG
Beijing

Ruifeng YANG
Beijing

Shizhong YANG
Beijing

Song YANG
Beijing

Tian YANG
Shanghai

Xizhong YANG
Beijing

Yongfeng YANG
Nanjing

Yongping YANG
Beijing

Zhiyun YANG
Beijing

Zundong YIN
Beijing

Terry C.F. YIP
Hong Kong

Osamu YOKOSUKA
Chiba

Hong YOU
Beijing

Zobair M. YOUNOSSEI
Washington

Chaohui YU
Hangzhou

Hon Ho YU
Macau

Jun YU
Hong Kong

Ming-Lung YU
Kaohsiung

Yanyan YU
Beijing

Zujiang YU
Zhengzhou

Zhenghong YUAN
Shanghai

Man-Fung YUEN
Hong Kong

Mengsu ZENG
Shanghai

Yongyi ZENG
Fuzhou

Jing ZHANG
Beijing

Liaoyun ZHANG
Taiyuan

Lingyi ZHANG
Lanzhou

Wenhong ZHANG
Shanghai

Xinxin ZHANG
Shanghai

Xuehong ZHANG
Orange

Yonghong ZHANG
Beijing

Yuexin ZHANG
Urumqi

Zheng ZHANG
Shenzhen

Haitao ZHAO
Beijing

Jingmin ZHAO
Beijing

Shousong ZHAO
Bengbu

Suxian ZHAO
Shijiazhuang

Weifeng ZHAO
Nanjing

Xinyan ZHAO
Beijing

Yingren ZHAO
Xi'an

Hui ZHENG
Beijing

Min ZHENG
Hangzhou

Minghua ZHENG
Wenzhou

Sujun ZHENG
Beijing

Xin ZHENG
Wuhan

Zizheng ZHENG
Xiamen

Jian ZHOU
Shanghai

Jun ZHOU
Beijing

Xinmin ZHOU
Xi'an

Yongjian ZHOU
Guangzhou

Chuanlong ZHU
Nanjing

Ying ZHU
Dalian

Zhijun ZHU
Beijing

Hui ZHUANG
Beijing

Guizhou ZOU
Hefei

Hongmei ZU
Xining

Weize ZUO
Shihezi

(In alphabetical order)

Conference Information

Venue

China National Convention Center, Beijing (CNCC)
No.7 Tianchen East Road, Chaoyang District, Beijing

Official Language

English

Registration Office Location and Opening Hours

- 25 March (Tuesday) 14:00 - 18:30
- 26 March (Wednesday) 07:30 - 18:30
- 27 March (Thursday) 07:30 - 18:30
- 28 March (Friday) 07:30 - 18:30
- 29 March (Saturday) 07:30 - 18:30
- 30 March (Sunday) 07:30 - 16:00

*Registration Office is at the Lobby, the Level 1, CNCC

Poster Area Location and Opening Hours

• Even Number

Mounting time	13:00 - 16:00, 27 March (Thursday)
Display time	17:00 - 18:00, 27 March (Thursday)
	08:00 - 15:00, 28 March (Friday)
Removal time	15:00 - 15:30, 28 March (Friday)

• Odd Number

Mounting time	17:30 - 18:00, 28 March (Friday)
	08:00 - 09:00, 29 March (Saturday)
Display time	09:00 - 17:00, 29 March (Saturday)
Removal time	17:00 - 17:30, 29 March (Saturday)

*Poster Area is at the Ballroom C, the Level 1, CNCC

Exhibition Location and Opening Hours

- 27 March (Thursday) 17:00 - 18:30
- 28 March (Friday) 09:00 - 18:00
- 29 March (Saturday) 09:00 - 18:00

*Exhibition is at the Ballroom A+B, the Level 1, CNCC

Speakers Ready Room Location and Opening Hours

- 25 March (Tuesday) 14:00 - 18:00
- 26 March (Wednesday) 07:30 - 18:00
- 27 March (Thursday) 07:30 - 18:00
- 28 March (Friday) 07:30 - 19:00

- 29 March (Saturday) 07:30 - 18:00
- 30 March (Sunday) 07:30 - 16:00

*Speakers Ready Room is at the 206 (A+B), the Level 2, CNCC

Abstracts Book

Please visit <https://www.apasl2025beijing.com> for the Abstract Book of APASL 2025 BEIJING

WIFI

Free Wireless Internet access will be available for all participants in CNCC.

Please connect to “**APASL 2025 BEIJING**”

Password: **apasl2025**

Lunch Box

- 26 March (Wednesday) 12:00 - 13:35
- 27 March (Thursday) 12:00 - 13:50
- 28 March (Friday) 12:00 - 13:00
- 29 March (Saturday) 12:15 - 13:15
- 30 March (Sunday) 12:00 - 13:00

*The pickup location is on the voucher. Please show your voucher to get your meal.

Cloakroom

- 26 March (Wednesday) - 29 March (Saturday) 08:00 - 18:00
- 30 March (Sunday) 08:00 - 16:00

*Behind the Registration Office, the Level 1, CNCC

Information Desk (Lost and Found)


- 26 March (Wednesday) - 29 March (Saturday) 07:30 - 18:30
- 30 March (Sunday) 07:30 - 16:00

*Information Desk is at the Lobby, the Level 1, CNCC

Attendance Certificate

Each attendee will receive a participation certificate upon checking in.

Transportation Map



BEIJING CAPITAL INTERNATIONAL AIRPORT

Terminal 1/2

Taxi 28km

Time 40mins

~ 90CNY

Terminal 3*

Taxi 29km

Time 44mins

~ 96CNY

DAXING INTERNATIONAL AIRPORT

Taxi 73km

Time 70Mins

~ 240CNY

BEIJING SOUTH RAILWAY STATION

Taxi 26km

Time 45Mins

~ 75CNY


北京城市轨道交通线网图



Olympic Park Station to CNCC Walking Map



You can take **subway Line 8 and 15** to stop at Olympic Park Station (E Southwest Exit) and walk to China National Convention Center (CNCC) about 5 Mins.




① Registration Office

② Ballroom A/B/C
- Exhibition
- Innovation Theater
- Poster Area

③ Function Hall A/B/C

④ Faculty Lounge



⑤ Meeting Room
202 - 203


⑥ Speakers Ready Room
206 (A+B)

⑦ Media Room
210 A

⑧ Interview Room
210 B

⑨ APASL 2025 Secretariat
215


Level 3



10 Meeting Room
306 A

11 Business Center

Level 4



12 Plenary Hall A

13 Auditorium

14 Meeting Room
401-407

Instructions for Attendees

- The conference holds the copyright for all content presented at the meeting. Please refrain from taking photographs, recording video demonstrations, or capturing images of presentation slides without permission.
- Please do not distribute or display any academic or promotional materials in the venue without prior approval from the Organizing Committee.
- Participants attending the 34th Annual Meeting of APASL on March 26 to 30 must wear valid badges. Participants without badges will be denied entry by the staff.
- To help maintain cleanliness of session rooms, participants must remove all beverages, food containers, and conference materials.
- To help keep background noise to a minimum, all participants must switch the mobile phone to silent or vibration mode.
- Attendees are requested to comply with all conference disciplines and regulations.

Instructions for Speakers

- Please confirm presentation times and venue locations when checking in.
- Please arrive 15 minutes before the session starts and check in with the moderator.
- All invited speakers and presenters MUST submit the presentation documents in PPT format to the Speaker Ready Room at least 2 hours before your presentation and preload your presentation content to the conference laptop.
- Personal computers are not allowed on site. The PDF format presentation file is not supported.
- The presentation documents which you have submitted will be available on the computer on the podium. Please open and operate the slides by yourself.
- Please strictly adhere to the conference schedule and manage your presentation time. Timing equipment will be used to strictly control the lecture duration.

*Speakers Ready Room is at the 206 (A+B), the Level 2, CNCC

Instructions for Moderators

- Please arrive at the meeting room 15 minutes in advance to review any changes in the conference schedule, check for absent speakers, and ensure that presentation equipment and other conference devices are functioning properly..
- Please introduce the presenter at the beginning of each presentation. When introducing the presenter, please keep it brief and concise, mentioning only their name and affiliation. This will help to stay on schedule and not delay the session.
- Please manage your time strictly to ensure that no session exceeds its allotted time, as all conference sessions are tightly scheduled.
- Please organize appropriate discussions (a question-and-answer session) related to the topic, maintaining order in the session..
- In case of any special circumstances, you can notify the venue staff and explain the situation to the conference affairs group and the scientific committee.

Instructions for Oral Presentation

Presentation Time

APASL-WHO ELIMINATION FORUM (27 March) : **10mins** (8mins presentation + 2mins Q&A)

ORAL SESSION (28-30 March) : **10mins** (8mins presentation + 2mins Q&A)

PLENARY SESSION (29 March) : **15mins** (12mins Presentation + 3mins Q&A)

YOUNG INVESTIGATOR SESSION (29-30 March) : **10mins** (8mins presentation + 2mins Q&A)

LATER BREAKER SESSION (29-30 March) : **12mins** (10mins Presentation + 2mins Q&A)

- Kindly verify the presentation schedules and the locations of the venues during the check-in process.
- Please make sure to be present 15 minutes ahead of the start of the session and check in with the moderator.
- All Oral presenters **MUST** submit the presentation documents in PPT format to the Speaker Ready Room at least 2 hours before your presentation.
- Usage of personal computers is not permitted. Also, the system does not support presentation files in PDF format.
- The presentation documents you've submitted will be accessible in the computer located on the podium. Kindly open and handle the slides on your own.
- Kindly follow the conference schedule scrupulously and handle your presentation time properly. The timing equipment will be used to rigorously limit the length of each lecture.

*Speakers Ready Room is at the 206 (A+B), the Level 2, CNCC

Instructions for Poster Presentation

- Each poster presenter will be provided with a poster board, poster number will be prepared by secretariat.
- Please prepare your poster with dimensions of 80cm in width and 140cm in height. Presenter should bring the poster with Movable self-adhesive vinyl for display on-site.
- Posters should be affixed to the designated boards according to their assigned poster numbers in the poster area located at the Ballroom C, the Level 1, CNCC.
- Presenters should promptly remove their posters during the designated poster tear-down time. No exceptions will be allowed. Any posters left after the removal period will be removed.
- APASL 2025 BEIJING is not responsible for posters and materials left on poster boards after the stated hours.

Instructions for E-Poster Presentation

- Display time: 17:00, 27 March - 17:45, 29 March
- Location: E-Poster Area will be located at the Ballroom C
- The presenting authors of the E-poster are not required to attend in person.

Travel Award

Presentation No	Presenting Author
AA0001	Rungfah SAEHAN , <i>Bangkok</i>
AA0017	Pinky JUNEJA , <i>New Delhi</i>
AA0020	Kullanat KHAWKHIAW , <i>Khon Kaen</i>
AA0025	Soe Thiha MAUNG , <i>Bangkok</i>
AA0042	Debashish PAUL , <i>Cox's Bazar</i>
AA0046	Kristian Orap ORANTE , <i>Quezon</i>
OP0006	Ajeet Singh BHADORIA , <i>New Delhi</i>
OP0034	Shrey BHATT , <i>New Delhi</i>
OP0076	Sujit CHAUDHURI , <i>Saltlake</i>
OP0104	Tongluk TEERASARNTIPAN , <i>Bangkok</i>
OP0128	Vipul GAUTAM , <i>New Delhi</i>
OP0131	Syed Mujahid HASSAN , <i>Karachi</i>
OP0172	Kathleen Madera MONFORT , <i>Quezon</i>
OP0191	Chitchai RATTANANUKROM , <i>Khon Kaen</i>
OP0266	Amarsana JAZAG , <i>Ulan Bator</i>
OP0351	Rifaldy FAJAR , <i>Yogyakarta Special Zone</i>
OP0375	Tamoghna BISWAS , <i>New Delhi</i>
OP0376	Anmol ANMOL , <i>New Delhi</i>
OP0377	Snigdha VERMA , <i>New Delhi</i>
PP0319	Joseorlando Mendoza NICOLAS , <i>Quezon</i>

Young Investigator Award

Presentation No	Presenting Author
YI0001	Mohamed ABDEL-SAMIEE, <i>Cairo</i>
YI0002	Ning YU, <i>Guangzhou</i>
YI0003	Rex W.H. HUI, <i>Hong Kong</i>
YI0004	Deepa JANAKIRAMAN, <i>Chennai</i>
YI0005	Hong LI, <i>Beijing</i>
YI0006	Xinyue ZHAO, <i>Beijing</i>
YI0007	Xitang LI, <i>Wuhan</i>
YI0008	Ka Shing CHEUNG, <i>Hong Kong</i>
YI0009	Yating ZHANG, <i>Hong Kong</i>
YI0010	Haiying ZHANG, <i>Beijing</i>
YI0011	Zhujun CAO, <i>Shanghai</i>
YI0012	Shanghao LIU, <i>Nanjing</i>
YI0013	Tingting LI, <i>Suzhou</i>
YI0014	Jie SUN, <i>Beijing</i>
YI0015	Huy Huu NGUYEN, <i>Ho Chi Minh City</i>
YI0016	Tian YANG, <i>Shanghai</i>
YI0017	Raghuram NELLURI, <i>Jamshedpur</i>
YI0018	Hongping XIA, <i>Singapore</i>
YI0019	Minjun LIAO, <i>Beijing</i>
YI0020	Anna Elizabeth Di BARTOLOMEO, <i>Sydney</i>

Young Investigator Award

Presentation No	Presenting Author
YI0021	Yuan LIU, <i>Beijing</i>
YI0022	Suzhen JIANG, <i>Beijing</i>
YI0023	Zikun MA, <i>Beijing</i>
YI0024	Chuan PANG, <i>Beijing</i>
YI0025	Mingjian PIAO, <i>Beijing</i>
YI0026	Lu HAN, <i>Guiyang</i>
YI0027	Jiyuan ZHOU, <i>Guangzhou</i>
YI0028	Peng FANG, <i>Hangzhou</i>
YI0029	Yingcheng WU, <i>Shanghai</i>
YI0030	Xi HE, <i>Beijing</i>
YI0031	Jinjin LUO, <i>Hangzhou</i>
YI0032	Ling ZHOU, <i>Guangzhou</i>
YI0033	Lu JIANG, <i>Shanghai</i>
YI0034	Angel C.K. MA, <i>Hong Kong</i>
YI0035	Guangyong SUN, <i>Beijing</i>
YI0036	Jing ZENG, <i>Shanghai</i>
YI0037	Nipun VERMA, <i>Chandigarh</i>
YI0038	Tingyang WEI, <i>Beijing</i>
YI0039	Haiyu WANG, <i>Guangzhou</i>
YI0040	Xiajie WEN, <i>Beijing</i>

A RELIABLE, EXPERIENCED PRODUCER OF PLASMA-DERIVED MEDICINES

For more than 100 years, Grifols has been working to improve the health and well-being of people around the world. With the world's largest network of plasma donation centers, Grifols is a leading producer of essential plasma-derived medicines for the treatment of rare and chronic conditions.

A FRACTIONATION CAPACITY OF:

22 MILLION LITERS
OF PLASMA PER YEAR

MORE THAN 390 PLASMA DONATION CENTERS
WORLDWIDE

AN AVERAGE OF
MORE THAN 10 MILLION DONATIONS
PER YEAR

值得信赖 且经验丰富的 血浆衍生药品生产商

基立福是一家拥有超过110年历史的全球化医疗保健公司，致力于改善全球人类的健康和福祉。基立福是治疗罕见病及慢性病必需的血浆衍生药品的领先生产商，拥有着全球规模庞大的血浆捐献中心网络。

***血浆分馏能力：**

每年**2,200**万升血浆

全球超过**390**家血浆捐献中心

每年血浆捐献中心接受

超过**1,000**万份血浆捐献

***基立福储存资料**

CN-APBS-2500002



Tenofovir Amibufenamide Tablets

TMF is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults.



This advertisement is intended for medical and pharmacy professionals only.

【INDICATIONS AND USAGE】

This product is indicated for the treatment of chronic hepatitis B virus infection in adults.

【DOSAGE AND ADMINISTRATION】

This product should be used under the supervision of a physician who is experienced in the treatment of chronic hepatitis B. 25 mg (one tablet) taken orally once daily with food.

【CONTRAINDICATIONS】

This product is contraindicated in patients who are hypersensitive to the active ingredient or any of the excipients of this product. (Please refer to the PRESCRIBING INFORMATION for details).

【ADVERSE REACTIONS】

Common adverse reactions are elevated alanine aminotransferase (ALT), elevated parathyroid hormone, elevated aspartate aminotransferase (AST), hypophosphatemia, and dyslipidemia. (Please refer to the PRESCRIBING INFORMATION for details).

【APPROVAL NUMBER】

国药准字H20210029



Purchase and use in accordance with a doctor's prescription. Please refer to the PRESCRIBING INFORMATION for details.



Company: Jiangsu Hansoh Pharmaceutical Group Co., Ltd

Manufacturer: Changzhou Hengbang Pharmaceutical Co., Ltd

Address: No.1028, Liaohe Road, Xinbei District, Changzhou, China

Zip code: 213000

Customer Service: 400 828 5227

Monday to Friday 9:00-17:00 (except holidays)

Website: <http://www.hansoh.cn>

苏药广审(文)第 250915-00714 号

Program at a Glance

26 - 30 March 2025

Program at a Glance

26 March 2025 (Wednesday)

09:00 - 15:40	THINKING MORE: HEPATITIS B AND C ELIMINATION DIALOGUE IN ASIA PACIFIC	Auditorium, Level 4
08:30 - 17:00	APASL-EASL JOINT WORKSHOP Timely Clinical Decision Making for Advanced Chronic Liver Disease	Function Hall C, Level 1
09:00 - 16:45	APASL-AASLD JOINT WORKSHOP Be-A-Professional: Research and Publication	Function Hall A, Level 1

27 March 2025 (Thursday)

08:00 - 17:00	BASIC SCIENCE COURSE Biomarkers: Diagnosis and Drug Discovery	Function Hall A, Level 1
08:15 - 17:00	APASL-WHO ELIMINATION FORUM Evidence-Based Policy-Making in Public Health	Auditorium, Level 4
08:00 - 17:00	POSTGRADUATE COURSE Obesity, Metabolism and the Liver	Function Hall (B+C), Level 1
08:30 - 16:30	LIVER IMAGING COURSE Non-Invasive Diagnosis and Precision Intervention	402 (A+B), Level 4
17:00 - 18:00	WELCOME RECEPTION	South Lobby, Level 1

28 March 2025 (Friday)

09:15 - 09:45	OPENING CEREMONY	Plenary Hall A, Level 4
09:45 - 11:45	OPENING AND PRESIDENTIAL LECTURES	Plenary Hall A, Level 4
13:00 - 13:15	AWARD CEREMONY	Plenary Hall A, Level 4
13:15 - 14:45	AWARD SESSION	Plenary Hall A, Level 4
14:45 - 15:45	CONSTRUCTION OF NEW LIVER HEALTH COMMUNITY IN ASIA PACIFIC REGION	Plenary Hall A, Level 4
15:45 - 18:45	STATE OF THE ART LECTURE	Plenary Hall A, Level 4
13:15 - 14:45	CONCURRENT SESSION 01 Translation of Science into Hepatitis B Cure - Virological Perspective	Function Hall A, Level 1
13:15 - 14:45	CONCURRENT SESSION 02 Genetic and Rare Liver Diseases	Function Hall B, Level 1
13:15 - 14:45	CONCURRENT SESSION 03 Multidisciplinary Approach and Transplantation in HCC	Function Hall C, Level 1
13:15 - 14:45	CONCURRENT SESSION 04 Hepatology in the Age of Artificial Intelligence (AI)	402 (A+B), Level 4
13:15 - 15:45	AUTOIMMUNE LIVER DISEASE COURSE	Auditorium, Level 4

Program at a Glance

15:00 - 16:30	CONCURRENT SESSION 05 Translation of Science into Hepatitis B Cure - Immunological Perspective	Function Hall A, Level 1
15:00 - 16:30	CONCURRENT SESSION 06 Drug Induced Liver Injury (DILI)	Function Hall B, Level 1
15:00 - 16:30	CONCURRENT SESSION 07 Etiology and Disease Burden of Liver Cancer	Function Hall C, Level 1
15:00 - 16:30	CONCURRENT SESSION 08 Gut Microbiota and the Liver Health	402 (A+B), Level 4
16:00 - 17:15	TRADITIONAL MEDICINE COURSE	Auditorium, Level 4
16:00 - 17:00	APASL DIGITAL PATHOLOGY CONSENSUS	205 (A+B), Level 2
16:45 - 17:45	APASL GUIDELINES 01	Function Hall C, Level 1
13:15 - 14:15	ORAL SESSIONS	
	01: Liver Cancer Management 1	401, Level 4
	02: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 1	403, Level 4
	03: Management of Advanced Chronic Liver Disease (ACLD) 1	405, Level 4
	04: Hepatitis C 1	406, Level 4
	05: Hepatitis B and Delta 1	407, Level 4
14:15 - 15:15	ORAL SESSIONS	
	06: Liver Cancer Management 2	401, Level 4
	07: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 2	403, Level 4
	08: Management of Advanced Chronic Liver Disease (ACLD) 2	405, Level 4
	09: Hepatitis C 2	406, Level 4
	10: Hepatitis B and Delta 2	407, Level 4
15:30 - 16:30	ORAL SESSIONS	
	11: Liver Cancer Management 3	401, Level 4
	12: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 3	403, Level 4
	13: Management of Advanced Chronic Liver Disease (ACLD) 3	405, Level 4
	14: Hepatitis C 3	406, Level 4
	15: Hepatitis B and Delta 3	407, Level 4
16:30 - 17:30	ORAL SESSIONS	
	16: Liver Cancer Management 4	401, Level 4
	17: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 4	403, Level 4

Program at a Glance

18: Management of Advanced Chronic Liver Disease (ACLD) 4	405, Level 4
19: Public Health 1	406, Level 4
20: Hepatitis B and Delta 4	407, Level 4

29 March 2025 (Saturday)

08:00 - 08:48	LATER BREAKER SESSION 01	Plenary Hall A, Level 4
08:00 - 09:00	WOMEN LEADERSHIP IN HEPATOLOGY	Auditorium, Level 4
08:00 - 09:00	MORNING SESSION 01 - 05	401 - 407, Level 4
08:30 - 16:45	APASL ACLF RESEARCH CONSORTIUM	205 (A+B), Level 2
09:00 - 10:30	PLENARY SESSION 01	Plenary Hall A, Level 4
09:15 - 10:45	MULTIDISCIPLINARY FORUM	Auditorium, Level 4
09:15 - 10:45	CONCURRENT SESSION 09 Novel Concept and Future Therapy for Hepatitis B	Function Hall A, Level 1
09:15 - 10:45	CONCURRENT SESSION 10 Mechanism and Therapeutic Targets: Incretin and Endocrine Based Therapies	Function Hall B, Level 1
09:15 - 10:45	CONCURRENT SESSION 11 Prediction and Risk Stratification of HCC	Function Hall C, Level 1
09:15 - 10:45	CONCURRENT SESSION 12 Alcohol Intake and the Body	402 (A+B), Level 4
10:30 - 12:00	PLENARY SESSION 02	Plenary Hall A, Level 4
11:00 - 12:00	YOUNG INVESTIGATOR SESSION 01	Function Hall A, Level 1
11:00 - 12:00	YOUNG INVESTIGATOR SESSION 02	Function Hall B, Level 1
11:00 - 12:00	YOUNG INVESTIGATOR SESSION 03	Function Hall C, Level 1
11:00 - 12:00	YOUNG INVESTIGATOR SESSION 04	402 (A+B), Level 4
13:30 - 15:00	PLENARY SESSION 03	Plenary Hall A, Level 4
15:00 - 16:30	PLENARY SESSION 04	Plenary Hall A, Level 4
13:30 - 15:00	CONCURRENT SESSION 13 New Discovery in HBV: Detection, Monitoring and Prediction	Function Hall A, Level 1
13:30 - 15:00	CONCURRENT SESSION 14 New Pharmacological Agents Discovery for MASH and Liver Fibrosis	Function Hall B, Level 1
13:30 - 15:00	CONCURRENT SESSION 15 Early Diagnosis and Surveillance for Liver Cancer	Function Hall C, Level 1
13:30 - 15:00	CONCURRENT SESSION 16 Transforming Management Landscape of Primary Biliary Cholangitis	402 (A+B), Level 4

Program at a Glance

15:15 - 16:45	CONCURRENT SESSION 17 The Hope of Hepatitis Delta Cure	Function Hall A, Level 1
15:15 - 16:45	CONCURRENT SESSION 18 Clinical Trials for Steatosis and Fibrosis: Inbetween Success and Failure	Function Hall B, Level 1
15:15 - 16:45	CONCURRENT SESSION 19 More and Longer Survival Opportunity for Early-Intermediate Stage Liver Cancer	Function Hall C, Level 1
15:15 - 16:45	CONCURRENT SESSION 20 ACLF Consensus and Controversy	402 (A+B), Level 4
11:00 - 12:00	GLOBAL STEAOTIC LIVER DISEASE SUMMIT	Auditorium, Level 4
13:30 - 16:45	EDITORS FORUM	Auditorium, Level 4
17:00 - 18:00	APASL GUIDELINES 02	Function Hall C, Level 1
17:00 - 18:00	GLOBAL LIVER CANCER SUMMIT	Auditorium, Level 4
09:00 - 10:00	ORAL SESSIONS	
	21: Liver Surgery and Transplantation 1	401, Level 4
	22: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 5	403, Level 4
	23: Liver Fibrogenesis and Cirrhosis 1	405, Level 4
	24: Public Health 2	406, Level 4
	25: Hepatitis B and Delta 5	407, Level 4
10:00 - 11:00	ORAL SESSIONS	
	26: Liver Surgery and Transplantation 2	401, Level 4
	27: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 6	403, Level 4
	28: Liver Fibrogenesis and Cirrhosis 2	405, Level 4
	29: Public Health 3	406, Level 4
	30: Hepatitis B and Delta 6	407, Level 4
11:00 - 12:00	ORAL SESSIONS	
	31: Liver Surgery and Transplantation 3	401, Level 4
	32: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 7	403, Level 4
	33: Liver Fibrogenesis and Cirrhosis 3	405, Level 4
	34: Others Hepatitis, Infections and the Liver 1	406, Level 4
	35: Hepatitis B and Delta 7	407, Level 4
13:30 - 14:30	ORAL SESSIONS	
	36: Liver Oncology 1	401, Level 4
	37: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 8	403, Level 4

Program at a Glance

	38: Liver Fibrogenesis and Cirrhosis 4	405, Level 4
	39: Others Hepatitis, Infections and the Liver 2	406, Level 4
	40: Hepatitis B and Delta 8	407, Level 4
14:30 - 15:30	ORAL SESSIONS	
	41: Liver Oncology 2	401, Level 4
	42: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 9	403, Level 4
	43: Liver Fibrogenesis and Cirrhosis 5	405, Level 4
	44: Liver Injury and Toxicity 1	406, Level 4
	45: Hepatitis B and Delta 9	407, Level 4
15:45 - 16:45	ORAL SESSIONS	
	46: Liver Oncology 3	401, Level 4
	47: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 10	403, Level 4
	48: Liver Fibrogenesis and Cirrhosis 6	405, Level 4
	49: Liver Injury and Toxicity 2	406, Level 4
	50: Hepatitis B and Delta 10	407, Level 4
16:45 - 17:45	ORAL SESSIONS	
	51: Liver Oncology 4	401, Level 4
	52: Immune-Mediated Chronic Liver Diseases 1	403, Level 4
	53: Liver Fibrogenesis and Cirrhosis 7	405, Level 4
	54: Liver Injury and Toxicity 3	406, Level 4
	55: Hepatitis B and Delta 11	407, Level 4
18:30 - 20:30	CULTURE NIGHT	Plenary Hall A, Level 4

30 March 2025 (Sunday)

07:30 - 08:00	GENERAL BUSINESS MEETING	Auditorium, Level 4
08:00 - 12:00	CURE FORUM	Auditorium, Level 4
08:00 - 09:00	YOUNG INVESTIGATOR SESSION 05	Function Hall A, Level 1
08:00 - 09:00	YOUNG INVESTIGATOR SESSION 06	Function Hall B, Level 1
08:00 - 09:00	YOUNG INVESTIGATOR SESSION 07	Function Hall C, Level 1
08:00 - 09:00	YOUNG INVESTIGATOR SESSION 08	402 (A+B), Level 4
08:00 - 09:00	MORNING SESSION 06 - 09	403 - 407, Level 4
09:00 - 10:30	CONCURRENT SESSION 21 Hepatitis C Beyond Cure	Function Hall A, Level 1

Program at a Glance

09:00 - 10:30	CONCURRENT SESSION 22 Pathophysiology of Liver Cirrhosis in 2025: Better Patient Care and Potential Therapeutic Targets	Function Hall B, Level 1
09:00 - 10:30	CONCURRENT SESSION 23 Revolution in the Management of Advanced Liver Cancer	Function Hall C, Level 1
10:30 - 12:00	CONCURRENT SESSION 24 Infectious Disease and the Liver	Function Hall A, Level 1
10:30 - 12:20	CONCURRENT SESSION 25 Portal Hypertension and Complications: Consensus and Questions Before 2026	Function Hall B, Level 1
10:30 - 12:00	CONCURRENT SESSION 26 Current Challenge and Future Development of Liver Cancer	Function Hall C, Level 1
12:25 - 13:45	LATER BREAKER SESSION 02	Auditorium, Level 4
13:45 - 15:00	APASL 2025 BEIJING DEBRIEF	Auditorium, Level 4
08:00 - 09:00	ORAL SESSIONS 56: Basic Science & Pathology 1	401, Level 4
09:00 - 10:00	ORAL SESSIONS 57: Liver Oncology 5 58: Immune-Mediated Chronic Liver Diseases 2 59: Liver Fibrogenesis and Cirrhosis 8 60: Basic Science & Pathology 2 61: Hepatitis B and Delta 12	401, Level 4 403, Level 4 405, Level 4 406, Level 4 407, Level 4
10:00 - 11:00	ORAL SESSIONS 62: Pediatric and Genetics 63: Miscellaneous 64: New Technology 65: Basic Science & Pathology 3 66: Hepatitis, Infections and the Liver	401, Level 4 403, Level 4 405, Level 4 406, Level 4 407, Level 4
15:00 - 15:45	CLOSING CEREMONY	Auditorium, Level 4



雅培异常凝血酶原 PIVKA-II 检测

与**AFP**互为补充
实现**肝癌标志物**的联合检测

PIVKA-II可用于对**已确诊的肝癌患者**
进行**动态监测**以辅助判断疾病进展或治疗效果




产品名称：异常凝血酶原(PIVKA-II)测定试剂盒(化学发光微粒子免疫检测法)
注册证号：国械注进 20163401514
生产企业：Abbott GmbH & Co. KG
禁忌内容或注意事项详见说明书

AFP- 甲胎蛋白
CMIA- 化学发光微粒子免疫检测法

产品名称：甲胎蛋白测定试剂盒(化学发光微粒子免疫检测法)
注册证号：国械注进 20163402877
生产企业：Abbott Ireland Diagnostics Division

沪械广审(文)第250723-14458号 广告
ADD-130604-CHN-ZHS

Managed Care



Combining FibroScan® + aMAP/FAST screening tools with evidence-based TCM therapies, we deliver end-to-end solutions for liver disease management.



FibroScan®

- Global pioneer VCTE and CAP patent technology, with over 90% consistency of test results compared to liver biopsy.
- Three major parameters (CAP, LSM, SSM) and original scores (FAST, Agile) help to accurately stratify liver disease management.
- 200+ global guidelines and consensus recommendations, over 5200 peer-reviewed literatures, is the gold standard of non-invasive solutions for comprehensive liver health management.



Fufang Biejia Ruangan Tablets

- The first NMPA-approved drug for anti-liver fibrosis.
- Liver Softening Specialist** In CHB patients receiving long-term antiviral therapy and Biejia Ruangan Tablets, the 5-year liver fibrosis reversal rate was **76.7%**, and the 7-year liver cancer risk decreased by **51.1%**^[1].
- Recommended by 26 authoritative guidelines and consensus from 11 medical societies.



KE ZHI Capsules

- The first NMPA-approved drug for fatty liver disease.
- Triple Lipid-lowering Effect** Reduces BMI, liver fat, and blood lipids in patients with NAFLD^[2].
- Recommended by 5 authoritative guidelines and consensus from 3 medical societies.



Scan to Protect families from the HCC

*References [1]. Ji D, et al. J Hepatol. 2022 Dec;77(6):1515-1524. [2]. Ning H, et al. J Clin Hepatol, 2017, 33(001):137-140.

* For Medical Professionals Only

Scientific Program

26 March 2025

Wednesday

26 March | Wednesday

Scientific Program

09:00 - 15:40 THINKING MORE: HEPATITIS B AND C ELIMINATION DIALOGUE IN ASIA PACIFIC

09:00 - 10:20 SESSION 01
Disease Burden and Elimination Progress

Auditorium Level 4 Moderators: Gang CUI, *Beijing*
Jun YAN, *Beijing*
Zijian FENG, *Beijing*

09:00 - 09:10 **Welcome**
Yu WANG, *Beijing*

09:10 - 09:30 **Dynamic Epidemiology of Viral Hepatitis**
Zundong YIN, *Beijing*

09:30 - 09:50 **Progress of Viral Hepatitis C Elimination**
Jian LI, *Beijing*

09:50 - 10:10 **Breakthrough and Barriers: Hepatitis E Vaccination**
Zizheng ZHENG, *Xiamen*

10:10 - 10:20 **Panel Discussion**

10:20 - 10:30 Break

10:30 - 12:00 SESSION 02
Triple Elimination and MTCT

Auditorium Level 4 Moderators: Xiaofeng LIANG, *Beijing*
Xiaoping TANG, *Guangzhou*
Weijuan YAN, *Beijing*

10:30 - 10:50 **Progress on Elimination Mother-To-Child Transmission of HIV, Syphilis and Hepatitis B in China**
Ailing WANG, *Beijing*

10:50 - 11:10 **Global Grogress Toward EMTCT of HBV Globally**
John W. WARD, *Decatur*

11:10 - 11:30 **Health Care and Patient Recording System**
Zhongdan CHEN, *WHO*

11:30 - 11:50 **New Approach to Prevent MTCT**
Calvin Q. PAN, *New York*

11:50 - 12:00 **Panel Discussion**

12:00 - 13:00 Lunch

26 MAR
WED

Scientific Program

26 March | Wednesday

26 MAR
WED

13:00 - 14:40	SESSION 03 Experience and Insights
Auditorium Level 4	Moderators: Zhijie AN, <i>Beijing</i> Zengde LI, <i>Beijing</i> Zhongfu LIU, <i>Beijing</i>
	Overseas Experience
13:00 - 13:20	Personalized Healthcare for Patients with Chronic Hepatitis B Milan J. SONNEVELD, <i>Rotterdam</i>
13:20 - 13:40	Micro-Elimination of Hepatitis C Graham FOSTER, <i>London</i>
	China Experience
13:40 - 13:55	China Experience - Hainan Biao WU, <i>Haikou</i>
13:55 - 14:10	China Experience - Guangdong Yan LI, <i>Guangzhou</i>
14:10 - 14:25	China Experience - Fujian Yongyi ZENG, <i>Fuzhou</i>
14:25 - 14:40	China Experience - Shandong Yan KOU, <i>Jinan</i>
14:40 - 15:40	SESSION 04 Prevention and Elimination
Auditorium Level 4	Moderators: Huaqing WANG, <i>Beijing</i> Hui ZHENG, <i>Beijing</i>
14:40 - 15:00	Screening, Diagnosis and Management for HBV Bingliang LIN, <i>Guangzhou</i>
15:00 - 15:20	Adult Vaccination for Hepatitis B Fuqiang CUI, <i>Beijing</i>
15:20 - 15:40	Panel Discussion

26 March | Wednesday

Scientific Program

08:30 - 17:00

APASL-EASL JOINT WORKSHOP Timely Clinical Decision Making for Advanced Chronic Liver Disease

Course Directors

Jidong JIA, *Beijing*
Necati ORMECI, *Istanbul*
Aleksander KRAG, *Odense*
Xiaoyuan XU, *Beijing*

08:30 - 10:15

SESSION 01 Preventing Patients from the First Decompensation

Function Hall C
Level 1

Moderators: Necati ORMECI, *Istanbul*
Jidong JIA, *Beijing*

08:30 - 08:35

Welcome Speech
Lai WEI, *Beijing*

08:35 - 08:40

Welcome Speech
Aleksander KRAG, *Odense*

08:40 - 09:00

Viral Hepatitis
Teerha PIRATVISUTH, *Hat Yai*

09:00 - 09:20

Autoimmune and Cholestatic Liver Diseases
Ana LLEO, *Milan*

09:20 - 09:40

Alcohol Related Liver Diseases
Aleksander KRAG, *Odense*

09:40 - 10:00

Obesity and Metabolic Liver Diseases
Rino A. GANI, *Jakarta*

10:00 - 10:15

Panel Discussion

10:15 - 10:30

Break

10:30 - 12:05

SESSION 02 Care for the Rare: Management of Genetic and Metabolic Disorder

Function Hall C
Level 1

Moderators: Ana LLEO, *Milan*
Xiong MA, *Shanghai*

10:30 - 10:50

Hereditary Hemochromatosis-Iron and the Liver
Darrell H.G. CRAWFORD, *Brisbane*

10:50 - 11:10

Wilson's Disease-Copper and the Liver
Jidong JIA, *Beijing*

11:10 - 11:30

Genetic Cholestatic Liver Diseases-Bile, Lipid and the Liver
Gideon M. HIRSCHFIELD, *Toronto*

11:30 - 11:50

Inherited Hyperbilirubinemia-Problems and Perspectives
Sujun ZHENG, *Beijing*

11:50 - 12:05

Panel Discussion

12:05 - 13:35

Lunch

26 MAR
WED

Scientific Program

26 March | Wednesday

26 MAR
WED

13:35 - 15:10 SESSION 03 When and How: Medication, Endoscopic and/or Interventions

**Function Hall C
Level 1** Moderators: Aleksander KRAG, *Odense*
Yu CHEN, *Beijing*

13:35 - 13:55 **Infection, Sepsis and Encephalopathy**
Debbie SHAWCROSS, *London*

13:55 - 14:15 **Portal Hypertension and Variceal Bleeding**
Necati ORMECI, *Istanbul*

14:15 - 14:35 **Acute-on-Chronic Liver Failure**
Tao HAN, *Tianjin*

14:35 - 14:55 **Portal Vein Thrombosis**
Juan Carlos GARCIA-PAGAN, *Barcelona*

14:55 - 15:10 **Panel Discussion**

15:10 - 15:25 Break

15:25 - 17:00 SESSION 04 Life Saving Measures: Critical Care Management

**Function Hall C
Level 1** Moderators: Debbie SHAWCROSS, *London*
Tao HAN, *Tianjin*

15:25 - 15:45 **Endoscopic and Radiological Interventions**
Huiguo DING, *Beijing*

15:45 - 16:05 **Nutrition and Albumin Therapy**
Paolo ANGELI, *Padova*

16:05 - 16:25 **Therapeutic Plasma Exchange and Hemodynamic Stability**
Rakhi MAIWALL, *New Delhi*

16:25 - 16:45 **Artificial Liver Support System and Transplantation**
Yu CHEN, *Beijing*

16:45 - 17:00 **Panel Discussion**

26 March | Wednesday

Scientific Program

09:00 - 16:45

APASL-AASLD WORKSHOP Be-A-Professional: Research and Publication

Course Directors

W. Ray KIM, *Palo Alto*
Huiying RAO, *Beijing*
Terry C.F. YIP, *Hong Kong*

09:00 - 10:30

SESSION 01 From Design Concept to Result Conclusion

**Function Hall A
Level 1**

Moderators: Lai WEI, *Beijing*
W. Ray KIM, *Palo Alto*

09:00 - 09:05

Welcome Speech
Lai WEI, *Beijing*

09:05 - 09:10

Welcome Speech
W. Ray KIM, *Palo Alto*

09:10 - 09:30

Study Design and Sample Size Calculations
W. Ray KIM, *Palo Alto*

09:30 - 09:50

Data Management and Statistical Analyses
Terry C.F. YIP, *Hong Kong*

09:50 - 10:10

Research Team Building
Norah TERRAULT, *Los Angeles*

10:10 - 10:30

Q&A

10:30 - 10:45

Break

10:45 - 12:05

SESSION 02 From Submission to Publication

**Function Hall A
Level 1**

Moderators: Wen XIE, *Beijing*
Terry C.F. YIP, *Hong Kong*

10:45 - 11:05

Liver Related Journals: Impact Factor and Journal Selection
Sang Hoon AHN, *Seoul*

11:05 - 11:25

Manuscript Preparation and Submission
Elizabeth E. POWELL, *Brisbane*

11:25 - 11:45

Response to Reviewers' Comments and Result
Mazen NOUREDDIN, *Houston*

11:45 - 12:05

Q&A

12:05 - 13:35

Lunch

26 MAR
WED

Scientific Program

26 March | Wednesday

26 MAR
WED

13:35 - 15:05	SESSION 03 Break-Out Session: Abstracts Presented in Small Groups
Function Hall A Level 1	Group 1: Viral Hepatitis Moderator: Sang Hoon AHN, <i>Seoul</i>
13:35 - 13:50	The National Burden of Hospitalized Liver Diseases from 2017 to 2022: A Thailand Nationwide Population-Based Cross-Sectional Time Series Study Rungfah SAEHAN, <i>Songkla</i>
13:50 - 14:05	Evolving Trends in Liver Cirrhosis in Pakistan (2002-2022): Causes and Future Predictions Abhishek LAI, <i>Karachi</i>
14:05 - 14:20	Altered T Cell Profile May Contribute to the Cirrhosis-Associated Immune Regulation in Paediatric Portal Hypertension: A Pilot Tengfei SI, <i>Hangzhou</i>
14:20 - 14:35	Tertiary Lymphoid Structures in Hepatocellular Carcinoma: Influence on Immune Cell Profiles in Tumors and on Efficacy of Adjuvant PD-1 Inhibitor Therapy After Hepatectomy Jiayong SU, <i>Nanning</i>
14:35 - 14:50	Liver Fibrosis, Based on Fibrosis-4 Index, is Associated with Coronary Stent Failure and Cardiovascular Outcomes in Patients After Coronary Stenting Na TIAN, <i>Wenzhou</i>
14:50 - 15:05	Benefits of Terlipressin for the Prevention from Acute Kidney Injury in Patients with Liver Cirrhosis and Ascites Yong HE, <i>Shenyang</i>
15:05 - 15:20	Break
401 Level 4	Group 2: Metabolic and Genetics Moderator: Huiying RAO, <i>Beijing</i>
13:35 - 13:50	Trained Human Bone Marrow Mesenchymal Stem Cells Improve the Therapeutic Outcomes in ConA-Induced Acute Liver Failure Via Enhancing Immunoregulation Bingqi LI, <i>Hangzhou</i>
13:50 - 14:05	Targeting of Inflammatory Monocytes Via CCL2/CCR2 Signaling as a Therapeutic Strategy Against Autoimmune Hepatitis by Using Macrophage-Derived Extracellular Vesicles Xiaoli FAN, <i>Chengdu</i>
14:05 - 14:20	A Novel and User-Friendly Model for Precise Identification of Concurrent Bacterial Infections in Older Patients with Acute-on-Chronic Liver Diseases (AoCLD): Evidence from a Nationwide, Multicenter and Prospective Study Ju ZOU, <i>Changsha</i>
14:20 - 14:35	Simvastatin Ineffective in Improving Hepatopulmonary Syndrome in Cirrhosis Patients (HEPSIM Trial)-Results of a Double-Blind Randomised Controlled Trial [NCT05187715]. Akhil DESHMUKH, <i>New Delhi</i>

26 March | Wednesday

Scientific Program

14:35 - 14:50	Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: Is There an Association with Coagulation, Platelet-Related, Folate Cycle Gene and Janus Kinase 2 Gene Polymorphisms? Diana DADUNS, <i>Moscow</i>
14:50 - 15:05	Break
402A Level 4	Group 3: Advanced Chronic Liver Disease Moderator: Jidong JIA, <i>Beijing</i>
13:35 - 13:50	Single Cell Fixed RNA Profiling Reveals Hepatocytes (Cyp2e1+Cyp1a2+Tnx1+) Drives Liver Fibrosis Regression Via Retinoic Acid Receptor Responder 2 Duc Minh PHAM, <i>Osaka</i>
13:50 - 14:05	Risk of Variceal Haemorrhage with Calcium Channel Blockers in Patients with Cirrhosis: A Territory-Wide Retrospective Cohort Study Junlong DAI, <i>Hong Kong</i>
14:05 - 14:20	Exosomal miR-499a-5p from Human Umbilical Cord Mesenchymal Stem Cells Attenuates Liver Fibrosis via Targeting ETS1/GPX4-Mediated Ferroptosis in Hepatic Stellate Cells Zheng WANG, <i>Wuhan</i>
14:20 - 14:35	Versican Upregulation and Matrix Remodeling in Mesenteric Lymph Nodes Hinder CD4+ T Cell Migration, Driving Systemic Infections in Cirrhosis Pinky JUNEJA, <i>New Delhi</i>
14:35 - 14:50	The Role of the Non-Invasive Diagnostic Method - FibroScan in Liver Diseases Saltanat Efendiyeva MAHARRAMZADE, <i>Baku</i>
14:50 - 15:05	Break
402B Level 4	Group 4: Liver Cancer Moderator: Elizabeth E. POWELL, <i>Brisbane</i>
13:35 - 13:50	Distinct Molecular Pathways Regulated by Activated AKT and YAP Signaling During Intrahepatic Cholangiocarcinoma Progression Jinqiu ZHAO, <i>Chongqing</i>
13:50 - 14:05	Targeting Glutamine Metabolism is a Potential Strategy for Cholangiocarcinoma Treatment Kullanat KHAWKHIAW, <i>Khon Kaen</i>
14:05 - 14:20	Single-Cell Spatial Proteomic Landscape of Intrahepatic Cholangiocarcinoma Immune Microenvironment Reveals Immune Evasion via FSTL1-Negative Macrophage Wenzhu LI, <i>Nanjing</i>
14:20 - 14:35	Coordination of Solute Carrier Family 39 Member 1 and Dynamin-Related Protein 1 Facilitates Hepatocellular Carcinoma Recurrence by Impairing Mitochondrial Quality Control Rui LI, <i>Shenzhen</i>

26 MAR
WED

Scientific Program

26 March | Wednesday

26 MAR
WED

14:35 - 14:50	Diagnostic Performance of Tumor Markers DCP and AFP in Patients With Hepatocellular Carcinoma and High-Risk Individuals in Mongolia Munguntsetseg BATKHUU, <i>Ulaanbaatar</i>
14:50 - 15:05	Improved Glycemic Control Over Time in Patients with Type 2 Diabetes Mellitus (T2DM), with and without Cirrhosis: A Territory-Wide Cohort Study in Hong Kong From 2000-2023 Mary Yue WANG, <i>Hong Kong</i>
15:05 - 15:20	Break
403 Level 4	Group 5: Viral Hepatitis Moderator: Mark SULKOWSKI, <i>Baltimore</i>
13:35 - 13:50	Hepatitis B Surface Antigen Seroclearance Rate after Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B-A Systematic Review and Meta-Analysis Soe Thiha MAUNG, <i>Bangkok</i>
13:50 - 14:05	Clinical Efficacy and Safety of Long-Term Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam Thong Duy VO, <i>Ho Chi Minh City</i>
14:05 - 14:20	A Novel Machine Learning Model to Predict Liver-Related Events (LREs) in Patients with Chronic Liver Disease (CLD) Guanlin LI, <i>Guangzhou</i>
14:20 - 14:35	PD-1 is Required for the Early Expansion of HBV-Specific CD8+ T Cells and does Not Suppress Their Effector Function During the Acute Phase of HBV Infection. Jia LIU, <i>Wuhan</i>
14:35 - 14:50	HBV Replication Facilitates Drug Resistance of Hepatocellular Carcinoma Via CD133 Regulating Self-Renewal of Liver Cancer Stem Cells Kuanhui XIANG, <i>Beijing</i>
14:50 - 15:05	Effect of Switching from Prior Nucleos(t)ide Analogue(s) to Tenofovir Alafenamide on Lipid Profile and Cardiovascular Risk in Patients with Chronic Hepatitis B Witchayaporn PRAGUYLERTLUCK, <i>Songkla</i>
15:05 - 15:20	Break
405 Level 4	Group 6: Metabolic and Genetics Moderator: Mazen NOUREDDIN, <i>Houston</i>
13:35 - 13:50	The Association Between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease in Egyptian Patients Ahmed Mokhtar YAHIA, <i>Cairo</i>
13:50 - 14:05	Fibrotic MASH Resolution VCTE Index for the Non-Invasive Diagnosis of Fibrotic MASH Resolution and Prediction of Liver-Related Events: A Global Multicenter Study Gong FENG, <i>Xi'an</i>
14:05 - 14:20	A - Ketobutyrate is A Metabolite of Transsulfuration Pathway that Activates Autophagy and Improves Glucose Tolerance and Hepatic Steatosis in MAFLD Dan ZHANG, <i>Kunming</i>

26 March | Wednesday

Scientific Program

26 MAR
WED

14:20 - 14:35	TNFRSF12a Potentially Represents a Common Mechanism Linking Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Heart Failure Fan DU, <i>Nanchang</i>
14:35 - 14:50	Association of Dietary Water-Soluble Vitamins with MAFLD Among Adults: Evidence from NHANES 2003-2018 Jia LIU, <i>Tianjin</i>
14:50 - 15:05	Unsupervised Partitional Clustering of Hemoglobin A1c (HbA1c) Level and Trajectory Stratify the Risk of Liver-Related Complications in Patients with Type 2 Diabetes (T2D) Nana PENG, <i>Hong Kong</i>
15:05 - 15:20	Break

406 Level 4

Group 7: Advanced Chronic Liver Disease
Moderator: Norah TERRAULT, *Los Angeles*

13:35 - 13:50	Wnt7a from Hepatic LyEC Facilitates Cholangiocyte Proliferation During Liver Regeneration Aarti SHARMA, <i>New Delhi</i>
13:50 - 14:05	Single Cell RN-Sequencing Delineates CD8+Tissue Resident Memory T Cells Maintaining Rejection in Liver Transplantation Xinqiang LI, <i>Qingdao</i>
14:05 - 14:20	PINK1/Parkin Inhibits Hepatocyte Succinate Accumulation and Promotes Liver Regeneration by Mediating the Ubiquitination and Degradation of Sigma-1 Protein Jian XU, <i>Nanjing</i>
14:20 - 14:35	NAT10 Promotes Liver Regeneration Via mRNA ac4C Modification in a Mouse Model of Hepatectomy Qingjing WANG, <i>Shanghai</i>
14:35 - 14:50	Challenges of Rapid Scale-Up of Laboratory Capacity to Respond to the Emerging Hepatitis C Crisis Among Refugees in Cox's Bazar, Bangladesh Debashish PAUL, <i>Cox's Bazar</i>
14:50 - 15:05	Break

407 Level 4

Group 8: Liver Cancer
Moderator: W. Ray KIM, *Palo Alto*

13:35 - 13:50	Real-World Experience of Lenvatinib Monotherapy in Advanced Hepatocellular Carcinoma Patients: A Study from Bali Dwijio Anargha SINDHUGHOSA, <i>Bali</i>
13:50 - 14:05	Disease Time Burden in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Therapy Matthew ShingHin CHUNG, <i>Hong Kong</i>

Scientific Program

26 March | Wednesday

26 MAR
WED

14:05 - 14:20	Exploring Immune Checkpoint Inhibitor Rechallenge of Durvalumab Plus Tremelimumab in Advanced Hepatocellular Carcinoma: Analysis of Post-imAE Readministration and Sequential Treatment after Atezolizumab Plus Bevacizumab Takuya YONEMOTO, <i>Chiba</i>
14:20 - 14:35	Efficacy of N-Acetylcysteine in Preventing Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis Kristian Orap ORANTE, <i>Manila</i>
14:35 - 14:50	A Retrospective Study of Immune Checkpoint Inhibitors-Based Combination Therapy in Patients with HCC for Liver Injury Luping LIN, <i>Fuzhou</i>
14:50 - 15:05	Break

15:20 - 16:45	SESSION 04 Presentation Skills
Function Hall A Level 1	Moderators: Sang Hoon AHN, <i>Seoul</i> Huiying RAO, <i>Beijing</i>
15:20 - 15:40	Presentation Skills: How to Catch Attention and Interact with Audience Jidong JIA, <i>Beijing</i>
15:40 - 16:00	Presentation Skills: How to Catch Attention and Interact with Audience Mark SULKOWSKI, <i>Baltimore</i>
16:00 - 16:20	How to Response to Q&A and Discussion? Carmen C.L. WONG, <i>Hong Kong</i>
16:20 - 16:45	Q&A and Wrap-up

Scientific Program

27 March 2025

Thursday

Scientific Program

27 March | Thursday

08:00 - 17:00

BASIC SCIENCE COURSE **Biomarkers: Diagnosis and Drug Discovery**

Course Directors

Moderators: Ju-Tao GUO, *Doylestown*
Pei-Jer CHEN, *Taipei*
Hongsong CHEN, *Beijing*

08:00 - 09:30

SESSION 01 **Hepatitis B Virus Life Cycle and Biomarkers**

Function Hall A
Level 1

Moderators: Yasuhito TANAKA, *Kumamoto*
Hongsong CHEN, *Beijing*

08:00 - 08:20

Mechanism of Covalently Closed Circular DNA (cccDNA) Formation
Ju-Tao GUO, *Doylestown*

08:20 - 08:40

Interplay of HBV RNA and HBsAg in Hepatitis B Virus Infection
Jie WANG, *Beijing*

08:40 - 09:00

Endosomal and Autophagic Vesicle Pathways in HBV Biogenesis
Mengji LU, *Essen*

09:00 - 09:20

Innate and Adaptive Immunity of HBV Infection
Ailong HUANG, *Chongqing*

09:20 - 09:30

Panel Discussion

09:30 - 09:40

Break

09:40 - 11:10

SESSION 02 **Biomarkers for HBV: Implications for Diagnosis and Treatment**

Function Hall A
Level 1

Moderators: Ju-Tao GUO, *Doylestown*
Jie WANG, *Beijing*

09:40 - 10:00

Classic Biomarkers in Current Clinical Practice
Henry L.Y. CHAN, *Hong Kong*

10:00 - 10:20

Novel and Emerging Biomarkers: Implication for Diagnosis and Treatment
Peter REVILL, *Melbourne*

10:20 - 10:40

Hepatitis B Core - Related Antigen for Determining the Therapeutic Effectiveness
Yasuhito TANAKA, *Kumamoto*

10:40 - 11:00

Application of HBV RNA in Clinical Practice
Jian SUN, *Guangzhou*

11:00 - 11:10

Panel Discussion

11:10 - 11:20

Break

27 MAR
THU

27 March | Thursday

Scientific Program

11:20 - 12:50	SESSION 03 Biomarkers of Chronic Liver Disease and Transplantation
Function Hall A Level 1	Moderators: Peter REVILL, <i>Melbourne</i> Jian SUN, <i>Guangzhou</i>
11:20 - 11:40	Non-invasive Tests (NITs) for MASH Mark MUTHIAH, <i>Singapore</i>
11:40 - 12:00	Biomarkers for Liver Cirrhosis and Portal Hypertension Jordi GRACIA-SANCHO, <i>Barcelona</i>
12:00 - 12:20	Biomarker of DILI Robert FONTANA, <i>Ann Arbor</i>
12:20 - 12:40	Biomarkers for Liver Transplantation Kwan MAN, <i>Hong Kong</i>
12:40 - 12:50	Panel Discussion
12:50 - 13:50	Lunch
13:50 - 15:20	SESSION 04 Biomarkers and Liver Cancer
Function Hall A Level 1	Moderators: Robert FONTANA, <i>Ann Arbor</i> Kwan MAN, <i>Hong Kong</i>
13:50 - 14:10	Biomarkers for Liver Cancer Surveillance and Prediction from Chronic Liver Disease Xiaoguang DOU, <i>Shenyang</i>
14:10 - 14:30	Biomarkers for Early Detection and Diagnosis Xuehong ZHANG, <i>Orange</i>
14:30 - 14:50	Biomarkers and New Targets for Future HCC Treatment Masatoshi KUDO, <i>Osaka</i>
14:50 - 15:10	Prognostic Indicator and Recurrence Risk Prediction after Resection Pei-Jer CHEN, <i>Taipei</i>
15:10 - 15:20	Panel Discussion
15:20 - 15:30	Break
15:30 - 17:00	SESSION 05 Biomarkers Discovery and Validation
Function Hall A Level 1	Moderators: Masatoshi KUDO, <i>Osaka</i> Ailong HUANG, <i>Chongqing</i>
15:30 - 15:50	Omics-based Biomarker Discovery Aleksander KRAG, <i>Odense</i>
15:50 - 16:10	Spatial Transcriptomics for Biomarker Discovery Valerie CHEW, <i>Singapore</i>

27 MAR
THU

Scientific Program

27 March | Thursday

16:10 - 16:30	Artificial Intelligence-Driven Radiomics Analysis for HCC Kun WANG, <i>Beijing</i>
16:30 - 16:50	Identification of Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Liver Cancer Jian ZHOU, <i>Shanghai</i>
16:50 - 17:00	Panel Discussion

17:00 - 18:00	WELCOME RECEPTION	South Lobby, Level 1
---------------	-------------------	----------------------

27 MAR
THU

27 March | Thursday

Scientific Program

08:15 - 17:00

APASL-WHO ELIMINATION FORUM Evidence-Based Policy-Making in Public Health

08:15 - 09:40

SESSION 01 Progress Towards Eliminating Viral Hepatitis by 2030: Statistics and Evidence I

**Auditorium
Level 4**

Moderators: Hui ZHUANG, *Beijing*
Masao OMATA, *Kofu*
Zhongdan CHEN, *WHO*

08:15 - 08:20

Welcome and Introduction

Lai WEI, *Beijing*

08:20 - 08:25

Welcome and Introduction

Daniel LOW-BEER, *WHO*

08:25 - 08:40

Global Progress in Viral Hepatitis Elimination

Daniel LOW-BEER, *WHO*

08:40 - 08:55

Prevention and Control of Viral Hepatitis: Past, Current and Future

Chinese Expert

08:55 - 09:10

HBV EMTCT

Jinlin HOU, *Guangzhou*

09:10 - 09:25

Elimination of HBV as a Public Health Problem

Saeed HAMID, *Karachi*

09:25 - 09:40

Elimination of HCV as a Public Health Problem: Long - term Clinical Outcomes After a Decade

Gamal SHIHA, *Mansoura*

09:40 - 11:00

SESSION 02 Progress Towards Eliminating Viral Hepatitis by 2030: Statistics and Evidence II

**Auditorium
Level 4**

Moderators: Alexander V. NERSESOV, *Almaty*
Xiaoguang DOU, *Shenyang*

09:40 - 09:50

WHO Guidelines Updates and Implementation

Po-Lin CHAN, *WHO*

09:50 - 10:00

Lessons from Regions: Implementing Towards Hepatitis Elimination-WPRO

Kiyohiko IZUMI, *WHO*

10:00 - 10:10

Lessons from Regions: Implementing Towards Hepatitis Elimination-SEARO

Po-Lin CHAN, *WHO*

10:10 - 10:25

Country Experience 1: Improving of Timely Birth Dose of HBV Vaccines

Fuqiang CUI, *Beijing*

10:25 - 10:40

Country Experience 2: Optimizing Services Models to Maximizing Coverage of Screening, Diagnosis, and Treatment of Viral Hepatitis

Yoshiyuki UENO, *Yamagata*

27 MAR
THU

Scientific Program

27 March | Thursday

10:40 - 10:55 **Country Experiences 3: Adapting National Viral Hepatitis Information System**

Elizabeth E. POWELL, *Brisbane*

10:55 - 11:00 **Panel Discussion**

11:00 - 12:00 **SESSION 03** **Updates and Reports from the Countries and Regions I**

Auditorium Level 4 Moderators: Tawesak TANWANDEE, *Bangkok*
Saeed HAMID, *Yerevan*

11:00 - 11:10 **Kazakhstan**
Alexander V. NERSESOV, *Almaty*

11:10 - 11:20 **New Zealand**
Edward J. GANE, *Auckland*

11:20 - 11:30 **Azerbaijan**
Gulnara AGHAYEVA, *Baku*

11:30 - 11:40 **China**
Yu WANG, *Beijing*

11:40 - 11:50 **Australia**
Darrell H.G. CRAWFORD, *Brisbane*

11:50 - 12:00 **Egypt**
Gamal SHIHA, *Mansoura*

12:00 - 13:30 Lunch

13:30 - 15:00 **SESSION 04** **Updates and Reports from the Countries and Regions II**

Auditorium Level 4 Moderators: Hasmik GHAZINYAN, *Hat Yai*
Khin Maung WIN, *Yangon*

13:30 - 13:40 **India**
Manoj K. SHARMA, *New Delhi*

13:40 - 13:50 **Turkey**
A. Kadir DOKMECI, *Ankara*

13:50 - 14:00 **Indonesia**
Rino A. GANI, *Jakarta*

14:00 - 14:10 **Pakistan**
Saeed HAMID, *Karachi*

14:10 - 14:20 **Japan**
Yoshiyuki UENO, *Yamagata*

14:20 - 14:30 **Malaysia**
Rosmawati MOHAMED, *Kuala Lumpur*

14:30 - 14:40 **Philippines**
Jose D. SOLLANO, *Manila*

27 MAR
THU

27 March | Thursday

Scientific Program

14:40 - 14:50 **Russia**
Olga TARASOVA, *Moscow*

14:50 - 15:00 Break

15:00 - 17:00 **SESSION 05**
Updates and Reports from the Countries and Regions III

Auditorium Level 4 Moderators: Rosmawati MOHAMED, *Kuala Lumpur*
Gulnara AGHAYEVA, *Baku*

15:00 - 15:10 **Thailand**
Tawesak TANWANDEE, *Bangkok*

15:10 - 15:20 **Uzbekistan**
Erkin MUSABAEV, *Tashkent*

15:20 - 15:30 **Mongolia**
Oidov BAATARKHUU, *Ulaanbaatar*

15:30 - 15:40 **Myanmar**
Khin Maung WIN, *Yangon*

15:40 - 15:50 **Armenia**
Hasmik GHAZINYAN, *Yerevan*

15:50 - 17:00 **Oral Presentation**

15:50 - 16:00 **Sanitary Intervention with HeberNasvac in Cuba to Treat all HBsAg Positive Chronic Hepatitis B Patients Before 2027**
Gerardo Enrique GUILLEN, *Havana*

16:00 - 16:10 **Social Support for Hepatitis C Patients in Two Cities, China: a Cross-Sectional Study**
Jiejun YU, *Beijing*

16:10 - 16:20 **Advancing Viral Hepatitis B and C Elimination in Bangladesh: Achievements, Challenges, and Future Directions**
Md Ismail GAZI, *Dhaka*

16:20 - 16:30 **Best Practices for Engaging with Communities Affected by Hepatitis B**
Thomas TU, *Newcastle*

16:30 - 16:40 **Launch of the First World Hepatitis Testing Week**
Cary JAMES, *Geneva*

16:40 - 16:50 **A Multifaceted Approach to Viral Hepatitis Elimination: The Preventive Hepatology Initiative**
Ajeet Singh BHADORIA, *Rishikesh*

16:50 - 17:00 **Advancing Hepatitis B Elimination in New Zealand: Lessons from Community Engagement and Service Delivery Innovations**
Sarah DAVEY, *Whakatane*

17:00 - 17:10 **Wrap-Up and Closing**

George K.K. LAU, *Hong Kong*
Yu WANG, *Beijing*

27 MAR
THU

Scientific Program

27 March | Thursday

08:00 - 17:00

POSTGRADUATE COURSE **Obesity, Metabolism and the Liver**

Course Directors

Yuemin NAN, *Shijiazhuang*
Jacob GEORGE, *Sydney*
Vincent W.S. WONG, *Hong Kong*
Jiangao FAN, *Shanghai*

08:00 - 09:35

SESSION 01 **Disease Burden and Public Health**

**Function Hall (B+C)
Level 1**

Moderators: Jacob GEORGE, *Sydney*
Yuemin NAN, *Shijiazhuang*

08:00 - 08:05

Welcome Speech
Lai WEI, *Beijing*

08:05 - 08:25

The Trend in Epidemiology and Disease Burden of Metabolic Dysfunction-Associated Liver Diseases
Zobair M. YOUNOSSI, *Washington DC*

08:25 - 08:45

Understanding the Impact of Obesity: Diabetes and Liver Disease in Modern Society
Wah Kheong CHAN, *Kuala Lumpur*

08:45 - 09:05

Impact of Alcohol and Metabolic Syndrome on Liver - Related Outcomes
Junping SHI, *Hangzhou*

09:05 - 09:25

Obesity and Metabolic Dysfunction
Diana A. PAYAWAL, *Manila*

09:25 - 09:35

Panel Discussion

09:35 - 09:40

Break

09:40 - 11:10

SESSION 02 **Pathogenesis and Risk Factor**

**Function Hall (B+C)
Level 1**

Moderators: Wah Kheong CHAN, *Kuala Lumpur*
Jiangao FAN, *Shanghai*

09:40 - 10:00

Pathogenesis of Metabolic Dysfunction and the Organs
Jingmin ZHAO, *Beijing*

10:00 - 10:20

Obesity and Overnutrition: Interplay of Metabolism and Inflammation
Necati ORMECI, *Istanbul*

10:20 - 10:40

Alcohol Consumption, Fat and Liver Injury
Chaohui YU, *Hangzhou*

10:40 - 11:00

Genetics and Environmental Risk Factors
Leon ADAMS, *Perth*

11:00 - 11:10

Panel Discussion

11:10 - 11:20

Break

27 MAR
THU

27 March | Thursday

Scientific Program

11:20 - 12:50	SESSION 03 Diagnosis and Monitoring
Function Hall (B+C) Level 1	Moderators: Diana A. PAYAWAL, <i>Manila</i> Minghua ZHENG, <i>Wenzhou</i>
11:20 - 11:40	Diagnosis Criteria and the Implication in Decision Making Jiangao FAN, <i>Shanghai</i>
11:40 - 12:00	Stages and Risk Accessment George B.B. GOH, <i>Singapore</i>
12:00 - 12:20	Non-invasive Tools to Identify Patients with T2DM and Fibrotic MASH Laurent CASTERA, <i>Paris</i>
12:20 - 12:40	Non - Invasive Assessment: Monitoring and Surrogate Endpoint for Clinical Trial Rohit LOOMBA, <i>La Jolla</i>
12:40 - 12:50	Panel Discussion
12:50 - 13:50	Lunch
13:50 - 15:20	SESSION 04 Current Guidelines and Co-Managment
Function Hall (B+C) Level 1	Moderators: George B.B. GOU, <i>Singapore</i> Jingmin Zhao, <i>Beijing</i>
13:50 - 14:10	Diabetes and Endocrine/MASH Norbert STEFAN, <i>Tübingen</i>
14:10 - 14:30	Cardiovascular Disease (CVD) / MASH Chun-Jen LIU, <i>Taipei</i>
14:30 - 14:50	Chronic Kidney Disease (CKD) / MASH Minghua ZHENG, <i>Wenzhou</i>
14:50 - 15:10	Viral Hepatitis / MASH Jie LI, <i>Nanjing</i>
15:10 - 15:20	Panel Discussion
15:20 - 15:30	Break
15:30 - 17:00	SESSION 05 Patients Care and Management in 2025 and Near Future
Function Hall (B+C) Level 1	Moderators: Vincent W.S. WONG, <i>Hong Kong</i> Yuqiang MI, <i>Tianjin</i>
15:30 - 15:50	Lifestyle Intervention and Care Standards Emmanuel TSOCHATZIS, <i>London</i>
15:50 - 16:10	Patients Selection and Management: Endoscopic Bariatric and Metabolic Surgery Cunchuan WANG, <i>Guangzhou</i>

27 MAR
THU

Scientific Program

27 March | Thursday

16:10 - 16:30	Patients Selection & Monitoring: Treatment Response and Discontinuation W.Ray KIM, <i>Palo Alto</i>
16:30 - 16:50	Metabolic Drug in Metabolic Liver Disease Han-Chieh LIN, <i>Taipei</i>
16:50 - 17:00	Panel Discussion

17:00 - 18:00	WELCOME RECEPTION	South Lobby, Level 1
---------------	-------------------	----------------------

27 MAR
THU

27 March | Thursday

Scientific Program

08:30 - 16:30

LIVER IMAGING COURSE
Non-Invasive Diagnosis and Precision Intervention

Course Directors

Lungen LU, *Shanghai*
Manoj K. SHARMA, *New Delhi*
Grace L. SU, *Ann Arbor*

08:30 - 10:00

SESSION 01
Diagnosis, Staging and Monitoring of Chronic Liver Disease
402 (A+B)
Level 4

Moderators: Grace L. SU, *Ann Arbor*
Lungen LU, *Shanghai*

08:30 - 08:50

Endoscopic Ultrasound-Guided Liver Biopsy

Kegin HU, *Irvine*

08:50 - 09:10

Ultrasound Imaging for Diagnosis of Liver Fibrosis

Manoj K. SHARMA, *New Delhi*

09:10 - 09:30

Endoscopic Ultrasound for Diagnosis of Portal Hypertension

Cosmas R.A. LESMANA, *Jakarta*

09:30 - 09:50

VCTE and MRE of Liver Stiffness

Seung Up KIM, *Seoul*

09:50 - 10:00

Panel Discussion

10:00 - 10:15

Break

10:15 - 11:45

SESSION 02
Diagnosis and Staging of Liver Lesion
402 (A+B)
Level 4

Moderators: A. Kadir DOKMECI, *Ankara*
Xiaobin FENG, *Beijing*

10:15 - 10:35

Early Diagnosis and Screening for HCC

Hon Ho YU, *Macau*

10:35 - 10:55

Emerging Imaging Tools for HCC Surveillance

Jeong Min LEE, *Seoul*

10:55 - 11:15

BCLC and CNLC: Imaging in Staging of HCC

Mengsu ZENG, *Shanghai*

11:15 - 11:35

The Application and Current Progress of Three-Dimensional Visualization in Hepatectomy

Yannan LIU, *Beijing*

11:35 - 11:45

Panel Discussion

11:45 - 13:15

Lunch

27 MAR
THU

Scientific Program

27 March | Thursday

27 MAR
THU

13:15 - 14:45	SESSION 03 Interventional Procedures (Image-Guided Therapy)
402 (A+B) Level 4	Moderators: Keqin HU, <i>Irvine</i> Xiaolong QI, <i>Nanjing</i>
13:15 - 13:35	Image Guided Procedures for Portal Hypertension and Variceal Bleeding A. Kadir DOKMECI, <i>Ankara</i>
13:35 - 13:55	Stereotactic Ablative Radiotherapy (SABR/SBRT) Jason C.H. CHENG, <i>Taipei</i>
13:55 - 14:15	The Current Status and Advance of Yuttrium 90 SIRT for HCC Xiaobin FENG, <i>Beijing</i>
14:15 - 14:35	Image-Guided Ablation for Liver Cancer Ping LIANG, <i>Beijing</i>
14:35 - 14:45	Panel Discussion
14:45 - 15:00	Break
15:00 - 16:30	SESSION 04 Artificial Intelligence and Data Analysis
402 (A+B) Level 4	Moderators: Manoj K. SHARMA, <i>New Delhi</i> Ping LIANG, <i>Beijing</i>
15:00 - 15:20	Utilizing Automated Extraction of Imaging Features within Computed Tomography (CT) Scans Grace L. SU, <i>Ann Arbor</i>
15:20 - 15:40	Digital Pathology/Artificial Intelligence and qFibrosis Aileen WEE, <i>Singapore</i>
15:40 - 16:00	Detection of Cirrhosis and Portal Hypertension by AI Xiaolong QI, <i>Nanjing</i>
16:00 - 16:20	Management of HCC Using AI and Imaging Data Jingfeng LIU, <i>Fuzhou</i>
16:20 - 16:30	Panel Discussion
17:00 - 18:00	WELCOME RECEPTION South Lobby, Level 1

Scientific Program

28 March 2025

Friday

Scientific Program

28 March | Friday

09:15 - 09:45

OPENING CEREMONY

Plenary Hall A
Level 4

Moderators: Xiaoyuan XU, *Beijing*
Yu WANG, *Beijing*

09:45 - 11:45

OPENING AND PRESIDENTIAL LECTURES

Plenary Hall A
Level 4

Moderators: Shuichiro SHIINA, *Tokyo*
Yuemin NAN, *Shijiazhuang*

09:45 - 10:05

APASL and Hepatology International
Masao OMATA, *Kofu*

10:05 - 10:25

Hepatology in Asia
Shiv K. SARIN, *New Delhi*

10:25 - 10:45

Liver Disease Burden in Public Health
Yu WANG, *Beijing*

10:45 - 11:05

Gastroenterology and the Liver
Necati ORMECI, *Istanbul*

11:05 - 11:25

Future Hepatology
Lai WEI, *Beijing*

11:25 - 11:45

Precision Surgery in Liver Disease
Jia-Hong DONG, *Beijing*

11:45 - 12:00

Break

13:00 - 13:15

AWARD CEREMONY

Plenary Hall A
Level 4

Chairs: Lai WEI, *Beijing*
Necati ORMECI, *Istanbul*

13:00 - 13:15

Award Presentation

Award Presentation Guest
Masao OMATA, *Kofu*

Award Presentation Guest
Shiv K. SARIN, *New Delhi*

Award Presentation Guest
Jose D. SOLLANO, *Manila*

Award Presentation Guest
Lai WEI, *Beijing*

28 MAR
FRI

28 March | Friday

Scientific Program

13:15 - 14:45 AWARD SESSION	
Plenary Hall A Level 4	Chairs: Lai WEI, <i>Beijing</i> Necati ORMECI, <i>Istanbul</i>
13:15 - 13:35	APASL Okuda-Omata Distinguished Award Jidong JIA, <i>Beijing</i>
13:35 - 13:55	APASL Powell-Sarin Achievement Award Ming-Lung YU, <i>Kaohsiung</i>
13:55 - 14:15	APASL Lesmana-Sollano Great Mentor Award Manoj K. SHARMA, <i>New Delhi</i>
14:15 - 14:30	APASL Rising Star Award Shang-Chin HUANG, <i>Taipei</i>
14:30 - 14:45	APASL Rising Star Award Jing CHEN, <i>Hong Kong</i>
14:45 - 15:45 CONSTRUCTION OF NEW LIVER HEALTH COMMUNITY IN ASIA PACIFIC REGION	
Plenary Hall A Level 4	Moderator: Lai WEI, <i>Beijing</i>
Panel Members:	Panel Discussion Masao OMATA, <i>Kofu</i> Shiv K. SARIN, <i>New Delhi</i> W. Ray KIM, <i>Palo Alto</i> Jia-Hong DONG, <i>Beijing</i> Yu WANG, <i>Beijing</i> Marc WELLS, <i>London</i> Fangqian JIN, <i>Shanghai</i> Li SUN, <i>Xiamen</i>
15:45 - 18:45 STATE OF THE ART LECTURES	
Plenary Hall A Level 4	Session 01 Moderators: Necati ORMECI, <i>Istanbul</i> Xiaoyuan XU, <i>Beijing</i>
15:45 - 16:05	Recent Development and Future Prospect of Artificial Liver Support System Lanjuan LI, <i>Hangzhou</i>
16:05 - 16:25	Evolving Strategies in LDLT for HCC: Insights from Two Decades of Experience Chao-Long CHEN, <i>Kaohsiung</i>
16:25 - 16:45	Immunology and the Liver Fu-Sheng WANG, <i>Beijing</i>

28 MAR
FRI

Scientific Program

28 March | Friday

28 MAR
FRI

Session 02

Moderators: Jose D. SOLLANO, *Manila*
Enqiang LINGHU, *Beijing*

16:45 - 17:05

Portal Hypertension in Advanced Liver Disease

Shiv K. SARIN, *New Delhi*

17:05 - 17:25

Dynamic Shift of Etiologic Profiles of HCC in Japan and Asia Observed over Half a Century

Masao OMATA, *Kofu*

17:25 - 17:45

From Hepatitis to Liver Cancer

George K.K. LAU, *Hong Kong*

Session 03

Moderators: Osamu YOKOSUKA, *Chiba*
Xiaoguang DOU, *Shenyang*

17:45 - 18:05

Traditional and Modern Medicine in Liver Disease

Jidong JIA, *Beijing*

18:05 - 18:25

Public Health and Drug Development in Liver Disease

Jinlin HOU, *Guangzhou*

18:25 - 18:45

Ablation for Hepatocellular Carcinoma: Current Status and Future

Shuichiro SHIINA, *Tokyo*

13:15 - 14:45

CONCURRENT SESSION 01

Translation of Science into Hepatitis B Cure - Virological Perspective

Function Hall A
Level 1

Moderators: Jian SUN, *Guangzhou*
Yock Young DAN, *Singapore*

13:15 - 13:35

Silencing cccDNA Function and HBV Replication

Patrick KENNEDY, *London*

13:35 - 13:55

Blocking HDV/HBV Entry Through NTCP for Curative Therapy: Opportunities and Challenges

Wenhui LI, *Beijing*

13:55 - 14:15

Inhibitors of Viral Translation

Marc G. GHANY, *Bethesda*

14:15 - 14:35

Gene Editing Technologies and HBV DNA

Thomas TU, *Sydney*

14:35 - 14:45

Panel Discussion

14:45 - 15:00

Break

28 March | Friday

Scientific Program

13:15 - 14:45	CONCURRENT SESSION 02
	Genetic and Rare Liver Diseases
Function Hall B Level 1	Moderators: Huichun XING, <i>Beijing</i> Jinhui YANG, <i>Kunming</i>
13:15 - 13:35	Neonatal Cholestatic and Transplantation Qian LU, <i>Beijing</i>
13:35 - 13:55	Genetics and Rare Liver Diseases in Children Seema ALAM, <i>New Delhi</i>
13:55 - 14:15	Cholestasis Liver Diseases Jianshe WANG, <i>Shanghai</i>
14:15 - 14:35	Common and Unique Pathogenic Mechanisms of Pediatric Cholestatic Diseases Saul KARPEN, <i>Richmond</i>
14:35 - 14:45	Panel Discussion
14:45 - 15:00	Break
13:15 - 14:45	CONCURRENT SESSION 03
	Multidisciplinary Approach and Transplantation in HCC
Function Hall C Level 1	Moderators: Shiyun BAO, <i>Shenzhen</i> Canhong XIANG, <i>Beijing</i>
13:15 - 13:35	Radiotherapy Strategies for Unresectable HCC Yoshiyuki UENO, <i>Yamagata</i>
13:35 - 13:55	Surgical Treatments for Advanced Liver Malignant Tumors Kiyoshi HASEGAWA, <i>Tokyo</i>
13:55 - 14:15	Recent Development of Living Donor Transplantation in Asia Pacific Region Zhijun ZHU, <i>Beijing</i>
14:15 - 14:35	Current Guidelines of Liver Transplantation Jinzhen CAI, <i>Qingdao</i>
14:35 - 14:45	Panel Discussion
14:45 - 15:00	Break
13:15 - 14:45	CONCURRENT SESSION 04
	Hepatology in the Age of Artificial Intelligence (AI)
402 (A+B) Level 4	Moderators: Liqun WU, <i>Qingdao</i> Carmen C.L. WONG, <i>Hong Kong</i>
13:15 - 13:35	Artificial Intelligence Analysis of Non-Contrast CTs in HCC Screening Wai-Kay SETO, <i>Hong Kong</i>
13:35 - 13:55	Application of AI in MASH Feng LIU, <i>Beijing</i>
13:55 - 14:15	Machine Learning for the Prediction of HCC Terry C.F. YIP, <i>Hong Kong</i>

28 MAR
FRI

Scientific Program

28 March | Friday

14:15 - 14:35 **Application of AI in ACLF Prediction**
Nipun VERMA, *Chandigarh*

14:35 - 14:45 **Panel Discussion**

14:45 - 15:00 Break

13:15 - 15:45 AUTOIMMUNE LIVER DISEASE COURSE

Auditorium Level 4 Moderators: Jidong JIA, *Beijing*
Atsushi TANAKA, *Tokyo*

13:15 - 13:20 **Opening**
Atsushi TANAKA, *Tokyo*

13:20 - 13:35 **AIH - General (Epidemiology, Etiology, Tx)**
Sombat TREEPRASERTSUK, *Bangkok*

13:35 - 13:50 **AIH in HBV - Epidemic Area**
Ming-Ling CHANG, *Taoyuan*

13:50 - 14:05 **AIH - ALF & ACLF**
Soek-Siam TAN, *Kuala Lumpur*

14:05 - 14:20 **AIH - PBC Overlap**
Cumali EFE, *Sanliurfa*

14:05 - 14:30 **Q&A, Panel Discussion**

14:30 - 14:45 **PBC - Epidemiology in Asia-Pacific**
Sook-Hyang JEONG, *Seoul*

14:45 - 15:00 **PBC - Diagnosis and Treatment**
Xiong MA, *Shanghai*

15:00 - 15:15 **PBC - Patient Reported Outcome Measure**
Martin WELTMAN, *Penrith*

15:15 - 15:30 **Current Status of PSC and IgG4-SC**
Hiroyuki ISAYAMA, *Tokyo*

15:30 - 15:40 **Q&A, Panel Discussion**

15:40 - 15:45 **Closing**
Jidong JIA, *Beijing*

15:00 - 16:30 CONCURRENT SESSION 05 Translation of Science into Hepatitis B Cure - Immunological Perspective

Function Hall A Level 1 Moderators: Mengji LU, *Essen*
Yanyan YU, *Beijing*

15:00 - 15:20 **Intrahepatic Inflammatory Processes Triggered by HBV-Specific T Cells**
Peng HU, *Chongqing*

28 MAR
FRI

28 March | Friday

Scientific Program

15:20 - 15:40	Tissue T Cells Immunity and HBV Clearance Dongliang YANG, <i>Wuhan</i>
15:40 - 16:00	Neutralization of HBV Ulrike PROTZER, <i>Munich</i>
16:00 - 16:20	Therapeutic Vaccine in CHB Antonio BERTOLETTI, <i>Singapore</i>
16:20 - 16:30	Panel Discussion
16:30 - 16:45	Break

15:00 - 16:30 CONCURRENT SESSION 06 Drug Induced Liver Injury (DILI)

Function Hall B Level 1 Moderators: Lungen LU, *Shanghai*
Hongmei ZU, *Xining*

15:00 - 15:20	Etiology of Drug Induced Liver Disease Yimin MAO, <i>Shanghai</i>
15:20 - 15:40	Immunotherapy for Cancer and DILI Nelia HERNANDEZ, <i>Montevideo</i>
15:40 - 16:00	Characteristics of Drug-induced Liver Injury in Chronic Liver Disease Sombat TREEPRASERTSUK, <i>Bangkok</i>
16:00 - 16:20	Diagnosis and Management Yogesh K. CHAWLA, <i>Chandigarh</i>
16:20 - 16:30	Panel Discussion
16:30 - 16:45	Break

15:00 - 16:30 CONCURRENT SESSION 07 Etiology and Disease Burden of Liver Cancer

Function Hall C Level 1 Moderators: Osamu YOKOSUKA, *Chiba*
Zhiliang GAO, *Guangzhou*

15:00 - 15:20	HBV-Related Liver Cancer Yuemin NAN, <i>Shijiazhuang</i>
15:20 - 15:40	HCV-Related Liver Cancer Ming-Lung YU, <i>Kaohsiung</i>
15:40 - 16:00	MASH-Related Liver Cancer Daniel Q. HUANG, <i>Singapore</i>
16:00 - 16:20	ALD-Related Liver Cancer Mindie H. NGUYEN, <i>Palo Alto</i>
16:20 - 16:30	Panel Discussion
16:30 - 16:45	Break

28 MAR
FRI

Scientific Program

28 March | Friday

28 MAR FRI	15:00 - 16:30	CONCURRENT SESSION 08 Gut Microbiota and the Liver Health
	402 (A+B) Level 4	Moderators: Weize ZUO, <i>Shihezi</i> Fei SHI, <i>Shenzhen</i>
	15:00 - 15:20	Microbiome and the Liver Disease Progression Jasmohan S. BAJAJ, <i>Richmond</i>
	15:20 - 15:40	Gut Microbiome/Metabolites in MASLD and HCC Via Gut-Liver Axis Jun YU, <i>Hong Kong</i>
	15:40 - 16:00	Microbiome Makers: Prediction and Prevention Dong Joon KIM, <i>Chuncheon</i>
	16:00 - 16:20	Gut Microbiota in the Prevention and Treatment of Liver Disease Biaoyang LIN, <i>Hangzhou</i>
	16:20 - 16:30	Panel Discussion
	16:00 - 17:15	TRADITIONAL MEDICINE COURSE
	Auditorium Level 4	Moderators: Chunjun XU, <i>Beijing</i> Jingtao LI, <i>Xi'an</i>
	16:00 - 16:15	Traditional Chinese Medicine Improves Liver Fibrosis by Regulating Epigenetics Xiaojaoyang LI, <i>Beijing</i>
	16:15 - 16:30	Nepetin in Compound Phyllanthus Urinaria L. Inhibits the Growth and Metastasis of Hepatitis B-associated Hepatocellular Carcinoma Via HBx/HIF-1α/VEGFA Pathway Guangdong TONG, <i>Shenzhen</i>
	16:30 - 16:45	Traditional Chinese Medicine Treatment for Metabolic-Associated Fatty Liver Disease at Shuguang Hospital Xuehua SUN, <i>Shanghai</i>
	16:45 - 17:00	Traditional Approaches in Treating Liver Diseases Worldwide Amarsanaa JAZAG, <i>Ulaanbaatar</i>
	17:00 - 17:15	Panel Discussion
	16:00 - 17:00	APASL DIGITAL PATHOLOGY CONSENSUS 205 (A+B), Level 2
	16:45 - 17:45	APASL GUIDELINES 01
	Function Hall C Level 1	Moderators: Necati ORMECI, <i>Istanbul</i> Diana A. PAYAWAL, <i>Manila</i>
	16:45 - 17:15	Acute Variceal Bleed Consensus Cosmas R.A. LESMANA, <i>Jakarta</i>
	17:15 - 17:45	Consensus on ACLF Shiv K. SARIN, <i>New Delhi</i>

28 March | Friday

ORAL SESSION

13:15 - 14:15 ORAL SESSION 01

Liver Cancer Management 1

401
Level 4

Moderators: Jiming YANG, *Tianjin*
Shuai WANG, *Beijing*

- | | | |
|--------|---------------|---|
| OP0007 | 13:15 - 13:25 | Hepatocellular carcinoma in Armenia: Liquid biopsies and primary assessment of molecular alterations prevalence
Hasmik GHAZINYAN, <i>Yerevan</i> |
| OP0008 | 13:25 - 13:35 | Des-gamma-carboxy prothrombin: A crucial biomarker for predicting aggressive hepatocellular carcinoma in patients with normal alpha-fetoprotein
Zaigham ABBAS, <i>Karachi</i> |
| OP0009 | 13:35 - 13:45 | Targeted Therapy with GPC3-Loaded Exosomes: IR780-Based Thermotherapy and Lenvatinib Chemotherapy in Hepatocellular Carcinoma
Shenan HUANG, <i>Nanchang</i> |
| OP0010 | 13:45 - 13:55 | CXCL2 Potentiates Neutrophil-mediated Anti-tumor Immunity by Inhibiting Cholesterol Biosynthesis in Hepatocellular Carcinoma
Xin LIU, <i>Beijing</i> |
| OP0011 | 13:55 - 14:05 | A Multi-institutional Analysis of Risk Factors and Predictive Model for Distant Metastasis After Hepatic Resection for Hepatocellular Carcinoma
Tian YANG, <i>Shanghai</i> |
| OP0012 | 14:05 - 14:15 | HCC risk stratification for cirrhosis patients: integrating radiomics and deep learning CT signatures of liver and spleen into clinical model
Yaru SHI, <i>Guangzhou</i> |

13:15 - 14:15 ORAL SESSION 02

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 1

403
Level 4

Moderators: Peng HU, *Chongqing*
Biaoyang LIN, *Hangzhou*

- | | | |
|--------|---------------|--|
| OP0013 | 13:15 - 13:25 | East Asian Sub-Analysis of a Phase 2 Trial of the Glucagon and GLP-1 Receptor Dual Agonist Survodutide in People with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Vincent W.S. WONG, <i>Beijing</i> |
| OP0014 | 13:25 - 13:35 | Gremlin1 plays a pivotal role in the progression of liver fibrosis by modulating mitochondrial dysfunction and oxidative stress.
Yonghong GUO, <i>Shanghai</i> |
| OP0015 | 13:35 - 13:45 | Fatty liver exacerbates ischemia reperfusion injury by impairing hepatocyte Nrf2 activation and enhancing macrophage STING signaling
Haoran HU, <i>Nanjing</i> |

28 MAR
FRI

ORAL SESSION

28 March | Friday

OP0016	13:45 - 13:55	Exploring the mechanism of anti-MAFLD liver fibrosis effect of Astragalus formula based on network pharmacology with RNA-seq and experimental validation Junran YANG, <i>Shanghai</i>
OP0017	13:55 - 14:05	The incidence of depression is increasing in the population of MAFLD especially with liver fibrosis: Analysis of data from NHANES 2017-2020. Xiaohe LI, <i>Beijing</i>
OP0224	14:05 - 14:15	Prevalence and Associated Risk Factors of Metabolic dysfunction-associated fatty Liver Disease in the Elderly People with type 2 diabetes Jing ZHANG, <i>Beijing</i>

13:15 - 14:15 ORAL SESSION 03 Management of Advanced Chronic Liver Disease (ACLD) 1

405
Level 4 Moderators: Yuanwen CHEN, *Shanghai*
Yajie WANG, *Beijing*

OP0019	13:15 - 13:25	Very low dose continuous infusions of terlipressin is not inferior to intermittent infusion of terlipressin for the control of acute variceal bleeding in patients with portal hypertension. Mohammed Forhad ABEDIN, <i>Comilla</i>
OP0020	13:25 - 13:35	A hepatology home-based care program for patients with cirrhosis improves readmissions and mortality. Leya NEDUMANNIL, <i>Melbourne</i>
OP0021	13:35 - 13:45	Arginine glutamate injection for the treatment of mild hepatic encephalopathy: an openlabel, randomized, controlled, non-inferiority trial Haibo ZHANG, <i>Beijing</i>
OP0022	13:45 - 13:55	Phased prediction scores of clinical multiple outcomes in Acute-on-Chronic Liver Failure (ACLF) patients: A prospective multicenter study Wenling WANG, <i>Beijing</i>
OP0023	13:55 - 14:05	Long-term prognosis and survival benefits of liver transplantation in acute-on-chronic liver failure: results of a cohort study Peng LI, <i>Hangzhou</i>
OP0024	14:05 - 14:15	Unveiling the continuum of acute-on-chronic liver failure: phenotypic insights into severity and outcomes Qian ZHANG, <i>Tianjin</i>

13:15 - 14:15 ORAL SESSION 04 Hepatitis C 1

406
Level 4 Moderators: Chuanlong ZHU, *Nanjing*
Sujun ZHENG, *Beijing*

OP0025	13:15 - 13:25	Efficacy and safety of cobopasvir plus sofosbuvir treatment for Chinese patients with chronic HCV infection: a large-scale, multicenter retrospective study Fangfang WEI, <i>Maoming</i>
--------	---------------	--

28 MAR
FRI

28 March | Friday

ORAL SESSION

OP0026	13:25 - 13:35	Coblopassvir and sofosbuvir treatment for Chinese patients with chronic HCV infection is safe and efficacious: a real-world study Aidi MA, <i>Lanzhou</i>
OP0027	13:35 - 13:45	Study of the Level of Proinflammatory γ-INF and Anti-inflammatory IL-4 in the Oral Fluid of HCV-Infected Patients Before and After Complex Treatment Vahe Yurii AZATYAN, <i>Yerevan</i>
OP0028	13:45 - 13:55	“Hepatitis Free Mongolia, Phase 2” - A provincial-level HCV Elimination Model in Rural Mongolia. Meredith POTTS, <i>Arizona</i>
OP0029	13:55 - 14:05	Safety, Tolerability, and Outcomes of Sofosbuvir/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: interim results from the STORC study Stacey SCHERBAKOVSKY, <i>California</i>
OP0030	14:05 - 14:15	Glecaprevir/Pibrentasvir in HIV/HCV-coinfected patients treated with bicitgravir Aleksandra BERKAN-KAWINSKA, <i>Lodz</i>

13:15 - 14:15 ORAL SESSION 05 Hepatitis B and Delta 1

407
Level 4

Moderators: Shaoyang WANG, *Fuzhou*
Yanhang GAO, *Changchun*

OP0212	13:15 - 13:25	FIB-5 and/or FIB-4 index for hepatic fibrosis evaluation in chronic hepatitis B. Mohamed ABDEL-SAMIEE, <i>Cairo</i>
OP0032	13:25 - 13:35	Relationship between Metabolic dysfunction-Associated Steatotic Liver Disease and Bone Mineral Density in Post-menopausal Women in Primary Healthcare Center Minseong KIM, <i>Incheon</i>
OP0033	13:35 - 13:45	The real life use of bulevirtide for treatment of chronic HDV infection: an interim analysis in the PITER cohort Loreta KONDILI, <i>Rome</i>
OP0034	13:45 - 13:55	Discontinuation of NUC Therapy In Non-Cirrhotic Chronic Hepatitis B Patients Shrey BHATT, <i>New Delhi</i>
OP0035	13:55 - 14:05	Effect of adjusting nucleos(t)ide analog antiviral treatment on the outcome of patients with low-level viremia associated with HBV Xuyang LI, <i>Beijing</i>
OP0036	14:05 - 14:15	30% of Inactive HBsAg Carriers Achieved Clinical Cure at 48 Weeks with Pegylated Interferon Alpha-2b Therapy: A Multicenter Real-World Study (STARHB Project in China)- 2.5 years Data Update Shan REN, <i>Beijing</i>

28 MAR
FRI

ORAL SESSION

28 March | Friday

14:15 - 15:15 ORAL SESSION 06

Liver Cancer Management 2

401
Level 4

Moderators: Yuan HUANG, *Beijing*
Yu WANG, *BFH Beijing*

- | | | |
|--------|---------------|---|
| OP0037 | 14:15 - 14:25 | THE IMPACT OF METFORMIN ON THE OVERALL SURVIVAL OF DIABETIC PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA ON IMMUNOTHERAPY: A META- ANALYSIS
Regina DIMACULANGAN, <i>Metro Manila</i> |
| OP0038 | 14:25 - 14:35 | CHEK1 suppresses hepatocellular carcinoma progression by modulating reprogramming of tumor-associated macrophages
Yanqiu LI, <i>Beijing</i> |
| OP0039 | 14:35 - 14:45 | Revisiting AASLD Guidelines: A Real-world Analysis of Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Patients
Yue HUANG, <i>Guiyang</i> |
| OP0041 | 14:45 - 14:55 | Pathological Study of the Tumor Microenvironment After Neoadjuvant Therapy in Hepatocellular Carcinoma: Why Does TACE Combined with Anti-Angiogenics and Immunotherapy Outperform TACE Alone?
Xintao HE, <i>Nanjing</i> |
| OP0042 | 14:55 - 15:05 | Classifications and Outcomes of Local Tumor Progression of Hepatocellular Carcinoma after Thermal Ablation: A Longitudinal Multicenter Study
Fangying Fan, <i>Beijing</i> |

14:15 - 15:15 ORAL SESSION 07

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 2

403
Level 4

Moderators: Xinyan ZHAO, *Beijing*
Ruyu LIU, *Beijing*

- | | | |
|--------|---------------|--|
| OP0043 | 14:15 - 14:25 | LIPID PROFILE AND LIVER STEATOSIS IN PATIENTS WITH ARTERIAL HYPERTENSION .
Aliya KONYSBEKOVA, <i>Astana</i> |
| OP0044 | 14:25 - 14:35 | Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population
Maurice MICHELI, <i>Mainz</i> |
| OP0045 | 14:35 - 14:45 | Safety of statins in Asian cohort with biopsy proven MASLD
Wei Lun LIOU, <i>Singapore</i> |
| OP0046 | 14:45 - 14:55 | Changing Landscape of Steatotic Liver Diseases and Liver Fibrosis in the United States During the COVID-19 Pandemic
Judong YANG, <i>Los Angeles</i> |
| OP0047 | 14:55 - 15:05 | Comparison Of Renal Impairment And Liver Fibrosis Between Diabetic And Non Diabetic Non-Alcoholic Fatty Liver Disease Patients
Kishore S, <i>New Delhi</i> |
| OP0048 | 15:05 - 15:15 | The role of the small intestine bacterial overgrowth in patients with metabolic dysfunction-associated fatty liver disease
Olga TARASOVA, <i>Moscow</i> |

28 MAR
FRI

28 March | Friday

ORAL SESSION

14:15 - 15:15 ORAL SESSION 08

Management of Advanced Chronic Liver Disease (ACLD) 2

405

Level 4

Moderator: Xiaobo LU, *Urumqi*

- OP0049 14:15 - 14:25 **Development and Validation of a Predictive Machine Learning Model for Short-Term Mortality in ICU Patients with Acute-on-Chronic Liver Failure**
Yeehui YEO, *Los Angeles*
- OP0050 14:25 - 14:35 **DPMAS therapy in acute-on-chronic liver failure patients: a prospective, multicenter and cluster-controlled study (PADSTONE Study)**
Beiling LI, *Guangzhou*
- OP0051 14:35 - 14:45 **Organ Failure-Based Clinical Classification at Onset of Acute-on-Chronic Liver Failure: A Prospective Multicenter Cohort Study**
Yu WANG, *BFH Beijing*
- OP0052 14:45 - 14:55 **Plasma Interleukin-33 as a Novel Diagnostic Marker for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Prospective Study**
Lanyue HUANG, *Wuhan*
- OP0053 14:55 - 15:05 **Dynamic Risk Assessment of Hepatic Encephalopathy: A Novel Network Approach**
Zixing WANG, *Beijing*
- OP0054 15:05 - 15:15 **Efficacy of Granulocyte Colony-stimulating Factor in hepatitis B virus-associated acute-on-chronic liver failure patients: A multicenter study**
Jinhua HU, *Beijing*

14:15 - 15:15 ORAL SESSION 09

Hepatitis C 2

406

Level 4

Moderators: Bimin LI, *Nanchang*
Feng LIU, *Jinan*

- OP0055 14:15 - 14:25 **Assessing Liver Fibrosis Regression Using Simple Blood Tests in Hepatitis C Virus (HCV) Patients Treated with Direct-Acting Antiviral Agents**
Hamza BENAZZOUZ, *Rabat*
- OP0056 14:25 - 14:35 **The study of the risk of long-term adverse events in patients with hepatitis C after treatment with Direct-acting antivirals**
Jing LIANG, *Tianjin*
- OP0057 14:35 - 14:45 **Efficacy and Prognosis of Direct-Acting Antiviral Therapy in Chronic Hepatitis C-Related Decompensated Cirrhosis**
Jianping LI, *Guangzhou*
- OP0058 14:45 - 14:55 **Clinical Characteristics of Patients with Chronic Hepatitis C and Genotype 3 Infection in Northwest China: a Multicenter Cross-sectional Study**
Yishan LIU, *Xi'an*

28 MAR
FRI

ORAL SESSION

28 March | Friday

- | | | |
|--------|---------------|---|
| OP0059 | 14:55 - 15:05 | 12-week treatment of sofosbuvir/velpatasvir plus ribavirin and sofosbuvir/velpatasvir/voxilaprevir for HCV patients with GT3b and compensated cirrhosis: a multicenter, randomized, open-label study in China
Rui HUANG, <i>Beijing</i> |
| OP0060 | 15:05 - 15:15 | Safety and Efficacy of Direct-acting Antiviral Agents Therapy in Patients with Liver Failure Complicated by HCV Infection
Feilan Yang, <i>Changsha</i> |

14:15 - 15:15 ORAL SESSION 10 Hepatitis B and Delta 2

407 Level 4 Moderators: Li CHEN, *Shanghai*
Min CONG, *Beijing*

- | | | |
|--------|---------------|--|
| OP0061 | 14:15 - 14:25 | Machine learning-based model used for predicting the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A retrospective study
Feixiang XIONG, <i>Beijing</i> |
| OP0062 | 14:25 - 14:35 | The novel and potent sodium/taurocholate co-transporting polypeptide inhibitor JH-B10 blocks hepatitis B virus entry
Juan CHEN, <i>Chongqing</i> |
| OP0063 | 14:35 - 14:45 | Estimation of Serum Antioxidant Activity with Liver Function tests in patients with Hepatitis B
Saira BALOCH, <i>Jamshoro</i> |
| OP0064 | 14:45 - 14:55 | A nationwide seroepidemiology study of hepatitis D virus infection in South Korea
Sungwon LEE, <i>Bucheon</i> |
| OP0065 | 14:55 - 15:05 | High Prevalence of Occult Hepatitis B Infection in Hepatitis C Virus-Infected Patients With Hepatocellular Carcinoma From Armenia
Hasmik GHAZINYAN, <i>Yerevan</i> |
| OP0066 | 15:05 - 15:15 | Comparative Study of treatment of HBV ACLF Patients by tenofovir without albumin infusion and tenofovir with albumin infusion
Sharker Mohammad SHAHADAT, <i>Dhaka</i> |

15:30 - 16:30 ORAL SESSION 11 Liver Cancer Management 3

401 Level 4 Moderators: Xuezhang DUAN, *Beijing*
Yu WANG, *BFC Beijing*

- | | | |
|--------|---------------|---|
| OP0067 | 15:30 - 15:40 | An ultrasound-based interpretable machine learning model for the classification of small hepatocellular carcinoma
Fangying FAN, <i>Beijing</i> |
| OP0068 | 15:40 - 15:50 | Efficacy and Safety of Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Retrospective, Multicenter Cohort Study
JingKun CHEN, <i>Nanning</i> |

28 MAR
FRI

28 March | Friday

ORAL SESSION

OP0069	15:50 - 16:00	The Impact and Mechanisms of Neurofibromin 1 (NF1) on the Progression of Intrahepatic Cholangiocarcinoma Zhengfeng XUAN, <i>Nanning</i>
OP0070	16:00 - 16:10	Impact of Immune-Related Adverse Events on Survival in the Immunotherapy of Advanced Hepatocellular Carcinoma Nan ZHANG, <i>Beijing</i>
OP0071	16:10 - 16:20	Efficacy and safety of pembrolizumab and lenvatinib in combination with GEMOX via different administration routes (HAIC vs intravenous) in advanced intrahepatic cholangiocarcinoma: a retrospective analysis of real-world evidence Hongli YU, <i>Beijing</i>
OP0072	16:20 - 16:30	Retrospective Analysis of Efficacy Differences Between Lenvatinib and Sorafenib in Patients with Mid-to-Late Stage Hepatocellular Carcinoma Complicated by Diabetes Jiaqi LIU, <i>Beijing</i>

15:30 - 16:30 ORAL SESSION 12 Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 3

403
Level 4 Moderator: Shuai WANG, *Beijing*

OP0073	15:30 - 15:40	Pruritus and fatigue in patients with metabolic dysfunction associated steatotic liver disease (MASLD): Data from the Global NASH/MASH Registry Zobair YOUNOSSI, <i>Washington DC</i>
OP0074	15:40 - 15:50	Effectiveness of Lifestyle Change and Silymarin in Normalizing and Reducing Liver Enzyme Levels in Patients with NAFLD and Metabolic Syndrome: focus on body weight loss Sakkarin CHIRAPONGSATHORN, <i>Bangkok</i>
OP0075	15:50 - 16:00	Cardiovascular disease and age-related Non-alcoholic fatty liver disease in Mongolia Byambatsetseg TOGTUUNBAYAR, <i>Ulan Bator</i>
OP0076	16:00 - 16:10	Real-World Evaluation of Therapy with Saroglitazar in MASLD-Associated Compensated Advanced Chronic Liver Disease (cACLD) : An Open-Label, Single-Center Study Sujit CHAUDHURI, <i>Kolkata</i>
OP0077	16:10 - 16:20	ASSESSMENT OF FIBROSIS CHANGE RATES IN MASH DRUG-TRIAL PLACEBO-ARM VIA PATHOLOGIST READINGS AND qFIBROSIS VALUES Kutbuddin AKBARY, <i>Singapore</i>
OP0078	16:20 - 16:30	AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study Dean TAI, <i>Singapore</i>

28 MAR
FRI

ORAL SESSION

28 March | Friday

15:30 - 16:30 ORAL SESSION 13

Management of Advanced Chronic Liver Disease (ACLD) 3

405

Level 4

Moderator: Sujun ZHENG, *Beijing*

- | | | |
|--------|---------------|--|
| OP0079 | 15:30 - 15:40 | Association between triglyceride-glucose index and short-term mortality among patients with acute-on-chronic liver failure
Qiao ZHANG, <i>Xi'an</i> |
| OP0080 | 15:40 - 15:50 | High incidence of liver-related events and hospitalizations in patients with viral- and alcohol-associated cirrhosis and grade 1 ascites
Haiyu WANG, <i>Guangzhou</i> |
| OP0081 | 15:50 - 16:00 | Circulating cell-free mitochondrial DNA as a prognostic biomarker in patients with HBV-related acute-on-chronic liver failure
Qiankun HU, <i>Shanghai</i> |
| OP0082 | 16:00 - 16:10 | Optimization of timeframe criteria to define recompensation and stable recompensation in patients with HBV-related cirrhosis
Zhiying HE, <i>Beijing</i> |
| OP0083 | 16:10 - 16:20 | Indocyanine green clearance test via pulse dye densitometry for portal hypertension diagnosis in compensated advanced chronic liver disease patients
Miaoxia LIU, <i>Guangzhou</i> |
| OP0084 | 16:20 - 16:30 | A Novel Non-Invasive Diagnostic Model for High-Risk Varices in Cirrhosis: A Multicenter Retrospective and Prospective Study
Junliang FU, <i>Beijing</i> |

15:30 - 16:30 ORAL SESSION 14

Hepatitis C 3

406

Level 4

Moderators: Shaoyang WANG, *Fuzhou*
Yuanyuan KONG, *Beijing*

- | | | |
|--------|---------------|---|
| OP0085 | 15:30 - 15:40 | A multi-center, prospective, single-arm trial followed by an 12/48 week observational clinical trial to evaluate the safety and efficacy of SOF/VEL treatment and prophylactic use of TAF in patients with GT1-6 HCV/HBV coinfection
Ning LIN, <i>Beijing</i> |
| OP0086 | 15:40 - 15:50 | Exploration of Strategies for Conducting Universal Hepatitis C Virus (HCV) Screening among the General Population in China
Qiran ZHANG, <i>Shanghai</i> |
| OP0087 | 15:50 - 16:00 | Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial
Ye ZHANG, <i>Nanjing</i> |
| OP0088 | 16:00 - 16:10 | Peer-to-peer Education Improves Screening and Treatment among Family Members of patients with HCV mono-infection or HIV/HCV co-infection
Yang LUO, <i>Yuxi</i> |

28 March | Friday

ORAL SESSION

- OP0089 16:10 - 16:20 **Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a salvage therapy for chronic hepatitis C patients with failed previous direct-acting antivirals treatment**
Jie XIA, *Chongqing*
- OP0090 16:20 - 16:30 **Evaluation of blood droplet volumes on the Cobas Plasma Separation Card for HCV RNA testing in resource-limited settings**
Benjamin LA BROT, *Karachi*

15:30 - 16:30 ORAL SESSION 15 Hepatitis B and Delta 3

407
Level 4 Moderators: Xin ZHENG, *Wuhan*
Xiangmei CHEN, *Beijing*

- OP0091 15:30 - 15:40 **Characterisation of the Relationship Between HBsAg Loss and ALT Elevation During Bepirovirsen Treatment in Patients With Chronic Hepatitis B**
LinMing SHEN, *Waltham, MA*
- OP0092 15:40 - 15:50 **Evaluating Persistence in Patients with Chronic Hepatitis B (CHB) Infection Treated with Long-term Nucleos(t)ide Analogues (NAs) in Japan**
Shinya KAWAMATSU, *Tokyo*
- OP0093 15:50 - 16:00 **Clinical aspects of Hepatitis Delta - a retrospective analysis of patients' data from 2004 to 2024**
Gulnara AGHAYEVA, *Baku*
- OP0094 16:00 - 16:10 **Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg(-) Subjects with Chronic Hepatitis B Virus Infection**
Ed GANE, *Auckland*
- OP0095 16:10 - 16:20 **Predictors of alanine aminotransferase (ALT) flares in patients initiating treatment for chronic hepatitis B virus (HBV) infection: A Hong Kong-based electronic health record (EHR) database study**
Myriam DRYSDALE, *London*
- OP0096 16:20 - 16:30 **Impact of Hepatitis B Surface Antigen (HBsAg) Loss on Long-term Clinical Outcomes in Hong Kong Patients with Chronic Hepatitis B Virus (HBV) Infection: A Retrospective Cohort Study**
Myriam DRYSDALE, *London*

16:30 - 17:30 ORAL SESSION 16 Liver Cancer Management 4

401
Level 4 Moderators: Zhiyun YANG, *Beijing*
Minghui LI, *Beijing*

- OP0097 16:30 - 16:40 **Investigation of the ceRNA mechanism by which Qizhu Anticancer Prescription enhances the expression of senescence-related genes in hepatocellular cancer cells**
Rui HU, *Shenzhen*

28 MAR
FRI

ORAL SESSION

28 March | Friday

OP0098	16:40 - 16:50	Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy for Systemic Chemotherapy Refractory Pancreatic Cancer with Liver Metastases Yaqin WANG, <i>Beijing</i>
OP0099	16:50 - 17:00	Oncolytic virus M1-c6v1 combined with camrelizumab and apatinib in patients with advanced hepatocellular carcinoma: A phase 2 open-label trial evaluating safety, and efficacy Chan XIE, <i>Guangzhou</i>
OP0100	17:00 - 17:10	The Role of Non-Invasive Scores and Treatment Modalities in Hepatocellular Carcinoma: A Single-Center Experience Meral Akdoğan KAYHAN, <i>ANKARA</i>
OP0101	17:10 - 17:20	A multicenter case–controlled study on laparoscopic hepatectomy versus microwave ablation as first-line therapy for 3–5 cm hepatocellular carcinoma in patients aged 60 and older Zhen WANG, <i>Beijing</i>
OP0102	17:20 - 17:30	Efficacy and safety of tremelimumab plus durvalumab in participants from mainland China with unresectable hepatocellular carcinoma: extension cohort of the randomized, open-label, multicenter, global, Phase 3 HIMALAYA study Zhenggang REN, <i>Shanghai</i>

16:30 - 17:30 ORAL SESSION 17 Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 4

403 Level 4		Moderators: Yali LIU, <i>Beijing</i> Li CHEN, <i>Fuzhou</i>
OP0103	16:30 - 16:40	Prevotella copri-produced 5-aminopentanoic acid promotes pediatric metabolic dysfunction-associated steatotic liver disease Lu JIANG, <i>Shanghai</i>
OP0104	16:40 - 16:50	Performance of ChatGPT4.0 in predicting advanced liver fibrosis in patients with metabolic dysfunction-associated steatotic liver diseases: a comparative analysis with conventional diagnostic tools Tongluk TEERASARNTIPAN, <i>Bangkok</i>
OP0105	16:50 - 17:00	Regulatory Impact of ATG-125 on Fatty Acid Oxidation and Farnesoid X Receptor Signaling Pathways, as well as Mitochondria Biogenesis Contributing to Metabolic Dysfunction-Associated Fatty Liver Disease in High-Fat and High-Sucrose Diet Mice Tzung Yan LEE, <i>Taoyuan</i>
OP0106	17:00 - 17:10	Automated MRI liver segmentation to accurately quantify hepatic steatosis in MASLD Jing ZHANG, <i>Beijing</i>
OP0107	17:10 - 17:20	Epigenetic regulation of H3K27ac-Mediated Gene Expression Reveals TDO2 as a Pivotal Therapeutic target in Metabolic Associated Steatohepatitis Liver Disease Yunshu TANG, <i>Hefei</i>
OP0108	17:20 - 17:30	Long-term Prognosis of Chronic Hepatitis B Patients with Nonalcoholic Steatohepatitis from A Multicenter RCT Wenjing WANG, <i>Beijing</i>

28 MAR
FRI

28 March | Friday

ORAL SESSION

16:30 - 17:30 ORAL SESSION 18

Management of Advanced Chronic Liver Disease (ACLD) 4

405

Level 4

Moderators: Jinzhen CAI, *Qingdao*
Ruyu LIU, *Beijing*

- | | | |
|--------|---------------|---|
| OP0109 | 16:30 - 16:40 | Direct Oral Anticoagulants for Budd-Chiari Syndrome Following Percutaneous Angioplasty in A Chinese Cohort
Chengjian WU, <i>Chengdu</i> |
| OP0110 | 16:40 - 16:50 | Intrahepatic immune cell profiling in advanced chronic liver disease: unraveling etiology-specific patterns with single-cell sequencing analysis
Jing LIU, <i>Wuhan</i> |
| OP0111 | 16:50 - 17:00 | National survey of awareness of human serum albumin indications and actual practice in decompensated cirrhosis among physicians in China
Chenxi ZHANG, <i>Shanghai</i> |
| OP0112 | 17:00 - 17:10 | Study on the indications and prognosis of glucocorticoids in patients with acute-on-chronic liver failure
Jiaxuan ZHOU, <i>Dalian</i> |
| OP0113 | 17:10 - 17:20 | Development of a Novel Prognostic Model for Evaluating Survival Outcomes in Patients with Acute-on-Chronic Liver Failure
Wende LI, <i>Beijing</i> |
| OP0114 | 17:20 - 17:30 | PLASMA EXCHNAGE IN ACLF ALCOHOLIC HEPATITIS PATIENTS WITH mDF&gt;90 improves 28-day survival but poor 90-day survival.
Vinod ARORA, <i>New Delhi</i> |

16:30 - 17:30 ORAL SESSION 19

Public Health 1

406

Level 4

Moderators: Min CONG, *Beijing*
Chuanlong ZHU, *Nanjing*

- | | | |
|--------|---------------|--|
| OP0115 | 16:30 - 16:40 | The Fujian Mobile Application based HBV Screening Program: Increased Linkage to Care Through Technology?
Lai WEI, <i>Beijing</i> |
| OP0116 | 16:40 - 16:50 | The Guangdong HBV Screening Program: A Template for China?
Lai WEI, <i>Beijing</i> |
| OP0117 | 16:50 - 17:00 | The cost-effectiveness of albumin in the management of hepatorenal syndrome in patients hospitalized for decompensated cirrhosis in urban China
Cristina COLL-ORTEGA, <i>Barcelona</i> |
| OP0118 | 17:00 - 17:10 | Genotype distribution, clinical manifestations, therapy and molecular genetic peculiarities of virus-related liver diseases in Mongolian population
Oidov BAATARKHUU, <i>Ulaanbaatar</i> |

28 MAR
FRI

ORAL SESSION

28 March | Friday

- OP0119 17:10 - 17:20 **Clinical Profile and Patient Reported Outcomes (PROs) in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Patients Enrolled in the Global NASH/MASH Registry from Asian Countries**
Zobair M Younossi, *Washington, DC*
- OP0120 17:20 - 17:30 **Human albumin uses in cirrhosis complications in China: a national questionnaire survey**
Zhan ZENG, *Beijing*

16:30 - 17:30 ORAL SESSION 20 Hepatitis B and Delta 4

407
Level 4 Moderators: Feng LIU, *Jinan*
Bimin LI, *Nanchang*

- OP0121 16:30 - 16:40 **V-001: a novel hepatitis B antiviral drug that regulates HBV DNA, surface and e antigen by activating the PI3K-AKT-mTOR/4EBP1 axis**
Xiaoquan LIU, *Guangzhou*
- OP0122 16:40 - 16:50 **HBx-mediated Epigenetic Reprogramming through the ncBAF Complex to Promote HBV cccDNA Transcription**
Xiaoxue YUAN, *Beijing*
- OP0123 16:50 - 17:00 **The Mechanism and Application of Regulating Hepatitis B Virus Replication by ACE-tRNA.**
Xingwen YANG, *Beijing*
- OP0124 17:00 - 17:10 **SHBs mitigates sorafenib-induced apoptosis in hepatocellular carcinoma via activation of RAF1/MEK/ERK signaling pathway**
Shuxiang WU, *Fuzhou*
- OP0125 17:10 - 17:20 **Rapid hepatitis B surface antigen reduction: results from a phase Ib study evaluating multiple ascending doses of HT-102, a neutralizing antibody against HBsAg in chronic hepatitis B patients**
Lungen LU, *Shanghai*
- OP0126 17:20 - 17:30 **Predictors of functional cure in pediatric chronic hepatitis B**
Lin CHEN, *Beijing*

28 MAR
FRI

Scientific Program

29 March 2025

Saturday

Scientific Program

29 March | Saturday

08:00 - 08:48		LATER BREAKER 01
Plenary Hall A Level 4		Moderators: Manoj K. SHARMA, <i>New Delhi</i> Jie LI, <i>Beijing</i>
08:00 - 08:12	C1ORF131 a Novel Target to Enhance Liver Regeneration and Protect Against Chronic Liver Disease Torsten WUESTEFELD, <i>Singapore</i>	
08:12 - 08:24	Association and Cumulative Incidence of Renal Graft Dysfunction Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Single-Center, Single-Arm Retrospective Cohort Study Airene Pre TENEDERO, <i>Manila</i>	
08:24 - 08:36	Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma: Interim Analysis of an Open-label, Multi-center Phase IIIb Study (TREMENDOUS Study) Huichuan SUN, <i>Shanghai</i>	
08:36 - 08:48	The Efficacy and Safety of Seladelpar in the Asian Subpopulation of Patients With Primary Biliary Cholangitis: Results From the RESPONSE and ASSURE Studies Yoon Jun KIM, <i>Seoul</i>	
08:48 - 09:00	Break	
08:00 - 09:00		WOMEN LEADERSHIP IN HEPATOLOGY
Auditorium Level 4		Moderator: Diana A. PAYAWAL, <i>Manila</i>
08:00 - 08:05	Opening Remarks Lai WEI, <i>Beijing</i>	
08:05 - 08:20	Women's Leadership in Hepatology-Breaking Barriers Diana A. PAYAWAL, <i>Manila</i> Key Topics: <ul style="list-style-type: none"> • Current Landscape: Women in Hepatology Leadership Roles • Barriers to Research Funding, Academic Promotions, and Clinical Leadership • Strategies for Empowering the Next Generation: Mentorship, Networking, and Advocacy 	
08:20 - 08:35	Scientific Insights-Sex-Specific Differences in Liver Disease Hong YOU, <i>Beijing</i> <ul style="list-style-type: none"> • Impact of Sex Hormones on Liver Disease Progression (HBV, MAFLD, ALD, AIH, PBC) • Unique Challenges in Managing Hepatology in Pregnancy 	
08:35 - 08:55	Panel Discussion Moderator: Jie LI, <i>Beijing</i> <ul style="list-style-type: none"> • How to Increase Women's Representation in Hepatology Research and Clinical Leadership • Future Directions for the Women in Hepatology Committee 	
08:55 - 09:00	Closing Remarks Masao OMATA, <i>Kofu</i> Shiv K. SARIN, <i>New Delhi</i>	

29 MAR
SAT

29 March | Saturday

Scientific Program

08:00 - 09:00	MORNING SESSION 01
401 Level 4	Moderator: Huiguo DING, <i>Beijing</i>
08:00 - 08:30	Treat All Strategy in CHB Management Mario G. PESSOA, <i>Sydney</i>
08:30 - 09:00	Hepatitis B Management Ian H. CUA, <i>Manila</i>
08:00 - 09:00	MORNING SESSION 02
403 Level 4	Moderator: Jun LI, <i>Hangzhou</i>
08:00 - 08:30	Lessons from Failure: Setbacks and Unexpected Turnarounds in Early Clinical Trials of Novel Anti-HBV Drug Candidates Junqi NIU, <i>Changchun</i>
08:30 - 09:00	From Pre-Clinical to Clinical: Phase 1 Study of HBV Edward J. GANE, <i>Auckland</i>
08:00 - 09:00	MORNING SESSION 03
405 Level 4	Moderator: Yongjian ZHOU, <i>Guangzhou</i>
08:00 - 08:30	Porto-Sinusoidal Vascular Disorder: New Naming of Old Disease Yongfeng YANG, <i>Nanjing</i>
08:30 - 09:00	Role of Liver Sinusoidal Endothelial Cells in Chronic Liver Disease and Portal Hypertension Jordi GRACIA-SANCHO, <i>Barcelona</i>
08:00 - 09:00	MORNING SESSION 04
406 Level 4	Moderator: Xiangmei CHEN, <i>Beijing</i>
08:00 - 08:30	New Initiatives to Increase Hepatitis B Screening and Treatment Samuel SO, <i>Palo Alto</i>
08:30 - 09:00	HBV-Specific Immunity and Their Applications in the Functional Cure Zheng ZHANG, <i>Shenzhen</i>
08:00 - 09:00	MORNING SESSION 05
407 Level 4	Moderator: Lei WANG, <i>Jinan</i>
08:00 - 08:30	Autoimmune Liver Disease Ying HAN, <i>Xi'an</i>
08:30 - 09:00	Diagnosis and Treatment of Immune Related Liver Injury Zhili WEN, <i>Nanchang</i>

29 MAR
SAT

Scientific Program

29 March | Saturday

08:30 - 16:45 APASL ACLF RESEARCH CONSORTIUM 205(A+B), Level 2

09:00 - 10:30 PLENARY SESSION 01

Plenary Hall A
Level 4

Moderators: Zujiang YU, *Zhengzhou*
Yingren ZHAO, *Xi'an*

- 09:00 - 09:15 **Differential Impacts of Age and Sex on Diagnostic Rates and Incidences of Hepatic Events in Patients with Chronic Viral Hepatitis**
Grace WONG, Hong Kong
- 09:15 - 09:30 **Readily Available Indices of Liver Fibrosis and Insulin Resistance Associated With Cancer and Cardiovascular Disease Outcomes**
Xuehong ZHANG, New Heaven
- 09:30 - 09:45 **Novel MAF6 Risk Score Outperforms Non-Invasive Scores for Early MAFLD Detection – A Study of 33,255 Residents from India's Capital City**
Kanica KAUSHAL, New Delhi
- 09:45 - 10:00 **Prognostic Value of Polymeric Immunoglobulin Receptor in Patients with Primary Biliary Cholangitis**
Faling WU, Wenzhou
- 10:00 - 10:15 **Single Cell RNA Sequencing Reveals Intrahepatic and Peripheral Immune Landscapes Related to Autoimmune Hepatitis Patients**
Xinghuan FU, Beijing
- 10:15 - 10:30 **Improved Ursodeoxycholic Acid Response with Corticosteroid in Primary Biliary Cholangitis with Moderate-to-Severe Interface Hepatitis**
Yulong SHANG, Xi'an

09:15 - 10:45 MULTIDISCIPLINARY FORUM Across Disciplines and Beyond Borders

Auditorium
Level 4

Moderator: Huiying RAO, *Beijing*

09:15 - 09:45 SESSION 01 Establishing a Multidisciplinary Team

Hospital Management Perspectives: Implementation of a Multidisciplinary Team for Liver Disease
Masao OMATA, Kofu

Liver University: Translational Research and Multidisciplinary Patient Care for Liver and Hepatobiliary Diseases
Shiv K. SARIN, New Delhi

Multidisciplinary Collaboration for Patient Selection and Management in Liver Transplantation
Chao-Long CHEN, Kaohsiung

From Molecular Virology to Policy Making: The Role of PUHI, CDC and CFHPC in Liver Disease
Yu WANG, Beijing

29 MAR
SAT

29 March | Saturday

Scientific Program

Pathologist in Liver Disease: Interdisciplinary Team to Unravel the Molecular and Cellular Mechanisms of Liver Cancer and Hepatitis
Irene O.L. NG, *Hong Kong*

09:45 - 10:15

SESSION 02
How to Achieve and Facilitate Multidisciplinary Collaboration

Clinical Researcher: From Hepatitis B to Hepatitis C and Liver Cancer
George K.K. LAU, *Hong Kong*

Multidisciplinary Approaches to Liver Fibrosis
Lungen LU, *Shanghai*

Radiation Therapy and Multidisciplinary Approach to Liver Cancer
Jinsil SEONG, *Seoul*

Multi-omics and Translational Research in Precision Medicine and Surgical Liver Oncology
Pierce K.H. CHOW, *Singapore*

Organization and Conduction of Multidisciplinary Collaboration
Lai WEI, *Beijing*

10:15 - 10:45

SESSION 03
The Role in Multidisciplinary Collaboration

Translating Statistics and Data for the Communication Between Medical Experts and the Public
Po-Lin CHAN, *WHO*

Diverse Roles of Nurse in the Holistic Care and Management of Patients
Fengli GAO, *Beijing*

Unity in Diversity: Gastroenterologist and Hepatologist
Jose D. SOLLANO, *Manila*

The Role of Physician in Surgical and Interventional Procedures
Rino A. GANI, *Jakarta*

Transforming Basic Science into Clinical Practice and Public Health
Tawesak TANWANDEE, *Bangkok*

10:45 - 11:00

Break

09:15 - 10:45

CONCURRENT SESSION 09
Novel Concept and Future Therapy for Hepatitis B
**Function Hall A
Level 1**

Moderators: Wanhua REN, *Jinan*
Xinmin ZHOU, *Xi'an*

09:15 - 09:35

Achieving Functional Cure and Elimination of HBV
Anna S.F. LOK, *Ann Arbor*

09:35 - 09:55

Current and Future Perspectives of Interferon
Guiqiang WANG, *Beijing*

09:55 - 10:15

Combination Therapies of Direct-Acting Antivirals and Immunomodulatory Agents
Markus CORNBERG, *Hannover*

29 MAR
SAT

Scientific Program

29 March | Saturday

10:15 - 10:35 **Sequential Therapy: Strategy for Functional Cure of CHB**
Hong REN, *Chongqing*

10:35 - 10:45 **Panel Discussion**

10:45 - 11:00 Break

09:15 - 10:45 **CONCURRENT SESSION 10** **Mechanism and Therapeutic Targets: Incretin and Endocrine Based Therapies**

Function Hall B Level 1 Moderators: Mario G. PESSOA, *Sao Paulo*
Jianxiang LIU, *Beijing*

09:15 - 09:35 **Old and New Classes of Lipid Metabolism and Glucose Control Agents PAN-PPAR-Agonist**
Won KIM, *Seoul*

09:35 - 09:55 **Fibroblast Growth Factors and Pleiotropic Effects on MASH Resolution and Fibrosis Improvement FGF21**
Mazen NOUREDDIN, *Houston*

09:55 - 10:15 **Metabolic Actions of Thyroid Hormones and Thyromimetics in the Liver THR β**
Jacob GEORGE, *Sydney*

10:15 - 10:35 **The Future of Single, Dual and Triple Incretin Receptor Agonists GPL-1 / GCGR/GIP**
Yingying LUO, *Beijing*

10:35 - 10:45 **Panel Discussion**

10:45 - 11:00 Break

09:15 - 10:45 **CONCURRENT SESSION 11** **Prediction and Risk Stratification of HCC**

Function Hall C Level 1 Moderators: Xiaobo LU, *Urumqi*
Shuchen LI, *Harbin*

09:15 - 09:35 **Novel Models for Better HCC Prediction**
Yuanyuan KONG, *Beijing*

09:35 - 09:55 **Predicting Chronic Hepatitis C-Related HCC**
Chia-Yen DAI, *Kaohsiung*

09:55 - 10:15 **Liver Cancer Risk Estimation: Metabolic Dysfunction and Alcohol Intake in CHB**
Sang Hoon AHN, *Seoul*

09:55 - 10:15 **Prediction of HCC Recurrence after Curative Surgery**
Wai-Kay SETO, *Hong Kong*

10:35 - 10:45 **Panel Discussion**

10:45 - 11:00 Break

29 MAR
SAT

29 March | Saturday

Scientific Program

09:15 - 10:45		CONCURRENT SESSION 12 Alcohol Intake and the Body
402 (A+B) Level 4		Moderators: Ian H. CUA, <i>Manila</i> Jianning JIANG, <i>Nanning</i>
09:15 - 09:35		Alcohol Consumption and Liver Injury Yanhang GAO, <i>Changchun</i>
09:35 - 09:55		Classification and Relationship of Alcohol Intake and Metabolic Dysfunction Norah TERRAULT, <i>Los Angeles</i>
09:55 - 10:15		Severe Alcoholic Liver Disease Song YANG, <i>Beijing</i>
10:15 - 10:35		Potential Therapeutic Targets of Inflammatory Mediators for Alcohol-Associated Hepatitis Bin GAO, <i>Bethesda</i>
10:35 - 10:45		Panel Discussion
10:45 - 11:00		Break
10:30 - 12:00		PLENARY SESSION 02
Plenary Hall A Level 4		Moderators: Chong TANG, <i>Chengdu</i> Changqing YANG, <i>Shanghai</i>
10:30 - 10:45		An Unique Childhood Liver Disease-Analysis of Role of Autophagy in Disease Pathobiology Kim VAIPHEI, <i>Mohali</i>
10:45 - 11:00		Metabolic Stress in Alcoholic Fatty Liver Drives Sublethal Cellular Toxicity via Protein Translation Machinery Perturbation Induced by Ribosome Collisions Takeshi SAITO, <i>Los Angeles</i>
11:00 - 11:15		Comparison of Pharmacological Therapies for Metabolic Dysfunction-Associated Steatohepatitis: Systematic Review and Network Meta-analysis Daniel HUANG, <i>Singapore</i>
11:15 - 11:30		Pan-PPAR Agonist Chiglitazar for the Treatment of High-Risk Metabolic Dysfunction-Associated Steatohepatitis Coexisting with Type 2 Diabetes: A Randomized, Double-Blind, Phase 2 Trial Zhiyan YU, <i>Shanghai</i>
11:30 - 11:45		Association Between Asymmetric Dimethylarginine, Its Change and Subclinical Carotid Atherosclerosis in Non-Alcoholic Fatty Liver Disease Min LI, <i>Beijing</i>
11:45 - 12:00		Intestinal TM6SF2 Protects Against Metabolic Dysfunction-Associated Steatohepatitis Through the Gut-Liver Axis Xiang ZHANG, <i>Hong Kong</i>
12:00 - 12:15		Break

29 MAR
SAT

Scientific Program

29 March | Saturday

11:00 - 12:00	YOUNG INVESTIGATOR SESSION 01
Function Hall A Level 1	Moderators: Qi WANG, <i>Beijing</i> Suxian ZHAO, <i>Shijiazhuang</i>
11:00 - 11:12	Sudoscanfor Detection of Small Fiber Neuropathy Changes in Hepatitis C Virus Infected Cirrhotics Mohamed ABDEL-SAMIEE, <i>Cairo</i>
11:12 - 11:24	Long-Term Dynamic Changes of Alanine Aminotransferase Levels During nucleos(t)ide Analogues Treatment are Associated with Liver-Related Events Among Patients with Chronic Hepatitis B in China Ning YU, <i>Guangzhou</i>
11:24 - 11:36	Development and Validation of Machine Learning Models for Predicting Long-Term Hepatitis B Surface Antigen Seroclearance Rex W.H. HUI, <i>Hong Kong</i>
11:36 - 11:48	The Genetic Blueprint of Paediatric Liver Disorders Deepa JANAKIRAMAN, <i>Chennai</i>
11:48 - 12:00	Molecular Events Linked to Adverse Outcomes of Liver Fibrosis in Patients with Chronic Hepatitis B After Antiviral Treatment Hong LI, <i>Beijing</i>
12:00 - 12:15	Break

11:00 - 12:00	YOUNG INVESTIGATOR SESSION 02
Function Hall B Level 1	Moderators: Qishui OU, <i>Fuzhou</i> Yuanwen CHEN, <i>Shanghai</i>
11:00 - 11:12	Hypertension and Hyperlipidemia Increase the Risk of Extrahepatic Malignancy in the MASLD Cohort: A Cross-Sectional Study in China. Xinyue ZHAO, <i>Beijing</i>
11:12 - 11:24	Fgl2-C3aR Axis Mediated Nets Promote Intravascular Coagulation and Liver Fibrosis in MAFLD Progression Xitang LI, <i>Wuhan</i>
11:24 - 11:36	Gut Microbiota Predicts Treatment Response to Empagliflozin Among Metabolic Dysfunction-Associated Steatotic Liver Disease Patients without Diabetes Mellitus Ka Shing CHEUNG, <i>Hong Kong</i>
11:36 - 11:48	Hepatic TM6SF2 Activates Anti-Tumor Immunity to Suppressed Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma and Boosts Immunotherapy Yating ZHANG, <i>Hong Kong</i>
11:48 - 12:00	Detection and Assessment of Antigen of Hepatitis E Virus in Urine Haiying ZHANG, <i>Beijing</i>
12:00 - 12:15	Break

29 MAR
SAT

29 March | Saturday

Scientific Program

11:00 - 12:00 YOUNG INVESTIGATOR SESSION 03	
Function Hall C Level 1	Moderators: Xiangmei CHEN, <i>Beijing</i> Yonghong ZHANG, <i>Beijing</i>
11:00 - 11:12	Study Of Infections in Hospitalized Patients with Liver Cirrhosis in Mainland China: a Prospective Cohort Study for the SONIC Consortium Zhujun CAO, <i>Shanghai</i>
11:12 - 11:24	Development and Validation of a Home-Based (LiverHome) Score to Predict Advanced Fibrosis and Liver-Related Outcomes in the General Population Shanghao LIU, <i>Nanjing</i>
11:24 - 11:36	Construction of a Combined Predictive Model for Liver Fibrosis Staging in Chronic Hepatitis B Patients Based on Capsid-Antibody-Complexes Tingting LI, <i>Suzhou</i>
11:36 - 11:48	IFITM1 Aggravates ConA-Induced Autoimmune Hepatitis by Promoting NKT Cell Activation through Increased AMPK-Dependent Mitochondrial Function Jie SUN, <i>Beijing</i>
11:48 - 12:00	Prevalence of Autoantibodies and Clinical Features in Patients with Autoimmune Hepatitis at University Medical Center HCMC Huy Huu NGUYEN, <i>Ho Chi Minh</i>
12:00 - 12:15	Break
11:00 - 12:00 YOUNG INVESTIGATOR SESSION 04	
402 (A+B) Level 4	Moderators: Xuebing YAN, <i>Xuzhou</i> Hai LI, <i>Tianjin</i>
11:00 - 11:12	Prognostic Discordance Among Five Major Staging Systems for Early-stage Hepatocellular Carcinoma: A Multi-institutional Analysis of 4,623 Patients Tian YANG, <i>Shanghai</i>
11:12 - 11:24	Plasma Exchange (PLEX) does not Improve Post-transplant Survival and Increase Risk of Sepsis in Patients with Acute on Chronic Liver Failure Raghuram Nelluri, <i>Jaipur</i>
11:24 - 11:36	Serine/Threonine Kinase 39 Contributes to the Progression of Liver Fibrosis to Cancer and is Promising Drug Target Hongping XIA, <i>Singapore</i>
11:36 - 11:48	Development of a CT Radiomics and Clinical Feature Combined Model for Predicting Early Recurrence of Surgical Resected Hepatocellular Carcinoma Minjun LIAO, <i>Beijing</i>
11:48 - 12:00	Variation in Clinical Decision Making across Tertiary Hospital Hepatocellular Carcinoma Multidisciplinary Tumour Boards Anna Elizabeth Di BARTOLOMEO, <i>Sydney</i>
12:00 - 12:15	Break

29 MAR
SAT

Scientific Program

29 March | Saturday

13:30 - 15:00

PLENARY SESSION 03

Plenary Hall A
Level 4

Moderators: Zhili WEN, *Nanchang*
Jia LI, *Tianjin*

- 13:30 - 13:45 **Durability of Response in Chinese Responders from the Global Phase 2b Study of Bepirovirsen in Participants With Chronic Hepatitis B**
Man Fung YUEN, *Hong Kong*
- 13:45 - 14:00 **SCG101 TCR-T Therapy Achieves Rapid and Sustained HBsAg Reduction with >30% HBsAg Loss in HBV-Related Hepatocellular Carcinoma Patients**
Shunda DU, *Beijing*
- 14:00 - 14:15 **Combination Treatment of TLR7 Agonist and Anti-PD-L1 Reconstitute Protective Immunity in Virally Suppressed Chronic Hepatitis B Patients**
Yuying CHEN, *Wuhan*
- 14:15 - 14:30 **Investigating HBV DNA Integration and its Role in Genomic Instability Through HBx Expression**
Dong LI, *Sydney*
- 14:30 - 14:45 **HBsAg loss in Inactive Chronic Hepatitis B Carriers is Dependent on Level of qHBsAg and Interferon Response: A Randomised Control Trial**
Seng Gee LIM, *Singapore*
- 14:45 - 15:00 **Efficacy Analysis of a Novel Indocyanine Green-Human Serum Albumin Complex (ICG-HSA) Assisted Near-Infrared Fluorescence-Guided Laparoscopic Anatomic Liver Resection for Hepatocellular Carcinoma: A Single-Center, Double-Blind, Prospective Randomized Contr**
Qingyun XIE, *Chengdu*

15:00 - 16:30

PLENARY SESSION 04

Plenary Hall A
Level 4

Moderators: Shichun LU, *Beijing*
Ying HAN, *Xi'an*

- 15:00 - 15:15 **A novel HCV Micro-elimination Model: Government - Led Hospital-Drug Rehabilitation Center Cooperation (GHRC) in Southwest China**
Siyuan GAO, *Kunming*
- 15:15 - 15:30 **Prospective Observation of Liver Stiffness in SVR Cases Using Fibro - scan-Liver Stiffness Changes Plateau after 5 years, But Carcinogenesis Continues-**
Shuntaro OBI, *Yamanashi*
- 15:30 - 15:45 **The Role of Chronic Hepatitis B in Accelerating Fibrosis Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease**
Fajuan RUI, *Nannjing*
- 15:45 - 16:00 **TOX3 Promotes Liver Fibrosis by Regulation of Hepatic Immune Microenvironment and Crosstalk with Hepatocyte**
Shaoping SHE, *Beijing*
- 16:00 - 16:15 **Chronic Kidney Disease in Hospitalized Patients with Cirrhosis, a Global Perspective**
Qing XIE, *Shanghai*

29 MAR
SAT

29 March | Saturday

Scientific Program

13:30 - 15:00	
CONCURRENT SESSION 13	
New Discovery in HBV: Detection, Monitoring and Prediction	
Function Hall A Level 1	Moderators: Minghua SU, <i>Nanning</i> Yan Wang, <i>Beijing</i>
13:30 - 13:50	Transcriptionally Active Hepatitis B Virus integration in patients with HBsAg Loss Xinxin ZHANG, <i>Shanghai</i>
13:50 - 14:10	Detection and Visualization of HBV RNA, DNA, and cccDNA Zhenghong YUAN, <i>Shanghai</i>
14:10 - 14:30	Biomarkers-Guided Treatment Decisions in Chronic Hepatitis B Loey L.Y. MAK, <i>Hong Kong</i>
14:30 - 14:50	Using HBsAg Thresholds for Stopping Nucleos(t)ide Analogues in CHB Seng Gee LIM, <i>Singapore</i>
14:50 - 15:00	Panel Discussion
15:00 - 15:15	Break
13:30 - 15:00	
CONCURRENT SESSION 14	
New Pharmacological Agents Discovery for MASH and Liver Fibrosis	
Function Hall B Level 1	Moderators: Bo FENG, <i>Beijing</i> Hui YANG, <i>Guangzhou</i>
13:30 - 13:50	Impact of PNPLA3 rs738409 Polymorphism on MAFLD Jing ZHANG, <i>Beijing</i>
13:50 - 14:10	The Role of HSD17B13 in MAFLD Junping SHI, <i>Hangzhou</i>
13:50 - 14:10	Spatial and Single-Nucleus Transcriptomics Reveal Atlas of Liver Cirrhosis Reversal after Entecavir Plus Biejia-Ruangan Compound Treatment: Results of A Randomized Study Yongping YANG, <i>Beijing</i>
14:30 - 14:50	Main Drug Targets for Anti-Liver Fibrosis Chenghai LIU, <i>Shanghai</i>
14:50 - 15:00	Panel Discussion
15:00 - 15:15	Break
13:30 - 15:00	
CONCURRENT SESSION 15	
Early Diagnosis and Surveillance for Liver Cancer	
Function Hall C Level 1	Moderators: Lei WANG, <i>Jinan</i> Xin ZHENG, <i>Wuhan</i>
13:30 - 13:50	HCC Surveillance and Risk Stratification Tawesak TANWANDEE, <i>Bangkok</i>
13:50 - 14:10	A-HOC and APASL Guidelines Ryosuke TATEISHI, <i>Tokyo</i>

29 MAR
SAT

Scientific Program

29 March | Saturday

13:50 - 14:10	Cell-Free DNA Testing for Early HCC Surveillance Rong FAN, <i>Guangzhou</i>
14:30 - 14:50	Early Detection and Care of Liver Cancer Grace L.H. WONG, <i>Hong Kong</i>
14:50 - 15:00	Panel Discussion
15:00 - 15:15	Break

13:30 - 15:00 CONCURRENT SESSION 16 Transforming Management Landscape of Primary Biliary Cholangitis

**402(A+B)
Level 4** Moderators: Kittiyod POOVORAWAN, *Bangkok*
Yongning XIN, *Qingdao*

13:30 - 13:50	Pathophysiology of PBC Atsushi TANAKA, <i>Tokyo</i>
13:50 - 14:10	Beyond Current Pruritus Management: A Call for New Approaches Ying HAN, <i>Xi'an</i>
14:10 - 14:30	Clinical Advances and Collaboration: Keys to Futuring PBC Care Xinyan ZHAO, <i>Beijing</i>
14:30 - 14:50	PBC: Putting the Patient First Carrie FRENETTE, <i>Foster City</i>
14:50 - 15:00	Panel Discussion
15:00 - 15:15	Break

15:15 - 16:45 CONCURRENT SESSION 17 The Hope of Hepatitis Delta Cure

**Function Hall A,
Level 1** Moderators: Gulnara AGHAYEVA, *Baku*
Ming YANG, *Beijing*

15:15 - 15:35	Epidemiology of Hepatitis Delta Jie LI, <i>Beijing</i>
15:35 - 15:55	Diagnosis of Hepatitis D Chun-Jen LIU, <i>Taipei</i>
15:55 - 16:15	Entry Inhibitor for HBV/HDV Saeed HAMID, <i>Karachi</i>
16:15 - 16:35	Opportunities and Challenges for Hepatitis Delta Cure Tarik ASSELAH, <i>Paris</i>
16:35 - 16:45	Panel Discussion
16:45 - 17:00	Break

29 MAR
SAT

29 March | Saturday

Scientific Program

15:15 - 16:45 CONCURRENT SESSION 18 Clinical Trials for Steatosis and Fibrosis: In-between Success and Failure

**Function Hall B
Level 1**

Moderators: Hasmik GHAZINYAN, *Yerevan*
Junping SHI, *Hangzhou*

- 15:15 - 15:35 **Insight from Terminated Trials: Wrong Direction or Wrong Design?**
Rohit LOOMBA, *La Jolla*
- 15:35 - 15:55 **Revisiting the Ongoing Trials after the First Approval**
Laurent CASTERA, *Paris*
- 15:55 - 16:15 **Non-Invasive Diagnosis and Artificial Intelligence: Catalyst for Success?**
Vincent W.S. WONG, *Hong Kong*
- 16:15 - 16:35 **Current and Future Role of Asia Pacific in the Trials: Observer or Player?**
Hong YOU, *Beijing*
- 16:35 - 16:45 **Panel Discussion**
- 16:45 - 17:00 Break

15:15 - 16:45 CONCURRENT SESSION 19 More and Longer Survival Opportunity for Early-Intermediate Stage Liver Cancer

**Function Hall C
Level 1**

Moderators: Rino A. GANI, *Jakarta*
Yan HUANG, *Changsha*

- 15:15 - 15:35 **Advancement in Surgical Procedures and Patient Selection**
Albert C.Y. CHAN, *Hong Kong*
- 15:35 - 15:55 **Prediction Model for Surgical Site Infection (SSI) after Hepatectomy**
Feng SHEN, *Shanghai*
- 15:55 - 16:15 **Landscape of Locoregional Therapies for Liver Cancer in 2025**
Shuichiro SHIINA, *Tokyo*
- 16:15 - 16:35 **The Role of Neo-Adjuvant and Adjuvant Immunotherapy**
Haitao ZHAO, *Beijing*
- 16:35 - 16:45 **Panel Discussion**

15:15 - 16:45 CONCURRENT SESSION 20 ACLF Consensus and Controversy

**402 (A+B)
Level 4**

Moderators: Shaojie XIN, *Beijing*
Jinjun CHEN, *Guangzhou*

- 15:15 - 15:35 **ACLF East Meet West**
Ashok CHOUDHURY, *New Delhi*
- 15:35 - 15:55 **Prognostic Model for Predicting Survival Outcomes**
Jun LI, *Hangzhou*
- 15:55 - 16:15 **Reversal of ACLF**
Zaigham ABBAS, *Karachi*

29 MAR
SAT

Scientific Program

29 March | Saturday

16:15 - 16:35 **Novel Therapeutic Approaches and the Future Management**
Rajiv JALAN, *London*

16:35 - 16:45 **Panel Discussion**

11:00 - 12:00 GLOBAL STEATOSIS LIVER DISEASE SUMMIT What Should We Do after the First Drug Approved by FDA

Auditorium Level 4 Moderator: Lai WEI, *Beijing*

11:00 - 11:05 **Welcome & Introductions**
Lai WEI, *Beijing*

11:05 - 11:25 **Current Clinical Practice and Issues in the Regions**
Representatives from Societies
APASL / AASLD / EASL / ALEH

11:25 - 11:45 **Implication of New Drug: Approval Timeline and Experience in the Regions**
Representatives from Societies
APASL / AASLD / EASL / ALEH

11:45 - 11:55 **Q&A and Open Discussion from Floor**
Panel and Floor Audience

11:55 - 12:00 **Wrap Up**
Lai WEI, *Beijing*

12:00 - 12:15 Break

13:30 - 16:45 EDITORS FORUM

13:30 - 15:10 SESSION 01

Auditorium Level 4 Moderators: Lai WEI, *Beijing*
George K.K. LAU, *Hong Kong*

13:30 - 13:50 **The Role of Official Journal and the Development of Society**
Masao OMATA, *Kofu*

13:50 - 14:10 **The Trend of Research in Hepatology**
Shiv K. SARIN, *New Delhi*

14:10 - 14:30 **Clinical Gastroenterology and Hepatology**
Charles J. KAHN, *Indianapolis*

14:30 - 14:50 **iLiver**
Jia-Hong DONG, *Beijing*

14:50 - 15:10 **Infectious Diseases & Immunity**
Fu-Sheng WANG, *Beijing*

15:10 - 16:45 SESSION 02

Auditorium Level 4 Moderators: Jidong JIA, *Beijing*
Jinlin HOU, *Guangzhou*

29 MAR
SAT

29 March | Saturday

Scientific Program

15:10 - 15:30	Journal of Clinical and Translational Hepatology Hong REN, <i>Chongqing</i>
15:30 - 15:50	Hepatology TBD
15:50 - 16:10	Journal of Viral Hepatitis Mark SULKOWSKI, <i>Baltimore</i>
16:10 - 16:30	The Lancet Gastroenterology and Hepatology Robert N. BRIERLEY, <i>London</i>
16:30 - 16:45	Panel Discussion
16:45 - 17:00	Break

17:00 - 18:00 APASL GUIDELINES 02

Function Hall C Level 1 Moderators: Masao OMATA, *Kofu*
George K.K. LAU, *Hong Kong*

17:00 - 17:30	Nutrition in Liver Diseases Diana A. PAYAWAL, <i>Manila</i>
17:30 - 18:00	Consensus on Functional Cure of Hepatitis B Lai WEI, <i>Beijing</i>

17:00 - 18:00 GLOBAL LIVER CANCER SUMMIT Awareness and Action Enhancing Liver Cancer Surveillance

Auditorium Level 4 Moderator: Masao OMATA, *Kofu*

17:00 - 17:05	Welcome & Introductions Masao OMATA, <i>Kofu</i>
17:05 - 17:25	Early Diagnosis and Surveillance Strategy in the Region Representatives from Societies APASL / AASLD / EASL / ALEH
17:25 - 17:45	Current and Emerging Tools in the Regions Representatives from Societies APASL / AASLD / EASL / ALEH
17:45 - 17:55	Q&A and Open Discussion from Floor Panel and Floor Audience
17:55 - 18:00	Wrap Up Masao OMATA, <i>Kofu</i>

18:30 - 20:30 CULTURE NIGHT

Plenary Hall A, Level 4

29 MAR
SAT

ORAL SESSION

29 March | Saturday

9:00 - 10:00 ORAL SESSION 21

Liver Surgery and Transplantation 1

401
Level 4

Moderators: Yongfang JIANG, *Changsha*
Yinying LU, *Beijing*

- | | | |
|--------|---------------|---|
| OP0127 | 09:00 - 09:10 | Significance of Auto-antibodies in Living Liver Donor Liver Transplantation: A Scoping Review
Bochao JIANG, <i>Singapore</i> |
| OP0128 | 09:10 - 09:20 | Long-Term Survival in Pediatric Living Donor Liver Transplant Recipients who have Survived the First Year of Surgery: Experience from India
Vipul GAUTAM, <i>New Delhi</i> |
| OP0129 | 09:20 - 09:30 | Long-term results of patients undergoing liver transplantation due to celiac disease
Murat HARPUTLUOGLU, <i>Malatya</i> |
| OP0130 | 09:30 - 09:40 | Biliary complications after liver transplantation: Single center experiences
Abdulkadir DÖKMECI, <i>Ankara</i> |
| OP0131 | 09:40 - 09:50 | The Role of Transpapillary Cholangioscopy-Assisted Negotiation of Anastomotic Strictures in Living Donor Liver Transplant Recipients in Post Failure ERCP: Groundbreaking Findings from the Largest Global Real-World Dataset
Syed Mujahid HASSAN, <i>Karachi</i> |
| OP0132 | 09:50 - 10:00 | BOLD, A Phase 3, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Odevixibat in Infants With Biliary Atresia After Kasai Portoenterostomy – Study Design and Current Status
Shan ZHEN, <i>Shanghai</i> |

9:00 - 10:00 ORAL SESSION 22

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 5

403
Level 4

Moderators: Hui YANG, *Taiyuan*
Jing ZHANG, *Beijing*

- | | | |
|--------|---------------|--|
| OP0133 | 09:00 - 09:10 | Causal association of cholesterol metabolism-related proteins with Hepatocellular Carcinoma (HCC) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a Mendelian randomization study
Dianzhe TIAN, <i>Beijing</i> |
| OP0134 | 09:10 - 09:20 | Cannabinoid-2 Receptor Depletion Contributes to Metabolic Dysfunction-Associated Fatty Liver Disease via Regulating Microbiota-derived Tryptophan Metabolites Indole-3-lactic
Weiting CHENG, <i>Changsha</i> |
| OP0135 | 09:20 - 09:30 | Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis (MASH)
Jidong JIA, <i>Beijing</i> |

29 MAR
SAT

29 March | Saturday

ORAL SESSION

- OP0136 09:30 - 09:40 **The non-invasive assessment of liver fibrosis in metabolic dysfunction associated steatotic liver disease (MASLD) in the Chinese population: a scoping review**
Qianqian ZHENG, *Shijiazhuang*
- OP0137 09:40 - 09:50 **Adverse outcomes and HBsAg seroclearance of chronic hepatitis B complicated with metabolic dysfunction-associated steatotic liver disease: A cohort study**
Jialan WANG, *Ningbo*
- OP0138 09:50 - 10:00 **The relationship between the ratio of red blood cell distribution width to albumin concentration and the incidence and mortality risk of metabolic dysfunction-associated fatty liver disease.**
Zixuan QIU, *Beijing*

9:00 - 10:00 ORAL SESSION 23 Liver Fibrogenesis and Cirrhosis 1

405 Level 4 Moderators: Hongxia LIANG, *Zhengzhou*
Yan Wang, *Beijing*

- OP0140 09:00 - 09:10 **Dedicated stent decreases the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients**
Xuefeng LUO, *Chengdu*
- OP0141 09:10 - 09:20 **The Potential Mechanism of Action and Active Ingredients of Ruangan Granules Against Liver Fibrosis**
Liu YANG, *Beijing*
- OP0142 09:20 - 09:30 **Cryptotanshinone targets PPAR γ to reduce nonalcoholic fatty liver disease**
Tao WANG, *Shanghai*
- OP0143 09:30 - 09:40 **Safety and Efficacy of Xiaozhi Formula in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized, Controlled, Placebo Clinical Trial**
Liping YOU, *Shanghai*
- OP0144 09:40 - 09:50 **Study on the key pharmacodynamic components of Total Astragalus saponins (TAS) in improving Cholestatic Liver Disease (CLD)**
Linzhang ZHANG, *Shanghai*
- OP0381 09:50 - 10:00 **Improved Survival Outcomes in Cirrhotic Patients with Acute Variceal Bleeding Following Full Adherence to Clinical Practice Guideline (CPG) Quality Metrics: A Retrospective Cohort Study**
Laurence LAUREL, *Manila*

9:00 - 10:00 ORAL SESSION 24 Public Health 2

406 Level 4 Moderators: Ping WANG, *Beijing*
Rui HUANG, *Beijing*

- OP0145 09:00 - 09:10 **Prevalence of Hepatitis B Virus (HBV) Infection Based on Routine Screening of Hospitalized Patients**
Hongzhan SUN, *Taizhou*

29 MAR
SAT

ORAL SESSION

29 March | Saturday

OP0146	09:10 - 09:20	The application of aMAP risk score for predicting hepatocellular carcinoma development among individuals with hepatitis B virus-infection in community Mingfang JI, <i>Zhongshan</i>
OP0147	09:20 - 09:30	Novel Subtypes of Non-alcoholic Fatty Liver Disease and their Distinct Adverse Outcomes and Genetic Profiles Li WANG, <i>Beijing</i>
OP0148	09:30 - 09:40	The cost-effectiveness of albumin in the management of spontaneous bacterial peritonitis in patients with decompensated cirrhosis in urban China Liu YANG, <i>Shanghai</i>
OP0149	09:40 - 09:50	Lipid metabolism indicators provide tools for the diagnosis of nonalcoholic fatty liver disease: Results of a nationwide survey Chang FU, <i>Changchun</i>
OP0150	09:50 - 10:00	Cost-effectiveness of different strategies in achieving a functional cure in CHB Jing CHEN, <i>Hong Kong</i>

9:00 - 10:00 ORAL SESSION 25 Hepatitis B and Delta 5

407
Level 4 Moderators: Gaofeng LU, *Zhengzhou*
Weifeng ZHAO, *Nanjing*

OP0151	09:00 - 09:10	Anti-PD-1 antibody combined with nucleos(t)ide analogue and peg-IFNα enhances anti-HBV efficacy and T cell response in AAV-HBV mice and patients with chronic hepatitis B Taiyu HE, <i>Chongqing</i>
OP0152	09:10 - 09:20	Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study Man Fung YUEN, <i>Hong Kong</i>
OP0153	09:20 - 09:30	Similarities and differences of xalnesiran-based combination regimens aimed to achieve functional cure in the Piranga phase 2 platform study Remi KAZMA, <i>Basel</i>
OP0154	09:30 - 09:40	Targeted enrichment long-read single-cell transcriptomics reveal the clonal expansion of hepatocytes infected with HBV Yanfang HUANG, <i>Shanghai</i>
OP0155	09:40 - 09:50	5-Year Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B Patients Zhihong LIU, <i>Guangzhou</i>
OP0156	09:50 - 10:00	Decanoylcarnitine improves liver mitochondrial dysfunction in HBV infection by enhancing fatty acid β-oxidation Ye SUN, <i>Nanjing</i>

29 MAR
SAT

29 March | Saturday

ORAL SESSION

10:00 - 11:00 ORAL SESSION 26**Liver Surgery and Transplantation 2****401
Level 4**Moderators: Minghua SU, *Nanning*
Haiying LU, *Beijing*

- OP0157 10:00 - 10:10 **Cure Probability After Hepatectomy for Patients with HBV-Associated Hepatocellular Carcinoma: A Multi-institutional Analysis**
Tian YANG, *Shanghai*
- OP0158 10:10 - 10:20 **Characterization of CD8+ MAIT cells in Liver Transplant Immunity**
Hailun CAI, *Fuzhou*
- OP0159 10:20 - 10:30 **Safety and efficacy of tenofovir alafenamide in liver transplant recipients**
Yinghong SHI, *Shanghai*
- OP0160 10:30 - 10:40 **Paraspinal Vein Shunt (PVS): A Potential Key Factor Leading to Hepatic Myelopathy**
Jidong JIA, *Beijing*
- OP0161 10:40 - 10:50 **Survival benefit from neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors for resectable intermediate or advanced hepatocellular carcinoma (GUIDANCE002): a multicenter, retrospective study**
Dalong YANG, *Nanning*
- OP0162 10:50 - 11:00 **The Impact of Early Graft Dysfunction On Renal Dysfunction After Orthotopic Liver Transplantation: A Multicenter, Retrospective, Longitudinal Cohort Study**
Nie YU, *Hongkong*

10:00 - 11:00 ORAL SESSION 27**Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 6****403
Level 4**Moderators: Zheng ZHANG, *Shenzhen*
Feng LIU, *Beijing*

- OP0163 10:00 - 10:10 **INSR Exists on the Mitochondria of Hepatocytes and Correlates with the Severity of MAFLD**
Yifei Qi, *Beijing*
- OP0164 10:10 - 10:20 **Distribution of estimated glomerular filtration rate in MASLD across continents and according to country**
Jing ZHAO, *Wuxi*
- OP0165 10:20 - 10:30 **Global Burden, Temporal Trends, and Future Predictions of Alcohol-Related and Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma From 1990 to 2050: A Population-Based Analysis of GBD 2021 Data**
Zixuan XING, *Xi'an*
- OP0166 10:30 - 10:40 **Muscle fat content quantified by L3-PDFFPsoas is strongly associated with fibrosis in patients with metabolic dysfunction-associated steatotic liver disease**
Ziming AN, *Shanghai*

29 MAR
SAT

ORAL SESSION

29 March | Saturday

- OP0167 10:40 - 10:50 **Advanced Glycation End Products (AGEs) Promote Inflammation in Metabolic Associated Fatty Liver Disease (MAFLD) by Downregulating miR-9-5p Expression and Up-regulating EGR1 in Kupffer Cells**
Qingyun SUN, *Beijing*
- OP0168 10:50 - 11:00 **Cluster analysis-based novel phenotypes for metabolic dysfunction-associated fatty liver disease population and their associations with long-term adverse outcomes**
Wenjing NI, *Nanjing*

10:00 - 11:00 ORAL SESSION 28 Liver Fibrogenesis and Cirrhosis 2

405
Level 4 Moderators: Xuezhong DUAN, *Beijing*
Jinghua FAN, *Kunming*

- OP0169 10:00 - 10:10 **Assessing Significant Liver Fibrosis in Psoriasis Patients with MASLD: Predictors and the Role of Non-invasive Tests**
Kanteera SRIYUDTHSAK, *Bangkok*
- OP0170 10:10 - 10:20 **Inhibition of heme-thiolate monooxygenase CYP1B1 prevents hepatic stellate cell activation and liver fibrosis by accumulating trehalose**
Wen XIE, *Pennsylvania*
- OP0171 10:20 - 10:30 **Deficiencies of micronutrients in potential liver transplant candidates- A Cross-sectional study**
Manesh KUMAR, *Karachi*
- OP0172 10:30 - 10:40 **Assessment of Micronutrient Status and Its Association with Clinical Outcomes in Adult Patients with Compensated and Decompensated Liver Cirrhosis Seen at a Tertiary Institution: A Single-arm Retrospective Cohort Study**
Kathleen Madera MONFORT, *Manila*
- OP0173 10:40 - 10:50 **A Comparative Study of Ginger and Turmeric-Derived Edible Extracellular Vesicles (EVs) in Alleviating Liver Injury**
Pdebishree SUBUDHI, *New Delhi*
- OP0174 10:50 - 11:00 **Attenuation of Gut Urease Activity and Ammonia Production by Melittin in Experimental Cirrhosis**
Deepika JAKHAR, *New Delhi*

10:00 - 11:00 ORAL SESSION 29 Public Health 3

406
Level 4 Moderators: Wei HOU, *Tianjin*
Yannan LIU, *Beijing*

- OP0175 10:00 - 10:10 **A mHealth-assisted multifaceted lifestyle intervention for childhood obesity and NAFLD: A cluster randomized clinical trial (the SCIENT study)**
Hui WANG, *Beijing*

29 MAR
SAT

29 March | Saturday

ORAL SESSION

OP0176	10:10 - 10:20	Worldwide burden of liver cancer due to metabolic dysfunction-associated steatohepatitis from 1990 to 2019: insights from the Global Burden of Disease study Minshan HUANG, <i>Kunming</i>
OP0177	10:20 - 10:30	Burden of pancreatic cancer and its attributable risk factors in 204 countries and territories, 1990-2021: results from the Global Burden of Disease Study 2021 Zhifeng ZHAO, <i>Beijing</i>
OP0178	10:30 - 10:40	Novel Phenotypes of Lean Male Metabolic Dysfunction-associated Fatty Liver Disease and Their Long-term Outcomes: A Data-driven Cohort Study Shutong WU, <i>Beijing</i>
OP0180	10:40 - 10:50	Analysis of the Present Research Landscape on Non-Governmental Organizations: Emphasizing Fundamental Development Challenges and Solutions Cunduo JIN, <i>Beijing</i>

10:00 - 11:00 ORAL SESSION 30 Hepatitis B and Delta 6

407
Level 4 Moderators: Zhongji MENG, *Shiyan*
Ying ZHU, *Dalian*

OP0181	10:00 - 10:10	Identification of an effective HBV cccDNA inhibitor BAY87-2243 and its potential anti-HBV mechanisms Sihui LI, <i>Chongqing</i>
OP0182	10:10 - 10:20	The GADA model for diagnosing HCC in Chinese hepatitis B patients was developed and validated across multiple centers Yamei WEI, <i>Xinjiang</i>
OP0183	10:20 - 10:30	A single post-treatment LSM measured at various timepoints shows predictive value for liver-related clinical outcomes Yameng SUN, <i>Beijing</i>
OP0184	10:30 - 10:40	Use of Sodium-Glucose Co-Transporter-2 Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B, Type 2 Diabetes, and Varying Fibrosis Status Xianhua MAO, <i>Hong Kong</i>
OP0185	10:40 - 10:50	External Validation of the GOLDEN Model for Predicting HBsAg Loss in Non-cirrhotic Chronic Hepatitis B Patients with Interferon-alpha Based Therapy Xingmei LIAO, <i>Guangzhou</i>
OP0186	10:50 - 11:00	Results of Nucleos(t)ide Analog Treatment Discontinuation in Hepatitis B e-Antigen-Negative Chronic Hepatitis B: NUCSTOP Study Hakan SENTURK, <i>Istanbul</i>

29 MAR
SAT

ORAL SESSION

29 March | Saturday

11:00 - 12:00 ORAL SESSION 31

Liver Surgery and Transplantation 3

401
Level 4

Moderators: Guohong DENG, *Chongqing*
Zhongjie HU, *Beijing*

- | | | |
|--------|---------------|--|
| OP0187 | 11:00 - 11:10 | Technical Improvements and Outcomes in Pediatric Living Donor Liver Transplantation
Yuhua DENG, <i>Chongqing</i> |
| OP0188 | 11:10 - 11:20 | Beta-catenin/Sirtuin 1/Farnesoid X Receptor Pathway Promotion of Portal Vein Ligation and Parenchymal Transection-Induced Rapid Liver Regeneration
Yifan TONG, <i>Hangzhou</i> |
| OP0189 | 11:20 - 11:30 | Circulating Tumor-specific Cell-free Tumor DNA is Useful in Monitoring Recurrence of HBV-related HCC after Liver Transplantation
Shiou-Hwei YEH, <i>Taipei</i> |
| OP0190 | 11:30 - 11:40 | GPX3 regulates liver regeneration by preserving mitochondrial quality control
Yuechen WANG, <i>Nanjing</i> |
| OP0191 | 11:40 - 11:50 | Study of overall survival and factors affecting outcomes in chronic hepatitis C patients undergoing liver transplantation: A single-centered cohort study
Chitchai RATTANANUKROM, <i>Khon Kaen</i> |
| OP0192 | 11:50 - 12:00 | The Impact of Sarcopenia on Early Postoperative Mortality in Living Donor Liver Transplant Recipients with End-Stage Liver Disease
Alp ATASOY, <i>Istanbul</i> |

11:00 - 12:00 ORAL SESSION 32

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 7

403
Level 4

Moderators: Zhongji MENG, *Shiyan*
Rui HUANG, *Beijing*

- | | | |
|--------|---------------|---|
| OP0193 | 11:00 - 11:10 | The Gut Microbiota-Metabolite-Host Metabolism Interaction Mechanism in MAFLD: From Multidimensional Analysis to Precision Intervention
Malan QING, <i>Kunming</i> |
| OP0194 | 11:10 - 11:20 | Insulin-Like Growth Factor Binding Protein 7 as a Biomarker for Hepatic Fibrosis and Cardiac Dysfunction in Metabolic Dysfunction-Associated Fatty Liver Disease
Wenjing NI, <i>Nanjing</i> |
| OP0195 | 11:20 - 11:30 | Mechanistic Study of Resmetirom in Treating MAFLD Mouse Model: Gut Microbiota Remodeling and Metabolic Regulation
Chen HANG, <i>Kunming</i> |

29 MAR
SAT

29 March | Saturday

ORAL SESSION

OP0196	11:30 - 11:40	A Personalized Risk Score and Predictive Model for Stratifying High Depression Risk in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A 5-Year Follow-Up Study of 103,954 Patients from the UK Biobank Mingxing HUANG, <i>Zhuhai</i>
OP0197	11:40 - 11:50	Turicimonas muris Disrupts Treg/Th17 Balance through CXCL9 to Promote the Progression of MAFLD Longyun WU, <i>Shanghai</i>
OP0018	11:50 - 12:00	DC-SIGN+ Macrophages Mitigate Metabolic dysfunction-associated fatty liver disease via Fine-Tuning TLR4 Signaling Cascades and Modulating Inflammatory Secretory Profiles Jinxia LIU, <i>Nantong</i>

11:00 - 12:00 ORAL SESSION 33 Liver Fibrogenesis and Cirrhosis 3

405 Level 4 Moderators: Hui YANG, *Taiyuan*
Yongqian CHENG, *Beijing*

OP0199	11:00 - 11:10	EVALUATING IMPACT OF WEIGHT CHANGES ON HISTOLOGICAL PATTERNS OF LIVER FIBROSIS IN MASH: IMPLICATIONS FOR SPATIAL INTERROGATION Mark MUTHIAH, <i>Singapore</i>
OP0200	11:10 - 11:20	Progerin-Induced Premature Senescence Aggravates Hepatic Fibrosis by Activating the cGAS-STING Pathway Bingxin LU, <i>Zhengzhou</i>
OP0201	11:20 - 11:30	MSC-derived exosomes attenuates periductal fibrosis by inhibiting Th 17 differentiation in human liver multi-lineage organoids and Mdr2-/- mice models Hongcui CAO, <i>Hangzhou</i>
OP0202	11:30 - 11:40	RBM25 promotes liver fibrogenesis by regulating chondroitin sulfate E metabolism in macrophages Shiming GONG, <i>Shanghai</i>
OP0203	11:40 - 11:50	Detection of minimal hepatic encephalopathy in Chinese patients with cirrhosis based on the Stroop-CN model: A prospective multicenter study Junliang FU, <i>Beijing</i>
OP0204	11:50 - 12:00	HIF-1α/LTBP2 axis activate HSCs to promote liver fibrosis by interacting with LOXL1 via the ERK pathway Mengxin LU, <i>Shanghai</i>

11:00 - 12:00 ORAL SESSION 34 Others Hepatitis, Infections and the Liver 1

406 Level 4 Moderators: Xuebing YAN, *Xuzhou*
Haitao ZHAO, *Beijing*

OP0205	11:00 - 11:10	Inverse Correlation of Th2-Specific Cytokines with Hepatic Egg Burden in <i>S. mansoni</i>-Infected Hamsters Verena Von BUELOW, <i>Giessen</i>
--------	---------------	--

29 MAR
SAT

ORAL SESSION

29 March | Saturday

OP0206	11:10 - 11:20	Hepatitis A Beyond Childhood Causing Diagnostic and Therapeutic Challenges in Addis Ababa, Ethiopia Abate Bane SHEWAYE, <i>Addis Ababa</i>
OP0207	11:20 - 11:30	Late Onset Encephalitis in a Young Indian Male with Acute Liver Failure Due to Hepatitis A Simi TAHILIANI, <i>New Delhi</i>
OP0208	11:30 - 11:40	Post COVID Condition and long-term COVID-19 Impact on hepatic decompensation and survival in Cirrhosis: a propensity matched observational study Perna SHARMA, <i>Chandigarh</i>
OP0209	11:40 - 11:50	Hepatic helminth infection modulates the immune responses induced by different types of SARS-CoV-2 vaccines Jinpeng SU, <i>Munich</i>
OP0210	11:50 - 12:00	Etiology and Diagnostic Roadmap in Patients with Non-viral Chronic Liver Injury Yanfei FENG, <i>Nanning</i>

11:00 - 12:00 ORAL SESSION 35 Hepatitis B and Delta 7

407
Level 4 Moderators: Meifang HAN, *Wuhan*
Yandi XIE, *Beijing*

OP0211	11:00 - 11:10	Deep Learning-Based Super-Resolution CT Radiomics Enhances Prognosis prediction for Patients with Hepatitis B virus related Acute-on-Chronic Liver Failure Xueyun ZHANG, <i>Shanghai</i>
OP0031	11:10 - 11:20	Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in High Viral Suppression Rates in Untreated HBeAg+ Subjects with Chronic Hepatitis B Virus Infection Man Fung YUEN, <i>Hong Kong</i>
OP0213	11:20 - 11:30	Unexpected Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam Van Huy VO, <i>Ho Chi Minh</i>
OP0214	11:30 - 11:40	The Profiles and Signatures of miRNAs in Different Phases of Natural History of Chronic HBV Infection Mengji LU, <i>Bochum</i>
OP0215	11:40 - 11:50	Long-Term Clinical Outcomes in Hepatitis B Patients Achieving Clinical Cure with Interferon or Nucleos(t)ide Analog Therapy Zhenhuan CAO, <i>Beijing</i>
OP0216	11:50 - 12:00	Characteristics of HBV integration in pediatric patients with chronic hepatitis B infection Na WU, <i>Chongqing</i>

29 MAR
SAT

29 March | Saturday

ORAL SESSION

13:30 - 14:30 ORAL SESSION 36 Liver Oncology 1

401
Level 4

Moderators: Jinhui YANG, *Kunming*
Jinhua HU, *Beijing*

- | | | |
|--------|---------------|--|
| OP0217 | 13:30 - 13:40 | Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort study
Xuemei TAO, <i>Tianjin</i> |
| OP0218 | 13:40 - 13:50 | Effectiveness and Safety of Atezolizumab Combined with Lenvatinib as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: a Retrospective Study
Ying LUO, <i>Beijing</i> |
| OP0219 | 13:50 - 14:00 | Hepatocellular carcinoma in non-cirrhotic hepatectomy specimens: Morpho-molecular characterisation with prognostic relevance
Archana RASTOGI, <i>New Delhi</i> |
| OP0220 | 14:00 - 14:10 | AI-Enhanced Tumor Volume Assessment for Hepatocellular Carcinoma Treatment Efficacy: A Superior Alternative to Diameter-Based Evaluation Criteria
Dianzhe TIAN, <i>Beijing</i> |
| OP0221 | 14:10 - 14:20 | Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a multi-center cohort study
Wangyong SHUAI, <i>Hefei</i> |
| OP0222 | 14:20 - 14:30 | AKR1B10 as a New Diagnostic and Prognostic Serum Marker for Hepatocellular Carcinoma
Deliang CAO, <i>Hengyang</i> |

13:30 - 14:30 ORAL SESSION 37 Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 8

403
Level 4

Moderators: Rongqi WANG, *Shijiazhuang*
Hai LI, *Shanghai*

- | | | |
|--------|---------------|--|
| OP0223 | 13:30 - 13:40 | EXPLORING PREDICTORS OF RAPID PROGRESSION TO MAJOR ADVERSE LIVER OUTCOMES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Ying SHANG, <i>Stockholm</i> |
| OP0225 | 13:40 - 13:50 | Diagnostic Efficacy of Non-invasive Test Results for Liver Steatosis Determination in MASLD Patients
Yanhua DING, <i>Changchun</i> |
| OP0226 | 13:50 - 14:00 | Dietary change affects steatosis patterns in hepatocellular carcinoma with Metabolic Dysfunction-Associated Steatotic Liver Disease analyzing by SHG/TPE microscopy imaging combined with scRNA-seq
Yuyun SONG, <i>Beijing</i> |

29 MAR
SAT

ORAL SESSION

29 March | Saturday

- OP0227 14:00 - 14:10 **Reconsider: Ferroptosis in NAFLD, molecular mechanisms of its regulation, and therapeutic implications**
Zhen YUAN, *Shanghai*
- OP0228 14:10 - 14:20 **PD-1 Inhibitor-Induced Ca²⁺ Overload Triggering T Cell Apoptosis in MASLD-HCC**
Hao SHEN, *Shanghai*

13:30 - 14:30 ORAL SESSION 38 Liver Fibrogenesis and Cirrhosis 4

405
Level 4 Moderators: Ying ZHU, *Dalian*
Haiying LU, *Beijing*

- OP0229 13:30 - 13:40 **Neuropilin-1 promotes liver fibrosis by reprogramming M2 polarization of macrophages and crosstalk with hepatic stellate cells**
Chenxi LIU, *Jinan*
- OP0230 13:40 - 13:50 **Comparison of Clinical Characteristics and Prediction of intrapulmonary vascular dilatation and Hepatopulmonary Syndrome in Patients with Cirrhosis**
Yingfei WANG, *Beijing*
- OP0231 13:50 - 14:00 **Safety and immunogenicity of hepatitis E vaccine in compensated liver cirrhosis with chronic hepatitis B**
Xuejiao LIAO, *Shenzhen*
- OP0232 14:00 - 14:10 **DIABETES MELLITUS AS A KEY INDEPENDENT PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B AND CONCURRENT HEPATIC STEATOSIS**
Jie LI, *Nanjing*
- OP0233 14:10 - 14:20 **Transcriptomic and Cellular Traits of Liver Fibrosis Regression in Chronic Hepatitis B Patients on Treatment**
Wei CHEN, *Beijing*
- OP0234 14:20 - 14:30 **YB-1 contributes to liver fibrosis by mediating the capillarization of liver sinusoidal endothelial cells through the Twist1/EndMT pathway**
Zhenyang SHEN, *Shanghai*

13:30 - 14:30 ORAL SESSION 39 Others Hepatitis, Infections and the Liver 2

406
Level 4 Moderators: Han BAI, *Shenyang*
Gaofeng LU, *Zhengzhou*

- OP0235 13:30 - 13:40 **A novel model for identifying infections in patients with acute-on-chronic liver diseases (AoCLD) : a nationwide, multicentre, prospective cohort study**
Hui ZHOU, *Changsha*
- OP0236 13:40 - 13:50 **Underlying Conditions, Etiology, Clinical Characteristics, and Long-term Prognosis in Patients with Pyogenic Liver Abscess A Retrospective Cohort Study**
Mingzhu TAO, *Guangzhou*

29 March | Saturday

ORAL SESSION

OP0237	13:50 - 14:00	Risk factors for poor 90-day outcomes of 816 acute hepatitis E inpatients in Shanghai, China: a retrospective analysis Xue MEI, <i>Shanghai</i>
OP0238	14:00 - 14:10	Prevalence and Characteristics of Bacterial and Fungal Infections in End-Stage Liver Disease: A Multi-Center, Cross-Sectional Study from Central China Wei LIU, <i>Wuhan</i>
OP0239	14:10 - 14:20	Hepatitis E virus X domain critically supports viral replication through its intricate interdomain interaction with the RNA-dependent RNA polymerase Xiaohui DING, <i>Xuzhou</i>
OP0240	14:20 - 14:30	Mechanisms Underlying Cyclosporine A-Mediated Promotion of HEV Replication Disen YUAN, <i>Beijing</i>

13:30 - 14:30 ORAL SESSION 40 Hepatitis B and Delta 8

407
Level 4 Moderators: Guizhou ZOU, *Hefei*
Ping WANG, *Beijing*

OP0241	13:30 - 13:40	Transcriptional features of peripheral blood B lymphocyte in children with chronic hepatitis B (CHB) treated with the Interferon α Yanwei ZHONG, <i>Beijing</i>
OP0242	13:40 - 13:50	HBsAg Declines and Immune Responses Following a Single Dose of VRON-0200: Interim Results from a Phase1B Study for HBV Functional Cure in Chronic HBV-Infected Patients Grace LH WONG, <i>Hong Kong</i>
OP0243	13:50 - 14:00	Prevalence of metabolic dysfunction-associated steatotic liver disease and its impact on liver fibrosis in patients with chronic hepatitis B Jian WANG, <i>Nanjing</i>
OP0244	14:00 - 14:10	Evaluation of the Efficacy and Safety of a PD-1 Inhibitor Combined with Peg-IFNα in Patients with Chronic Hepatitis B: A Prospective Nonrandomized Controlled Trial Chenrui LIU, <i>Xi'an</i>
OP0245	14:10 - 14:20	The Impact of Hepatitis D Virus Infection on the Clinical Efficacy of Antiretroviral Therapy in Patients Coinfected with Hepatitis B and HIV Yaozu HE, <i>Guangzhou</i>
OP0246	14:20 - 14:30	A Novel Strategy for Identifying Liver Fibrosis Regression in On-Treatment Chronic Hepatitis B Patients Using Serum Proteomics Mengyang ZHANG, <i>Beijing</i>

29 MAR
SAT

ORAL SESSION

29 March | Saturday

14:30 - 15:30 ORAL SESSION 41 Liver Oncology 2

401
Level 4

Moderators: Yongfang JIANG, *Changsha*
Yali LIU, *Beijing*

- | | | |
|--------|---------------|---|
| OP0247 | 14:30 - 14:40 | Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy
Bixing ZHAO, <i>Fuzhou</i> |
| OP0248 | 14:40 - 14:50 | Gut microbial metabolite butyrate suppresses hepatocellular carcinoma growth via CXCL11-dependent enhancement of natural killer cell infiltration
Menghan ZHANG, <i>Jinan</i> |
| OP0249 | 14:50 - 15:00 | 4-hydroxyhippuric acid drives SLC22A4+ neutrophils to deteriorate CD8+T cell anti-tumor immunity in hepatocellular carcinoma
Hanyi ZENG, <i>Guangzhou</i> |
| OP0250 | 15:00 - 15:10 | Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma
Liyang REN, <i>Beijing</i> |
| OP0251 | 15:10 - 15:20 | Efficacy and Safety of the Combination of Envafolelimab and Lenvatinib in Unresectable Hepatocellular Carcinoma: a Single-arm, Multicentre, Exploratory Phase II Clinical Study
Yunwei HAN, <i>Luzhou</i> |
| OP0252 | 15:20 - 15:30 | A Pilot Study of Adoptive Natural Killer Cell Therapy Combined with Microwave Ablation for Hepatocellular Carcinoma
Qian CAI, <i>Beijing</i> |

14:30 - 15:30 ORAL SESSION 42 Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 9

403
Level 4

Moderators: Ruifeng YANG, *Beijing*
Hui YANG, *Guangzhou*

- | | | |
|--------|---------------|--|
| OP0253 | 14:30 - 14:40 | Danggui Shaoyao Powder Ameliorates Metabolic Dysfunction-Associated Steatohepatitis by Suppressing Hepatic Macrophage NLRP3 inflammasome
Qian HUANG, <i>Shanghai</i> |
| OP0254 | 14:40 - 14:50 | The relationship between liver iron assessed by magnetic resonance imaging R2* and MASLD: a cross-sectional and longitudinal study
Ru-Tao LIN, <i>Shanghai</i> |
| OP0255 | 14:50 - 15:00 | The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study
Yao DOU, <i>Shijiazhuang</i> |

29 MAR
SAT

29 March | Saturday

ORAL SESSION

- OP0257 15:00 - 15:10 **ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study**
Stanley WANG, *California*
- OP0258 15:10 - 15:20 **Effect of Essential phospholipids on hepatic steatosis and quality of life in patients with MASLD associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity – a Phase IV, randomized double-blind clinical trial**
Norbert STEFAN, *Würzburg*

14:30 - 15:30 ORAL SESSION 43 Liver Fibrogenesis and Cirrhosis 5

405 Level 4 Moderators: Weifeng ZHAO, *Nanjing*
Qin PAN, *Shanghai*

- OP0259 14:30 - 14:40 **A Dynamic Model of Liver Fibrosis Regression Based on Longitudinal Liver Stiffness Measurements in Chronic Hepatitis B Patients**
Jiayi ZHANG, *Beijing*
- OP0260 14:40 - 14:50 **A Novel Non-invasive Model to Identify HRV in Patients with HBV-related Cirrhosis**
Peishuang XU, *Guangzhou*
- OP0261 14:50 - 15:00 **Ferrous Sulfide Nanosheet as a Novel Drug Delivery System for Lanifibranor to Ameliorate Liver Fibrosis**
Yinuo YANG, *Jinan*
- OP0262 15:00 - 15:10 **EUS criteria for predicting the occurrence of decompensation or death in patients with compensated cirrhosis**
Lili ZHAO, *Tianjin*
- OP0263 15:10 - 15:20 **Effects of Nucleoside analogues on liver fibrosis remission in patients with HBV-related hepatocellular carcinoma**
Jianrong LI, *Guangxi*
- OP0264 15:20 - 15:30 **Epidemiology and distribution of traditional Chinese medicine syndrome differentiation of non-alcoholic fatty liver disease (NAFLD) in traditional Chinese medicine liver disease clinics**
Li LI, *Beijing*

14:30 - 15:30 ORAL SESSION 44 Liver Injury and Toxicity 1

406 Level 4 Moderator: Song YANG, *Beijing*
Yannan LIU, *Beijing*

- OP0265 14:30 - 14:40 **A specialist liver home-based nursing program following inpatient admission facilitates alcohol abstinence in patients with cirrhosis.**
Leya NEDUMANNIL, *Epping*
- OP0266 14:40 - 14:50 **Characteristics of DILI, HILI and alcohol induced liver injury among 4087 patients in Mongolia**
Amarsana JAZAG, *Ulan Bator*

29 MAR
SAT

ORAL SESSION

29 March | Saturday

OP0267	14:50 - 15:00	Mas1 deficiency protects against acute liver failure by suppressing the FXR/S1P/Raf-dependent NETosis in mice Bo YANG, <i>Shanghai</i>
OP0268	15:00 - 15:10	Characterization of mucosal-associated invariant T cells in drug induced liver injury Zherui LIU, <i>Beijing</i>
OP0269	15:10 - 15:20	Ethanol decreases CPT2-mediated Carnitine catabolism to promote stemness in alcoholic hepatocellular carcinoma Xiaoxue YUAN, <i>Beijing</i>
OP0270	15:20 - 15:30	IL-8 Expression in Drug-Induced Liver Injury (DILI) and Its Correlation with Pathological Inflammation Diandian HAO, <i>Changchun</i>

14:30 - 15:30 ORAL SESSION 45 Hepatitis B and Delta 9

407 Level 4 Moderators: Jinghua FAN, *Kunming*
Wei HOU, *Zibo*

OP0271	14:30 - 14:40	Clinical Characteristics and Risk Factors for HBsAg Clearance in Patients with Acute Hepatitis B Virus Infection: A Retrospective Study in China Lu ZHANG, <i>Chongqing</i>
OP0272	14:40 - 14:50	Patients and healthcare providers' perspectives for functional cure of HBV: a qualitative interview study in China Yao ZHANG, <i>Beijing</i>
OP0273	14:50 - 15:00	Comparison of Antiviral Efficacy of Nucleos(t)ide Analogs Monotherapy or Combined with Interferon-α in Children with HBeAg-positive Chronic Hepatitis B Aged 1-6 Years Ziwei WANG, <i>Beijing</i>
OP0274	15:00 - 15:10	Less circulating T follicular helper 17 cells defected the anti-HBV humoral immunity in CHB patients Shengxia YIN, <i>Nanjing</i>
OP0275	15:10 - 15:20	Sustained functional cure in chronic hepatitis B patients treated with peginterferon alpha-2b combined with TDF: Reports at 52 weeks extended follow-up after a phase 3 trial Guiqiang WANG, <i>Beijing</i>
OP0276	15:20 - 15:30	Serum HBV RNA Distribution in Patients with Chronic Hepatitis B Jiaojiao WANG, <i>Chongqing</i>

15:45 - 16:45 ORAL SESSION 46 Liver Oncology 3

401 Level 4 Moderators: Hongmei ZU, *Xining*
Zhenhuan CAO, *Beijing*

OP0277	15:45 - 15:55	Contrast-enhanced ultrasound based intelligent model for multi classification diagnosis of focal liver lesion Wenzhen DING, <i>Beijing</i>
--------	---------------	--

29 MAR
SAT

29 March | Saturday

ORAL SESSION

OP0278	15:55 - 16:05	Proteomics-Based Identification of Promising Serum Biomarkers for Early Diagnosis of HBV-Related HCC in a Longitudinal Follow-Up Cohort Junjie CHEN, <i>Shanghai</i>
OP0279	16:05 - 16:15	A Prognostic Signature of Phagocytosis Regulators Predicts Outcomes and Immune Landscape in Hepatocellular Carcinoma Hao CUI, <i>Tianjin</i>
OP0280	16:15 - 16:25	Impact of Splenic CD101+ Neutrophils and Mechanism of Their Phenotypic Transformation during Hepatocellular Carcinoma Progression Gaixia HE, <i>Xi'an</i>
OP0281	16:25 - 16:35	Early Diagnosis of HBV-related HCC: Application of Liquid Biopsy Technology Based on DNA Methylation Xueying HUANG, <i>Beijing</i>
OP0282	16:35 - 16:45	Albumin-Bilirubin Grade As Predictor of Survival in Hepatocellular Carcinoma Patients treated with Thermal Ablation Erika Johanna Panadero TANADA-ESCANLAR, <i>Manila</i>

15:45 - 16:45 ORAL SESSION 47

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity 10

403 Level 4	Moderators: Qishui OU, <i>Fuzhou</i> Xinmin ZHOU, <i>Xi'an</i>	
OP0283	15:45 - 15:55	The stages of liver fibrosis and steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are associated with specific fatty acid metabolic pathways Vladimir BESSONOV, <i>Moscow</i>
OP0284	15:55 - 16:05	Central obesity further increases the risk of adverse liver outcomes in patients with high BMI Sherlot Juan SONG, <i>Hong Kong</i>
OP0285	16:05 - 16:15	Association of metabolic score for visceral fat with metabolic dysfunction-associated steatotic liver disease: A cross-sectional study of NHANES 2017-2020. Zhihong ZHAO, <i>Nanchang</i>
OP0286	16:15 - 16:25	Sarcopenic obesity Increased the Risk of Metabolic Associated Steatotic Liver Disease and Fibrosis in Elderly Residents Xiaohui LIU, <i>Beijing</i>
OP0287	16:25 - 16:35	Insufficient Control of Cholestatic Pruritus in Primary Biliary Cholangitis (PBC) With Current Therapies: Baseline Data From the East Asian Population Enrolled in the Phase 3 GLISTEN (Global Linerixibat Itch STudy of Efficacy and safety iN PBC) Study Xiong MA, <i>Shanghai</i>
OP0288	16:35 - 16:45	E2F2 reprograms macrophage function by modulating material and energy metabolism in the progression of metabolic dysfunction-associated steatohepatitis Zheng LIU, <i>Nanjing</i>

29 MAR
SAT

ORAL SESSION

29 March | Saturday

15:45 - 16:45 ORAL SESSION 48

Liver Fibrogenesis and Cirrhosis 6

405

Level 4

Moderators: Guizhou ZOU, *Hefei*
Meifang HAN, *Wuhan*

- | | | |
|--------|---------------|---|
| OP0289 | 15:45 - 15:55 | Baohuoside I inhibits Hepatocellular carcinoma through the UBE2C/P53 Pathway
Xin ZHANG, <i>Shanghai</i> |
| OP0290 | 15:55 - 16:05 | Analysis of the effect of Compound Yindan Decoction on intestinal microbiota in rats with acute intrahepatic cholestasis based on 16S rRNA gene sequencing technology
Xiaoling LI, <i>Beijing</i> |
| OP0291 | 16:05 - 16:15 | Qingchangeligan formula plays a protective role in mice with acute liver injury by regulating autophagy
Xiangying ZHANG, <i>Beijing</i> |
| OP0292 | 16:15 - 16:25 | Restoring energy metabolism by herbal medicine prevents alcohol-induced liver injury
Yao LIU, <i>Beijing</i> |
| OP0293 | 16:25 - 16:35 | Efficacy and Safety of He-Shu-Xiao-Ji Pill Combined with Standard Treatment Strategy in HBV-related Hepatocellular Carcinoma: A Single-center, Prospective Control, Real-world Cohort Study
Xiaoning ZHU, <i>Luzhou</i> |
| OP0294 | 16:35 - 16:45 | Anti-cancer Effects of Yiqi Rougan Jiedu Formula Combined with PD-1 Inhibitor on Hepatocellular Carcinoma in Mice with Loaded Tumors and Its Effects on The Balance of Treg/Th17 and Th1/Th2
Xuan WU, <i>Beijing</i> |

15:45 - 16:45 ORAL SESSION 49

Liver Injury and Toxicity 2

406

Level 4

Moderators: Hai LI, *Shanghai*
Yongning XIN, *Qingdao*

- | | | |
|--------|---------------|---|
| OP0295 | 15:45 - 15:55 | Comparison of Clinical Characteristics between Raw Polygonum Multiflorum and Polygonum Multiflorum Praeparata Induced Liver Injury
Wanna YANG, <i>Beijing</i> |
| OP0296 | 15:55 - 16:05 | Machine learning models based on fatty acid binding protein 4 help predict the chronic and lethal outcomes of patients with drug-induced liver injury
Haoshuang FU, <i>Shanghai</i> |
| OP0297 | 16:05 - 16:15 | IGF2 as a Potential Biomarker for Alcohol-Related Liver Disease and Its Mechanism of Regulating Alcohol-Induced Hepatocyte Injury through the Mitochondrial Quality Control System
Tian XIA, <i>Beijing</i> |
| OP0298 | 16:15 - 16:25 | Establishment and evaluation of ACR prediction model for assessing the severity of drug-induced liver injury
Na FU, <i>Shijiazhuang</i> |

29 MAR
SAT

29 March | Saturday

ORAL SESSION

OP0299	16:25 - 16:35	LncRNA NEAT1 In PBMCs Can Predict Liver Injury In Patients With Anti-tuberculosis Treatment Xi ZHAO, <i>Urumqi</i>
OP0300	16:35 - 16:45	Investigating the Mechanism of Scutellaria (Huangqin)-induced Liver Injury through Network Pharmacology and In Vitro Studies Tiantian GUO, <i>Beijing</i>

15:45 - 16:45 ORAL SESSION 50 Hepatitis B and Delta 10

407 Level 4	Moderators: Yongqian CHENG, <i>Beijing</i> Yandi XIE, <i>Beijing</i>	
OP0301	15:45 - 15:55	Correlation between serum hepatitis B core antibody and significant liver inflammation in children with HBeAg-positive chronic hepatitis B Yanwei ZHONG, <i>Beijing</i>
OP0302	15:55 - 16:05	The occurrence of low-level viremia in patients with chronic hepatitis B virus infection is related to gut microbiota and metabolites Tianquan HUANG, <i>Chongqing</i>
OP0303	16:05 - 16:15	Optimized Strategies in Hepatitis B Screening and Linkage to Care in Community Settings Qiran ZHANG, <i>Shanghai</i>
OP0304	16:15 - 16:25	Study on the efficacy of peginterferon therapy for inactive HBsAg carriers and the role of B lymphocytes in the clinical cure of chronic hepatitis B Zhenhuan CAO, <i>Beijing</i>
OP0305	16:25 - 16:35	Independent Predictive Factors for Rapid HBsAg Seroclearance at 24 Weeks in Chronic Hepatitis B Patients Undergoing Interferon Treatment Jianxia DONG, <i>Beijing</i>
OP0306	16:35 - 16:45	Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment Yibo DING, <i>Xuzhou</i>

16:45 - 17:45 ORAL SESSION 51 Liver Oncology 4

401 Level 4	Moderators: Weize ZUO, <i>Shihezi</i> Zhenhuan CAO, <i>Beijing</i>	
OP0308	16:45 - 16:55	Multicohort fecal metagenomes analysis contributes to non-invasive diagnosis for cholangiocarcinoma Zhigang REN, <i>Zhengzhou</i>
OP0309	16:55 - 17:05	Decade-Long Survival Insights: Upfront Ablation Outperforms Delayed Ablation in Colorectal Liver Oligometastases: A Comprehensive Nationwide Study Jianming LI, <i>Beijing</i>

29 MAR
SAT

ORAL SESSION

29 March | Saturday

OP0310	17:05 - 17:15	Targeted therapy and Deb-Tace: cardiovascular aspects of HCC Saule KUBEKOVA, <i>Astana</i>
OP0311	17:15 - 17:25	Specific gut microbiota contributes to metabolic associated fatty liver disease in male mice with DR3 deficiency Yuefang YE, <i>Hangzhou</i>
OP0388	17:25 - 17:35	The Role of Cell-Intrinsic Matrisome-Related Molecules in Human Hepatocyte Fate Maintenance Takeshi SAITO, <i>Los Angeles</i>

16:45 - 17:45 ORAL SESSION 52 Immune - Mediated Chronic Liver Diseases 1

403 Level 4	Moderators: Rongqi WANG, <i>Shijiazhuang</i> Xuefei DUAN, <i>Beijing</i>	
OP0312	16:45 - 16:55	Evaluation of Antiviral and Immunomodulatory Effects of Tenofovir amibufenamide in Chronic HBV-replication Mouse Models Jia LIU, <i>Wuhan</i>
OP0313	16:55 - 17:05	Phase I Studies of a Novel Pulsatile FXR Ligand for Treating Cholestatic Liver Diseases Eric H XU, <i>Shanghai</i>
OP0314	17:05 - 17:15	Linerixibat Has Low Potential of Ethnic Differences for the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis Ying KE, <i>Sydney</i>
OP0315	17:15 - 17:25	Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis in the RESPONSE Trial: A Phase 3 International, Randomized, Placebo-Controlled Study Barry CRITTENDEN, <i>California</i>
OP0316	17:25 - 17:35	Prediction of Moderate-to-Severe Interface Hepatitis in Primary Biliary Cholangitis Using Machine Learning and SHAP Shasha LI, <i>Nanjing</i>
OP0317	17:35 - 17:45	Phase II Studies of a Novel Pulsatile FXR Ligand for PBC and PSC Xiao XIAO, <i>Shanghai</i>

16:45 - 17:45 ORAL SESSION 53 Liver Fibrogenesis and Cirrhosis 7

405 Level 4	Moderators: Changqing YANG, <i>Shanghai</i> Han BAI, <i>Shenyang</i>	
OP0318	16:45 - 16:55	The effect of Jianpi Huoxue Tongluo Fang intervention on portal vein recanalization in rats with portal vein thrombosis Ruiyuan TIAN, <i>Jinan</i>
OP0319	16:55 - 17:05	Therapeutic mechanism study of He-he San-ji Formula on NASH-HCC through TREM2-mediated polarization of Tumor associated macrophages Mei-Jie SHI, <i>Guangzhou</i>

29 MAR
SAT

29 March | Saturday

ORAL SESSION

OP0320	17:05 - 17:15	The Imbalance of Homeostasis in Neutrophil Extracellular Traps is Associated with Portal Vein Thrombosis in Patients with Decompensated Cirrhosis Ying CAO, <i>Beijing</i>
OP0321	17:15 - 17:25	Exploring the Mechanism of Shuxuening Injection on Liver Fibrosis in Mice Based on Gut Microbiota and Non-Targeted Metabolomics Xin SUN, <i>Beijing</i>
OP0322	17:25 - 17:35	LOXL1 G153D Mutation Impedes Liver Fibrosis Regression After Etiology Removal Wen ZHANG, <i>Beijing</i>
OP0323	17:35 - 17:45	Carvedilol restoring gut microbiota homeostasis: a potential therapeutic mechanism for portal hypertension management Yarong HAO, <i>Shanghai</i>

16:45 - 17:45 ORAL SESSION 54 Liver Injury and Toxicity 3

406
Level 4 Moderators: Qin PAN, *Shanghai*
Wenyan LIANG, *Beijing*

OP0324	16:45 - 16:55	Hepatic Adverse Events of Novel Immunotherapy-Based Therapies in Clinical Trials: A Systematic Review and Meta-Analysis Minyan YE, <i>Fuzhou</i>
OP0325	16:55 - 17:05	Bavachinin caused cholestasis by down-regulating the expression of BAAT and disrupting glycocholic acid synthesis in human liver organoids Yu SU, <i>Beijing</i>
OP0326	17:05 - 17:15	Molecular mechanism of endoplasmic reticulum stress regulating DDX3X-TFEB signaling pathway to promote drug-induced liver injury Yaling CAO, <i>Beijing</i>
OP0328	17:15 - 17:25	The study on the efficacy of menstrual blood-derived mesenchymal stem cells in the treatment of alcoholic liver fibrosis. Jun GE, <i>Haikou</i>
OP0329	17:25 - 17:35	Establishment of an alcoholic liver fibrosis model using the combination of ethanol and pyrazole. Ang LI, <i>Haikou</i>

16:45 - 17:45 ORAL SESSION 55 Hepatitis B and Delta 11

407
Level 4 Moderators: Yinying LU, *Beijing*
Jie ZHAO, *Taiyuan*

OP0330	16:45 - 16:55	Long-term safety of tenofovir alafenamide in Chinese chronic hepatitis B patients treated for up to 8 years in 2 Phase 3 studies Jinlin HOU, <i>Guangzhou</i>
--------	---------------	---

29 MAR
SAT

ORAL SESSION

29 March | Saturday

- | | | |
|--------|---------------|--|
| OP0331 | 16:55 - 17:05 | Higher risk of postpartum phase transition to immune-active among HBeAg-positive pregnant women with indeterminate phase
Qiao TANG, <i>Chongqing</i> |
| OP0332 | 17:05 - 17:15 | The Efficacy and Safety of Pegylated Interferon Alpha Treatment in Patients with HBV Related Cirrhosis and HCC after Radical Surgery: Preliminary Data From The TERMINATOR Project
Qiuju SHENG, <i>Shenyang</i> |
| OP0333 | 17:15 - 17:25 | Long-term efficacy of tenofovir alafenamide in Chinese chronic hepatitis B patients treated for up to 8 years in 2 Phase 3 studies
Jinlin HOU, <i>Guangzhou</i> |
| OP0334 | 17:25 - 17:35 | Comparative Efficacy of IFN and Nuc Therapy regarding HBsAg loss in Chronic Hepatitis B Patients
Ruirui YOU, <i>Shanghai</i> |
| OP0335 | 17:35 - 17:45 | Responders to Prior BRIL-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study
Grace Lai-Hung WONG, <i>Hong Kong</i> |

Scientific Program

30 March 2025

Sunday

30 March | Sunday

Scientific Program

07:30 - 08:00

GENERAL BUSINESS MEETING

Auditorium, Level 4

08:00 - 12:00

CURE FORUM

Course Director

Jinlin HOU, *Beijing*

08:00 - 09:20

SESSION 01

Understanding Functional Cure for Hepatitis B

Auditorium
Level 4

Moderators: Masao OMATA, *Kofu*
Necati ORMECI, *Istanbul*

08:00 - 08:20

Consensus and Controversy of Functional Cure for Hepatitis B

George K. K LAU, *Hong Kong*
Chun-Jen LIU, *Taipei*

08:20 - 08:40

Current Treatment Options: Interferon, NUCs and Unmet Needs

Xiaoguang DOU, *Shenyang*
Teerha PIRATVISUTH, *Hat Yai*

08:40 - 09:00

Immunological Insights into Functional Cure

Fu-Sheng WANG, *Beijing*
Antonio BERTOLETTI, *Singapore*

09:00 - 09:20

Virological Insights into Functional Cure

Zhenghong YUAN, *Shanghai*
Peter REVILL, *Shanghai*

09:20 - 10:50

SESSION 02

Clinical Trials and Future Directions for the Cure of Hepatitis B

Auditorium
Level 4

Moderators: Shiv K. SARIN, *New Delhi*
Rino A. GANI, *Jakarta*

09:20 - 09:40

MicroRNAs (miRNAs) and Antisense Oligonucleotides (ASOs) in Hepatitis B Functional Cure

Jinlin HOU, *Guangzhou*
Man-Fung YUEN, *Hong Kong*

09:40 - 10:00

Gene Editing and Therapeutic Vaccine

Jidong JIA, *Beijing*
Edward J. GANE, *Auckland*

10:00 - 10:20

Combination Therapies: The Role of NUCs, Interferon and/or Immune Checkpoint Inhibitors in Combining miRNA and ASOs

Guiqiang WANG, *Beijing*
Young-Suk LIM, *Seoul*

10:20 - 10:50

Panel Discussion: Is miRNAs and ASOs the Final Answer?

30 MAR
SUN

Scientific Program

30 March | Sunday

10:50 - 12:00	SESSION 03 Clinical Trials and Future Directions for the Cure of Liver Diseases
Auditorium Level 4	Moderators: George K.K. LAU, <i>Hong Kong</i> Shuichiro SHIINA, <i>Tokyo</i>
10:50 - 11:10	Genetics and Autoimmune Liver Disease Xiong MA, <i>Shanghai</i> Atsushi TANAKA, <i>Tokyo</i>
11:10 - 11:30	Liver Steatosis and Fibrosis Lai WEI, <i>Beijing</i> Vincent W.S. WONG, <i>Hong Kong</i>
11:30 - 11:50	Liver Cancer Jun ZHOU, <i>Beijing</i> Pierce K.H. CHOW, <i>Singapore</i>
11:50 - 12:00	Panel Discussion: What is the Role of APASL?
12:00 - 12:25	Break
08:00 - 09:00	YOUNG INVESTIGATOR SESSION 05
Function Hall A Level 1	Moderators: Jinhua HU, <i>Beijing</i> Rongqi WANG, <i>Shijiazhuang</i>
08:00 - 08:12	Noninvasive Prediction of Liver Inflammation Grades in Chronic Hepatitis B Patients Based on DWI Combined with T2WI Signal Intensity Yuan LIU, <i>Beijing</i>
08:12 - 08:24	Therapeutic Options for Low-Level Viremia in Patients with Chronic Hepatitis B: Adding on Peginterferon α-2b as A Potentially Superior Option Suzhen JIANG, <i>Beijing</i>
08:24 - 08:36	The Validation of Histological Criteria from the IAIH - PG to Distinguish AIH from Drug-Induced Liver Injury in China Zikun MA, <i>Beijing</i>
08:36 - 08:48	Microwave Ablation Versus Repeat Liver Resection for Recurrent Intrahepatic Cholangiocarcinoma within Milan Criteria: A Long-Term Multicenter Cohort Study Chuan PANG, <i>Beijing</i>
08:48 - 09:00	Outcomes of Conversion Surgery After Immune Checkpoint Inhibitor-Based Combination Therapy in Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study Mingjian PIAO, <i>Beijing</i>

30 MAR
SUN

Scientific Program

30 March | Sunday

08:00 - 09:00

YOUNG INVESTIGATOR SESSION 06

Function Hall B
Level 1

Moderators: Zhongjie HU, *Beijing*
Minghui LI, *Beijing*

08:00 - 08:12

FAK - TRIM25 Promotes Hepatic Stellate Cell Activation And Aerobic Glycolysis By Inhibiting FBXW7-Mediated c-Myc Ubiquitination
Lu HAN, *Guizhou*

08:12 - 08:24

Integrating Multi - Omics and Machine Learning to Uncover the Causal Link Between Liver Cirrhosis and Hypothyroidism
Jiyuan ZHOU, *Guangzhou*

08:24 - 08:36

Jieduan-Niwan Formula Alleviates Macrophage Pyroptosis in Acute-on - Chronic Liver Failure Through Modulation of the GSK-3 β /NLRP3/ Caspase-1 Pathway
Peng FANG, *Hangzhou*

08:36 - 08:48

Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen - Presenting Warriors
Yingcheng WU, *Shanghai*

08:48 - 09:00

Positive Histological Expression of ARGINASE is a Favorable Factor for Hepatocellular Carcinoma Recurrence
Xi HE, *Beijing*

08:00 - 09:00

YOUNG INVESTIGATOR SESSION 07

Function Hall C
Level 1

Moderators: Tarik ASSELAH, *Paris*
Shizhong YANG, *Beijing*

08:00 - 08:12

COSSH Diagnostic Framework Outperforms in Acute-on-Chronic Liver Failure: Evaluation from A Global Aetiology Cohort
Jinjin LUO, *Hangzhou*

08:12 - 08:24

Metabolic Dysfunctions Increase Liver-Related Events in Patients with HBV-related Compensated Cirrhosis
Ling ZHOU, *Guangzhou*

08:24 - 08:36

Multi-Omics Analyses of the Gut Microbiota and Metabolites in Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
Lu JIANG, *Shanghai*

08:36 - 08:48

Perspective on Illness Perception and Self-Management Behaviours from Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease and Healthcare Professionals: An Exploratory Qualitative Study
Angel C.K. MA, *Hong Kong*

08:48 - 09:00

Impaired Mitochondrial Oxidative Phosphorylation in Hepatic DNTregs Leads to Reduced Immunoregulatory Function and Exacerbated MASLD Progression
Guangyong SUN, *Beijing*

30 MAR
SUN

30 March | Sunday

Scientific Program

08:00 - 09:00		YOUNG INVESTIGATOR SESSION 08
402 (A+B) Level 4		Moderators: Youqing XU, <i>Beijing</i> Jie GAO, <i>Beijing</i>
08:00 - 08:12		Cerium Dioxide Nanoparticles Ameliorate Steatohepatitis in Rats Induced by High-Fat, High-Cholesterol Diet by Regulating the mTOR/SREBP-1 Signaling Pathway Jing ZENG, <i>Shanghai</i>
08:12 - 08:24		Regional and Temporal Disparities in the Etiologies and Outcomes of Acute-on-Chronic Liver Failure: Insights from Two Decades of the APASL-ACLF Research Consortium Nipun VERMA, <i>Chandigarh</i>
08:24 - 08:36		A Novel Body Composition Score Based on CT Imaging in Predicting All-Cause and Liver-Related Mortality in Cirrhosis: A Retrospective Cohort Study Tingyang WEI, <i>Beijing</i>
08:36 - 08:48		Baveno VII Algorithm was Able to Stratify the Risk of Portal Hypertension-Related Events in Patients with HBV-Related Cirrhosis Haiyu WANG, <i>Guangzhou</i>
08:48 - 09:00		The Diagnostic Value of 26 Fibrosis or Cirrhosis Models in Community-Based Patients with NAFLD Xiajie WEN, <i>Beijing</i>
08:00 - 09:00		MORNING SESSION 06
403 Level 4		Moderator: Shaojie XIN, <i>Beijing</i>
08:00 - 08:30		The Trend in Management of HCC: Surgical and Non-Surgical Pierce K.H. CHOW, <i>Singapore</i>
08:30 - 09:00		Safety and Efficacy of PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Combination Therapy in Patients with Advanced Hepatocellular Carcinoma Combined with Hyperbilirubinemia Fanping MENG, <i>Beijing</i>
08:00 - 09:00		MORNING SESSION 07
405 Level 4		Moderator: Huichun XING, <i>Beijing</i>
08:00-08:30		The Role and Prognosis of Glucocorticoids in the Treatment of Liver Failure Rongkuan LI, <i>Dalian</i>
08:30-09:00		Immune Checkpoint Inhibitors in the Functional Cure of Chronic Hepatitis B: An Overview of Progress and Challenges Junliang FU, <i>Beijing</i>

30 MAR
SUN

Scientific Program

30 March | Sunday

08:00 - 09:00

MORNING SESSION 08

406
Level 4

Moderator: Jun LI, *Nanjing*

08:00 - 08:30

The Expansion of TIPS (Transjugular Intrahepatic Portosystemic Shunt) in the Treatment of Portal Hypertension
Li YANG, *Chengdu*

08:30 - 09:00

Liver Cirrhosis and Complications
Jinghang XU, *Beijing*

08:00 - 09:00

MORNING SESSION 09

407
Level 4

Moderator: Yan HUANG, *Changsha*

08:00 - 08:30

Management of Chronic Hepatitis B with Indeterminate Phase
Chao WU, *Nanjing*

08:30 - 09:00

Exploratory Evaluation of Hepatic Tissue Changes in Hepatitis B Virus-Related Compensated Cirrhosis Treated with Human Umbilical Cord-Derived Mesenchymal Stem Cells
Yingan JIANG, *Wuhan*

09:00 - 10:30

CONCURRENT SESSION 21 Hepatitis C Beyond Cure

Function Hall A
Level 1

Moderators: Thomas TU, *Sydney*
Yuxin ZHANG, *Urumqi*

09:00 - 09:20

Screening for Hepatocellular Cancer Post-SVR, Challenges and Opportunities
Paul Y. KWO, *Redwood City*

09:20 - 09:40

Simplified HCV Treatment for Eligible Patients with Pan-Genotypic Regimens
Wan-Long CHUANG, *Kaohsiung*

09:40 - 10:00

Individualized Risk Stratification Using HCC Risk Scores after SVR
Gamal SHIHA, *Mansoura*

10:00 - 10:20

The Role of HCV RNA Point-of-Care (POCT) and Conventional Hepatitis C Testing
Alexander J. THOMPSON, *Melbourne*

10:20 - 10:30

Panel Discussion

30 MAR
SUN

30 March | Sunday

Scientific Program

09:00 - 10:30 CONCURRENT SESSION 22 Pathophysiology of Liver Cirrhosis in 2025: Better Patient Care and Potential Therapeutic Targets

**Function Hall B
Level 1**

Moderators: Oidov BAATARKHUU, *Ulaanbaatar*
Zhiyun YANG, *Beijing*

09:00 - 09:20

Oxidative Stress and Hepatic Stellate Cells: Key Drivers of Liver Fibrosis and Cirrhosis
Natalia NIETO, *Chicago*

09:20 - 09:40

Understandings From Decompensation to Recompensation
Hong YOU, *Beijing*

09:40 - 10:00

Blood Inflammatory Markers and Acutely Decompensated Cirrhosis
Qing XIE, *Shanghai*

10:00 - 10:20

The Role of Microbiome in Liver Cirrhosis: Current and Future Microbiome-Targeted Therapeutics
K. Rajender REDDY, *Philadelphia*

10:20 - 10:30

Panel Discussion

09:00 - 10:30

CONCURRENT SESSION 23 Revolution in the Management of Advanced Liver Cancer

**Function Hall C
Level 1**

Moderators: Heping HU, *Shanghai*
Yongjian ZHOU, *Guangzhou*

09:00 - 09:20

Systemic Therapy for Advanced HCC
Stephen L. CHAN, *Hong Kong*

09:20 - 09:40

Combination Therapy for Advanced HCC
Tian YANG, *Shanghai*

09:40 - 10:00

Challenges and Opportunities: Multidisciplinary Management of Intrahepatic Cholangiocarcinoma
Canhong XIANG, *Beijing*

10:00 - 10:20

Future Prospect of Immunotherapy and Vaccine for HCC
Hongsong CHEN, *Beijing*

10:20 - 10:30

Panel Discussion

10:30 - 12:00

CONCURRENT SESSION 24 Infectious Disease and the Liver

**Function Hall A
Level 1**

Moderators: Yan GAO, *Beijing*
Liaoyun ZHANG, *Taiyuan*

10:30 - 10:50

Liver Disease in People with Human Immunodeficiency Virus (HIV)
Mark SULKOWSKI, *Baltimore*

10:50 - 11:10

The Current Understanding of HIV/HBV Coinfection
Taisheng LI, *Beijing*

30 MAR
SUN

Scientific Program

30 March | Sunday

11:10 - 11:30 **Coronavirus Disease 2019 (COVID 19) in Patients with Chronic Liver Disease**
Wenhong ZHANG, *Shanghai*

11:30 - 11:50 **Liver Fluke and Cholangiocarcinoma (CCA)**
Kittiyod POOVORAWAN, *Bangkok*

11:50 - 12:00 **Panel Discussion**

10:30 - 12:20 **CONCURRENT SESSION 25** **Portal Hypertension and Complications: Consensus and Questions Before 2026**

Function Hall B Level 1 Moderators: Barjesh C. SHARMA, *New Delhi*
Guohong DENG, *Chongqing*

10:30 - 10:50 **Pathophysiology and Management of Portal Hypertension and Complications**
Norifumi KAWADA, *Osaka*

10:50 - 11:10 **Liver Cirrhosis and AKI Management**
Jun LI, *Hangzhou*

11:10 - 11:30 **Comprehensive Management of End-Stage Liver Disease Complicated by Infections**
Qin NING, *Wuhan*

11:30 - 11:50 **Current and Future Treatment for Portal Hypertension and Varices**
Guadalupe GARCIA-TSAO, *Milford*

11:50 - 12:10 **Altered Mental Status in Cirrhosis: Etiologies Other Than Hepatic Encephalopathy**
Barjesh C. SHARMA, *New Delhi*

12:10 - 12:20 **Panel Discussion**

10:30 - 12:00 **CONCURRENT SESSION 26** **Current Challenge and Future Development of Liver Cancer**

Function Hall C Level 1 Moderators: Yun DAI, *Beijing*
Min ZHENG, *Hangzhou*

10:30-10:50 **Exploring Novel Ways to Improve the Efficacy of Immunotherapy**
Lunxiu QIN, *Shanghai*

10:50-11:10 **Pre-transplant Use of Immune Check Point Inhibitor in Patients with Hepatocellular Carcinoma**
Ju Dong YANG, *Los Angeles*

11:10-11:30 **Multimodal AI and Biomedical Research**
Guangyu WANG, *Beijing*

11:30-11:50 **Precise Diagnosis and Treatment of Complex Biliary Diseases Based on Liver Panoramic Digital Pathology**
Shuo JIN, *Beijing*

11:50 - 12:00 **Panel Discussion**

30 MAR
SUN

30 March | Sunday

Scientific Program

12:25 - 13:45		LATER BREAKER 02
Auditorium Level 4	Moderators: Elizabeth E. POWELL, <i>Brisbane</i> Yu CHEN, <i>Beijing</i>	
12:25 - 12:37	Community Participation as A Strategy for Hepatitis B Virus Prevention in Kerala, S India : A Success Story Leena MOHANAN, <i>Trivandrum</i>	
12:37 - 12:49	Robust HBsAg Loss after AHB-137 Treatment in HBeAg-Negative Chronic Hepatitis B Patients on NA Therapy: 24-Week ON Treatment and 8-Week OFF Treatment Results from an Ongoing Multicenter, Randomized, Open-Label Phase IIa Study Yanhua DING, <i>Changchun</i>	
12:49 - 13:01	40% of Interferon-Experienced Chronic Hepatitis B Patients Achieved HBsAg Loss Through 24 Weeks of Peginterferon Alpha-2b Retreatment: Interim Analysis from Ongoing LEADING Study Qing XIE, <i>Shanghai</i>	
13:01 - 13:13	Higher End of Treatment (EOT) HBsAg Loss and Seroconversion Rates in Participants with Chronic HBV Infection Receiving Elebsiran (BRII-835) and Pegylated Interferon Alfa-2a (PEG-IFNa) Compared to PEG-IFNa Alone: Week 48 Results from Ongoing ENSURE Study Jidong JIA, <i>Beijing</i>	
13:13 - 13:25	Concurrent or Sequential Use of Pegylated Interferon Alpha with Xalnesiran-Based Combination Therapy in Nucleos(t)ide Analogue Suppressed Chronic Hepatitis B Patients: Results of 96 Weeks of Follow-up from A Long-Term Observational Study Xieer LIANG, <i>Guangzhou</i>	
13:25 - 13:45	Break	
13:45 - 15:00		APASL 2025 BEIJING DEBRIEF
Auditorium Level 4	Moderator: Hong YOU, <i>Beijing</i>	
13:45 - 14:00	Viral Hepatitis Jian SUN, <i>Guangzhou</i>	
14:00 - 14:15	MAFLD Huiying RAO, <i>Beijing</i>	
14:15 - 14:30	Autoimmune Liver Disease Xiong MA, <i>Shanghai</i>	
14:30 - 14:45	ACLF Jinhua HU, <i>Beijing</i>	
14:45 - 15:00	HCC TBD	
15:00 - 15:45		CLOSING CEREMONY
Auditorium Level 4	Moderators: Yuemin NAN, <i>Shijiazhuang</i> Necati ORMECI, <i>Istanbul</i>	

30 MAR
SUN

ORAL SESSION

30 March | Sunday

08:00 - 09:00 ORAL SESSION 56

Basic Science & Pathology 1

401
Level 4

Moderators: Heping HU, *Shanghai*
Anlin MA, *Beijing*

- | | | |
|--------|---------------|--|
| OP0336 | 08:00 - 08:10 | ACSL4 Identified as a Potential Prediction Biomarker for Invasion and Metastasis of Hepatocellular Carcinoma via Multi-center Study
Yusufukadier MAIMAITINIJIATI, <i>Beijing</i> |
| OP0337 | 08:10 - 08:20 | Gut-liver axis modulation empowers natural killer T cells for liver cancer immunotherapy
Ting LUO, <i>Beijing</i> |
| OP0339 | 08:20 - 08:30 | Decoding Extracellular Vesicle-Derived circRNAs in Cholangiocarcinoma: A Multi-Omics Machine Learning Approach to Predict Immunotherapy Resistance
Prihantini PRIHANTINI, <i>West Java</i> |
| OP0340 | 08:30 - 08:40 | ATG16L1-mediated macrophage metabolic reprogramming promotes liver regeneration
Xinyu ZHAN, <i>Nanjing</i> |

09:00 - 10:00 ORAL SESSION 57

Liver Oncology 5

401
Level 4

Moderators: Yonghong ZHANG, *Beijing*
Wenyan LIANG, *Beijing*

- | | | |
|--------|---------------|--|
| OP0341 | 09:00 - 09:10 | Predictive Value of pgRNA for Recurrence in Advanced Hepatocellular Carcinoma and Its Potential Mechanisms
Yifan HAN, <i>Beijing</i> |
| OP0342 | 09:10 - 09:20 | Deep Learning-Driven Discovery of Extracellular Vesicle-Derived Circular RNAs as Biomarkers of Immune Checkpoint Inhibitor Resistance in Hepatocellular Carcinoma
Rifaldy FAJAR, <i>Yogyakarta</i> |
| OP0343 | 09:20 - 09:30 | PHGDH acts as an RNA-binding protein to stabilize PRKCD mRNA and promote hepatocellular carcinoma progression
Pai PENG, <i>Chongqing</i> |
| OP0344 | 09:30 - 09:40 | PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction
Kang WU, <i>Chongqing</i> |
| OP0345 | 09:40 - 09:50 | Long Noncoding RNA FTX Exhibits Dual Roles in Hepatocellular Carcinoma Progression: Implications for Anoikis Resistance and Metastasis
Nannan ZHANG, <i>Jinan</i> |

30 MAR
SUN

30 March | Sunday

ORAL SESSION

09:00 - 10:00 ORAL SESSION 58

Immune-Mediated Chronic Liver Diseases 2

403

Level 4

Moderators: Yingdi LIU, *Beijing*
Ning CHEN, *Beijing*

- OP0347 09:00 - 09:10 **Concomitant dyslipidemia did not affect the long-term outcomes of patients with primary biliary cholangitis**
Qin XIAO, *Beijing*
- OP0348 09:10 - 09:20 **Current analysis of fatigue in patients with primary biliary cholangitis**
Ying HAN, *Beijing*
- OP0349 09:20 - 09:30 **Clinical Significance of Anti-Mitochondrial Antibodies and PBC-Specific Anti-Nuclear Antibodies in Evaluating Atypical Primary Biliary Cholangitis with Normal Alkaline Phosphatase Levels**
Shasha LI, *Nanjing*
- OP0350 09:30 - 09:40 **IgG4-associated autoimmune hepatitis: a case report and systematic review**
Chun Hsun LIAO, *Taipei*
- OP0351 09:40 - 09:50 **Decoding Long Non-Coding RNA-Driven Epigenetic Dysregulation in Steroid Resistance of Autoimmune Hepatitis: A Multi-Omics Machine Learning Approach**
Rifaldy FAJAR, *Yogyakarta*
- OP0352 09:50 - 10:00 **Acute Viral Hepatitis Unmasking Autoimmune Hepatitis**
Sunil TANEJA, *Chandigarh*

09:00 - 10:00 ORAL SESSION 59

Liver Fibrogenesis and Cirrhosis 8

405

Level 4

Moderators: Hongxia LIANG, *Zhengzhou*
Zhao LI, *Beijing*

- OP0353 09:00 - 09:10 **The advantage of Tomoelastography in the accurate diagnosis of chronic hepatitis B and non-alcoholic fatty liver fibrosis stage and significant liver fibrosis stage (F2)**
Huanhuan ZHANG, *Dongguan*
- OP0354 09:10 - 09:20 **Identification and validation of ferroptosis-related genes for acute-on-chronic liver failure by WGCNA and machine learning**
Yadong WANG, *Shijiazhuang*
- OP0355 09:20 - 09:30 **Ajugol improves hepatic fibrosis by modulating bile acid synthesis and arachidonic acid metabolism in mice**
Xia WEI, *Shanghai*
- OP0356 09:30 - 09:40 **Probiotics reduce the incidence of hepatic encephalopathy in patients with portal hypertension after Transjugular intrahepatic portosystemic shunt: A randomized controlled trial**
Xiaotong XU, *Beijing*
- OP0357 09:40 - 09:50 **Huangjia Ruangan Granules with Entecavir for Fibrosis Regression in Chronic Hepatitis B: A Multicenter, randomized, double-blind, Phase II Trial**
Jinghao ZHANG, *Shanghai*

30 MAR
SUN

ORAL SESSION

30 March | Sunday

OP0358 09:50 - 10:00 **IL-2R combined with THBS2 can predict the degree of liver fibrosis in patients with chronic hepatitis B**
Yiqi LIU, *Beijing*

09:00 - 10:00 ORAL SESSION 60

Basic Science & Pathology 2

406
Level 4

Moderators: Min ZHENG, *Hangzhou*
Ming YANG, *Beijing*

OP0359 09:00 - 09:10 **High Dietary Fiber Promotes Cholangiopathy and Biliary Fibrosis in Mice with Human-like Bile Acids Pool**
Wenqiang SHEN, *Groningen*

OP0360 09:10 - 09:20 **Immune Checkpoint Protein CD40 and Integrin $\alpha 5\beta 1$ in HCC: Mechanisms Supporting Tumor Survival and Therapy Potential**
Le Thanh THUY, *Osaka*

OP0361 09:20 - 09:30 **Faecalibaculum rodentium is a potential pathobiont in metabolic dysfunction-associated steatohepatitis (MASH) via B cell dysregulation**
Hong Sheng CHENG, *Osaka*

OP0363 09:30 - 09:40 **Analysis of histological spectrum and regenerative potential of hepatocytes as a predictor of outcome in acute-on-chronic liver failure (ACLF)- a large single-centre study**
Archana RASTOGI, *New Delhi*

OP0364 09:40 - 09:50 **The pan-PPAR Agonist Lanifibranor Improves Liver Inflammation, Ballooning, and Fibrosis in a Diet-induced Obese MASH Hamster Model of Binge Drinking**
Francois BRIAND, *Escalquens*

09:00 - 10:00 ORAL SESSION 61

Hepatitis B and Delta 12

407
Level 4

Moderators: Qi WANG, *Beijing*
Bo FENG, *Beijing*

OP0365 09:00 - 09:10 **A highly-stable CRISPR-Cas9 variant antagonizes HSC70-mediated degradation and promotes HBV genome destruction**
Yarong SONG, *Beijing*

OP0366 09:10 - 09:20 **Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: a multicenter clinical trial**
Mingyuan ZHANG, *Changchun*

OP0367 09:20 - 09:30 **Clinical efficacy of antiviral combined with anti-fibrotic Chinese patent medicine on recompensation of patients with first decompensated hepatitis B cirrhosis: a real-world evidence**
Xuejie ZHANG, *Beijing*

OP0368 09:30 - 09:40 **Peginterferon alpha-2b enhances HBsAg loss in nucleos(t)ide analogue-treated patients: Findings from a large real-world study(Everest Project)**
Chan XIE, *Guangzhou*

30 MAR
SUN

30 March | Sunday

ORAL SESSION

OP0370 09:40 - 09:50 **Prevalence of hepatitis B, C and D in the ethnic minority populations in two communes Cach Linh and Dai Son, Quang Hoa district, Cao Bang province, Vietnam**
Evgeniia LICHNAIA, *St.Petersburg*

10:00 - 11:00 ORAL SESSION 62 Pediatric and Genetics

401 Level 4 Moderators: Shizhong YANG, *Beijing*
Xuefei DUAN, *Beijing*

OP0371 10:00 - 10:10 **SBDS Gene Mutations induce Cholestatic Liver Injury via Disturbing FXR/BSEP Signaling-Mediated Bile Acid Excretion**
Yujiao ZHOU, *Chongqing*

OP0372 10:10 - 10:20 **Clinical penetrance of monogenic Rotor syndrome variants, LINE-1 insertions, and Variants of Uncertain Significance (VUS)**
Yue HAN, *Shanghai*

OP0373 10:20 - 10:30 **A Multimodal Neuroimaging and Hepatic Imaging Analysis of Distinct Clinical Manifestations in Wilson's Disease**
Chen LIANG, *Beijing*

OP0374 10:30 - 10:40 **Efficacy and safety analysis of interferon in the treatment of patients with HBeAg-negative chronic hepatitis B complicated with Gilbert syndrome**
Dacheng SHENG, *Beijing*

OP0375 10:40 - 10:50 **Cirrhotic cardiomyopathy among children with biliary atresia and genetic intrahepatic cholestasis: prevalence, natural history and outcomes**
Dr. ANMOL, *New Delhi*

OP0376 10:50 - 11:00 **Propanolol For Primary Prophylaxis For Variceal Bleed In Infants And Children With Biliary Atresia – Results Of A Single Blind Randomized Controlled Trial (BABB-Trial)**
Dr. ANMOL, *New Delhi*

10:00 - 11:00 ORAL SESSION 63 Miscellaneous

403 Level 4 Moderators: Ning CHEN, *Beijing*
Anlin MA, *Beijing*

OP0377 10:00 - 10:10 **Plasma exchange improves survival with native liver by three folds in wilson disease with New Wilson's Index ≥ 11 & early hepatic encephalopathy**
Dr. ANMOL, *New Delhi*

OP0378 10:10 - 10:20 **Evaluation of the present condition of hepatitis C infection in a comprehensive tertiary hospital in Beijing**
Runling ZHANG, *Beijing*

OP0379 10:20 - 10:30 **Preliminary results of non-interventional study to assess virological effectiveness, safety, and tolerability of NVR/RTV+SOF combination in HCV infected persons living with HIV**
Emiliya KRASAVINA, *Moscow*

30 MAR
SUN

ORAL SESSION

30 March | Sunday

10:00 - 11:00 ORAL SESSION 64 New Technology

405
Level 4

Moderators: Zhao LI, *Beijing*
Jie ZHAO, *Taiyuan*

- | | | |
|--------|---------------|---|
| OP0383 | 10:00 - 10:10 | Stain-free digital pathology imaging reveals microarchitectural insights into disease activity and scar evolution to enable outcome prediction in metabolic dysfunction-associated steatotic liver disease
Dean TAI, <i>Singapore</i> |
| OP0385 | 10:10 - 10:20 | Assessment of the Diagnostic Efficacy of a Novel Liver Cancer Biomarker: Multigene Methylation
Xiangsha KONG, <i>Beijing</i> |
| OP0386 | 10:20 - 10:30 | Machine Learning of liver magnetic resonance imaging signatures outperforms traditional prognostic scores in the prediction of 1-year mortality in patients with acutely decompensated cirrhosis
Qingren CAO, <i>Shanghai</i> |
| OP0387 | 10:30 - 10:40 | Evaluation of Hemodynamic Alterations in Patients with Intestinal Obstruction via Whole-Liver CT Perfusion Imaging and Development of a Clinical Prognostic Model.
Xiaodan YANG, <i>Shanghai</i> |

10:00 - 11:00 ORAL SESSION 65 Basic Science & Pathology 3

406
Level 4

Moderators: Jie GAO, *Beijing*
Tian YANG, *Shanghai*

- | | | |
|--------|---------------|--|
| OP0389 | 10:00 - 10:10 | A Novel Mitochondrial Micropeptide HRMM1 Interacts with ATP5B to Promote Energy Metabolism and Hepatocellular Carcinoma Progression
Wenli XU, <i>Nanning</i> |
| OP0390 | 10:10 - 10:20 | Qiling Xiaoji Formula enhances the immunotherapy of anti-PD-L1 antibody through the modulation of gut microbiota in hepatocellular carcinoma
Wenlan ZHENG, <i>Shanghai</i> |
| OP0391 | 10:20 - 10:30 | Generation and Transcriptomic Characterization of Injury-Resistant Functional Ductal Organoids Optimized by Genipin
Shiwen MA, <i>Hangzhou</i> |
| OP0392 | 10:30 - 10:40 | The role and pathogenesis of hydrogen sulfide in angiogenesis of HCC vascularized organoid
Lingna LYU, <i>Beijing</i> |
| OP0393 | 10:40 - 10:50 | OTUD5 suppresses interferon antiviral efficacy by targeting STAT1 for K27-linked ubiquitination
Jin LIU, <i>Suzhou</i> |


30 MAR
SUN

30 March | Sunday


ORAL SESSION

10:00 - 11:00 ORAL SESSION 66**Hepatitis, Infections and the Liver****407****Level 4**Moderators: Youqing XU, *Beijing*
Fanping MENG, *Beijing*

- | | | |
|--------|---------------|--|
| OP0394 | 10:00 - 10:10 | Clinical Features of Patients with Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome
Linxi FENG, <i>Chongqing</i> |
| OP0395 | 10:10 - 10:20 | The multi-center study of functional cure for inactive hepatitis B surface antigen carriers in China: interim analysis of E-cure study
Zhishuo MO, <i>Guangzhou</i> |
| OP0396 | 10:20 - 10:30 | The efficacy of antiviral therapy for HBV-infected children: A large-scale, multicenter prospective study (Sprout Project) - an interim analysis
Qing HE, <i>Beijing</i> |
| OP0397 | 10:30 - 10:40 | Stratifying the risk of Metabolic dysfunction-associated steatotic liver disease in HIV-Infected patients under antiretroviral therapy using transient elastography
Wei LYU, <i>Beijing</i> |
| OP0398 | 10:40 - 10:50 | Alarming rise in Spontaneous Fungal Peritonitis in Cirrhosis: Study of Epidemiology, Clinical Features, Risk Factors and Development of a Predictive Model for early diagnosis
Pratibha KATE, <i>New Delhi</i> |
| OP0399 | 10:50 - 11:00 | Non-invasive HIV Viral Load Prediction Based on Quantitative Ultrasound of Liver
Wei LYU, <i>Beijing</i> |



Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.



Source: Novo Nordisk Annual Report 2023 and data on file.

Novo Nordisk recognises that a significant proportion of the global population with **metabolic dysfunction-associated steatohepatitis (MASH)** live in the Asia-Pacific region and is participating as a sponsor at APASL with several activities throughout the congress.

经典本源 快速安全



针对肝病相关血小板减少症
生理性升板的促血小板生成药物



POSTER FREE PAPER

Even Number

Display time: 17:00 - 18:00, 27 March (Thursday)

08:00 - 15:00, 28 March (Friday)

Odd Number

Display time: 09:00 - 17:00, 29 March (Saturday)

The name marked with an underscore indicates the presenting author.

POSTER

Elimination Forum

- PP0001 Mass vaccination with community participation as a successful strategy for Hepatitis B virus Prevention in Kerala, S India
Shenoy Trivikrama Kotacherry, Leena K B

Public Health

- PP0002 A case of peptic ulcer caused by Mycobacterium abscessus
Zhang Pan, Liu Yuqin
- PP0003 Serum Levels of Oxidative Stress Markers in Patients with Hepatic Steatosis
Saira Baloch, Mohsin Shafi
- PP0004 Diagnostic Role of Neutrophil–Lymphocyte Ratio as Marker of Severity in Patients with Acute Cholangitis
Uzziel Romar Samoro Alonzo
- PP0005 Correlation between lipid-related obesity indicators and gallstone disease in U.S. adults
Chang Fu, Xiaocong Li, Kai Liu
- PP0006 Patient Acceptance and Willingness to Pay on Holistic Healthcare Management Service Based on Digital Platform: a Quantitative Survey
Zhuping Qian, Pingmei Jiang, Shuhua Zhang, Jun Ruan, Lin Wang, Aina Tu, Qing Xie
- PP0007 Cost-effectiveness of antiviral treatment for chronic hepatitis B virus infection in China under a standard clinical pathway
Mengdie Zhang, Xin Li
- PP0008 Assessing educational video intervention in increasing retention-to-care rates after population-wide screening for chronic hepatitis B: a randomized trial
KwanLung Michael Ko, LungYi Loey Mak, WaiKay Seto, WaiPan To, James Fung, ManFung Yuen
- PP0009 Treatment cost reduction in Indonesia – through market shaping, transparency and stakeholder collaboration – opening momentum for national scale-up of Hepatitis C
Robert Kosasih, Arief Budiman, Kushagar Dhall, Vy Bui, Yuhui Chan, Caroline Boeke, Caroline Thomas, Tri Setyanti, Oriel Fernandes, Ratna Budi Hapsari, Atiek Anartati
- PP0010 Readability, Language Diversity and Accessibility of Chronic Viral Hepatitis Patient Resources in Australia
Tony Sebastian, Isaac Moh, Janet Shin, Danielle Muscat, Julie Ayre, Karen Waller, Emily He
- PP0011 Relationship between hepatocellular tumor size and tumor markers
Badamsuren Erdene-Ochir, Byambatsetseg Togtuunbayar, Baatarkhuu Oidov, Amarsanaa Jazag, Erdenebayar Gonchig, Dolgormaa Batsaikhan, Ganchimeg Gelenkhuu
- PP0012 Exploring the Gaps in Disease Knowledge and Surveillance Practices in Cirrhotic Patients: A Prospective Study
Yumna Shahid, Faisal Wasim Ismail
- PP0013 The mediating effect of health literacy between social support and self-management ability in patients with chronic liver disease
Zhuping Qian, Pingmei Jiang, Zhujun Cao

- PP0014 National hepatitis elimination in Niue: a cost-effective model partnering with civil society. Telling the story through film creates an asset for regional elimination, inspiring health care workers and policy makers.
Hazel Heal, Alice Lee, Sue Huntley, Michael Schultz, Grizelda Mokoia, Edgar Akau'ola, Margaret Fraser
- PP0015 Pioneering Endoscopic Sleeve Gastroplasty Services in Rural Pakistan: Initial Outcomes from a Public Sector Program
Syed Mujahid Hassan, Hafiz Hamad Ashraf, Nadim Bajkani, Ahsan Ali Memon, Asad Ali Kori, Samreen Rao
- PP0016 Role of Blood Urea Nitrogen Level in Predicting Mortality among Patients with COVID-19: A Multicenter Retrospective and Descriptive Cohort Study
Uzziel Romar Samoro Alonzo
- PP0017 Post-endoscopic retrograde cholangiopancreatography pancreatitis independently predicts pancreatic cancer development in diabetic patients
KaShing Cheung, JingTong Tan, Xianhua Mao, WaiKay Seto
- PP0018 Efficacy of Potassium Competitive Acid Blockers (PCABs) vs Proton Pump Inhibitors (PPIs) for Healing of Duodenal Ulcers: A Systematic Review and Meta Analysis
Justine Pua Chua Ching, Ace Tan Chan
- PP0019 Clinical features and prognosis of Epstein-Barr virus-associated Hemophagocytic syndrome
Xiangyang Ye, Chao Guo, Rongrong Zhou
- PP0020 Global, Regional, and National Burdens of Non-alcoholic Fatty Liver Disease Attributable to Smoking from 1990 to 2021
Pengyue Zhang, Jie Zhu, Zhengqi Gao, Xiaodan Hong, Zhenhua Zhang
- PP0021 Trends, Inequalities, and Projections of Acute Viral Hepatitis in the Elderly: the Global Burden of Disease Study 2021
Qi Chen, Yaqi Deng, Jieyu Peng, Ping Wang, Yan Peng, Xiaowei Tang
- PP0022 Global trends and cross-country inequalities of acute hepatitis E in older population, 1990–2021: A comprehensive analysis
Deliang Huang, Zhibin Zhu, Jinghan Peng, Jun Chen
- PP0023 Analysis of screening and promoting referral of patients with chronic hepatitis B in a large-scale tertiary hospital in China.
Yijing Cai, Haibo Jia, Hang Han, Mingqin Lu
- PP0024 Trends and cross-country inequalities in the global burden of acute hepatitis A 1990–2021: A population-based study
Deliang Huang, Xiangchang Zeng, Qinxian Cai, Jun Chen
- PP0025 Development of machine learning-based personalized predictive models for risk evaluation of hepatocellular carcinoma in hepatitis B virus-related cirrhosis patients with low levels of serum alpha-fetoprotein
Xu Yuan, Zhang Bei, Zhou Fan, Yi Ying Ping, Yang Xin Lei, Ouyang Xiao, Hu Hui
- PP0026 Global Burden of Chronic Liver Disease and Temporal Trends: A Population-Based Analysis from 1990 to 2021 with Projections to 2050
Yunyu Zhao, Yajing Bo, Zixuan Xing, Jian Zu, Zhanpeng Yang, Yue Zhang, Yujiao Deng, Yi Liu, Lanting Zhang, Xiao Yuan, Yuan Wang, Henry Linda, Fanpu Ji, Mindie H Nguyen

- PP0027 Risk of advanced liver disease among individuals with hepatitis B virus infection with low level viremia compared to individuals with no evidence of hepatitis B virus infection
Paul Y Kwo, Laura E Telep, Leland J Yee, James Chuo, Betty Chiang, Sarjita D Naik, Catherine T Frenette, Amanda W Singer, Anand P Chokkalingam, Camilla S Graham
- PP0028 Mortality Burden of HBV/HCV-related Liver Cancer: A Comparative Analysis of Temporal and Spatial Trends from 1990 to 2050
Yujiao Deng, Jingyue Tan, Jian Zu, Zixuan Xing, Zhanpeng Yang, Yue Zhang, Yajing Bo, Xu Gao, Enrui Xie, Fanpu Ji, Yuan Wang
- PP0029 Multi-omics analysis reveals causal relationships and potential mediators between dietary preferences and risk of NAFLD
Shisheng Wu, Qingan Fu, Nuobei Zhang
- PP0030 A persistent global inequality in HBV-related liver cancer burden from 1990 to 2021: a secondary analysis of the global burden of disease study 2021
Siqi Gao, Qiuyu Guo, Zijun Liu, Shu Wang, Fanqi Kong, He Li
- PP0031 Global Distribution and Trends of Liver Cancer due to Nonalcoholic Steatohepatitis from 1990-2021
Jiawang Lu, Gang Qin, Jun-Tao Shu, Chun-Hu Li
- PP0032 Estimates and trends in the global burden of hepatocellular carcinoma by NASH from GBD Study between 1990 to 2021
Jing Liu, Mingwei Wang, Junping Shi
- PP0033 Global, regional, and national burdens of hepatitis E from 1990 to 2021 and forecasted incidence in 2030: Results from the Global Burden of Disease Study 2021.
Baiyun Wu, Yuxin Tian, Jing Zuo, Jieru Yang, Yuchen Fan
- PP0034 The disease burden of gallbladder and biliary tract cancer from 1990-2021: a population-based observational study from 2021 GBD database
Xiaoxiao Wang, Zixing Wang, Huiying RAO
- PP0035 Disproportionately Increase in Alcohol-related Liver Disease and Alcohol Use Disorder in Pojsakorn Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Pimtawan Jatupornpakdee, Preenapun Saokhieo, Natchaya Polpichai, Tanawat Attachaipanich, Thanathip Suenghataiphorn, Andrew F Ibrahim, Polathep Vichitkunakorn, Sakkarin Chirapongsathorn, Ashok Choudhury, Anand V Kulkarni, Karn Wijarnpreecha, Suthat Liangpunsakul, Apichat Kaewdech
- PP0036 Global burden of cirrhosis in childhood and adolescence, 2000–2021: a systematic analysis of the global burden of disease study 2021
Xueqi Yang, Baiyun Wu, Yuzhen Wang, Xinjing Yang, Yuchen Fan
- PP0037 Determining the length of time before receiving HCC treatment and assessment of reasons of delay in Mongolia
Gantsetseg Ulziibat, Erdenebayar Gonchig, Byambatsetseg Togtuunbayar, Batgerel Zagdragchaa, Erkhembayar Dimaa, Enkhbold Chinbold, Enkhtuya Damba, Oidov Baatarkhuu, Amarsanaa Jazag
- PP0038 An Analysis of Gender, Age Distribution, and Temporal Trends in Cholangiocarcinoma Mortality in the United States: A Population-based Study
Xindi Huang, Yuxin Guo, Xinyuan He, Zhanpeng Yang, Sikai Qiu, Yajing Bo, Xin Liu, YeeHui Yeo, Fanpu Ji, Ning Gao

- PP0039 The Prevalence and Incidence of Urinary Tract Infections in the Past Decade – A Meta-Analysis and Systematic Review
Wenjing Wang, Yan Wang
- PP0040 Branding as a Traditional Healing Practice for Jaundice: Remedy or Risk?
Md Ismail Gazi, Mohammad Salauddin Mia, Hema Binte Hamid, Mohammad Emrul Hasan
- PP0041 Risk of cancer associated with HBV, HCV, MASLD, alcohol and smoking
Carolyn Wallace, Samantha Hall, Devin Razavi-Shearer, Homie Razavi
- PP0042 The longer the occupational exposure to liver toxins, the higher the risk of NAFLD
Xiaoliang Li, Junrong Li, Zhongwen Feng, Taolong Zhou, Tao Luo, Kefeng Li, Mingxing
- PP0043 Update of A-HOC in Mongolia
Amarsanaa Jazag, Erdenebayar Gonchig, Byambatsetseg Togtuunbayar, Enkhbold Chinbold, Erkhembayar Dimaa, Enkhtuya Damba, Oidov Baatarkhuu
- PP0044 Utilization of Fecal Immunochemical Test in a Tertiary Government Hospital: A Retrospective Cohort Study
Bea Regine Panganiban, Jayson Villavicencio, Eric Yasay
- PP0045 The HBV immunization status of college students and the optimal booster immunization strategies for susceptible students: a study including four universities in China
Yarong Song, Yongliang Feng, Feng Jiang, Xingyan Xu, Peijuan Yang, Jie Wang, Jie Li
- PP0046 Neutrophil – lymphocyte ratio (NLR) and systemic inflammatory response index (SIRI) as predictors for all-cause mortality of nasal colonization of *Staphylococcus aureus* in the community setting: Evidence from NHANES 2001-2004
Ju Zou, Yuanyuan Xiao, Biyue Tian, Siyao Chen, Anhua Wu, Chunhui Li
- PP0047 Residual rate of mother-to-child transmission of HBV: findings from a newly introduced programme on post-vaccination serologic testing in Hong Kong
Chin Man Poon, Patrick Shingkan Chong, Vivien Waiman Tsui, Jeffrey Cinghon Lai, Zenith Hinyam Wu, Bonnie Chunkwan Wong
- PP0048 Interventions to Improve Medication Adherence in Patients with Chronic Liver Diseases: A Systematic Review
YooJeong Shin, Isaac HengBin Moh, Neha Sheriff, Angela Webster, Emily He, Karen Waller
- PP0049 Optimizing a hepatitis C screening model for general population using simple demographic
Chi Zhang, Yiqi Liu, Hong Zhao, Guiqiang Wang
- PP0050 The awareness of the link between liver cancer and hepatitis as a motivation for action – results of a globally representative survey
Cary James, Jessica Hicks, Alexandra Smith

Basic Science & Pathology

- PP0052 Impact of *Helicobacter Pylori* virulence genes (Cag A, Vac A) on Endoscopic findings in upper gastrointestinal tract in Egyptian patients with different Upper GIT Symptoms.
Mostafa Makram Arafa
- PP0053 Optimizing Induction Models for Acute Liver Failure in SD Rats
Bin Niu, Ao Lv, Liaoyun Zhang
- PP0054 Acute Stress Disorder Injure Interstitial Cells of Cajal in Gallbladder

HUANG ZHENPENG, HU QIU, KE WANG, JIWEI WAN, ZHI YANG

- PP0055 Impaired Liver Recovery in Retrorsine/Partial Hepatectomy Mice by Hepatocyte Hypertrophy and Progenitor Cell-Majored Cholangiocyte Differentiation
Yan Cui, Li Li, Yu He, Shan Shan, Lin Liu, Hongyi Li, Jiangbo Ren, Hui Wang, Miaoran Yang, Xinyan Zhao, Jidong Jia, Ping Wang
- PP0056 Single-cell atlas identifies transporter-type hepatocytes as drivers of repair in acute liver failure mice treated with hBMSCT transplantation
Heng Yao, Jing Zhang, Hui Yang, Suwan Sun, Xi Liang, Jing Jiang, Jiaojiao Xin, Dongyan Shi, Xin Chen, Jun Li
- PP0057 Blocking PI3K/Akt signal pathway promotes FoxA2 low-expressing liver progenitors to respond to differentiation reagent and differentiate towards hepatocytes.
Jiangbo Ren, Li Li, Ping Wang
- PP0058 Study on the synergistic mechanism of photodynamic therapy combined with ferroptosis inducer to induce ferroptosis in cholangiocarcinoma
Sifan Dong, An Jiang
- PP0059 Phosphatidylserine induce thrombotic tendency and liver damage in obstructive jaundice
Muxin Yu, Chuwei Zheng, Xiaoguang Wang, Jinming Zhang, Rong Peng, Guoming Lu
- PP0060 Brown adipose tissue derived extracellular vesicles administration alleviate acute liver injury in mice
Leyu Zhou, Li Yang
- PP0061 Transfer RNA-derived small RNA tsRNA-20 mediates activation of the ACPH/GRHL1 axis to facilitate liver cell regeneration in acute-on chronic liver failure
Mingxue Yu, Qiyi Zhao
- PP0062 Gankyrin-Deficiency Reprograms Intrahepatic Glucose And Lipid Metabolism To Delay Liver Regeneration
Liu Yitian
- PP0063 Bile Acid Receptor S1PR2-GSDMD Mediated Pyroptosis of Ly6C+ Macrophages in Regulating Liver Inflammation
Meng Chen, Xueqin Li, Hongyan Huang, Kunpeng Huang, Zhili Wen
- PP0064 Endotoxin tolerance inhibits NLRP3 inflammasome activation in macrophages 1 of septic mice by restoring autophagic flux through TRIM26
Shiwen Wu, Jiawen Chen, Chenyi Liu, Shu Li, Chao Cai, Mingqin Lu
- PP0065 Lactiplantibacillus plantarum MH-301 Reduces Helicobacter pylori Treatment-Related Adverse Events via Gut-Vaginal Axis: A Randomized, Double-Blind, Placebo-Controlled
Zhang Kai Ge, Zeng Yu Yu, Xie Zheng Yuan
- PP0066 Baicalein induces hepatic stellate cell senescence via inhibiting glycolysis by CEBPZ/p53/HK2 signaling pathway to inhibit liver fibrosis
Shuling Chen, Yang Wang, Ruiqi Li, Anyin Yang, Hongli Liu, Hao Ren, Jing Fan, Dandan Yin, Qingfang Xiong, Caiyun Zhang, Xixuan Wang, Yongfeng Yang
- PP0067 The role of gut-liver axis in the pathogenesis of Wilson's disease
Xiaoxiao Mi, Junping Shi

- PP0068 Aryl hydrocarbon receptor signaling activation in macrophages prevents cellular senescence and liver aging
Huishi Tan, Yongjian Zhou
- PP0069 The role and mechanism of intestinal epithelial ZO-1 protein in acute-on-chronic liver failure
Xu Lingyun, He Yingli
- PP0070 Impact of Donor Protein Intake on FMT Outcomes in Alcoholic Liver Disease Treatment
Ashi Mittal, Nishu Choudhary, Anupama Parasar, Kavita Yadav, Jaswinder Singh Maras, Shiv Sarin, Shvetank Sharma
- PP0071 Fecal cell-free transplantation exhibits efficacy similar to fecal microbiota transplantation in alleviating alcoholic liver disease in a murine model.
Nishu Choudhary, Ashi Mittal, Anupama Kumari, Jaswinder Maras, Kavita Yadav, Shvetank Sharma, Shiv Sarin
- PP0072 Histone deacetylase 6 inhibitor affects gut microbiome composition in alcoholic liver mice
Yuqi Zhao, Ruyi Peng, Zengrong Wu, Deliang Liu, Yuyong Tan
- PP0073 Experimental study on the regulation of immune mechanism in HepG2 mouse model by Yiqi Jiedu Formula
Ya Han, Guoliang Zhang
- PP0074 Bufalin Induces Macrophage-governed cGAS-STING Signaling Pathway to Remodel Immune Microenvironment in Hepatocellular Carcinoma
Shi Han Yu, Wen Lan Zheng, Xue Mei Zhang, Jia Shi, Wu Rong Du, Li Ming Zheng, Hao Liu, Hai Feng, Zhuo Yu
- PP0075 Pheat, a Comprehensive T Cell Atlas of Human Pan-hepatic Disease at Single-cell
Siyuan Chen, Chao Zhang, Fusheng Wang
- PP0076 Gut-liver-barrier dysfunction induced bioenergetic dysfunction in hematopoietic stem cell accounting for defective maturation and functional impairment of monocyte-macrophage in cirrhosis can be ameliorated by mitoquinol
Deepanshu Maheshwari, Nidhi Nautiyal, Manisha Bhardwaj, Sunidhi Diwakar, Nikita Sharma, Chhagan Bihari, Shiv Kumar Sarin, Anupam Kumar, Anupam Kumar
- PP0077 Expression of ORC1 Gene in the Histology of HBV-associated Hepatocellular Carcinoma
Qingmei Li, Jianning Jiang

Hepatitis B and Delta

- PP0078 The association of hepatitis B virus with extrahepatic tumors, mainly pancreatic cancer
YUCHAO LU, LAI WEI
- PP0079 Trace Serum HBsAg Is Associated with a Higher Risk of HBsAg Seroreversion after PEG-IFN-Induced HBsAg Loss
Na Gao, Haishi Wu, Mezuo Nian, Qiyi Zhao, Zhiliang Gao
- PP0080 Literature review of the epidemiology of chronic hepatitis B (CHB) infection in the paediatric population
Myriam Drysdale, Grace Dolman, Saifuddin Kharawala, Pooja Malhotra, Arnand Nair, Dickens Theodore, Marjan Hezareh
- PP0081 Deep sequencing reveals extensive expression of HBV integration in different phases of chronic HBV infection

Xiaoqi Yu, Demin Yu, Qiming Gong, Li Chen, Xinxin Zhang

- PP0082 Hepatocellular Carcinoma Research Productivity in Southeast Asia: A Bibliometric Analysis
Jan Bendric Co Borbe, Hensor Daugoy
- PP0083 Establishment and application of a new method for dual detection of HDV RNA and HBV DNA based on CRISPR technology
Feng Ren, Yuan Tian, Ling Xu, Zihao Fan, Yaling Cao
- PP0084 STING Activation Suppresses Viral Replication but Promotes Liver Inflammation and Fibrosis in Chronic Hepatitis B Concurrent with Metabolic Dysfunction-Associated Fatty Liver Disease
Wenhui Wu, Suping Hai, Xitang Li, Qiang Gao, Binghui Yu, Feiyang Xu, Xizhe Zheng, Junjian Hu, Xiaojing Wang, Qin Ning
- PP0085 Mitochondrial Regulation of Hepatitis B Virus Autophagic Degradation through Dual Modulation of Lysosomal acidification
Zhiqiang Wei, Yanying Yan, Lingzhu Zhao, Chen Li, Jinjin Qi, Zhengyun Xiao, Guohua Lou, Zhenggang Yang, Xueyu Wang, Min Zheng
- PP0086 Novel function of NUP153 in HNF4 α transcriptional upregulation contributes to promoting HBV replication
Qianqian Jiang, Zhao Zhou, Xinyu Du, Yukun Li, Guiwen Guan, Ting Zhang, Xin Liu, Danli Yang, Lin Wang, Xiangmei Chen, Hongsong Chen, Fengmin Lu
- PP0087 The Risk prognosis of withdrawal for Chronic Hepatitis B failure to meet discontinuation criteria: A systematic review and meta-analysis
Shuixian Du, Kezhen Hu
- PP0088 GDH1-dependent α -ketoglutarate promotes HBV transcription by modulating histone methylation on the cccDNA minichromosome
Shengtao Cheng, Hui Zhang, Ming Tan, Juan Chen
- PP0089 Liver Mechanosignaling as a Natural Anti-Hepatitis B Virus Mechanism
Jianyu Ye, Faghong Li, Ting Hua, Zhenghong Yuan, Jiming Zhang, Jieliang Chen
- PP0090 ATG16L1-mediated Autophagy Affects the Anti-HBV Effect of Dendritic Cells
Futing Liu
- PP0091 Expression of TIM-3 on the DC surface inhibits the antiviral effects of the HBV-DNA-induced cGAS-STING pathway
Mengqi Ruan
- PP0092 NF- κ B-inducible kinase expression activates type I/III interferon signaling via IRF1 to inhibit HBV replication and transcription in hepatocytes
Ziying Liu, Xiaoyong Zhang
- PP0093 Ubiquitinated Hepatitis D Antigen Induced Specific CD8+T Cell Inhibited HDV Replication via JAK/STAT Pathway in HDV Infected Liver Organoids
Leer Shen, Luying Tian, Qingxin Guo, Jinmei Chen, Xiaohua Chen
- PP0094 Hepatocyte-enriched miRNA-193b-3p Promotes Hepatitis B Virus Replication by Dual Activation of Viral Core Promoter Activity and Autophagy Induction by Targeting IGF-1R
Yingying Deng, Jiaxin Zheng, Yong Lin
- PP0095 Comparison of the value of different clinical diagnostic criteria in patients with ALD and HBV-related acute-on-chronic liver failure

Yanping Chen, Lingxia Wang, Zuxiong Huang

- PP0096 Study of the underlying mechanism of liver fibrosis based on a combination of network pharmacology, transcriptomics, metabolomics, and experimental validation strategies
Bei Gui, Lin Xiao Chi
- PP0097 AUF1 is a novel negative regulator for hepatitis B virus replication acting through a post-transcriptional manner
Chenxiao Qu, Jing Zhang, Danjuan Lu, Yi Wang, Wenhui Song, Yuxin Song, Jia Liu, Ting Zhang, Fengmin Lu, Xiangmei Chen
- PP0098 Host factors UBF1/2 binding to Hepatitis B virus cccDNA suppress HBV replication by inhibiting HBV promoters
Xinyu Du, Tianhao Mao, Lin Wang, Xiangmei Chen, Fengmin Lu
- PP0099 The host factor RBM25 promotes HBV cccDNA transcription and replication by regulating Yin Yang 1
Yukun Li, Tianhao Mao, Liwei Zheng, Zhao Zhou, Qianqian Jiang, Xinyu Du, Ziyuan Ma, Xin Liu, Ting Zhang, Guochao Wei, Yongzhen Liu, Lin Wang, Xiangmei Chen, Fengmin Lu
- PP0100 Nuclear receptor binding protein 1 enhances the activity of Hepatitis B virus core promoter to promote the replication of Hepatitis B virus
Zhao Zhou, Lin Wang, Xiangmei Chen, Fengmin Lu
- PP0101 Regulatory effects of siglec-9 on CD56dimNK cells in chronic HBV-infected patients and their different clinical regressions
Zhihao Zhao, Huijie Jiang, Xianggen Kong, Shiyu Cui, Xuemei Jiang
- PP0102 DNAJC9 binds to and enhances the transcription of Hepatitis B virus cccDNA by recruiting histone H3.3
Tianhao Mao, Xinyu Du, Yukun Li, Zhao Zhou, Deyao Li, Liwei Zheng, Danli Yang, Ting Zhang, Guixin Li, Xiangmei Chen, Fengmin Lu
- PP0103 Revealing HBV quasispecies at the single-cell level
Yanfang Huang, Yongping Liu, Jinhang He, Qiran Zhang, Wenhong Zhang, Qiu Chao
- PP0104 VDAC1-mediated Lipid Droplet-mitochondria Tethering Promotes Tumorigenesis and Inhibits HBV Replication in CHB Patients Concurrent with MASLD
Zhe Dai, Yin Gao, Guangde Zhou, Xiaoman Liu, Zhe Wang, Xianwei Liu, Huijun Chen, Yijin Wang
- PP0105 Intrahepatic CD161hiCD8+T cell recruitment has a pathogenetic potential in chronic HBV infection
Wanlu Duan, Jianfei Li, Qin Wang
- PP0106 Long-term antiviral treatment in patients with chronic hepatitis B, normal alanine aminotransferase, and mild liver inflammation and fibrosis
Youwen Tan
- PP0107 Screening and Identification of Entry Inhibitors for HBV Infection
Chen Chuyuan, Ziyang Liu, XuanYi Li, XiaoYong Zhang
- PP0108 CD300A+CD8+T cells promote functional cure in patients with chronic hepatitis B under PEG-IFN- α
Peng Zhang, Chao Zhang

- PP0109 Optimization of the preparing protocol improves human hepatocyte engraftment in humanized mice that support high infection of HBV
Zhenchuan Miao, Boyao Nie, Tianyu Zhang, Junhao Liu, Ziqian Yu, Binbin Yu, Yijuan Nie, Ming Yin
- PP0110 Serum HBcrAg and Anti-HBc predict as Predictor the state of intrahepatic replication-competent HBV DNA in chronic hepatitis B patients with HBsAg loss
Guangxin Yu, Yan Liu, Jiuxin Qu, Fengming Lu, Hao Liao
- PP0111 HBsAg Glycan Isomer (HBsAgGi): A Potential Circulating Biomarker for Monitoring cccDNA and Predicting Virologic Response in Chronic Hepatitis B
Zhiqing Hu, Jin Li, Yuanlan Ji, Min Wu, Fan Chen, Chuanwu Zhu, Li Zhu
- PP0112 5' preS1 deletions enhance HBV replication and transcription by upregulating the viral polymerase expression
Weicheng Xu, Ruijie Yang, Jing Li, Yingli He
- PP0113 HDV Full Genome Sequencing and Sensitive HBV Genotyping from a Large Cohort of HBV/HDV Co-infected Patients
Savrina Manhas, Silvia Chang, Ross Martin, Andrew Lopez, Harish Gopalakrishna, Brooke Swanson, Thomas Aeschbacher, Simin Xu, Roberto Mateo, Yang Liu, Chunfeng Li, Stephanie Narguet, Dzhamal Abdurakhmanov, Pietro Lampertico, Dmitry Manuilov, William Meyer, Christopher Koh, Tarik Asselah, Tomas Cihlar, Hongmei Mo, Evguenia Maiorova
- PP0114 CCR2 of CD4+CD8+CXCR5+ T cell regulated IL-21 and TNF- α secretion in CHB patients
Xin Tong, Shengxia Yin, Qi Gu, Jie Li
- PP0115 High-resolution Mapping of Chromatin Conformation Reveals the Mechanism of HBeAg-induced Macrophage Activation in HBV-related Liver Disease
Tiantian Liu, Xiaoyu Xie, Shujun Ma, Huiling Cao, Hongjun Bian, Wanhua Ren, Jianni Qi
- PP0116 MMP-9 Suppresses the Anti-HBsAg B Cell Response During Chronic HBV Infection
Dilhumare Ablikim, Yuhang Chen, Dongliang Yang, Xin Zheng, Jia Liu
- PP0117 Characterization of various genotype HBV carrier mouse models generated by AAV vector delivery
Zhenchuan Miao, Boyao Nie, Junhao Liu, Xue He, Weifeng Yang, Shujun Liu, Ming Yin
- PP0118 Metabolic Reprogramming of Intrahepatic Mononuclear Phagocytes in Nucleos(t)ide Analogues Treated Chronic Hepatitis B Virus Infection
Fengge Zhu, Liqiong Yang, Deliang Yang, Han Xiao, Xue Li, Wai Kay Seto, Man Fung Yuen, Lung Yi Mak
- PP0119 Association of HLA-DRB1 Alleles with Chronic Hepatitis B and Its Related Diseases
Bin Niu, Qiongjie Li, Rong Wang, Liaoyun Zhang
- PP0120 Functional Insights into Gut Microbiota-Metabolite Associations in Chronic Hepatitis B Under Tiaogan Buxu Jiedu Formula Intervention
Xiaoke Li, Tingyu Zhang, Shuo Li, Xin Sun, Yizi Ao, Shuying Hu, Jinyu Li, Hongbo Du, Yongan Ye
- PP0121 Study on the correlation between HLA-DR+CD38+CD8+ T cell changes and efficacy in the treatment of hepatitis B virus with interferon
Yanjie Lin, Guiqiang Wang

- PP0122 Dissecting antibody-mediated effects of NK cell reveals a cytotoxic CX3CR1+KLRC2-CD16hi subset linked to favorable outcomes in chronic HBV infection
Libo Tang, Yuhao Wang, Zhaofeng Zeng, Yurong Gu, Zihan Jin, Linnan Song, Xuan Yi, Lingtao Zhang, Yujing Zhang, Weiying He, Liping Wang, Weixin He, Jianru Sun, Xiaoqin Lan, Xiangyong Li, Shihong Zhong, Yongyin Li
- PP0123 Comparative Analysis of Peg-IFN- α -2b andplus Nucleos(t)ide Analog Therapy in Patients with Compensated Hepatitis B virus-related Cirrhosis: Results from the CHESS2306
Taoran Geng, Qun Zhang, Haifang Cao, Ying Guo, Wenhua Zhang, Lan Ma, Liping Wang, Rui Zhao, Wei Wang, Wei Gou, Hui Wang, Qingge Zhang, Shihua Zhang, Limao Xu, Qingfa Ruan, Binbin Lin, Xiangzhong Liu, Hongli Wang, Yongning Xin, Yanzhen Bi, Haiyan Kang, Pengbin Gao, Ming Liang, Fenxiang Li, Caiyun Wu, Musong Li, Huiling Xiang, Qing Ye, Huixing Chen, Tao Ren, Yujin Jiang, Dianjie Dang, Chuan Liu, Xiaolong Qi
- PP0124 Inhibition of ACAT1 could promote HBV-specific T cell response and HBsAg clearance via up-regulation of biosynthesis of pantothenic acid and coenzyme A in mice.
Wangqin Qian, Ziyang Liu, Xiaoran Li, Shangfei Peng, Xiaoyong Zhang, Wei Zhu, Jikun Qian, Yuan Ma, Xuan Huang
- PP0125 Peripheral Helper CD4+ T Cell Functionality distinguishes between Acute Resolving and Chronic Hepatitis B
Chao Zhang, Xiaoyu Li, Peng Zhang, Qiaolan Lv, Fusheng Wang
- PP0126 HBsAg Exposure Promotes Hepatocellular Carcinoma in Offspring Through Upregulation of HBEGF
Jing Ning, Chao Zhang, Shigang Ding
- PP0127 Correlation Analysis Between HBV DNA and cccDNA Levels in Liver Tissues of HBV-HCC Patients and Tumor Markers
Yuanlang Ji, Xiaoyuan Hu, Zhiqing Hu, Xiaolong Zhu, Chuanwu Zhu, Li Zhu, Hua Xiao Yang, Jin Li
- PP0128 Hedyotis chrysotricha (Palib.) Merr aqueous extract inhibits hepatitis B virus, especially HBsAg via HNF4 α regulated by PI3K-AKT and MAPK-ERK1/2 pathway
Yina Yu, Yan Lou, Yunqing Qiu
- PP0129 ChIP-Seq Validation of Histone Modifiers in Seroconversion Associated with Hepatitis B Reactivation
Nirupma Trehanpati, Jayesh Kumar Sevak, Gayantika Verma, Mojahidul Islam, Gayatri Ramakrishna, Shiv Kumar Sarin
- PP0130 Identification of early biomarkers for acute-on-chronic hepatic dysfunction based on
Jing Zuo, Yuxin Tian, Hangyu Ma, Zhengjie Qu, Jieru Yang, Yuchen Fan
- PP0131 CLU/PROK2 in chronic Hepatitis B: an exploratory study on its role as a potential diagnostic biomarker and therapeutic target with persistent positive in HBV DNA level receiving entecavir treatment
Jie Wei
- PP0132 Reduction of Bacteroides fragilis in gut microbiome of CHB patients promotes liver injury
Qiuhong You, Kaifeng Wang, Zhou Zhao, Heqi Zhou, Zhixian Lan, Hongyan Liang, Rui Deng, Wanying Li, Routing Wang, Kaikai Zhang, Dekai Zheng, Jian Sun
- PP0133 Efficacy of tenofovir alafenamide monotherapy compared to tenofovir disoproxil fumarate addition in chronic hepatitis B patients with low-level viremia after entecavir treatment
Zhongxiang Yang

- PP0134 Risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance and a novel prediction model establishment
Shuaibing Ying, Jinyao Dai, Yunqing Qiu, Yan Lou
- PP0135 The impact of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: A real-world study
Liangliang Wang, Xiaoyu Wang, Jiaqi Yu, Qingxi Wang, Bing Qiao, Jun Yu, Jing Chen, Yidi Han, Haifeng Zhang
- PP0136 APRI, FIB4, FIB5, GPR, AND AGPR SCORE: WHICH ONE IS BETTER IN EVALUATING FIBROSIS IN CHRONIC HEPATITIS B PATIENTS?
Yoshua Arif Putra, Luciana Sophie Mariana Rotty, Bradley Jimmy Waleleng, Fandy Albert Gunawan Gosal, Jeanne Winarta, Andrew Evron Pierre Waleleng
- PP0137 Comparative Efficacy and Safety of Pegylated Interferon-Alpha Monotherapy versus Combination Therapies with Entecavir or Tenofovir in Chronic Hepatitis B Patients
Huiqing Liang, Xiaoting Zheng, Qianguo Mao, Jiaen Yang, Qingfa Ruan, Chuncheng Wu, Yaoyu Liu, Siyan Chen, Luyun Zhang, Yan Dai, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen
- PP0138 Exploration and new suggestions on stage criteria of natural history for chronic hepatitis B
Tongjing Xing
- PP0139 The effect of Yiqi Jianpi formula based on the pathogenesis of deficiency syndrome on liver function and SIRS in patients with decompensated cirrhosis
WANG MIN
- PP0140 The predictive model for HBsAg clearance in patients with non-advantageous chronic hepatitis B treated with pegylated interferon
Wentao Kuai, Jia Xin Han, LIANG XU
- PP0141 More aggressive initiation of antiviral treatment contributes to blockading mother-to-child transmission of HBV DNA&RNA in neonatal umbilical cord blood
Huimin Liu, Wenting Chen, Yongjie Liang, Lijian Ran, Jing Wang, Haotian Luo, Songtao Zhao, Yan Zhu, Jie Xia, Guohong Deng, Qing Mao
- PP0142 Effectiveness and Safety of TAF in Chronic Hepatitis B Patients Over 30 Years Old with Normal ALT Levels and Positive Hepatitis B Virus DNA
Yanfang Li, Jing Sun, Xinxin Liu, Haifeng Yu, Youde Liu, Ning Sun
- PP0143 Baseline Serum Medium HBsAg: A Simple and Strong Predictor for Functional Cure of Chronic Hepatitis B
Qiyi Zhao, Zhishuo Mo, Hang Si, Mingzhu Liu, Yuan Tang, Zhaoxia Hu, Ning Wen, Zhiliang
- PP0144 Correlation between FIB-4 index and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A prospective cohort study
Gang Wan, Xuesong Gao, Xuefei Duan
- PP0145 Dynamic assessment of liver steatosis on the risk of hepatocellular carcinoma in patients with chronic hepatitis B by ultrasound
Mingyue Xiao, Yuankai Wu, Xiaomei Wang, Nana Wang, Yutian Chong, Jie Ren, Lili Wu
- PP0146 Prevalence and clinical characteristics of HBV-infected patients with HBsAg and anti-HBs coexistence
Xinru Wang, Chuanmeng Zhang, Wei Wang, Li Xiao, Yilin He, Bo Wang, Jianchun Xian

- PP0147 Lymphocyte Mitochondrial Metabolism as a Predictor of Clinical Cure in Chronic Hepatitis B Patients Treated with PegIFN- α
Zutao Chen, Qingzhen Han
- PP0148 Dramatic paradigm shift in antidiabetic drug use in patients with chronic hepatitis B and diabetes mellitus from 2000 to 2023: a territory-wide study
Grace Wong, Lililan Liang, Terry Yip, Jimmy Lai, Vincent Wong
- PP0149 The predictive value of bilirubin after in HBV-ACLF artificialpatients after artificial liver surgery liver surgery and its relationship with liver regeneration
Yuqi Chen, Huaqian Xu, Chunyan Li, Shanhong Tang
- PP0150 Analysis of serum HBV pgRNA levels in chronic hepatitis B patients with HBV DNA below the detection limit and below the quantification limit after long-term nucleotide analogues
Yiheng Zhang, Tao Li, Yundong Qu, Lei Wang, Yan Wang
- PP0151 Establishment of a Bile Acid-based Risk Model to Predict the Progression to Cirrhosis and Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Xue Mei Zhang, Li Ming Zheng, Wen Lan Zheng, Jia Shi, Shi Han Yu, Wu Rong Du, Hao Liu, Hai Feng, Zhuo Yu
- PP0152 Efficacy of peginterferon alfa-2b monotherapy in initial treatment of patients with HBeAg negative chronic hepatitis B
Jing Chen, Jianmei Lin
- PP0153 To Explore the Relationship between ESPL1 Gene and p53 Gene in HCC Patients and to Analyze Its Diagnostic Value for HCC
Yanfei Feng, Jianning Jiang
- PP0154 The epidemiological characteristics of patients with chronic hepatitis B: a single-center retrospective study
Yanqin Du, Yandan Zheng, Hua Wang, Xin Zheng
- PP0155 Impact of Hepatic Steatosis on the Efficacy of Antiviral Treatment for Chronic Hepatitis B and the Establishment of a Predictive Model
Guanghui Ren, Shi Yin, Ying Zhu
- PP0156 Evaluating the Added Value of MRI in Detecting Significant Hepatic Histological Changes in Chronic HBV Patients with Normal ALT Levels
Jiarui Zhong, Junhao Zha, Shenghong Ju
- PP0157 Current status and challenges in the diagnosis, treatment and management of hepatitis B virus infected patients
Yani Zhou, Wei Wu, Sisi Yang, Yida Yang
- PP0158 Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment
Shu E Xiong, Hang Jia, Xu Feng Quan, Bo Yun Liang, Si Hong Lu, Yi Cheng, Hua Wang, Han Xin Li, Ling Xu, Su Meng Li, Tong Wang, Yi Wen Shu, Jia Yu Yu, Jia Liu, Xin Zheng
- PP0159 Association of High-Density Lipoprotein Cholesterol Levels with 90-day Mortality in Patients with HBV-ACLF
Ke Shi, Ying Feng, Xianbo Wang

- PP0160 Dynamic Expression of IFI27 and IFI44L as Predictive Biomarkers for Clinical Cure in Chronic Hepatitis B Under Interferon Therapy
Xiyao Chen, Liang Peng
- PP0161 Evaluation of Clinical Efficacy of Jiedu Liangxue Jianpi Prescription in Patients with HBV-
Ke Shi, Ying Feng, Xianbo Wang
- PP0162 Analysis of the Efficacy and Safety of TAF and TDF in Pregnant Women with HBV Infection Across Different Age Groups
Xu Jiang, Chengjing Tao, Chun Zhao, Tongtong Chen, Liuyi Lu, Shourong Liu
- PP0163 Changes of HBV RNA in HBeAg-Positive Chronic Hepatitis B Patients with Low-Level Viremia Following Maintenance or Modification of Treatment Regimens with Nucleos(t)ide Analogues or Interferon Add-On Therapy
Yushuang Zhang, Tao Li, Lei Wang
- PP0164 Efficacy Analysis of Postpartum Discontinuation and Continued Antiviral Therapy in Pregnant Women with Mother-to-Child Transmission Prevention
Rui Zhao, Shengnan Sun, XiaoLin Shi
- PP0165 Early Antiviral Efficacy of Tenofovir Alafenamide Fumarate in the initial treatment of Normal Alanine Transaminase and hepatitis B virus DNA positive chronic hepatitis B virus infection: a 48-week Multicenter and Retrospective Study from China
Qirui Song, Wenkang Gao, Qinzhi Deng, Ling Yang, Jianjun Lou, Fan Du, Jie Li, Yue Chen, Jianfeng Zhong, Zhaowei Tong, Jie Ye, Jiangshan Lian, Yida Yang
- PP0166 Clinical value of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy
Xiaojing Zhang, Fengmin Lu, Rui Wu, Qiaofei Jin, Yijun Zhou, Chen Wang, Huaguo Shao, Shourong Liu
- PP0167 Analysis of HBeAg Clearance Rates and Associated Factors in Treatment-Naïve HBeAg-Positive Chronic Hepatitis B Patients: A Comparison Between Entecavir and Tenofovir
Yuliang Zhang, Xin Wan, Shipeng Ma, Liang Wang, Qian Liu, Yulun Tang, Shanfei Ge
- PP0168 GGT to PLT Ratio Predicts Progression of Liver Fibrosis in NAs-treated Chronic Hepatitis B Patients with Advanced Fibrosis in Combination with PEG-IFN α Therapy
Ling Li, Xia Wang, Huili Li, Yiru Zhao, Guangde Yang, Juanjuan Fu, Li Li, Guojun Li, Xiuchen Pan
- PP0169 A Model to Estimate Survival in Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Based on Dynamic Changes in Objective Parameters
RUI ZHOU
- PP0170 The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon treatment in chronic hepatitis B: A real-world study
Jiaxin Han, Liu Yang, Wentao Kuai, Yuqiang Mi, Liang Xu
- PP0171 From Guidelines to Practice: Assessing the 2022 CHB Guidelines in Clinical Use
Xiao Zhong, Ruochan Chen, Zebing Huang, Jun Chen, Yan Huang
- PP0172 Analysis of the Correlation between HBsAg and HBsAb Double Positive and Liver Fibrosis in Patients with Chronic Hepatitis B
Futing Liu
- PP0173 Safety and efficacy profiles of Tenofovir amibufenamide fumarate and Entecavir in treatment-naïve patients with chronic hepatitis B: A comparative assessment

- Shipeng MA, Liang Wang, Yuliang Zhang, Xin Wan, Qian Liu, Yulun Tang, Shanfei Ge
- PP0174 Characteristics and factors affecting serum HBV RNA in chronic hepatitis B patients achieving complete virological response after nucleoside analogues therapy.
Juanli Wu, Yushuang Zhang, Han Gao, Yiheng Zhang, Lei Wang, Yundong Qu, Tao Li
- PP0175 Changes in renal function in chronic hepatitis B patients treated initially with entecavir versus tenofovir alafenamide fumarate and related influencing factors
Shipeng MA, Liang Wang, Yuliang Zhang, Xin Wan, Qian Liu, Yulun Tang, Shanfei Ge
- PP0176 Functional Cure of Hepatitis B in Recipients with Chronic Hepatitis B Following Allogeneic Hematopoietic Stem Cell Transplantation Therapy
Qiannan Wang, Yushan Liu, Qijuan Zang, Qiao Zhang, Pan Huang, Yamin Wang, Yingli He
- PP0177 Novel Biomarkers for Non-Invasive Diagnosis of Significant Liver Pathology in Immune-Tolerant Chronic Hepatitis B Infection
Xinjie Li, Meijie Shi, Feng Guo, Yingjie Qi, Ming Lin, Xiaoling Liu, Pengyuan Kang, Yuqi Zhang, Shanshan Ji, Yizhong Hu, Jinbao Huang, Hui Zhuang, Xihong Wang, Xiaozhong Wang, Xiaoling Chi, Tao Shen
- PP0178 Functional Cure of Hepatitis B in Recipients with Chronic Hepatitis B Following Allogeneic Hematopoietic Stem Cell Transplantation Therapy
Qiannan Wang, Yushan Liu, Qijuan Zang, Qiao Zhang, Pan Huang, Yamin Wang, Chengbin Zhu, Yingli He
- PP0179 Does metabolic-related fatty liver disease speed up the progress of liver fibrosis in patients with chronic hepatitis B ?
Li Ying Guo, Quan Wei Xu, Hui Sun, Ao Chen, Jia Wen Shang, Xi Liang Wu, Jie Zhao, Jing Miao
- PP0180 No Causal Relationship Between Chronic Hepatitis B and Anxiety or Depression: A Mendelian Randomization Study
Cunliang Deng, Xiaozhou Mao, Xiaoling Liu
- PP0181 Comparative Effectiveness and Safety of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Patients with HBV-Associated Decompensated Cirrhosis: Insights from a Retrospective Real-World Analysis
Lu Chen, Mingqin Lu
- PP0182 Lipid Profile and Cardiovascular Risk in Treating Hepatitis B with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide: A Propensity Score-Matched Cohort Study
Tingdan Ye, Lin Zhu, Ke Mi, Calvin Q Pan
- PP0183 Efficacy and Safety of Tenofovir Amibufenamide in Chronic Hepatitis B: A Real-World Analysis of Monotherapy and Combination Therapy with Pegylated Interferon Alpha
Jingjing Li, Jiaquan Huang
- PP0184 Development of a nomogram to predict 5 years mortality in patients with hepatitis B-related cirrhosis of Portal vein thrombosis: A retrospective study
Yang Zhou, Feixiang Xiong, Jialiang Chen, Xiaoli Liu, Peipei Meng, Tong Wu, Xiaomin Ji, Yuyong Jiang, Yixin Hou
- PP0185 The relationship between HBV DNA levels and liver fibrosis scores
Mengyu Tao, Xincheng Wu, Xiaoping WU

- PP0186 Combination therapy of entecavir, peginterferon alpha and granulocyte-macrophage colony stimulating factor enhanced HBsAg loss and HBsAb response
Wu Di, Da Huang, Shifang Peng, Yongping Chen, Fengchun Yang, Xiaoyun Zhang, Lei Fu, Lanman Xu, Jiaji Jiang, Qi Zheng, Xinyue Chen, Yali Liu, Xiaoguang Dou, Ke Ma, Xi Dong, Peng Wang, Li Sun, Ruoyi He, Yuchen Tian, Ping Yin, Weiming Yan, Meifang Han, Qin Ning
- PP0187 Safety and Effectiveness of Tenofovir Amibufenamide for Pregnant Women with Chronic Hepatitis B
Ruyue Chen, Yanqin Ai, Xueyan Lv, Yuehang Wang, Yajie Pan, Qinglei Zeng
- PP0188 HBsAg Clearance in Chronic Hepatitis B Patients Treated with Interferon: A Large-Scale Observational Study
Daqiong Zhou, Jianru Jia, Feng Zhao, Wei Qin, Jiangyu Liu, Zichen Zhang, Zhenhuan Cao
- PP0189 A real-world study of the efficacy of tenofovir amibufenamide (TMF) in the treatment of patients with chronic hepatitis B and its effect on blood glucose and lipid levels
JUN LI, Baixin Qian, QING YE
- PP0190 ALT/(qHBsAg × age) ratio at week 12 predicts HBsAg seroclearance and seroconversion in nucleos(t)ide analogue-experienced chronic hepatitis B patients receiving Peg-IFN α add-on therapy
JIAYI WANG, Ning Han, Huan Liu, Juan Liao, Xuebing Chen, Yilan Zeng, Lang Bai, Hong Li, Lingyao Du, Mengya Liu, Chen Zhou, Libo Yan, Hong Tang
- PP0191 Serum HBsAg decline combined with the quantification of HBcrAg and HBsAb at the end of treatment of Peg-IFN predict HBsAg loss at 96 weeks after withdrawal for CHB patients
QianJun Wu, Jie You, Wenyu Wu, Misi Gu, Wu Di, Weiming Yan, Peng Wang, Qin Ning, Meifang Han
- PP0192 Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide and entecavir in the hepatitis B virus related acute-on-chronic liver failure patients: A single-centre retrospective study
Xiao Chuan Diao, Qian Jun Wu, Mi Si Gu, Fei Huang, Yue Chen, Yi Xuan Zhang, Qin Ning, Mei Fang Han
- PP0193 Prediction and Validation of HBsAg Clearance with Extended Interferon Therapy: A Multicenter Study
Fei Yan, Xiulan Xue, Ying Guo, Fei Tang, Jing Chen, Yicheng Lin, Xinyu Chen, Qin Du, Xiaoyan Wang, Jianyong Zeng, Weili Yin, Jing Liang, Lei Liu, Fang Wang, Baiguo Xu, Qing Ye, Huiling Xiang
- PP0194 Outcome analysis of hepatitis B related chronic acute liver failure patients in Qingdao area in recent 10 years
Zhao Hanwen, Ren Lili, Niu Qinghui
- PP0195 Development and validation of a predictive model for HBsAg seroclearance after Peg-IFN-based therapy in patients with HBeAg-negative chronic hepatitis B: a multicentre study
Shuai Gao, Xuemei Jiang, Jing Zhao, Juan Xu, Sikui Wang, Yanping Yin, Jun Shi, Xiao Wang, Lijun Yu, Cheng Xu, Zhenghua Zhao, Yanqing Xing, Kai Wang
- PP0196 The effect of tenofovir amibufenamide on lipid metabolism in patients with chronic hepatitis B is less than that of tenofovir alafenamide
Jishen Zhang, Xiaoxiong Hu
- PP0197 Efficacy of Zhenqifuzheng capsule combined with Tenofovir Amibufenamide in treating chronic hepatitis B

Zhong Hua

- PP0198 Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with non-alcoholic f
Youwen Tan
- PP0199 ESPL1 as a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma Associated with Hepatitis B Virus: A Study of Expression Regulation and Biological Impact
Bobin Hu, Hang Wang, Long Huang, Hongqian Liang, Yanfei Feng, Rongming Wang, Huan Liang, Minghua Su, Jianning Jiang
- PP0200 Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 48 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301
Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatyana Stepanova, Grace M Chee, Dmitry Manuilov, Sarah Arterburn, Audrey H Lau, Anu Osinusi, Florence Christian-Cox, Frank Duff, Julian Schulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, Heinerr Wedemeyer, Pietro Lampertico
- PP0201 Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-based Treatment in Hepatitis B e Antigen-negative and Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B
Jeong Heo, Scott K Fung, Maria Buti, Roberto Mateo, Tahmineh Yazdi, Frida Abramov, John F Flaherty, Thomas Aeschbacher, Yu Hu, Silvia Chang, Hongyuan Wang, Hongmei Mo, Young Suk Lim, Edward J Gane, Kosh Agarwal
- PP0202 Characterization of Changes in Noninvasive Fibrosis Markers Over 8 Years of Tenofovir-based Treatment in Patients With Chronic Hepatitis B Enrolled in Two Phase 3 Trials
Jinlin Hou, Laurent Castera, Ming Lung Yu, Maria Buti, Frida Abramov, Hongyuan Wang, Hongyuan Wang, Ben L Da, Dana Tedesco, Leland J Yee, John F Flaherty, Harry Janssen, Milan J Sonneveld
- PP0203 Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B patients
W Ray Kim, Young Suk Lim, Harry LA Janssen, Sang Hoon Ahn, Ira Jacobson, Masashi Mizokami, Grace Wong, Frida Abramov, Leland J Yee, Hongyuan Wang, Carrie Frenette, John F Flaherty, Scott K Fung, Patrick Marcellin, Wai Kay Seto, Kosh Agarwal, Jinlin Hou, Seng Gee Lim, Jia Horng Kao, Maria Buti
- PP0204 Prognostic Value of Combined HBV pgRNA and MELD Score for Mortality in HBV-Related Acute-on-Chronic Liver Failure
Chen Fenlan, Zhang Xiongle, Cheng Jilin, Liping Chen
- PP0205 Study on the Differences in Gut Microbiota and Metabolites Between Relapsed and Non-relapsed CHB Patients After Drug Discontinuation
Xiaoke Li, Xin Sun, Shuo Li, Tingyu Zhang, Yizi Ao, Shuying Hu, Jinyu Li, Hongbo Du, Yongan Ye
- PP0206 Efficacy of NAs Combined With PegIFN α -2b in Chronic Hepatitis B Patients With / Without Metabolic-related Fatty Liver Disease: A Multicenter, Prospective Real-world Study

Huxibaiheti , Dou Jing, Zeng Sheng Tao, Da Xin, Lu Xiao Bo, Wu Yan Qin, Maimaitiaili ·Tuerxun, Zhang Yong Ping, Wang Zhuan Guo, Maimaitijiang ·Wubuliaishan, Wang Jun, Yue Yong Hong, Wang Xiao Bo, Chen Min, Ma Yan, Sayilaxi ·Jieensinue, Ning Zhong Hui, Xu Qiang, Wang Hong Feng, Ni Ka, Ailifeire ·Abulajiang, Zhang Rong, Guo Feng, Wu Xu, Wang Xiao Zhong

- PP0207 Current Status of HBV Infection in Infertility Patients: A Preliminary Survey Report
Wei Xue, Jiexiao Wang, Yingren Zhao, Jinfeng Liu
- PP0208 Impact of In Utero and Postnatal Tenofovir Exposure on Growth and Development in Infants Born to Pregnant Women with Hepatitis B Virus Infection
HUAN LIANG, BOBIN HU, RONGMING WANG, HENGKAI LIANG, LU WEI, QINGMEI LI, TUMEI SU, QIANBIN Yin, JIANNING JIANG
- PP0209 High-risk factors associated with significant liver damage in chronic hepatitis B patients with “immune tolerance” phase
Xuyang Li, Mengwen He, Chunyan Wang, DONG JI, Fusheng Wang
- PP0210 The Impact of Hepatic Steatosis on the Efficacy of Pegylated Interferon Therapy in Chronic HBV Infection
Pengxuan Wu, Shan Ren, Dacheng Sheng, Jianxia Dong, Jing Zhao, Sujun Zheng
- PP0211 Effect of type 2 diabetes on the efficacy of nucleoside (acid) analogues in chronic hepatitis B
Minghui Zeng, Liang Xu, Yuqiang MI
- PP0212 High-risk factors associated with significant liver damage in young chronic hepatitis B patients with normal alanine aminotransferase
Yifan Guo, Chunyan Wang, Dong Ji, Fusheng Wang
- PP0213 Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers with Hepatitis B
Xingfei Pan, Liyang Zhou, Jing Hu, Panpan Zhai, Xueting Ou, Fang He, Calvin Pan
- PP0214 Association of AFP Elevation with HBsAg Loss During IFN-Based Therapy in Chronic Hepatitis B
Mezuo Nian, Haishi Wu, Na Gao, Zhiliang Gao
- PP0215 Transcriptional characteristics of T cells in children with chronic hepatitis B and poor antiviral efficacy
Yanwei Zhong, Min Zhang, Ce Shi, Ruiyang Yuan, Jia Liu, Yanbo Yu, Fang Chu, Wenling Wang, Xiuchang Zhang
- PP0216 Interferon-α induces robust neutralizing anti-HBs production by restoring the HBsAg-specific B cell immune response in nucleos(t)ide analogues experienced chronic hepatitis B patients
Zhize Yuan, Da Huang, Di Wu, Yuying Chen, Jiang Chang, Yizhi Wu, Ran Zhao, Weiming Yan, Qin Ning
- PP0217 Research on the Regulation of Intestinal Microbiota in Chronic Hepatitis B(CHB) Patients by Tiaogan Buxu Jiedu formula(TGBXJD)
Xiaoke LI, Ylzi Ao, Shuo Li, Shuying Hu, Tingyu Zhang, Xin Sun, Jinyu Li, Hongbo Du, Yongan YE
- PP0218 Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in Patients with Hepatitis B Cirrhosis: A Retro-Pro prospective Observational Study
Jun Chen, Lihua Duan, Xueyao Yang, Xuexuan Li, Shang Gao, Zebing Huang, Yan Huang

- PP0219 Prognostic Evaluation and Clinical Classification of Hepatitis B-Related Acute-on-Chronic Liver Failure
Cai Xianghao, Xiao Xiaolong, Liao Yingying, You Lijie, Zhang Yibo, Gong Jiao, Chong Yutian, Li Xinhua
- PP0220 A review of published data and comparison of Asia-Pacific and international guidelines on the use of quantitative HBsAg in the management of chronic hepatitis B
Hong You, Norah Terrault, Kosh Agarwal, Tarik Asselah, Carla Coffin, Chari Cohen, Markus Cornberg, Robert G Gish, Cary James, Harry LA Janssen, Pietro Lampertico, Jeffrey Lazarus, Sabela Lens Garcia, Mark S Sulkowski, Yasuhito Tanaka, Thomas Tu, Grace Wong, Shayon Salehi, Patrick Kennedy
- PP0221 Impact of Antiviral Treatments on Male Sexual Function in Chronic Hepatitis B Patients: A Cross-Sectional Study
Chengrun Song, Yujing Li, Yonghong Wang, Wei Jiang, Menglan Wang, Yachao Tao, Taoyou Zhou, Fang He, Jiajie Lu, Xuezhong Lei, Hong Tang, Enqiang Chen
- PP0222 Characteristics of monocytes with different clinical outcomes of antiviral therapy in children with hepatitis B
Yanwei Zhong, Yuxi Ning, Min Zhang, Xiuchang Zhang, Ce Shi, Ruiyang Yuan, Wenling
- PP0223 Significant Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients with Low-Level Viremia: A Liver Biopsy-Based Cross-Sectional Study
Mengwen He, Jie Zhou, Le Li, Yan Liu, Wucan Yang, Jing Chen, Yudong Wang, George Lau, DONG JI
- PP0224 Peginterferon alpha-2b retreatment promotes HBsAg loss in chronic hepatitis B patients with low HBsAg levels: Report at 48 weeks follow-up after a phase 3 trial
Fengqin Hou, Jia Shang, Qing Xie, Chunliang Lei, Jianmei Lin, Guoxin Hu, Zhiliang Gao, Yilan Zeng, Jiabin Li, Qianguo Mao, Liying Zhu, Jun Chen, Xiaozhong Wang, Zuxiong Huang, Jiming Zhang, Ping An, Xiulan Xue, Yan Huang, Tianyan Chen, Jianqi Lian, Yueyong Zhu, Huiling Xiang, Xinyue Chen, Hui Guo, Ruoyi He, Yalin Yin, Li Sun, Guqiang Wang
- PP0225 HBV screening, diagnosis and treatment model for family members of HBV-related HCC patients
Peng Wang, Tiaojiao Luo, Min Zhou, Huabang Zhou, Heping Hu
- PP0226 Impact of Nucleos(t)ide Analogues on the Serum Lipids in Patients with Chronic Hepatitis B: a Prospective Cohort Study in China
Xun Qi, Xiongyue Cao, Xinyan Li, Yuxian Huang, Jiming Zhang, Liang Chen
- PP0227 The renal safety of tenofovir alafenamide fumarate for the long-term treatment of chronic hepatitis B liver fibrosis/cirrhosis confirmed by histological
Jialing Zhou, Xiaoning Wu, Chuanwu Zhu, Jiming Zhang, Ping Li, Tao Han, Huiguo Ding, Chenghai Liu, Wen Xie, Qing Xie, Yali Zong, Jidong Jia
- PP0228 Prevalence and clinical characteristics of hepatitis D
Lihua Lin, Xiuhua Yang, Yaping Wang, Xiaowen Jiang, Pei Zhou, Aiqi Lu, Chujiang Li, Calvin Pan, Yujuan Guan
- PP0229 Epidemiological and clinical profiles of patients with chronic hepatitis B with different serum hepatitis B surface antigen levels
Tao Fan, Li Zhu, Ye Xiong, Chao Jiang, Shaoqiu Zhang, Jian Wang, Yuxin Chen, Shengxia Yin, Jie Li, Chuanwu Zhu, Xingxiang Liu, Chao Wu, Rui Huang

- PP0230 \Evolution and Challenges in Antiviral Therapy for Chronic Hepatitis B: Trends in Nucleoside/nucleotide analogues (NAs), Resistance Mutations, and Genotypic
Guo Luyao, Wei Feili, Guo Shan, Liu Fang, Ma Lina, Hu Zhongjie
- PP0231 Anti-HBc IgM associates with acute flare and HBeAg/HBsAg loss in chronic hepatitis B patients with acute exacerbation
Ying Zhang, Ying Zhu, Yi Zhou, Zhaoxia Tan, Yunjie Dan, Xin Zou, Guohong Deng, Wenting Tan
- PP0232 The Predicting Value of Plasma Soluble Programmed Death-1 on HBV Virological Response after Antiviral Therapy of Chronic Hepatitis B Patients
Hu Hao, Huaping Xie, Yanhua Bi, Yurong Gu
- PP0233 Analysis of liver pathological characteristics and influencing factors in patients with an inactive HBsAg carrier status
Shan Ren, Xin Yang Zhang, Su Jun Zheng, Rong Shan Fan, Qing Fa Ruan, Wen Qi Huang, Hai Bing Gao, Xiu Lan Xue, Fang Yang, Xin Yue Chen
- PP0234 THE VALUE OF THE MELD SCORE AND THE AE MODEL IN PREDICTING ACUTE-ON-CHRONIC LIVER FAILURE IN PATIENTS WITH SEVERE ACUTE EXACERBATION OF CHRONIC HEPATITIS B VIRUS INFECTION
Hai ThiThu Nguyen, Van Huy Vo, Hoang Huu Bui
- PP0235 The impact of long - term nucleos(t)ide analogs treatment on metabolism of chronic hepatitis B patients
Yan Li, Huichun Xing
- PP0236 The distribution and risk factors of serum HBV RNA (+) in HBV related post-liver transplantation recipients
Lijun Wang, Qiuju Tian, Qun Zhang, Fengchao Liu, Chuanshen Xu, Jinzhen Cai, Wei Rao
- PP0237 Hepatocellular Carcinoma Risk Reduction Associated with Antiviral Treatment in Non-Cirrhotic Chronic Hepatitis B Patients: A Comparative Meta-Analysis
Alice Stead, Arpan Mohanty, Laura Telep, Amanda Singer, Tristan Curteis, Zarena Jafry, Anna Zolotor, Carrie Frenette, Kyle Hammond, Dona Khoshabafard, Tom McQuaid, Robin K
- PP0238 Characteristics and risk factors of anti-tuberculosis drug-induced liver injury in patients with HBV infection and tuberculosis
Huiqin Huang, Bin Gu, Jiancai Chen
- PP0239 Therapeutic effect and influencing factors analysis of TMF and other nucleoside (acid) analogues combined with Peg-IFN- α -2b in treatment of CHB
Xiaoxia Geng, Xianbo Wang, Jingyu Yang, Yao Cao, Yiheng Yang, Ting Feng, Hengjian Du
- PP0240 A prospective study of the efficacy and safety of lifestyle intervention in patients with chronic hepatitis B and non-alcoholic fatty liver disease
Lufeng Li, Jing Wang, Jiaqi Wang, Jie Xia, Guohong Deng, Qing Mao
- PP0241 Effectiveness and Safety of 48-Week Tenofovir Amibufenamide in Patients with Hepatitis B Virus-Related Cirrhosis: A Retrospective Real-World Study
Xueyan Lv, Rueyue Chen, Zhuangzhuang Zhai, Yuehang Wang, Xuejing Yu, Yajie Pan, Qinglei Zeng
- PP0242 Chronic Kidney Disease in Hepatitis B Patients: Risk Analysis from NHANES 2017–2020
Ke Mi, Tingdan Ye, Calvin Q Pan

- PP0243 Efficacy of antiviral treatment for CHB patients younger than 30 years old
Senlin You, Xiaoqiong Tang, Hong Tang, Hong Li
- PP0244 Hepatic Fat Attenuation Changes During IFN Therapy Linked to CHB Treatment Outcomes
HAISHI WU, NA GAO, MEZUO NIAN, ZHILIANG GAO
- PP0245 Effectiveness and Safety of 48-Week Tenofovir Amibufenamide in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Real-World Study
Yuehang Wang, Ruyue Chen, Xueyan Lv, Zhuangzhuang Zhai, Xuejing Yu, Yajie Pan, Qinglei Zeng
- PP0246 Development and Validation of a Novel Scoring System for Determining Treatment Eligibility for Patients with Chronic Hepatitis B
Shaoqiu Zhang, Jian Wang, Chao Jiang, Li Zhu, Tao Fan, Ye Xiong, Renling Yao, Juan Xia, Xiaomin Yan, Yuanwang Qiu, Xingxiang Liu, Chuanwu Zhu, Rui Huang, Chao Wu
- PP0247 Expression of CD161+CD8+ T Cells in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma
Chenrui Liu, Na Huang, Yaping Li
- PP0248 Incidence and Determinants of Functional Cure in Chronic Hepatitis B Virus-Infected Leukemia Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Xiong Dan Ping, Lin Jing, Wei Feng Zhao
- PP0249 The combination of PegIFN α 2b and nucleos(t)ide analogues may impact the renal tubular reabsorption function
Yujing Li, Chengrun Song, Jing Zhou, Yonghong Wang, Taoyou Zhou, Fang He, Yachao Tao, Jiajie Lu, Wei Jiang, Menglan Wang, Xuezhong Lei, Hong Tang, Enqiang Chen
- PP0250 The diagnostic value of serum CHI3L1 in the progression of chronic liver disease and prognosis of liver cancer
Haiying Zhang, Yuyuan Jia, Runling Zhang, Huiying Rao
- PP0251 The clinical characteristics of clustering families with HBV infection and unfavorable
Ze Zhang, Taotao Yan, Danfeng Ren, Tianzhi Ni, Shan Fu, Yingli He, Jinfeng Liu, Yuan Yang, Yingren Zhao
- PP0252 Influencing factors of liver biopsy for patients with chronic hepatitis B in the indeterminate
Ye Xiong, Tao Fan, Li Zhu, Jian Wang, Shaoqiu Zhang, Juan Xia, Renling Yao, Yue Yang, Bei Jia, Jie Li, Yuanwang Qiu, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang
- PP0253 Research on the Regulation of Metabolites in CHB Patients by Tiaogan Buxu Jiedu Formula(TGBXJD)
Xiaoke Li, Shuying Hu, Shuo Li, Yizi Ao, Tingyu Zhang, Xin Sun, Jinyu Li, Hongbo Do, Yongan Ye
- PP0254 Gastric Perforation and Perisplenic Abscess: A Rare Complication of Tissue Adhesive Treatment for Gastric Varices
Qiongjie Li, Bin Niu, Rong Wang, Liaoyun Zhang
- PP0255 Research on the Correlation between Single Nucleotide Polymorphism in the NTCP Gene and Liver Diseases
Zhuandi Niu, Yuxing Ma, Wenli Du, Junzhe Jiao, Ruijuan Yan, Zhanjie Chang, Haibo Zhang, Jingtao Li

- PP0256 Robust and sustained hepatitis B surface antigen reduction after HT-101 dosed twice in chronic hepatitis B patients: results from a phase I study including extension follow-up data
Wen XIE, Yanbin Wang, Liang Chen, Xun Qi, Jinlin Hou, Xuebing Yan, Junqi Niu, Hongxin Piao, Dong Wang, Yanqin Ma, Shanzhong Zhang, Zhipeng Zhang, Lijuan Ding, Hong Ma, Jidong Jia
- PP0257 Mechanisms Underlying Delayed loss of HBeAg and HBV DNA Following HBsAg Seroclearance in PEG-IFN α Treated Patients of chronic hepatitis B
Bei Jiang, Xiangmei Chen, Fengmin Lu
- PP0258 Evaluating the diagnostic value of different field strengths MRI diffusion-weighted imaging in liver inflammation grading in chronic hepatitis B patients
Yuan Liu, Jinghui Dong, Hongwei Ren, Yanan Zhang, Huiyi Ye, Jianming Cai
- PP0259 Spontaneous Mobilization of Bone Marrow-Derived Stem Cells and Prognosis of Patients with Acute-on-Chronic Hepatitis B Liver Failure
RUI ZHOU
- PP0260 A Novel Point-of-Care Assay for Profiling HBV-Specific T Cell Dynamics in Clinical Samples
Nina Le Bert, Yun Ji, Anthony T Tan, Rajneesh Kumar, Shou Kit Hang, Alessandro Sidoli, Wan Cheng Chow, Qing Zhu, Antonio Bertoletti
- PP0261 The Effects of Granulocyte Colony-stimulating Factor on the Marrow-derived Stem Cells Mobilization and Prognosis in Patients with HBV-Related Acute-on-Chronic Liver Failure
RUI ZHOU
- PP0262 Identification of RAD51AP1 as a Key Gene in Hepatitis B Virus-Associated Hepatocellular Carcinoma
Xiaoling Liu, Yonghong Wang, Qiaoli Zhao, Meiling Wan, Changfeng Sun, Cunliang Deng
- PP0263 Combination treatment with siRNA (elebsiran) and therapeutic vaccine (BR11-179) induced anti-HBs associated with Pre-S1/S2-specific T cell responses and HBsAg reduction in a subset of chronic hepatitis B participants
Ying Tan, Bing Wang, Nina Le Bert, Grace Lai-Hung Wong, Mark W Douglas, Ariel Lee, Chong Zhu, Jianxiang Lv, Dong Li, Haiyan Ma, Xiaofei Chen, Yun Ji, Man Fung Yuen, Jieliang Chen, Antonio Bertoletti, Qing Zhu
- PP0264 The safety and efficacy of PD-1 antibody combined with pegylated interferon- α therapy to promote the clinical cure in nucleoside (acid) analogues-suppressed chronic hepatitis B
Hongmin Wang, Xiaoying Li, Fusheng Wang, Junliang Fu
- PP0265 High levels of HBV DNA integration by high-throughput viral integration detection method predict non-responsiveness of antiviral treatment
Misi Gu, Wenyu Wu, Jie You, Fei Huang, Qianjun Wu, Yixuan Zhang, Peng Wang, Dong Xi, Weiming Yan, Xiaojing Wang, Tao Chen, Di Wu, Qin Ning, Meifang Han
- PP0266 ORC1 Protein as a Serum Marker of HBV-associated Hepatocellular Carcinoma
Su Tumei, Jiang Jianning
- PP0267 Impact of Peg-IFN α on Peripheral Blood PD-1 Levels in Patients with Chronic Hepatitis B: A Non-Randomized Controlled Study
Chenrui Liu, Yaping Li, Yikai Wang, Jia Li, Shuangsoo Dang
- PP0268 Pulsed Enhanced Immunomodulatory/Antiviral Therapy Improved Clinical Cure Rate of Chronic Hepatitis B: a Multicenter and Prospective Study

Lisha Yang, Siqi Sun, Huan Cai, Heng Liu, Shanyan Zhang, Xiaoli Zhang, Guodong Yu, Yida Yang, Hongyu Jia

- PP0269 Artificial Liver Support System Improves One-year Prognosis of Patients with Hepatitis B virus-associated Acute-on-Chronic Liver Failure
Xiaoqin Lan, Changze Hong, Jinjun Chen
- PP0270 The clinical features of patients with Porto-Sinusoidal Vascular Disease (PSVD) accompanied by chronic HBV infection: a retrospective study in China
Jinyu Wang, Tiantian Hu, Xiangyu Chi, Hao Wang, Jiming Zhang
- PP0271 USP43-mediated regulation of STAT1 K33-linked ubiquitination inhibits interferon antiviral function
Chuanwu Zhu, Jin Liu, Feng Qian, Li Zhu, Ming Li, Yuanmei Chen, Yinling Wang, Yujuan
- PP0272 Angiopoietin-like protein 3: a promising prognostic biomarker for patients with acute-on-chronic liver failure caused by hepatitis B virus
Xueying Zhang, Yasi Tu, Qunfang Rao, Daxian Wu
- PP0273 FIND HDV AND DETERMINE ITS STATUS IN TURKEY "SITU(HD)VATION TURKEY"
Mustafa Kemal CELEN, Cigdem MERMUTLUOGLU, Yesim TASOVA, Ismail YILDIZ, Yakup DEMIR, Pinar CAKMAK, Tuba DAMAR CAKIRCA, Ulkiye YETIM, Yasar BAYINDIR
- PP0274 A novel mechanistic viral dynamics modeling (MVDm) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study
Annabelle Lemenuel-Diot, Selma El Messaoudi, Jeremie Guedj, Sylvie Retout, Franziska Schaedeli-Stark, Amine Ait-Ali, Nelson Guerreiro, Sijie Lu, Farouk Chughlay, Claire McGeown, Remi Kasma, for the Piranga Study Group
- PP0275 Ntcp Inhibitors: A New Frontier in Acute and Chronic Liver Injury Management
Liang Shi, Miaomiao Liang, Xiaojia Liu, Junzhe Jiao, Ruijuan Yan, Zhanjie Chang, Haibo Zhang, Jingtao Li
- PP0276 Dynamic Fluctuation Patterns and Levels of Anti-HBs on the Risk of HBsAg Relapse
Shiji Xu, Jin Yang, Lili Wu, Bingliang Lin, Zhiliang Gao
- PP0277 Prognostic Value of Inflammatory Markers Including Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, Mean Platelet Volume, Platelet Distribution Width, and Red Blood Cell Distribution Width in Viral Hepatitis: A Systematic Review and Meta-Analysis
Hanieh Radkhah

Hepatitis C

- PP0278 To construct a prediction model of recompensation in HBV-related decompensated cirrhosis patients combined with the inflammation index MLR
Xu Huaqian, Tang Shanhong
- PP0279 Socioeconomic determinants of chronic liver disease : Experience from Karachi, Pakistan.
Bushra Shahid
- PP0280 Prognostic value of inflammation-related model in hepatitis B acute-on-chronic liver failure
Xu Huaqian, Tang Shanhong
- PP0281 Ethnic disparities in extrahepatic manifestations among people with HCV infection: a population-based study in British Columbia

- Dahn Jeong, Stanley Wong, Hector A Velasquez Garcia, Prince A Adu, Jean D Makuza, Sofia R Bartlett, Alnoor Ramji, Eric M Yoshida, Richard L Morrow, Amee R Manges, Mohammad E Karim, Amanda Yu, Georgine Cua, Mel Krajden, Naveed Z Janjua
- PP0282 Resistance-Associated Substitution in patients with HCV genotype 1b hepatitis: Outcomes of treatment with Ledipasvir and Sofosbuvir in Mongolia
Purevsod Lkhagvasuren, Naranzul Nyamsuren, Tulgaa Khosbayar, Jazag Amarsanaa, Oidov Baatarkhuu
- PP0283 Beyond Viral Clearance: Evaluating Long-Term Clinical Outcomes in HCV Patients After DAAs Therapy
Xiao Yan Wang, Bin Niu, Liao Yun Zhang, Yi Hui Hou
- PP0284 HCV epidemiological characteristics in Qinghai province, China.
Yajing Li, Zhaolan Yan, Jinhua Deng, Liping Yang, Hongmei Zu
- PP0285 The Risk Factors Associated with Liver Cancer and Cirrhosis in Chronic Hepatitis C Patients and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir
Hao Xiong, Shaokun Pan, Chaohui Zhou, Hong Shi, Youhua Xie, Jinsheng Guo
- PP0286 A Multi-Organizational Collaborative Model for HCV Elimination in Methadone Maintenance Clinics
Cailian Cai, Shan Shi, Hangfeng Liu, Ruyi Luo, Lanjuan Li, Likui Wei, Hongjiang Li, Hongyu Liu, Fangpeng Ling, Bingling Fan, Minghua Su
- PP0287 Relationship between Systemic Immune-inflammation Index (SII) and Hepatitis C Virus Infection: NHANES 2005-2012
Zhang Kai Ge, Zeng Yu Yu, Xie Zheng Yuan
- PP0288 A standardized HCV management process in a county contributes to HCV elimination : an HCV elimination project in Xing'an County
Huanwen Chen, Zengxue Lu, Zhongyuan Zhou, Xianxin Tang
- PP0289 Compare the efficacy and safety of different treatment strategies for patients with tuberculosis combined with Chronic hepatitis C
Qiong Hu, Yongping Xie, Guoen Lv, Changzheng Hu, Chunyu Chen, Longting Xie, Junyi Lin, Xiangling Liu, Gang He
- PP0290 Efficacy and Safety of Coblopassvir and Sofosbuvir in Patients with Hepatitis C in Northwest China
Lu Yan, Maimaitijiang Wubuliaishan, Xiaoni Kou, Maimaitiaili Tuerxun, Mingbo Yang, Fanpu Ji, Yingli He, Jiuping Wang, Longdong Zhu, Xiaohong Gao, Fuchun Jing, Xiangchun Ding, Du Du, Ye Zhang, Hong Jiang
- PP0291 CHANGES IN CARBOHYDRATE METABOLISM DURING ERADICATION OF HCV INFECTION
Olga Tarasova, Yannick Ngameni, Elena Kukhareva, Lahana Ravoori, Nataliya Mazurchik
- PP0292 The SVR10K study: A Real-World Data with Pangenotypic Direct-Acting Antivirals Across Multiple Diverse Regions
Grace LaiHung Wong, Mario Reis ALVARE-DA-SILVA, Fatima Higuera-de-la-Tijera, Ming Lung Yu, Soo Aleman, Javier Garcia-Samaniego, Joaquin Cabezas, Marta Casado, Mohamed Alzaabi, Aastha Chandak, Marta Mart í nez, Artak Khachatryan, Linda Chen, Candido Hernandez, Yu Jun Wong

- PP0293 Research on Intervention Measures to Improve the Diagnosis and Treatment Rates of Hepatitis C in Hospitals
Jian Li, Lei Luo, Wenlong Yang
- PP0294 Mendelian randomization analysis reveals Hepatitis C infection is causally associated with extrahepatic cancer
Xiaoqing Liu, Yunling Xue, Peng Hu
- PP0295 Analysis of the efficacy and safety of coblopassvir and sofosbuvir treatment for Chinese patients with hepatitis C virus genotype 3 infection
Li Liu, Yan Su, Jiabao Chang, Jing Zhang, Yali Liu
- PP0296 Real-World Observational Study on Acute Hepatitis C
Yanqin Ai, Qinglei Zeng
- PP0297 Effectiveness and Safety of Sofosbuvir-Velpatasvir in Children with Acute Hepatitis C: A Case Series Study
Ruyue Chen, Xueyan Lv, Yuehang Wang, Zhuangzhuang Zhai, Xuejing Yu, Yajie Pan, Qinglei Zeng
- PP0298 Incidence of hepatic decompensation after viral hepatitis C (VHC) eradication using direct-acting antiviral treatmentsDAAs
Hajar Elibrahimi, Maryeme Kadiri, Fatimazahra Chabib, Nawal Lagdali, Mohamed Borahma, Fatimaezzahrae Ajana
- PP0299 Four systems of closed-loop management combined with grassroots education to enhance screening and linkage to care of hepatitis C patients in Qinghai, China.
Guoying Yu, Jie Ma
- PP0300 Hepatitis C virus elimination in methadone maintenance treatment patients in Beijing
Yijin Zhang, Nan Liu, Yaping Liu, Ping Gao, Hongjie Li, Lili Gao, Xuesong Gao, Xuefei Duan
- PP0301 HCV Screening and Treatment Cascade in a tertiary hospital of North China
Pang Chunmiao, Zhang Guomin
- PP0302 Hepatitis C Genotype Distribution in Pregnant Women and Its Impact on Pregnancy
Yue Xin, Cai Min
- PP0303 "Test and Treat" Simplified Strategy for in-Hospital HCV Micro-Elimination in Zigong City, Sichuan, China
Chunfang You, Yangyang Pu, Jing Tang, Wei Deng, Chunqi Zheng, Xuerong Wang, Dan Song, Jie Wang, Yuting Diao, Juan Tang
- PP0304 HCV Self-Testing (HCVST): A Feasible and Acceptable Approach for Hepatitis C Screening in the Urban Slum Population of Northern India
Ajeet Singh Bhadoria, Amrita Mehndiratta, Kathirvel Selv, Rajesh Somvanshi, Muhammad Shahid Jamil, Niklas Luhmann
- PP0305 Collaborative HCV micro-elimination model in Zigong city, Sichuan, China: a call-back
Chunfang You, Yangyang Pu, Wei Deng, Jing Tang, Chunqi Zheng, Xuerong Wang, Dan Song, Jie Wang, Yuting Diao, Juan Tang
- PP0306 High rates of active hepatitis C (HCV) infection and rapid treatment initiation: results from Thailand's first key population-led HCV test and treat intervention

Artit Wongsu, Rena Janamnuaysook, Kanokwan Sinchai, Atachai Phunkron, Supakorn Sangtong, Jakkrapatara Boonruang, Supanat Thitipatarakorn, Sirin Tangcharoensathien, Saman Sumalu, Surang Janyam, Pongpeera Patpeerapong, Nittaya Phanuphak, Reshmie A Ramautarsing

- PP0307 Hepatitis C Screening and Elimination Among Ex-Drug Users in Community Drug Rehabilitation Centers in Guangdong, China
Guan Jiajun, Chen Xiaoqiao, Ouyang Yanling, Liang Zhiming, Huang Yong, Tong Long, Liang Huixin, He Tingshan, Fan Liting, Hong Li
- PP0308 HEPATOCELLULAR CARCINOMA ASSOCIATED WITH CHRONIC HEPATITIS C, CLINICAL PROFILE, MANAGEMENT OUTCOMES AND SURVEILLANCE STRATEGY OF THE PUNJAB HCV MODEL: REAL WORLD DATA FROM THE PUBLIC HEALTH ANCHAL SANDHU, MADHUMITA PREMKUMAR, RADHAKRISHANN DHIMAN, AJAY KUMAR DUSEJA, PRERNA SHARMA, ARKA DE, SUNIL TANEJA, NIPUN VERMA, SAHAJ
- PP0309 Novel use of point-of-care hepatitis C virus RNA test for rapid confirmation of sustained virological response after direct acting antivirals among prisoners in Hong Kong
Loey Mak, Rex Hui, James Fung, WaiKay Seto, Manfung Yuen
- PP0310 Prevalence and Trends of Hepatitis C Infection in Pregnant Women in Xi'an, China: A 10-Year Retrospective Study
He Ying Li, Liu Geng Wen, Zhang Qiao
- PP0311 Sex and ethnic differences in long-term mortality following hepatitis C cure: A real-world multinational cohort study
Fanpu Ji, Mindie NGUYEN
- PP0312 Alert system for HBV and HCV: challenge to eliminate viral hepatitis
Kazuyoshi Kon, Akira Uchiyama, Hiroo Fukada, Shunhei Yamashina, Kenichi Ikejima
- PP0313 A government-leading HCV elimination model for diagnosed but untreated patients in Yuxi, China
Shifu Li, Rusong Yang, Yang Luo
- PP0314 Resident physician-leading HCV micro-elimination strategy in a tertiary hospital: identification of diagnosed but untreated patients and linkage to care
Shuhan Yang, Zehong Tan, Hao Pang, Na Yang, Yao Tang, Xinglin Fu, Lyping Chen, Fan Yang, Bo Qin
- PP0315 ZERO-HD project accelerate HCV elimination in 22 hemodialysis centers in Sichuan, China
Xiaoxia Geng, Yiheng Yang, Yao Cao, Xianbo Wang, Daqing Hong, Ting Feng, Jingyu Yang, Hengjian Du, Rongzhen Tang
- PP0316 Outcomes of systematic HCV screening and treatment among refugees, Cox 's Bazar humanitarian emergency, Bangladesh
SM Niaz Mowla, Debashish Paul, Polin Chan, Jorge Martinez, Md Shahidul Islam, Farhad Hussain, Abu Toha Bhuiyan, Charles Erik Halder, Abdullah Al Noman, Aarti Shrikrishana
- PP0317 Impact of the Characteristics Distribution of In-Hospital Hepatitis C Patients on the Current Diagnosis and Treatment Situation
Sun Sheng Nan, Xu Jin, Shi Xiao Lin
- PP0318 High HCV prevalence among pregnant Rohingya refugee women: implications for public health response in humanitarian settings, Cox's Bazar, Bangladesh

SM Niaz Mowla, Debashish Paul, Polin Chan, Jorge Martinez, Md Shahidul Islam, Farhad Hussain, Abu Toha Bhuiyan, Charles Erik Halder, Abdullah Al Noman, Aarti Shrikrishana

Others Hepatitis, Infections and the Liver

- PP0319 Comparison of Outcomes Between Spontaneous Bacterial Peritonitis and Culture Negative Neutrocytic Ascites among Liver Cirrhosis Patients with End-Stage Renal Disease on Hemodialysis
JoseOrlando Mendoza Nicolas, Jade Jamias
- PP0320 IgG4-AIH in a Young Male Patient with Decompensated Cirrhosis: A Case Report
Wen Gao
- PP0321 Tuberculous Cystic Hepatic Mass with EBV-related Smooth Muscle Tumors of the Liver and Spleen in an Immunosuppressed Patient
Kevindaeile Simbulan Torralba, James Malicdem Montesa, Karen Joaquin Sotalbo
- PP0322 A MYSTERIOUS SPONTANEOUS RESOLUTION OF PORTAL VEIN THROMBOSIS AND PSEUDOANEURYSM IN A 30-YEAR-OLD MALE: A CASE REPORT
IRSON THURS DORIA, CLARISSE ENRIA PORRAS, AARON VELASCO
- PP0323 Impact of Ursodeoxycholic Acid on COVID-19 Outcomes: A Systematic Review and Meta-Analysis
Omar Elkoumi, Ahmed Elkoumi, Mariam Khaled Elbairy, Younes F. Samara, Abdullah Yousef Aldalati, Mostafa Adel T. Mahmoud, Ahmad Beddor, Ayah Abdulgadir, Mohamed S. Elgendy, Ahmed Lotfy, Mohamed A. Aldemerdash
- PP0324 A novel nomogram for the early identification of coinfections in elderly patients with COVID-
Ju Zou, Xiaoxu Wang, Jie Li, Min Liu, Xiaoting Zhao, Ling Wang, Xuyuan Kuang, Yang Huang, Jun Quan, Ruochan Chen
- PP0325 Development of a human-neutralizing monoclonal antibody that effectively blocks hepatitis A virus infection both in vitro and in vivo
XIN ZHENG, Asuka Hirai-Yuki, Kazutaka Terahara, Noriyuki Watanabe, Ryosuke Suzuki, Osamu Kotani, Noriyo Nagata, Michiyo Kataoka, Bryan Yonish, Kento Fukano, Daisuke Yamane, Eriko Ohsaki, Keiji Ueda, Tomoyuki Shiota, Kazuhiro Takimoto, Tadaki Suzuki, Masanori Isogawa, Takayuki Uchihashi, Stanley M Lemon, Yoshimasa Takahashi, Masamichi Muramatsu
- PP0326 Timing Transplantation versus Medical Treatment in Acute Liver Failure and Associated Outcomes: Insights from an Indian High-Volume Transplant Centre
Vipul Gautam, Dibya Jyoti Das, Shaleen Agarwal, Vikram Kumar, Sanjiv Saigal, Subhash
- PP0327 Clinical analysis of severe patients with hepatitis E overlapping chronic hepatitis B in Nantong area
Guo Jian Shao, Mei Ling Yang
- PP0328 One-Pot Assay Based on CRISPR/Cas13a Technology for HEV RNA Point-of-Care Testing
Zihao Fan, Ling Xu, Yaling Cao, Tianxu Liu, Yao Gao, Xiangying Zhang, Zhongping Duan, Calvin Q Pan, Lin Wang, Feng Ren
- PP0329 Machine learning-based serum proteomic profiles for predicting prognosis for patients with HEV-related acute liver failure
Changyi Ji, Mengmeng Gu, Luyu Wang, Hongtao Wang, Jian Wu, Chinese Consortium for the Study of Hepatitis E

- PP0330 Does glucocorticoid therapy improve the short-term outcomes in patients with acute hepatitis
YUYI ZHANG, LIUJUAN JI, YU LIU, YING ZOU, HUI ZHU, ZHENG GUO ZHANG, WEI YUAN, ZHIPING QIAN, XUE MEI
- PP0331 Single-Cell Sequencing of Peripheral Blood Mononuclear Cells Reveals Distinct Immune Response Landscapes in Mild versus Severe Hepatitis E Virus Infection
Xiaoman Liu, Jian Wu, Yijin Wang
- PP0332 Liver function tests alterations in leptospirosis in the Kashmir, Pakistan. A retrospective
Usman Ghani, SyedLal Shah, Sultan Salahuddin
- PP0333 Identification and function of G-quadruplex in genomic RNA of hepatitis E virus
Yuebao Li, Tianxu Liu, Lin Wang
- PP0334 Prevalence and determinants of hypoglycaemia in acute hepatitis due to hepatitis A and hepatitis E. Insights from the Kashmir, Pakistan.
Usman Ghani, Abrar Umar
- PP0335 Hepatitis E virus infection and kidney injury in nonimmunocompromised host: Clinical investigation and rabbit model study
Weigang Zhang, Qiyu He, Hao Wang, Lei Qin, Yu Wang, Yuting Wang , Wei Chen , Wei He , Lin Wang, Yunjie Lu
- PP0336 The diagnostic value of gut microbiota analysis for acute hepatitis E infection in the elderly
Mengmeng Gu, Changyi Ji, Jian Wu, Chinese Consortium for the Study of Hepatitis E
- PP0337 Changing etiology of HCC in Mongolia, an A-HOC initiative update
Amarsanaa Jazag, Erdenebayar Gonchig, Byambatsetseg Togtuunbayar, Enkhbold Chinbold, Erkhembayar Dimaa, Bolorchimeg Batsaikhan, Oidov Baatarkhuu
- PP0339 Disseminated Hepatic and Gastrointestinal Tuberculosis Mimicking Crohn's Disease with Biliary Sclerosis: A Rare Case in an Immunocompetent Patient
Kimberly Nadine Mendez Manalastas, Louie Figueroa, James Malicdem Montesa
- PP0340 Aneurysmal Splenic Vein With Arteriovenous Fistula In A 57-year-old Cirrhotic Patient With Refractory Portal Hypertension: A Case Report
Yrah Damiene Magdaluyo Fernandez, Ferdinand Maitim Anzo, Ma. Cristina Caluag Africa, Kevin Rae Ramirez Lumunsad
- PP0341 Isolated Gastric Varices (SARIN IGV1) Secondary to a Porta Hepatis Mass in a Patient with Disseminated TB: A Rare Case Report
Sam Nogoy Fandood
- PP0342 Receptor tyrosine kinases signaling involves Echinococcus-host intercommunication: a potential therapeutic target in liver echinococcosis
Haijun Gao, Fangye Zhou, Xiaojin Mo, Ting Zhang
- PP0343 Global Research Trends and Hotspots of Autophagy in Liver Failure: A Bibliometric and Visualized Study Based on Web of Science from 2007 to 2024
Huan Wu, Long Wu, Can Li, Quan Zhang, Mao Mu
- PP0344 Neurogenic shock after liver biopsy: A case report
Bahejianati NUERBOLATI, Songsong XIE
- PP0345 A single-center, retrospective cohort study on the histological and clinical features of unexplained liver injury

Lingling Yang, Zhikun Wang, Ke Bai , Linqian Wu, Hui Zhu, Lifang Chen, Liangtao Zeng, Zhili Wen

- PP0346 A novel model for distinguishing infections from patients with acute-on-chronic liver disease (AoCLD) and systemic inflammatory response syndrome (SIRS): A nationwide, multicenter, prospective cohort study
Hui Zhou, Hai Li, Guo Hong Deng, Xian Bo Wang, Xin Zheng, Jin Jun Chen, Yan Huang, Ruochan Chen
- PP0347 Meta analysis of the safety and efficacy of fibrates in the treatment of non-alcoholic fatty liver disease
Yunfei Hu
- PP0348 Prevention of Nosocomial Cross-Infection of Special Pathogens during Digestive Endoscopy Examination in Infectious Disease Specialty Hospitals
Liping Chen, Jing Wang, Zhenyu Fan, Jingmao Yang, Cuili Lu, Xiangjun Ji, Chunyan Lu , Yahong Xu, Jilin Cheng
- PP0349 Clostridium butyricum-Derived Metabolites Enhance Gut-Liver Axis Integrity to Mitigate LPS-Induced Hepatic Inflammation
Jui Chen Tsai, Kai Hung Tsai, Ho Yu Kuo, Pei Han Fan, Hsiao Li Chuang, Hsiao Li Chuang
- PP0350 Clinical Features and Treatment Outcomes of Hepatobiliary Tuberculosis: A Case Series and Literature Review
Tristan Paulo Madrigal, Cyrus Jan David, Ariane Marielle Valle, Mara Teresa Panlilio
- PP0352 The clinical characteristics of drug-induced liver injury among brucellosis patients
Zhongshu Pu, Xin Xue, Xiaohong Niu, Xinren Zhou
- PP0353 CT Imaging Characteristics of Paradoxical Reactions in Perihepatic and Hepatic
Xiang Li
- PP0354 Beyond the Blush: Managing Hepatic Arterioportal Fistula in a 77-Year-Old Female with Hepatocellular Carcinoma
Christine Paredes Velasquez, Sharlene Chan, Madaline D Labio
- PP0355 Analysis of a case of Clonorchis sinensis infection treated by traditional Chinese medicine
Xia Ning, Jun Chun Xu
- PP0356 Sepsis-Induced Vascular Endothelial Cell Injury: The Crucial Role of Mitochondrial Quality Control
Tian Xia, Jiachi Yu, Ruibing Li, Chengbin Wang
- PP0357 GSTA3-mediated Prdx4 S-glutathionylation maintains mitochondrial homeostasis and inhibits hepatocyte pyroptosis to protect against sepsis-associated liver injury.
Peng Qu, Xu Li
- PP0358 MTM16 ameliorates diet-induced cholesterol gallstones by inhibiting LXRα
CHI YIRONG, PENG ZIYI, ZHANG JIE Chi, ZHANG RUIJIA, ZHAO JINGWEN
- PP0359 Non-cirrhotic Portal Hypertension from a Portal Vein Fusiform Aneurysm with Arteriovenous Malformation: A Case Report
Derek Caisip Clutario, Angelo Banzon Lozada
- PP0360 Portal vein thrombosis caused by hereditary protein S deficiency: a report of 2 cases
Xiaoying Ye, Xiaoxiao Mi, Ling Gong

PP0361 Analysis of Factors Associated with Liver Dysfunction in Patients with Brucellosis: A Retrospective Observational Study
Rong Wang, Bin Niu, Yinghan Wang, Xin Zhang, Yuke Wang, Haiyan Tian, Liaoyun Zhang

PP0362 A rare presentation of scrub typhus: as acute liver failure
Sonali Chaturvedi

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity

PP0363 HOMA-IR AS A MARKER FOR DIAGNOSIS OF METABOLIC ASSOCIATED FATTY LIVER DISEASE(MAFLD) IN WOMEN WITH POLYCYSTIC OVARIAN DISEASE(PCOD)
Siddhant Jain

PP0364 Integrated analysis of the role of gut microbiome-associated metabolites in the detection of MASH-related cirrhosis
Feixiang Xiong, Xuejie Zhang, Yuyong Jiang, Peipei Meng, Yang Zhou, Xiaomin Ji, Jialiang Chen, Tong Wu, Yixin Hou

PP0365 Single-cell RNA Sequencing Reveals the Heterogeneity of Monocyte-derived Macrophages in Metabolic Dysfunction-associated Steatotic Liver Disease
Haozhe Xu, Lu Yang, Dong Zhang, Guangyong Sun

PP0366 Study on the mechanism of action of Qi Zhu Formula in the treatment of metabolic associated fatty liver disease based on network pharmacology and experimental validation
JUNRAN YANG, Qiuyi Zhang, Zhenhua Zhou

PP0367 THE ROLE OF GENES AND OXIDATIVE STRESS MARKERS IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE.
Hina Parveen, Sumit Rungta

PP0368 CORRELATION OF SERUM VITAMIN B12, FOLATE, AND MAGNESIUM LEVELS WITH SEVERITY OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
Kartik Goel, Shailesh Kumar, Vijay Kumar, Lokesh Kumar Sharma

PP0369 Non alcoholic fatty liver disease associated with cancer
Harshita Dubey, Sathya Veera Merla, Jaideep Menda, Amar Ranajn

PP0370 The Impact of Parental Non-Alcoholic Fatty Liver Disease and Alcoholic Liver Disease on the risk of Fatty Liver Disease in their offspring: A Meta-Analysis
Regina Dimaculangan, Nikko Raymundo, Joseph Dumagpi, Juliet Cervantes

PP0371 CD73 enhances the immunoregulatory functions of hepatic Tregs through enzymatic and nonenzymatic pathways in MASLD development
Xinjie Zhong, Hua Jin, Chunpan Zhang, Yongle Wu, Dong Zhang, Guangyong Sun

PP0372 Integrative Analysis of Gut Microbiota and Metabolites in Individuals with Metabolic Associated Fatty Liver Disease
Ning Han, Libo Yan, Hong Tang

PP0373 Association of NAFLD and chronic hepatitis B: A bi-directional two-sample mendelian randomization
Bei Jiang

PP0374 Rifaximin improves nonalcoholic steatohepatitis in mice by modulating the Helicobacter-DCA-Fxr signaling pathway

Jie Jian

- PP0375 Microbiota-derived Indole-3-propionic acid mediates the therapeutic effects of Qushi Huayu Prescription on metabolic dysfunction-associated steatohepatitis
Binbin Zhang, Yuqing Pan, Yiyang Hu, Yu Zhao
- PP0376 Baicalein Alleviates Insulin Resistance by Regulating YTHDF1 Expression through the AKT Signaling Pathway to Reduce Gluconeogenesis in MAFLD Mice
Huilian Shi, Yuanyuan Chen
- PP0377 Inositol Hexaphosphate and inositol ameliorate metabolic dysfunction-associated steatohepatitis in WD/CCl4 treatment mice
Zhao Chen, Chenxiao Qu, Wenhui Song, Danjuan Lu, Yi Wang, Yuxin Song, Xiangmei Chen
- PP0378 MiR-210-3p ameliorates MASH-related fibrosis by targeting ISCU and induces ferroptosis in hepatic stellate cell.
Zixing Dai, Chuanlong Zhu
- PP0379 Mechanistic Insights Into ZhiGan Formula for Treating Nonalcoholic Steatohepatitis Through Gut-Liver Axis Modulation
Yousheng Mo, Shuangwei Li, Langping Yi, Bowen Gao, Ming Lin, Meijie Shi, Huanming Xiao, Xiaoling Chi
- PP0380 Trans Fatty Acids Regulate the Growth and Proliferation of Hepatocellular Carcinoma Cells via the OPN-NF- κ B Signaling Axis
Peici Yan, Xiao Hu, Yunting Shao, Lizhe Liu, Ran Guo, Rui Hu, Wenbin Li
- PP0381 The proportion of the rs738409 GG homozygous and risk of fibrosis in patients with biopsy-proven NAFLD the meta analysis : Exploring mediation pathways through intermediate histological features.
Shuixian Du
- PP0382 Intestinal NLRP3 deficiency aggravates MASLD mice via reduced butyrate production
Li Chen, Haoyu Jia, Shanshan Li, Jing Li, Changqing Yang
- PP0383 Myricetin ameliorates MAFLD by enhancing mitochondrial function and promoting PINK1/Parkin-dependent mitophagy
Weilong Xu, Jiangyi Yu, Hideki Fujii, Xiqiao Zhou
- PP0384 Trans Fatty Acids Induce the Construction of HCC-Microenvironment by Accelerating the Process of Liver Fibrosis
Xiangnan Wang, Xiao Hu, Peici Yan, Ran Guo, Gang Li, Naoki Tanaka
- PP0385 Effects of metformin on inflammation and triglyceride accumulation in non-alcoholic fatty liver mice
Zeng Bin
- PP0386 Traditional Medicine Yiqi Huoxue Relieves Nonalcoholic Steatohepatitis by Remodeling Intestinal Microbiota and Metabolites
Yaoyao Mao, Jiawei Cui, Zhandong Lin, Congyue Zhang, Yuemin Nan
- PP0387 The Metabolic Status in Non-alcoholic Fatty Liver Disease and its Subtypes: A Pilot Study
Yanqi Lan, Ying Lu, Shiqi Hu, Shuohua Chen, Yanhong Wang, Shouling Wu, Li Wang
- PP0388 Intracellular C3 Prevents Non-alcoholic Fatty Liver Disease Via Regulatiing Iron Homeostasis in Hepatocytes

Yinling Li, Binbin Zhang, Junping Shi

- PP0389 The Impact of MAFLD on the Clinical Cure of NAs-treated Chronic Hepatitis B Patients add-on PEG-IFN-alfa Therapy
Hui Li Li, Xia Wang, Ling Li, Yi Ru Zhao, Juan Juan Fu, Li Li, Guang De Yang, Xiu Cheng
- PP0390 Gremlin1 Regulates the Expression of Dlk1 in Adipose Tissue
Qinghong Yu, Yifei Qi, Shijin Bai, Shiyu Wang, Tianhui Liu
- PP0391 Clusterin/Apolipoprotein J expression modulates tamoxifen metabolism in liver and mitochondrial imbalancing in breast cancer
Ya Wen Chang, Hung Yu Sun
- PP0392 The Regulatory Role of IFI44 in the Chronic Experimental Colitis and Non-alcoholic Fatty Liver Disease Dual-Disease model
Huan Yu
- PP0393 Ethnicity based differences in liver and abdominal fat distribution
Charlie Diamond, Vivian Lee, Yiyang Han, Desiree Faye Toh, Jennifer A Bryant, Redha Boubertakh, Sophie Riddell, Elizabeth Shumbayawonda, Helena Thomaides Brears, Thu Thao Le, Calvin WL Chin
- PP0394 Norcholic acid: a novel risk factor of early kidney injury with metabolic dysfunction-associated fatty liver disease
Danqin Sun, Mengyang Zhong, Cuifang Xu, Jiahui Zhang, Wenying Chen, Fuqiang Yuan, Giovanni Targher, Christopher D Byrne, Jing Zhao, Ana Liu, Mingming Su, Junping Shi, Yan Ni, Minghua Zheng
- PP0395 Blautia wexlerae Enhances Intestinal Indole Levels to Inhibit Lipid Absorption via the Ahr/Cyp1A1 Pathway and Suppress NASH Progression
Binbin Zhang, Junping Shi
- PP0396 Salvianolic acid B mitigates metabolic dysfunction-associated steatohepatitis in mice via up-regulating SIRT1 to inhibit hepatocyte ferroptosis
Xiaoxi Zhou, Yadong Fu, Jinxing Lv, Zheng Zhang, Yue Liang, Wei Liu, Jiamei Chen, Ping
- PP0397 Tropomyosin-4 aggravates metabolic dysfunction-associated steatohepatitis by promoting hepatic stellate cell migracytosis
Zhiping Wan, Xiang Cai, Xiaoquan Liu, Xiaoan Yang, Qingqing Feng, Hong Deng
- PP0398 OX40L-PIP5K1a-MAPK pathway upregulates bone-marrow derived macrophages activation and M1 polarization promoting MASLD
Zihan Zhang
- PP0399 Deletion of HO-1 perturbs Hepatocyte Mitochondria-associated Endoplasmic Reticulum Membranes Dynamics and Calcium homeostasis
Dong Dong Li, Chang Min Cai, Wen Zhao, Yuemin Nan
- PP0400 Single-cell and spatial multi-omic profiling implicates the senescence-associated CD74+ endothelial cells-mediated metabolic remodeling in MASH progression
Rui Zhang, Yuan Liang, Ling Lu
- PP0401 CD73 enhances the immunoregulatory functions of hepatic Tregs through enzymatic and nonenzymatic pathways in MASLD development
Xinjie Zhong, Hua Jin, Chunpan Zhang, Yongle Wu, Dong Zhang, Guangyong Sun

- PP0402 Genome-wide CRISPR Screening Identifies NOC2L as an Epigenetic Determinant of Hepatocyte Steatosis
Jianxu Chen, Jiandi Chen, Minzhao Gao, Chengmin Ma, Yuan Liu, Yanzhi Han, Xiaofeng Li
- PP0403 Mechanism of Genipin 1-gentiobioside Targeting IRAK4 to Inhibit NLRP3 Inflammasome Activity in Liver Macrophages to Alleviate Metabolic Dysfunction-Associated Steatohepatitis Inflammation
Zhuoyuan Wang, QinMei Sun, Beiyu Cai, Xin Xin, Ziming An, Qian Huang, Sheng Lv, Furong Qiu, Qin Feng
- PP0404 MELK blunts metabolic dysfunction-associated steatohepatitis through modulating Lars2-mediated mitochondrial homeostasis in hepatocytes
Jing Qi, Jiabin Huang, Yufei Wang, Lanqian Li, Xin Zhang, Xi Zheng, Zhengyi Tan, Xueqing Yan, Zixiong Zhou
- PP0405 INTESTINAL EPITHELIAL CELL OSTEOPONTIN PROTECTS AGAINST METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS BY ALTERING THE BILE ACID COMPOSITION AND THE GUT MICROBIOME
Hui Han, Nithyananthan Subramaniam, Xiaodong Ge, Sai Komakula, Chao Wang, Jeongwoo Park, Daniel Lantvit, Grace Guzman, Bruno Ramos Molina, Natalia Nieto
- PP0406 Picrorhiza kurroa and Boerhaavia diffusa: Potential Phytotherapeutics for Hepatic and Endothelial Dysfunction in Metabolic Associated Fatty Liver Disease
Tahseen Khan, Akash Mourya, Vaibhav Tiwari, Rajni Yadav, Himanshi Himanshi, Aishwarya Bhatnagar, Shiv Kumar Sarin, Savneet Kaur, Dinesh Mani Tripathi
- PP0407 NEDD4 regulates TGF-beta/SMAD signaling pathway through ubiquitinated decorin to ameliorate Metabolic Dysfunction-Associated Steatohepatitis
Rui Jin, Nan Geng, Shengxia Yin, Qianwen Zhao, Jie Li
- PP0408 Targeted Delivery of IGFBP7 Antisense Oligonucleotide to the liver Protects Mice Against Aiting Yang, Xuzhen Yan, Yiwen Wang, Hong You
- PP0409 Myostatin Regulates the Muscle-Liver Axis by Inducing Hepatocyte Senescence via SLC7A11 Ubiquitination in Metabolic Dysfunction-Associated Steatohepatitis
Nan Geng, Qianqian Chen, Fajuan Rui, Wenjing Ni, Yixuan Zhu, Zhiwen Fan, Shengxia Yin, Qianwen Zhao, Jie Li
- PP0410 NPM1 inhibits mitophagy in hepatocytes through hindering ANT2 ubiquitination and facilitates metabolic dysfunction-associated steatotic liver disease
Caijun Rao, Zhipeng Du
- PP0411 HFCF diet alters Klb histone methylation inducing MASLD by regulating KLB expression
Yu Hua Ruan, Fang Ji
- PP0412 GINS2 Accelerated Non-Alcoholic Fatty Liver Disease via Regulating TFEB Mediated
Zhaohong Mo, Mingbei Zhong, Gangping Feng, Kai Ke, Xinghuang Yi, Guandou Yuan, Songqing He, Shuangdi Duan
- PP0413 Results of triple therapy for fatty liver disease (NAFLD) in Mongolia
Amarsanaa Jazag, Erdenebayar Gonchig, Byambatsetseg Togtuunbayar, Enkhtuya Damba, Batgerel Zagdragchaa, Bolorchimeg Batsaikhan, Davaajav Bavuudorj, Oidov Baatarkhuu, Davaajav Bavuudorj
- PP0414 CD133 drives MASLD-related hepatocellular carcinoma and is a therapeutic target
Yasi PAN, Xiang ZHANG, Chi Chun WONG, Huarong Chen, Kai YUAN, Jun YU

- PP0415 The Differential Diagnosis of Lipid Metabolism in Alcohol-associated liver disease and Non-alcoholic fatty liver disease by Time-of-Flight Secondary Ion Mass Spectrometry
Mingxin Qiu, Yang Wang, Yao Zhao, Lei Sun
- PP0416 Paeoniflorin ameliorates Metabolic dysfunction-associated steatohepatitis via inhibiting JAK2/STAT1/CXCL10 pathway
QinMei Sun, Xin Wang, SiTing Gao, Xin Xin, Yiyang Hu, Qin Feng
- PP0417 FGF21 counteracts ERS-induced hepatic steatosis aggravated by loss of Fam172a gene
Herui Wei, Fan Xiao, Hongshan Wei
- PP0418 Exacerbation of MASH by Nicotine: Insights into Gut Dysbiosis and HIF-1 α Regulation
Fangfang Yi, Xiaodong Wang, Yilun Huang, Dazhi Chen, Yongping Chen
- PP0419 Redefining the noninvasive assessment of liver fibrosis
Zhen Yuan, Junhua Ma
- PP0420 Inhibition of FATP5 Alleviates the Progression of NASH by Increasing SCD1 Activity thereby Inhibiting Hepatic Ferroptosis
Yiran Liu, Jiazhi Liao, Suhong Xia
- PP0421 Heme oxygenase-1 attenuates nonalcoholic steatohepatitis via inhibiting mitochondrial
Li Dongdong, Zhi Jing Wu, Jia Cen Cao, Wen Zhao, Shou Song Zhao
- PP0422 Chinese medicine Ger-Gen-Chyn-Lian-Tang Mitigates High-Fat Diet-Induced Liver Steatosis and Metabolic Dysregulation Through Multi-Target Mechanisms
Tzung Yan Lee
- PP0423 Role and Mechanism of YAP in hepatocyte in the Pathogenesis of MASH
Xiaowei Ling
- PP0424 Deregulation of FTO isoforms correlates with the progression of metabolic dysfunction associated steatotic liver disease and its amelioration with Entacapone
Sunita Giri, Vijay Kumar
- PP0425 Preclinical studies of a novel hydrolysis-based prodrug for treating metabolic dysfunction associated steatohepatitis
Gongxin He, Xiubo Tang, Jia Meng, Hao Wu, Kai Hou, Wenyuan Fan, Chunyan Yao, Xiaowu Chen
- PP0426 Association of Endothelial Nitric Oxide Synthase Trafficking Inducer with Endothelial Dysfunction Markers in Patients with Metabolic Dysfunction-Associated Steatotic Liver
Balasubramaniyan Vairappan, Kalaivani Subramani, Sunitha V, Jayaprakash Sahoo
- PP0427 Heme Oxygenase-1 Improve Mitochondrial Function and Apoptosis in Non-Alcoholic Steatohepatitis
Xiwei Yuan, Yuemin Nan
- PP0428 Potassium Citrate Monohydrate Alleviates Hepatic Lipid Peroxidation in Metabolic Dysfunction-associated Fatty Liver Disease via AMPK-autophagy-ferroptosis Axis
Jingyuan Xu, Longyun Wu, Xiaolan Lu
- PP0429 Wei-Ling-Tang Oral Solution Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Regulating Gut-Liver Axis
You Yanying, Wu Minxia, Zeng Danyi, Xing Qingqing, Xue Hanxin, Pan Jinshui

- PP0430 Genipin 1- β -D-gentiobioside alleviates MASH by inhibiting hepatocyte PP2A enzymatic
Xin Xin, Feng Qin, Xie Cen Group, Huang chenggang group, Hu yiyang Group
- PP0431 Mechanistic Investigation of Sitravatinib's Therapeutic Potential in Hepatic Fibrosis: A
Comprehensive Analysis of Function and Molecular Pathways
Huan Zhang, Fajuan Rui, Qianwen Zhao, Jie Li
- PP0432 DPP-4 inhibition by linagliptin attenuates lipotoxicity-induced metabolic associated fatty liver
disease by regulating M1/M2 macrophage polarization
Fen Zhuge
- PP0433 Blood metabolic Panels for identifying advanced Fibrosis and Inflammation in among patients
with MASH
Yan Huang, Jiaqi Li, Bingyin Du, Zhujun Cao, Xiaozhen Guo, Cen Xie, Qing Xie
- PP0434 Suppression of Baicalein on Myeloid-Derived Suppressor Cells in Nonalcoholic
Steatohepatitis through m6A Modification of NRF2
Huilian Shi, Yuanyuan Chen
- PP0435 Homocysteine Carbon Dot as a Novel Therapeutic Strategy for MAFLD and MASH
Junda Li, Yongquan Chi, Wenzhu Li, Haipeng Jiang, Wei Xu, Shanke Sun, Jianhua Rao
- PP0436 Intracellular C3 Alleviates Hepatic Lipid Accumulation via Interacting with USP4
Yinling Li, Binbin Zhang, Haitao Wang, Junping Shi
- PP0437 High-fat and high-fructose diet feeding induces MASLD in mice by affecting the liver-gut axis
of lipid metabolism
Xiangyun Zou, Wenying Qi, Yue Chen, Xu Cao, Qiuyue Wang, Xiaobin Zao
- PP0438 RGS16 Promotes Restoration of Mitochondrial Function through Activation of AGXT2 in
Miaomiao Tian, Huiling Cao, Shujun Ma, Xi Zhao, Wanhua Ren, Jianni Qi, Zhen Yang
- PP0439 HBV Does Not Protect Against Steatosis in Adults with Metabolic Dysfunction-Associated
Fatty Liver Disease
Jie Zhou, Jing Chen, Yudong Wang, Yan Liu, Dong Ji, George LAU
- PP0440 IDENTIFICATION OF THE KEY GENES RELATED TO BOTH LIPID METABOLISM AND
INFLAMMATION IN MAFLD
Xin Dai, Yuhong Hu, Bangmao Wang, Samar H Ibrahim, Hailong Cao
- PP0441 Machine Learning-Enhanced Bioinformatics Analysis Identifies Glycosylation Genes, Immune
Cell Infiltration in Non-Alcoholic Steatohepatitis
Shan Hong, Lei Sun
- PP0442 Alterations of Differential Expressing Genes or Metabolites Were Associated with MASLD
Malignant Transformation
Min Yao, Min Xu, Tiantian Ruan, Rongfei Fang, Qun Xie, Wenli Sai, Dengfu Yao
- PP0443 The application prospects of Resmetirom combined with GLP-1 receptor agonists in the
treatment of MASLD
Zhen Yuan, Junhua Ma
- PP0444 Enhanced expression of FTO gene in the liver correlates with progression of Metabolic
Dysfunction Associated Steatotic Liver Disease
Sunita Giri, Vijay Kumar

- PP0445 Relationship Between Serum Vitamin D Levels and Metabolic-Associated Fatty Liver Disease in Hypertensive Adults: Evidence from the 2017-2018 NHANES Cycle
Liu Mengmeng, Fei Yue, Xu Xiaohong, Li Xue, Lin Han, Guo Yonghong
- PP0446 SENP3 promotes hepatocyte steatosis via de-SUMOylation of SREBP2
Linxi Chen, Nian Fu, Qianyu Tang, Yang Hu, Xiaohua Jiang, Wenjing Peng
- PP0447 Focus on a new perspective of NAFLD: re-understand the characteristics of lipid droplets
Zhen Yuan, Junhua Ma
- PP0448 Elevated levels of serum GM3 as a novel diagnostic biomarker for hepatic steatosis
Moran Hu, Ziyu Liu, Zhenzhen Fu, Hongwen Zhou, Yingyun Gong
- PP0449 New Diagnosis of NASH - Imaging Changes Combined with Non Invasive Serum Biomarkers
Zhen Yuan, Junhua Ma
- PP0450 Investigating heat shock protein dysregulation and immune cell dynamics in non-alcoholic steatohepatitis by integrated multi-RNA seq analysis
Andrew Dong, Qian Wang
- PP0451 Let's Get acquainted the function of macrophages in NAFLD
Zhen Yuan, Junhua Ma
- PP0452 Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology
Zhu Yu Jin, Zhang Yan, Rao Yao, Jiang Yong, Liu Yong Gang, Li Jian Zhou, Yuan Jia Qi, Zhao Ying, Zheng Wen Wen, Ma Lin, Wang Chun Yan, Li Jia
- PP0453 Metabolic Associated Fatty Liver Disease : latest advances in pathological mechanisms, diagnostic techniques, and treatment strategies
Zhen Yuan, Junhua Ma
- PP0454 Steatotic Liver Disease Associated with Hepatitis C: Analysis of Determinants and Hajar Elibrahimi, Maryeme Kadiri, Fatimazahra Chabib, Nawal Lagdali, Mohamed Borahma, Fatimaezzahrae Ajana
- PP0455 Prevalence of Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Cardiac, Kidney, Metabolic Conditions (CKM) in Adults: A Community-Based Study
Jing Zeng, Zhen Yang, Jian Gao Fan
- PP0456 Evaluation of different non-invasive models in assessing lean metabolic associated fatty liver disease in people living with HIV
Wei Xu, Yinzhong Shen, Chen Jun, Renfang Zhang
- PP0457 Golgi protein 73: Charting new territories in diagnosing significant fibrosis in MASLD: A prospective cross-sectional study
Shan Hong, Hongshan Wei
- PP0458 Development and Validation of a comorbidity burden based model for predicting chronicity following acute drug-induced liver injury
Shuo Zhang, Zhijing Wang, Lu Xia, Bing Ji, Yang Li, Changqing Yang
- PP0459 PPARs family as a target and regulator of epigenetic mechanism in NASH
Zhen Yuan, Junhua Ma

- PP0460 Additive effect of SAMM50 and MBOAT7 variants on the histological severity of metabolic-associated steatotic liver disease
Jinhan Zhao, Jing Zhang, Yang Zhang, Fanqiang Meng, Xiaodie Wei, Qiqige WuYun
- PP0461 Association of Sarcopenia and Physical Activity on the Severity of MASLD
Xiaodie Wei, Jing Zhang, Xiaohui Liu, Jinhan Zhao
- PP0462 Diagnostic performance of ultrasound-derived fat fraction (UDFF) to quantify hepatic steatosis in a biopsy-proven cohort
Yi Dong MD, Yunlin Huang, Ying Wang, Li Wei, Juan Cheng, Xiuyun Lu, Rui Cheng
- PP0463 Machine learning model using R2* radiomics for predicting metabolic dysfunction-associated steatohepatitis
Xiaodie Wei, Jing Zhang, Chen Shao, Shi Qi, Jinhan Zhao, Jing Zhao
- PP0464 Association between the Life's Essential 8 Health Behavior Score and All-cause Mortality in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
Yan Han, Jing Tang, Na Wu, Zhao Li, Hong Ren, Peng Hu, Zhiwei Chen
- PP0465 Appraising the causal role of depression in the risk of multiple chronic liver diseases: A Meta-analysis and bi-directional Mendelian randomization study
Huan Wu, Long Wu, Can Li, Quan Zhang, Mao Mu
- PP0466 Could Targeted Reduction of Liver Fat Reduce Blood Glucose Levels in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) : A Meta-analysis
Zhaoqian Xu, Xinlei Zhang, Linong Ji, Xiantong Zou
- PP0467 Association of blood lead concentrations and all-cause mortality in US adults with MASLD: a prospective cohort study
Jinhan Zhao, Jing Zhang, Yang Zhang, Xiaodie Wei
- PP0468 Semaglutide reduced hepatic steatosis assessed by ultrasound-derived fat fraction in metabolic dysfunction-associated steatotic liver disease patients
Yunlin Huang, Yi Dong, Ying Wang, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu
- PP0469 The Relationship Between Quantitative Fibrosis Parameters and Non-Invasive Fibrosis Tests in MASLD
Xiaodie Wei, Jing Zhang, Chen Shao, Qiang Yang, Shi Qi, Jinhan Zhao, Jing Zhao
- PP0470 Focus on cardiometabolic risk factors on the risk of cholelithiasis in patients with MASLD
YuanYing Zhao, TianYuan Yang, Qi Wang, Yue Li
- PP0471 Single machine nomogram for risk estimation of early Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD))
Tiansu Lv, Xiqiao Zhou
- PP0472 Application of IMB Model-Based Self-Management Interventions in Non-Alcoholic Fatty Liver Disease
Run Zhou, Wei Zhang, Ting Ting Kong, Jie Fu, Lan Chun Liu, Jie Li, Ping Jun Shi
- PP0473 Comparative efficacy of pharmacologic therapies for MAFLD in improving fibrosis: Systematic review and network meta-analysis
Xiao Han, Xiaowei Ai, Yameng Sun, Shuyan Chen, Xinyu Zhao, Hong You
- PP0474 Risk stratification for patients with MASLD based on cardiometabolic risk factors
Yiheng Zhang, Yan Wang, Tao Li, Yundong Qu

- PP0475 Associations between Skeletal Muscle Strength and Chronic Kidney Disease in Patients with MAFLD: a large-scale study involving four separate cohorts
Xinlei Zhang, Yeqing Gu, Jing Zhao, Peiwu Zhu, Wenying Chen, Gang Li, Wenye Li, Wen Zheng, Ni Zhang, Lili Chen, Giovanni Targher, Christopher D Byrne, Kaijun Niu, Danqin Sun, Minghua Zheng
- PP0476 Regional liver fibrosis progression analyzed by digital pathology with artificial intelligence is associated with renal function decline
Danqin Sun, Jiaqi Shen, Xiaofei Tong, Yayun Ren, Haiyang Yuan, Yangyang Li, Xinlei Wang, Suidan Chen, Peiwu Zhu, Xiaodong Wang, Christopher D Byrne, Giovanni Targher, Lai Wei, Vincent WS Wong, Dean Tai, Arun J Sanyal, You Hong, Minghua Zheng
- PP0477 Lower Plasma Lipoprotein(a) Threshold in MASLD Patients with Advanced Fibrosis
Tie Xiao, Huihui Liu, Na Tian, Liyou Lian, Kaiwen Miao, Yuting Li, Lili Chen, Haiyang Yuan, Mulong Du, Shanshan Wu, Giovanni Targher, Christopher D Byrne, Michael D Shapiro, Gregory YH Lip, Xiaodong Zhou, Jianjun Li, Minghua Zheng
- PP0478 A case of liver disease with complex causes
JIE WEN LUO, RONG YUE ZHANG
- PP0479 A 15-years-old of Gilbert and non-alcoholic fatty liver associated cirrhosis with esophagogastric variceal bleeding
Hua Liu, Fushuang Ha, Zhao De Song, Jun Jun Cai, Min Hong Lv
- PP0480 Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
Hongye Peng, Chunli Lu, Mo Zhao, Xiaoqiang Huang, Shuxia Huang, Ziwen Zhuo, Jing Liu, Wenliang Lv
- PP0481 Glycometabolism-based prediction of metabolic associated fatty liver disease in patients with type 2 diabetes mellitus
Zhenjun Yu, Mengdie Chen, Jie Chen, Yuetao Zhang, Ping Feng, Xiaosheng Teng
- PP0482 Bidirectional relationship between obesity and NAFLD and their Effects on Cardiovascular and Hepatic Outcomes: A Mendelian Randomized Study
Qi Huang, Linong Ji, Xiantong Zou
- PP0483 Association between newly consensus defined metabolic hyperferritinemia criteria and mortality in patients with MAFLD: evidence from a nationwide population-based study
Jia Li, Jie Zhang, Chao Sun
- PP0484 Clinical and pathological features and prognostic analysis of progressive liver fibrosis in metabolic dysfunction associated steatotic liver disease
Liuyi Chang, Yafen Dong, Moli Shao, Zikun Ma, Xinyan Zhao
- PP0485 Diagnostic value of FibroScan and nonalcoholic fatty liver fibrosis score in nonalcoholic fatty liver with normal alanine aminotransferase
Youwen En Tan
- PP0486 Longitudinal changes in alanine aminotransferase (ALT) enhance risk assessment for liver-related events in patients with type 2 diabetes (T2D) with different ALT levels at diagnosis
Nana Peng, Sherlot Juan Song, Mary Yue Wang, Jimmy CT Lai, Grace LH Wong, Vincent WS Wong, Terry CF Yip

- PP0487 Analysis of the impact of concurrent HBV infection on the oral microbiota of patients with MAFLD based on 16S rDNA sequencing
Jingjing Zhang, Song Feng, Dali Zhang, Jian Xue, Pengcheng Liu, Shuangnan Fu, Man Gong, Hui Feng, Ning Zhang
- PP0488 An Accurate Race and Ethnic-specific Novel Index for the Diagnosis of Metabolic Dysfunction-associated Steatotic Liver Disease: A population-based study
Xinyuan He, Zhiluo Yang, Takanori Ito, Hideyuki Hyogo, Masafumi Ono, Kentaro Oniki, Tetsuhito Kojima, Zhanpeng Yang, Sally Tran, Zixuan Xing, Yi Liu, Naoyoshi Kariya, Shinya Yokoyama, MingHua Zheng, Junji Saruwatari, Hirokazu Takahashi, Lei Zhang, Takashi Honda, Mindie H Nguyen, Fanpu Ji
- PP0489 Diagnostic and prognostic performance of the Agile 3+ score in chronic hepatitis B and concurrent MASLD after complete viral suppression with nucleos(t)ide analogues
Hongsheng Yu, Yuexiang Ren, Mingkai Li, Hu Can, Hao Jiang, Yinan Huang, Bin Wu, Jianning Chen, Yidong Yang
- PP0490 Evaluation of the Clinical Effect of High-Protein Low-Glycemic (HPLG) Diet Intervention on the Rehabilitation of Patients with MAFLD and T2DM
Taolong Zhou, Xiaoliang Li, Kefeng Li, Mingxing Huang
- PP0491 Prevalence of Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Cardiac, Renal, Metabolic Conditions (CRM) in Adults: A Community-Based Study
Jing Zeng, Zhen Yang, Jian Gao Fan
- PP0492 Differences in Glucose and Lipid metabolism Characteristics between Lean and Obese patients with Metabolic Associated Fatty Liver Disease
Huanming Xiao, Meijie Shi, Zhiheng Chen, Yubao Xie, Yousheng Mo, Chaozhen Zhang, Ming Lin, Xiaoling Chi
- PP0493 Identifying Heterogeneity in Newly Diagnosed Metabolic Dysfunction-associated Steatotic Liver Disease Using Group-Based Multi-trajectory Models
Chenlu Yang, Yang Zhou, Shutong Wu, Shuohua Chen, Shouling Wu, Li Wang
- PP0494 Reduction in Liver Stiffness after One-Year Intervention Is Associated with Improvement in Glucose and AST Levels: A Longitudinal Chinese Cohort Study of Biopsy-Proven MASLD Patients
Meng Lu, Mingyu Zhu, Mingjie Wang, Hu Li, Qingling Wang, Li Chen
- PP0495 The correlation between Hepatic Controlled Attenuation Parameter (CAP) value and Insulin Resistance (IR) was stronger than that between Body Mass Index, Visceral Fat Area and IR
Zhouhuiling Li
- PP0496 Impact of Lowering ALT Upper Limit of Normal on Reducing Missed Diagnosis of MASH and Significant Fibrosis in MAFLD Patients
Jie Liu, Hang Yang, Jia Li
- PP0497 Lower cerebral blood flow in the right median cingulum is associated with liver fat fraction in metabolic dysfunction-associated fatty liver disease (MAFLD)
Jingjie Zhao, Hao Wang, Chaoru Han, Di Cao, Ruimin Jiao, Hong You
- PP0498 Synergic Effect of Pancreatic Steatosis and MASLD on Risk of New-onset Heart Failure in the General Population: A Prospective Analysis of the UK Biobank
Liyu Lian, Tianyi Xia, Zhongwei Chen, Caiyun Wen, Xiaodong Zhou, Tie Xiao, Giovanni Targher, Christopher D Byrne, Yee Hui Yeo, Shenghong Ju, Wenyue Liu, Minghua Zheng

- PP0499 Is hepatic steatosis an independent risk factor for advanced fibrosis in Chronic hepatitis B patients with metabolic dysfunction-associated steatotic liver disease?
Ming Lin, Meijie Shi, Huanming Xiao, Yubao Xie, Chaozhen Zhang, Yousheng Mo, Folai Zeng, Mengling Han, Xiaoling Chi
- PP0500 Depression in Metabolic dysfunction-associated steatotic liver disease (MASLD) in a population cohort in S India
Leena K B, Shenoy T Kotacherry, Jayakumar P Pillai, Guruprasad P Aithal
- PP0501 Liver histology and Non invasive tests (NITs) for hepatic fibrosis in a large cohort of metabolic dysfunction-associated steatotic liver disease (MASLD) in Kerala, S India
Shenoy T Kotacherry, Leena B
- PP0502 Non-alcoholic fatty liver disease increased the risk of subclinical carotid atherosclerosis
Xintian Ren, Pegnfei Sun, Yu Wang, Yanfang Tan, Xinyan Zhao, Min Li
- PP0503 The Relationship Between Body Fat Distribution and the Progression of MASLD
Xiaodie Wei, Jing Zhang, Jinhan Zhao, Sitong Chen
- PP0504 Real-World Assessment of Saroglitazar for improving FAST Score and Fibroscan Parameters (LSM and CAP) in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): An Open-Label, Prospective Study
Sunil B Daschakraborty, Arnabja Ghosh
- PP0505 Characterizing Nonalcoholic Fatty Liver Disease (NAFLD) in Lean individuals in a tertiary care hospital: A cross-sectional study
Shamim Nazir, Zaigham Abbas
- PP0506 HBV increases the risk of cirrhosis in adult patients with metabolic dysfunction-associated fatty liver disease
Jianjun Wang, Jing Chen, Lei Li, DONG JI, Yudong Wang, George LAU, Yan Liu
- PP0507 Cross-Sectional Survey and Analysis of the Prevalence of MAFLD in HIV-1 Infected Individuals in Zhejiang Province
Yongzheng Guo, Biao Zhu
- PP0508 Non-invasive tests for advanced fibrosis in metabolic-dysfunction associated steatotic liver disease and other comorbidities
Mingkai Li, Hongsheng Yu, Jianning Chen, Yidong Yang
- PP0509 Comparison of the efficacy of different non-invasive assessments in identifying MASLD at high risk of mortality: A population-based study from NHANES III
Yajing Bo, Xinyuan He, Yunyu Zhao, Ming Chen, Yichen Yang, Xubing Zhou, Xiao Yuan, Zhiluo Yang, Fanpu Ji, Ning Gao
- PP0510 Risk factors of atherosclerotic plaque formation in metabolic dysfunction-associated steatotic liver disease
Weihaio Peng
- PP0511 Incidence and Characterization of Small Intestinal Bacterial Overgrowth (SIBO) in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients
Shamim Nazir, Zaigham Abbas
- PP0512 Development of Metabolic dysfunction and Alcohol-associated Liver Disease (Met-ALD) in Young Indian Adults : An Observational Study of Clinical and Socio-Demographic Correlates and opportunities for Integrated and early intervention

Mohit Kumar Varshney, Shiv Kumar SARIN

- PP0513 Associations Between Sensitivity to Thyroid Hormones and Hepatic Steatosis in People with Obesity
Yifang Zhang
- PP0514 Prediabetes (PreDM) and diabetes mellitus type 2 (DM) are strongly associated with severe liver steatosis and advanced fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients
Sasunova Armida, Alexey Goncharov, Vasily Isakov
- PP0515 Diabetes mellitus (DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with an increased consumption of saturated fatty acids and higher liver steatosis grades.
Vasily Isakov, Sasunova Armida, Alexey Goncharov
- PP0516 Evaluation of NAS and Fibrosis Stage of Non-Alcoholic Steatohepatitis in Pediatric Patients Across Different Age Groups
Peng Xu, Shuhong Liu, Yi Dong, Jianguo Yan, Lili Cao, Dong Ji, Jingmin Zhao, Min Zhang
- PP0517 Exploring the Relationship Between Serum Ferritin and Metabolic-Associated Fatty Liver Disease in Adolescents Based on NHANES Database
Liu Mengmeng, Fei Yue, Xu Xiaohong, Li Xue, Lin Han, Huang Zhenghaoyu, Guo Yonghong
- PP0518 The Influence of Metabolic Dysfunction-Associated Fatty Liver Disease on the Risk of Cirrhosis and Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Zixiang Huang, Jilian Fang, Dan Guo, Zixing Wang, Yafan Wang, Qian Jin, Danli Ma, Huiying Rao, Feng Liu, Nan Wu
- PP0519 The Construction of a Combined Predictive Model based on the Association Between Metabolic Associated Fatty Liver Disease and Hyperglycemia in a Health Examination Cohort
Sha Wu, Daiyi Zhang, Jin Li, Qinkao Xuan, Xiaodong Qian, Chuanwu Zhu, Jianhong Pu, Li
- PP0520 MAFLD and IBD: A Crossroad of Metabolic Risk and Disease Flare
Pulkit Mehrotra, Punit Mehrotra, Vengadakrishnan K
- PP0521 Time trends in Trivandrum Cohorts of Metabolic dysfunction Associated Steatotic Liver
Shenoy T Kotacherry, Leena K B, Jayakumar P Pillai, Guruprasad Aithal P
- PP0522 Accuracy of non-invasive tools for diagnosis of metabolic dysfunction associated steatotic liver disease (MASLD) in primary care settings: Russian experience
Alexey Goncharov, Vasily Isakov, Sasunova Armida, Camilat Gapparova, Yulia Chekhonina
- PP0523 Estimated glucose disposal rate as a novel index in diabetic patients with metabolic syndrome for estimation of liver fat content index
Hanieh Radkhah, Diar Zooravar
- PP0524 Predictive Factors for the Therapeutic Effect of Pemaifibrate in MASLD Patients
Tomohide Kurahashi, Atsushi Hosui, Naoki Hiramatsu
- PP0525 The Relationship Between the Recently Renamed "Metabolic-Associated Fatty Liver Disease" and Colorectal Cancer
Liyue Hu, Suyi Wang, Quanwei Xu, Wei Ni
- PP0526 Histone Methylation as a Biomarker for MASH Progression to Hepatocellular Carcinoma
Xinlei Qi, Anna Li, Xi Guan, Junzhe Jiao, Ruijuan Yan, Zhanjie Chang, Haibo Zhang, Jingtao

- PP0527 Metabolic Associated Fatty Liver Disease from a Mechanobiology Perspective: Cellular Responses and Disease Evolution
Yushan Li, Haibo Zhang, Junzhe Jiao, Ning Wang, Zhanjie Chang, Ruijuan Yan, Jingtao Li
- PP0528 SGLT2 Inhibitors And Nonalcoholic Fatty Liver Disease (NAFLD): Meta-Analysis of Randomized Trials Evaluating Hepatic Steatosis and Fibrosis
Demver Plamenko Gomez, Wilmyr Francisco Hababag, Celeste Ong-Ramos
- PP0529 Fecal Angptl4 as a non-invasive diagnostic indicator for gut-liver health in MASLD
Damien Chua, Hong Sheng Cheng, Rattanaporn Kiatbumrung, Pornjira Somnark, Yin Hao Lee, Natthaya Chuaypen, Pisit Tangkijvanich, Nguan Soon Tan
- PP0530 The mevalonate pathway regulates double negative regulatory T cells immunoregulatory function in MASLD
Wang Xiyu, Jin Hua, Sun Guangyong, Zhang Dong
- PP0531 Single-cell proteomics and spatial proteomics revealing unique new pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD)
Tiansu Lv, Xiqiao Zhou
- PP0532 Study on the action mechanism of the spleen-strengthening and lipid-regulating herbal formula on MAFLD, based on network pharmacology and experimental validation
Da Wang, Dan Zhang, Mengwei Li, Yingxue Shen, Rongting Zhao, Jinxiu Li, Jianjun Liu, Lanqing Ma
- PP0533 Phase 2 Studies of a Novel Pulsatile FXR Ligand for MASH
Gaihong Wang, Jingjing Shi, Guanguan Zhao, Hualing Pan, Shengsheng Yang, Rong Deng, Zhenwei Zhang, Eric H Xu, Robert W Barish, Mark Todd Leibowitz, Idalia A Acosta, Carmen E Landaverde, Eric J Lawitz, Mark Todd Leibowitz, Stanley H Hsia, William E Sanchez, Douglas S Denham, Robert A Jenders, Gary Michael Reiss, Francisco Velazquez, Kathryn Jean Lucas, Raja Mohi-Ud-Din, Manuel E Rodriguez, Robert W Barish
- PP0534 Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes
Yiheng Zhang, Yan Wang, Juanli Wu, Tao Li, Yundong Qu
- PP0535 Effectiveness of Silymarin Combined with Diet and Exercise in Normalizing and Reducing Liver Enzymes in Patients with NAFLD and Metabolic Syndrome.
Wattana Sukeepaisarnjaroen, Roongruedee Chaiteerakij, Elvie Victorine B. Razon Gonzalez, Rafiz Abdul Rani, Maria Teresita R Andal Gamutan, Marie Michelle Simbol Cloa, Leilanie Salgado, Ekawee Sripariwuth, Madaline Eternity Labio, Sakkarin Chirapongsathorn, Taned Chitapanarux, Laura Colombo, Nageswara Rao Yeluchuri, Sanjay Hadigal, Amit Ravindra Birajdar
- PP0536 Comparative Efficacy and Safety of Drugs for non-cirrhotic NAFLD: A Systematic Review and Network Meta-Analysis
Yuanming Chen, Xinyu Yang, Wei Shen, Peiru Zhang, Xudong Yang, Qianrang Lu, Qi Ling, Xiao Xu, Di Lu
- PP0537 Effectiveness of Silymarin Combined with Diet and Exercise in Normalizing and Reducing Liver Enzymes in NAFLD and Metabolic Syndrome Patients with Underlying Medical

Wattana Sukeepaisarnjaroen, Roongruedee Chaiteerakij, Elvie Victoriette B. Razon Gonzalez, Rafiz Abdul Rani, Maria Teresita R. Andal Gamutan, Marie Michelle Simbol Cloa, Leilanie Salgado, Ekawee Sripariwuth, Madaline Eternity Labio, Sakkarin Chirapongsathorn, Taned Chitapanarux, Laura Colombo, Nageswara Rao Yeluchuri, Sanjay Hadigal, Amit Ravindra Birajdar

- PP0538 Evaluating the utility of Noninvasive Markers (FLI, LAP, FIB-4, HSI, and NFS) for Diagnosing Early Liver Disease: baseline data from an observational study with NAFLD patients with Metabolic Syndrome

Wattana Sukeepaisarnjaroen, Roongruedee Chaiteerakij, Elvie Victoriette B. Razon Gonzalez, Rafiz Abdul Rani, Maria Teresita R. Andal Gamutan, Marie Michelle Simbol Cloa, Leilanie Salgado, Ekawee Sripariwuth, Madaline Eternity Labio, Sakkarin Chirapongsathorn, Taned Chitapanarux, Laura Colombo, Nageswara Rao Yeluchuri, Sanjay Hadigal, Amit Ravindra Birajdar

- PP0539 *Pediococcus acidilactici* (PA53) Ameliorates MAFLD by Regulating the Gut-Liver Axis
Yue Niu, Shurui Bu

- PP0540 Impact of Silymarin on Quality of Life in Patients with NAFLD and Metabolic Syndrome
Wattana Sukeepaisarnjaroen, Roongruedee Chaiteerakij, Elvie Victoriette B. Razon Gonzalez, Rafiz Abdul Rani, Maria Teresita R. Andal Gamutan, Marie Michelle Simbol Cloa, Leilanie Salgado, Ekawee Sripariwuth, Madaline Eternity Labio, Sakkarin Chirapongsathorn, Taned Chitapanarux, Laura Colombo, Nageswara Rao Yeluchuri, Sanjay Hadigal, Amit Ravindra Birajdar

- PP0541 Integrative metabolomics and network pharmacology analysis reveals the therapeutic effect of Jiangan-Jiangzhi Pill on non-alcoholic steatohepatitis
Lianxin Xu, Yuekui Wang, Wentao Kuai, Shuangjie Yu, Minghui Zeng, Jiaxin Han, Xuemei Tao, Lifeng Han, Liming Wang, Rui Su, Liang Xu, Yuqiang Mi

- PP0542 Body Mass Index is More Effective than Waist Circumference as an Evaluation Metric for Liver Fibrosis and Steatosis in MAFLD Patients
Zhengzhao Lu, Cheng Huang, Xinyu Zhao, Wei Ji, Jingjie Zhao, Tingting Xiao, Dongxu Wang, Dong Xu, Hong You

- PP0543 To Determine Risk Factors in the Development of MASLD/MASH in “Isolated Anti-HBc IgG Positive” Immunosuppressive Patients Using Antiviral Prophylaxis (IMMUNASH Study)
Cigdem Mermutluoglu, Mustafa Kemal Celen, Yasar Bayındır, Fethiye Akgul, Pinar Çakmak, Tuba Damar Çakırca, Yusuf Arslan, Ismail Yıldız, Yesim Tasova

- PP0544 The effects of target positioning repetitive Transcranial Magnetic Stimulation on weight and appetite craving levels in patients with nonalcoholic fatty liver disease: A randomized controlled study
Lei Sun, Jianin Kong, Junping Shi

- PP0545 AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study
Mary Rinella, WenWei Tsai, Julie Dubourg, Katharine Grimmer, Eduardo Martins, Pierre Bedossa, Kutbuddin Akbary, Dean Tai, Marie O'Farrell, George Kemble, Rohit Loomba

- PP0546 Efficacy of Saroglitazar in treatment of Metabolic associated fatty liver disease (MAFLD)
Abdullah Al Mukit

- PP0547 Non alcoholic fatty liver - advances in treatment breakthroughs
Zhen Yuan, Junhua Ma

- PP0548 The Role of Nutritional Status in Post-Transplant Dysglycemia Among Liver Transplant Recipients
Nguyen Thu Ha, Dao Thi Hao, Chu Thi Phuong Nam, Nguyen Thi Huong
- PP0549 Plasma FSTL-1 accurately assesses MASH-associated liver fibrosis stage
Yongquan Chi, Wenzhu Li, Junda Li, Haipeng Jiang, Wei Xu, Shanke Sun, Xiaoguo Li, Xiaolong Qi, Jianhua Rao
- PP0550 The Effect and Mechanism of Cordycepin on Metabolic-associated Fatty Liver Disease
Yu Zhang, Xiaoxiong Hu
- PP0551 Association between coffee consumption habits and Non-alcoholic fatty liver disease in community-dwelling populations: data from the National Health and Nutrition Examination Survey 2013–2018
Penglin Chen, Shiyan Wang, Tao Zhang, Enqiang Chen
- PP0552 Serum Metabolomics Uncovers the Mechanisms of QinghuaFang in Preventing Non-Alcoholic Fatty Liver Disease
Le Wang, Chunyan Wang, Ying Li

Liver Injury and Toxicity

- PP0553 Paracetamol Toxicity treated with Hemoperfusion: A Case Report
Sam Nogoy Fandood
- PP0554 Survival benefit of S-adenosyl-L-methionine in hospitalized patients with alcoholic hepatitis: a real-world cohort study
Fangfang Duan, Yazhi Wang, Yongping Zhang, Song Yang
- PP0555 Composition of gut microbiota and alcohol-related liver disease: A systematic review and meta-analysis
Xuanxuan Niu, Huichun Xing
- PP0556 Hidden Danger: Hepatotoxicity Linked to Nutritional Supplements
Silvia Cvekova
- PP0557 Rare Hepatic Subcapsular Hematoma Post-ERCP in an Adult Healthy Female
JESIAH JANELLE DELOS REYES, CELINA ADRANEDA
- PP0558 Comparative Study of RUCAM and RECAM for Causality Assessment in a Chinese Multi-center Prospective Drug-induced liver injury Cohort
Yao Meng, Mengmeng Zhang, Tiantian Guo, Zikun Ma, Jinxin Gu, Cen Zhang, Runjie Wei, Meng He, Mengyu Zhao, Yu Wang, Yan Wang, Xinyan Zhao
- PP0559 Analysis of Clinicopathologic Feature and Diagnostic Difficulties of Drug-induced Autoimmune-like Hepatitis (DI-ALH) and Review of Literature
Ying Qun Xiao, Chong Xie, Fu Wang Xu
- PP0560 Case Report of Myeloproliferative Neoplasm Complicated with Hepatic Sinusoidal Obstruction Syndrome and Focal Segmental Glomerulosclerosis
Yuxuan Song, Yajing Zhen, Hui Ma, Bo Feng, Yandi Xie
- PP0561 Depressed TFAM Promotes Acetaminophen-induced Hepatotoxicity Regulated by DDX3X-PGC1 α -NRF2 Signaling Pathway
Yaling Cao, Sisi Chen, Zihao Fan, Ling Xu, Zhenzhen Pan, Mei Liu, Feng Ren

- PP0562 Sinusoidal Obstructive Syndrome Following Allogeneic Stem Cell Transplant: A Case Report of Recovery in a 65-Year-Old Male
Weilun Gao, Chuyi Liao
- PP0563 Effects of *Lactobacillus plantarum* on intestinal microbiota and plasma metabolism in mice with alcohol-related liver injury
Yifan Xu, Yanxu Hao, Song Yang, Huichun Xing
- PP0564 Propensity Score Matching Analysis for alcohol-related liver disease
Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang
- PP0565 Dysbiosis of the gut microbiota associated with death in alcoholic liver cirrhosis with
Min Quan, Min Li, Yifan Xu, Song Yang
- PP0566 Evaluation of the HepG2-Ethanol Model for Transcriptomic Analysis in Preclinical Research of Alcohol-Related Liver Disease
Yang Wang, Xiaoxue Yuan, caixia Zhao, Jiayi Li, Ronghua Jin, Xi Wang, Song Yang
- PP0567 Myosteatosis is closely associated with sarcopenia and worse short-term outcomes in male patients with ARLD in China
Yu Zhang, Song Yang
- PP0568 Comparison of Baseline Characteristics and Survival Rates in ALD Patients with and Without Metabolic Syndrome
Yazhi Wang, Fangfang Duan, Song Yang
- PP0569 Vitamin D deficiency is related to liver disease severity and predict sarcopenia and spontaneous bacterial peritonitis in alcohol-related liver disease: a cross-sectional study
Qiufeng He, Fangfang Duan, Song Yang
- PP0570 Involvement of oxidative stress, lipid dysmetabolism and gut microbial dysbiosis in oxaliplatin-induced fatty liver disease: evidence from a tree shrew model
Youzhi Lin, Yulei Lu, Fei Yi, Chunlong Gui, Xinglong Tan, Wende Chen
- PP0571 APRI can be used as an effective predictor of liver injury in patients with hepatocellular carcinoma treated with PD-1/PD-L1 inhibitor combination therapy : A single-center retrospective study
JingMing Zhang, Zheng Ling, Zheng Ling, RongHui Xie, YuRou Jin
- PP0572 Clinical Features and Prognosis of Drug-Induced Liver Injury in the Context of Non-Alcoholic Fatty Liver
Zhao Ying, Li Jian Zhou, Liu Yong Gong, Zhu Yu Jing, Zhang Yan, Zheng Wen Wen, Ma Lin, Wang Chun Yan, Li Jia
- PP0573 Efficacy and safety of magnesium isoglycyrrhizinate in preventing novel antitumor drug-induced liver injury in patients with malignant hematological diseases: a multicenter,
Chen Liang, Li Liu, Rong Li Zhang, Dong Lin Yang, Yi He, Ai Ming Pang, Si Zhou Feng, Ming Zhe Han, Er Lie Jiang
- PP0574 Substance P promotes the interaction between liver sinusoidal endothelial cell and macrophage through Gas6-MerTK to mediate inflammation resolution and repair in APAP-
Fan Li, Yi Ming Wang, Ming Ni, Ling Lu
- PP0575 Clinical and Subclinical Characteristics and Treatment Results of Acute Liver Failure at Thai Nguyen National Hospital

Le Thu Hien, Le Quoc Tuan, Dinh Cong Tiep, Dinh Cong Dang

- PP0576 Biomimetic Ceria Lipoprotein Nanoparticle Enable NAC-Enhanced Macropinocytosis-Dependent Liver-Targeting Delivery for the Treatment of APAP-Induced Liver Injury
Yaoxing Chen, Gan Jiang, Yan Huang, Shuying Song, Haoshuang Fu, Bingying Du, Xiaoling Gao, Qing Xie
- PP0577 Metabolomics and non-invasive clinical biomarkers for Polygonum multiflorum-induced cholestasis hepatitis after histological confirmation
Jing Jing, Jiabo Wang, Xinyan Zhao, Ruilin Wang
- PP0578 A prognostic model for pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome based on sarcopenia
Yangyang Zhou, Yuhu Song
- PP0579 Atractylodes macrocephala polysaccharides ameliorate acetaminophen-induced acute liver injury through intestinal flora
Jiali Wu, Shuai Gong, Biao Jia, Yangpeng Li, Jiao Guo
- PP0580 D-mannose protects against acetaminophen-induced hepatotoxicity in mice
Qin Haixia, Tong Shiwen, Yin Wenwei
- PP0581 Persistent Jaundice in A 20-Year-Old : A Rare Case of Drug Induced Liver Injury Associated with DRESS Syndrome Induced by Meropenem
Shahnaz Medina, Maulana Suryamin, Irwin Tedja, Radita Ikapratiwi
- PP0582 Macrophage-specific TREM1 up-regulation exacerbates drug-induced hepatic steatosis through macrophage inflammatory polarization.
JING LIU
- PP0583 Oral Budesonide as an Effective Alternative Treatment of Immune-Mediated Hepatobiliary Toxicities Associated with Immune Checkpoint Inhibitors: A Case Series
Lan Sun Wang, Antonio Pizourno Machado, Kadon Nathaniel Caskey, Abdullah Shaikh, Ethan Miller, Yinghong Wang, Haochi Zhang
- PP0584 Sirolimus Efficacy in Treating Steroid-Resistant Immune-Mediated Liver Injury: Two Clinically Successful Case Reports
Shuying Huang, Tao Zeng, Jiao Gong, Yutian Chong, Xinhua Li
- PP0585 A retrospective study of clinical characteristics and steroid therapy in immune checkpoint inhibitor-mediated hepatitis
Feilan Yang, Lei Fu
- PP0586 Interleukin-19 Is a Key Determinant of Selectively Limiting Proinflammatory Macrophage Infiltration and Protects Against Drug-induced Liver Injury
Xiao Peng, Gao Yan Hang, He Yong
- PP0587 Clinicopathological Features and Genetic Susceptibility Screening of Recurrent Drug-induced Liver Injury (RDILI-GS)
Mengmeng Zhang, Lan Wang, Yao Meng, Tiantian Guo, Zikun Ma, Yu Wang, Xinyan Zhao
- PP0588 Risk Factors for Acute Hepatitis Induced by Anti-Tuberculosis medications in the Kashmiri population.
Usman Ghani, Abrar Umar

- PP0589 HYX1-derived exosomal let-7c-5p protects against acute liver failure by inhibiting SLC11A2-mediated ferroptosis
Qi Yang, Huixin Tang, Xiaoxuan Liu, Li Bai, Yu Chen
- PP0590 Clinical features and prognosis of two pathological acute cholestatic patterns
Jialuo Wang, Yuxiang Gong, Yuan Yang, Shasha Li, Yujia Lu, Yongfeng Yang
- PP0591 Knockout of Zinc- α 2-glycoprotein 1 (AZGP1) Disrupts Metabolic Homeostasis and Enhances Inflammatory Responses, Exacerbating Liver Injury
Pan Xu, Wan Zhou, Wei Cai, Yuhang Zhou, Yuerong Zhang, Qiufu Wang, Fang Wei
- PP0592 Clinical characteristics of drug-induced autoimmune-like hepatitis
Dantong Ma, Shuang Yang, Lili Gao, Xuesong Gao, Xuefei Duan
- PP0593 Modulatory Effects of the Clostridium Metabolites, p-cresyl Sulfate and p-cresyl Glucuronide on Primary Biliary Cholangitis Inflammations
Haiyan Yu, Haiyan Fu, Yingmei Tang
- PP0594 Drug interaction with UGT1A1 polymorphism increases the occurrence of drug-induced liver injury
Yujia Lu, Keying Ou, Yueyang Ma, Chuansu Yuan, QingFang Xiong
- PP0595 Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) Mediates Ferroptosis in Hepatocytes During Acetaminophen-induced Liver Injury and Predicts Clinical Outcomes
Yu Wang, Pengchong Li, Xue Wang, Jiahao Yuan, Yan Wang, Zikun Ma, Mengmeng Zhang, Yao Meng, Tiantian Guo, Jinxin Gu, Cen Zhang, Jidong Jia, Xinyan Zhao
- PP0596 Validation of BNR-6 prognostic model and clinical application of HMGB1 and CK18 in chronic Drug-Induced Liver Injury
Yuting Xiong, Chunyan Wang, Jing Chen, Yudong Wang, George Lau, DONG JI
- PP0597 Immune checkpoint inhibitor-associated hepatitis with grade ≥ 4 (severe) survival: analysis of clinical and prognostic factors
Song Song Yuan
- PP0598 Analysis of lesions of liver in postmortem cases in Indian population
Amar Ranjan, Harshita Dubey, Jaideep Menda, Sathya Veera Merla
- PP0599 Alcoholic cardiomyopathy in patients with alcoholic liver cirrhosis: a study across 10 years
Chunya Wang, Jing Chen, Yupeng Guo
- PP0600 Prolonged Elevated Heart Rate and 90-Day Mortality in Acute Liver Failure
Chenglong Ge
- PP0601 NOX2 Ablation Is A Promising Strategy Against Acute Liver Injury By Reversing Oxidative Stress, Mitochondrial Dysfunction And cGAS-STING Pathway-Dictated Inflammatory
Ziyi Yang, Gaoyue Guo, Chao Sun
- PP0602 Macrophage HIF-1 α inhibition alleviates inflammation-induced acute liver failure in mice
Zhifu Xie, Xiangrong Kong, Wei Liu, Jingya Li
- PP0603 Co-exposure to per- and polyfluoroalkyl substances and microplastics aggravated hepatotoxicity in a sex-dependent manner
Tingting Wu, Xiu Wang

- PP0604 Programmed cell death factor 4 aggravates sepsis-induced liver damage through disturbed mitochondrial quality control system
Jiachi Yu, Ruibing Li, Tian Xia, Jia Huang, Jiacheng Jin, Mianyang Li
- PP0605 The Pitfall of Fasting: Glucose Deprivation and Reacquisition Exacerbate Acute Liver Injury in Mice by Triggering a Pro-inflammatory Response in Macrophages and NK Cells
Boyu Long, Yijuan Qin, Feng Xiang, Hong Ren, Wenwei Yin
- PP0606 SOX9 promotes hepatocyte proliferation via paracrine TGF- α during liver regeneration
Shuqing Liu
- PP0607 Research on the Impact of ER Stress on Apoptosis in Acute and Chronic Liver Injury under the Intervention of TCM
Peipei Huang, Haibo Zhang, Ruijuan Yan, Zhanjie Chang, Junzhe Jiao, Jingtao Li
- PP0608 Protective Effects of Macrophage Iron Deposition on Liver Inflammation via STAT1/NF- κ B Pathway Inhibition in Experimental Acute Liver Injury
Xiaofan Wang, Ziyu Rong, Tianhui Liu, Ping Wang, Lin Liu, Xu Fan, Xinyan Zhao, Min Cong, Jidong Jia

Immune-Mediated Chronic Liver Diseases

- PP0609 Case report: Complete viral suppression after switching to Tenofovir Amibufenamide (TMF) in a chronic hepatitis B patient with renal function impairment
JUN LI, BAOXIN QIAN, Qing Ye
- PP0610 Serum High Sensitivity C Reactive Protein (HS-CRP) as a Marker of Steroid Responsiveness and Event-Free Survival (EFS) in Autoimmune Hepatitis, and its Correlation With Liver Fibrosis on Histology
Simi Tahiliani, Manish Kumar
- PP0611 Comparison of the Diagnostic Value of RPR, GPI, FIB-4 and APRI in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis Overlap Syndrome in Advanced Liver
Cailian Cai, Hongyu Liu, Keshan Wang, Chao Jin, Fangpeng Ling, Bingling Fan, Minghua Su
- PP0612 Genetic association of lipids and lipid-lowering drug target genes with autoimmune liver disease, chronic viral hepatitis and cirrhosis
Tao Yang, Lu Muhan
- PP0613 Neutrophil extracellular traps promote autoimmune hepatitis through inhibiting the suicide of CD8+ T cells
Han Wang
- PP0614 Fatty Acid β -oxidation Enhances the Immune Regulatory Function of Double Negative T cells through pSTAT4-OX40 Signaling Pathway
Zeyu Wang, Hua Jin, Guangyong Sun, Dong Zhang
- PP0615 Construction of hybrid biomimetic nanosystem of mesenchymal stem cells and dendritic cells and its targeted therapy for CD4+ T cells in autoimmune hepatitis
Mengyi Shen, Leyu Zhou, Jingping Liu, Li Yang
- PP0616 Extracellular inosine induces anergy in B cells to alleviate autoimmune hepatitis
Nana Cui, Qiwei Qian, Yujie Zhou, Heng Zhang, Xiong Ma
- PP0617 The Application of Budesonide in the Treatment of Autoimmune Hepatitis - A Systematic Review Based on the PubMed Database

Shenan Huang, Qibo Hu

- PP0618 Predictors of Recompensation in Immunosuppressive Therapy for Autoimmune Hepatitis Patients with Decompensated Cirrhosis
Yujie Zhang, Fan Yang, Yunke Peng, Xiaoyan Ao, Xianglin Wang, Li Yang, Xiaoli Fan
- PP0619 MSCs ameliorate primary sclerosing cholangitis by reprogramming the intestinal microbiota and augmenting vitamin B6
Hongcui Cao, Yingduo Yu, Deying Chen, Qiaoling Pan, Jiong Yu, Lanjuan Li
- PP0620 Coexistence of autoimmune hepatitis with other extra-hepatic autoimmune diseases
Hajar Elibrahimi, Maryeme Kadiri, Fatimazahra Chabib, Nawal Lagdali, Mohamed Borahma, Fatimaezzahrae Ajana
- PP0621 Case report : An elderly male autoimmune hepatitis with cholelithiasis and azathioprine-related severe myelosuppression was treated
JUN LI, YANKAI YANG, JIA LIAN
- PP0622 Predictors of response to steroids in children and adolescents with treatment naïve Severe Autoimmune hepatitis
SAMANNAY DAS, Rajeev Khanna, Vikrant Sood, Bikrantbiharilal Raghuvanshi, Seema Alam, Tamoghna Biswas, Anmol Anmol, Archana Rastogi
- PP0623 Exploring the spectrum of autoimmune hepatitis: acute, acute-on-chronic, and chronic forms
Dan Zhou, Yi Shen, Jie Sun, Li Yang
- PP0624 PD-L1 Loading Dendritic Cell Significantly Attenuate Liver Injury in AIH Mouse via Regulating Th1/Th2 Cytokines
Lisha Yang, Siqi Sun, Jun Liu, Xuying Yin, Heng Liu, Huan Cai, Shanyan Zhang, Jueqing Gu, Hongyu Jia
- PP0625 Hepatic Failure in a Middle-aged Female with Chronic Hepatitis B: Possible Coexistence with Autoimmune Hepatitis or Interferon-induced Autoimmune-like Hepatitis
Xinhua Ren, Qi Wang, Wen Xie
- PP0626 Clinical observation on PBC-AIH overlap syndrome treated with methylprednisolone instead of prednisone acetate combined with Ursodeoxycholic Acid (UDCA)
Zheng Huan Wei, Meng Ping, Li Yu Chan
- PP0627 Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH pathology Group: Multicenter validation with Focus on Chronic Liver Diseases in China
Li Wang, Yongfeng Yang
- PP0628 Mechanisms of Akkermansia muciniphila in the Treatment of Autoimmune Hepatitis
Chenchen Wang, Yang Liu
- PP0629 Therapeutic plasma exchange does not improve survival in autoimmune hepatitis related Acute on Chronic liver failure- An analysis from AARC database
Sunil Taneja, Nipun Verma, Ajay Duseja, Shiv Sarin, Rakhi Maiwall, Ashok Choudhury, Vinod Arora, Mohamed Rela, Dinesh Jothimani, Mamun Al Mahtab, Shahinul Alam, Saeed Hamid, Amna Subhan Butt, Wasim Jafri, Akash Shukla, Manoj Sahu, Sombat Treeprasertsuk, Kessarin Thanapirom, Hasmik Ghazinyan, Abdul Kadir Dökmeci, Zaigham Abbas, P N Rao, Anand Kulkarni, Mithun Sharma, Anil Arora, Ashish Kumar, Sudhir Maharishi, Sargsyan Violeta, Saurabh Mukewar, Ruveena Bhavani, Sunil Dadhich, Sanjeev Sachdeva, Joy Vargese, Gupse Adali

- PP0630 Autoimmune Hepatitis - Primary Biliary Cirrhosis (AIH-PBC) Overlap Syndrome Unmasked during Anti-Tuberculosis Therapy
Tristan Paulo Madrigal, Katrina Austero, Mara Teresa Panlilio
- PP0631 AUTOIMMUNE HEPATITIS PRESENTING AS IRON OVERLOAD IN AN ADULT MALE: A DIAGNOSTIC CHALLENGE
Ferdinand Maitim Anzo, JoseGuillain E Cataluña
- PP0632 Diagnostic potential of Ribosomal protein L30 in Primary Biliary Cholangitis
Zhiyu Zeng, Dongliang Li, Xiaoyong Zhang
- PP0633 Cross-Disciplinary and Cross-Cultural Evaluation of the PBC-40 Scale
Dingrong Dong, Hongli Liu
- PP0634 A Worse subgroup of PBC: jaundice in patients with ductopenia
Tingting Lv, Weijia Duan, Xinyan Zhao, Jidong JIA
- PP0635 Global Epidemiology of Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
Jarell Tan, Ambrose Chung, Jing Hong Loo, Ethan Quek, Sagar Sharma, Corrine Lee Singh, Jacqueline Yap, Wei Xuan Tay, Yu Jun Wong
- PP0636 Clinical Significance and Potential Mechanisms of Impaired Glucose Tolerance in Primary Biliary Cholangitis
Yinan Hu, Ying Han, Yulong Shang
- PP0637 ANALYSIS OF EPIDEMIOLOGY, THERAPY OF PRIMARY BILIARY CHOLANGITIS AND OVERLAP SYNDROME
Lahana Ravoori, Elena Kuharewa, Anastasiya Zhuravleva, Olga Tarasova
- PP0638 Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-Controlled RESPONSE Trial
Alejandra Villamil, Ziad Younes, Christopher L Bowlus, John M Vierling, Adam Vasura, Andrea Galli, Mordechai Rabinovitz, Frederik Nevens, Susheela Carroll, Ke Yang, Linda Wu, Daria B Crittenden, Charles A McWherter, Eric J Lawitz
- PP0639 Effectiveness and Safety of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis
Yansheng Liu, Yulong Shang, Ying HAN
- PP0640 Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE
Eric J Lawitz, Palak J Trivedi, Kris V Kowdley, Stuart C Gordon, Christopher L Bowlus, Maria Carlota Londono, Gideon M Hirschfield, Aliya Gulamhusein, Linda Wu, Daria B Crittenden, Shuqiong Zhuo, Carrie Heusner, Cynthia Levy
- PP0641 Phase I Studies of a Novel Pulsatile FXR Ligand for Treating Cholestatic Liver Diseases
Guanguan Zhao, Jingjing Shi, Gaihong Wang, Hualing Pan, Shengsheng Yang, Rong Deng, Zhenwei Zhang, Jia Li, Eric H Xu
- PP0642 Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial
Andreas E Kremer, Cynthia Levy, Marlyn J Mayo, Christopher L Bowlus, Kris V Kowdley, Gideon M Hirschfield, Susheela Carroll, Ke Yang, Linda Wu, Daria B Crittenden, Charles A McWherter, David EJ Jones

- PP0643 Direct bilirubin demonstrates superior predictive value for long-term outcomes compared to total bilirubin in patients with primary biliary cholangitis
Sha Chen, Buer Li, Shuxiang Li, Tingting Lv, Weijia Duan, Jidong Jia
- PP0644 Long-Term Safety of Seladelpar 10 mg With Up to 5 Years of Treatment in Patients With Primary Biliary Cholangitis
Palak J Trivedi, Stuart C Gordon, Aliya Gulamhusein, Alejandra Vilamil, Eric J Lawitz, John M Vierling, Maria Carlota Lodoño, Andreas E Kremer, Christopher L Bowlus, Sarah Proehl, Shuqiong Zhuo, Linda Wu, Daria B Crittenden, Charles A McWherter
- PP0645 Single-Cell RNA Sequencing for a Rare Case of Primary Biliary Cholangitis-Associated Hepatocellular Carcinoma Reveals a Distinct Immune Landscape and Potential Therapeutic Targets
Zhenwei Qian, Jie Han, Aizier Ainiwaer, Yinying Lu
- PP0646 Genetic association and causal relationship between multiple modifiable risk factors and autoimmune liver disease: a two-sample mendelian randomization study
Mingjun Liu, Weize Gao, Zhan Wang, Yongxin Li
- PP0647 Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay
Mingjun Liu, Zhan Wang, Yongxin Li, Weize Gao
- PP0648 Exon 3 of the Numb gene is equivalent to full-length Numb in alleviating cholestatic liver fibrosis through inhibition of the ductular reaction
Yannan Xu, Mengyao Zong, Wen Xu, Shihao Zhang, Danyang Wang, Xinrui Zheng, Feifei Xing, Junyi Zhan, Jiamei Chen, Gaofeng Chen, Ping Liu, Wei Liu, Yongping Mu
- PP0649 Concurrent Nonalcoholic Fatty Liver Disease Decreased Liver Fibrosis Severity in Patients with Primary Biliary Cholangitis
Zilong Wang, RUI HUANG
- PP0650 Sulfasalazine Improves ANIT-Induced Cholestasis
Xuan Wang, Jing Xu, Yu Zhang, Hnag You, Jing Xiao, Zongyi Liu, Yong Sun, Duo Li, Mingli Peng
- PP0651 Neutrophil extracellular traps-induced pyroptosis of liver sinusoidal endothelial cells exacerbates intrahepatic coagulation in cholestatic mice
Muxin Yu, Jinming Zhang
- PP0652 Biochemical Response and Clinical Outcome of Primary Biliary Cholangitis Patients with Mild Interface Hepatitis
Tingting Lv, Weijia Duan, Xinyan Zhao, Jidong JIA
- PP0653 Analysis of pathological and clinical features of primary biliary cholangitis with inadequate response to ursodeoxycholic acid
Hongmei Wu, Jialin Qu, Xiaofeng Shi, Yu Lei(Corresponding author)
- PP0654 Clinical Characteristics and Treatment situation of Primary Biliary Cholangitis in Guangxi of China
JINFENG LI, Diefei Hu
- PP0655 Diagnostic Distribution of Patients Positive Alone for Anti-sp100: A Retrospective Study Based on Liver Biopsy

Hongli Liu, Xing Liu, Yifan Hu, Shasha Li, Xixuan Wang, Yijun Bao, Yu Zhang, Li Wang, Zhixiang Du, Miaoyang Chen, Qingfang Xiong, Yandan Zhong, Caiyun Zhang, Duxian Liu, Ping Huang, Wenquan Zeng, Min Ai, Kai Zhang, Yongfeng Yang

- PP0656 Effectiveness of Statins as an Adjuvant Therapy for Primary Biliary Cholangitis: A Meta-Analysis Study
Xuan Guoyun, Ye Ming, Song Zirui, Liu Ning, Shao Lichun, Xuan Yunhao, Xuan Lele
- PP0657 Lipid peroxidation of intrahepatic biliary epithelial cells in Primary Biliary Cholangitis
Ting Jiang, Hui Jin Yang
- PP0658 Alkaline Phosphatase Changes With Seladelpar Across Subgroups of Primary Biliary Cholangitis Patients in the RESPONSE Trial
Kris V Kowdley, Kidist K Yimam, Sonal Kumar, Edward Mena, Alan Bonder, K Gautham Reddy, Christophe Corpechot, Susheela Carroll, Ke Yang, Linda Wu, Daria B Crittenden, Charles A McWherter
- PP0659 Clinical analysis of 168 patients with primary biliary cholangitis
Li Wang
- PP0660 Relationship between pruritus, sleep disorders and anxiety and UDCA dose in patients with primary biliary cholangitis: a cross-sectional study
Yunzhuan Zhao, Jing Liang
- PP0661 Calycosin attenuates primary sclerosing cholangitis in mice by up-regulating TGR5
Enqi Tang, Xiaohan Yu, Qun Zhou, Zheng Zhang, Yue Liang, Wei Liu, Ping Liu, Jiamei Chen
- PP1199 Cholangiocyte-associated B Cells Drive CCR5⁺CD4⁺ TRM Cells Cytotoxicity via IL-15R α -IL-15 Signaling in Primary Biliary Cholangitis
Xiting Pu, Zhuwan Lyu, Yuyang Liu, Xiong Ma, Zhengrui You

Pediatric and Genetics

- PP0663 A rare etiology of hepatic steatosis
Shasha Li, Xing Liu, Yongfeng Yang
- PP0664 Genetic and clinical landscape of progressive familial intrahepatic cholestasis type 1: Novel ATB8B1 variants and genotype-phenotype correlation
Hui Lin
- PP0665 Phenotype Genotype Observations of Novel Biallelic Variants of DoubleCortin Domain - Containing protein 2 (DCDC2) Related Neonatal Sclerosing Cholangitis - "Expanding Horizon"
Deepa Janakiraman, Nirmala Dheivamani, Sindhuja T A, Senthilkumar R, Winston Thomas
- PP0666 Integration of hepatitis B virus DNA into hepatocyte genomes of cirrhotic chronic hepatitis B children
Pan Zhao, Yin Chen, Yi Dong, Shizhang Wei, Weijie Li
- PP0667 Clinical and Genetic Study of Adult Progressive Familial Intra-hepatic Cholestasis 3 in
Zhu Ping, Liu Ying, Tian Jia Jun, Xiang Hui Ling
- PP0668 Perioperative Management, Ethical Concerns, and Outcomes of Pediatric Domino Liver Transplants from Maple Syrup Urine Disease Donors
Vipul Gautam, Vikram Kumar, Vijaykant Pandey, Sumit Goyal, Vaibhav Nasa, Vivek Yadav, Shweta A Singh, Dibya Jyoti Das, Subhash Gupta

- PP0669 Comparative Analysis of Serum Sphingolipid Profile and Blood Lipids in Individuals with Gilbert's Syndrome and Healthy Control
Haitian Yu, Chen Liang, Shan Tang, Dacheng Sheng, Jianxia Dong, Xinyue Chen, Zhongjie Hu, Zhongping Duan, Wei Hou, Sujun Zheng
- PP0670 Ultrasonographic evaluation of gallbladder motor function in the diagnosis and prognosis of intrahepatic cholestasis of pregnancy
Zhen Tian, Fei WANG, Minghui Tai
- PP0671 Characterizing infections in pediatric acute liver failure: Epidemiology, trends, risk factors and prognosis
Tamoghna Biswas, Bikrant Bihari Lal, Vikrant Sood, Pratibha Kale, Vikas Khillan, Rajeev Khanna, Seema Alam
- PP0672 Rotational Thromboelastometry Versus Conventional Haemostatic Tests in Children with Decompensated Cirrhosis undergoing Invasive Procedures: A Randomized Controlled Trial
Snigdha Verma, Seema Alam, Bikrant Bihari Lal, Rajeev Khanna, Vikrant Sood, Meenu Bajpai, Amar Mukund
- PP0674 The prevalence of UGT1A1 gene polymorphisms in patients with suspected Xiangsha Kong, Bo Feng, Zixiang Huang, Xu Cong, Yijun Shi, Xiaofang Liu, Nan Wu
- PP0675 Genetic Diagnosis Distribution in Hepatobiliary Ciliopathy Patients: A Retrospective Study
Hongli Liu, Caiyun Zhang, Xing Liu, Yifan Hu, Shasha Li, Xixuan Wang, Yijun Bao, Yu Zhang, Li Wang, Zhixiang Du, Miaoyang Chen, Qingfang Xiong, Yandan Zhong, Duxian Liu, Ping Huang, Wenquan Zeng, Min Ai, Kai Zhang, Yufeng Zheng, Yuhang Weng, Zhiyuan Xu,
- PP0676 Clinical characteristics, treatment effects and predictive factors of liver cirrhosis in patients with Wilson's disease hepatic type
Yujia Lu, Chuansu Yuan, Yueyang Ma, Keying Ou, QingFang Xiong
- PP0677 ERCP combined with Jianpi Qingdan decoction was used in the treatment of anastomotic stricture complicated with suppurative cholangitis with Biloma in children with PH1 after liver transplantation
Shi Xin
- PP0678 A Case of Cholestasis in an Adult Male: The Mystery of a Long-Unresolved Condition
Ying Liu, Ping Zhu, Ling Hui Xiang
- PP0679 PKHD1-deficient cholangiocytes promote HSC activation through STAT3-initiated transcriptional activation of SPP1
Mengfan Jiao, Chuanlong Zhu
- PP0680 AI-Driven Single-Cell Spatial Multi-Omics Mapping of Hepatic Immune Niches in Wilson's Disease: Exploring Copper-Induced Immunometabolic Dysregulation for Targeted Therapy
Sahnaz Vivinda Putri, Prihantini Prihantini, Rifaldy Fajar, Rini Winarti, Claudya Ananta Suryatomo, Andi Nursanti Ureng
- PP0681 A case of Wilson's disease easily diagnosed as autoimmune hepatitis
Lingling Yang, Hui Zhu, Lifang Chen, Jingyu Zhang, Liangtao Zeng, Zhili Wen
- PP0682 Liver transplantation for the treatment of arginase-1 deficiency
Dan Liu, Bin Wu, Yandong Sun, Dahong Teng, Jinzhen Cai

- PP0683 Cholestasis amelioration with growing ages despite intractable hepatobiliary injury: JAG1 genotyping-based clinical characterization on 43 pediatric patients with Alagille syndrome
Li Guo, Tao Jiang, Jianwu Qiu, Mei Deng, Weixia Lin, Xiaoling Long, Xiangran Cai, Qing Zhou, Shuangjie Li, Yuanzong Song
- PP0684 ASSERT-EXT: Final Data From an Open-Label, Phase 3 Study of Odevixibat in Patients With Alagille Syndrome
Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Philip Bufler, Mara Cananzi, Piotr Czubkowski, Ozlem Durmaz, Ryan Fischer, Giuseppe Indolfi, Wikrom W Karnsakul, Florence Lacaille, Way S Lee, Giuseppe Maggiore, Mathias Ruiz, Etienne Sokal, Ekkehard Sturm, Wendy L Van der Woerd, Andrew Wehrman, Fatine Elaraki, Judy Zhu, Alejandra Ramirez-Santiago, Qingqing Li, Henkjan J Verkade
- PP0685 Research trends and hotspots of adult Alagille syndrome: A bibliometric analysis
Qing Liu, Chao Sun
- PP0686 Efficacy and Safety Of Odevixibat In A Subgroup Of Adult Patients With Progressive Familial Intrahepatic Cholestasis In The PEDFIC 2 Study
Henkjan J Verkade, Janis M Stoll, Qingqing Li, Tao Gu, Fatine Elaraki, Alejandra Ramirez-Santiago
- PP0687 Cuproptosis-associated hub gene identification and immune cell infiltration patterns in Wilson disease
Shan Tang, Wei Hou, Haitian Yu, Sujun Zheng
- PP0688 Open-Label Study of Odevixibat Safety and Tolerability in Infants Aged <12 Months With Alagille Syndrome: Clinical Study Design
Nadia Ovchinsky, Quanhong Ni, Roshawn Watson, Qingqing Li, Alejandra Ramirez-Santiago
- PP0689 Polymorphisms of Plasminogen Activator Inhibitor-1 (rs1799889) Gene as a Risk Factor of Childhood-Onset of Cavernous Transformation of the Portal Vein
Evelina Trashkun, Diana Daduns, Kseniya Gulyaeva, Maxim Privalov, Maria Nadinskaia
- PP0690 Recurrent liver dysfunction resulting in the diagnosis of XMEN disease in a 20-year-old male
Rongqiang Liu, Chun Liu, Xuheng Teng, Ling Gong
- PP0691 A Rare Case of Banti's Syndrome Cured by Autosplenectomy
Clarisse Bayani Porras, IRSON LECIAS DORIA, Alex Alcasid
- PP0693 Triple Rare Thrombosis Including Portal Vein Thrombosis Associated with Vaccine-Induced Immune Thrombotic Thrombocytopenia after Gam-COVID Vac Vaccination
Maxim Privalov, Kseniya Gulyaeva, Alina Volkova, Diana Daduns, Evelina Trashkun, Maria Nadinskaia
- PP0694 A Rare Cause of Abdominal Pain and Recurrent Epistaxis
Mingyu Zhu, Yiqi Du, Li Chen
- PP0695 Coexistence of two rare diseases - Wilson's disease and primary myelofibrosis - in an adult patient
Xiaowei Ai, Zhen Wu, Lijuan Feng, Xinyan Zhao, Xiaojuan Ou, Wei Zhang, Hong You

Liver Fibrogenesis and Cirrhosis

- PP0696 Ubiquitin-specific protease 22 deubiquitinates SMAD2 and promotes hepatic stellate cells activation in hepatic fibrosis
Jing Chen, Cuihua Lu

- PP0697 The Real-World Study of Morphological Liver Re-compensation in HBV-Related Decompensated Cirrhosis with Antiviral Therapy
Qijuan Zang, Yinglii He
- PP0698 Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4) in Chronic Liver Disease: An Analytical Cross-sectional Study
Federico Peralta, Marc Yumena, Sarah Bellido
- PP0699 Partial Splenic Embolization in a Cirrhotic Patient with Refractory Variceal Bleeding and Portal Venous Thrombosis
Rafael Mendoza, David Nagtalon, Ryan Uy, Federico Peralta, Jasmin Gundayao, Suzette Kho-Herman, Ramon Santos-Ocampo
- PP0700 Cannabinoid receptors improve cholestatic liver fibrosis by altering macrophage phenotype and HIPPO/YAP signaling pathway
Jing LI, Suxian ZHAO, Yuemin NAN
- PP0701 mechanism of dact2 gene inhibiting the occurrence and development of liver fibrosis
Shenan Huang, Zhili Wen
- PP0702 Association Between Helicobacter pylori CagA Seropositivity and Liver Fibrosis and Cirrhosis: A Mendelian Randomization Study
Jiao Li, Mingming Zhang, Hong Li
- PP0703 Gut Akkermansia muciniphila mitigates hepatic fibrosis by modulating riboflavin metabolism through the gut-liver axis
Lu Zhang, Lu Cui-HUA
- PP0704 The diagnostic value of serum ORC1 in the progression of HBV-related liver fibrosis
Hongqian Liang, Long Huang, Aoli Ren, Minghua Su, Bobin Hu, Qingmei Li, Tumei Su, Qianbing Yin, Aining Li, Jianning Jiang
- PP0705 Zinc-LNPs reverse liver fibrosis through regulating macrophage polarization
Chengxia Xie, Chen Li
- PP0706 Helicobacter pylori-derived outer membrane vesicles induce liver fibrosis progression through activating NLRP3 inflammasome
JIAO LI, Xiaona Song, Yalin Shen, Hong Tang, Hong Li
- PP0707 The Deubiquitinase MYSM1 Stabilizes GSN to Exacerbate Liver Fibrosis by Inhibiting Hepatocyte Autophagy
Han Ding, Le Wang, Songbo Zhao, Wanhua Ren, Qiang Zhu
- PP0708 METTL3 suppresses liver fibrosis via m6A methylation-dependent miR-30d-5p maturation
Zhijing Wang, Xiya Lu, Jing Li, Meiyi Song, Changqing Yang
- PP0709 FOXM1 and FUBP3 Cooperatively Regulate Hepatic Stellate Cells for the Amelioration of Liver Fibrosis
Chaoxu Fu, Hongxin Piao
- PP0710 The mechanism of puerarin ameliorates liver fibrosis in mice based on the regulation of TGF- β /Smad/SOX4 pathway
Liu Yu Hui, Liu Yi, You Yu

- PP0711 Human Umbilical Cord-Derived Mesenchymal Stem Cells Attenuate Liver Fibrosis by Inhibiting Hepatocyte Ferroptosis Through Mitochondrial Transfer
Zhiyu Xiong, Yingan Jiang
- PP0712 GLS2 Modulates LSEC Capillarization during Hepatic Fibrosis via O-GlcNAc Glycosylation of ESRRB
Xingyuan Yang, Yanfang Lu, Xianxi Li, Rui Wang, Xiaoli Ma, Bingxin Lu, Yanqin Yue, Wang Guo, Jian Hou, Xiaoying Luo
- PP0713 Construction and Effectiveness Analysis of Prediction Model for Cirrhotic Cardiomyopathy
Shuping Ma
- PP0714 Simvastatin exerts anti-hepatic fibrosis effects and mechanisms through modulation of M1 macrophage function
Wanping Yan, Wei YE
- PP0715 IL-15-Activated CD38+HLA-DR+CD8+ T Cells Induce Liver Injury in Cirrhosis via JAK/STAT5 and PI3K/mTOR Pathways
Ke Liu, Wei Ye
- PP0716 Study on the Improvement of Liver Fibrosis by Shuxuening: Multilayer Mechanistic Evidence Based on Network Pharmacology and Molecular Docking
Tingyu Zhang, Xin Sun, Shihao Zheng, Wenying Qi, Xiaoke Li, Xiaobin Zao
- PP0717 Plasma Proteomics Identify Biomarkers and Pathogenesis of Portopulmonary Hypertension
JiaLin Du, Diandian Hao, Hui Wang, YuZe Song, YuLin Ren, Xiaoyu Wen
- PP0718 Akkermansia muciniphila: A Potential Modulator in Mitigating Liver Fibrosis
Lei Ma, Huichun Xing
- PP0719 Aging Accelerates the Progression of Liver Fibrosis via Hyperacetylation of HnRNP U at K28 Site
Xiaoli Ma, Jian Hou, Jinying Liu, Wang Guo, Xingyuan Yang, Yanqin Yue, Bingxin Lu, Rui Wang, Xianxi Li, Yu Guo, Bingyong Zhang, Xiaoying Luo
- PP0720 Interleukin10 induces senescence of hepatic stellate cells to promote the immune function of natural killer cells to attenuate liver fibrosis
Yuehong Huang, Yizhen Chen, Xiaozhong Wang
- PP0721 Targeted Delivery of ITSN1 siRNA to Restore VEGF-Regulated Differentiation of LSEC for the Treatment of Liver Fibrosis
Lanting Zhang, Yunyu Zhao, Yi Liu, Xiao Yuan, Weiming You, Yichen Yang, Zixuan Xing, Ning Gao, Fengping Wu, Wangxiao He, Fanpu Ji
- PP0722 A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and Metabolic Associated Steatohepatitis (MASH)
Yuanping Shi, Yuanyuan Zhang, Linong Ji, Xiantong Zou
- PP0723 Portal hypertension contributes to ascites formation via piezo1-nuclear factor kappa B-aquaporin1 pathway in liver cirrhosis
Ning Wei, Li Du, Long Zhuang Xiao, Lei Zhang, Yang Yang Zhou, Hao Nan Gao, Hui Ming Liu, Bo Cheng Wang, Hua Xiao Hou, Yan Li, Hu Yu Song
- PP0724 HK2-Mediated Metabolic Reprogramming in Liver Fibrosis: A Multi-Omics Approach
Lu Han, Fan Lu, Shao Jie Chen, Qing Xiu Zhang, Hua Yue Wu, Tao Huang, Xue Ke Zhao

- PP0725 Cardiac failure following transjugular intrahepatic portosystemic shunt patients with cirrhosis
Shu Me Du
- PP0726 IL1 β -upregulated SFXN1 promotes HSC activation and liver fibrosis through inducing mitochondrial dysfunction and NLRP3 inflammasome activation
Zhipeng Du, Xu Han, Caijun Rao
- PP0727 MOLECULAR MECHANISMS OF TRANSCRIPTION FACTOR ZEB2 IN HEPATIC STELLATE CELL ACTIVATION AND LIVER FIBROSIS REGULATION
Qianwen Zhao, Fajuan Rui, Jie Li
- PP0728 Empagliflozin reduces CC4-induced liver fibrosis in mice
Fushuang Ha, Junqing Yan, Junjun Cai, Yin Gu, Tao Han
- PP0729 MSC-derived exosomes modified with SAP enhances its therapeutic effect on liver fibrosis via CXCL6/ERK/MEK pathway
Qian Ding, Guangchuan Wang
- PP0730 Hepatic Stellate Cell-derived Microfibrillar-associated Protein 2 Prevents Liver Fibrosis by Regulating Extracellular Matrix and Inflammation
Wen Zhang, Wenyue Wu, Ning Zhang, Hong Li, Yameng Sun, Xiaodong Ge, Hui Han, Shuyan Chen, Anjian Xu, Sai SantoshBabu Komakula, Chao Wang, Nithyananthan Subramaniam, Qi Han, Aiting Yang, Xuzhen Yan, Natalia Nieto, Hong YOU, Wei Chen
- PP0731 Molecular Characterization of PANoptosis-Related Genes Associated with Immune Dysregulation in Liver Cirrhosis
Jiahao Yuan, Yu Wang, Xu Fan, Xinyan Zhao, Jidong Jia, Min Cong
- PP0732 Host Fstl1 Defines the Impact of Stem Cell Therapy on Liver Fibrosis by Potentiating the Early Recruitment of Inflammatory Macrophages
Xiaohong Zheng, Siyuan Tian, Ting Li, Jingbo Wang, Wen Ning, Ying Han
- PP0733 Neutrophil-specific MicroRNA-142 Restricts Liver Fibrosis by Limiting the Formation of Neutrophil Extracellular Traps
Shujun Ge, Shijia Ling, Yawen Hao, Ningning Ma, Yong He
- PP0734 Pantoprazole prevents the occurrence and progression of liver fibrosis through inhibiting the activation of hepatic stellate cells partly via a glycolysis decrease
Jingguo Li, Shun Yao, Hai Jin, Xuemei Liu, Biguang Tuo
- PP0735 Nuclear factor I-B delays liver fibrosis by inhibiting chemokine ligand 5 transcription
Qianqian Chen, Zhiwen Fan, Hongju Yang, Nan Geng, Fajuan Rui, Wenjing Ni, Yue Huan, Chao Wu, Shengxia Yin, Wei An, Qianwen Zhao, Jie Li
- PP0736 Microfibrillar-Associated Protein 4 from Hepatic Stellate Cells: A Novel Target for Liver
Wenyue Wu, Wen Zhang, Hong Li, Yameng Sun, Ning Zhang, Xiaoning Wu, Xuzhen Yan, Aiting Yang, Wei Chen, Hong You
- PP0737 DIDS EFFECTIVELY AMELIORATES LIVER FIBROSIS IN MICE
Shun Yao, Hai Jin, Guo Rong Wen, Jia Xing Zhu, Xue Mei Liu, Bi Guang Tuo
- PP0738 Atractylodes macrocephala polysaccharides inhibit cGAS/STING pathway to ameliorate liver fibrosis
Jiao Guo, Jiali Wu, Xianzhe Hu, Jia Biao, Yangpeng Li

- PP0739 The characteristics and metabonomics of gut microbiota in liver cirrhosis patients and the effect of *S. Boulardii* on it
YU ZHU, Wei Wei
- PP0740 Itaconate ameliorates liver fibrosis by elevating GDF15 production
Ningning Ma, Jinming Zhang, Yawen Hao, Shijia Ling, Yixin Li
- PP0741 The prophylactic antibiotics do not influence the clinical outcomes of patients with Child A cirrhosis and acute variceal bleeding.
Jiajia He
- PP0742 Clinical and Laboratory Characteristics and Features of Blood Oxygenation Indicators in Patients with Liver Cirrhosis and Pulmonary Complications
Anastasiia Tsymbal, Maria Karnaushkina, Olga Arisheva, Lyubov Goreva, Marina Markova, Svetlana Avdoshina, Zhanna Kobalava
- PP0743 Hepatocyte Growth Factor Upregulates Neuropilin-1 Expression via Retinoic Acid Receptor Alpha, Exacerbating Liver Fibrosis
Han Ding, Huanran LV, Songbo Zhao, Le Wang, Wanhua Ren, Qiang Zhu
- PP0744 Metabolic Dysfunction Associated Steatotic Liver Disease in Patients with HCV Associated Liver Cirrhosis
Sona Sargsyan, Violeta Sargsyan, Hasmik Ghazinyan, Vahe Yurii Azatyan, Anahit Gurgeni Isakhanyan, Naira Gyulazyan
- PP0745 New strategies for the staged diagnosis of liver cirrhosis.
Lilit Martin Arshakyan
- PP0746 SOFA Score in Patients with Decompensated Liver Cirrhosis: Role in Assessing Severity and Prognostic Significance
Anastasiia Tsymbal, Maria Karnaushkina, Olga Arisheva, Lyubov Goreva, Marina Markova, Svetlana Avdoshina, Zhanna Kobalava
- PP0747 Reshaping the gut microbiota by FMT ameliorates the alcoholic liver disease via modulating α -linolenic acid metabolism and short-chain fatty acids
Rong Su, Shaoqi Yang, Hao Wang
- PP0748 Ang1/Ang2 Dysregulation is associated with the development of liver fibrosis in mice models
Minghua Lin
- PP0749 Selective Targeting Hepatic Stellate Cell-derived THBS2 Mitigates Liver Fibrosis by Inhibiting SPP1
Hong Li, Wenyue Wu, Ning Zhang, Wen Zhang, Yameng Sun, Shuyan Chen, Qi Han, Xuzhen Yan, Aiting Yang, Hong You, Wei Chen
- PP0750 The Clinical and Prognostic Significance of Early Termination of T6MH in Patients with Liver Cirrhosis
Anastasiia Tsymbal, Maria Karnaushkina, Olga Arisheva, Lyubov Goreva, Marina Markova, Svetlana Avdoshina, Zhanna Kobalava
- PP0751 Recurrent Upper Gastrointestinal Bleeding Secondary to Splenic Vein Sclerosis: A Case Report on Non-Cirrhotic Portal Hypertension
Chelsea Tauro Tantuco, Joseph Cruz Bocobo
- PP0752 Construction of diagnostic models for each stage of patients with cirrhosis combined with portal hypertension respectively based on HVPG

Wei Gou

- PP0753 Case Report – Esophageal Varices in Pregnancy
Sam Nogoy Fandood
- PP0754 Focus on the practical application value of HVPg in patients with liver cirrhosis
Wei Gou
- PP0755 To investigate the clinical diagnostic value of serum extra-spindle pole-like protein 1 (ESPL1) detection for HBV-related liver fibrosis process
Long Huang, Hongqian Liang, Aoli Ren, Minghua Su, Bobin Hu, Qingmei Li, Tumei Su, Qianbing Yin, Yanfei Feng, Jianning Jiang
- PP0756 A Rare Complication of Decompensated Cirrhosis: Forward or Backward?
Pengyue Zhang, Zhenhua Zhang, Yanyan Wei
- PP0757 The prevalence and mortality of stage 1, 2 and 3 of acute kidney injury in cirrhosis: a systematic review and meta-analysis.
Meng Yue Wan
- PP0758 Analysis of Clinical Characteristics and Prognosis in Young Hepatitis B Cirrhosis: a Propensity Score Matching Study
Pengyue Zhang, Wenjuan Zhang, Xinlei Chen, Xiaodan Hong, Zhenhua Zhang
- PP0759 The mortality risk of acute kidney injury stage 1A and 1B in cirrhosis: a systematic review and meta-analysis.
Meng Yue Wan
- PP0760 Development and validation of a predictive nomogram for sarcopenia in patients with decompensated cirrhosis
Yangyang Zhou, Yuhu Song
- PP0761 The impact of changes in skeletal muscle mass on the prediction of long-term survival in patients with liver cirrhosis
Huiping Liang, Chang Zhang, Yuchao Wu, Yingren Zhao, Yuan Yang, Xiaoping Tang
- PP0762 Non-invasive assessment of liver fibrosis regression in patients with chronic hepatitis B
Qiang Li, Professor Liang Chen research group
- PP0763 Case report: POEMS syndrome with portal hypertension
Xiaotong Xu, Qinghua Meng, Jianjun Li
- PP0764 Association between glycemic variability and risk of acute kidney injury in non-diabetic cirrhotic patients: analysis of the MIMIC-IV database
Yaxin Li, Huiguo DING
- PP0765 Meta-analysis of the safety of non-selective β -blockers in the treatment of cirrhotic patients with ascites
Jiansong Wan
- PP0766 FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients Without Antiviral Therapy
Qiang Li, Professor Liang Chen research group
- PP0767 Study of the sleep quality and psychological state of patients with hepatitis B liver cirrhosis
Aili Fan, Jiawen Feng, Qing Ye

- PP0768 Mitochondrial membrane potential of CD8+ T cells predicting infection and acute-on-chronic liver failure within 90 days in cirrhotic patients
Xixuan Wang, Shuling Chen, Jing Fan, Yuxiang Gong, Hongli Liu, Lili Wang, Xiaoning Feng, Hui Zhou, Wenquan Zeng, Changhua Yi, Caiyun Zhang, Qingfang Xiong, Hao Ren,
- PP0769 Gut microbiome composition in patients with liver cirrhosis with and without hepatic encephalopathy: A systematic review and meta-analysis
Xiaotong Xu, Qinghua Meng, Jianjun Li
- PP0770 Analysis of pathological diagnosis and clinical diagnosis in 1752 cases undergoing routine liver biopsy
Airong Hu, Suwen Jiang, Jialan Jiang, Menghan Jin, Ken Lin, Ying Fan, Haojin Zhang, Shiyang Fang, Shiqi Yang
- PP0771 New subtype of recompensation (intermittent recompensation) in patients with HBV-related decompensated cirrhosis
Shuai Xia, Zhiying He, Jialing Zhou, Zhongjie Hu, Yan Huang, Chungqing Zhang, Yanqin Hao, Wei Rao, Jing Wang, Yongfeng YANG, Xinyu Zhao, Xiaojuan Ou, Jidong JIA, Xiaoning Wu, Bingqiong Wang, Hong YOU
- PP0772 The correlation between the ratio of ALT to qHBsAg and the recompensation of HBV-related patients with cirrhosis: A retrospective cohort study based on the Baveno VII criteria
Ya Ping Xu, Yan Wang
- PP0773 Machine Learning Model for Predicting Rebleeding Risk after Endoscopic Variceal Ligation in Esophageal Variceal bleeding: A Chinese multicenter cohort study
Junyi Zhan, Yongping Mu
- PP0774 Assessments of sarcopenic obesity and its predictors based on CT imaging in patients with cirrhosis: a large-scale retrospective study
Yuteng Yang, Changjie Tie, Tingyang Wei, Zixing Wang, Rui Huang
- PP0775 Study on the active components of Fuzheng Huayu formal and their anti-fibrotic mechanisms
Jiamei Chen, Wei Liu, Ping Liu
- PP0776 Metabolomics in 28-day prognosis of acute-on-chronic liver failure
Ying Xiao, Yan Liu, Caiyan Zhao, Yadng Wang
- PP0777 Dose-response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B
Chi Zhang, Yiqi Liu, Hong Zhao, Guiqiang Wang
- PP0778 Prevention of hepatic encephalopathy following transjugular intrahepatic portosystemic: lactulose plus rifaximin vs. lactulose monoprophyllaxis
Shu Du Mei
- PP0779 Chopsticks Challenge: Innovating CHE Diagnosis with the 1-Minute Clamping Soybean Test
Yilong Liu, Xiaolin Li, Weifen Xie, Pingfang Hu
- PP0780 Analysis of Risk Factors for Portal Thrombosis after Endoscopic Treatment in Cirrhotic Patients with Severe Gastroesophageal Varices
Jiamei Zhou, Tao HAN, Huiling Xiang, Feng Zhang, Huizhe Wang, Baiguo Xu
- PP0781 LSM decreased in on-treatment CHB patients led to remarkably high false negative rates of advanced liver fibrosis or cirrhosis evaluated by pre-treatment thresholds

Xiaoning Wu, Jialing Zhou, Yameng Sun, Bingqiong Wang, Shuyan Chen, Chenghai Liu, Hongxin Piao, Huiguo DING, Shuai Xia, Tongtong Meng, Luqi Tang, Xiaojuan Ou, Hong You, Jidong Jia

- PP0782 Platelets Count and Spleen Area for ruling out High Risk Varices in patients with Porto-Sinusoidal Vascular Disease
Li Li Zhao, Ping Han, Yuanyuan Zhao, Jie Liu, Jia Li
- PP0783 Meta-analysis: Global Prevalence of Bacterial Infections in Patients with Liver Cirrhosis
Yuxin Tian, Baiyun Wu, Qi An, Yinping Wu, Jing Zuo, Yuchen Fan
- PP0784 Changing spectrum and disparities of etiology of liver cirrhosis in male and female patients in Tianjin, China
Li Li Zhao, Ping Han, Yuanyuan Zhao, Jie Liu, Jia Li
- PP0785 A study of clinical characteristics in 43 patients with porto-sinusoidal vascular disease
Chengjian Wu, Yi Shen, Xuefeng Luo
- PP0786 Which Non-Invasive Test Is More Useful in the Assessment of Liver Fibrosis in Patients Receiving Methotrexate?
Taylan METİN, Seydi ERÖZCAN, Orhan ZENGİN, Sezgin BARUTÇU, Ayhan BALKAN, Mehmet Ali ŞAHAN, Mehmet KARAÇALI, Murat Taner GÜLŞEN
- PP0787 Case Report of Acquired Hepatocerebral Degeneration: An Underrecognized Complication of Advanced Liver Disease
Hasmik Ghazinyan, Aram Mirijanyan, Lusine Navoyan, Ashkhen Keryan, Tatevik Shahinyan
- PP0788 Porto-Sinusoidal Vascular Disease: A group of portal hypertension Different from Liver
Jie Liu, Lili Zhao, Yuying Jin, Yuhang Yu, Jia Li
- PP0789 PLT was an independent blood biomarker for diagnosis of HBV-related cirrhosis before and during antiviral therapy
Yizhou Liu, Jialing Zhou, Yameng Sun, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Qiushuang Guan, Tongtong Wang, Shuai Xia, Luqi Tang, Qiannan Jiang, Xiaojuan Ou, Hong You, Xiaoning Wu
- PP0790 Diagnostic value of Liver biopsy in Evaluation of Liver Disease- 50 Case Study
Abul Hayat Manik, Faroque Ahmed
- PP0791 One case report of the upper gastrointestinal bleeding as the first manifestation of polycythemia vera
Xiwei Yuan, Lei Liu, Qianqian Li, Qing Ye
- PP0792 Retrospective Exploration of the Impact of Traditional Chinese Medicine Antifibrotic Treatment on the Prognosis of Hepatitis B Cirrhosis Based on the Real World
YANG LIU, XIUHUI LI
- PP0793 Shugan Xiaozhi formula improved inflammatory injury in MCD-induced NASH mice model by regulating HMGB1/NF-κB/NLRP3 mediated pyroptosis
Ruili Du, Wang Shuai, Kaili Ge, Guangdong Tong, Lidian Luo
- PP0794 Metabolic differences among patients with cirrhosis using Q ExactiveTM hybrid quadrupole Orbitrap mass spectrometry technology
Ying Xiao, Jie Lu, Suyan Xu, Zhinian Wu, Wei Wang, Ru Ji, Tingyu Guo, Zeqiang Qi, Hua Tong, Yadong Wang, Caiyan Zhao

- PP0795 The effective ingredients identification and pharmacodynamics exploration of the Qu-Tan-Huo-Xue Formula in the treatment of Non-Alcoholic Fatty Liver Disease
Qinghua Peng, Xiaoning Zhu , Jing Wang
- PP0796 The mechanism of Fuzheng Huayu capsule improves metabolic dysfunction-associated steatohepatitis induced liver fibrosis by regulating ATF3 to inhibit scar-associated
Chen Zou, Xiao Xu, Qian Huang, Ping Liu, Yiyang Hu, Xin Xin, Qing Feng
- PP0797 The Jieduan-Niwan Formula in treating acute-on-chronic liver failure based on PANoptosis-mediated regulation of hepatocytic death
Ye Qianling, Zheng Yihao, Wang Hanjing, Du Yuqiong, Ma Chongyang, Zhang Qiuyun
- PP0798 Shenge Formula reduces hepatic lipid deposition in patients with Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Rongjie Zhang, Jia Lv, Longshan Ji, Yanxi Zheng, Xin Zhang, Yating Gao, Xuehua Sun, Man Li, Yueqiu Gao
- PP0799 Electroacupuncture Attenuates Hepatic Steatosis by Activating Hepatic Vagal Nerve in High-Fat Diet-Induced Metabolic Associated Fatty Liver Disease Mice
Yuge Zhou, Liye Lu, Xuehua Sun, Xiaoni Kong
- PP0800 Research on Traditional Chinese Medicine External Treatment for Hiccup after Interventional Surgery for Liver Cancer
Wei Xiao Guo
- PP0801 Discussion on the pathogenesis and treatment of metabolism-related fatty liver disease based on the theory of “Xuqi (虚气) - Kenang (窠囊)” and the evolution of pathogenesis and treatment of metabolic fatty liver disease
Guangqin ZHU, Jinrong ZHANG, Jiping ZHANG, Yike SUN, Sunlin HU, Shuran MA
- PP0802 Research status of traditional Chinese medicine in preventing and treating NAFLD by regulating gut microbiota
Yifan Zhang, Qingjing Ru
- PP0803 Yin-chen Wu-ling powder inhibits MAPKs/CXCL1/CXCR2-induced neutrophil infiltration to alleviate LPS/D-GalN-induced acute liver failure
Liyue Lu, Jiacheng Lin, Xiaoni Kong
- PP0804 Modulation Hepatic Farnesoid X Receptor and Gut Microbiota of Puerarin in High-Fat Diet-Induced Obese Mice
Tzung Yan Lee
- PP0805 Schisantherin A attenuates biliary fibrosis by targeting PPAR α in mice
Zheng Zhang, Enqi Tang, Yue Liang, Xiaohan Yu, Wei Liu, Gaofeng Chen, Yongping Mu, Ping Liu, Jiamei Chen
- PP0806 Catalpol ameliorates liver fibrosis through suppressing AKT/NF- κ B signal pathway in rodent models
Liang Yue, Cheng Tianyu, Pu Jiaying, Zhang Zheng, Ma Wanyu, Liu Wei, Mu Yongping, Zhang Hua, Jiamei Chen, Liu Ping
- PP0807 Clinical Observation on Efficacy and Safety of Fushui Paste in the Treatment of Hepatitis B-related Liver Cirrhosis with Moderate and Severe Ascites: A Propensity Score Analysis
Xiaoya Yang, Yangyang Xue, Kaili Ge, Chunshan Wei

- PP0808 The Mechanism of Icaritin in Liver Fibrosis: Insights from Metabolomics and Gut Microbiota
Yugin Li, Wentao Kuai, Yuqiang Mi, Liang Xu
- PP0809 Pien Tze Huang plus entecavir improves hepatic fibrosis in Chinese patients with chronic hepatitis B
Xin Zhang, Liwen Zhang, Longshan Ji, Suthat Liangpunsakul, Jinghao Zhang, Fei Hong, Hua Lyu, Seonghwan Hwang, Chunyan Gou, Yuyong Jiang, Xiaorong Chen, Qin Li, Guangdong Tong, Anna Zhang, Jing Wang, Xiaodong Li, Mingxin Zhang, Xuehua Sun, Man
- PP0810 Total Sanghuangporus vaninii extract attenuates liver fibrosis by inhibiting hepatocyte ferroptosis via Nrf2-GPX4 signaling pathway
Siqi Gao, Qiuying Xu, Lumeng Yao, Xingxing Wang, Jianjun Wu, Luping Qin
- PP0811 Yiqi Huoxue Lishui Decoction regulates Nrf2/GPX4 signaling pathway to inhibit ferroptosis and improve liver fibrosis in rats
Jingjing Liu, Qi Dai
- PP0812 Safety of chronic consumption of Ayurvedic Formulations in Chronic Liver Disease (CLD): A Retrospective Study
Yogesh Bendale, Ketaki Jagtap, Avinash Kadam, Anjali Pote
- PP0813 Unveiling Transient Portal Hypertension: A Rare Complication of EBV Infection
Lianhui Zhao, Ke Xu, Gang Wang, Huajun Zhao
- PP0814 Registry Clinical Trials on Treatment of Cirrhotic Portal Hypertension Evaluated by Hepatic Venous Pressure Gradient: A Systematic Review
Lianhui Zhao, Huajun Zhao
- PP0815 Avatrombopag for the treatment of immune checkpoint inhibitor/targeted therapy-related thrombocytopenia in patients with hepatocellular carcinoma: A prospective, multicenter, single-arm trial
Wang Yong Shuai, Luo Da Yong, Wang Ji Zhou
- PP0816 Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors
Qianqian Zheng, NAOKI TANAKA
- PP0817 Timing of Endoscopic Intervention and Its Impact on the Prognosis of Patients with Liver Cirrhosis and Esophageal-Gastric Variceal Bleeding
Shenan Huang, Zhili Wen, Chaomin Ruan
- PP0818 Exploratory Evaluation of Hepatic Tissue Changes in Hepatitis B Virus-Related Compensated Cirrhosis Treated with Human Umbilical Cord-Derived Mesenchymal Stem
Yingan Jiang, Zhi Zeng, Jingmin Zhao, Pingji Liu
- PP0819 High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide, but not coronary artery disease, may be associated with further decompensation and death in liver cirrhosis
Liyan Dong, Yao Xiao, Yibing Li, Yong He, Yu Liu, Xingshun Qi, Huishan Wang
- PP0820 Evaluation of Percutaneous Microwave Ablation of the Spleen Combined with Splenic Artery Occlusion for Treating Secondary Hypersplenism: A Single-Arm Study
Xing Li, Huikai Li, Yong Xu, Tongguo Si, Rui Xia, Mao Yang, Rentao Li, Yang Liu
- PP0821 Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and esophagogastric variceal bleeding.
Botao Wu

- PP0822 The efficacy and safety of painless gastroscopy assisted esophageal and gastric variceal ligation for secondary prevention of variceal bleeding in patients with liver cirrhosis
Rui Zhang
- PP0823 Unraveling the Molecular Mechanism of YAP Gene Knockout in Liver Fibrosis: A Multi-Omics Approach Integrating Transcriptomics and proteomics
Siyuan Wang, Shihui Liu, Chuanmiao Liu, Wen Zhao
- PP0824 Resting-State fMRI Global Small-World Network as a Mediator Between Glymphatic System and Cognitive Function in Patients with Minimal Hepatic Encephalopathy
Qian Zhang, Zhenliang Xiong, Ming Zhong, Hong Peng
- PP0825 Reducing the occurrence of decompensated events and improving liver function in post-TIPS cirrhotic patients by selective COX-2 inhibitors: A retrospective study
Zhu Yang, Jinhang Gao, Chengwei Tang
- PP0826 To explore the risk factors for transjugular intrahepatic portosystemic shunt in the treatment of esophageal and gastric variceal bleeding and recurrent decompensation events
LIU Yu Hui, Jiang Xiang, You Yu
- PP0827 Application of speckle tracking echocardiography in cirrhotic cardiomyopathy patients: a single center observational study.
Jiakun Liu, Cuncao Wu, Xiaoxiao Hu, Rui Huang
- PP0828 The Actual Performance of Large Language Models in Providing Liver Cirrhosis-Related Information: A Comparative Study
Yanqiu Li, Xianbo Wang
- PP0829 Application and clinical observation of low molecular weight heparin in the treatment of liver failure patients with artificial liver
Zishan Deng
- PP0830 Investigation of KC10, a Novel DNMT1 Degradar, in Anti-Hepatic Fibrosis Therapy: Efficacy and Mechanisms.
Xingping Su, Taixiong Xue, Qun Wei, Tinghong Ye
- PP0831 Overlap Between Body Composition Abnormalities and Associated Sex-specific Prognostication in Patients with Decompensated Cirrhosis: A Retrospective Cohort Study
Jie Yang, Chao Sun
- PP0832 Liver-to-Spleen Volume Ratio Predicts Further Decompensation after TIPS in Patients With Cirrhosis
Xinyu Chen, Yicheng Lin, Jiajun Tian, Fenghui Li, Kefeng Jia, Rong Lv, Chao Yang, Jiayin Wang, Huiling Xiang
- PP0833 Skeletal muscle abnormalities as independent risk factors for sleep disturbances in patients with liver cirrhosis: a cross-sectional study
Shuangzhe Yao, Binbin Peng, Wenqin Liu, Chao Sun
- PP0834 SGLT2 inhibitors might be a novel therapeutic option for cirrhotic ascites
Hanlu You, Yuan Gao, Yunyi Gao, Liwei Liu, Menghua Wu, Luyao Guo, Feili Wei, Zhongjie Hu, EASTERN study group
- PP0835 The decrease of portal vein pressure affects the postoperative efficacy of TIPS in patients with ascites

- Yicheng Lin, Xinyu Chen, Huiling Xiang, Jiajun Tian, Fenghui Li, Kefeng Jia, Rong Lv, Chao Yang, Jiayin Wang
- PP0836 The influence of portal vein thrombosis recanalization on prognosis
Wang Chunyu, Wang Yu
- PP0837 Investigation of HO-1 Regulation of Liver Fibrosis Related to Nonalcoholic Fatty Liver Disease Through the SIRT1/TGF- β /Smad3 Pathway
Mengjiao Sun, Congyue Zhang, Yuemin Nan
- PP0838 Development of a Predictive Model for Further Decompensation after Transjugular Intrahepatic Portosystemic Shunt in Patients with Decompensated Cirrhosis
Xinyu Chen, Yicheng Lin, Jiajun Tian, Fenghui Li, Kefeng Jia, Rong Lv, Chao Yang, Jiayin Wang, Huiling Xiang
- PP0839 Study Of Peripheral Muscle Stiffness In Patients With Cirrhosis Using Shear Wave Elastography
Angel Sara Sajeew, Shalini Thapar Laroia, Shiv Kumar SARIN, Ananthu Narayan
- PP0840 Managing Gastric Fundus Variceal Bleeding: Comparative Outcomes of TIPS and EUS-Guided Therapy
Chenyue Zhang, You Deng, Weina Lu, Xinyan Zhao, Yu Wang, Fuliang He
- PP0841 Cirrhotic patients with acute variceal bleeding and an indication for pre-emptive TIPS: real-life results
Jiajia He
- PP0842 Effect of Glycyrrhizin on Fibrosis Regression in Chronic Hepatitis B Patients Treated with Entecavir
Xun Qi, Yi Zhang, Qiankun Hu, Yuxian Huang, Jiming Zhang, Liang Chen
- PP0843 Clinical Value of Trace Metal Elements in Assessing Liver Compensation Ability in Cirrhosis Patients
Cui Yufeng, Qian Baoxin, Cui Hao, Ye Qing, Wang Ning, Sun Mingyu, Yuan Xiwei
- PP0844 Clinical Application of Super-Resolution Contrast-Enhanced Ultrasound in Evaluating Liver Microvessels in Patients with Cirrhosis
Jieyang Jin, Jie Ren
- PP0845 Clinical value of assessing liver compensatory capacity in patients with liver cirrhosis using trace element selenium and related indicators
LiXia Sun, Qing Ye
- PP0846 Analysis of clinical characteristics of portal vein thrombosis in cirrhotic patients with esophagogastric varices after endoscopic treatment
Wen Guo, Yaxin Chen, Kun Yin, Hao Liang, Yanan Zhang, Ning Lu, Manli Cui, Mingxin
- PP0847 Correlation Analysis of Indocyanine Green with Hepatic Function CTP and MELD in Patients with Cirrhosis
Yuyu Li, Feng Guo, Lei Yang, Zhaoxia Liu
- PP0848 Metabolic Reprogramming in Hepatic Stellate Cells: Unveiling a Novel Therapeutic Target for Liver Fibrosis
Bingbing He, Haibo Zhang, Jie Wu, Xi Guan, Ruijuan Yan, Zhanjie Chang, Junzhe Jiao, Jingtao Li

PP0849 An Investigation into The Clinical Traits and Contributing Variables of MAFLD and Its Constituents in Individuals With Colorectal Polyps
Suyi Wang, Liyue Hu, Quanwei Xu, Ni Wei

PP0850 Clinical characteristics of 128 cirrhotic patients with esophagogastric varices and portal hypertensive gastropathy
Yaxin Chen, Wen Guo, YaNan Zhang, Kun Yin, Ning Lu, ManLi Cui, MingXin Zhang

Management of Advanced Chronic Liver Disease (ACLD)

PP0851 Recurrent Hepatic Encephalopathy secondary to Portosystemic Shunting in an Adult Filipino with Liver Cirrhosis from Wilson Disease
Jeremie Canlas Manarang, Edhel Santiago Tripon

PP0852 Impact of a High-Protein Diet on Patients with Chronic Liver Disease and Worsening Ascites
Usman Ghani, SyedLal Shah

PP0853 Analysis of the Short-term Efficacy and Safety of Tenofovir Amibufenamide in the Treatment of Patients with HBV-related Acute-on-chronic Liver Failure
Jing Cui, ChengJie Cui, ShuXian Zang, Na Fu, YueMin Nan

PP0854 Actein Inhibits NETosis in Acute Liver Failure by Targeting the Mac-1/RhoA-GTP Axis
Yi Zhang, Xianbo Wang

PP0855 TERLIPRESSIN GIVEN BY CONTINUOUS INTRAVENOUS INFUSION VERSUS INTRAVENOUS BOLUSES IN THE TREATMENT OF HEPATORENAL SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
Bea Regine Panganiban, Jayson Villavicencio, Cary Amiel Villanueva, Janice Jill Lao

PP0857 Immune Dysfunction and Metabolic Imbalance Shape the Transcriptomic Landscape of Acute Decompensation and Acute-on-Chronic Liver Failure in Decompensated Cirrhosis
Jiyang Chen, Sisi Yang, Zelu Meng, Guodong Yu, Xiaoli Zhang, Chanyuan Ye, Yinfeng Lu, Xianbin Xu, Xia Yu, Yu Shi, Yida Yang

PP0859 Quercetin inhibits mitophagy-mediated apoptosis and inflammatory response by targeting the PPAR γ /PGC-1 α /NF- κ B axis to improve acute liver failure
Huan Wu, Long Wu, Li Luo, Ting Ye Wu, Xiu Qing Zhang, Fang Bao Zhang

PP0860 Comparison clinical character of Acute Liver Failure from Acute Fatty Liver of Pregnancy and Hepatitis B in Pregnancy: case series Study
Zhiyu Zeng, Shasha Sha Li, Dongliang Li

PP0861 Bacterial infection in acute-on-chronic liver failure: time to antibiotics treatment and mortality
Hongcui Cao, Xinyi Chen, Jiong Yu, Qiaoling Pan, Lanjuan LI

PP0862 Alpha-fetoprotein and APRI as predictive markers for patients with Type C hepatitis B-related acute-on-chronic liver failure: a retrospective study
Yan Chun Li

PP0863 A novel predictive model for viral hepatitis-associated acute on chronic liver failure
Hongcui Cao, Xinyi Chen, Jiong Yu, Haijun Huang, Jian Wu, Lanjuan LI

PP0864 Diagnostic accuracy of the new and old leukocyte esterase reagent strips in rapid diagnosis of spontaneous bacterial peritonitis among patients with acute-on-chronic liver failure
Chen Li, Haibin Su, Jinhua Hu

- PP0865 Increased serum Prdx1 induces hepatocytes death and positively correlates with progress of hepatitis B virus-related acute-on-chronic liver failure
Ying He, Jing Liu, Qiyao Liu, Yongfang Jiang
- PP0866 Downregulation of connexin 32-based gap junctions underlies MSC-sEVs-attenuated ferroptosis in acute-on-chronic liver failure
Zhihui Li, Jing Zhang, Bingliang Lin
- PP0867 Analysis of risk factors for secondary infection in patients with liver failure treated with artificial liver
Xiaoting Wang
- PP0868 Minimal Hepatic Encephalopathy Predicts Mortality in Patients with Acute-on-chronic Liver Failure Defined by the Asian-Pacific Association for the Study of the Liver
Qiuyu Cheng, Yunhui Liu, Zhongyuan Yang, Meng Zhang, Tingting Liu, Yuxin Niu, Wei Liu, Lanyue Huang, Yuzhao Feng, Xiaoyun Zhang, Xiaoping Luo, Tao Chen, Qin Ning
- PP0869 Prognostic Value of Plasma Level of Superoxide Dismutase in HBV-related Acute-on-chronic Liver Failure
Zhen Tian, Fei WANG
- PP0870 Phase characteristics and Risk Factors of acute-on-chronic liver failure with invasive pulmonary aspergillosis
Yushan Liu, Qiannan Wang, Pan Huang, Chengbin Zhu, Qijuan Zang, Qiao Zhang, Yamin Wang, Juan Li, Taotao Yan, Jinfeng Liu, Yuan Yang, Yingli He
- PP0871 A Novel Prognostic Model for Hepatitis B Virus-Related Acute-On-Chronic Liver Failure: Harnessing Nutrient Anabolism Markers
Jiao Yuan, Wen Ting Peng, Chuan Jiang, Lei Fu, Shi Fang Peng
- PP0872 Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression
Xi Liang, Jinjin Luo, Qian Zhou, Jiaojiao Xin, Jiaqi Li, Jing Jiang, Meiqian Hu, Peng Li, Pengcheng Chen, Heng Yao, Huafen Zhang, Xingping Zhou, Jiaxian Chen, Wen Hu, Bingqi Li, Shiwen Ma, Xiao Wu, Xiao Li, Jing Zhang, Xin Chen, Dongyan Shi, Jun Li, Chinese Group on the Study of Severe Hepatitis B (COSSH)
- PP0873 Three ACLF Criteria Supporting Unified Management of Previous and First-Time Decompensation
Meiqian Hu, Jinjin Luo, Yu Wu, Jing Zhang, Jiaojiao Xin, Jing Jiang, Dongyan Shi, Yu Chen, Jun Li
- PP0874 Efficacy and safety of first-line nucleos(t)ide analogues for hepatitis B virus-related liver failure: A systematic review and network meta-analysis
Weixiu Li, Qinxuan Wang, Yijue Wang, Tengyue Hu, Lingyao Du, Libo Yan, Hong Tang
- PP0875 Combined Serum Interleukin (IL)-6 and IL-8 as Diagnostic Biomarkers for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure Patients
Lanyue Huang, Wei Liu, Yunhui Liu, Yuxin Niu, Yuzhao Feng, Qiuyu Cheng, Meng Zhang, Tingting Liu, Mi Song, Qin Ning, Tao Chen
- PP0876 Inflammation and Progressive Liver Failure Promote the Occurrence of Invasive Fungal Infections in Acute-on-Chronic Liver Failure Patients
Feixiang Xiong, Yuyong Jiang, Yixin Hou
- PP0877 LPS promotes inflammation via proteasomal degradation of Atg13 in HSCs during ACLF

Zhen Tian, Fei WANG

- PP0878 Correlation study of GRO α , IP-10 and coagulation dysfunction in chronic and acute liver
Xueshi Zhou, Xinyue Chen, Hejuan Du, Tingting Su, Xiaoye Guo, Yuanwang Qiu, Weifeng Feng Zhao
- PP0879 Results of Artificial Liver support System and liver transplantation in patients with Acute on chronic liver failure
KHIEN VAN VU
- PP0880 Antibiotics exposure in acute-on-chronic liver failure disrupted gut microbiota, induced hepatitis inflammation and reduced survival rate
Yang Shujuan, He Yingli
- PP0881 Iodine-131 combined with plasma exchange treatment in Graves' hyperthyroidism patients with severe liver injury
Xin Fang Zhu, Bing Yao Wang, Fu Xia Ta, Jian Ming Zheng
- PP0882 Association between indirect bilirubin percentage-to-albumin ratio and short-term prognosis of acute-on-chronic liver failure treated with artificial liver support system
Weixi Tang, Yuanji Ma, Lingyao Du, Lang Bai, Hong Tang
- PP0883 Nutritional Management in Post-Liver Transplant Recipients with Acute Liver Failure: A Case Series
Dao Thi Hao, Nguyen Thu Ha, Nguyen Thi Huong, Chu Phuong Nam
- PP0884 The impact of inflammatory markers on prognosis in advanced chronic liver disease: insights from a prospective cohort study
Jing Liu, Sumeng Li, Yanan Liu, Fengqin Zhou, Xin Zheng
- PP0885 Re-ACLF or ACLF-Again: a Distinct Entity ?- A Prospective study from tertiary care centre
RAMPARTAP SWAMI, SUNIL K DADHICH, ARIHANT SETH
- PP0886 OBSERVATIONAL STUDY OF CLINICAL AND MICROBIOLOGICAL PROFILE OF INFECTION IN ACUTE-ON-CHRONIC LIVER FAILURE PATIENTS AND OUTCOME
YADUVIR SINGH MEENA, SUNIL K DADHICH, RAMPARTAP SWAMI
- PP0887 Risk Factors and Prognosis Associated with Adverse Outcomes in Discharged Cirrhotic Patients Admitted for Acute Decompensation
Xin Zhang, Liang Qiao, Hai Li
- PP0888 Revealing Subtypes of Acute-on-Chronic Liver Failure Using Unsupervised Non-negative Matrix Factorization Clustering
Mengyi Zhang, Yee Hui Yeo, Jian Zu, Yingli He, Tao Chen, Yi Liu, Hirsh Trivedi, Yuan Wang, Xiaodan Sun, Zhujun Cao, Chun Ying Wu, Rajiv Jalan, Fanpu Ji
- PP0889 The plasma glucose levels associated with the risk of mortality in patients with acute-on-chronic liver failure
Meichuan Li, Han Hu, Shide Lin
- PP0890 To Explore the characteristics of nutritional metabolism with liver failure based on Metabolic
Yamin Wang, Yushan Liu, Qiao Zhang, Yingli He
- PP0891 Increased serum Prdx1 induces hepatocytes death and positively correlates with progress of hepatitis B virus-related acute-on-chronic liver failure
Ying He, Jing Liu, Qiyao Liu, Yongfang Jiang

- PP0892 Establishment and Verification of Diagnostic Marker System for Severity of Acute-on-chronic Failure Based on Methylation Chip
Jieru Yang, Hangyu Ma, Jing Zuo, Yiping Wu, Yuchen Fan
- PP0893 Effect of Combination Antiviral Therapy on Fatality Rate of Adults with Hepatitis B-Related Acute-on-Chronic Liver Failure: a Systematic Review
Muhammad Khifzhon Azwar, Amalia Nur Pratiwi, Leonard Nainggolan
- PP0894 Single-cell RNA sequencing reveals immune features in HBV and Wilson's disease related acute-on-chronic liver failure
Jing Liu, Sumeng Li, Shuhua Zhang, Hang Jia, Ruxia Zhou, Wenqing Zhou, Li Peng, Xiu Nie, Chunli Xu, Shenglei Shu, Jinyang Gu, Jun Wu, Xin Zheng
- PP0895 Objective To explore the investigation and influencing factors of medication compliance in elderly patients with cirrhosis at home
Wuxiaoyan Yucece Dengzhen
- PP0896 Advanced Care Planning for Liver Cirrhosis Patients in Singapore: Barriers to ACP and Influence of HCC Diagnosis on ACP Preferences
Danelle Lai, Marianne Anastasia De Roza
- PP0897 Clinical Research on Nutritional Intervention in Hepatic Encephalopathy: Progress and Perspectives
Zhendong Fu, Zhili Wen
- PP0899 Assessment of Risk Factors for Transient Severe Motion Artifacts on Gd-EOB-DTPA Enhanced MRI in high-risk patients
Lan Zhang
- PP0900 Performance of liver and spleen stiffness measurement for the diagnosis of varices in patients with cirrhosis
Jiratchaya Ngampimonsri, Panarat Thaimai, Nipaporn Siripon , Sirinporn Suksawatamnuay, Sombat Na Treeprasertsuk, Sombat Treeprasertsuk, Piyawat Komolmit, Kessarin
- PP0901 Clinical study of endoscopic variceal ligation and injection of tissue adhesive combined with sclerosing agent in the treatment of esophageal and gastric varices in liver cirrhosis
AN HU LE
- PP0902 Role of Fractional Excretion of Urea in Determining the Type of Acute Kidney Injury in Decompensated Cirrhosis Patients
Shabir Ahmad Lone, Ajay Kumar, Bhawna Mahajan, Deep Patel, Sanjeev Sachdeva, Ashok Dalal
- PP0903 Hepatic Encephalopathy in the Midst of Cirrhosis Complications: Insights from an Open Cohort Study
Zixing Wang, Suzhen Jiang, Feng Liu, Xiaoxiao Wang
- PP0904 Efficacy and Safety of Octreotide plus Midodrine in Decompensated Cirrhosis patients with Hepatorenal syndrome-Acute Kidney Injury
Deep Patel, Shabir Lone, Lovika Babbar, Ajay Kumar, Ujjawal Sonika, Sanjeev Sachdeva
- PP0905 Measurement of Liver and Spleen Stiffness to Predict High-Risk Esophageal Varices and Poor Clinical Outcomes in Patients with Cirrhosis and Hepatocellular Carcinoma

Kanteera Sriyudthsak, Sangdao Boonkaya, Salisa Wejnaruemarn, Panarat Thaimai, Nipaporn Siripon, Prooksa Ananchuensook, Sombat Treeprasertsuk, Piyawat Komolmit, Kessarin Thanapirom

- PP0906 The expression of IL-35 in the prophase of liver failure and its preliminary exploration for the mechanism of immunoregulation by IL-35 and glucocorticoids.
XinChi Zhang, YuFan Xiong, Li Chen
- PP0907 Use of Eltrombopag Among Patients with Liver Cirrhosis: A Case Series
JoseOrlando Mendoza Nicolas, Ira Inductivo Yu
- PP0908 Safety And Outcome of Endoscopic Procedure in Patients with Portal Hypertension Associated with Severe Thrombocytopenia or Anemia. A Retrospective Observational Study
Sanjeev Kumar Jha, Ravikant Kumar
- PP0909 A nomogram to predict the probability of esophagogastric variceal bleeding in patients with upper gastrointestinal bleeding
Xiong Ming
- PP0910 A Rare Case Report of Idiopathic Noncirrhotic Portal Hypertension Resulting in Recurrent Small Intestinal Bleeding in Elderly Women
Xiaoru Sun, Liqin Shi, Lizhe Ma, Chengwei Chen, Rongtao Lai, Xiaojin Wang, Muyun Liu
- PP0911 Disease knowledge in patients with cirrhosis – A perplexing find.
Leya Nedumannil, Catherine Yu, Mustafa Mohamedrashed, Diana Lewis, Siddharth Sood
- PP0912 The role of hepatic venous pressure gradient in patients with porto-sinusoidal vascular
Xiaofeng Zhang, Chao Chen, Qinjun He, Ling Zhou, Wei Wu, Jinjun Chen
- PP0913 Effect of post-TIPS anticoagulation in patients with cirrhosis and portal vein thrombosis
Fuliang He, Yu Wang, Jidong JIA
- PP0914 Determining the Optimal Portal Pressure Gradient After Small-Diameter TIPS for Ascites: A Cohort Study
Guofeng Liu, Xiaoze Wang, Li Yang, Xuefeng Luo
- PP0915 Endoscopic treatment as secondary prophylaxis ameliorates short-term mortality for acute esophagogastric variceal bleeding in older patients with cirrhotic hepatocellular carcinoma
Qi Li, Ruifeng Liu, Lingna Lyu, Chunlei Fan, Huiguo Ding
- PP0916 Do Systemic Inflammation, Severity and Treatment Modalities of hepatic encephalopathy Determine Prognosis in Patients with Acute Overt HE in Liver Cirrhosis?
Venkatesh V S, Sarang Mahanaik, Barjesh Chander Sharma, Sanjeev Sachdeva, Siddharth Srivastava, Ajay Kumar, Ashok Dalal, Ujjwal Sonika
- PP0917 A new non-invasive tool to predict CSPH in compensated cirrhosis
Tiantian Zhou, HUADONG YAN
- PP0918 A Rare Case of Immunoglobulin Light Chain (AL) Amyloidosis With Hepatic Involvement
Shrey Bhatt, Venkatesh Vaithiyam, Raviteja Reddy, Sanjeev Sachdeva, Ajay Kumar, Ashok Dalal, Surbhi Goyal, Sarika Singh
- PP0919 TIPS treatment for patients with cirrhosis with current bleeding after endoscopy treatment in Vietnam
KHIEN VAN VU, THANH VAN NGUYEN

- PP0920 Association between albumin infusion dose and clinical outcomes in hospitalized patients with acutely decompensated cirrhosis: A national cohort study
Zhujun Cao, Chenxi Zhang, Yingling Wang, Huadong Yan, Xiaoguang Dou, Qinghua Meng, Minghua Lin, Yongchao Xian, Xiaoping Wu, Yuerong Zhang, Caiyan Zhao, Honying Pan, Yongping Chen, Chenghai Liu, Peng Hu, Xiaorong Mao, Yufeng Gao, Min Deng, Lihua Huang, Minghua Su, Yingren Zhao, Longgen Liu, Qin Zhang, Lijuan Ouyang, Yang Ding, Wei Zhang, Haibin Gao, Jin Guan, Lingling Lai, Ning Zhou, Ziyue Li, Dujing Bao, Yi Chen, Yongping Mu, Huan Deng, Ni Jiang, Jiabin Li, Xinsheng Xie, Yiguang Li, HUAN LIANG, Taotao Yan, Dongmei Zhu, Rongkun Yin, Yuqian Hong, Minghao Cai, Yuhan Liu, Yaoxing Chen, Zhuping Qian, Ziqiang Li, Baoyan An, Haiguang Xin, Yaoren Hu, Chuanwu Zhu, Qing
- PP0921 Norfloxacin prophylaxis augments the risk of multi-drug-resistant bacterial infections through increasing rectal colonization in cirrhosis
Nipun Verma, Akash Roy, Jayant Agarwal, Divakar Reddy, Arun Valsan, Pratibha Garg, Saloni Munjal, Samonee Ralmilay, Parminder Kaur, Arka De, Madhumita Premkumar, Sunil Taneja, Ajay Duseja
- PP0922 Clinical value study of MELD-lactate model based on arterial lactate in type C hepatic encephalopathy
Zhang Pan, Liu Yu Qin
- PP0923 AARC-LA6 : a superior predictor of survival in ACLF patients with septic shock
Vishnu Girish, Rakhi Maiwall, Ashok Choudhury, Shiv Kumar Sarin
- PP0924 Ultrasound microprobe combined with argon labeling to assist in the identification of target blood vessels and precise treatment of gastric fundus degumming ulcer bleeding
Zhang Yuerong, Jiang Yuhui, Huang Ying, Zhou Wan
- PP0926 Therapeutic Efficacy and Prognostic Factors of CART for Refractory Ascites Associated with Liver Cirrhosis
Tomohide Kurahashi, Atsushi Hosui, Naoki Hiramatsu
- PP0928 Efficacy and Safety of Outpatient Human Albumin Infusions in Patients with Decompensated Cirrhosis and Ascites: A Real-World Cohort Study from Australia
Siddharth Sood, Michael Mil, Nicholas Hannah, Catherine Yu, Natlie Ngu, Dmitri Shek, Thang Dao, Jeremy Tse, James Williams, Lauren Tang, Callista Vania Raharjo, Shakira Hoque, Andrew Chan, Diana Lewis, Ammar Majeed, Jacob George, Kate Lynch, Golo Ahlenstiel, Rohit Sawhney, Jason Behary, Avik Majumdar, Jacinta Holmes, Sally Bell, Stuart
- PP0929 Prevalence of elevated Cancer Antigen-125(CA-125) in liver cirrhosis & correlation with disease severity scores & portal hypertension
Ritesh Kumar Gupta, Sakshi Sharma, Vaishali Bhardwaj, Lokesh Sharma
- PP0930 Diagnostic value of animal nomenclature test for mild hepatic encephalopathy
Ying Han, Xueying Liang, Yanna Liu, Keke Jin, Ajuan Zeng, Huiguo Ding
- PP0932 Precipitating factors and treatment modalities of hepatic encephalopathy in a north African country
Driss Azzouzi, Maryeme Kadiri, Fatima Zahra Chabib, Nawal Lagdali, Mohamed Borahma, Fatima Zahra Ajana, Hamza Benazzouz
- PP0933 Post-Transplant Biliary Stenosis in No-TIPS Patient with Hepatitis C and Alcohol-Related Cirrhosis: A Rare Case from Kosovo
Agon Turkaj, Fadil Sherifi, Malsore Emini, Jeton Shatri

- PP0934 Large Gastric Varices Successfully Treated with Coil-Assisted Retrograde Transvenous Obliteration (CARTO): A Case Report
Federico Peralta, David Nagtalon, Ryan Uy, Rafael Mendoza, Jasmin Gundayao, Ian Cua, Cicero Habito
- PP0935 Treatment of EGVB and Portal Hypertensive Biliopathy in a patient with PSVD by TIPS: A case report
Fuliang He, Yu Wang, Jidong JIA
- PP0936 Standalone medical therapy versus early endovascular intervention as the first step in the management of patients with primary Budd-Chiari syndrome: A randomized controlled trial
Sagnik Biswas, Shekhar Swaroop, Shubham Mehta, Arnav Aggarwal, Samagra Agarwal, Deepak Gunjan, Shivanand Gamanagatti, Shalimar .
- PP0937 Risk factors of non-malignant portal vein thrombosis and the clinical treatment
Baihetiyaer Abidan, Xiaoqing Zeng, Qunyang Yao, Dalong Sun, Jie Ying, Jinsheng Guo
- PP0938 Efficacy and long-term outcomes of endovascular interventions in Budd-Chiari Syndrome
Amar Mukund, Vaibhav Thakur, Ankur Jindal, Rakhi Maiwall, Yashwant Patidar, Shiv Kumar Sarin
- PP0939 Clinical characteristics of porto-sinusoidal vascular disorder with systemic autoimmune
Yanna Liu, Yanglan He, Yangjie Li, Han Ying, Chunlei Fan, Yanjing Wu, Hui Liu, Lingna Lv, Huiguo Ding

Liver Oncology

- PP0051 A nomogram based on clinical indicators and enhanced CT for prediction of VETC metastatic pattern in hepatocellular carcinoma
Kai Zhang, Yongquan Yu
- PP0940 Spatial Transcriptomics Integrated with Bulk RNA Sequencing Reveals the Prognostic Signatures and Immuno-infiltration in Hepatocellular Carcinoma Undergoing Immunotherapy, and Construction of Related Predictive Models Using Machine Learning
Zhenyu Zheng, Yuhao Lin, Siqi Xu, Xingte Chen, Junxin Wu
- PP0941 Cyclin-Dependent Kinase 2 is a potential target for cholangiocarcinoma treatment under diabetogenic glucose condition
Cheerapinya Taebprakhon, Kullanat Khawkhiaiw, Wunchana Seubwai, Sopit Wongkham , Charupong Saengboonmee
- PP0942 Protein C Licenses P62/mTOR-Mediated Autophagy Activation to Drive Hepatocellular Carcinoma Progression
Shuaibing Ying, Yunqing Qiu, Yan Lou
- PP0943 LHX3 promotes EMT process in hepatoma cell through β -catenin/TCF4 pathway
Zhonglan You, Jie Xia, Ke Chen, Jiaqi Wang, Jing Wang, Yi Fan, Qian Li , Lingjun Kong
- PP0944 LncRNA TIALD contributes to hepatocellular carcinoma metastasis via inducing AURKA lysosomal degradation
Yingchao Wang, Bixing Zhao, Xiaolong Liu
- PP0945 Efficacy and safety analysis of transarterial chemoembolization plus donafenib with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a prospective, single-arm, single-center, phase II clinical study
Jinpeng Li, Jinlong Song

- PP0946 Lysosomal autophagy-based degradation of hepatocellular carcinoma PD-L1 modulates tumor macrophage polarization to activate anti-tumor immunity
Xu Gao, Wangxiao He, Enrui Xie, Yue Zhang, Xindi Huang, Jinhai Wang, Jin Yan, Fanpu Ji
- PP0947 FoxO1 as a Hub in Immunosenescence Induced by Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng Jiedu Prescription
Yuqing Xie, Fengna Yan, Xiaoli Liu, Huiwen Yan, Zimeng Shang, Yaxian Kong, Zhiyun Yang
- PP0948 XPD inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells and its related mechanisms
Jie Jian
- PP0949 Short-term Efficacy and Safety Analysis of HAIC Combined with Targeted and Immunotherapy for Unresectable Hepatocellular Carcinoma with High-flow Hepatic
Jinpeng Li
- PP0950 Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: Clinical implications
Yingchao Wang, Yang Zhou, Niangmei Cheng, Bixing Zhao, Xiaolong Liu
- PP0951 Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma
Bixing Zhao, Mengchao Hepatobiliary Hospital of Fujian Medical University
- PP0952 Stage-Specific Transcriptome Landscape of Hepatocellular Carcinoma: Insights from Super and Poor Survivors with Prognostic Signature Identification
Xiaoqian Xu, Hao Wang, Lichen Shi, Cheng Huang, Hong You, Jidong Jia, Youwen He, Yuanyuan Kong
- PP0953 Role of the nucleotide excision repair function of CETN2 in the inhibition of the sensitivity of hepatocellular carcinoma cells to oxaliplatin
Hengcheng Tang, Huaduan Zi
- PP0954 Weissella confusa inhibits liver cancer lung metastasis by suppressing the secretion of ursodeoxycholic acid (UDCA)
Shuang Li, Yinying Lu
- PP0955 The Chinese herbal KangXianYiAi formula attenuates hepatocellular carcinoma by regulating the bile acid transporters and YAP expression
Xiaobin Zao, Xu Cao, Yijun Linag, Yongan Ye
- PP0956 Sinomenine Reduces the Proliferative Activity of Hepatocellular Carcinoma by Inhibiting Trim29 Expression
Jingjing He, Youcheng Zhang, Zheyuan Wang, Yawu Zhang, Zhiyan Pei, Yuanyuan Liu, Lingyi Zhang
- PP0957 Hu-Qi-San suppresses Sgp19-KRas intrahepatic cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment
Huang Xiuqin, Zhao Xin, Song Xinhua
- PP0958 High-resolution Quantitative Reconstruction of Microvascular Architectures in Mouse Hepatocellular Carcinoma Models
Yan Zhao, Haogang Zhao, Guohong Cai
- PP0959 Bioresponsive and Immunotherapeutic NPs to Remodel TME for Enhanced CAR-T Cell Anti-tumor Activity

Yuchan Xue, Songbo Zhao, Baihui Wang, Wanhua Ren, Qiang Zhu

- PP0960 The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination
Peng Chen, Zheyu Dong, Qiuyue Ye, Yuxin Zhou, Libo Tang, Yongyin Li
- PP0961 ACSS2-induced Acetyl-CoA accumulation and H3K27ac promotes VDAC1-mediated mitophagy and tumor growth in Hepatitis B virus-associated hepatocellular carcinoma
Shan Li, Ni Tang
- PP0962 Nimbolide attenuates pulmonary metastasis and inflammation in HCC mice
Balasubramaniyan Vairappan, Manoj Nagar, Amit Kumar Ram
- PP0963 Diagnostic Accuracy of AFP, AFP-L3%, and DCP in Early Detection of Hepatocellular Carcinoma Using the GALAD Score
Huy Huu Nguyen, Suong Bang Nguyen Thi, Bac Hoang Nguyen, Long Duy Tran Cong
- PP0964 An Extremely Rare Case of Epithelioid Angiomyolipoma of the liver in a Filipino female: a case report
ALYSSA CHAN, JOSE ESTEBAN CATALUNA
- PP0965 Integrated single-cell and spatial transcriptome reveal the intracellular and extracellular roles of tumor cell-derived osteopontin in promoting intrahepatic cholangiocarcinoma progression
Yuan Liang, Hao Wang, Ling Lv
- PP0966 Tumor Shrinkage Following Eplcusa Treatment: Exploring Potential Role of Direct-Acting Antivirals in HCV-Related Hepatocellular Carcinoma
Haipeng Jiang, Yongquan Chi, Wenzhu Li, Junda Li, Wei Xu, Shanke Sun, Jianhua Rao
- PP0967 The status of cytotoxic lymphocytes before transarterial chemoembolization plus systemic therapies serves as an indicator of therapeutic efficacy and prognosis in patients with advanced hepatocellular carcinoma
Haifeng Zhou, Wei Yang, Weizhong Zhou, Sheng Liu, Haibin Shi
- PP0968 Restore CYGB Expression and Attenuate HCC Progression by DNA Demethylation
Hoang Hai, Le ThiThanh Thuy, Nguyen Thi Ha, Pham Minh Duc, Norifumi Kawada
- PP0969 High chloride intake inhibits the carcinogenesis and growth of hepatocellular carcinoma
Li Zhang, Shun Yao, Hai Jin, Guorong Wen, Xuemei Liu, Biguang Tuo
- PP0970 Up-regulated Krüppel-like factor 5 Promotes Hepatocellular Carcinoma Progression via Activating Wnt3a Signaling
Wenli Sai, Min Xu, Hao Tang, Rongfei Fang, Min Yao, Dengfu Yao
- PP0971 Development and validation of functional liver imaging score model to predict prognosis of patients with hepatocellular carcinoma after surgical resection
Feier Ding, Jin Cui, Gongzheng Wang, Xu Qi, Lianbang Wang, Fangyu Zhou, Xinya Zhao
- PP0972 Multifocal Hepatocellular Carcinoma in A Young Noncirrhotic Female: A Case Report
ERIKA JOHANNA PANADERO TANADA, Stephen N Wong
- PP0973 Combined DeRitis ratio and alkaline phosphatase on the Prediction of Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma
Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin NAN

- PP0974 Development and Validation of an ESPL1-Based Risk Model for Early Detection of HBV-Related Hepatocellular Carcinoma
Luhuai Feng, Hengkai Liang, Bobin Hu, Lu Wei, Qingmei Li, Tumei Su, Qianbing Yin, Yanfei Feng, Long Huang, Hongqian Liang, Minghua Su, Jianning Jiang
- PP0975 Gadoxetic acid disodium (Gd-EOB-DTPA) contrast-enhanced abbreviated magnetic resonance imaging (MRI) for hepatocellular carcinoma surveillance in at-risk patients: a multi-center study in China
Lan Zhang
- PP0977 Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus
Lan Zhang
- PP0978 Construction and evaluation of prognostic model of liver cancer based on triple serum fluorescence indicator of aptamer
Jianming Zhou
- PP0979 A Digital Risk Stratification Management Platform Based on GAAD Score Improves the Early Diagnosis of Hepatocellular Carcinoma (HCC) through Screening Chronic Hepatitis B (CHB) Patients: A Real-World Study in China
Qing Yang, Manhua Zhong, Bing Liu, Kee Jit Thye, Xiaofeng Wang, Yanhong Chen, Linfang Li, Xiaolei Zhou, Cunying Pu, Yaoxiang Wu, Yong Li
- PP0980 Causal Associations between Sarcopenia-Related Traits and Primary Liver Cancer in the European Population: A Mendelian Randomization Study
Zuohu Niu, Chunjun Xu
- PP0981 Differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma based on MRI correlated with serum tumor markers: A multi-center study in China
Lan Zhang
- PP0982 A nomogram model for predicting the survival of patients with alcohol-related hepatocellular carcinoma
Chang Guo, Wucan Yang, Jing Chen, Yudong Wang, DONG JI, George LAU
- PP0983 Comparison of Hotgen Biotech and Abbott Architect in Measuring AFP and PIVKA-II for Hepatocellular Carcinoma Diagnosis
YUAN HUANG, Rui Ding, Xuzhen Qin
- PP0985 Dynamic PET/CT images and deep learning assessment for early diagnosis of liver cancer induced by DEN/CCl₄ in mice
Junnan Wang, Wei Dong, Junfei Jin
- PP0986 Radiographic response combined Radiomic features response predict pathologic complete response to systemic therapy in hepatocellular carcinoma
ShiQi Zhou, LuNa Wang, ZiYue Yang, ZiYi Wang, Bin Xu, XiaoDong Zhu, HuiChuan Sun
- PP0987 Detecting early stage hepatocellular carcinoma (HCC) with PSMA PET/CT – Preliminary analysis of the Hepa-SMART Trial
Nicholas Michael Hannah, Grace Kong, Sze Ting Lee, Kim Taubman, Sophia Xie, Leeanne Pasanen, Rodney Hicks, Siddharth Sood

- PP0988 Clinical Features and Treatment Strategies of CA19-9 Producing Benign Cystic Diseases: Systematic Review of Reported Cases
Xin Tong, Dinghong Xiao
- PP0989 Dependence of Tumor Markers DCP and AFP on Intrahepatic Tumor Burden and Imaging Features in Hepatocellular Carcinoma Individuals in Mongolia
Barkhas Batkhoo, Munguntsetseg Batkhoo, Nomuunaa Bayarbat, Khandmaa Narantsetseg, Tuvshinjargal Ulziibadrakh, Ganbolor Jargalsaikhan, Oyungerel Lkhagva-Ochir, Bekhbold Dashtseren, Purevjargal Bat-Ulzii, Zolzaya Doljoo, Baigal Narantuya, Uurtsaikh Baatarsuren, Enkhtuvshin Khorolgarav, Erdenechuluun Khorolgarav, Sharawdorj Gur, Orkhon Gombosuren, Regzedmaa Tsognemekh, Javzandolgor Nyamsambuu, Sumiya Byambabaatar, Byambasuren Ochirsum, Enkhnommin Ochirbat, Orkhonselenge Davaadamdin, Anujin Batkholboo, Badamsuren Mend-Amar, Munkhzaya Munkhbaatar, Tuvshinzaya Purevdorj, Enkhjargal Tsogtoo, Altankhuu Murdorj, Dahgwahdorj
- PP0990 Diffuse hepatic hemangiomas of radial growth: A rare manifestation
Ruiqi Zou, Yushi Dai, Fei Liu, Fuyu Li
- PP0991 Unmasking the Unknown: The Unexpected Discovery of Hepatic Epithelioid Hemangioendothelioma
Johanna Manalo La Rosa-Rimorin, Jose Esteban Cataluña
- PP0992 First case of ultrasound-guided percutaneous transhepatic cholangioscopy with bridging for bilateral biliary drainage of malignant hilar biliary obstruction
Gang Tang, Rui Chen, Rongxing Zhou
- PP0993 Metastatic Duodenal Gastrointestinal Tumor Masquerading as Multiple Liver Abscesses: A Case Report
Ma. Althea Kathrine Baniqued Elinzano
- PP0994 Myasthenia gravis-like symptoms following immune checkpoint inhibitor therapy for hepatocellular carcinoma: a case report
Fushuang Ha, Haoyu Wang, Junjun Cai, Jing Liang, Hua Liu
- PP0995 Developing a signature based on necroptosis-related lncRNAs to predict the prognosis and immunotherapy response of hepatocellular carcinoma
Yao Liu, Zheng Zhang, Lei Fu, Shifang Peng
- PP0996 ERAL1 down-regulates NDUFB1 through m6A reader IGF2BP2 to inhibit mitochondrial ATP synthesis and metastasis in hepatoma cells
Li Zhou, Manqiu Hu, Zhihang Zhou, Song He
- PP0997 Phase I, Single-Arm Exploratory Study of Radiotherapy (Photon) Based on "Anatomical Hepatectomy Segments" for Anatomical Liver Segments
Juhui Chen, Jingfeng Liu, Yongshi Shen, Zhongmei Lin
- PP0998 Risk Factors for Early-Onset HCC in Patients with HBV Infection
Bo Li, Songlian Liu, Lihua Lin, Ying Tan, Aiqi Lu, Qikai Ning, Binbin Chen, Calvin Pan, Jianping Li, Yujuan Guan
- PP0999 Lipid Phosphatase SAC1 Suppresses the Metastasis of Hepatocellular Carcinoma by Dual Activation of PI4P/NF2-MST1/2-LAST1/2-YAP Axis and Promoting YAP Cytoplasmic Retention through Interacting with 14-3-3
Haihan Tang, Hecun Zou, Yong Lin

- PP1000 Glucosamine suppresses growth and induces apoptosis of cholangiocarcinoma cells via inhibition of EGFR/STAT3 pathways and N-glycosylation
Orawan Waenphimai, Chatchai Phoomak, Charupong Saengboonmee
- PP1001 Neuroendocrine Tumor presenting as cystic lesion in the Liver and Pancreas
Ferdinand Maitim Anzo, Jessika Ang Chua, Juliet Gopez Cervantes
- PP1002 Endoscopic Ultrasound Guided tissue acquisition(EUS TA) is a safe and effective modality in diagnosis of focal liver lesions
SAWAN BOPANNA, Khusboo Madaan , Mohd Rafiq Najar, Gurwant Singh Lamba, Monika
- PP1003 Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: A case report
Sifan Dong, An Jiang
- PP1004 Analysis on clinicopathological characteristics and prognostic factors of gallbladder carcinoma from adenoma
Ruiqi Zou, Yushi Dai, Fei Liu, Fuyu Li
- PP1005 Dignosis of Intraductal Papillary Neoplasm of the Bile Duct with SpyGlass Cholangioscope
Yingyun Yang, Wanying Liao, Qiang Wang, Xi Wu, Aiming Yang
- PP1006 Construction and validation of a novel recurrence risk model for postoperative patients with stage I intrahepatic cholangiocarcinoma
Hui Wang, Xiaomeng Yao, Qing Wang, Chuchu Wan, Xinru Fan, Huabang Zhou, Hu
- PP1007 Efficacy and safety in Advanced Cholangiocarcinoma Using different doses of Lenvatinib Combined with PD-1 and GEMOX: A Retrospective Analysis of Real-World Evidence
Jiamin Chen, Weihong Ma, DONG JI, George LAU, Yinying Lu
- PP1008 Clinicopathological Features and Survival Outcomes of Pure Gallbladder Squamous Cell Carcinoma: A China experience
YuShi Dai, RuiQi Zou, Fei Liu, FuYu Li
- PP1009 LIVER-DOMINANT METASTATIC NEUROENDOCRINE TUMORS: A CASE SERIES AND REVIEW OF CLINICAL OUTCOMES
Ferdinand Maitim Anzo, Marpe Z Viray , IanHomer Y Cua , Kitchie Antipuesto
- PP1010 Mediation analysis of surgery in prognosis among postoperative intrahepatic cholangiocarcinoma patients
Hui Wang, Xinru Fang, Qing Wang, Huabang Zhou, Xiaomeng Yao, Wendi Liu, HU HEPING
- PP1011 Hepatocellular Cancer Metastasis to the Bone Mimicking as Osteosarcoma
PHILLIP ANDREW DAVID, ALEXANDER UY, ARLINKING ONG GO
- PP1012 Correlation of Protein Induced by Vitamin K Absence II (PIVKA-II) and Alpha-Fetoprotein (AFP) Levels to the Clinicopathologic Features of Hepatocellular Carcinoma (HCC)
Matthew Joseph Tan Po, Jenny L. Limquiaco, Derek Leand U. Tan, Adrian Alick L. Bonghanoy, Jan Catherine G. Carrera, Aaron Lemuel Y. Ong
- PP1013 ASAP Score as a Novel Prognostic Tool for Recurrence and Survival in Hepatitis B-related Hepatocellular Carcinoma Following Curative Resection
Dongxu Yin, Yongkang Diao, Junhong Chen, Yifan Wu, Kongying Lin, Jiahao Xu, Han Wu, Chao Li, Lihui Gu, Lanqing Yao, Xinfei Xu, Mingda Wang, Feng Shen, Tian Yang

- PP1014 Profiling the Roles of MicroRNAs Associated with Cancer Stem Cells, Drug Resistance, Metastasis, and Recurrence in Hepatocellular Carcinoma: A Systematic Review, Network analysis, and Experimental Initial Verification
Yuanyuan Jiang, Xiaoning Zhu, Jing Wang
- PP1015 The Role and Mechanisms of PYCR1 in Regulating Proline Biosynthesis Through Metabolic Pathways in the Development of Intrahepatic Cholangiocarcinoma
Xincheng Xie, Hemin Xie
- PP1016 Mechanisms of Hepatic Progenitor Cell Aberrant Differentiation into Cancer: Factors Influencing the Transition from Cell Differentiation to Tumorigenesis
Leyi Li, Junzhe Jiao, Ruijuan Yan, Fenli Song, Xi Guan, Zhanjie Chang, Haibo Zhang,
- PP1017 Tumor Biology Characteristics Score Based on AFP and PIVKA-II Predicts Recurrence and Survival After Curative Resection for Hepatocellular Carcinoma
Mingda Wang, Chao Li, Yongkang Diao, Lanqing Yao, Han Liu, Yongyi Zeng, Zhong Chen, Han Wu, Xinfei Xu, Lihui Gu, Jiahao Xu, Feng Shen, Tian Yang
- PP1018 AKR1D1 represses hepatocellular carcinoma progression and immune evasion by reprogramming fatty acid metabolism via STAT3
Yuxi Lin, Yutian Chong
- PP1019 Expression of ESPL1 gene in HBV-associated HCC cancer tissues and its relationship with tumor pathological features
Qianbing Yin, Bobin Hu, Minghua Su, Rongming Wang, Qingmei Li, Tumei Su, Yanfei Feng, Long Huang, Hongqian Liang, Luhuai Feng, Yang Lu, Jianning Jiang
- PP1020 Expression of NOP2 in Hepatocellular Carcinoma and Its Effects on the Proliferation, Migration, and Invasion of Liver Cancer
Qi Wang, Hao Ding
- PP1021 Expression of the FCGBP Gene in Hepatocellular Carcinoma Tissues and Its Role in Prognostic Assessment
Hang Wang, Bobin Hu, Jianning Jiang
- PP1022 Investigation of the Expression and Spatial Distribution of Acylglycerol Kinase in patients with HCC and Its Prognosis Significance
Gaixia He, Pengpeng Zhu, Qi Shang, Huan Deng, Ping Liu, Ziwei Du, Zongfang Li
- PP1023 PPAR γ -ELOVL1-16:0-PPAR γ -STIP1 as a Mechanotransduction Pathway Promoting HCC
Xingyuan Chen, Kunyuan Wang, Huan Wang, Xiuling Fu, Jin Li, Linchao Chen, Haoyu Lin, Zhihao Pei, Shiming Liu, Hui Yang
- PP1024 The Aging and Metabolic Characteristics of Hepatocellular Carcinoma were Analyzed and The Prognostic Model was Established Based on TCGA Database
Mengru Hua, Yuqing Xie, Xiaoli Liu, Lihua Yu, Huiwen Yan, Zimeng Shang, Guangyuan Huo, Zhiyun Yang
- PP1025 Causal Role of Immune Cells in Hepatocellular Carcinoma: a bidirectional mendelian randomization study
Yuting Liu, Zimeng Shang, Xiaoli Liu, Huiwen Yan, Yuqing Xie, Guangyuan Huo, Zhiyun
- PP1026 STAB1+ Senescent Macrophages Are Driven to Infiltrate and Uniquely Shape an Immunosuppressive Microenvironment in Hepatocellular Carcinoma
Longyang Zhou, Guangyong Sun, Dong Zhang

- PP1027 Hepatitis B Doubly Spliced Protein (HBDSP) Promotes Migration and Invasion in Hepatoma Cells by Up-regulating YAP Expression in Epithelial-Mesenchymal Transition (EMT)
Xiazhen Xu, Yibin Peng, Yuxin Ping, Tiantian Shao, Qiong Wu, Xu Lin, Wannan Chen
- PP1028 Causal relationship between gut microbiota and hepatocellular carcinoma: A Mendelian randomization and case-control study
Wentao Kuai, Liu Yang, LIANG XU
- PP1029 AHCTF1 functions as an oncogenic factor and promotes tumor progression in hepatocellular carcinoma
Zhang Nuobei
- PP1030 The macrophage cytoskeletal protein AIF1 contributes to the immunosuppressive microenvironment in hepatocellular carcinoma by upregulating SPP1
Hao Cai, Min Deng, Huichuan Sun
- PP1031 The role and mechanism of Colec12, a key gene for immunosuppression in hepatocellular carcinoma
Hongyan Huang, Zhili Wen
- PP1032 Machine Learning-Driven Multi-Omics Integration Identifies Ferroptosis-Associated Biomarkers of Therapy Resistance in Hepatocellular Carcinoma
Rifaldy Fajar
- PP1033 p53-regulated tsRNA-6 promotes proliferation in HCC cells by mediating DNA homologous recombination repair
Guanzi Chen, Wenli Xu, Fuyang Hong, Yusheng Jie
- PP1034 N4BP2L1 Inhibits Glycolysis in Hepatocellular Carcinoma Cells by Promoting Ubiquitination of HIF-1 α
Xiaoling Liu, Yonghong Wang, Qiaoli Zhao, Changfeng Sun, Cunliang Deng
- PP1035 Dual Prognostic Impact of Preoperative Platelet Count Abnormalities on Long-term Oncologic Outcomes After Hepatic Resection for Hepatocellular Carcinoma: Insights from A Multicenter Analysis of 3,116 Patients
Jiahao Xu, Xuedong Wang, Yingjian Liang, Hongwei Guo, Han Liu, Yifan Wu, Hong Wang, Yahao Zhou, Yongyi Zeng, Lei Cai, Tian Yang
- PP1036 NOL9 Regulates β -Catenin Stability and Ribosome Biogenesis in Hepatocellular Carcinoma
Xiyao Chen, Liang Peng, Chan Xie, Xin Song
- PP1037 Bioinformatic Analysis of Macrophage Polarization and RNA Methylation-Associated Differentially Expressed Genes in Hepatocellular Carcinoma
KONGLI FAN
- PP1038 Silencing of Xeroderma Pigmentosum Group D Gene Promotes Hepatoma Cell Growth by Reducing P53 Expression
Lang Chen
- PP1039 Identification of Gut Microbiota and Bile Acid Metabolite Signatures for Predicting Response to Lenvatinib and Anti-PD-1 Combination Therapy in Hepatocellular Carcinoma
Jie Han, Zhenwei Qian, Aizier Ainiwaer, Yinying Lu
- PP1040 Prognostic value of N1/N2 neutrophils heterogeneity and tertiary lymphoid structure in hepatocellular carcinoma patients
Yanfei Lang, Weiwei Fu, Shigang Ding

- PP1041 The Role of DDX10 in Hepatocellular Carcinoma Metastasis: Regulation of Ferroptosis
Mingyu Zhang, Jiazhi Liao, Suhong Xia
- PP1042 COMPREHENSIVE ANALYSIS OF THE ROLE OF TUMOR-ASSOCIATED ANTI-SMGGS AUTOANTIBODY IN HEPATOCELLULAR CARCINOMA
WEI HOU
- PP1043 The mechanism of m5C methylation regulated energy metabolic reprogramming of hepatocellular carcinoma mediated by ALYREF/UGP2 signaling axis involved in tumor progression
JUAN LU
- PP1044 The Mechanism of Metabotropic Glutamate Receptor 5 in the Tumorigenesis, Progression and Angiogenesis of Hepatocellular Carcinoma
Jing Li, Shuixiang He, Guohong Cai, Yan Zhao
- PP1045 Comparison of platelet count and function between hepatocellular carcinoma and liver
Meng Zhang, Zhichun Dang, Ting Li, Chenrui Liu, Muqi Wang, Na He, Yaping Li
- PP1046 A PAN-CANCER ANALYSIS OF THE ROLE OF ZC3HAV1 IN HUMAN CANCERS
WEI HOU
- PP1047 KRI1 Promotes Hepatocellular Carcinoma Progression by Affecting the Structure and Function of Nucleoli through Liquid-Liquid Phase Separation
Yu Lu
- PP1048 PAN-CANCER ANALYSIS OF CAMSAP FAMILY AND UNRAVELLING THE ONCOGENIC ROLE IN HEPATOCELLULAR CARCINOMA
WEI HOU
- PP1050 AN INTEGRATED ANALYSIS OF THE ROLE OF tsRNA-Thr-5-0015 IN HUMAN TUMORS ACROSS MULTIPLE CANCER TYPES
WEI HOU
- PP1051 Development and validation of pyruvate metabolism associated gene signatures to predict prognosis and immunotherapy response in hepatocellular carcinoma
Ning Wang
- PP1052 INTEGRATED BIOINFORMATIC ANALYSIS OF THE ROLE OF WNK1 IN HEPATOCELLULAR CARCINOMA
WEI HOU
- PP1055 Extracellular volume (ECV) derived from spectral CT to assess vessels encapsulating tumor clusters (VETC) pattern in hepatocellular carcinoma: a pilot study
Yongquan Yu, Xingbiao Chen, Hongsheng Zhang

Liver Cancer Management

- PP1053 Matrine improves sorafenib resistance in hepatocellular carcinoma by regulating cell cycle, mitochondrial function, and epithelial-mesenchymal transition through inhibiting the Notch1 signaling pathway
Man Zhao, Fei Yin
- PP1054 Hepatic Arterial Infusion Chemotherapy with mFOLFOX in Advanced Gallbladder Cancer: An Approach with Potential for Conversion and Enhanced Survival

Zhang Ya Jun, Guo Gui Min, Wei Zhan Qi, Yang Ming, Liu Ying, Zhang Yue Wei

- PP1056 Comparison of the efficacy and safety of HAIC combined with Camrelizumab and Apatinib versus TACE in the treatment of intermediate-advanced HCC
Haojie Zhang
- PP1057 Transcatheter arterial chemoembolization combined with immune checkpoint inhibitors plus molecular targeted therapy after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis: a multicenter prope
Junhao Mei, Jian Lu, Gaojun Teng
- PP1058 Research Trends and Hotspots in Copper Metabolism in Hepatocellular Carcinoma: A Visual Analysis Based on Web of Science
Yi Zhang, Zhi Li, Hezhao Wang, Jinlong Li, Tianle Fu, Congxi Xu, Xinhao Gao, Huiyang Fan, Shihao Guo, Jitao Wang, Dengxiang Liu
- PP1059 Prediction of Response to Hepatic Arterial Infusion of Raltitrexed and Oxaliplatin (Ralox-HAIC) combined with lenvatinib and camrelizumab for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Prospective, Single-arm clinical study
Peilin Zhu, Guosheng Yuan, Chengguang Hu, Yongru Chen, Kaiyan Su, Wenli Li, Qi Li, Xiaoyun Hu, Mengya Zang, Yangda Song, Jinzhang Chen
- PP1060 Evaluation of the efficacy of interventional therapy combined with/without targeted and immunotherapy in patients with Child-Pugh B hepatocellular carcinoma and analysis of the beneficiary population: a single-center, retrospective study
Xuwei Guo, Fei Yin, Guangjie Han, Man Zhao, Xiaoling Duan, Jinfeng Wang, Jianfei Shi, Xin Han
- PP1061 Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma
Quan Wang, Zhang Xue Duan
- PP1062 Efficacy of sequential radiotherapy after the combination of transcatheter arterial chemoembolization with lenvatinib and anti-PD-1 antibodies for unresectable hepatocellular carcinoma
Xiangye Ou, Zhenxin Zeng, Deyi Liu, Junyi Wu, Jiayi Wu, Yinan Li, Han Li, Maolin Yan
- PP1063 Impact of Switching from ETV to TDF or TAF on the 3-Year Recurrence Rate After RFA Treatment in HBV-Related HCC Patients
Xue Zhang, Baiguo Xu, Jing Liang
- PP1064 Prognostic Value of Systemic Immune-Inflammatory Index Combined with Prognostic Nutritional Index in Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization, Lenvatinib and PD-1 Inhibitors
Zhenxin Zeng, Xiangye Ou, Rongjian Pan, Yinan Li, Deyi Liu, Han Li, Jiayi Wu, Junyi Wu, Maolin Yan
- PP1065 Comprehensive analysis of radiologic cancer-free (rCF) status through various treatment approaches in advanced-stage hepatocellular carcinoma
Keisuke Koroki, Sadahisa Ogasawara, Ryo Izai, Takuya Yonemoto, Teppei Akatsuka, Chihiro Miwa, Sae Yumita, Masanori Inoue, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Shinichiro Nakada, Nozomu Sakai, Masayuki Yokoyama, Masayuki Ohtsuka, Naoya Kato
- PP1066 Advanced HCC: does TACE has a role to play in its management?
Vasav Tyagi, Amar Mukund, Ashok Choudhury, Yashwant Patidar, Shiv Kumar Sarin

- PP1067 Gamma-Glutamyl transferase: A Prognostic Biomarker in Advanced Stage Hepatocellular Carcinoma treated with SBRT
Deepti Sharma, Babu Lal Meena, Hanuman Prasad Yadav, Shiv Kumar Sarin
- PP1068 Demographic profile, disease characteristics and management trajectory of hepatocellular carcinoma (HCC) in Kerala, S India over four decades
K T SHENOY, Leena K B
- PP1069 Efficacy and Safety of Regorafenib vs. Regorafenib Combined with PD-1 Inhibitors as a Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Retrospective Analysis of Real-World Evidence
Weihong Ma, Yinying Lu, DONG JI, George LAU
- PP1070 Hepatocellular carcinoma (HCC) presents at an advanced stage in Kerala, South India : Unmet need
Leena K B, Shenoy T Kotacherry
- PP1071 Survival analysis of hepatic arterial infusion chemotherapy on progression-free survival in advanced hepatocellular carcinoma with portal vein tumor thrombus
Wenchang Wang, Zhongbin Li, Mengwen He, Jing Chen, Yudong Wang, DONG JI, George LAU
- PP1072 Peripheral immune features synergizing neutrophil-to-lymphocyte ratio in prediction of poor survival of hepatocellular carcinoma after thermal ablation
Fangying Fan, Ping Liang, Jie Yu
- PP1073 Huqi formula suppresses hepatocellular carcinoma growth by modulating the PI3K/AKT/mTOR pathway and promoting T cell infiltration
Donghao Yin, Xiaojun Wang, Xiuhui Li
- PP1074 Mechanism study of "Hedyotis diffusa - Scutellaria barbata" in the treatment of primary liver cancer: based on network pharmacology, molecular docking, and in vitro experimental verification
Meng Xu, LiangGuo Zhang
- PP1075 Decoding Glycogen Metabolism in HCC: A novel Prognostic Biomarkers and Therapeutic Targets
Anna Li, Xinlei Qi, Haibo Zhang, Ruijuan Yan, Zhanjie Chang, Junzhe Jiao, Jingtao Li
- PP1076 Long-term Prognostic Impact of Traditional Chinese Medicine on Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Retrospective Cohort Study
Ping Xue Zhang, Hui Xiu Li
- PP1077 Impact of Aerobic Glycolysis on the Tumor Microenvironment in Hepatocellular Carcinoma
Mengzhuo Liu, Haibo Zhang, Ning Wang, Yazhu Liu, Ruijuan Yan, Zhanjie Chang, Junzhe Jiao, Jingtao Li
- PP1078 Adjuvant transarterial chemoembolization after truly curative resection does not improve survival of patients with hepatocellular carcinoma at high risk of recurrence: a target trial
Jia-Yong Su, De-Jia Huang, Shao-Ping Liu, Xiao-Ling Xu, Shu-Chang Chen, Jun-Jie Ou, Jian-Rong Li, Tai-Xin Yang, Wen-Yang Li, Yuan Fan, Zhao-Chan Wen, Le Chen, Zhen Qin, Bei-Bei Long, Da-Zhi Li, Jiang-Hong Huang, Yi-Jia Li, Jun-Chi Zhong, Xiu-Mei Liang, Liang Ma, Masatoshi Kudo, Jian-Hong Zhong
- PP1079 ER α promotes HCC cell progression via PHF5A/PI3K/AKT signaling pathway

Xiang Cai, Shufang Pan, Yutian Chong

- PP1080 Single-cell RNA sequencing revealed that the enrichment of TPI1+ malignant hepatocytes was linked to HCC metastasis and immunosuppressive microenvironment
Yuxin Liang, Deyuan Zhong, Xiaolun Huang, Jin Shang
- PP1081 Impact of Jinlong Capsule on Prognosis of Patients with Hepatocellular Carcinoma: A Propensity Score Matching Study
Ke Shi, Ying Feng, Xianbo Wang
- PP1082 Novel cellular senescence related molecular subtypes and prognostic characteristics of hepatocellular carcinoma
Yuling Liang, Yuqing Xie, Xiaoli Liu, Lihua Yu, Huiwen Yan, Zimeng Shang, Guangyuan Huo, Wanxin Shi, Juan Du, Zhiyun Yang
- PP1083 Traditional Chinese Medicine in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus
Wanxin Shi, Huiwen Yan, Xiaoli Liu, Lihua Yu, Yuqing Xie, Zimeng Shang, Guangyuan Huo, Yuling Liang, Xinhui Wang, Zhiyun Yang
- PP1084 Preoperative Prognostic Model Combining Tumor Burden Score and Tumor Markers to Predict Long-term Outcomes Following Hepatectomy for Intrahepatic Cholangiocarcinoma: A Multi-Institutional Analysis
JUN FU, Yongyi Zeng
- PP1085 Glycodeoxycholic acid stimulates antitumor immune response by driving macrophages toward M1 phenotype in hepatocellular carcinoma
Mingxia Deng, JING LIU, Li Zhang, Yichun Zhang, Haoyang Hu, Jinyao Dai, Shaohua Dong, Lushun Jiang, Shuaibing Ying, Zhijuan Zhang, Yujing Wang, Keer Zhu, Yan Lou, Yunqing
- PP1086 Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma
Xiaoli Zhang, Jianzhou Li, Mimi Zhou, Yingli He, Yalei Zhao
- PP1087 A m6A-Altering Variant of MRPL34 Predisposes to Hepatocellular Carcinoma via Regulating Oxidative Phosphorylation
Jiaxuan Chen, Jia Hou, Ke Jiang, Deke Jiang
- PP1088 Qualitative study of health professionals attitudes and perceptions regarding palliative and supportive care in hepatocellular carcinoma
Cameron Goffon, Anna Di Bartolomeo, Shalini Wijekulasuriya, Shenghan Cai, Rose Boutros, Fiona Stafford-Bell, Kim Caldwell, Geoffrey McCaughan, Amany Zekry, Simone I Strasser, Miriam Levy, Caitlin Sheehan, Stephen Goodall, Jan Maree Davis, Linda Sheahan, Ken Liu, Sally Greenaway, Scott Davison, Thang Du Huynh, Zujaj Quadri, Yvonne Zurynski, Meera Agar, Jacob George
- PP1089 A case of intrahepatic bile duct papillary tumor with invasive adenocarcinoma
Linhui Hu, Hua Wan, Li Liang, Yan Wang
- PP1090 Anti-hepatocellular carcinoma activities of novel hydrazone derivatives via downregulation of interleukin-6
AHMED Nabil, MARWA Abdel-Motaal, MITSUHIRO Ebara, GAMAL Shiha, HASSAN M. E. Azzazy
- PP1091 Impact of Regular Surveillance Compliance on Survival Outcomes After Curative Resection for Hepatocellular Carcinoma

Lanqing Yao, Jinbo Gong, Lei Cai, Lihui Gu, Yingjiang Liang, Hongwei Guo, Kongying Lin, Ziqiang Li, Qixuan Zheng, Yahao Zhou, Tinghao Chen, Zhong Chen, Hong Wang, Han Liu, Han Wu, Feng Shen, Tian Yang

- PP1092 Hepatic arterial infusion chemotherapy sequential transarterial embolization combined with lenvatinib and tislelizumab in patients with high-risk unresectable hepatocellular carcinoma: an update analysis of a phase 2 trial
Jian-Hong Zhong, Zhu-Jian Deng, Lu-Nan Qi, Zhu-Shun Chen, Zhi-Ming Zhang, Bang-De Xiang, Liang Ma
- PP1093 Risk Factors for Extrahepatic Metastasis after Microwave Ablation of Hepatocellular
Xueqin Tian, Jiapeng Wu, Chuan Pang, Jie Yu, Ping Liang
- PP1094 A novel preoperative inflammation score system established for postoperative prognosis predicting of intrahepatic cholangiocarcinoma
JUN FU, Yongyi Zeng
- PP1095 Case Report: Laparoscopic Hepatectomy for Recurrent Hepatocellular Carcinoma Following Two Previous Surgical Interventions
Shubing Wei, Chenfenglin Yang, Jieru Ding, Xiao Zhang, Wen Hu, Pinchu Chen, Yao Li, Qifan Zhang
- PP1096 Safety and Efficacy of Cryoablation Plus Lenvatinib versus TACE Plus Lenvatinib in Unresectable Hepatocellular Carcinoma
Chang Xiu Juan, Wang Di, Huang Jia Gan, Pang Jian Zhi, Zhang Wei, Zeng Zhen, Wenjing Wang
- PP1097 Case Report: Surgical Management of Synchronous Double Primary Cancers in the Liver and Duodenum
Chenfenglin Yang, Shubing Wei, Xiao Zhang, Jieru Ding, Wen Hu, Pinchu Chen, Yao Li, Qifan Zhang
- PP1098 A Promising Outcome: Hepatectomy for Primary Liver Neuroendocrine Tumor. A Case
ClairePrincess Ypil Quiñones, EllieMay Belarmino Villegas
- PP1099 Novel LPS-A4 score as a predictive model of hepatocellular carcinoma development in patients with chronic hepatitis B
Jingjing Song, Yuemin Nan
- PP1100 The 15-year Prognostic Analysis of Solitary Hepatocellular Carcinoma No More Than 5cm Treated by Microwave Ablation : Primary HCC versus Local Tumor Progression
Yannan Qiao, Ping Liang
- PP1101 Exosome miR-509-3p as a Novel Therapeutic Strategy Inhibits Metastasis of Hepatocellular Carcinoma via APOD/Wnt2B signaling pathway
Keqing Zhong, Wenrui Zhao, Nannan Zhang, XiaoLin Tang, Yucui Qin, Xiaochang Wang,
- PP1102 TACE with or without Lenvatinib as Adjuvant Therapy for HCC with microvascular invasion (MVI) or Portal Vein Thrombus(Cheng's I/II):A Single-Center, Prospective, Non-Randomized Cohort Study
Chengpei Zhu, Feng Wu, Zibo Xu, Chengjie Li, Liang Di, Xiaofei Zhao, Yang Tan, Shanshan Wang, Kai Liu, Haitao Zhao, Daobing Zeng, Guangming Li
- PP1103 Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma: a multi-center study

DaLong Yang, Ning Peng, JunLiang Nong, ShaoPing Liu, Ze Su, YaQun Yu, FanJian Zeng, Kang Chen, YiHe Yan, HongBing Yao, WenFeng Li, Chuang Qin, MingSong Wu, XiaoFeng Dong, Jie Liu, PeiSheng Wu, TengMeng Zhong, YaoZhi Chen, GuoDong Wang, XianShuang Mao, JunJie Ou, Lin Ye, XueYao Wang, FuQuan Yang, YongYu Yang, MianJing Li, YongRong Liang, YongCheng Lai, QingQing Pang, FuXing Li, ShuChang Chen, XiuMei Liang, BangDe Xiang, Liang Ma, JianHong Zhong

- PP1104 Reversal of CD8+ T Cell Exhaustion Phenotype in Hepatocellular Carcinoma Models by Yangyin-Fuzheng-Jiedu Formula
Zimeng Shang, Xiaoli Liu, Huiwen Yan, Zhiyun Yang, Xinhua Song
- PP1105 Efficacy of Lenvatinib and Afatinib in Subsequent-Line Treatment of EGFR-Mutant Advanced Biliary Tract Cancer
Jiongyuan Li, Longhao Zhang, Nan Zhang, Mingjian Piao, Ziyu Xun, Chengjie Li, Shuofeng Li, Xu Yang, Shanshan Wang, Boyu Sun, Xiaobo Yang, Haitao Zhao
- PP1106 Multi-kingdom gut microbiota in predicting severe immune-related adverse events in advanced hepatobiliary cancers
Chengpei Zhu, Xiaobo Yang, Hanping Wang, Haitao Zhao
- PP1107 Traditional Chinese Medicine in Patients with Hepatocellular Carcinoma and anemia
Wanxin Shi, Huiwen Yan, Zhibo Dang, Mengge Li, Xiaoli Liu, Xinhui Wang, Lihua Yu, Songwei Li, Zhiyun Yang
- PP1108 Efficacy and Safety of Transcatheter Arterial Chemoembolisation Combined with Lenvatinib plus Anti-PD1 Inhibitors versus Transcatheter Arterial Chemoembolisation Alone for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Xiangye Ou, Zhenxin Zeng, Deyi Liu, Junyi Wu, Jiayi Wu, Yinan Li, Han Li, Maolin Yan
- PP1109 Variceal bleeding in cirrhotic patients with hepatocellular carcinoma on systemic treatment
Yangjie Li, Ajuan Zeng, Yueyang Yu, Lingna Lyu, Ying Han, Huiguo Ding
- PP1110 Combining with immunotherapy is a promising modality of regorafenib treatment in patients with unresectable hepatocellular carcinoma
Tianxiang Li, Jingyu Cao, Bin Han, Song Wang, Zixiang Li, Yuan Guo, Jinzhen Cai, Liqun
- PP1111 FSP1 inhibitor icFSP1 sensitizes hepatocellular carcinoma to Lenvatinib by activating
Congyue Zhang, Mengjiao Sun, Yue Shi, Yaoyao Mao, Zhandong Lin, Jiawei Cui, Yuemin
- PP1112 Basing on clinical-radiologic model to predict the efficacy and prognosis of systemic therapy for hepatocellular carcinoma
Xing Rong Zheng, Xin Song, Xiyao Chen, Liang PENG, Chan Xie
- PP1114 Association of T cell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC
Anthony Tan, Shoukit Hang, Adeline Chia, Nicole Tan, Thinesh Krishnamoorthy, Wancheng Chow, Regina Wong, Alessandro Sidoli, Luen Wai, Antonio Bertoletti
- PP1116 The efficacy and safety of sintilimab as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative hepatic resection: a prospective, single-arm, multicentric cohort study
JiaYong Su, Ning Peng, ShaoPing Liu, XiaoLing Xu, JunJie Ou, Ze Su, Liang Ma, JianHong Zhong
- PP1117 The efficacy and safety of camrelizumab as adjuvant therapy in hepatocellular carcinoma patients at high-risk of recurrence after resection

- LeiPo Lin, JiaYong Su, Ning Peng, Ze Su, Kang Chen, Min Luo, FuQuan Yang, Liang Ma, ShaoPing Liu, JianHong Zhong
- PP1118 Prognostic factors and an innovative nomogram model for hepatocellular carcinoma patients at high-risk of recurrence after resection with adjuvant PD-1 inhibitors
JiaYong Su, Wei Tian, Ning Peng, ShaoPing Liu, XiaoLing Xu, Ze Su, Kang Chen, Min Luo, FuQuan Yang, ShuChang Chen, Liang Ma, JianHong Zhong
- PP1119 Immune Checkpoint Inhibitors plus Targeted Therapy for Hepatocellular Carcinoma with Extrahepatic Metastasis: a multicentric retrospective study
ZhuJian Deng, Ze Su, JunLiang Nong, Lin Ye, Chuang Qin, XueYao Wang, YongCheng Lai, ZhiYin Liang, MinSong Chen, JinYuan Guo, MuLan Wu, FeiMin Tang, JianHong Zhong
- PP1120 Radiotherapy with or without Immune checkpoint inhibitors and tyrosine kinase inhibitors in Hepatocellular Carcinoma involving major portal vein and/or inferior vena cava tumor thrombus: a retrospective cohort study
QianQian Tang, ZhuJian Deng, ChengXian Ma, JianHong Zhong
- PP1121 H3K9 Lactylation Promotes Stemness of Double Negative T cells through NAD⁺ Metabolic Reprogramming
Jingjing Zhu, Zihan Zhang, Guangyong Sun, Dong Zhang
- PP1122 Silibinin suppresses HCC metastasis via regulating Trx-LIN00152-ANGPT1 signaling
Yuxin Liang, Deyuan Zhong, Yahui Chen, Yahui Chen, Xiaolun Huang, Jin Shang
- PP1123 Anti-programmed cell death protein-1 therapy in primary liver cancer-induced type 1 diabetes mellitus: A case report
Ting Li, Chenrui Liu, Wenxue Zhao, Mei Li, Xiaozhen Geng, Miaomiao Zhang, Siwen Dang, Shuangsoo Dang, Yaping Li
- PP1124 Drug type of adjuvant PD-1 inhibitors in hepatocellular carcinoma patients at high risk of recurrence after resection: a prospective, multicentric cohort study
JiaYong Su, JinMing Wang, Ning Peng, ShaoPing Liu, XiaoLing Xu, JunJie Ou, Kang Chen, Ze Su, Min Luo, FuQuan Yang, Le Li, Liang Ma, JianHong Zhong
- PP1125 Discontinuation of targeted and immunotherapy do not increase the re-bleeding rate after endoscopic treatment for gastroesophageal variceal bleeding in patients with advanced liver cancer
Wang Huishan, Fang Ye, Jiang Siyu, Huang Xiaoquan, Ma Lili, Chen Shiyao
- PP1126 Effect of TACE combined with tislelizumab on patients with advanced liver cancer and influencing factors of prognosis
Gang Wu
- PP1127 SIRP α promotes tumor immune escape in hepatocellular carcinoma by inducing T cell
Xue Zhang, Dongbo Chen, Pu Chen, Shaoping She, Yao Yang, Liying Ren, Hongsong Chen
- PP1142 A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells
Anthony Tan, Shoukit Hang, Nicole Tan, Thinesh Krishnamoorthy, Wancheng Chow, Regina Wong, Alessandro Sidoli, Luen Wai, Antonio Bertoletti
- PP1146 Exploration of the therapeutic effect and mechanism of intestinal microbiota transplantation combined with PD-1 inhibitors on liver cancer
Wenjie Chen, Xiaoxiong Hu

Liver Surgery and Transplantation

- PP1113 Cholangioscopy Assisted Guidewire Placement in a Pinhole Iatrogenic Common Hepatic Duct Stricture
Syed Mujahid Hassan, Asmat Ullah, Nasir Mehmood, Nadim Bajkani, Rani Tulsi
- PP1115 Managing Post-Laparoscopic Cholecystectomy Biliary Leakages and Strictures Following Failed ERCP Procedures Using Single Operator Cholangioscopy: Single Centre Experience
Syed Mujahid Hassan, Nasir Mehmood, Rani Tulsi
- PP1128 Serine glycine restriction aggravates hepatic ischemia-reperfusion injury
Moujie Yang, Junfei Jin, Wei Dong
- PP1129 Research Progress on New Metastatic Mode Vessels That Encapsulate Tumor Clusters Pattern of Hepatocellular Carcinoma
Huiyang Fan
- PP1130 Surgical clip migration in the biliary tract: 3 cases report and literature review
Zhipeng Sun, Lei Yang
- PP1131 PTX3 exacerbates hepatocyte pyroptosis in hepatic ischemia – reperfusion injury by promoting macrophage M1 polarization
Peng Jiang, Jinzhen Cai
- PP1132 Blocking the CXCL12/CXCR4 axis on Kupffer cells to regulate immune microenvironment changes and improve liver transplantation
Yurong Luo, Xinqiang Li, Jinzhen Cai
- PP1133 PAK1 promotes gluconeogenesis to attenuate steatotic liver graft injury via lactylation of PCK1 mediated by phosphorylation of GCN5
Fengqiang Gao, Xiao Xu
- PP1134 The mechanisms of lactate in regulating hepatocyte and neutrophil inflammation and function in HIRI
Peiyang Fang, Zihan Zhang, Dong Zhang, Guangyong Sun
- PP1135 Total bile acid is a useful tool for evaluating the risk of portal hypertension in patients with hepatocellular carcinoma who have undergone hepatectomy
Dali Zhang, Xiaofeng Zhang, Lixin Li, Hui Ren, Yudong Wang, George Lau, Zhenwen Liu
- PP1136 Reprogramming of bile acid metabolism attenuates liver inflammation during ischemia/reperfusion injury
Kunpeng Huang, Meng Chen
- PP1137 Enhancement of Liver Regeneration in Mice through DDX3X-CD36 Pathway-Mediated Promotion of Hepatic Lipid Accumulation
Zhenzhen Pan, Ling Xu, Feng Ren
- PP1138 Minimally invasive Versus Open Pancreatoduodenectomy for Periapillary Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gang Tang, Rui Chen, Rongxing Zhou
- PP1139 Restoring Bile Flow: Managing Iatrogenic Bile Duct Injury and Disconnection Following Laparoscopic Cholecystectomy with Cholangioscopy and Stenting – A Case Report
Syed Mujahid Hassan

- PP1140 Percutaneous transhepatic cholangioscopy with biliary stent placement under direct visualization for malignant hilar biliary obstruction when ERCP fails: a cohort study
Gang Tang, Rui Chen, Rongxing Zhou
- PP1141 Novel non-invasive liver reserve and fibrosis signature to evaluate severe post-hepatectomy liver failure in patients with hepatocellular carcinoma
Feng Zhang
- PP1143 The Safety and Feasibility of the "Pan-Gate Theory" Combined with "Regional Hepatic Inflow Occlusion" in Laparoscopic Liver Resection for Hepatocellular Carcinoma: A Single-Arm, Retrospective Study
Chenfenglin Yang, Wen Hu, Yao Li, Pinchu Chen, Qifan Zhang
- PP1144 Prognostic model predicting overt hepatic encephalopathy in patients treated with transjugular intrahepatic portosystemic shunt
Yongqing Chen, Juan Kang
- PP1145 Study on the Feasibility and Significance of Long-duration Intermittent Pringle Maneuver in Laparoscopic Difficult Hepatic Segmentectomy
Yao Li, Chenfenglin Yang, Pinchu Chen, Zhouhang Xu
- PP1147 Managing Difficult-to-Treat Common Bile Duct Stones using Intraductal Electrohydraulic Lithotripsy Using Single Operator Cholangioscopy: Four -year Experience from a Single
Syed Mujahid Hassan, Nasir Mehmood, Rani Tulsi
- PP1148 Robotic pancreaticoduodenectomy is associated with reduced morbidity compared with conventional laparoscopic pancreaticoduodenectomy: A systematic review and meta-
Gang Tang, Rongxing Zhou, Rui Chen
- PP1149 Intraoperative Application of IDUS for Precise Localization of Surgical Margins in Perihilar Cholangiocarcinoma: A Case Report
Yue Liu, Hongguang Wang
- PP1150 Cholangioscopy-Assisted Selective Cannulation of Bile Duct and Closure of Bronchobiliary Fistula: A Rare Case Report
Asmat Ullah, Syed Mujahid Hassan, Sandeep Kumar
- PP1151 Comparative Analysis of Gastric Bypass and Gastric Restrictive Surgery in Obese Patients with Non-Alcoholic Fatty Liver Disease
Pardeep Kumar
- PP1152 Redefining Possibilities: Liver Resection as a Key Strategy for Giant Hepatocellular
Julianus Uwuratuw, Citra Aryanti
- PP1153 Progression-free survival as a surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma: a multicentric retrospective study
DaLong Yang, Ze Su, Chuang Qin, XiaoFeng Dong, YongRong Liang, YongCheng Lai, PeiSheng Wu, YaoZhi Chen, MingSong Wu, WenFeng Li, Ning Peng, JunLiang Nong, YaQun Yu, Kang Chen, FanJian Zeng, ShaoPing Liu, HongBing Yao, Jie Liu, JunJie Ou, TengMeng Zhong, GuoDong Wang, XianShuang Mao, FuQuan Yang, Lin Ye, YiHe Yan, XueYao Wang, MianJing Li, YongYu Yang, ShuChang Chen, QingQing Pang, FuXing Li, Yaojie Li, GuoGao Qiu, WenZhen He, WenTong Lin, JianLi Huang, XiuMei Liang, Liang Ma,
- PP1154 Optimized Outcomes Using the Medial Reduction Technique for the Left Lateral Segment in Infants Undergoing Living Donor Liver Transplantation
Vipul Gautam, Vikram Kumar, Shaleen Agarwal, Subhash Gupta

- PP1155 A Novel Technique of Transhepatic Cholangioscopy-Assisted Negotiation of Post-Liver Transplant Anastomotic Stricture
Syed Mujahid Hassan, Abdul Wahab Dogar, Mohsin Hussain Khoso, Yousuf Memon, Asmat Ullah
- PP1156 Single-cell RNA sequencing reveals immune dynamics after steatotic liver donor
Hao Li, Yiran Xu
- PP1157 Combination of Single-Use Duodenoscope and Single-Use Cholangioscope for Managing Post-liver Transplant Anastomotic Site Leakage: A Case Series
Syed Mujahid Hassan, Abdul Wahab Dogar, Asmat Ullah, Nasir Mehmood, Nadim Bajkani
- PP1158 Transplantation versus hepatectomy for Hepatocellular carcinoma $\leq 2\text{cm}$: The experience of single center
Xuguang Hu
- PP1159 Single-center experience on 1500 cases of liver transplantation
Jinzheng Cai, Qingguo Xu
- PP1160 Frequency and Management of Bile Cast Syndrome in Living Donor Liver Transplant Patients: A Case Series
Syed Mujahid Hassan, Nasir Mehmood, Rani Tulsi, Asmat Ullah, Nadim Bajkani, Sanaullah Kalwar, Abdul Wahab Dogar
- PP1161 Intraductal Electrohydraulic Lithotripsy for the Management of Bile Cast Syndrome in Living Donor Liver Transplant Patients: A Case Series
Syed Mujahid Hassan, Rani Tulsi, Nasir Mehmood
- PP1162 Evaluation of the effect of thrombectomy through umbilical vein for portal vein thrombosis after liver transplantation
Dan Liu, Jinzheng Cai, Bin Wu, Dahong Teng, Yandong Sun
- PP1163 Single-center experience of ex vivo liver resection and autotransplantation for complex liver tumors
Di Zhang, Jianhong Wang, Yong Zhang, Jinzheng Cai
- PP1164 Application of Hisense CAS in preoperative evaluating split and living donor liver volume in liver transplantation
Feng Wang, Imran Muhammad, Shuxian Wang, Jinzheng Cai
- PP1165 Comprehensive Analysis of Complex Liver Transplantation: A Single-Center Experience
Jinzheng Cai
- PP1166 Deciphering the Molecular Crosstalk Between Ferroptosis and Peroxisomes in Macrosteatotic Graft Failure Following Liver Transplantation: A Multi-omics Perspective
Zhengtao Liu, Shusen Zheng
- PP1167 Overcoming ERCP Failures and Navigating Complexities in Post-Transplant Biliary Care: Groundbreaking Insights from the World's Largest Real-World Dataset on Transpapillary Cholangioscopy-Assisted Management of Strictures, Casts, Leaks and Stones.
Syed Mujahid Hassan, Nasir Mehmood, Rani Tulsi
- PP1168 Report of a case of Alagille syndrome combined with axonal Charcot-Marie-Tooth atrophy type 2HH treated with parental liver transplantation
Yuhua Deng, Xiaoke Dai

- PP1169 Transhepatic Cholangioscopy-Assisted Negotiation of Post-Liver Transplant Anastomotic Strictures in Patients with Prior Failed Endoscopic and Radiological Interventions: A Novel Technique with Unprecedented Real-World Data
Syed Mujahid Hassan, Rani Tulsi, Nasir Mehmood, Abdul Wahab Dogar, Mohsin Hussain, Yousuf Memon, Asmat Ullah
- PP1170 Postoperative peak lactate as a robust predictor for short-term prognosis and development of an updated risk prediction model for early graft failure after liver transplantation
Wanqing Wu, Yu Nie, Peihua Cao, Zhaofeng Lin, Manqi Zhuang, Lin Feng, Kebo Zhong
- PP1171 Intraductal Electrohydraulic Lithotripsy Using Single Operator Cholangioscopy for the Management of Intrahepatic Duct Stones Above the Anastomotic Stricture in Living Donor Liver Transplant Recipients: A Case Series.
Syed Mujahid Hassan, Nasir Mehmood, Ahmed Khan, Rani Tulsi
- PP1172 Immunosuppressive Medication Non-Adherence In Liver Transplant Recipients In Viet Nam
Anh Van Nguyen Thi, Thanh Van Le
- PP1173 Managing Biliary Leakages in Living Donor Liver Transplant Recipients After a Failed ERCP Using Single Operator Cholangioscopy: A Case Series
Syed Mujahid Hassan, Nasir Mehmood, Rani Tulsi
- PP1174 Different severity and disparate clinical outcomes between EAD sub-criteria and proposal of a new EAD classification after liver transplantation
Lin Feng, Jinbo Huang, Qiang Zhao, Yu Nie
- PP1175 Expanding Horizons and Overcoming Boundaries: Comprehensive Cholangioscopy Findings from Single-Center Real-World Data
Syed Mujahid Hassan, Rani Tulsi, Nasir Mehmood, Asmat Ullah, Abdul Wahab Dogar, Nadim Bajkani, Rahim Bux Bhatti
- PP1176 Plasma Exchange in Managing Early Allograft Dysfunction Following Adult Living Donor Liver Transplant
Raghuram Nelluri, Harshil Shah, Hemanth Ghanta, Karan Raj Kumar, Anand Nagar, Vinay Kumar Mahala, Vivek Anand Saraswat, Naimish N Mehta
- PP1177 Fluoroscopy Guided Piercing Technique for Negotiation of Occluded post-Living Donor Liver Transplant Anastomotic Stricture Using Blunt Hard End of Guidewire Via Single Operator Cholangioscopy
Syed Mujahid Hassan
- PP1179 LH5: A Multivariable Model for Predicting Adverse Events of Giant Liver Hemangioma
Yongquan Chi, Wenzhu Li, Wei Xu, Shanke Sun, Haipeng Jiang, Junda Li, Jianhua Rao
- PP1181 Diagnostic performance of SWE and predictive models based on SWE for post hepatectomy liver failure: a systematic review and meta-analysis
Lan Zhang

New Technology

- PP1178 Hemoadsorption (CytoSorb®) therapy in a patient with sepsis, acute kidney injury and acute fulminant hepatitis
M GOLAM AZAM
- PP1180 Multi-omics characterization of autophagy-related molecules in liver cancer

Lin Ye

- PP1183 Non-invasive Vascular Geometric Model for Predicting Portal Pressure Gradient in Patients with Cirrhosis: A Multicenter Study
Ling Yang, Jiawei Zhang, Yi Xiang, Chuan Liu, Ziyu Ni, Yechong Huang, Shaoting Zhang, Xiangman Zhang, Xiaolong Qi
- PP1184 Effect of bed head elevation on reducing the incidence of choking under anesthetic endoscopic ultrasonography in patients with submucosal tumors
Nie Xin Hua
- PP1185 Clinical Sentiment Analysis by Large Language Models Enhances the Prediction of Hepatorenal Syndrome in Decompensated Cirrhosis
Mason Lai, Cynthia Fenton, Jessica Rubin, ChiungYu Huang, Mark J Pletcher, Jennifer C Lai, Giuseppe Cullaro, Jin Ge
- PP1186 Construction and validation of a machine learning-based model predicting early readmission in patients with decompensated cirrhosis
Fang Yang, Chao Sun
- PP1187 Metabolic networks and classification models for type C hepatic encephalopathy: a preliminary study
Xin Wen, Tianyi Xue, Xiangsha Kong, Ran Fei, Suzhen Jiang, Zixing Wang
- PP1188 CT-based radiomics model is useful for differentiating porto-sinusoidal vascular disorder with portal hypertension from liver cirrhosis
Yanglan He, Yanna Liu, Qian Yu, Ying Han, Chunlei Fan, Hui Liu, Lingna Lv, Yanjing Wu, Huiguo Ding
- PP1189 A CT-based deep learning radiomics scoring system for predicting the prognosis to repeat TACE in patients with hepatocellular carcinoma: A multicenter cohort study
Yanmei Dai
- PP1190 CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication
Qiang Li, Professor Liang Chen research group
- PP1191 Burning mouth syndrome linked with Parkinson's disease
Dexton Johns
- PP1192 Assessing the causal relationship between plasma proteins and liver function: novel insights into pathological mechanisms and therapeutic implications
Tao Yang, Han Mu Lü
- PP1193 Bioinformatics analysis identifies BST1 as a potential therapeutic target associated with extracellular trapping of neutrophils in patients with acute liver failure
Mengyu Tao, Jiwei Fu, Xiaoping Tao
- PP1194 Association of hemostatic status and liver pathology with portal venous system thrombosis in porto-sinusoidal vascular disease
Yanglan He, Hui Liu, Yanna Liu, Ying Han, Chunlei Fan, Huiguo Ding, Lingna Lv
- PP1195 Elevated Bacterial Vesicles Carrying Virulence Factors and Epitope Mimicry Contribute to Hepatic Injury in Autoimmune Hepatitis
Swati Thangariyal, Sukriti Baweja, Chhagan Bihari, Shiv Kumar Sarin
- PP1196 Clinical use and performance of 7-microRNA panel to diagnose hepatocellular carcinoma

Xiangsha Kong, Zhenyu Wang, Huimin Liu, Chaoran Xia, Haiyan Wu, Nan Feng, David H Peng, Huiying Rao

PP1197 Will Percutaneous Transhepatic Portal Drainage Be the End of Portal Venous Pneumatosis, the 'Disease of the Angel of Death'?

Wei Li, Bo Shao Duan, Ming Yang Han, Yi Kang

PP1198 The multimodality image-guided robotic system for percutaneous intervention of liver: the preliminary clinical application

Fan Xiao, Ping Liang

益路护肝



SAIL TO
THE HEALTH

奋 / 楫 / 扬 / 帆

口服中等剂量天然型维生素E是针对
MASH患者安全有效的基础治疗手段

Moderate doses of oral Vitamin E
is a safe and effective basic
treatment for MASH patients



浙江医药
ZHEJIANG MEDICINE

来益®

- Natural Vitamin E -





膜力修复 思廿升级

Membrane Renewal. 20 Years of Advancing Liver Care

思复® 20载 2005-2025

思复®多烯磷脂酰胆碱注射液——肝细胞膜修复剂

Sifu® Polyene Phosphatidylcholine Injection — A Hepatocyte Membrane Repair Agent



独特的肝细胞膜修复作用机制

Unique Mechanism for Hepatocyte Membrane Repair



肝脏聚集浓度高，直接修复肝细胞膜及细胞器膜，改善肝功能

High Hepatic Accumulation Enabling Direct Repair of Hepatocyte and Organelle Membranes to Improve Liver Function



安全性高，植物提取，专利技术，品质保证

High Safety, Plant-Derived, Patented Technology, Quality Assured



近40个权威临床指南、专家共识、临床路径等共同推荐

Endorsed by Nearly 40 Authoritative Clinical Guidelines, Expert Consensus, and Clinical Pathways

国家医保乙类

国药准字H20057684

海思科以研发创新驱动发展

Haisco Drives Development Through R&D Innovation



E-POSTER

Display time:

17:00, 27 March (Thursday) - 17:45, 29 March (Saturday)

The name marked with an underscore indicates the presenting author.

E-Poster

- EP0001 Stepping up micro-elimination of HCV infection among people who inject drugs through a multisectoral collaborative approach in Hong Kong
Bonnie Chun Kwan Wong, Chin Man Poon, Zenith Hin Yam Wu

Public Health

- EP0002 Cohort Profile: The Chronic Hepatitis B Infection and Liver Disease (HEPCARE) Study in Jiangsu, China
Jiang Jie, Song Ci, Qian Jiao, Wang Siyu, Zhai Xiangjun
- EP0003 Patient Education by Liver Pharmacist improves cirrhosis patients' adherence to therapy in Singapore General Hospital (SGH).
Wong Jia Jie, Yee Mei Ling, Samuel Rocky Candra
- EP0004 The Assessment of Quality of Life in Patients With Chronic Liver Disease
Lkhagvasuren Batbaatar, Doljinsuren Enkhbayar, Bayarmaa Nyamaa
- EP0005 Cost-effectiveness analysis of oral antiviral therapy in patients with indeterminate chronic hepatitis B infection
Haiyan Zhuo, Jin-Shui Pan
- EP0006 Celiac disease and diabetes nutrition care -an e learning module
Dexton Johns
- EP0007 Tuberculosis in Pregnancy after in Vitro Fertilization and Embryo Transfer
Ju Zou, Jie Li, Xiaoxu Wang, Min Liu, Ling Wang, Ruochan Chen
- EP0008 Risk-based screening programme as an effective strategy to identify previously untested people having family members or sexual partners with HBV infection
Chin Man Poon, Zenith Hinyam Wu, Bonnie Chunkwan Wong
- EP0009 Barriers to accessing healthcare for patients with cirrhosis and portal hypertension in Bangladesh: A mixed method study
Md Ismail Gazi, Hema Binte Hamid
- EP0010 Bibliometric Analysis of Air Pollution and Liver Diseases: A Comprehensive Study of Global Research Landscape, Hotspots, and Trends
Xinxin Guo, Wenying Qi, Size Li, Qiuyue Wang, Wei Wang, Shihao Zheng
- EP0012 Does Digital Aging, Social Capital, and Macroeconomic Factors Matter on Recovery Advancement Among Elderly with Liver Disease?
Ester Marnita Purba, Rosinta Hotmaida Pebrianti Purba, Helen Try Juniasti, Yesika Simbolon, Hepri Ardianson Purba, Lintong Hottua Simbolon
- EP0013 Global burden of liver cancer 1990–2021 and 20 years forecast: results from the global burden of disease study 2021
Yikai Wang, Chenrui Liu, Meng Zhang, Liu Yang, Muqi Wang, Xiaqing Zhou, Wenjun Wang, Juanjuan Shi, Yaping Li, Xin Zhang, Xiaoli Jia, Shuangshuo Dang
- EP0014 “She Power” —The Development and Contribution of Female Physicians in Hepatology
Omer Aytikin, CUNDUO JIN, MINGYANG LI, LAI WEI
- EP0015 Global, regional, and national health inequalities in hepatitis B virus-related liver cancer in 204 countries, 1990-2021

Dongjie Wu, Wenliang Lv

- EP0016 Global Burden of NAFLD, NAFLD-related Cirrhosis and NASH-related Liver Cancer from 1990 to 2021: A Systematic Analysis for GBD 2021
Ziwei Guo, Wenliang Lv
- EP0017 Effect of Hemocoagulase Injection Combined with Omeprazole for Hemoglobin Level and Coagulation Index in Patients with Upper Gastrointestinal Bleeding
Zeng Xiao Dong, Cheng Bo, Mei Ting, Liu Wei, Zhang Xiao Chun
- EP0018 The Relationship Between Serum Hyaluronic Acid Levels and Child-Pugh Classification in Patients with Non-Alcoholic Fatty Liver Disease
Xiao Zhihua
- EP0019 The impact of non-alcoholic fatty liver disease and liver fibrosis on cardiovascular disease and mortality in patients with hypertension: results from UK Biobank and NHANES cohorts
Tingya Wan, Yanqiu Huang, Yang Yang
- EP0020 Unveiling the Endocrine Connections of NAFLD: Evidence from a Comprehensive Mendelian Randomization Study
Fan Li, Zhili Wen
- EP0021 A Study on the Incidence of HCC in Mongolia from 2014 to 2023
Dashchirev Munkh-Orshikh, Oidov Baatarkhuu, Nyamsuren Naranzul, Oidov Amarsanaa
- EP0022 Declining new incidence of Acute viral hepatitis in Mongolia
Dashchirev Munkh-Orshikh, Oidov Baatarkhuu, Nyamsuren Naranzul, Jazag Amarsanaa
- EP0023 Dietary Fiber Intake Associated with Risk of Liver Cirrhosis: NHANES 2017-2020
Si Qin Wan, Ying Ping Xie
- EP0024 Intractable ascites with acute renal failure caused by bladder fistula after pelvic fracture
Shisheng Wu
- EP0025 Low-density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease Risk: Identifying Stratum-Specific Thresholds for Cardiovascular Health in the MASLD population
Di Zhou, Li Wang
- EP0026 The causal relationship between liver disease and osteoporosis: A Two-Sample Mendelian Randomization Study
Bukun Zhu, Wei Zhang
- EP0027 Impact of high fasting plasma glucose on liver cancer burden in China: A comprehensive analysis of trends from 1990 to 2021
Zhouwei Zhan, Bijuan Chen, Jingfeng Liu, Zengqing Guo
- EP0028 Age, Period, and Cohort Analysis of 40 Years of Liver Cancer Incidence in Hong Kong (1983–2022)
Jing Chen, Dong Ji, George LAU
- EP0029 Age differences in the association between alcohol consumption and risk of hepatocellular carcinoma: A nationwide
Mi Na Kim, Kyungdo Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
- EP0030 Imaging-Based Modalities for Identifying At-Risk MASH: A Diagnostic Test Meta-Analysis

Zixuan Zhang, Shyna Zhuoying Gunalan, Mei Chin Lim, Mark Dhinesh Muthiah

- EP0031 Dabie bandavirus and Mycoplasma pneumoniae Co-infection: a Case Report
Yasi Tu, Miao Deng, Xueying Zhang, Tianxin Xiang, Daxian Wu
- EP0032 Assessing knowledge, attitude and practices of barbers, tattooists and manicurists regarding prevalence of Hepatitis B and C virus infection
Ariuntuya Jargalsaikhan, Bayarsaikhan Ochirchuulgan
- EP0033 Results of the First Pilot Program to Develop a National Program for the Elimination of Hepatitis C in the Republic of Kazakhstan
Alma Serkpayevna Aubakirova, Gulnara Utepergenovna Kulkayeva , Shakhlo Sobirovna Sadirova, Homie Razavi, Kulpash Sagyndykovna Kaliaskarova, Marzhan Siyazbekovna Zhanasbayeva, Asiya Kairbayevna Turgambayeva
- EP0034 Perspectives on Treatment Endpoints of Future Curative Therapies for Chronic Hepatitis B
J Don Chen, Han Fu Cheng
- EP0035 Associations of accelerated biological aging and genetic susceptibility with risk of incident cirrhosis and hepatocellular carcinoma
Tian Tian, Jing Wang, Jing Ni
- EP0036 Unveiling the Unseen Threat: Understanding How Young Singaporean Adults Perceive Viral Hepatitis
Leon Lim Ming Hsien, Tsang Wan Xuan Isabelle, Joshua Paul Lee Shang Wei, Phua Hwee Pin, Tan Hui Wen, Lo Hok Lui Jasmine, Samuel Nicholas Chia, Wong Zhong Keat, Vera Wee Xin En, Adrian Tan Hang Pin, Ng Hui Lan Doris, Kuo Chao Yew
- EP0037 Quality evaluation of liver cirrhosis related-short video information on social media platforms
Sicheng Yang, Xiaodong Zhou
- EP0038 Progress and Challenges in Preventing Mother-to-Child Transmission of Hepatitis B, HIV, and Syphilis in Mongolia: A Cross-Sectional Study
NCCD Mongolia, Mongolian National University of Medical Sciences, Mongolia, Otgonjargal Otgoo Ganbold
- EP0039 Outcomes of the ongoing Hepatitis Prevention, Control, and Elimination Program in Mongolia
Oidov Baatarkhuu, Purevsod Lkhagvasuren, Nyamsuren Naranzul, Jazag Amarsanaa
- EP0040 Hepatitis B immunization among Mongolian healthcare workers: Nation-wide survey
Nyamsuren Naranzul, Purevsod Lkhagvasuren, Badrakh Burmaajav, Nyamdavaa Khurelbaatar, Jazag Amarsanaa, Oidov Baatarkhuu
- EP0041 The long term follow-up of the efficacy and safety of nucleoside analogues in the prevention of mother-to-child transmission of hepatitis B virus with high viral load
Hua Zhang, Yunxia Zhu, Qian Bian
- EP0042 Challenges in implementing the national HBV elimination program in Bangladesh
Hema Binte Hamid, Md Ismail Gazi

Basic Science & Pathology

- EP0043 WNK4 promotes Huh7 cells viability via secretion of mutation α 1-antitrypsin
Zhenkun Li, Meijuan Wang, Song Yi , Lina Wu, Wei Zhang, Donghu Zhou, Qianyu Zhu, Pingping He, Hengcheng Tang, Bei Zhang, Xiumei Sun, Jian Huang, Xuemei Zhong, Xiaojuan Ou

- EP0044 Differences in Relative Abundance of Mucosa-Associated Colonic Microbiota in Colorectal Cancer with Liver Metastases
Nikko Darnindro, Murdani Abdullah, Ninik Sukartini, Cleopas Martin Rumende
- EP0045 Prolyl endopeptidase regulates PPAR - γ - FGF21-SIRT1 signaling pathway to improve high-fat diet induced non-alcoholic fatty liver disease in mice
Ping Jing Xiong
- EP0046 Liver specific knockout of Neu1 promotes hepatic gluconeogenesis and lithocholic acid accumulation in old mice
Shujun Jiang, Yanliang Zhang, Qianyan Yue, Shiran Mei, Aoyi Wang
- EP0047 Construction Liver Disease Model and it's Application on Drug Screening
Riao Dao, Tegshjargal Badamjav, Bayar Hexig
- EP0048 Deciphering the zebrafish hepatic duct heterogeneity and cell plasticity using lineage tracing and single-cell transcriptomics
Jiarui Mi
- EP0049 The Absorption and Distribution of Oral Hyaluronic Acid for Cirrhotic Animals
Jia-Yi Huang, Kai-Wen Huang
- EP0050 Laminin $\gamma 2$ monomer induces hepatocyte transformation through the EGFR / c-Jun pathway
Nobuaki Funahashi, Hikari Okada, Ryo Kaneko, Taro Yamashita, Naohiko Koshikawa
- EP0051 Exploring the mechanism of ursolic acid in preventing liver fibrosis and improving intestinal microbiota based on NOX2/NLRP3 inflammasome signaling pathway
Linxiang Liu, Qi Liu, Xuan Zhu
- EP0052 Mechanisms of AURKB-Mediated Migration and Invasion in Hepatocellular Carcinoma
Rongkuan Li, Binyang Song
- EP0053 cis-stilbene glucoside induced liver injury through activating ferroptosis pathway
Xue Wang, Yu Su, Xinyan Zhao
- EP0054 B3GAT3 inhibits cell senescence and promotes the progression of liver cancer by modifying CDK4 by glycosylation
Bin Cheng, Zhongji Meng
- EP0055 Research Progress on Acetylation in Liver Cancer
Nian Fang, Caiqing Zhao
- EP0056 Research Progress on Methylation in Gastric Cancer: From Mechanisms to Clinical
Nian Fang, Caiqing Zhao
- EP0057 YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/ β -catenin axis
Xiaodong Shi
- EP0058 High expression levels of CLEC4M indicate poor prognosis in patients with hepatocellular carcinoma
Luo Liu Ping
- EP0059 Study on the effect of LncRNA NEAT1 on hepatic stellate cells
Zhu Haiyan

- EP0060 Cystathionine γ -lyase Downregulation Contributes to Hepatocyte Injury and Dysfunction via Regulation of Histone Lysine Methylation
Wei Zhang, Cichun Wu, Wenhui Liu, Zhengshan Tang, Shifang Peng, Lei Fu, Xin Ni
- EP0061 Cathepsin K alleviates liver fibrosis by inhibiting TGF- β 1-induced HSCs activation and promoting their apoptosis
Zhandong Lin, Yuemin Nan, Yue Shi, Yaoyao Mao, Jiawei Cui, Congyue Zhang, Jingjing
- EP0062 LPS-Induced Lysosomal Membrane Permeabilization Participates in the Apoptosis of Biliary Epithelial Cells
Feng Yang, Tang Ying Mei
- EP0063 The relationships between ECM deposition and hepatic functionalization/ vascularization during fetal Liver development
Tegshjargal Badamjav, Namur Narid, Riao Dao, Bayar Hexig
- EP0064 HERV 2365 as a Prognostic Marker and Therapeutic Target in Intrahepatic Cholangiocarcinoma: Insights into Its Role in Tumor Progression and Immune Microenvironment
Yang Zhong, Feng Jing Liu
- EP0065 Research Progress on Lipid-Associated Macrophages in Liver Diseases
Simiao Li, Jiamin Xu, Yingmei Tang
- EP0066 THE PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
Xiaodong Ge, Hui Han, Romain Desert, Sukanta Das, Zhuolun Song, Sai SB Komakula, Wei Chen, Daniel Lantvit, Natalia Nieto
- EP0067 Temporal Kinome Profiling in Alcohol-Associated Liver Disease Reveals Therapeutic Targets in MAPK-p38 and PI3K-AKT Pathways
Manisha Yadav, Abhishak Gupta, Yash Magar, Neha Sharma, Sanju Rao, Sushmita Pandey, Rimsha Saif, Nupur Sharma, Vasundhra Bindal, Gaurav Tripathi, Babu Mathew, Anupama Parasar, Shiv Kumar Sarin, Jaswinder Singh Maras
- EP0068 HBx protein promote hepatic adiponectin resistance via miR-143-5p/PP2Ac/AMPK pathway
Zekun Zeng, Wenfang Zheng, Peng Hou, Shumei Lin
- EP0070 Mechanism of hepatocyte-specific TRIF knockout ameliorating cognitive dysfunction of HFD-induced MASLD mice based on multi-omics sequencing analysis
Lilin Hu
- EP0071 Effects of Jiedu Liangxue Jianpi Prescription on Gut Microbiota and Lipid Metabolism Against Acute Liver Failure
Ke Shi, Ying Feng, Xiabo Wang
- EP0072 Study on the Mechanism of Rhein in Repairing Pathological Damage and Inflammation in Hepatic Encephalopathy via the Gut-Liver-Brain Axis
Xuemeng Yang, Xiang Li, Donghao Yin, Feili Wei, Ianhua Hu
- EP0073 Exploring the Role of Gut-Derived Metabolites in Liver-Brain Signal Transmission
Xi Zhang, YunLong Yao, LiuJie Zhu, ChenYu Fei

- EP0074 Mechanisms Driving Liver Cancer Through Gut Microbiota Dysbiosis Based on Human and Animal Studies
YunLong Yao, Xi Zhang, LiuJie Zhu, ChenYu Fei
- EP0075 Gut-Liver-Brain Axis in Non-Alcoholic Fatty Liver Disease: Mechanistic Insights
Xi Zhang, Yao Yunlong, ChenYu Fei, LiuJie Zhu
- EP0076 Study on Molecular Mechanisms of Gut Microbiota and Bile Acid Metabolism in Influencing Hepatic Ischemia-Reperfusion Injury and Its Application in Therapy
Meiqi Zhao, Yao Yao, Huiru Liu, Fengmei Wang
- EP0077 SCFAs Alleviate MASH through YY Peptide-Mediated Gut-Liver Axis
Yao Liu, Juan Chen
- EP0079 Multi-Omics Profiling Highlights Nfil3-Driven Gut Barrier and Immune Dysregulation in HCC under Sleep Deprivation
KaiHung Tsai, JuiChen Tsai, HoYu Kuo, PeiHan Fan, WeiHao Peng, LiLing Wu
- EP0080 Bowel obstruction and anticoagulation, is there a link?
Irgen Tafaj, Frenkli Tushi, Oksana Allko, Ermir Tafaj, Liri Çuko, Guido Muharremi
- EP0081 Bacteriological Aspect of the Oral Cavity in Patients with Viral Hepatitis B in the Republic of Armenia for 2024
Vahe Yuri Azatyan, Lazar Karleni Yessayan, Minas Aristakesi Poghosyan, Melaniya Vahagi Shmavonyan, Hasmik Levoni Ghazinyan, Kristina Artashesi Porksheyanyan, Iren Kareni Parunakyan, Tamara Rubeni Gevorgyan
- EP0082 Effect of hepatitis B virus on the secretory function of macrophages
Chaohui Chen, Li Li, Jing Chen, Xiaoqing Tan, Tao Zhang, Qi Yin, Tao Shen
- EP0083 Multifunctional Biomimetic Nanocarriers for Dual-Targeted Immuno-Gene Therapy Against Hepatocellular Carcinoma
Yupeng Sun, Yongyi Zeng, Xiaolong Liu
- EP0084 Direct Visualization of Immune Status for Tumor-Infiltrating Lymphocytes by Rolling Circle Amplification
Yupeng Sun, Yongyi Zeng, Xiaolong Liu
- EP0085 Increased fatty acid synthesis in hepatic macrophages contributes to APAP-induced liver
Xiaoyong Jiang, Hua Wang, Chaojie Hu
- EP0086 Analysis of the Systemic Inflammatory Response in Hepatitis B Virus-related Acute-on-chronic Liver Failure According to Three Definitions
Yating Ding, Zuxiong Huang, Huiling Chen
- EP0087 The Role of LDLR+ Myeloid-Derived Suppressor Cells (MDSCs) in Liver Transplantation
Xin Zhou, Jinzhen Cai
- EP1059 Youthful gut microbiome improves liver function and suppresses HCC in the elderly
Xiaoying Zhong, Rongliwen Ou, Anirban Chakraborty, Tapas K Hazra, Don W Powell, Qingjie

Hepatitis B and Delta

- EP0088 Influential factors associated with the reduction of peripheral blood neutrophils by PegIFN α and predictive analyses
Jiarui Zheng, Bo Feng

- EP0089 Efficacy and Safety of Tenofovir Alafenamide in Patients with HBV-related Hepatocellular Carcinoma following Radical Surgery: A Multicenter, Prospective Clinical Study
Kai Wen, Yongcong Yan, Kai Mao, Zhiyu Xiao
- EP0090 The rate of HBsAg loss in chronic hepatitis B patients with low HBsAg titer treated with tenofovir alafenamide fumarate
Limin Wang
- EP0091 Evaluation of HBs Ag and HBe Ag Seroconversion Rates in Patients Diagnosed with Chronic Hepatitis B: 10-Year Retrospective Analysis
Muge Deniz Toygar, Fatih Karasin, Asena Dogan Ontas, Sila Akhan
- EP0092 Longer-Lasting Sustained Undetectable serum HBV RNA During Nucleos(t)ide Analogue Therapy Is Associated With a Lower Risk of Clinical Relapse in HBeAg-Positive Patients with Chronic Hepatitis B
Xingyu Lu, Shi Liu, Rui Deng, Ge Zeng, Wanying Li, Wendong Liu, Xieer Liang, Jie Peng, Sheng Shen, Rong Fan, Jinlin Hou, Jian Sun
- EP0093 Hepatitis D-Related Liver Disease as a Major Indication for Liver Transplantation: Experience from a New Liver Transplant Program
Zaigham Abbas, Zeeshan Hyder, Darayus P Gazder, Aasia Sabeen, Shamim Nazir, Manesh Kumar
- EP0094 Screening of key candidate complement molecules based on bioinformatics analysis and exploring their correlation with HBV-related hepatocellular carcinoma
Qi Yin, Jianqiong Wang, Xiaoqing Tan, Chaohui Chen, Tao Zhang, Li Li, Tao Shen
- EP0095 Inducible T cell co-stimulator expression contributes to HBV-ACLF morbidity and mortality
Xueping Yu, Yijuan Zheng, Huatang Zhang, Jiming Zhang, Zhijun Su
- EP0096 Functional B cell deficiency promotes intrahepatic HBV persistence and impairs the development of anti-HBV T cell responses
Dan Zhu, Zhili Wen
- EP0097 Hepatitis B surface antigen (HBsAg) loss in patients from China with chronic hepatitis B (CHB) infection treated with peginterferon (PEG-IFN): A systematic literature review
Xin He, Zhiliu Tang, Yingling Liu, Junfeng Wang
- EP0098 Glycosyltransferase B3GAT3 promotes HBV replication and expression through the LAPTM5-lysosomal DDX17 axis
Bin Cheng, Zhongji Meng
- EP0099 Hepatitis B virus-mediated Suppression of Megakaryocyte Differentiation through UBE4B Upregulation and Modulation of p53 and ERK1/2
Yao Xin Fan, HUI Nan Jiang, Qiu JU Sheng, Yan Wei Li, Chong Zhang, Chao Han, Yang Ding, Xiaoguang DOU
- EP0100 CRISPR/Cas12b assisted loop-mediated isothermal amplification for easy, rapid and sensitive quantification of chronic HBV DNA in one-pot
Haipo Xu, Gengping Lin, Ronghua Chen, Zhixiong Cai, Yupeng Sun, Xiaolong Zhang, Bixing Zhao, Yongyi Zeng, Jingfeng Liu, Xiaolong Liu
- EP0101 SLC22A1 exerts anti-HBV effect by activating JAK/STAT pathway
Yu Huiying, Pang Xiuqing, Li Bin, Guo Huili, Wu Lili, Gao Zhiliang

- EP0102 High expression levels of the host gene GLIPR1 inhibit HBV replication
Kunyu Zhao, Lin Wang, Xiangmei Chen, Fengmin Lu
- EP0103 Exploration into the mechanism of the anti-HBV effect of siRNA in conjunction with interferon- α based on a humanized mouse model of type I interferon receptor
Lifen Zhu, Yaping Wang, Pei Zhou, Haiyi Cai, Yujuan Guan, Feng Li
- EP0104 The map characteristics of HBsAg-specific B-cell receptor in the functional cure of chronic hepatitis B
Haiyi Cai, Yaping Wang, Lifen Zhu, Pei Zhou
- EP0105 Changes of hepatitis B core antigen-specific T lymphocytes in patients with chronic hepatitis B after antiviral therapy and drug withdrawal
Bixia Liu, Fen Fen Wang, Peng Chengming
- EP0106 Disulfide bond disruption and antigenicity reduction of HBsAg by C138R mutation in the S gene contribute occult hepatitis B virus infection
Xinlei Chen, Xiaodan Hong, Pengyue Zhang, Chunhui Tao, Zhenhua Zhang
- EP0107 HBx facilitates HBV cccDNA minichromosome remodeling and transcription by interacting with RBBP4 to recruit the NURF complex
Kexin Xu, Haibo Yu
- EP0108 Prediction of Liver-Related Mortality Risk in Patients with Hepatitis B Cirrhosis Based on Severe Sarcopenia and Serum Omics
Lei Yang, ZhaoXia Liu, YuYu Li, Chao Ma, JinHua JING, ZhuanGuo Wang, ZhongHui Ning, SaYiLaXi JieEnSiNuEr, XiaoBo Wang, Qiang Xu, XiaoZhong Wang, Feng Guo
- EP0109 Interferon Induced MiR-7705 Modulates The Anti-virus Activity Of Cholesterol 25-Le Wang, Guangyun Tan
- EP0110 Detection of hepatitis delta virus in sexual secretions
Oyungerel Lkhagva-Ochir, Saruul Enkhjargal, Anir Enkhbat, Oyungerel Ravjir, Nyamtsengel Vangan, Naranjargal Dashdorj, Odgerel Oidovsambuu
- EP0111 A Study on the Clinical Prognosis and Risk Factors of Acute Viral Hepatitis D in Mongolia
Buyandelger Davaakhuu, Badamnachin Batsukh, Munkhbayar Uuganchimeg, Tserendorj Chinbayar, Jazag Amarsanaa, Oidov Baatarkhuu
- EP0112 Cirrhosis staging in patients with HBV and HBV/HDV co-infection: Comparative study in Mongolia
Munkhbayar Uuganchimeg, Badamnachin Batsukh, Buyandelger Davaakhuu, Tserendorj Chinbayar, Oidov Baatarkhuu
- EP0113 Bulk RNA seq and single-cell RNA seq were used to investigate immune genes associated with the risk of viral progression in chronic hepatitis B (CHB) patients with major depressive disorder (MDD)
YaDi Li, Huiguo Ding
- EP0114 Proteomic Analysis of Plasma-derived Exosomes in the Different Disease Phases of Chronic Hepatitis B
Meng Zhao, Saisai Zhang, Ka Ho Wong, Wai Ping Yam, Lot Sum Yeung, Lung Yi Mak, Wan Hin Hui, Man Fung Yuen, Wai Kay Seto
- EP0115 A Study on the Hepatitis B serologic immune status and antibody levels among health care workers in Mongolia

- Naranzul Nyamsuren, Amarsanaa Jazag, Burmaajav Badrakh, Khurelbaatar Nyamdavaa, Baatarkhuu Oidov
- EP0116 Hepatitis B and Delta virus infection and associated risk factors among health workers in Mongolia
Naranzul Nyamsuren, Amarsanaa Jazag, Burmaajav Badrakh, Khurelbaatar Nyamdavaa, Baatarkhuu Oidov
- EP0117 The Burden and Prevalence of Hepatitis D Virus Infection in HBsAg-Positive Populations: Insights from Arkhangai Province, Mongolia
Byambasuren Amgalan, Nyamdavaa Khurelbaatar, Oidov Baatarkhuu
- EP0118 Mechanism of HBx-E2 affecting liver regeneration by regulating exosome-loaded SPHK2
Qingguo Xu, Jinzhen Cai
- EP0119 The Impact of HBV Infection on Gut Microbiota Using Chinese Woodchuck Model with Woodchuck Hepatitis Virus (WHV) Infection
Hui Deng, Bin Zhu, Shiyu Zhang, Bin Zhang, Dilihumar Zaire, Shuting Liu, Shunchang Zhou, Jian Xiong, Xuecheng Yang, Xuemei Feng, Yinping Lu, Xin Zheng, Baoju Wang
- EP0120 Evaluation of the therapeutic efficacy of alafenamide fumarate and tenofovir amibufenamide in the treatment of chronic hepatitis B patients with concomitant hyperlipidemia
Jie Li, Wei Feng Zhao
- EP0121 Cystathionine gamma-lyase as an inflammatory factor and its link with immune inflammation in hepatitis B virus-related liver disease
Chao Jin, Minghuasu
- EP0122 Developing an accurate assay for detection of serum HBV RNA and SP1 variant in CHB based on long-read sequencing
Yueyue Chen, Mengchun Wang, Lijuan Wu, Jingyan Zeng, Zerui Yang, Yuxin Liu, Haijun Deng, Yu Xiang, Lu Han, Yao Zhao, Ailong Huang, Hongchun Luo, Yuan Hu
- EP0123 HBx activates HSC and mediates Liver Fibrosis through HBx/LncH19/PRC2 Signaling Axis
Fengchun Shi, Demin Yu, Xinxin Zhang
- EP0124 Down-regulation of serum exosome-derived miR-375-3p is independently associated with improvement of interface hepatitis and regression of fibrosis in patients with chronic hepatitis
Ran Xu, Sihao Wang, Yan Chen, Yongping Yang
- EP0125 Treatment of Chronic Hepatitis B: Current Status and Chinese Medicine Research
Shihao Zheng, Size Li, Wenying Qi, Xiaoke Li, Xiaobin Zao, Yongan YE, Peng Zhang
- EP0126 Bibliometric Analysis of Hepatitis B Virus and Immune Cell Research (2004-2024): Trends, Hotspots, and Key Gene Networks
Size Li, Wenying Qi, Shihao Zheng, Wei Wang, Qiuyue Wang, Xiaoke Li, HongBo Du, Qiyao Liu, Xiaobin Zao, Yongan Ye
- EP0127 Study on immune regulation and metabolic regulation of TLR8 receptor agonist TQA3810
Yuning Zhu, Yuan Wei, Juan Li
- EP0128 Retrospective Analysis of Clinical Cure in Chronic Hepatitis B Patients Treated with Interferon: Impact of Early Viral Response and Treatment Strategies
Qingxian Cai
- EP0129 Interferon-Stimulated Gene Expression Patterns in Chronic Hepatitis B

- Cisem Cinar, Sibel Yildiz Kaya, Sinem Firtina, Bilgul Mete, Omer Fehmi Tabak, Esra Arslan Ates
- EP0130 HBsAg Clearance is Associated with Sporadic Clustering of CD3-Positive T Cells in the Liver of a Novel Immunocompetent Ist-HBV Mouse Model
Qiong Li, Bo Peng, Jiamin Wang, Jiaqi Yang, Zhongmin Zhou, Zexi Tan, Yinyan Sun, Bin Li, Xiaorong Mao, Wenhui Li
- EP0131 CLINICAL OUTCOMES OF HEPATITIS B VIRUS (HBV) INFECTION IN PREGNANT FILIPINO WOMEN AT A TERTIARY HOSPITAL: AN ANALYTICAL PROSPECTIVE CROSS-SECTIONAL STUDY
Ma. Althea Kathrine Baniqued Elinzano
- EP0132 Post-Vaccination Hepatitis B Immunity in Individuals Aged 10 to 35 Years
Doljinsuren Enkhbayar, Nyam Biziya, Lkhagvasuren Batbaatar, Uranbaigali Dashnyam
- EP0133 Effectiveness and safety of TAF in DNA-positive patients aged >30 years with chronic hepatitis B
Jun Yu, Mengmeng Du, Haiying Sun, Dan Shen, Bing Qiao, Jieyu Liu, Yicheng Wang, Shulun Sun, Xiaobin Wang, Zirong Wen, Yong Zhou, Zhensheng Liu
- EP0134 High Prevalence of Cirrhosis at Time of Hepatitis Delta Virus (HDV) Diagnosis Reflects Gaps and Delays in Timely HDV Testing and Diagnosis Among Veterans with Chronic Hepatitis B Infection in the United States
Zeyuan Yang, Joseph Lim, Janice Jou, Ramsey Cheung, Robert Wong
- EP0135 A retrospective study of Glucocorticoids on outcome of patients with HBV-related acute-on-chronic liver failure
Li Jiajing, Xun Yunhao
- EP0136 Development and validation of a novel prognostic nomogram for hepatitis B virus-related acute-on-chronic liver failure patients receiving artificial liver therapy
Xiaofang Wang
- EP0137 Comparison of the Efficacy and Safety of Tenofovir Fumarate and Tenofovir Disoproxil Fumarate in the Treatment of Patients with hepatitis B-related acute-on-chronic liver failure
Baoyixia Mu Ababakeli, Zhang Jie, Pan Ke Jun, Lu Xiao Bo
- EP0138 Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase: A Systematic Review and Meta-analysis
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You
- EP0139 Predictors of durable HBsAg loss after pegylated interferon-based therapy in HBeAg-negative CHB patients: a multicenter real-world study
Jun Chen, Xueyao Yang, Zebing Huang, Yan Huang
- EP0140 Predictive Factors for Clinical Cure in the Treatment of HBeAg(-) Chronic Hepatitis B or Compensated Cirrhosis: A Prospective Observational Study
Yanqing Lv, Huifan Ji
- EP0141 Development and validation of a nomogram to predict recompensation in HBV-related Acute-on-chronic liver failure: a multicenter retrospective study
Zhang Junchao, Lin Yehong, Zhu Yueyong
- EP0142 Efficiency of traditional Chinese medicine comprehensive therapy in the treatment of hepatitis B-related liver fibrosis

Yuting Diao, Yueying Zeng, Wei Deng, Jing Tang, Chunfang You

- EP0143 Prognostic Value of Combined HBV pgRNA and MELD Score for Mortality in HBV-Related Acute-on-Chronic Liver Failure
Fenlan Chen, Liping Chen, Xiongle Zhang, Wen Lin, Chaohui Liu, Jian Huang, Shizhong Lin
- EP0144 Effectiveness and Safety of Tenofovir Alafenamide for naïve CHB patients with MAFLD
Haifeng Zhang, He Wang, Jing Chen, Lina An, Bing Qiao, Liangliang Wang, Wei Wu, Xiaoyu Wang, Yong Zhou, Zhensheng Liu
- EP0145 Serum sodium, calcium and chlorine on patients with decompensated ascites of hepatitis B cirrhosis Predictive value analysis of the occurrence of recompensation
Jie Chen, Huaqihu Xu, Shanhong Tang
- EP0146 Changes in renal function in CHB patients with Peg-IFN combined with nucleos(t)ide analogs Third Affiliated Hospital of Sun Yat-sen University, Gao Zhi Liang, Deng Hong, Zhao Jin Hua
- EP0147 Study on the efficacy and long-term safety of preventing mother-to-child transmission in HBV-infected pregnant women at different gestational periods
Linling Qi, Mengyan Wang, Chengjing Tao, Shourong Liu
- EP0148 Reducing HCC Risk in CHB: A Meta-Analysis of PEG-IFN with TAF vs. ETV Treatments
Yijie Lin, Huatang Zhang, Xing Wang, Xueping Yu
- EP0149 Short-term efficacy and safety of TAF in DNA-positive patients aged 30 years or older with chronic hepatitis B
Yinong Feng, Li Zhou, Shaoyuan Shi, Zehong Wang, Xuanxuan Wang, Fan D
- EP0150 Effect of NUC therapy on patients with hepatitis B-related decompensated cirrhosis combined with ascites
Jin Yue, Xu Zhao, Minghui Tian, Xiaofeng Shi, Genghua Li, Ying Guo, Lan Zhou, Xiaoqing
- EP0151 TDF and its analogs have not survival advantage over entecavir for patients with Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure
Xinyi Xu, Yu Shi, Jifang Sheng
- EP0152 The coexistence of HBeAg/HBeAb and elevated IL-4 levels correlates with serological conversion in patients with Hepatitis B-induced Acute-on-chronic Liver Failure
Chao Zhou, Simiao Yu, Jingjing Zhang, Shuangnan Fu, Ning Zhang, Man Gong, National Major Project Research Group (No. 2018ZX10725506-002)
- EP0153 The impact of abnormal FPG and lipids metabolisms on Clinical Outcomes of HBV-related chronic liver disease
Yingying Zhao, Song Yang, Huichun Xing
- EP0154 New-generation nucleotide analogues in treating chronic hepatitis B within Asian population: a systematic review and network meta-analysis of randomized controlled trials
Jinlin Hou, Zhihong Liu, Zhizhen Hu, Lei Shu, Fanru Nie
- EP0155 Clinical research on early efficacy and safety of TMF for the treatment of patients with chronic hepatitis B
Xiaoli Tian, Xin Chen, Yan Ni, Songlin Wu, Cunliang Deng
- EP0156 Impact of Regular Hepatocellular Carcinoma Surveillance and Associated predictors on Outcomes in High-Risk Chronic Hepatitis B Patients: A Retrospective Cohort Study
Nattanont Pongsiriwet, Apinya Leerapun

- EP0157 Study on influencing factors of hepatitis B surface antibody level in infants from mothers infected with chronic HBV
Xiwen Yan, Huiyuan Liu, Keng Chen, Keli Yang, Ying Zhu, Yu Chen
- EP0158 Characteristics of Intestinal Microecology and Metabolism in HBV-ACLF Patients
Ke Shi, Ying Feng, Xianbo Wang
- EP0159 Sphingomyelin and Lysophosphatidylcholine Linked to HBV-ACLF Occurrence and Prognosis: A Metabolomics Study
Ke Shi, Feng Ying, Xianbo Wang
- EP0160 Single-Cell RNA Sequencing Reveals Immunological Characteristics of Chronic Hepatitis B Patients Clinically Cured by Sequential Nucleos(t)ide Analog and PEG-IFN α -2b Therapy
Dazhi Zhang, Chang Shu, Zhiling Zhou, Huimin Fan, Yuankang Luo
- EP0161 Decreased bilirubin after artificial liver treatment in HBV-ACLF patients
Guofeng Xu, Wan-Xiang Jiang
- EP0162 Clinical curative effect and safety evaluation of multiple intermittent or continuous combined peg IFN- α -2b treatment for chronic hepatitis B patients
Jie Zhang, Bao Xiao Lu, Baoyixia Mu Ababaikeli
- EP0163 Study on the Viral Recurrence Rate after Treatment with Entecavir and Tenofovir Alafenamide in Patients with HBeAg-Negative Chronic Hepatitis B
Nanchang university, Chengming Guo
- EP0164 Safety of Tenofovir Alafenamide in the Context of Hyperlipidemia and Cardiovascular Diseases: A Nationwide Analysis
Jae Young Kim, Hyuk Kim, Jeong Ju Yoo, Sang Gyune Kim, Young Seok Kim
- EP0165 A Predictive Model for Functional Cure in Chronic HBV Patients Treated with Pegylated Interferon Alpha: A Comparative Study of Multiple Algorithms Based on Clinical Data
Yamei Ye, Yong Lin, Chun Lin, Chen Pan
- EP0166 Long-Term Follow-Up Study on Achieving Functional Cure with Antiviral Treatment in Pediatric Hepatitis B Cirrhosis Patients
Yamei Ye, Chun Lin, Yong Lin, Chen Pan
- EP0167 Effect of Tenofovir Alafenamide switching on metabolic changes in chronic hepatitis B treated with tenofovir disoproxil fumarate: A Retrospective Study
Tawesak Tanwandee, Pasinee Jintanapanya
- EP0168 Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve Mothers: An Observational Study
Xueyao Yang, Jun Chen, Yan Huang, Zebing Huang
- EP0169 The Decrease of 5-hydroxymethylcytosine and Its Clinical Significance in Hepatitis B virus-related Hepatocellular Carcinoma: A Cross-sectional Study
Yansheng Jia, Zhiquan Liu, Muwei Dai, Meilan Cui, Erhei Dai, Calvin Pan
- EP0170 The relationship between hypoglycemia, hypolipidemia, and patients with hepatitis B- related acute-on-chronic liver failure.
Yunming Tang, Hong Cao, Ying Liu

- EP0171 Whole-course management improve diagnosis and treatment rates of chronic hepatitis B in Nanfang Hospital
Chunxiu Zhong, Yao Zhu, Yaqiang Zhang, Leyuan Wu, Xieer Liang, Junhua Yin, Li Liu, Zhihong Liu, Jinlin Hou, Rong Fan
- EP0172 The applicability and clinical characteristics of EASL-CLIF and APASL criteria in Chinese patients with hepatitis B-related acute-on-chronic liver failure
Lingxia Wang, Zuxiong Huang, Yanping Chen
- EP0173 Clinical analysis of chronic hepatitis B complicated with mycoplasma pneumoniae
Chen Gao
- EP0174 Effect of emitinofovir combined with thymidin α 1 treatment on surface antigen in patients with compensatory stage of hepatitis B cirrhosis
Chen Gao
- EP0175 Decompensated HBV-Related Cirrhosis with Multiple Complications Managed Without Liver Transplantation: A Triumph of Medical Therapy and Nutritional Support
Lydia Miriam Abraham, Fadl H Veerankutty, Maya Peethambaran
- EP0176 Misuse of the Lower Limit of Detection in HBV DNA Testing and Anti-HBe Positive Status Will Significantly Impact the Diagnosis of Occult HBV Infection
Bo Wang, Xinru Wang, Li Xiao, Jian Chun Xian
- EP0177 Analysis of efficacy and safety of entecavir combined with pegylated interferon and human interferon in the treatment of patients with chronic hepatitis B
Hongliang Dong, Wei Ye
- EP0178 A case of a patient with chronic hepatitis B treated sequentially with tenofovir combined with pegylated interferon alpha
Zhe Huang, Yaping Wang, Jianping Li
- EP0179 Optimization of Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients with Partial Virological Response to ETV, TDF, or TAF: A Retrospective Analysis
Xueyao Yang, Jun Chen, Yan Huang, Zebing Huang
- EP0180 Antiviral Treatment Efficacy in Chronic Hepatitis B Patients with Liver Biopsy-Confirmed Steatosis
Xi Tang, Honglian Bai
- EP0181 Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights from a Nationwide Cohort Study
HyunBin Choi, JaeYoung Kim, JeongJu Yoo, SangGyune Kim, YoungSeok Kim
- EP0182 Comparative Analysis of Antiviral Treatment Regimens in CHB Patients with a Family History of Liver Cancer
Qinyao Xu, Ting Liu, Xiangyong Li
- EP0183 Analysis of HBV RNA Status in Different Stages of Natural History of Chronic hepatitis B Virus Infection
Han Gao
- EP0184 Correlation Between Serum Ferritin and Hepatitis B Surface Antigen in Chronic Hepatitis B Patients During Peginterferon α -2b Therapy
Chenhao Wang, Meiya Chen

- EP0185 Retrospective Analysis of Clinical Efficacy in 162 Chronic Hepatitis B Patients with Low-Level Viremia
Qiqun Gu, Mei Wu, ChengYi Wan, Wanfeng Yang, Xuehua Sun, Yueqiu Gao
- EP0186 The clinical prognostic value of COSSH-ACLF II model in HBV-ACLF patients receiving abiotic artificial liver therapy
Peng ZHU, Lili WU, Gang QIN
- EP0187 Effect of HDL on clinical features and prognosis of HBV-related hepatocellular carcinoma
Na Liu, Lu Lu Zhou
- EP0188 Investigation on main causes and risk factors of primary hepatocellular carcinoma in Yan 'an area
Na Liu, Lu Lu Zhou
- EP0189 Risks Factors and Establishment and Verification Nomogram Models for Advanced Fibrosis in Chronic Hepatitis B
Shiyi Liu, Wang Dian, Gonying Chen, Shiqin Qian
- EP0190 Comprehensive study of clinical features and laboratory findings of chronic viral hepatitis
Badamnachin Batsukh, Munkhbayar Uuganchimeg, Buyandelger Davaakhuu, Tserendorj Chinbayar, Nyamsuren Naranzul, Jazag Amarsanaa, Oidov Baatarkhuu
- EP0191 Tuberculosis Treatment Related Immune Reconstitution Inflammatory Syndrome resulting in Acute-On-Chronic Liver Failure from Hepatitis B Flare: A Case Report
Leon Lim Ming Hsien, Yang Wei Lyn
- EP0192 The clinical significance of serum Bile acids profile in hepatitis B – related chronic liver
ZhenLuo Jiang, Mengyuan Hu, Xue Li, XiaoYu Qian, ShuHui Nie, You Zhao, LILI Shen, LIYun Fu
- EP0193 Research on TCM syndromes and manifestations of chronic hepatitis B based on factor analysis and cluster analysis
Hailiang Liu, Changquan Ling
- EP0194 Predictors of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues
Liang Wang, Yuliang Zhang, Xin Wan, Xiaoping WU, Shipeng MA, Shanfei Ge
- EP0195 Impact of antiviral effect and initiation time on mother to child transmission in pregnant women with extremely high HBV DNA loads
Wei Yi, Weihua Cao, Gang Wan, Shiyu Wang, Shiyu Wang, Ziyu Zhang, Xinxin Li, Yao Xie, Minghui Li
- EP0196 HBsAg loss in chronic hepatitis B patients with HBsAg decline plateau can be enhanced by PEG-IFN intermittent treatment
Minghui Li, Weihua Cao, Shiyu Wang, Xinxin Li, Ziyu Zhang, Tingting Jiang, Wen Deng, Lu Zhang, Yao Lu, Ruyu Liu, Shuling Wu, Ge Shen, Yuanjiao Gao, Hongxiao Hao, Xiaoxue Chen, Leiping Hu, Mengjiao Xu, Wei Yi, Yao Xie
- EP0197 Efficacy and Immunological Mechanisms of Pegylated Interferon α -2b in Treatment-Naive Patients with Chronic Hepatitis B
Shufen Song, Shuilin Sun

- EP0198 Clinical and Economic Impact of Bacterial Infection and Antibiotic De-escalation on HBV-Related Acute-on-Chronic Liver Failure: A Real-World Study Based on Inverse Probability of Treatment Weighting
Bin Zhang, Dilihmaer Zhayier, Shiyu Zhang, Shuting Liu, Hongming Huang, Jin Tian, Bin Zhu, Baoju Wang
- EP0199 Epidemiology of HDV Infection at UC San Diego Health
Sanjana Sanghani
- EP0200 Aspirin use and risk of HCC and gastrointestinal bleeding in patients with HBV-related cirrhosis: A landmark analysis
Mi Na Kim, Jae Seoul Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
- EP0201 Comparison of Efficacy between Nucleos(t)ide Analogues Therapy and Combination Therapy of Pegylated interferon- α and Nucleos(t)ide Analogues in Entecavir-treated Chronic Hepatitis B Patients with Low-level Viremia
Lilin Wang, Junfeng Lu, Dan Liu, Shan Ren, Xinyue Chen, Zhongjie Hu, Sujun Zheng
- EP0202 Questionnaire survey on implementation and implementation of China Chronic Hepatitis B Diagnosis and Treatment Guidelines (2022 edition)
Hongyu Zhang, Hongxia Liang
- EP0203 Influencing factors of low level viremia in patients with chronic hepatitis B during nucleos(t)ide analogue treatment
Hua Qian, Li SHI
- EP0204 Predictive value of serum HBcrAg for HBeAg seroconversion and transaminase normalization in patients with chronic hepatitis B treated with pegylated interferon α -2a
Xie Huaping, Hu Hao, Huang Zexuan, Gu Yurong
- EP0205 TMF for treatment of elderly patients with chronic hepatitis B
Jun Yu, Yong Zhou, Bing Qiao, Mengmeng Du, Haifeng Zhang, Haiying Sun, Dan Shen, Yicheng Wang, Zirong Wen, Xiaobin Wang, Shu Lun Sun
- EP0206 Characterization and Efficacy of Antiviral Therapy in CHB Patients with Normal Alanine aminotransferase - A Real-World Study
Fang Cuijuan
- EP0207 the predictive value of D-dimer combined with fibrinogen (FIB) in the progression of hepatitis B associated acute-on-chronic preliver failure
Jun Lu, Zhen Zhang, Jun Zhang, Hua Hai Chen
- EP0208 Analysis of the Incidence and Risk Factors of Colorectal Polyps in Patients with Chronic Hepatitis B (CHB) Complicated with Metabolic-Associated Fatty Liver Disease (MAFLD)
Lin Ma, Yan Zhang, Ying Zhao, Yujin Zhu, Wenwen Zheng, Chunyan Wang, Jia Li
- EP0209 Metabolomic Analysis Identifies Altered Amino Acid Metabolism in HBeAg-positive Chronic Hepatitis B Patients Undergoing Long-term Antiviral Therapy
Qi An, Zhengjie Qu, Xueqi Yang, Ruoxi Jia, Jieru Yang, Zehua Zhao, Yuchen Fan
- EP0210 Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in "Grey Zone" Stages of Chinese Patients with Chronic Hepatitis B
Hangyu Ma, Xueyan Yang, Yuxin Tian, Xidong Li, Yingli He, Qiao Yang, Minghua Zheng, Yubao Zheng, Yue Yu, Lingyun Xu, Tao Zhang, Yu Shi, Yuchen Fan

- EP0211 Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: a retrospective cohort study
He Chen, Xiucheng Pan
- EP0212 Efficacy and Safety of Tenofovir Amibufenamide (TMF) in HBV-Related End-Stage Liver Disease (HBV-ESLD) Patients: A Real-world Study
Yuexia Liu, Ziyue Li, Chuan Shen, Caiyan Zhao
- EP0213 A Higher Decrease in HBsAg and Higher Rates of HBsAg Clearance with Peginterferon α -2b in HBeAg-Negative Low-Level Viremia Patients
Fengmin Lu, Suzhen Jiang, Bo Feng, Sujun Zheng, Hao Wu, Junliang Fu, Dong Ji, Yinong Feng, Juanhua Wang, Yao Xie, Xiaobo Lu, Qing Mao, Jie Qiu, Tianyan Chen, Qinghua Lu, Jia Shang, Xiaoping Wu, Chaoshuang Lin, Lingyi Zhang, Yueyong Zhu, Liaoyun Zhang, Qingfa Ruan, Liting Zhang, Zhengbin Zhao, Hong Wan, Jie Peng, Zujiang Yu, Haifeng Yu, Guoxin Hu, Haidong Zhao, Qing Ye, Xiaoying Li, Wenqi Huang, Shuangsoo Dang, Wenling Jia, Chunlan Zhang, Xuezhong Lei
- EP0214 Therapeutic options for persistent low-level viremia (LLV) in patients with chronic hepatitis B: Peginterferon α -2b as a potentially superior option for HBeAg-positive
Suzhen Jiang, Bo Feng, Sujun Zheng, Hao Wu, Junliang Fu, Dong Ji, Yinong Feng, Juanhua Wang, Yao Xie, Xiaobo Lu, Qing Mao, Jie Qiu, Tianyan Chen, Qinghua Lu, Jia Shang, Xiaoping Wu, Chaoshuang Lin, Lingyi Zhang, Yueyong Zhu, Liaoyun Zhang, Qingfa Yuan, Liting Zhang, Zhengbin Zhao, Hong Wan, Jie Peng, Zujiang Yu, Haifeng Yu, Guoxin Hu, Haidong Zhao, Haidong Zhao, Qing Ye, Xiaoying Li, Wenqi Huang, Shuangsoo Dang, Wenling Jia, Chunlan Zhang, Xuezhong Lei, Fengmin Lu
- EP0215 Viral kinetics after nucleos(t)ide analogues withdrawal in HBeAg-positive chronic hepatitis B patients and HBV stable cells reveal the delayed rebound pattern of hepatitis B virus RNA
Wanying Li, Rui Deng, Xingyu Lu, Rong Fan, Xieer Liang, Hongyan Liang, Wanying Liang, Ge Zeng, Yidan Chen, Sheng Shen, Shi Liu, Jinlin Hou, Jian Sun
- EP0216 Analysis of a Case of Chronic Hepatitis B and Its Acute Exacerbation
Liu Qian
- EP0217 Entecavir plus Bushen Granule improved the effectiveness for HBeAg negative chronic hepatitis B: A multicenter, randomized, double-blind, placebo-controlled clinical trial
Longshan Ji, Xin Zhang, Jinghao Zhang, Hua Lyu, Hui Wang, Qin Zhang, Li Li, Xianbo Wang, Chunjun Xu, Peng Guo, Dewen Mao, Weibing Shi, Xiaodong Li, Fenping Li, Wenxia Zhao, Yong Zhang, Jing Wang, Lihong Qu, Xuehua Sun, Man Li, Yueqiu Gao
- EP0218 Persistent low-level viremia (LLV) significantly impairs HBeAg and HBsAg clearance in chronic hepatitis B patients
Fengmin Lu, Suzhen Jiang, Bo Feng, Sujun Zheng, Hao Wu, Junliang Fu, Dong Ji, Yinong Feng, Juanhua Wang, Yao Xie, Xiaobo Lu, Qing Mao, Jie Qiu, Tianyan Chen, Qinghua Lu, Jia Shang, Xiaoping Wu, Chaoshuang Lin, Lingyi Zhang, Yueyong Zhu, Liaoyun Zhang, Qingfa Ruan, Liting Zhang, Zhengbin Zhao, Hong Wan, Jie Peng, Zujiang Yu, Haifeng Yu, Guoxin Hu, Haidong Zhao, Qing Ye, Xiaoying Li, Wenqi Huang, Shuangsoo Dang, Wenling Jia, Chunlan Zhang, Xuezhong Lei
- EP0219 Tenofovir alafenamide vs. tenofovir disoproxil fumarate in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a propensity scores matching analysis
Seong Hee Kang, Young Kul Jung
- EP0221 FACTORS INFLUENCING ANTIVIRAL MEDICATION ADHERENCE AMONG CHRONIC HEPATITIS B PATIENTS IN ADDIS ABABA: A MULTICENTER CROSS-SECTIONAL

Kaleb Assefa Berhane, Lela Alemayehu Gebeyehu

- EP0222 Exploring Serum Ferritin as a potential Indicator for the Severity of Cirrhosis and Hepatocellular Carcinoma
Sumiya Sumiya Byambaatar, Baigal Narantuya, Purevjargal Bat-Ulzii, Oyungereloyungerel Lkhagva-Ochir, Barkhas Batkhuu, Tuvshinjargal Ulziibadrakh, Byambasuren Ochirsum, Naranjargal Nara Dashdorj
- EP0223 Comparative analysis of clinical efficacy and safety of combined pegylated interferon a-2b in 489 patients with chronic hepatitis B
Weihua Ju Hongyi Chen... Zhicheng Zhang
- EP0224 Efficacy comparison of nucleoside (acid) analogues with interferon combination therapy and monotherapy for functional cure in patients with chronic hepatitis B: a meta-analysis of randomized controlled trials
Yaqin Zhang
- EP0225 Identification and Validation of Neutrophil Extracellular Trap-Related Biomarkers in Acute-on-Chronic Liver Failure.
Yunyun Wang, Cheng Peng, Xiaoqin Liu, Minggqin Lu, Wei Lin
- EP0226 Histological Findings in Antigen E Positive and Negative in Chronic Hepatitis B
Mustafa Zanyar Akkuzu, Berat Ebik
- EP0227 A ferritin-based nanodrug achieved HBsAg clearance through autophagy
Yixin Dong, Xizhi Yin, Xiangru Shan, Chuanlong Zhu
- EP0228 Uncovering the silent burden of stigma: lived experiences of individuals with chronic hepatitis B infection
Verity Smith, Menita Asriah, Katherine Fernelius, Joyeta Das, Laura Grant, Vera Gielen, Shannon Keith
- EP0229 Alcohol-induced dendritic cell and it derived exosome promotes specific T cell immunity in HBV transgenic mice and patients with chronic hepatitis B
Xingzhong Miao, Xiaoshuang Zhou, Chaonan Liu, Honglin Shi, Fang Liu, Hongbo Shi, Yingmin Ma
- EP0230 Besifovir Reduces Hepatocellular Carcinoma Risk Compared to Tenofovir Disoproxil Fumarate: Large-Scale Cohort Study
YoonE Shin, JaeYoung Kim, Hyuk Kim, JeongJu Yoo, SangGyune Kim, YoungSeok Kim
- EP0231 History and trends of hepatitis B virus integration: a bibliometrics based visual analysis
Jia Liu, Yanzhen Bi, Shousheng Liu, Longhai Xu, Yongning Xin
- EP0232 Evaluating markers predicting off-treatment wellness and early remission in hepatitis B (EMPOWER-B)
Sarah Bae, Dong Li, Harout Ajoyan, Delgerbat Boldbaatar, Henrik Zhang, Jacob George, Thomas Tu, Mark W Douglas
- EP0233 Preliminary Study on Novel Immunomodulatory Treatment Regimens for Clinical Cure of Chronic Hepatitis B and Predictors of Efficacy
Jiarui Zheng, Bo Feng
- EP0234 Editing of HBV DNA in vitro and in vivo using a CRISPR/Cas9 Base Editor approach
Zak Janetzki, Laura McCoullough, Joan Ho, Thomas Payne, Stewart Fabb, Colin Pouton, Mohamed Fareh, Joesph Trapani, Margaret Littlejohn, Peter Revill

- EP0235 Research Advances in PEG-IFN α -2b for the Clinical Cure of Hepatitis B
Pei Yao Zhang, Ji Hong An
- EP0236 96-week treatment of Pradefovir vs. Tenofovir Disoproxil Fumarate in chronic hepatitis B patients
Yanhang GAO, Junqi NIU, Guicheng WU, Guoqiang ZHANG, Guangming LI, Lvfang YAO, Weidong LIU, Jia SHANG, Yunsong YU, Weifeng ZHAO, Jinlin HOU, Shuangshuo DANG, Shufang YUAN, Guoxing HU, Bei ZHONG, Hui CHEN, Suling CHEN, Xiaoping DONG, Xiangping XIE, Zhenguo LIU, Zong ZHANG, Xinwen SONG, Qing MAO, Yongfang JIANG, Chenxin MENG, Zhaoxu YUAN, Zhijun SU, Qianguo MAO, Yichun BAO, Lei YU, Youwen Med,youwen Tan, Huizhen Med,youwen FAN, Zhiyong Med,youwen JIAO, Xihua FU, Qingfeng SUN, Yuanyuan XU, Xuebing YAN, Jinfeng Liu, Yufeng GAO, Hainv GAO, Guangxia CHEN, Jianwei HUANG, Hesong CUI, Shihong WU, Xiaobo LU, Zhihong LIU, Fengjun LIU, Xiangjun LI, Shuilin SUN, Guofeng DING, Tao HAN, Xiaozhong WANG, Wenhai ZHAO, Mingque XIANG, Xuebing CHEN, Wenyan HE, Shuang LU, Wenting ZENG, Qiming HU, Zhongfeng WANG, Fei KONG, Xinrui WANG, Dengke ZHANG, Weili JIN, Daidi Wang, Chi ZHANG, Xiuhong WEN, Yuan WANG, Nini LIU, Zhongqiang GAO, Yaiuan
- EP1044 Risk factors for portal vein thrombosis in patients with viral liver cirrhosis from Moldova
Adela Turcanu, Lucia Cobiltean, Sanda Buruiana
- EP1056 Association between gallbladder polyps and hepatitis B virus infection
Qianqian Niu, Donghao Yin, Yang Liu, Xueping Zhang, Xiuhui Li
- EP1060 Evaluation of Liver Fibrosis and Predictors of Improved Liver Fibrosis in Patients with HBV-Induced Cirrhosis Treated with TDF
Le Thu Hien, Le Quoc Tuan, Dinh Cong Tiep, Dinh Cong Dang
- EP1061 Effectiveness of Phyllanthus Urinaria Leaves Combined with Tenofovir in Treatment of Chronic Hepatitis B
Le Thu Hien, Le Quoc Tuan, Dinh Cong Dang, Dinh Cong Tiep
- EP1062 AI-Driven Identification of Resistance-Associated Mutations and Geographic Hotspots in Hepatitis Delta Virus Genomes
Prihantini Prihantini, Rifaldy Fajar, Sahnaz Vivinda Putri, Zetrix Ellena Wohlan, Andi Nursanti Ureng

Hepatitis C

- EP0237 Treatment outcome of combination therapy of Pegylated interferon- α 2a, Sofosbuvir and Ribavirin for 12 weeks versus combination of Sofosbuvir and Ribavirin for 24 weeks in HCV Genotype 3 chronic hepatitis & compensated cirrhosis patients
Mainuddin Ahmed
- EP0238 Elucidate the Enzyme Activity in Patients with Hepatitis "C"
Mohsin Shafi, Saira Baloch
- EP0239 An estimated glomerular filtration rate elevation after direct acting antiviral treatment in chronic hepatitis C patients
Gantogtokh Dashjams, Aminerdene Ganzorig, Yumchinsuren Tsendendorj, Dolgion Daramjav, Enkhmend Khayankhyarvaa, Bolor Ulziitsogt, Otgongerel Nergui, Ganchimeg Dondov, Tegshjargal Badamjav, Tulgaa Lonjid, Batbold Batsaikhan, Chia Yen Dai
- EP0240 Changes In Alpha-fetoprotein And PIVKA-II Levels In patients With Non-alcoholic Fatty Liver Disease And Chronic hepatitis C

Sona Sargsyan, Violeta Sargsyan, Hasmik Ghazinyan, Vahe Azatyan, Naira Gyulazyan

- EP0241 Impact of Heated Tobacco Product and Cigarette Smoking on the Oral Cavity in Patients with HCV in Armenia: A Pilot Study
Vahe Yurii Azatyan, Lazar Karleni Yessayan, Minas Aristakesi Poghosyan, Melaniya Vahagi Shmavonyan, Karmen Telmani Sahakyan
- EP0242 Efficacy and safety of tenofovir amibufenamide in the treatment of patients over 65 years of age with chronic hepatitis B
Sasa Chu, Feng Gao, Xing Liu, Cheng Xu
- EP0244 Current status of diagnosis and treatment of patients with genotype 3 chronic hepatitis C and management strategy
Faying Li, Guoying Yu
- EP0245 A rare case of biliary pain as an extrahepatic manifestation of chronic hepatitis C
Tongluk Teerasantipan, Tinh Khampaen
- EP0246 Temporal Dynamics and Treatment Outcomes in HCV-HIV Coinfection: A Multicenter Retrospective Study from Korea
Jae Yoon Jeong, Seongwoo Nam, Su Jong Yu, Jeayeon Park, Na Ryung Choi, Soon Sun Kim, Jae Hyun Yoon, Hyuk Soo Eun, Jonggi Choi, Ki Tae Yoon, Young Kul Jung, Soo Young Park, Geum Youn Gwak, Tae Yeob Kim, Do Young Kim, Ji Hoon Kim, Jin Woo Lee, Jeong
- EP0247 Drug-drug interactions associated with comedication in patients with Hepatitis C virus undergoing direct-acting antivirals: An analysis of administrative claims database in Japan
Daisuke Nakamoto, Yi Piao, Hajime Mizutani, Ryoza Wakabayashi, Satoshi Otokita, Alice Stead, Candido Hernandez, Masahisa Jinushi
- EP0248 Meta-analysis of the renal safety of sofosbuvir in the treatment of chronic hepatitis C patients
Moran Zhang
- EP0249 Studying the relationship between cryoglobulinemia and liver fibrosis in patients with chronic hepatitis C virus infection
Aminerdene Ganzorig, Gantogtokh Dashjamts, Yumchinsuren Tsedendorj, Dolgion Daramjamts, Enkhmend Khayankhyarvaa, Bolor Ulziitsogt, Otgongerel Nergui, Ganchimeg Dondov, Tegshjargal Badamjav, Tulgaa Lonjid, Batbold Batsaikhan, Batbold Batsaikhan
- EP0250 A Study on Enhancing Early Screening for Viral Hepatitis Before Outpatient Endoscopic Examinations: Results and Insights
Feng Jin Liu, Lian Hong Bai, Xing Xiao Mai, Feng Jin Liu
- EP0251 Analysis of clinical characteristics, diagnosis, and treatment status of hepatitis C virus associated hepatocellular carcinoma
Chen Gao
- EP0252 Hepatitis C elimination at a women's drug rehabilitation center - a single center data review
Yueming Xiao, Lei Fu
- EP0253 Declining Prevalence of HCV Infection in Shenyang City, Northeast China, from 2015 to 2022: A Hospital-Based Study Focusing on the Reproductive Population and Mother-to-Child Transmission
Weijia Zhu, Moni Cheng, Yi Yang, Lirong Yang, Hongda Zheng, Jingjing An, Lianrong Zhao, Han Bai

- EP0254 Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir for the Retreatment of Chronic Hepatitis C Patients with DAA Relapse
Jun Chen, Lihua Duan, Xueyue Yang, Zebing Huang, Yan Huang
- EP0255 Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) retreatment achieves sustained virological response in direct-acting antiviral experienced patients with hepatitis C virus: a
Zhu Chen, Li Wang, Chuang Jie Mao, Liang Huang, Yi Lan Zeng, Xue Zhong Lei
- EP0256 Fibrosis Assessment In Patients With Chronic Viral Hepatitis C/Viral Hepatitis B Coinfection Vs. Viral Hepatitis C/Occult Viral Hepatitis B Coinfection: A Monocentric Moroccan
Soukaina Belhaj, Maryeme Kadiri, Driss Azzouzi, Chabib Fatima zahra, Lagdali Nawal, Mohamed Borahma, Fatimazahra Ajana
- EP0257 Hepatitis C And Its Concern Over Tattoo Parlour Popularity
Narendra Gemawat
- EP0258 Analysis of risk factors and construction of prediction model for liver cancer in patients with hepatitis C cirrhosis who achieve sustained virological response
Lirong Yang, Chao Han, Yi Yang, Moni Cheng, Hongda Zheng, Jingjing An, Aisha Yussuf Abdalla, Lianrong Zhao, Han Bai
- EP0259 Attempts to micro-elimination of hepatitis C virus in a tertiary care hospital: timely case identification and linkage to care.
Lijun Chang, Fankun Kong, Yali Ma, Xiuli Wang, Zhiyong Guo, Shihong Wu
- EP0260 HCV Elimination Pilot Program in Hospital to Support Hepatitis C Elimination 2030
Jun Chen, Zebing Huang, Yan Huang
- EP0261 HCV elimination campaign in Yining area, Xinjiang, China.
Jing Chen, Juanjuan Ke, Aikeremu Aierken, Xia Liang
- EP0262 Practice and effect evaluation of multidisciplinary diagnosis and treatment model in the construction of screening, diagnosis and treatment system for hepatitis C in hospitals
Weihua Wang
- EP0263 Government-led, multi-party collaborative HCV elimination project based on the universal medical check-up in Khotan region, Xinjiang, China.
Amina Mamuti, Maimaitijiang Wubuliaishan
- EP0264 A New Model for Hepatitis C Elimination: CDC-Dispatched Follow-Up Specialist at Hospital
Jingcheng Xu, Minchang He, Yongchun Li
- EP0265 Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment
Daisuke Nakamoto, Yi Piao, Hajime Mizutani, Michael Lopresti, Yunosuke Chikamura, Dilip Makhija, Jamie Zagorski, Kyungmin Kwon, Masahisa Jinushi, Yuichiro Eguchi
- EP0266 Relink of diagnosed but untreated HCV patients in Liangzhou District of Wuwei City in Gansu Province
Fu Xin, Zhengqi Wu, Huijuan Wang, Qing Nie, Xiaoyan Zhang, Ruihan Zhang
- EP0267 A New Approach to Eliminating Hepatitis C: CDC and Primary Care Physicians Join Forces to Accurately Identify and Treat Hepatitis C Patients
Xiaoyong Nie, Hui Cui, Yanru Xie, Jin Yang, Wei Zhao, Lingling Qi, Xiulan Li, Miaorong Liu, Lijun Chang, Qingwen Zhang, Xueqing Zhang, Hongmei Li

- EP0268 Self-testing strategy to eliminate Hepatitis C as per WHO's goal: Analysis of disease burden and cost-effectiveness
Sang Hoon Ahn, Gyeongseon Shin, Beom Kyung Kim, Hankil Lee
- EP0269 Exploring the Hepatitis C Elimination Model among Blood Donors: Insights from the Blood Center and Hospital in Shenzhen's Bao'an District
Caiyue Fang, Yang Yu, Chenghui Huang, Yu Zhang, Yizhong Liu, Sheng Zhang, Suqin Gan, Cui Zhang
- EP0270 Beijing Hepatitis C Elimination Plan Implementation Evaluation: A Retrospective Study in a Tertiary Hospital.
Zhao Fan, Yang Rui Feng
- EP0271 Analyzing the Treatment Cascade in Hepatitis C in South Korea
SangBong Ahn, JooHyun Oh
- EP0272 Elimination of Hepatitis C (HCV) with a Holistic Liver proposal in substance users (PWUD) in Mexico, a model for Latin America
Graciela Elia Castro Narro, Wendy Vanessa Sánchez Hernández, Carmen Torres Mata, Monserrat Lovaco Sánchez, Maria Fernanda Bautista Garín, Mario Cesar García Alanís, Ricardo Gutierrez Monterubio, Juan Adrian Torres Diaz, Nayeli Cointia Flores García, Yahve Ivan López Méndez, Eva Juarez Hernandez, Valeria Ailyn Cortes Mollinedo, Daniel Fernando Pérez Larios, Alethse De la Torre Rosas, David Kershenobich Stalnikowitz
- EP0273 Challenges and Gaps in the Hepatitis C Cascade of Care: A Retrospective Study at Dr. Kariadi General Hospital, Indonesia
Lily Chandrawati, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso, Hery Djagat Purnomo
- EP0274 Government-Led Early Screening, Prevention, and Treatment Program for Viral Hepatitis: Results and Insights
Miaoxin Lu, Dahua Guo, Xiaoting Liang, Hai Lan, Xian Tang, Guoyong Lai
- EP0275 Cost-effectiveness analysis of direct-acting antivirals for chronic hepatitis C from a societal perspective and across age subgroups in South Korea
Jihyun An, Won Sohn, Joo Hyun Sohn, Yong Kyun Cho, Sang Hoon Ahn, Jinhye Cha, Dilip Makhija, Rob Blissett, Seung Up Kim, Adam Igloi-Nagy
- EP0276 Current status of HCV Micro-elimination in a detoxification center in Chongqing, Southwestern China
Tianju Li, Xiaohua Tan, Hua Li, Jing Pan, Mingque Xiang, Xianghui Yang, Wangjie You, Rongzhen Wan
- EP0277 Collaboration between CDC and Designated Hospitals Contributes to the Elimination of HCV in High- prevalence Areas
Wenfang Yuan, Yajing Zhang
- EP0278 Triple Safeguards to Improve HCV Screening and Referral Rates in Hospitalized Patients
Feng Jin Liu, Hong Hong Chen, Hong Lian Bai, Xing Xiao Mai
- EP0279 Latest Research Progress in Hepatitis C Therapy
Pei Yao Zhang, Ji Hong An

Others Hepatitis, Infections and the Liver

- EP0280 Global, regional, and national burden of acute hepatitis E, 1990–2021: a systematic analysis for the global burden of disease study 2021
Chenyi Liu, Chao Cai, Mingqin Lu, Taiting Shi, Shu Li, Jiawen Chen, Shiwen Wu, Huifang Zhang
- EP0281 Current situation of fatty liver disease in Mongolia
Tuvshinzul Zulaa Battogtokh
- EP0282 Effects of Disorders of Glucose and Lipid Metabolism on Clinical Outcomes of Viral Infectious Diseases (SARS-CoV-2 and Hepatitis B Virus Infections)
Yingying Zhao, Song Yang, Huichun Xing
- EP0283 One case of autoimmune hepatitis patient repeatedly infected with COVID-19
Wang Kun
- EP0284 Epidemiological And Clinical Features Of Hepatitis E Among HIV Positive People And MSM
Xiaobo Lu, Epargul Tursuntuhti, Rongjiong Zheng, Kejun Pan, Mamatali Ubul, Xiaolong Lu
- EP0285 Clinical features and outcomes of Epstein-Barr viral hepatitis
Sukbae Kim, Hyundeok Shin, Ilhan Song
- EP0286 Global research trends of liver regeneration from 1998 to 2023: a bibliometric analysis
Jiayann Shan, Shanhong Tang
- EP0287 Application of ARIMA model in predictions of incidence of Hepatitis E in Yunnan Province
Billian Zhu, Yingmei Tang, qinnian LI
- EP0288 Predicting the onset of Hepatitis E virus-induced Acute Liver Failure: a 13 and half years' clinical data from a regional infectious disease treatment center in China
Chong Chen, Liujuan Ji, Jun Ma, Weixia Li, Xuhua Jiang, Liang Chen
- EP0289 Preliminary study of mitochondrial dysfunction in patients with hepatitis E virus-triggered acute-on-chronic liver failure
Chong Chen, Liang Chen
- EP0290 The Application of Insect Drugs in Liver Diseases in Traditional Chinese Medicine
Fan E Cheng, Xiaobin E Zao
- EP0291 Clinical and Epidemiological Characteristics of 61 Hepatitis E Patients
Lihua Yuan, Minghui Sun, Rui Hua, Yue Qi, Fang Xu, Hao Zhou
- EP0292 Zinc compounds could suppress hepatitis A virus replication
Tatsuo Kanda, Reina Sasaki-Tanaka, Shuji Terai
- EP0293 Detectable HBV PreS deletion mutants at baseline predicted delayed immune reconstitution and increased inflammation in HIV/HBV co-infected patients undergoing long-term ART
Xianglong Lan, Quanyang Gao, Haisheng Yu, Linghua Li, Fengyu Hu
- EP0294 Burden of Disease from Hepatitis B, Hepatitis C, and NAFLD in the Asia-Pacific Region, 1990-2021
Shufang Pan, Xiang Cai, Kaixiang Zhou, Jianyun Zhu, Yutian Chong
- EP0295 Case report: A rare case of pyruvate kinase deficiency and Crigler-Najjar syndrome type II with a novel pathogenic variant of PKLR and UGT1A1 mutation
Huan Wu, Long Wu, Quan Zhang, Fang Bao Zhang

- EP0296 Q Fever: A Case Report Emphasizing Diagnostic and Therapeutic Challenges
Lihua Lin, Keng Chen, Bo Li, Guofang Tang, Ying Zhu, Huiyuan Liu
- EP0297 A CASE REPORT ON DUAL PORTAL HYPERTENSION IN HEPATIC TUBERCULOSIS
Amal Joseph, Prajob Prasad, Jeby Jacob, Harikumar R Nair
- EP0298 The neutrophil extracellular trapping net showed high activation and depletion in patients with chronic and acute liver failure
Zuxiong Huang, Huiling Chen, Dongpeng Bao, Yating Ding
- EP0299 Budd Chiarii syndrome associated with Immunoglobulin light chain systemic Amyloidosis: Case report
Ruzanna Lorik Safaryan, Lusine Mardanyan, Hasmik Ghazinyan, Aren Nersisyan, Ashkhen Keryan, Aram Mirijanyan
- EP0300 Thoracic Cryptococcus Infection in a Healthy Elderly: A Case Report
Gao Yi Dan, Chen Gong Ying
- EP0301 Diagnosis, treatment and care of liver cirrhosis complicated by necrotizing fasciitis
Ying Mei Tang, Ting Gu
- EP0302 Hepatic failure with Providencia rettgeri infection: case report
Yan Fangfei, Han Meiwen, Guan Qianting, Guo Qinghao, Zeng Zhilin, Yao Junxia, Xi Dong
- EP0303 Liver cell carcinoma and high-density lipoprotein: a Mendelian randomization study
Weifeng Zhou
- EP0304 Analysis of Clinical Characteristics and Risk Factors for Blood Culture-Positive Klebsiella Pneumoniae Liver Abscess
Huifang Zhang, Shiwen Wu, Ruicong Chen, Shanshan Li, Mingqin Lu
- EP0305 Analysis of the application value of systemic inflammatory response index in patients with acute-on-chronic liver failure co-infection
Hui Li, Haibin Su
- EP0306 Cytomegalovirus Infection Leading to Liver Failure: A Case Report
Lihua Yuan, Minghui Sun, Rui Hua, Yue Qi, Fang Xu, Hao Zhou
- EP0307 A Case of Acute Liver Failure in Hemophagocytic Lymphohistiocytosis managed with Therapeutic Plasma Exchange
Desiree Carriaga Lacuin
- EP0308 Methyl-binding domain protein 2 represses HLA-DR expression on monocytes, facilitating secondary infection in patients with HBV-ACLF
Xiaoqin Liu, Xueyun Zhang, Qiankun Hu, Xueping Yu, Jian Sun, Mingqin Lu, Jiming Zhang, Yuxian Huang
- EP0309 Follicular helper T cells and autoimmune hepatitis
Wei Shi Ya
- EP0310 Asymptomatic gallbladder agenesis
Lijuan Chen, Xiaobing Wu, Guangchuan Wang
- EP1055 Mortality associated with multidrug-resistance in Enterobacteriaceae infections in end-stage liver disease: a propensity score-weighted retrospective study
Jinghuan Lin, Ling Wang, Shibin Zhu, Jialin Li, Zhihua Liu, Jing Hu

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Toxicity

- EP0311 Interleukin-24 improves metabolic dysfunction-associated steatohepatitis by promoting autophagy
Jiawei Cui, Yaoyao Mao, Zhandong Lin, Congyue Zhang, Shaoya Li, Yuyuan He, Yuemin
- EP0312 COFFEE CONSUMPTION IN ARMENIAN PATIENTS WITH MAFLD
Narina Sargsyants
- EP0313 Research Progress on the Treatment of MASH with GPX2-Mediated Ferroptosis Pathway
Junjiao Xu, Minghao Liu
- EP0314 Identification and Validation of Disulfidptosis-associated RNA methylation regulators as Novel predictive Biomarkers of severe fibrosis in steatotic liver disease
Jiang Jingjing, Weiwei Lou, Qing Li, Ziqiang Li, Qing Xie, Rongtao Lai
- EP0315 Role of gut microbiota-associated gut-derived factors in metabolic-associated fatty liver
Jun Qin
- EP0316 The YBX1/CD36 positive feedback loop-mediated lipid accumulation drives metabolic dysfunction-associated steatotic liver disease
Qingqing Zhang, Qichao Ge, Xingpeng Wang, Hui Dong, Lu Lungen
- EP0317 Hepatocyte-derived exosomes load miR-106b by DHX9 and activate hepatic stellate cells via DAB2/actin cytoskeleton in MAFLD
Sun Ji, Zhang Dianbao, Li Yiling
- EP0318 New advancements in research of non-alcoholic fatty liver disease
Mingyi Dong, Zhili Wen
- EP0319 No causal relationship between serum Vitamin D levels and Alcoholic Liver Disease: A Two-Sample Bidirectional Mendelian Randomization Study
Huan Wu, Long Wu, Quan Zhang, Can Li, Yang Hai Li, Fang Bao Zhang
- EP0320 Identification of Potential Metabolic Biomarkers for Metabolic Associated Steatohepatitis by Bioinformatics Analysis and Machine Learning
Xie Hao Ran, Wei Lai
- EP0321 Circular RNA Sequencing Identifies CircRNA as a Novel Biomarker in Nonalcoholic Fatty Liver Disease
Yiyun Jiang, Xueli Zhang, Bokang Zhao, Shuhong Liu, Qingsheng Liang, Chaonan Guo, Ying Sun, Li Zhu, Meiling Li, Yan Li, Haiyan Wei, Ping Liang, Junqi Niu, Zhengsheng Zou, Lina Jiang, Jingmin Zhao
- EP0322 Prophylactic effects of nutrition, dietary strategies, exercise and lifestyle on nonalcoholic fatty liver disease
Hao Song, Xiangyong Hao, Xin Su, Jian Li, Youbao Ye, Cailiu Wang, Xiao Xu, Guanglong Pang, Wenxiu Liu, Zihan Li, Tian Luo
- EP0323 Relationship between MASLD and H. pylori Infection
Linfang Zhang
- EP0324 The mechanism whereby Id-1 promotes the development of non-alcoholic fatty liver disease
Lijun Wan

- EP0325 Protective Effects of GLP-1 Receptor Agonists on MASLD Through the Primary Bile Acid Biosynthesis Pathway
Yang Zhou, Shutong Wu, Chenlu Yang, Di Zhou, Li Wang
- EP0326 Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population
Jiarui Zheng, Bo Feng
- EP0327 Effects of Berberine on Liver Injury and Hepatocyte IL-17RA/NF- κ B Signaling Pathway of Diabetes Mellitus-related MASH
Xin Wang, Yuhan Wang, Ning Yao, Xin Wang, Ying Qin, Yunjuan Wu, Yajie Chen, Ying Su
- EP0328 Molecular mechanism of SETDB2 promoting the progression of metabolic dysfunction-associated steatohepatitis by regulating macrophage polarization
Baiyi Liu, Zilong Wang, Xiaoxiao Wang, Feng Liu, Huiying Rao
- EP0329 Effects of Angelicae Sinensis Radix Combined with Paeoniae Radix Alba on Antioxidant and Hepatocytes Regeneration in Mice with High-Fat Diet-induced MASH
Yuhan Wang, Qi Zhu
- EP0330 Exploring the Potential of KHK RNA Interference Patent in MAFLD Therapy
Huiwen Ren, Che Bian, Zhilin Luan, Haibo Zhang, Ruijing Zhang, Huili Zhu
- EP0331 Suppression of IRS-2 aggravated hepatocyte senescence by regulating autophagy in high-fat diet state
Qingxin Guo, Ting Yao, Luying Tian, Leer Shen, Jinmei Chen, Xiaohua Chen
- EP0332 Role of SIRT1-Mediated Macrophage Polarization in NMN-Mediated Alleviation of HFD-Induced Fatty Liver
Tingting Shen, Yuelan Wu, Hongming Nie, Qin Zhang
- EP0333 Identification of m6A-associated autophagy genes in non-alcoholic fatty liver
HUANG ZIQING
- EP0334 Ileal FXR knockdown ameliorates nonalcoholic fatty liver disease in rats via modulating bile acid metabolism mediated by gut microbiota
Junjun Wang, Jiaqi Gao, Hui Dong, Lungen Lu
- EP0335 Neutrophil damage liver regeneration after hepatectomy in MASLD mice through Neutrophil extracellular traps
Shuang Wang
- EP0336 Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice
Jian Zhang, Huiwen Wang, Nianqi Zhou, Jinqing Liu, Lijian Tao, Zhangzhe Peng, Gaoyun Hu, Lei Fu, Shifang Peng
- EP0337 β -Hydroxybutyrate Enhances Malate Dehydrogenase 2 β -Hydroxybutyrylation to Alleviate Mitochondrial Dysfunction and Hepatic Steatosis in MASLD
Jingshu Cai, Wenxuan Li, Chunli Wu, Hongbin Ni, Wenjun He, Yuanfeng Gu, Yuehua You, Jiayu Li, Xiaoqiu Xiao, Li Ma
- EP0338 Electroacupuncture at Zusanli (ST36) alleviates metabolic dysfunction-associated steatotic liver disease (MASLD)
Yuanyuan Luo, Hao Wang, Weifen Xie, Xin Zeng

- EP0339 Generative AI Models for Virtual Staining in MASLD Histology
Cheng Xianda, Ng Cheng Han, Gwyneth Soon, Eunice Tan, Daniel Huang, Nicholas Syn, Mark Muthiah
- EP0340 Impact of Maternal Obesity and Trained Immunity on Offspring Liver Disease Development
HyunPhil Shin, Sanghui Park, Moonhyung Lee
- EP0341 Functional analysis of normal prion proteins (PrPC) in metabolism-associated fatty liver disease (MAFLD)
Qiongya GU, Hayato URUSHIMA, Tsutomu MATSUBARA, Hideto YUASA, Atsuko DAIKOKU, VuThai Hung, NguyenDuc Vien, Chiho KADONO, Hikaru NAKAI, Kazuo IKEDA
- EP0342 ENHO knockout mice exhibit sex-dependent progression of MAFLD
Yingkun Qiu, Yimeng Wang, Yuehong Huang
- EP0343 Study of the Association Between Subclinical Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease
Aarsha Sadar, Ajith Roni Damodaran, Arunraj C. N., Jayaprakash R.
- EP0344 Reverse of fatty liver disease by cultured Ginseng Cambium Stem Cell (gCMC) in HFD induced MASLD mice
Jincheng Wang, Weijin Gong, Qingzhou Huang, Yinong Ye
- EP0345 The regulatory role of iron regulatory protein 2 on systemic iron metabolism in iron overload disease
Pengyao Yang, Ning Zhang, Qin Ouyang, Anjian Xu, Yanmeng Li
- EP0346 YAP in LSECs promotes macrophage recruitment and M1 polarization via inhibiting CD151 during MASLD progression
Junjun Wang, Yufei Yang, Zhenyang Shen, Guangwen Chen, Hui Dong, Xiaobo Cai, Lungen
- EP0347 Mechanistic studies on the regulation of fatty acid oxidation by liraglutide via SIRT1 in hepatocytes
Yuting Zhang, jie wang,bo shen,ruijing wang
- EP0348 The Bidirectional Relationship Between Sarcopenia and MAFLD: Insights From Animal Models and Molecular Analysis
Yeyu Song, Yameng Liu, Cen Xie, Jiangao Fan
- EP0349 Gender-based difference in patterns of Metabolic Dysfunction-Associated Steatotic Liver disease associated hepatocellular carcinoma induced by diethylnitrosamine combined western diet in mice
Ke Yin, Yuyun Song, Ran Fei, Xu Cong, Baiyi Liu, Zilong Wang, Xin Ai, Minjun Liao, Yayun Ren, Kutbuddin Akbary, Qiang Yang, Xiao Teng, Huiying Rao, Xiaoxiao Wang, Feng Liu
- EP0350 MICROBIAL-DRIVEN HUMANIZED MICE MODELS OF STEATOSIS LIVER DISEASE PROPAGATE LIVER FIBROSIS VIA GUT BARRIER DYSFUNCTION AND PORTAL SYSTEMATIC INFLAMMATION
LI Ming, ZHOU Lei, KOH Xiu Qi, ZHU Mengtong, Anna XinYi NG, Nur HalisahBinte JUMAT, Jazleen LEO, LIU Lin, Gwyneth ShookTing SOON, YockYoung DAN, Jonathan WJ LEE
- EP0351 Global trends and research hotspots of immune cells and MAFLD: a bibliometric and visual analysis from 2004 to 2024
Shihao Zheng, Wenying Qi, Size Li, Qiuyue Wang, Qiyao Liu, Xiaoke Li, Jiixin Zhang, Xiaobin Zao, Yongan YE, Peng Zhang

- EP0352 Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review
Shihao Zheng, Peng Zhang
- EP0353 Age-dependent regulation on serum extracellular vesicles in obese and lean patients with metabolic associated fatty liver disease
TzuYi Chen, SinTian Wang, ShuRong Chen, KungChia Young, XingMin Li
- EP0354 Identification of a liver fibrosis and disease progression-related transcriptome signature in non-alcoholic fatty liver disease
Lixin Pan, Wei Tian, Zhihao Huang, Jianrong Li, Jiayong Su, Qiuyan Wang, Xiaohui Fan, Jianhong Zhong
- EP0355 Unraveling the Protective Role of Sirt7 in Macrophage/Kupffer Cell Response to Metabolic Dysfunction-Associated Steatohepatitis
Zhenyuan Yang, Mahit Karadigudha
- EP0356 The link between ambient air pollution and fatty liver disease and its metabolic components is established
Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You
- EP0357 Novel Risk Stratification Model for Metabolic Associated Fatty Liver Disease Using Multiple Biomarkers: A Comprehensive Risk Assessment Approach
Kwang Min Kim, Kwang Cheol Koh
- EP0359 OBESITY WITHOUT OBESITY OR HOW THE ACCUMULATION OF FAT IN THE LIVER AFFECTS HUMAN BODY COMPOSITION
Ilona Minosayn, Olga Tarasova, Lahana Ravoori, Elena Kuharewa
- EP0360 CLINICAL, BIOCHEMICAL, AND INSTRUMENTAL CHARACTERISTICS OF METABOLIC DYSFUNCTION-ASSOCIATED LIVER CIRRHOSIS
Mirkhozhi Khuzhamurotov, Sayfullo Avezov
- EP0361 Association between nontraditional lipid parameters and the risk of type 2 diabetes and prediabetes in patients with nonalcoholic fatty liver disease: from the national health and nutrition examination survey 2017–2020
Jierui Liu, Nuobei Zhang
- EP0362 Molecular Mechanisms and Treatment Strategies of Non alcoholic Fatty Liver Disease
Haiyu Yan
- EP0363 Differential risk of hepatocellular carcinoma based on antidiabetics in patients with metabolic dysfunction-associated fatty liver disease
HanAh Lee, HyungJoon Kim, YoungYoun Cho, JeongHoon Lee, SeungUp Kim, Hwiyoung
- EP0364 Survey and correlation analysis on Body Mass Index and Gamma-glutamyl transpeptidase levels among adults in northern China
Chaojian He, Qingqiang Yi, Lei Zhao
- EP0365 The Redefinition of Metabolic Dysfunction-associated Fatty Liver Disease May Improve the Detection of Liver Fibrosis in Children
Jingmin Zhao, Wei Li, Lina Jiang, Meiling Li, Dan Zhao, Li Zhu, Bokang Zhao, Yisi Liu, Yan Li, Yiyun Jiang, Shuhong Liu, Ping Liang, Junqi Niu
- EP0366 Analysis of the Correlation between Helicobacter pylori Infection and Non-Alcoholic Fatty Liver Disease

Tao Li

- EP0367 Age, Serum Interleukin-10 and Immune Disorders are Related to the Survival of Patients with Wilson Disease-related Acute-on-Chronic Liver Failure
Yifan Zeng, Lin Chen
- EP0368 The sex-specific causal role of visceral adipose tissue in metabolic dysfunction-associated steatotic liver disease susceptibility: results from mendelian randomization
Yutian Cao, Xiqiao Zhou
- EP0369 Better diagnostic efficacy of NFS score in NAFLD/MAFLD patients with advanced liver
Hong Yu, Wei Sun, Jing Dou, Litifu Abudumijiti, Guzainuer Yiliyaer, Zhonghui Ning, Qiang Xu, Huiling Du, Xin Da, Xiaozhong Wang, Feng Guo
- EP0370 Clinical studies on the development of recompensation in alcoholic decompensated liver cirrhosis
LI YA JING, Fangfang Duan, Xiao en XIN, Hong mei Zu, Song Yang
- EP0371 Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma
Kegong Xiong, Kunyu Ke, Jinfeng Kong, Taishun Lin, Qingbiao Lin, Su Lin, Yueyong Zhu
- EP0372 Exploring the severity and risk factors of non-alcoholic fatty liver disease based on the SAF scoring system
Hui Ming Li, Xin Xin Li
- EP0373 GLYCEMIC CONTROL, STEATOSIS AND FIBROSIS IMPROVEMENT AFTER SUSTAINED VIROLOGIC RESPONSE IN TYPE 2 DIABETES PATIENTS WITH CHRONIC HEPATITIS C: A THREE-YEAR FOLLOW-UP STUDY
Chingchu Lo, MeiTsu Chen, Jowjyh Hwang, Chienhung Lin, Hsushen Cheng, YiTang Liao, PoYen Hsiao, ChenYu Lo
- EP0374 Incidence of MAFLD-associated HCC in MAFLD patients with different fibrosis stages: a systematic review and meta-analysis
Yulei Lin, Shousheng Liu, Keqing Feng, Yongning Xin
- EP0375 Association of the MBOAT7 rs641738 gene polymorphism with susceptibility of MAFLD and CAD
Chengfeng Li, Zhenzhen Zhao, Jie Zhang, Shousheng Liu, Yongning Xin
- EP0376 Sex-specific differences in the effect of remnant cholesterol on diabetes in patients with metabolic dysfunction-associated fatty liver disease: NHANES 2017-March 2020 Pre-Huangxin Zhu, Zhili Wen
- EP0377 Different fibrosis parts correlated with different types of vascular proliferation in two independent MASLD cohorts
Zhengxin Li, Yayun Ren, Qiang Yang, Xiao Teng, Dean Tai, Ian R Wanless, Jorn M Schattenberg, Chenghai LIU
- EP0378 The comparison of the consistency of FibroTouch and FibroScan in the diagnosis of metabolic associated fatty liver disease and liver stiffness
Xinhe Zhang, Yiling Li
- EP0379 Non Invasive Parameters compared to FibroScan for the assessment of liver stiffness and controlled attenuation paramter (CAP) in patients with Steatotic Liver Diease
Amal Joseph, Harikumar R Nair

- EP0380 The effect of sodium-glucose cotransporter-2 inhibitors in treatment of metabolic dysfunction-associated fatty liver disease in patients with type 2 diabetes mellitus
Elena Kukhareva, Eliza Mankieva, Olga Tarasova, Anastasiya Zhuravleva , Irina Kurnikova , Rita Politidis
- EP0382 Aspirin use and the risk of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort and Mendelian randomization study
Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, JeongHoon Lee, Su Jong Yu, JungHwan Yoon, Yoon Jun Kim
- EP0383 Risk factors of atherosclerotic plaque formation in metabolic dysfunction-associated steatotic liver disease
Weihao Peng
- EP0384 The relationship between genotype and clinical phenotype in patients with Wilson's disease
Minghui Sun, Rui Hua, Lihua Yuan, Fang Xu, Yue Qi, Hao Zhou
- EP0385 Association between Hearing Loss and MAFLD among Older Adults: Results from NHANES 2017–2020
Linjun Chen, Jiayi Mao, Hanxiang Zhong
- EP0386 Analysis and study of risk factors related to the progression of metabolic associated fatty liver disease: A retrospective cohort study
JUNRAN YANG, Zhenhua Zhou
- EP0387 A Comparison of the Clinical and Pathological Traits between NAFLD Patients with and without Obesity
Rong Zhang, Jiensinue Sayilaxi, Shicheng Ren, ABuLaJiang AiLiFeiRe, Xiaobo Wang, Xiaozhong Wang
- EP0388 Body weight history and the prognosis of the elderly population with fatty liver disease
Xinyi Yang, Lihua Wang, Jing Zhan, Su Lin
- EP0389 New algorithms for predicting significant liver fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease and chronic hepatitis B
Shan Hong, Lei Sun, Hongshan Wei
- EP0390 A case of early-onset liver fibrosis with PYROXD2 variation
Zhenyao Jiang, Junping Shi, Xiaoxiao Mi
- EP0391 ASSOCIATION BETWEEN ULTRASOUND AND VCTE-CAP DETERMINED STEATOSIS WITH DISEASE SEVERITY IN A CANADIAN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) COHORT
Chinmay Bera, Nashla Hamdan, Mina Fakhriyehasl, Kartik Jhaveri, Keyur Patel
- EP0392 The Association Between Consumer Behavior and MAFLD: Mediating Role of the Healthy Dietary Index 2020
Lihua Wang, Xinyi Yang, Jing Zhan, Su Lin
- EP0393 Change in cT1 following interventions in MASLD: A systematic review and meta-analysis
Anneli Andersson, Rohit Loomba, Elizabeth Shumbayawonda, Cayden Beyer, Sofia Mouchti, Raj Vuppalachchi, Mukesh Harisinghani, Saima Ajaz, Amreen Dinani, Amitava Banerjee, Mark Muthiah, Andrea Dennis, Michele Pansini

- EP0394 BMI and liver enzyme distribution of biochemical indicators of metabolic syndrome in adults in Northern China
Chaojian He, Qingqiang Yi, Lei Zhao
- EP0395 Study on clinical efficacy of Lanzhang Granules in the treatment of non-alcoholic fatty liver disease and its regulation of intestinal flora
YUCHEN FANG, LIANJUN XING
- EP0396 The role of the thyroid gland in metabolic-associated fatty liver disease (MAFLD): current status and prospects
Mingyang Jin, Xiaoxiao Mi, Junping Shi
- EP0397 Metabolic related fatty liver disease and its components and clinical characteristics and related risk factors analysis of colorectal cancer
Quanwei Xu, Wei Ni
- EP0398 The Utility of Biomarkers in Diagnosing MASH
Hiroshi Numao, Masayoshi Ko, Koji Shimaya
- EP0399 A Mendelian Randomization Study on the Correlation between NSAIDs and NASH
Yi Li, Jihong An
- EP0400 The Correlation between NSAIDs and NASH: A Meta-Analysis Study
Yi Li, Jihong An
- EP0401 Meta-Analysis Study on the Impact of NSAIDs on the Pathological Process of NASH: Research Proposal
Yi Li, Jihong An
- EP0402 Analysis on the Prevention of NASH Progression by NSAIDs
Yi Li, Jihong An
- EP0403 Correlation Analysis between BMI Index and Sleep Disorders in Patients with Non-alcoholic Fatty Liver Disease: Insights from NHANES 2017-2020
Guowang Li, Yachun Xue, RU Wang, Hui Guo
- EP0404 Clinical and Biochemical Distinctions Between Anti-Mitochondrial Antibody-Positive Metabolic Dysfunction-Associated Fatty Liver Diseases and Primary Biliary Cholangitis
Xin Zeng, Tingting Lv, Xiang Shu Li, Sha Chen, Buer Li, Xinyan Zhao, Weijia Duan, Jidong
- EP0405 External validation of PLEASE score for hepatocellular cancer prediction in advanced metabolic dysfunction-associated fatty liver disease
Huapeng LIN, Seung Up Kim, Vincent Wong
- EP0406 Factors influencing survival of patients with Steatotic Liver Disease
Benedix Sim, Daniel Q Huang, Mark Dhinesh Muthiah, Cheng Han Ng, Hirokazu Takahashi
- EP0407 Association Between Serum Uric Acid Levels and Lipid Profiles in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Cross-Sectional Analysis
Guowang Li, Yachun Xue, Hui Guo
- EP0408 Comparative Analysis on Clinicopathological Features of MASLD and MetALD related Hepatocellular Carcinoma
Junke Hu, Liang Zhang, Xiangmei Chen, Liming Qi, Lei Sun
- EP0409 Epidemiological Trends and Risk Analysis of NAFLD in Southern Taiwan

- ChiaYen Dai, PoCheng Liang, ChungFeng Huang, ChihWen Wang, ChungFeng Huang
- EP0410 Study on the Correlation Between Liver Fatty Change Severity and Pancreatic Elastase in Patients with Fatty Liver
Ziying Xu, Tong Dang, Jing Wang
- EP0411 Trivandrum Cohort of Metabolic dysfunction Associated Steatotic Liver Disease (Cohort 3)
Shenoy T Kotacherry, Leena K B, Jayakumar P Pillai
- EP0412 Early Asian contributions to the formation of the concept of steatotic liver disease, rediscovery of the Itoh's paper
Takeshi Nihei, Ken Ohkawara, Hiroshi Kashimura
- EP0413 Clinical Observation on the Treatment of Hyperlipidemia Nonalcoholic Steatohepatitis by Jianpi Huatan Qushi Prescription Combined with Hufu Tongbian Scrapping Therapy
Siyang Wang, Dongfang Shang, Chenlu Zhao, Hao Wu, Minghao Liu, Wenxia Zhao
- EP0414 Exploring the role and mechanism of endoplasmic reticulum stress in children with NAFLD based on the 'San jiao' theory
Tong Liu, Shanzheng Li, Sutong Liu, Lihui Zhang, Wenxia Zhao
- EP0415 IMPROVEMENTS IN NON-INVASIVE MARKERS OF MASH AND FIBROSIS WERE ASSOCIATED WITH HISTOLOGICAL MASH RESOLUTION WITH TIRZEPATIDE TREATMENT OF NON-CIRRHOTIC MASH
Rohit Loomba, Jerome Boursier, Elisabetta Bugianesi, Raj Vuppalanchi, Masato Yoneda, Eric Lawitz, Yuanyuan Tang, Bram Brouwers, Mark Hartman, Arun Sanyal
- EP0416 High expression of ANT1 enhances the exercise sensitivity of nonalcoholic fatty liver disease by efferocytosis and lipolysis
Yiting Qian, Wenzhuo Yang
- EP0417 Mendelian Randomization and Single-Cell Sequencing Reveal NEDD4 as a Key Protective Factor in Non-Alcoholic Fatty Liver Disease
Zhao Fang Cheng, Li Rong Kuan
- EP0418 The impact of rs738409 and rs2896019 SNPs of PNPLA3 in Metabolic dysfunction-Associated Steatotic Liver Disease
Dolgion Daramjav, Yumchinsuren Tsendendorj, Baljinnyam Tuvdenjamts, Yesukhei Enkhbat, Ganchimeg Dondov, Enkhmend Khayankhyarvaa, Otgongerel Nergui, Gantogtokh Dashjamts, Bolor Ulziitsogt, Tegshjargal Badamjav, Batbold Batsaikhan, Davaadorj Duger, Khurelbaatar Nyamdavaa, Tulgaa Lonjid
- EP0419 Clinical Risk Factors for Advanced Fibrosis in Pathology-Proven Steatotic Liver Disease: a Retrospective Study
ChenTe Huang, ShangChin Huang, ChiaLin Kang, TanSia Wang, HauJyun Su, TungHung Su, TaiChung Tseng, ShihJer Hsu, ChunMing Hong, ChenHua Liu, HungChih Yang, PeiJer Chen, JiaHorng Kao, ChunJen Liu
- EP0421 Tryptophan Metabolites in the Progression of Liver Diseases
Maria Reshetova, Pavel Markin, Svetlana Appolonova, Ismail Yunusov, Oksana Zolnikova, Vladimir Ivashkin
- EP0422 Effect of Jianpi Huazhuo Fang on a mice model with metabolic associated fatty liver disease: Gut Microbiota and Metabolomics Analysis
Rong Zhang, Shi Ren, Xiaozhong Wang

- EP0423 Fibrosis in MAFLD: Unveiling New Targets for Antifibrotic Therapy
Xi Zhang, YunLong Yao, LiuJie Zhu, ChenYu Fei
- EP0424 Correlation between FTO gene polymorphisms rs9939609 and Metabolic dysfunction-associated steatotic liver disease
Yumchinsuren Tsedendorj, Dolgion Daramjav, Yesukhei Enkhbat, Ganchimeg Dondov, Enkhmend Khayankhyarvaa, Gantogtokh Dashjamts, Otgongerel Nergui, Aminerdene Ganzorig, Bolor Ulziitsogt, Tegshjargal Badamjav, Batbold Batsaikhan, Shiirevnyamba Avirmed, Tulgaa Lonjid
- EP0425 Extended Evaluation of Saroglitazar in Metabolic Dysfunction-Associated Steatotic Liver Disease: Efficacy and Safety Insights
Sandesha Ghorpade, Santosh Hajare
- EP0426 Study on the Protective Mechanism of Dihydroquercetin in Regulating the Autophagy-NLRP3 Inflammasome Axis in Metabolic Dysfunction-Associated Steatohepatitis
Ao Shen, Bing Wu, Pengfei Wu, Cheng Zhang, Yuqiao Zeng , Li Wang, Likun Wang
- EP0427 Dihydroquercetin's Impact on Lipid Metabolism and Inflammatory Responses in Metabolic dysfunction-associated steatohepatitis : An In-Depth Study
Bing Wu, Pengfei Wu, Cheng Peng Zhang, Yuqiao Peng Zeng , LI Wang, Ao Shen, Likun
- EP0428 Establishing a Model of Metabolic Associated Fatty Liver Disease in THLE2 Hepatocytes through Free Fatty Acid Intervention
Qiuyue Wang, Wenying Qi, Size Li, Shihao Zheng, Xiangyun Zou, Xiaobin Zao, Qiyao Liu
- EP0429 Prevalence of Liver and Cardiovascular Conditions in Patients with Type 2 Diabetes Mellitus (T2DM).
Owen Altamisy Naharudin, Pei Yiyang, Mark Cheah, Yong Mong Bee, Hong Chang Tan, Kevin Teh, George Goh
- EP0430 Network pharmacology-based study on the mechanism of action of San Qi-Dan Shen tablets in the treatment of MAFLD
Mengwei Li, Da Wang, Dan Zhang, Jinxiu Li, Rongting Zhao, Lanqing Ma
- EP0431 Advances in lipid metabolism mediated macrophage regulation of fatty liver disease associated with metabolic dysfunction
Cai Fenqing
- EP0432 Prevalence of Liver and Cardiovascular Conditions in Patients with Type 2 Diabetes Mellitus (T2DM)
Owen Altamisy Naharudin, Pei Yiyang, Mark Cheah, Yong Mong Bee, Hong Chang Tan, Kevin Teh, George Goh
- EP0433 Early diagnosis model for nonalcoholic fatty liver disease: bioinformatics analysis and experimental validation
Kanglong Zhang, Yiming Gan, Yihua Chen, Zhiwei Jiang, Qiao Lei, Shuqin Yu, Jie Zheng, Guoxin Hu
- EP0434 Establishment and validation of MAFLD machine learning non-invasive prediction model based on intelligent Chinese medicine tongue diagnosis
Shaojie Duan, Jialiang Chen, Shukun Yao
- EP1045 Low short-chain-fatty-acid-producing activity of the gut microbiota is associated with hypercholesterolemia and liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease

Xinlu Cao, Oksana Zolnikova, Roman Maslennikov, Elena Poluektova, Maria Zharkova, Vladimir Ivashkin

EP1054 Augmenter of liver regeneration (ALR) crotonylation assists in mitochondria-ER contact to alleviate hepatic steatosis

Xiao Lin Wang, Jia Hao He, Ping Xie, Yuan Wu, Ling Yue Dong, Wei An

EP1058 Pemafibrate modulates peroxisome proliferator-activated receptor alpha and prevents alcohol-associated liver disease

Joseph George, Takashi Saito, Mutsumi Tsuchishima, Mikihiro Tsutsumi

Liver Injury and Toxicity

EP0435 Multi-center retrospective analysis of clinical characteristics and efficacy evaluation of patients with alcoholic hepatitis treated by corticosteroid in China

Liwei Zhuang, Fangfang Duan, Xingjun Chen, Yongping Zhang, Jinling Dong, Song Yang

EP0436 Bioimpedance phase angle in patients with alcoholic cirrhosis Child-Pugh class A without oedema syndrome

Nikolay Kisliy, Svetlana Kislaya, Larisa Bychkova

EP0437 The Impact of The Number of Comorbidities on The Prognosis of Alcoholic Cirrhosis

Wei Li, Fangfang Duan, Song Yang

EP0438 Systematic review and meta-analysis of traditional Chinese medicine treatment for non-alcoholic fatty liver disease

Jiaxuan Xu, Herong Cui

EP0439 Bifidobacterium pseudocatenulatum alleviates alcoholic fatty liver disease, strengthens the intestinal barrier and modulates the gut microbiota and metabolites

Yating Li, Liya Yang, Lanjuan Li

EP0440 Xiaoyao Powder Ameliorates Alcoholic Liver Injury by regulating Oxidative Stress and lipid metabolism.

Xinyue Zhang, Jiale Qin, Qinglan Wang

EP0441 Construction of a Non-invasive Diagnostic Model for Alcoholic Cirrhosis Complicated with Spontaneous Bacterial Peritonitis Based on Machine Learning

Qin Zhang, Yuyong Jiang, Feixiang Xiong, Hao Yu

EP0442 Predictors of In-hospital Mortality among Cirrhotic Patients in Ethiopia: A Multicenter Retrospective Study

Abate Bane Shewaye, Tamrat Petros Elias, Kaleb Assefa Berhane

EP0443 Late-Onset Immunotherapy-Related Hepatotoxicity Vs. Drug-Induced AIH In A Filipino Patient With Diagnosed Breast CA St 4 On Trastuzumab: A Case Report

Chanelle Niebres Filio, Celina Celeste Adraneda

EP0444 A case of severe liver injury with long incubation period caused by albendazole

Chaojian He, Qingqiang Yi

EP0445 HDAC6 Inhibitor ACY-1215 Improves Gefitinib-Induced Liver Injury via Inhibiting TLR4/MyD88/MAPK/ NF- κ B Pathway

Jianglei Li, Mengmeng Xu, Shifeng Fu, Liu Han, Feihong Deng, Rong Li, Siyi Wang, Deliang Liu, Yuyong Tan

- EP0446 Analysis of the clinical characteristics of liver injury in 153 patients with initial treatment of lung cancer
Yaqian Mao, Dingying Zhou, Ziwei Yuan, Yuanbin Zhong
- EP0447 Impact of Liver Injury on Hepatocyte Regeneration and Its Mechanisms
Bin Zhou
- EP0448 The role and mechanism of C3aR1 in acute-on-chronic liver failure
Qiuli Xie, Wenli Xu, Tingfeng Xu, Zhi Tan, Pengzhan Deng, Lijuan Liao
- EP0449 A case of rifampicin in the treatment of persistent dyssecretion of hepatocytes
Siqi Liu, Zhenjing Jin
- EP0450 Activatable chemiluminescence probe based on four-arm PEG-conjugated-pyropheophorbide-a for in vivo autofluorescence-free imaging of peroxynitrite
Xiaolong Zhang, Jianmei Ke, Yongyi Zeng, Xiaolong Liu
- EP0451 Salazopyridine protects Con-A induced liver injury in mice by inhibiting MAPK pathway
Zhihui Wang
- EP0452 Risk factors of liver injury caused by immune checkpoint inhibitors in patients with lung
Xinyu Li, Gongying Chen
- EP0453 Characteristics Changes of fecal metabolome in patients with pulmonary tuberculosis before and after anti-tuberculosis treatment
Shuting Wang
- EP0454 STING modulates HBV-related acute-on-chronic liver failure by mediating autophagy and macrophage polarization
Hao Zhang, Qin Wang, Qiang Zhou
- EP0455 Impact of Serum Lipid Levels on Immune Therapy-Related Liver Injury in Patients with Pan-cancer: A Cohort Study
Lei Jing, Lv Minzhi, Zhang Ningping, Liu Tianshu
- EP0456 Efficacy and Hepatotoxicity of Tumor Treatment with Immune Checkpoint Inhibitors - A meta-analysis
Wang Dian, Gao Yi Dan, Li Jing, Zhang Xiang Bo, Liu Shi Yi, Li Xin Yu
- EP0457 Kupffer cells regulate iNKT cells through IL-12 to mitigate the extent of APAP-induced damage in the liver
Yinling Li, Shuang Wen, Xichen Chen, Wene Zhao, Shuwei Li, Junping Shi, Haitao Wang
- EP0458 Multiple cell-type interactions drive invariant NKT cell hepatitis
Jiaxin Tan, Yong He, Man Li
- EP0459 Development and Validation of a Machine Learning-Based Clinical Prediction Model for Monitoring Liver Injury in Patients with Pan-Cancer Receiving Immunotherapy
Yi Wang, Jing Lei, Ningping Zhang, Minzhi Lv, Tianshu Liu
- EP0460 A rare clinical case of drug induced cholestasis due to Tribulus Terrestris supplementation
Aren Nersisyan, Ashken Keryan, Ruzanna Safaryan, Hasmik Ghazinyan, Lusine Mardanyan
- EP0461 A case of drug-induced liver and renal failure death caused by rifampicin and literature
Lu Jin, Huang Han Ping

- EP0462 Spectrum of drug-induced liver injury: Experience from Nepal.
DILIP SHARMA, Sudhamshu KC, Niyanta Karki
- EP0463 DDX3X-GSK3 β Interaction Regulates Liver Regeneration and Recovery from Acetaminophen-Induced Liver Injury in Mice
Yinkang Mo, Zihao Fan, Ling Xu, Feng Ren
- EP0464 A Case of Concealed Cholestatic Drug-Induced Liver Injury from Anabolic-Androgenic
Xinhua Ren, Qi Wang, Wen Xie
- EP0465 Metagenomic Analysis of Gut Microbiota in Drug-Induced Liver Injury
Kaini He, Xiaoyan Guo
- EP0466 Lcn2 mediates mesenchymal stem cell's small extracellular vesicles to inhibit hepatocyte ferroptosis in acute liver failure
Shibo Meng, Jing Zhang, Bingliang Lin
- EP0467 Arsenic-Induced Porto-sinusoidal Vascular Disorder: A Case Report of Multisystem Involvement and Diagnostic Challenges
Guanhua Zhang, Weijia Duan, Yu Wang, Xinyan Zhao
- EP0468 Rosuvastatin-Induced Drug-Induced Liver Injury: The "Adventure" of the 49-Year-Old Woman's Liver and Genetic Factors
Yu Xinlei
- EP0469 Risk Factors and T Cell Receptor Repertoire in rheumatic patients with Liver Injury Induced by Tripterygium Wilfordii
Qiong Luo, Rong Rong Li, Meng Li, Ji Han Huang, Guang Yao Li, Yan Chun He, Zu Shan Zhou, Jing Xian Zhang, Dong Hao Xie, Dong Yi He, Yan Yan Tao, Sun Xin, Cheng Hai Liu
- EP0470 Effect of intestinal flora and its metabolite Trimethylamine N-oxide on hepatocytes
Rui Sun, Jiayi Ma, Xiaoru Wang, Yuying Cai, Lei Li, Shanshan Wang
- EP0471 Efficient analysis of hepatotoxicity and mechanisms of environmental pollutants with network toxicology and molecular docking strategy: P-phenylenediamine antioxidants and their quinone derivatives as an example
Haihang Dong, Yinqiang Zhang, Yujie Cai
- EP0472 Clinical features and risk factors of brucellosis complicated with liver damage: a real-world
Xiaobo Lu, Tongtong Shao, DiLina YiBulayin, Jing Chen, Li Zhang, Ying Wang, Rongjiong Zheng, Xiangming Hu, Wenting Xie
- EP0473 Rare Hepatic Subcapsular Hematoma Post-ERCP in an Adult Healthy Female
Jesiah Janelle Delos Reyes, Celina Celeste Adraneda
- EP0474 Clinical Characteristics of 131 Wilson's Disease Patients Across Gender and Age Groups
Lu Zhang, Jieru Peng, Qiwen Zhang, Wencheng Long, Yao Dong, Yueshan Wang, Zhong Li, Lu Long, Yaxin Li, Qiaoling Jin, Lin Deng, Lin Cai, Dailan Yang, Juan Liao, Chunxia Yang
- EP0475 A Clinical Study of serum sCD25 used to predict short-term prognosis in patients with Acute-On-Chronic Liver Failure
Fu Yi Wei, Wang Rong Qi
- EP0476 Study on the Mechanism of Punicalagin in Attenuating CCl₄-Induced Acute Liver Injury by Inhibiting Mitophagy
Chen Dongmei, Huang Yuehong

- EP0477 A study of factors influencing health-related quality of life in patients with wilson's disease based on the Tobit model
Yao Dong, Jieru Peng, Wencheng Long, Lu Zhang, Qiwen Zhang, Yueshan Wang, Zhong Li, Yaxin Li, Qiaoling Jin, Lin Cai, Juan Liao, Chunxia Yang
- EP0478 Exploring the Relationship between the Optimal Number of Artificial Liver Treatments and the Prognosis of Patients with Acute-on-Chronic Liver Failure: A Retrospective Cohort Study
Xiangnan Teng, Yuanji Ma, Kunping Cui, Lingyao Du, Changhai Liu, Qingmin Zeng, Tengyue Hu, Hong Tang, Lang Bai
- EP0479 Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study over Five-Year
Jieru Peng, Lu Zhang, Yao Dong, Lin Cai, Zhong Li, Linshen Xie, Juan Liao, Chunxia Yang
- EP0480 Clinical Characteristics and Risk Factors Analysis of Sepsis-Related Liver Injury
PanJinliang ZhengRongjiong LuXiaobo
- EP0481 A Multicenter Real-World Study evaluating the efficacy of Polyene Phosphatidylcholine injection in improving liver function among patients with liver injury
Ning Lin, Jinghang Xu, Yifan Han, Zhan Zeng, Yanyan Yu, Xiaoyuan Xu
- EP0482 Clinicopathologic Features of Immune Checkpoint Inhibitors Associated Liver Injury
Hua Ying Lai, Sha Huang, Lu Ping Lin
- EP0484 Rare gene mutation: the hidden 'culprit' that triggers venous thrombosis - [MAST2]
Cao Sirui
- EP0485 Jiedu Huayu Extract Alleviate Acute Liver Failure via Promotion of GPX4 Expression and Inhibition of D-GalN/LPS-Induced Ferroptosis
Yong Lin, Fuli Long

Immune-Mediated Chronic Liver Diseases

- EP0486 Primary Biliary Cholangitis Combined with Multiple Synchronous Primary Malignant Tumors: A Case Report and Review of the Literature
Xue Zeng, Hong Wang
- EP0487 IgG4-related hepatopathy mimicking hepatocellular carcinoma: a case report and literature review
Tingfeng Yu, Yongtong Wu, Ning Tan, Jingwen Wang, Yanyan Zhuang, Lingyun Wang
- EP0488 Characteristics of and Predictors Associated with Recompensation in AIH-related Decompensated Cirrhosis
Xiaolong Lu, Lin Han, Caizhe Gu, Ying Sun
- EP0489 Evaluation of Cyclosporine A and Mycophenolate Mofetil for Patients with Autoimmune Hepatitis at Risk of Myelosuppression
Tianyu Mao, Xiao Xiao, Xiong Ma
- EP0490 T-MSCs Alleviates Autoimmune Hepatitis in a ConA Mouse Model by Inhibiting Follicular Helper T Cell Activation
Long Xu, Wanwan Shi, Jiandan Qian, Yanjie Lin, Xinghuan Fu, Jiaxi Ma, Yan Wang, Guiqiang Wang

- EP0491 A comparative analysis of two histological criteria for diagnosing autoimmune hepatitis in Chinese patients
Huayang Zhang, Haoyu Wen, Lishuang Lin, Yu Chen, Zunguo Du, Xiong Ma, Qi Miao
- EP0492 ANALYSIS OF PERIPHERAL BLOOD PBMC CYTOKINE LEVELS IN DIFFERENT STAGES OF CHRONIC HEPATITIS B PATIENTS
Huan Cai, Hongyu Jia
- EP0493 The role and mechanism of TNFAIP3 regulating mitophagy in autoimmune hepatitis were studied
Lijia Wang
- EP0494 Development and validation of a non-invasive prediction model of autoimmune hepatitis in patients with liver diseases
Li Wang, Yongfeng Yang
- EP0495 Ulcerative colitis and autoimmune hepatitis: a two-sample Mendelian randomization study
Zixiang Huang, Zhili Wen
- EP0496 Paeoniae Radix Rubra ameliorates concanavalin A-induced hepatic injury through modulating NLRP3 signaling pathway and Treg/Th17 balance
Yan Zhong, Zherui Liu, Ying Sun, Shuhong Liu, Binxia Chang, Jianyu Li, Lin Han, Yun Zhu
- EP0497 Clinical characteristics and influencing factors of patients with AIH significant liver fibrosis (\geq Wei Sun, Hong Yu, Jing Dou, Zhuanguo Wang, Zhonghui Ning, Xiaobo Wang, Qiang Xu, Jingtao Li, Feng Guo, Xiaozhong Wang
- EP0498 Bach2 Inhibits Tc1 Cell Differentiation by Regulation T-bet Transcription Function in Autoimmune Liver Disease
Xinyu Weng, Shouhan Yao, Yelei Cen, Yanning Liu, Guohua Lou
- EP0499 A case report of hepatolenticular degeneration easily misdiagnosed as AIH
Xiao Hong LI, RongZhu
- EP0500 Injured hepatocytes-derived extracellular vesicles cooperate with macrophage to promote
Jie Sun, Yi Shen, Yanyi Zheng, Li Yang
- EP0501 Research on the prescription regularity and pharmacodynamics mechanism of traditional Chinese medicine for the treatment of autoimmune hepatitis based on data mining and network pharmacology
DI GUO
- EP0502 A case report of IgG4-RD: multiple organs involved biliary tract, pancreas, salivary and
Derek NganWa Wong
- EP0503 The effectiveness and safety of low dose glucocorticoid treatment in AIH-related decompensated cirrhosis.
Yuxiao Zou, Xiayu Gan, Hongli Xiong, Ruizao Zheng, Lamei Ke, Linqian Feng, Huihong Yu
- EP0504 Increasing prevalence of autoimmune hepatitis in Canterbury, New Zealand: a population-based study
Catherine Tian, Catherine Stedman, Michael Burt, Jeffrey Ngu
- EP0505 Investigating the Molecular Mechanism of Yinchenhao decoction in Treating Autoimmune Hepatitis through Network Pharmacology and Molecular Docking Methods
Xin Li

- EP0506 Advances in Exosome Research in Autoimmune Hepatitis
Pei Yao Zhang, Ji Hong An
- EP0507 The Value of Computer-aided Counting of MUM1 Positive Plasmacytes in the Diagnosis of Autoimmune Hepatitis
Xinxin Wang, Zuhua Gao
- EP0508 Study on the Mechanism of CD36 in Gut Microbiota-Regulated Intestinal Barrier Function in Autoimmune Hepatitis
Che Xu
- EP0509 Analysis of Clinical Characteristics and Risk Factors of Autoimmune Hepatitis Complicated with Extrahepatic Autoimmune Diseases in the Han Population
Yueyang Ma, Yujia Lu, Keying Ou, Chuansu Yuan, Bin Liu, Duxian Liu, Yongfeng Yang, Qingfang Xiong
- EP0510 A preliminary study on the effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis
Yushu Yang, Lixia Gao
- EP0511 Abnormal copper metabolism secondary to primary biliary cholangitis suspected Wilson's disease: a case report and literature review
Yongtong Wu, Tingfeng Yu, Ning Tan, Jingwen Wang, Yanyan Zhuang, Lingyun Wang
- EP0512 CPE+ vWF+ Endothelial Cells play a promising role in Primary Biliary Cholangitis
Linxiang Huang, Zixuan Qiu, Xiaoxiao Wang, Zilong Wang, Bo Feng
- EP0513 Shared genetic landscape of autoimmune liver diseases and related autoimmune diseases
Tong Wu
- EP0514 A Rare Case of Primary Biliary Cholangitis with Multiple Myeloma
Ashkhen Keryan, Aren Nersisyan, Ruzanna Safaryan, Hasmik Ghazinyan, Aram Mirijanyan
- EP0515 The association between Hashimoto's Thyroiditis and Autoimmune Liver Disease: A Two-Sample Mendelian Randomization Research
Zhang Jingyi, Tang Yingmei
- EP0516 Identification of new potential therapeutic targets of autoimmune liver diseases through proteome-wide Mendelian randomization
Zian Wang, Jinglan Jin, Ruihong Wu
- EP0517 Prevalence and Effect on Prognosis of Sarcopenia in Patients with Primary Biliary
Jiaqi Yang, Shuangshuang Jiang, Qingling Fan, Guanya Guo, Ying Han
- EP0518 Cholesterol-modified prognostic nutritional index as an independent prognostic biomarker in primary biliary cholangitis patients
Huiling Zhu, Mengyao Zheng, Jinhui Yang
- EP0519 TREM2 Protects Against Primary Biliary Cholangitis by Upregulating Cathepsin S
Jiamin Xu, Simiao Li, Yingmei Tang
- EP0520 Causal Associations Between Gut Microbiota and Cholestatic Liver Diseases: A Mendelian Randomization Study
Jiaqi Yang, Gang Ma, Guanya Guo, Ying Han

- EP0521 Health-related quality of life in Chinese patients with primary biliary cholangitis.
Xian Yang, Jieting Duan, Yingmei Tang, Jingyi Zhang, Xiang Kui, Jiamin Xu
- EP0522 A Double-blind, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Obexcholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Primary Biliary Cirrhosis Patients With an Inadequate Response to Ursodeoxycholic Acid
XU LI, Youwen Tan, Yuanyuan Xu, Lei Li, Lihua Zhong, Zuxiong Huang, Li Yang, Fengmei Wang, Sikui Wang, Jun Ye, Liping Liu, Jinhui Yang, Yingjian Zhang, Bangjie Zhang, Yi Li, Xiaozhong Wang, Hangyuan Wu, Yongning Xin, Qingfang Xiong, Yuan Huang, Xiaowei Xu, Lili Hao, Lihua Qing, Wenyi Sun, Kezhen Liu, Xiong Ma, Junqi Niu
- EP0523 Research Progress on the Diagnostic Ability and Predictive Performance of Different Prognostic Scores as Non-Invasive Models for PBC Liver Fibrosis
Feng Juan, Li Yuetian, Tang Yingmei
- EP0524 Sarcopenia in Female PBC Patients: A Study of Clinical Traits and Risk Factors
Zhang Jingyi, Tang Yingmei
- EP0525 The Impact of Gut Microbiota on Primary Biliary Cholangitis
Li Yuetian, Tang Yingmei
- EP0526 Characteristics of differentially expressed genes in PBMC of primary biliary cholangitis
Fang Xu, Rui Hua, Lihua Yuan
- EP0527 Genetic Factors Shaping the Immune Pathways between Autoimmune Cholestatic Liver Disease and Extrahepatic Autoimmune Diseases
Bingping Liu, Guohui Lan, Xiaoxu Xie, Qi Zheng
- EP0528 IL-17A induces EMT in HiBECs through the p38 MAPK signaling pathway
Lin Li, Huabao Liu, Yi Huang
- EP0529 MRCP+ has a role in enhancing detection of high-grade strictures in primary sclerosing cholangitis
James Franklin, Charlotte Robinson, Elizabeth Shumbayawonda, Sarah Finnegan, Kartik Jhaveri
- EP0530 Test-retest Repeatability of PSC specific imaging biomarkers from quantitative MRCP
Tom Davis, George Ralli, Carlos Ferreira, Bruno Paun, Andrea Borghetto, Elizabeth Shumbayawonda, Sarah Finnegan, Andrea Dennis, Michele Pansini
- EP0531 IgG4-related Sclerosing Cholangitis And Tuberculosis Coexist — Is It A Dilemma?
Xuechen Liu, Lei Yang, Yuan Huang, Jun Yan, Amanda Liong, Liusheng Wu
- EP0532 Development of a Machine Learning-based Model to Distinguish between Primary Sclerosing Cholangitis and IgG4-related Sclerosing Cholangitis: a Multicenter Cohort Study
Chenyi Jiang, Tianyu Mao, Lei Shi, Min Lian, Xiong Ma, Chinese Autoimmune Liver Disease Consortium
- EP0533 Transcriptome-combined Mendelian randomization probes co-morbid genes and regulatory mechanisms in primary sclerosing cholangitis and ulcerative colitis
Lin Li, Chunyan Rao

Pediatric and Genetics

- EP0534 Intrauterine HBeAg exposure tailor TCR β chains and IgH chains of lymphocytes in cord

Jialin Li, Meiting Huang, Yaohua Hao, Xuelian Zhang, Xiaohuan Jiang, Shimin Yin, Jinghuan Lin, Xueru Yin, Shibei Zhu, Anqi Zheng, Zhanhui Wang, Hongkai Wu, Yunfei Gao, Zhihua

- EP0535 Integrative genome-wide analysis unveils the genetic landscape of gallstone disease and highlights novel loci with therapeutic potential
Jiarui Mi, Haotian Chen
- EP0537 Clinical characteristics and outcomes of 6 children with autoimmune hepatitis
Huijing Wei
- EP0538 Misdiagnosis of NTCP deficiency as intrahepatic cholestasis of pregnancy (ICP) and hepatic histopathological features: Report of 13 adult cases
Qiaorong Gan, Xuwei Wu, Aifang Lin, Zuxiong Huang
- EP0539 A novel prognostic model for pediatric acute liver failure
Wu Wei, Zhu Longchuan, Wan Shenghua
- EP0540 Genome-wide Association Study unveils the genetic landscape of bilirubin levels and identifies the protective role of indirect bilirubin in Inflammatory Bowel Disease
Jiarui Mi, Haotian Chen
- EP0541 Simultaneous determination of piperacillin, metronidazole, and tazobactam in plasma by UPLC – MS/MS and application to a pharmacokinetic study in pediatric liver transplant
Yuhua Deng, Cuiyao He
- EP0542 A Novel Compound Heterozygous ATP8B1 Mutation Identified in a Patient with Benign Recurrent Intrahepatic Cholestasis Type 1
Yi Liu, Yinghua Lan
- EP0543 Analysis of autoantibody positive rate and clinical characteristics in patients with hepatolenticular degeneration
Hui Jiang, Chen Liang, Shan Tang, Wei Hou, Hui Liu, Sujun Zheng
- EP0544 Protein C Deficiency as a Rare Etiology in Budd-Chiari Syndrome
NIKHIL TEJA KAMBHAMPATI, SIVA SUBRAMANIAM B, KARTHIKEYAN R
- EP0545 Genetic and Clinical Characteristics of COG4-CDG: A Review of Reported Cases
Shufang Pan, Shuru Chen, Jie Gao, Shaoquan Zhang, Jianyun Zhu, Yutian Chong
- EP0546 An adult X-SCID patient with multiple organ tuberculosis: a case report
Gao Jie, Chen Shu Ru, Pan Shu Fang, Zhu Jian Yun, Chong Yu Tian
- EP0547 A case of Gilbert syndrome combined with hyperhomocysteinemia
Chaojian He, Qingqiang Yi
- EP0548 A case of type II Crigler-Najjar syndrome complicated with chronic hepatitis B and hyperlipidemia
Chaojian He, Qingqiang Yi
- EP0549 SLC40A1-related Hemochromatosis Associated with a p.Y333H Mutation in Mainland China: a Pedigree Report
Yue Li
- EP0550 New JAG1 Mutation Causing Alagille Syndrome: A Case Report
Xuwei Wu, Zuxiong Huang

- EP0551 A case of Hereditary Spherocytosis caused by mutations in the SPTB and UGT1A1 genes
Pei Zhou, Yaping Wang, Bo Li, Jianping Li, Baojin Li, Canye Ma, Yujuan Guan
- EP0552 Analysis of UGT1A1 Gene Variation Spectrum in Patients With Hereditary Unconjugated Hyperbilirubinemia and Its Correlation with Clinical Characteristics
Xuheng Teng, Yiling ShenTu, Chun Liu, Rongqiang Liu, Ling Gong
- EP0553 Domino Orthotopic Auxiliary Liver Transplantation for the Treatment of Crigler-Najjar Syndrome Type II
Bin Wu, Jinzhen Cai, Dahong Teng, Yandong Sun, Dan Liu
- EP0554 Clinical phenotypic, molecular genotypic and the correlation analysis of pediatric patients with microvillus inclusion disease: A large-scale systematic review
Xiang Pan, Yuanzong Song, Hui Lin, Zhijun Mo
- EP0555 Diagnosis and Treatment of Congenital Liver Cirrhosis with Intrahepatic Bile Duct Segmental Dilatation (Caroli Syndrome): A Case Report
YinLing Zhou, LianJun Xing
- EP0556 CRISPR-Targeted Genome Editing of Urine-Derived Stem Cells for the Treatment of Wilson's Disease: From Bench to Potential Clinical Applications
Jiaqi Li, Pengfei Yu, Jiateng Zhang, Huaibin Zou, Yuanyuan Zhang, Yu Chen, Zhongping
- EP0557 Clinical Features and Genetic Mutation Analysis of Two Cases of Transient Infantile Hypertriglyceridemia Associated with the GPD1 Gene: A Chinese Study
Yi Dong, Chao Liu, Lili Cao, Jianguo Yan, Min Zhang
- EP0558 Hereditary Hemorrhagic Telangiectasia Coexisting with HBV-Related Cirrhosis: Diagnostic Challenges and Genetic Insights
Wenjuan Shi
- EP0559 Evaluation of diagnostic efficacy of Ttransientelastography for hepatic fibrosis in children with the Wilson's Disease
Xue Tian, Min Zhang
- EP0560 A Rare Case of Hereditary Hemorrhagic Telangiectasia Type 2 Diagnosed Through Multidisciplinary Collaboration
Bingqing Yang
- EP0561 Altered amplitude of low-frequency fluctuation and regional homogeneity in Gilbert 's syndrome: A resting-state fMRI study
Chun Liu, Rongqiang Liu, Xuheng Teng, Yiling Shentu, Junping Shi, Ling Gong
- EP0562 Clinicopathological features of porto-sinusoidal vascular disorder with a novel GIMAP5 mutation in a pair of Chinese twin siblings
Lei Sun, Junke Hu, Liang Zhang, Xiangmei Chen
- EP0563 A Case of Hemochromatosis with Hypogonadotropic Hypogonadism and Diabetes: Identification of a Homozygous TFR2 Mutation
Yao Liu, Jun Chen
- EP0564 Epidemiology And Clinical Features Of Vascular Liver Diseases Secondary To Myeloproliferative Disorders In Morocco: A Monocentric Experience
Soukaina Belhaj, Maryeme Kadiri, Fatimazahra Chabib, Nawal Lagdali, Mohamed Borahma, Fatimazahra Ajana

- EP0565 Clinical Characteristics and Pathological Scoring Analysis of Hepatic Amyloidosis
Yuxiang Gong, Yongfeng Yang, Yuan Yang, Jialuo Wang
- EP0566 A Case of COG4 Deficiency (Congenital Disorders of Glycosylation IIj)
Ling Zhou, Qinjun He, Haoming Mai, Zhihua Liu
- EP1048 Is Autoimmune Hepatitis Related to Genetic Syndromes in Children– a Case Series
SINDHUJA THATTI AUDIKESAVALU, DEEPA JANAKIRAMAN, NIRMALA DHEIVAMANI
- EP1049 RECURRENT ACUTE LIVER FAILURE (RALF) IN CHILDREN – UNRAVELING THE MYSTERY WITH NOVEL GENES– four case reports
SINDHUJA THATTI AUDIKESAVALU, DEEPA JANAKIRAMAN, NIRMALA DHEIVAMANI

Liver Fibrogenesis and Cirrhosis

- EP0567 Prognostic value of albumin correlation ratio and liver-abdomen area ratio in posthepatic cirrhosis
Zhou Yun, wenfeng Huang, hui Xiong
- EP0568 Correlation Between Ultrasonographic Findings and Ultrasound Elastography Results in Patients with Hepatitis B
Minseong Kim
- EP0569 Identifying potential anti-HBV active components of BSJP formula by promoting macrophage M1 polarization
Yilan Yang, Fengjie Qiao, Yufei Liu, Zhujun Gao, Yueqiu Gao, Man Li, Yunfeng Guan
- EP0570 HMGB1-mediated enhancement of glycolysis activates hepatic stellate cells by inhibiting ferroptosis in alcoholic hepatic fibrosis
Zhengyuan Xie
- EP0571 Study on the relationship between Notch with Wnt signaling pathways and hepatic fibrosis markers
Peng Chengming
- EP0572 Evaluation of the efficacy of TIPS in the treatment of patients with cirrhosis complicated with portal vein thrombosis
Ruyi Xie
- EP0573 Etiological composition and complication distribution of inpatients with cirrhosis: a study from two clinical centers in China
Yanan Fan, JINGHANG XU, Tongtong Ji, Yanyan YU
- EP0574 Analysis of clinical features of 11-year cirrhosis patients in a Chinese hospital
Yanan Fan, Jinghang Xu, Tongtong Ji, Yanyan Yu
- EP0575 The Influence of Focused Resolution Mode Care on Negative Mood in Patients with Esophageal and Gastric Varices Rupture
Lijuan Xu
- EP0576 Ursolic acid targets NLRP3 to inhibit M1 polarization of liver Kupffer cells and improve liver fibrosis in mice
Wan Yipeng
- EP0577 The effect of Ursolic acid on the activation of AP-1, NF- κ B induced by Ang II in HSC-T6 cells
Chen Tao

- EP0578 Evaluating The Prognostic Value Of The MELD 3.0 Score In Predicting Mortality In Cirrhosis Patients With Acute Variceal Bleeding.
Tram Nguyen Pham, Thong Duy Vo
- EP0579 Neocryptotanshinone ameliorates hepatic cirrhosis by activating PPAR α -mediated fatty acid metabolism
Guanyue Su, Xuemei Wang, Feilin Ge, Wenlong Miao, Lili Li, Hongxia Liang, Zhigang Ren
- EP0580 Effects of N-acetyl-seryl-aspartyl-lysyl-proline on transmembrane signaling of bile duct ligation (BDL)-induced liver fibrosis in rats.
Lei Zhang
- EP0581 Changes in Serum Albumin Function in Cirrhotic Patients: An Exploratory Study by Electron Paramagnetic Resonance Spectroscopy
LI Meng Qi, LI Wen Yu, Wang Qi, Zhao Hong, Ge Yi Di, Chen Wen Ya, Yang Hai Jun, Xie
- EP0582 Reduced glutathione enhances adipose tissue-derived mesenchymal stem cell engraftment efficiency for liver fibrosis by targeting TGF β 1/SMAD3/NOX4 pathway
Naishun Liao
- EP0583 Identification of LHPP as a potential target gene in liver fibrosis via comprehensive bioinformatic analysis
Yue Zhang, Yuan Song, Zhiqiang Tan, Xuan Zhu
- EP0584 GPR56 Function as a Key Repressor in Hepatocyte Pyroptosis and the Pathogenesis of Liver Fibrosis
Zhemini Shi, Lina Zheng, Qingbin Yao, Zhimei Hu, Xiaohui Han, Kun Zhang, Tao Han, Wei Hong
- EP0585 The global burden of cirrhosis and other chronic liver diseases in 2021
Jia Hong Koh, Nicholas Syn, Daniel Huang, Mark Muthiah
- EP0586 Circ_0098181 alleviated liver cirrhosis through targeting PKM2
Yuanyuan Luo, Xin Zeng
- EP0587 Predictive Value of Leucine Aminopeptidase Combined with APRI and FIB - 4 Scores for Liver Fibrosis and Early - stage Cirrhosis in Chronic Hepatitis B.
Haihang Dong, Yuying Tu, Yujie Cai, Yinqiang Zhang
- EP0588 Application of DPMAS \pm LPE in Patients with ACLF: A Single-Center Retrospective Study
YUYI ZHANG, WEI YUAN, YU LIU, YING ZOU, HUI ZHU, ZHENG GUO ZHANG, HONGYING GUO, LIUJUAN JI, ZHIPING QIAN, XUE MEI
- EP0589 Annexin A1 Promotes Liver Fibrosis by Regulating Macrophage Polarization
Zhenghui Song, Chen Yang, Yun Liu, Mingyong Li, Yijing Ye
- EP0590 Nuclear Receptor Nurr1 deactivate HSC through suppressing EMT
Pengguo Chen
- EP0591 Clinical efficacy analysis of thrombin treatment for upper gastrointestinal bleeding in patients with cirrhosis
Mengqi Kuang
- EP0592 Study on Abnormal Intestinal Flora and Metabolomics in Patients with Ascites in Posthepatitis B Cirrhosis

Wei Wei, Yuqiang Mi

- EP0593 Ttk Accelerates Hepatic Fibrosis Via Regulation Of Glutamine Metabolism In Hepatic Stellate Cell
Linying Lai, Bensong Duan
- EP0594 Alterations in Expression Profiles and Functional Role of Transcription Factor ETS1 in NK Cells during Liver Cirrhosis
Zixuan Guo, Zhi Chen
- EP0595 Significant Association of a Vitamin D Receptor Gene Haplotype with Hepatic Fibrosis in Patients with Chronic Hepatitis B
Sirinporn Suksawatamnuay, Prooksa Ananchuensook, Kanteera Sriyudthsak, Panarat Thaimai, Nipaporn Siriporn, Nunthiya Srisoonthorn, Supachaya Sriphoosanaphan, Piyawat Komolmit, Kessarin Thanapirom
- EP0596 The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria
Lixia Ma, Jing Zhang
- EP0597 Bone marrow mesenchymal stem cell-originated exosomes suppress activation of hepatic stellate cells through the miR-144-3p/SLC7A11 axis
Yanqin Hao, Rong Wang, Qing Zhou, Jiaolong Ren
- EP0598 Research on the Anti-fibrotic Role of Hepcidin through Modulating Macrophage Polarization
Ziyu Rong, Yingying Liu, Xiaofan Wang, Long Huang, Wei Cheng, Xu Fan, Xue Wang, Lin Liu, Ping Wang, Tianhui Liu, Min Cong
- EP0599 Cannabinoid-2 receptor activation ameliorates cholestatic liver fibrosis through the HIPPO/YAP signaling pathway
Jing Li, Suxian Zhao, Yuemin NAN
- EP0600 Whole transcriptome and proteome analyses of primary hepatic stellate cells identify etiology-independent signatures in advanced liver fibrosis
Yuwei Liu, Yutong Dong, Xiaomei Wang, Yanhang Gao, Junqi Niu
- EP0601 Chinese medicine for the treatment of liver cirrhosis: mechanism of cellular autophagy
Shihao Zheng, Wenying Qi, Jiaxin Zhang, Qiyao Liu, Xiaoke Li, Xiaobin Zao, Yongan Ye, Peng Zhang
- EP0602 Liver cirrhosis: current status and treatment options using Western or traditional Chinese medicine
Shihao Zheng, Jiaxin Zhang, Xiaoke Li, Xiaobin Zao, Wenying Qi, Yongan Ye, Peng Zhang
- EP0603 Research Advances in Caveolin-1-Mediated Liver Fibrosis
Pei Yao Zhang, Ji Hong An
- EP0604 Pharmacological Mechanism of Compound Biejia-Ruangan Tablet in the Treatment of Liver Cirrhosis: Insights from Network Pharmacology and Animal Experiments
Shihao Zheng, Qiuyue Wang, Size Li, Wenying Qi, Qiyao Liu, Xiaoke Li, Jiaxin Zhang, Xiaobin Zao, Yongan Ye, Peng Zhang
- EP0605 Exosomes from adipose-derived mesenchymal stem cells improve liver fibrosis by regulating the miR-20a-5p/TGFBR2 axis to affect the p38 MAPK/NF-κB pathway
Gan Lihong, Fang Nian

- EP0606 Mechanism Study of ADSCs Exosomal miR-140 Mediated ZFP36 in Inhibiting HSCs Activation by Regulating Ferroptosis and Autophagy
Ting Liu
- EP0607 Adjuvant treatment of nonalcoholic fatty liver fibrosis with probiotics and its effects on intestinal barrier function and serum inflammatory factors
Gan Lihong
- EP0608 Overexpression of Numb Gene Enhances the Therapeutic Effect of Mesenchymal Stem Cell Transplantation on Cholestatic Liver Fibrosis
Shi-hao Zhang, Ming-yan Yang, Fei-fei Xing, Jun-yi Zhan, De-xin Wang, Yong-ping Mu
- EP0609 Experimental study on the improvement of liver fibrosis by si-TANGO1 loaded human umbilical cord mesenchymal stem cell-derived apoptotic vesicles
Jin Lei, Haiyang Li
- EP0610 Exploring the Therapeutic Mechanism of Fufang Zhizigen Keli in the Treatment of Liver Fibrosis via the AGE/RAGE/Smads Signaling Pathway
Tianxiang Wang
- EP0611 Current perspectives and trends of macrophage in liver fibrosis: a bibliometric and visualization study
Yanbo Li, Zhengmin Cao, Wenliang Lyu
- EP0612 Chylous ascites secondary to Portal Hypertension from Liver Cirrhosis resolved by treatment with medium chain fatty acids, octreotide and large-volume paracentesis: A Case Report
Derek Caisip Clutario, Patricia Cabral Prodigalidad, Eternity Madaline Labio, Christine P Velasquez
- EP0613 Metabolic Signatures Across the Full Spectrum From Hepatitis to Cirrhosis to Hepatocellular Carcinoma
Simiao Yu, Ruilin Wang, Sici Wang, Haocheng Zheng
- EP0614 Risk of Liver Fibrosis in Patients with the Bacterial Overgrowth Syndrome.
Ilona Minosayn, Lahana Ravoori, Olga Tarasova
- EP0615 MEASUREMENT OF SPLEEN STIFFNESS FOR DIAGNOSIS OF ESOPHAGEAL VARICES IN PATIENTS WITH LIVER CIRRHOSIS
Sayfullo Avezov, Shoir Naimova
- EP0616 A Predictive Model for the Diagnosis of Hepatic Encephalopathy in Patients with Liver
Li Jinpeng
- EP0617 Radiomic Analysis of Contrast-Enhanced CT Predicts Recompensation in Hepatitis B-Related Decompensated Cirrhosis
Jianhao Qiu
- EP0618 Comparative study on the efficacy of TIPS and EVL in the treatment of esophageal variceal bleeding in patients with cirrhosis
Gejirifu De
- EP0619 Smoking modify Red blood cell distribution width albumin ratio on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease :NHANES 2017-March 2020 Pre-
Llinfei Luo, Zhili Wen
- EP0620 Integrated analyses and a novel nomogram for the prediction of significant fibrosis in patients

Mengxin Lu, Shuai Tao, Xinyan Li, Yi Zhang, Liang Chen

- EP0621 Based on Bibliometrics Analysis of Hepatic Sinusoidal Endothelial Cells in Liver Homeostasis and Disease-Related Fields
REN JING, Tang Shan Hong
- EP0622 Sarcopenia predicts the re-compensation in patients with decompensated cirrhosis
Ning Wei, Minghui Liu, Li Gu, Dong Xu, Yuhu Song
- EP0623 Water balance in patients with alcoholic liver cirrhosis without clinical signs of oedema
Svetlana Kislaya
- EP0624 Using Metabolomics to Identify Serum Biomarkers for Early Diagnosis of Liver Fibrosis
Tang Xiangjun, Guo Zhaopei, Fu Ya, Ou Qishui
- EP0625 The clinical characteristics analysis and etiological exploration of cryptogenic cirrhosis
Yali Liu, Yanhang Gao
- EP0626 Non-invasive predictive value of the Indocyanine green retention test in patients with varices needing treatment in cirrhosis
Zhou Lina, Lin Yong, Lin Chun, Pan Chen
- EP0627 Development and Validation of a Predictive Model for Acute Kidney Injury in Hospitalized Cirrhosis Patients
Shengong Lin, Wenhai Ke, Huaxi Ma, Haibing Gao
- EP0628 Establishment of a diagnostic model for liver fibrosis in patients with chronic hepatitis B
Xinru Guo, Minran Li, Jianhua Lu, Lihong Ye, Erhei Dai
- EP0629 Evaluating Long-Term Outcomes of Hepatitis C Treatment in Mongolia: A Five-Year Follow-Up Study in Arkhangai Province
Byambasuren Amgalan, Nyamdavaa Khurelbaatar, Oidov Baatarkhuu
- EP0630 Pay attention to the value of liver regeneration in the recompensation of decompensated cirrhosis
Wang Jiaying, Tang Shanhong
- EP0631 Predicting Esophageal Varices Requiring Treatment in Patients with Liver Cirrhosis Based on Non-invasive Ultrasound Parameters
Fei WANG
- EP0632 Carnitine Deficiency and Improvement of Subjective Symptoms by Administration of Carnitine in Patients with Liver Cirrhosis
Naoki Hotta
- EP0633 Transjugular Intrahepatic Portosystemic Shunt (TIPS) for the Treatment of Hepatic Sinusoidal Obstruction Syndrome (SOS): A Case Report of Normalization of Portal Pressure and Shunt Embolization After TIPS
Qing Zhang, Zhibo Xia, Huanyun Gao, Yunna Ma, Jianguo Chu, Jianhua Xu
- EP0634 Deep Learning Model Based on Elastic Ultrasound Predicts Liver Fibrosis in Potential NAFLD/NASH Patients
Yuan Liu
- EP0635 Research status and treatment progress of liver cirrhosis complicated with portal vein thrombosis

Wen Long He, Jin Zhu Wu

- EP0636 Diagnostic value of grip strength combined with major waist muscles in patients with liver cirrhosis complicated with sarcopenia
Jinhua Jing, Yi Jiang, Hong Yu, Wei Sun, Jing Dou, Zhonghui Ning, Zhuanguo Wang, Xiaobo Wang, Xiaozhong Wang, Feng Guo
- EP0637 Prevention of Liver Fibrosis and Hepatocellular Carcinoma Using Antiplatelet Drugs: A Systematic Review and Meta-Analysis
Yu Ting Zhang, Rui Jing Wang, Bo Shen, Jie Wang, Xiu Ying Zhang, Yang Yue
- EP0638 CHI3L1-Based Model as a Superior Diagnostic Tool for Stage 4 Fibrosis in Patients with Chronic Hepatitis B
Zhiwei Xie, Jinnian Lin, Chujing Li, Pei Zhou, Wenyu Wang, Songlian Liu, Honglian Bai, Jianping Li, CalvinQ Pan, Yujuan Guan
- EP0639 Alanine Transaminase to Platelet Ratio Index as a Simple Predicting Tool of Esophageal Varices in Patients with Cirrhosis: A Single Center Study in Indonesian Population
Riki Tenggara, Alver Prasetya, Novita Trisno, Yulia Tanti Narwati
- EP0640 Correlation analysis between HBVDNA levels and liver fibrosis index
Wangyingchun Wangyingchun, Anjihong Anjihong
- EP0641 High-Throughput Whole-Genome Methylation Study in Hepatitis B-Related Cirrhosis
Hangyu Ma, Jieru Yang, Jing Zuo, Yinping Wu, Yuchen Fan
- EP0642 The Model of Liver Stiffness plus Platelet Count can be Used to Simultaneously exclude High-risk Varices and Large Spontaneous Portal Systemic Shunts
Biao Wen, Jinjun Chen
- EP0643 Review of safety and indications of percutaneous liver biopsy in 727 patients
Rirun Chen, Chenghai Liu, Feng Xing
- EP0644 Impact of Acute Insults on the Outcomes of 76 Patients with Acute-On-Chronic Liver Failure in 2023
Hasmik Ghazinyan, Tatevik Shahinyan
- EP0645 Analysis of Clinical Risk Factors for Rebleeding after Endoscopic Secondary Prevention of Cirrhotic Esophagogastric Variceal Bleeding
Lijun Shen, Yuming Ma, Xuemei Ma, Chunsheng Chi, Liping Yan, Libing Wu, Qian Bi, Bo Jin
- EP0646 The predictive value of ultrasound measurement of spleen hardness for non-invasive diagnosis of liver cirrhosis with esophageal and gastric varices
Yupei Liu, Jia Li
- EP0647 UTILIZATION OF SYSTEMIC INFLAMMATORY MARKERS AS NON-INVASIVE PROGNOSTIC MARKERS FOR MORTALITY IN LIVER CIRRHOSIS: A RETROSPECTIVE COHORT STUDY
Ma. Althea Kathrine Baniqued Elinzano
- EP0648 Analysis of the histological factors contributing to the improvement of portal hypertension in patients with chronic hepatitis B cirrhosis
Meng Li, Jing Lv, Chenghai Liu
- EP0649 Research progress on anti-hepatic fibrosis mechanism of traditional Chinese medicine compound preparation

Yu Sulan, Zhengyuan Xie

- EP0650 Nutritional support therapy for liver cirrhosis
Jianhua Wu, Zhengyuan Xie
- EP0651 Esculentoside A improves steatohepatitis through PI3K and Nrf2-Keap1 pathways
Xinjie Mao, Zhili Wen
- EP0652 Observation on the efficacy and safety of moxifloxacin in the treatment of spontaneous peritonitis in liver cirrhosis
Chen Gao, Chen Gao
- EP0653 Observation on the Therapeutic Effect of Nucleoside Analogues Combined with Silibinin Capsules in Patients with Liver Fibrosis Caused by Chronic Hepatitis B
Chen Gao
- EP0654 Research Progress on the Therapeutic Effects of Astragalus Membranaceus in Liver Fibrosis
Jing Wang, zhenyu jiang, jiaxin lou, chi wang, wenting li
- EP0655 Gastrodin: A Traditional Chinese Medicine Extract that Modulates Glycolysis to Alleviate Liver Fibrosis Progression
Qian Liu, Jing Li, Siyu Zhao, Jiajia Li, Xin Li, Yongfeng Wang, Biguang Tuo, Hai Jin
- EP0656 In vivo experiments and transcriptome sequencing analysis to explore the effect and mechanism of KangXianYiAi formula in treating liver fibrosis
Yujie Wang, Xu Cao, Yijun Liang, Yongan Ye, Xiaobin Zao
- EP0657 Research status of traditional Chinese medicine (TCM) regulating PI3K/AKT signaling pathway to intervene liver fibrosis
Yuanhao Zhang, Zhanjie Chang, Jingtao Li, Qi Xi, Zhiqiang Sun
- EP0659 The Prevalence of Low-Level Viremia in the Treatment of Chronic Hepatitis B in China: A Systematic Review and Meta-Analysis
Lu Xie, Wei Guang Liu, Jun Hui Guo
- EP0660 Gallic acid mitigates high-fat and high-carbohydrate diet-induced steatohepatitis by modulating the IRF6/PPAR γ signaling pathway
Jiahao Qiu, Yan Xue, Xin Zhang, Zhi Shang, Yueqiu Gao
- EP0661 Serum and liver lipid metabolic characterization of NAFLD in rats induced by HFHFD and effect of Mailuoning oral liquid on alleviating steatosis
Sijia Wu, Wangya Jia, Lili Ji, Wei Liu, Hong Xu
- EP0662 Xiayuxue Decoction alleviates NASH by reshaping the gut microbiota, regulating bile acid metabolism and affecting m6A transcriptional modification
Jiewen Shi, Yang Cheng, Wei Liu
- EP0663 Transcriptome analysis of peripheral blood mononuclear cells revealed the critical role of CD4⁺ and CD8⁺T cells dysfunction and associated regulatory genes in NAFLD patients
Mei Zhong, Zhe Xu, Hua Zeng, Shuai Wang, Furong Huang, Yufeng Xing, Fengping Xu, Lidan Luo, Guangdong Tong
- EP0664 UPLC-Q-TOF-MS based investigation into the bioactive compounds and molecular mechanisms of Chaihubiejia Decoction against Cholestatic Liver Fibrosis
Haihang Dong, Yinqiang Zhang, Yujie Cai, Yuying Tu, Dongling Wang

- EP0665 Novel monomer-combinations from *Salvia miltiorrhiza* alleviate NLRP3 inflammasomes via promoting autophagy
Ruanyu Yan, Hongyu Wu, Yanyan Tao, Chenghai Liu, Yuan Peng
- EP0666 Multi-omics analysis reveals the mechanism of Shugan Xiaozhi decoction against Nonalcoholic steatohepatitis
Shuai Wang, Rui Li Du, Jia Hui Liu, Wei Chao Zhong, Chun Mei Zhang, Xia Jiang, Xiao Hui Wang, Qi Biao Wu, Guang Dong Tong, Li Dan Luo
- EP0668 Jia Wei Yin Chen Hao Tang enhances hepatocyte bile acid uptake and alleviates cholestatic liver disease by activating PPAR α /OATP1
Yan lu Ma, Yueqiu Gao, Zhi Shang, Xin Zhang
- EP0669 Multi-omics reveals ameliorative effect and underlying mechanism of aqueous extract of *Rhodiola rosea* L. on methionine choline deficiency diet-induced hepatic fat accumulation in mice
Qinying Feng, Shuling Wang, Wei Liu
- EP0670 The study of bupleurum polysaccharide enhances baicalin alleviating MCD-induced NASH based on regulating the gut microbiota and heightening Gut β -GUS
Anna Zhang, Luping Qin, Wei Liu, Jianjun Wu
- EP0671 The Effect of Compound *Phyllanthus urinaria* L. Targeting MDM/HDM on the Regulation of p53 in the Hepatocellular Carcinoma-Specific Metabolic Pathways
Hai Yan Du, Guang Dong Tong
- EP0672 Qushi Huayu Decoction ameliorates MAFLD induced by high-fat and high-sugar through NRF2 pathway against hepatocyte ferroptosis
Aojie Mao, Yuqing Pan, Chuchu Yu, Huajie Tian, Yu Zhao, Yiyang Hu
- EP0673 Histone methylation regulated by EZH2 promotes the formation of liver fibrosis and the inhibitory effect of Fuzheng Huayu Recipe
Xin Sun, Rirun Chen, Chenghai Liu
- EP0674 Anti-HBV effects of SFP-100-A polysaccharide component through reducing ROS via
Fengjie Qiao, Zhi Shang, YunFeng Guan, YiLan Yang, ZhuJun Gao, YuFei Liu, JunJie Shan, Man Li, YueQiu Gao
- EP0675 Development of a selected Pool of Clinical Outcomes for Metabolic Associated Fatty Liver Disease Intervention with Traditional Chinese Medicine: An evidence-based Study (2018-
Yuxin Sun, Guangdong Tong
- EP0676 Mechanism of luteolin in regulating the Nrf2 signaling pathway to ameliorate metabolism-associated fatty liver disease
Aojie Mao, Yuqing Pan, Chuchu Yu, Yu Zhao, Huajie Tian, Yiyang Hu
- EP0677 Based on TLR4/NF- κ B Signaling Pathway to Reveal the Mechanism of Rheum Officinale against Metabolic Dysfunction-Associated Steatohepatitis-Related Cirrhosis
Ying Qin, Xin Wang, Ning Yao, Xin Wang, Ying Su, Yajie Chen, Yunjuan Wu, Xinxin Su, Yajuan Geng
- EP0678 Revealing the protective effect and mechanism of the Yiqi Hexue formula on liver cirrhosis through UPLC-Q-Exactive Orbitrap-MS, network pharmacology, and experimental verification
Ying-xue Zhang, Xiao-ling Li, Feng-xia Sun

- EP0679 Study on the Role of the Shugan Xiaozhi Formula in Regulating Gut Microbiota and its Metabolite Lipopolysaccharides in the Inflammatory Mechanism of Non-Alcoholic Fungus Huang, Guangdong Tong, Haiyan Du
- EP0680 Eucommia ulmoides bark effectively alleviates nonalcoholic steatohepatitis by ameliorating lipid metabolism, inflammatory response, and fibrosis
JIANG XIAO YU, LIU WEI, QI SHENG LAN
- EP0681 Evidence Map of Clinical Research about the Treatment of Primary Liver Cancer with Traditional Chinese Medicine in Recent 10 Years
Jinzhen Huang, Zeming WU, Haiyan Du, Tao Cai, Nan He, Guangdong Tong
- EP0682 Integrated Metagenomics and Metabolomics for the Investigation of Mechanism of Anti-hepatic Fibrosis Effect of Taohong Siwu Decoction
Shengsheng Li, Yang Liu, Fangming Yang, Dingqi Zhang, Suping Ma, Zhun Xiao
- EP0683 Astragaloside IV inhibits the progression of hepatic fibrosis by regulating macrophage polarization via the JAK1/STAT1 signaling pathway
Wanchun Zhu, Yu Cui, Xin Zhang, Yunfeng Guan, Lingying Huang, Zhi Shang, Yueqiu Gao
- EP0684 Professor ZHAO Wenxia's experience in diagnosing and treating postmenopausal non-alcoholic fatty liver disease mainly through nourishing liver and kidney
QING ZHAO, Wenxia ZHAO
- EP0685 Effects of Shu-Gan-Hua-Zhi decoction in diabetes with MAFLD based on gut microbiota and metabolomics
Xing Liu, LiJia Zhang, MeiYuXi Li, XinYue Li, Zhen Zhang, Yan Wang
- EP0686 Research progress on the mechanism of action of active ingredients in goji berry for treating fatty liver
Qian Wang, Mei Yang, Qi Zhao
- EP0687 Case Report on Syndrome Differentiation and Treatment of Progressive Familial Intrahepatic Cholestasis by Integrating Traditional Chinese and Western Medicine
YanMei Cao, SuPing Ma
- EP0688 Exploration of Treating Insomnia in Liver Disease Based on the Theory of Simultaneous Treatment of Liver and Heart
Qian Wang, Xia Tian
- EP0689 Gallic acid alleviates oxidative stress-induced premature hepatocyte senescence in metabolic associated fatty liver disease by modulation of the AMPK/autophagy axis
Tong Xiao, Jiahao Qiu, Zhi Shang, Xin Zhang, Yueqiu Gao
- EP0690 Animal drugs in Biejiajian pills exerted anti-hepatocellular carcinoma effects through the Apelin signaling pathway
Yang Xu, BingZhao Du, QingYan Zhang, Qian Bi, Mingyi Shao
- EP0691 Percutaneous Transhepatic Cholangioscopic Lithotripsy Removed Hepatolithiasis Associated with Cavernous Transformation of Portal Vein
Rongxing Zhou, Qianyu Yan, Jingyi Zhang
- EP0692 Establishment of predictive model for recompensation in hepatitis B related decompensated liver cirrhosis
Xiaotong Ai, Jiaxuan Zhou, Rongkuan Li

- EP0693 Analysis of changes in blood lipid profile in patients with different types of liver cirrhosis after TIPS
QINNAN LI, YINGMEI TANG
- EP0694 Effects of Xiaozhi Huaxian Formula on Promoting Recompensation in Mice with MASH-related Cirrhosis Receiving BM-MSCs Transplantation Treatment
Ning Yao, Xin Wang, Xin Wang, Ying Qin, Yuhang Wang, Xinxin Su, Yajie Chen, Yunjuan Wu, Limin Tian
- EP0695 Meta-analysis of zinc supplementation in the treatment of liver cirrhosis
Yifan Gong, Xuqian Zhang, Chao Sun
- EP0696 Research dvances in microthrombus formation promoting hepatic fibrosis process
Chenrui Zhang, Zhizhong Yang, Yingmei Tang
- EP0697 Clinical Features and PBMC Transcriptomic Analysis of Acute Decompensated Cirrhosis Patients with Different Outcomes.
Zelu Meng, Jiyang Chen, Ying Nie, Yining Zhang, Yu Shi, Yida Yang
- EP0698 Efficacy of amitinofovir in the treatment of hepatitis B cirrhosis
Chen Gao
- EP0699 α -Vitamin E inhibits hepatic stellate cells activation to ameliorate liver fibrosis by promoting Nrf2 nuclear translocation
Rui Fang, Xue Wang, Bing Xu, Feng Zhang, Yuzheng Zhuge
- EP0700 EVL combined with ESD in the treatment of esophageal varices complicated with early esophageal cancer
Huan Ma, Jing Yuan He, Hua Xin Zhao, An Xiao Li
- EP0701 The Application of Non-Selective Beta-Blockers in Cirrhotic Portal Hypertension
Qi Wang, TONG BU
- EP0702 Study on the relationship between serum hepatocyte growth factor levels and liver function and prognosis in patients with cirrhosis
Shen Qi
- EP0703 Mechanism of PLG-mediated Bile Acid Metabolism Disorders Promoting Hepatic Fibrosis
Tongjing Hao, Qingman He, Dan She, Peng Lv
- EP0704 Prognostic Value of MELD-La Score in Evaluating Short-term Mortality of esophagogastric variceal bleeding
Xiaolong Ying, Sheng Shu, Qinghe Cheng, Zhidan Liao, Yingying Chen, Hailan Wan, Zihan Shen, Jun Chen, Bimin Li
- EP0705 Establishment and evaluation of a prognostic model for patients with first rupture of esophageal and gastrie varices in liver cirrhosis carcinoma
Xiaolong Ying, Qinghe Cheng, Sheng Shu, Yingying Chen, Zhidan Liao, Hailan Wan, Jun Chen, Zihan Shen, Bimin Li
- EP0706 Analysis of risk factors for liver cirrhosis complicated with infection
Yao Zeng
- EP0707 Novel Biomarkers for Early Detection of MAFLD: Beyond Traditional Liver Enzymes
YunLong Yao, Xi Zhang, ChenYu Fei, LiuJie Zhu

- EP0708 ALPS-HCC score: A Dynamic Liver Stiffness-Based Machine Learning Model to Predict Hepatocellular Carcinoma Risk
Yinan Huang, Hongsheng Yu, Can Hu, Hao Jiang, Bilan Yang, Xiaoli Xi, Bin Wu, Yidong
- EP0709 Mechanism research of natural small molecule α -Amyrin targeting Sirt1/PGC-1 α /PPAR α axis to regulate fatty acid metabolism reprogramming against liver cirrhosis
XUEMEI WANG, GUANYUE SU, FEILIN GE, ZHIGANG REN, ZUJIANG YU, HONGXIA LIANG
- EP0710 The Impact of Alcohol Consumption on Clinical Endpoint Events in Patients with Hepatitis B Cirrhosis Receiving Long-Term Antiviral Therapy: A Study Based on Real-World Data
Yuwei Wang, Huiguo Ding
- EP0711 Sleep disorders combined with anxiety and depression in hospitalized patients with liver cirrhosis and its influencing factors
Zhaoxia Liu, Yang Lei, Hong Yu, Jinhua Jing, Yuyu Li, Xiaozhong Wang, Feng Guo
- EP0712 Clinical Observation of Anluo chemical fiber pill in Treating Non-alcoholic Fatty Liver Disease with Liver Fibrosis
Wangyingchun Wangyingchun, Anjihong Anjihong
- EP0713 Long-term outcomes of carvedilol plus endoscopic variceal ligation in secondary prophylaxis of variceal bleeding
Xiao Liu, Yifu Xia, Junyuan Zhu, Xiaochen Liu, Lixia Xin, Guangchuan Wang, Mingyan Zhang, Zhen Li, Guangjun Huang, Chunqing Zhang
- EP0714 Treatment Efficacy and Risk Factors of Secondary Prophylaxis for Esophagogastric Variceal Bleeding in Elderly Cirrhotic Patients
Huang Yuwen, Ding Huiguo
- EP0715 Expression Changes of SGK1 in Patients with Acute-on-Chronic Liver Failure: A Study Based on Artificial Liver Treatment and Prognostic Model Construction
Zeqiang Qi, Tingyu Guo, Chang Liu, Yadong Wang
- EP0716 Development and Validation of a Radiomics-Based Prediction Model for Variceal Bleeding in Patients with Budd – Chiari Syndrome-Related Gastroesophageal Varices: A Multicentre
Zedong Wang, Huijie Nan, Suxin Li, Luhao Li, Lin Li, Shenyan Liu, Hai Li, Yanliang Bai, Xiaowei Dang
- EP0717 Analysis of the correlation between energy metabolism and dietary structure with prognosis in patients with liver cirrhosis
Xu Yang, Cai Dachuan
- EP0718 The predictive value of alkaline phosphatase, microbiome, and metabolomics characteristics for the improvement of liver cirrhosis and esophagogastric varices by carvedilol
Yupei Liu, Jia Li, Jie Liu, Li Li Zhao
- EP0719 Study on the correlation between serum zinc and lipid metabolism disorders in patients with liver cirrhosis
YUAN LIAO, JIE ZHANG
- EP0720 Long-term exposure to PM2.5 and the risk of incident cirrhosis: a large prospective cohort study in the UK Biobank
Jiang Xiannuan, Liang Zhaoyi, Xie Xiaoxu, Zheng Qi
- EP0721 Partial splenic embolization in the treatment of pleuroperitoneal fluid from cirrhosis

Song Lu Lu, Liu Chang Jiang

- EP0722 Visualizing global progress and challenges in esophagogastric variceal bleeding
De-xin Wang, Jun-yi Zhan, Feifei Xing, Wei Liu, Jiamei Chen, Ping Liu, Cheng-hai Liu, Yong-ping Mu
- EP1064 The Values of Acoustic Radiation Force Impulse Elastography of Liver in Evaluating the Degree of Liver Fibrosis in Alcoholic Liver Disease
LE THU HIEN, Le Quoc Tuan, Dinh Cong Dang, Dinh Cong Tiep

Management of Advanced Chronic Liver Disease (ACLD)

- EP0723 Role of Zinc Supplementation in Cirrhotic Patients with Hepatic Encephalopathy
Eman Rewisha, Ezz Abdelhameed Mehesen, Samar Ibrahim Ghanem, Eman Abdelsameea, Tamer Samir Abd-Elghafar
- EP0724 Noninflammatory diarrhea portends poor outcomes in patients with acute-on-chronic liver
Liu Wan Shu, Zhai Qing Hui, Xin Shao Jie
- EP0725 The efficacy and safety of glucocorticoids in hepatitis B virus-related acute-on-chronic liver failure: A retrospective cohort study based on propensity score matching
XU HONGKAI, Lian Jianqi, ZHANG YE, WANG CHUNFU, YU DENGHUI, HU FEI
- EP0726 Lymphocyte to high density lipoprotein ratio can predict the short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure patients
Linxiang Liu, Xuan Zhu
- EP0727 Low platelet to high-density lipoprotein ratio predicts poor short-term prognosis in hepatitis B-related acute-on-chronic liver failure
Linxiang Liu, Xuan Zhu
- EP0728 5-HETE exacerbates systemic inflammation in patients with ACLF by promoting the formation of NETs
Huilan Tu, Jianing Chen, Xia Yu, Xianbin Xu, Jifang Sheng, Yu Shi
- EP0729 The multicenter study of serum Alpha-fetoprotein screening for survival advantage in patients with Acute-on-chronic liver failure treated with artificial liver
Longchuan ZHU, Jingke ZENG, Guicai YUAN, Xue LIN, YuLin XU, Siqing RAN, Junpeng
- EP0730 Bioreactor production for extracorporeal therapies: Clogging issues and FBS-associated risks
Adrian Dominik, Marcus Frank, Jan Stange
- EP0731 Incidence of different infection characteristics in acute-on chronic liver failure: Meta-analysis and a systematic review
Yulei Lin, Yongning Xin
- EP0732 Comparison of the Effects of Sequential Double Plasma Molecular Adsorption System (DPMAS) Plasma Exchange (PE) with Continuous Venovenous Hemofiltration (CVVH) and DPMAS Sequential PE for Treating Liver Failure
Zerun Deng, Rongjiong Zheng, Lei Yao, Jinliang Pan, Shufang Zhang, Li He, Xiaobo Lu
- EP0733 Clinical efficacy analysis of DPMAS artificial liver treatment for slow plus acute liver failure
Chen Gao
- EP0734 Early Identification of Invasive Fungal Infection in Patients with Acute-on-Chronic Liver Failure: A Prediction Model Based on LASSO Regression

Yang Xu, Wang Xiaohao, Li Hu, Zhong Shan

- EP0735 Cirrhotic Patients Without Classical Acute Decompensation Events Complicated With Severe Jaundice Burdened With a High Risk For ACLF
Yan Zhang, Guohong Deng, Xiaobo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Zhongji Meng, Yanhang Gao, Zhiping Qian, Feng Liu, Xiaobo Lu, Yu Shi, Yubao Zheng, Hai Li
- EP0736 Single-cell transcriptome sequencing revealed CD16⁺ monocyte promote CD8⁺ T cell exhaustion via MIF/CD74 in ACLF patients
Zhouhan Wang, Zhihui Li, Wei Liang, Junyi Wang, Jing Zhang, Junfeng Chen, Bingliang Lin
- EP0737 Application and clinical observation of low molecular weight heparin in artificial liver for patients with liver failure
Wei Yu, Yixiao Zhou
- EP0738 Introducing Middle Cut-Off Membranes to Liver Support: Potential Clinical Implications on Cytokine Removal
Stine Koball, Adrian Dominik, Sebastian Koball, Jan Stange
- EP0739 Machine Learning empowers mortality prediction in patients with HBV-related Acute-on-Chronic Liver Failure
Ruoqi Zhou, Xia Yu, Wenting Tan, Xianbo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Beiling Li, Xinxin Liu, Zhiwei Li, Zhongji Meng, Yanhang Gao, Zhiping Qian, Feng Liu, Xiaobo Lu, Jia Shang, Huadong Yan, Yubao Zheng, Weituo Zhang, Shan Yin, Wenyi Gu, Guohong Deng, Xiaomei Xiang, Yi Zhou, Yixin Hou, Qun Zhang, Shue Xiong, Jing Liu, Ruochan Chen, Liyuan Long, Xiuhua Jiang, Sen Luo, Yuanyuan Chen, Chang Jiang, Jinming Zhao, Liujuan Ji, Xue Mei, Jing Li, Tao Li, Rongjiong Zheng, Xinyi Zhou, Qun Cai, Jifang Sheng, Hai Li, Yu
- EP0740 Comparison of Histological and Clinical Features of Pathologically Diagnosed Acute-on-Chronic Liver Failure in Fibrotic and Cirrhotic Chronic Liver Disease
Peixuan Ji, Wenyi Gu, Lei Xia, Yan Zhang, Jianyi Wei, Yuexiang Bian, Hai Li
- EP0741 Exploring the predictive value of serum lipids for short-term prognosis in patients with acute-on-chronic liver failure
Yunfeng Fu, Kaini Wu, Sicheng Yang, Yuanping Fan, Jianhao Qiu, Qi Zhu, Yating Pan, Xiaqin Chen, Sihai Chen, XiaoDong Zhou
- EP0742 The predictive value of five scoring models for acute-on-chronic liver failure in patients with acute decompensated hepatitis B cirrhosis
Gulinigaer Wusiman, Xiaotang Fan
- EP0743 Single-cell transcriptomics explains risk factors for ascites recurrence
Ying Nie, Zelu Meng, Yining Zhang, Sisi Yang, Yani Zhou, Yu Shi, Yida Yang
- EP0744 Exploring the effectiveness of the chronic management model in patients with advanced chronic liver disease
Wu Siqin
- EP0745 Impact of ascites grading and non-selective β -blockers on 1-year prognosis of Acute-on-chronic liver failure
Liu Wan Shu, Shen Li Jun, He Xi, Tian Hua, Zhai Qing Hui, Li Dong Ze, Xin Shao Jie, You Shao Li
- EP0746 Study of the correlation between red blood cell distribution width as well as red blood cell distribution width-to-platelet count ratio and the prognosis of acute-on-chronic liver failure

- Zhai Qing Hui, Liu Wan Shu, Cao Li Wei, Guo Ling Ling, Li Dong Ze, Xin Shao Jie, You Shao Li, You Shao Li
- EP0747 Study on the indications and prognosis of glucocorticoids in patients with acute-on-chronic liver failure
Jiaxuan Zhou, Rongkuan Li, Xiaotong Ai, Xinmei Chen
- EP0748 Plasma exosomal IDH2 and CTSB mRNA in HBV-ACLF facilitates the Immune cell infiltration and ferroptosis
Qi Huang, Xiaozhou Zhou
- EP0749 Association between red blood cell distribution width to albumin ratio and short-term all-cause mortality in critically ill cirrhotic patients with sepsis: A retrospective analysis of the MIMIC-IV database
Yuanji Ma, Jiayi Wang, Lingyao Du, Hong Tang
- EP0750 Dihydroquercetin mitigates acute-on-chronic liver failure by regulating the autophagy-NLRP3 inflammasome pathway
Cheng Zhang, Bing Wu, Pengfei Wu, Yuqiao Zeng , Ao Shen, Li Wang, Likun Wang
- EP0751 Association between Triglyceride-Glucose Index and Risk of Acute Kidney Injury in Patients with Cirrhosis: A Retrospective Analysis Based on the MIMIC-IV Database
Dianliang Fang, Wenxiu Li
- EP0752 Elevated Factor VIIIa & hyperfibrinolysis are associated with early rebleeding in acute-on-chronic liver failure with acute variceal bleeding
ANCHAL SANDHU, MADHUMITA PREMKUMAR, PRERNA SHARMA, KAMAL KAJAL, ARKA DE, SUNIL TANEJA, JASMINA AHLUWALIA, AJAY KUMAR DUSEJA
- EP0753 rhTPO elevates platelets through PF4 protein-related signaling pathways and promotes liver function recovery in ACLF patients
Gang Liu, Jing Liang
- EP0754 Apoptotic vesicles ameliorated acute-on-chronic liver failure by reducing macrophage-related inflammation
Wei Liang, Zhouhan Wang, Junyi Wang, Zhihui Li, Bingliang Lin
- EP0755 IL-17-producing CD8+ T Cells May Promote HBV Elimination in Patients With Hepatitis B Virus-related Acute-on-chronic Liver Failure
Genglin Zhang, Ting Zhang, Yujing Wang, Zhiliang Gao
- EP0756 An Artificial Intelligence-Driven Predictive and Therapeutic Decision Framework for Acute-on-Chronic Liver Failure: Insights from the KACLIF Cohort
Seong Hee Kang, Young Kul Jung, Jong Jin Hyun, Jung Wan Choe
- EP0757 The Clinical Features and Prognostic Analysis of Pulmonary Fungal Infections in ACLF
Jingjing Li, Xiping Zhao
- EP0758 Predictive value of serum HMGB1 combining HP and CER in patients with acute-on-chronic liver failure
Liuyao Shen, Long Xu, Xiaoqing Xiong, Shengchun Fan, Jun Hu, Min Wu
- EP0759 Gaps in palliative care for liver cirrhosis: An analysis on disease burden, timing and utilization of palliative services

Charlene Yeo Li Xin, Lionel See Kee Yon, Grace Yang, Charlene Tan Huimin, Su Qiqi, Tay Pei Yoke, Aiden Lin Yuda, Jolyn Tan Yi Ling, Koh Guan Hong, Loh Soak Yee, Lim Qian Hui, Marianne Anastasia De Roza

- EP0761 Sarcopenia and Its Impact on Prognosis in Cirrhotic Patients
Zhongwei Pan, Shicheng Zhao, Feng Jiang
- EP0762 METTL3 is involved in skeletal muscle protection through the mTOR pathway in cirrhosis
Minjie Jiang, Wanhua Ren, Qinghua Meng
- EP0763 Analysis of the Incidence and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS).
Li Zhangyun
- EP0764 Effect of Newman System Care Model in Patients with Decompensated Stage of Cirrhosis
Yayao Jie
- EP0765 Clinical Nursing Interventions in the Management of Hepatic Diseases: A Systematic Study
Liqi Wu
- EP0766 Prediction of Decompensation in Hepatitis B-Related Cirrhosis: A Clinical Study
Ping Rao
- EP0767 Partial Splenic Artery Embolization Combined with Endoscopic Treatment for Extrahepatic Portal Vein Occlusion with Gastric Variceal Bleeding
Lijuan Chen, Anbang Chen, Hongbin Zhu, Qian Li, Lixia Xin, Yifu Xia, Guangjun Huang, Lianhui Zhao, Chunqing Zhang, Guangchuan Wang
- EP0768 Deep Learning Integration of Spatial Transcriptomics and 4D Flow MRI for Early Prediction of Portal Hypertension in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease
Rifaldy Fajar, Cendall Aleya Za, Prihantini Prihantini, Iorio Harto Noysuah, Elfiany Syafruddin
- EP0769 Clinical Characteristics and Diagnostic Ideas of Portalpulmonary Hypertension: Analysis of One Difficult Case
Shaohua Guo, Huifan Ji, Xu Zhao
- EP0770 The Impact of Sleep Disturbances and Mental Health on the Outcomes of Acute and Chronic Viral Hepatitis in Mongolia
Purevsod Lkhagvasuren, Tserendulam Bat-Erdene, Chantsal Batjargal, Oyungerel Ravjir, Baatarkhuu Oidov
- EP0771 Echo-endoscopy (EUS) in the evaluation of portal hypertension (PH): a real-life endohepatological approach. Single-center study of 204 patients
FLORIANE SELLIER, Olivia Pietri, Xavier Adhoute, Margaux Caviezel, Marc Bourliere, Paul Castellani
- EP0772 Experience in diagnosis and treatment of 1 case of portopulmonary hypertension
Mengyao Zhang, Qian Zhang, Lanlan Yang, Zhenjing Jin
- EP0773 Solar Terms Characteristics Analysis and Prevention Strategies of Hospital Admissions for Cirrhosis of All Causes and Cirrhosis with Bleeding
Xiaoyue Gao, Jing Wang
- EP0774 Clinical Observation of a Patient with Hepatic Encephalopathy Complicated by Cirrhosis Following TIPS Treatment: A Case Report
Zhibo Xia, Qing Zhang, Jianguo Chu

- EP0775 Research progress of Chinese medicine in treating chronic liver disease by regulating
Shihao Zheng, Peng Zhang, Yongan Ye
- EP0776 Ontology Construction and Knowledge Graph of Integrated Traditional Chinese and Western
Medicine for Liver Disease Treatment
Fan E Cheng, Wenying Qi
- EP0778 Role of Myocardial Perfusion Scintigraphy and Cardiac Magnetic Resonance Imaging in
patients with Cirrhotic Cardiomyopathy
PRERNA SHARMA, MADHUMITA PREMKUMAR, BHUPENDRA KUMAR SIHAG,
ASHWANI SOOD, ANCHAL SANDHU, VISHESH KUMAR, HARISH BHUJADE
- EP0779 Effect of adjusting the dosage of lactulose according to patients' stool characteristics and
frequency on hepatic encephalopathy
Ying Han, Yuan Lve, Yanna Liu, Keke Jin, Ajuan Zeng , Xueying Liang, Huiguo Ding
- EP0780 Role of Macrophage Polarization in Artificial Liver Support Systems Treatment of Acute-on-
Chronic Liver Failure
Jing LI, Suxian ZHAO, Yuemin NAN
- EP0781 Validation and Comparison of Non-invasive Prediction Models based on Spleen Stiffness
Measurement to Identify cACLD Patients with Gastroesophageal Varices
Lin Tuo, Ting Li Yan, Ying Liu, Xingxiang Yang
- EP0782 A case of rare hepatic artery variant
Lijuan Chen, Xiaobing Wu, Hongbin Zhu, Guangchuan Wang
- EP0783 PORTAL VEIN TROMBOSIS IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS
Narina Sargsyants, Eleonaora Sargsyants
- EP0784 Unveiling the Overlap: Budd Chiari Syndrome Presenting as Heart Failure: A Case Report
Jonathan Lapuz De luna
- EP1047 Multimodal Liver Assessment with Endoscopic Ultrasound-guided Portosystemic Pressure
Gradient (EUS-PPG), EUS-liver biopsy & variceal screening: A single centre experience.
Amardeep Khanna, Evripidis Stefanidis, Prarthana Thiagarajan, Andrew Baxter, Hari
Sellappan, Guruprasad Aithal, Suresh Vassan Venkatachalapathy, Martin James
- EP1050 Efficacy of Octeotide Administration in Decreasing Mean Arterial Pressure (MAP) and
Hepatic Venous Pressure Gradient (HVP) in Portal Hypertension Patients: A Systematic
Review and Meta-Analysis
Nicholas Putra Lesmana, Stephen Dario Syofyan, Joshua Francisco Syofyan, Josia
Nathanael Wiradikarta, Juan Benedict Widjaja
- EP1051 Efficacy of Prazosin Supplementation in Decreasing Hepatic Venous Pressure Gradient,
Mean Arterial Pressure, and Increasing Hepatic Blood Flow in Cirrhotic Patients: A
Systematic Review and Meta-Analysis
Nicholas Putra Lesmana, Stephen Dario Syofyan, Joshua Francisco Syofyan, Juan Benedict
Widjaja, Josia Nathanael Wiradikarta
- EP1067 Prediction of acute-on-chronic liver failure in patients with acute decompensated cirrhosis
using computed tomography-based skeletal muscle parameters
Wuxi Zhang, Dong Dong, Yuhang Yuan, Ruoqi Sun

- EP1068 CT-based skeletal muscle radiomics predicts acute-on-chronic liver failure in patients with acute decompensation of cirrhosis
Wuxi Zhang, Dong Dong, Yuhang Yuan, Ruqi Sun

Liver Oncology

- EP0785 A rare case of high-grade undifferentiated soft tissue sarcoma of the liver
Fankun Kong, Yali Ma, Xiuli Wang, Zhiyong Guo, Lijun Chang
- EP0786 The absence of DSC2 is associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy
Zhi Li Wen, Li Guo
- EP0787 Protein C Licenses P62/mTOR-Mediated Autophagy Activation to Drive Hepatocellular Carcinoma Progression
Shuaibing Ying
- EP0788 Vessels that encapsulate tumor clusters (VETC): A promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations
Yanjiang Yin, Bowen Xu, Zhicheng Wei, Xu Che, Xinyu Bi, Jianqiang Cai
- EP0789 Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance
Shizhou Li, Yan Lin, Xing Gao, Dandan Zeng, Weijie Cen, Yuejiao Su, Jingting Su, Can Zeng, Zhenbo Huang, Haoyu Zeng, Shilin Huang, Minchao Tang, Xiaoqing Li, Min Luo, Zhihu Huang, Rong Liang, Jiazhou Ye
- EP0790 Bioinformatics-Based Molecular Subtyping of Hepatocellular Carcinoma and Its Clinical Significance
Yangyang Li
- EP0791 Patterns of liver metastasis in inoperable advanced stage Colorectal and Biliary Tract tumors and its impact on survival- An observational study.
Divyesh Kumar, Harish Bhujade
- EP0792 Immune cell infiltration patterns and prognostic significance in the microenvironment of hepatocellular carcinoma (HCC)
Rixiang Liu
- EP0793 Myofibroblast extracellular vesicle-mediated transfer of ITGA5 to tumor cells enhances cancer stemness in hepatocellular carcinoma
Yang Xiao, Chen Qu
- EP0794 Identification of alternative lengthening of telomeres-related genes prognosis model in hepatocellular carcinoma
Yuliang Chen, Yuliang Chen
- EP0795 Hypoxia induces hepatocellular carcinoma metastasis via the HIF-1 α /METTL16/Lnc-CSMD1-7/RBFOX2 axis
Bixing Zhao
- EP0796 A Novel LC3-Specific Inhibitor D5 as A Universal Autophagy Intervention to alleviate Drug Resistance in Anticancer Therapy
Chenkai Huang

- EP0797 Lnc-PLA2G4A-4 facilitates the progression of hepatocellular carcinoma by inducing versican expression via sponging miR-23b-3p
Bixing Zhao
- EP0798 Long non-coding RNA COX7C-5 promotes hepatocellular carcinoma progression via miR-581/ZEB2 axis
Bixing Zhao
- EP0799 Personalized neoantigen vaccine enhances the therapeutic efficacy of bevacizumab and anti-PD-1 antibody in advanced non-small cell lung cancer
Zhixiong Cai
- EP0800 Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
Ming Wu
- EP0801 Silk-Gel Powered Adenoviral Vector Enables Robust Genome Editing of PD-L1 to Augment Immunotherapy across Multiple Tumor Models
Ming Wu
- EP0802 Optimal Irreversible Electroporation Combined with Nano-Enabled Immunomodulatory to Boost Systemic Antitumor Immunity
Ming Wu
- EP0803 Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment
Ming Wu
- EP0804 Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration
Da Zhang
- EP0805 Engineering PEG10-assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination
Zhixiong Cai
- EP0806 Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma
Da Zhang
- EP0807 Targeting mesothelin enhances personalized neoantigen vaccine induced antitumor immune response in orthotopic pancreatic cancer mouse models
Zhixiong Cai
- EP0808 Combined vaccination of personalized neoantigens and shared MICB $\alpha 3$ antigen enhances the antitumor response by eliciting ILC1s-mediated tumor pyroptosis
Zhixiong Cai
- EP0809 Identification of tumor mutations in plasma based on Mutation Variant Frequency Change (MVFC)
Geng Chen
- EP0810 Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression
Da Zhang

- EP0811 Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency
Da Zhang
- EP0812 Utilization of Artificial Circular RNAs as miRNA Sponges and Anti-PD-1 scFv Expression Platforms to Suppress Hepatocellular Carcinoma Progression
Bixing Zhao
- EP0813 The Role of ETS2 in the Inhibition of Ferroptosis in Hepatocellular Carcinoma Cells Through GXP4 Ubiquitination and Degradation: Mechanisms and Clinical Diagnostic Implications
Xiong Kai
- EP0814 FBXO22 promoted Hepatocellular carcinoma (HCC) progression via paracrine myoinositol-induced M2-type macrophages
Mingyan He
- EP0815 SPP1:FOLR2 macrophage polarity identifies a novel stratification of tumor associated macrophage and provides treatment recommendations for hepatocellular carcinoma
Weixuan Xu, Xiong Chen
- EP0816 Diagnostic Value of Serum N-glycomics Markers in Prognostic Monitoring of Liver Cancer
Pengyuan Kang, Xinjie Li, Tao Shen
- EP0817 The Composition of Circulating Immune Cells After Treatment with Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma
Youngsun Lee, YangJae Yoo, Jihoon Kim, Eunho Choi, Yeonseok Seo, Youngkul Jung, Hyungjoon Yim, Jongeun Yeon, Kwansoo Byun
- EP0818 Exosomal miRNA as a Potential Biomarker for Predicting the Response to Atezolizumab and Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma
Youngsun Lee, Yangjae Yoo
- EP0819 Silencing CCND1 inhibits liver cancer stem cell differentiation and reduces 5-Fu resistance in HCC.
Qi Wang
- EP0820 Double-Responsive Mesoporous Silicon Nano-Drug System Suppresses Hepatoma Postoperative Recurrence and Metastasis through Combination of Chemotherapy and Ferroptosis
Di Wu
- EP0821 Tumor cell-intrinsic CD58 deficiency acting amidst the immunological synapse impairs CD8+ T cell anti-tumor immunity
Hanyi Zeng, Jiaping Yu, Haijian Wang, Lishan Ye, Siyu Wei, Li Liu
- EP0822 Exploring Glycosphingolipids and Tumor Microenvironment in Liver Cancer: Insights into CSC Properties, EMT Phenotypes, and Cell Motility
Yuhjin Liang
- EP0823 Intratumor Microbiome-Sphingononmas May Influence the Tumor Immune Microenvironment of Hepatocellular Carcinoma
Yiyang Sun, Zhongjie Hu, Feili Wei, Wei Hou
- EP0824 Ruminococcus and galactaric acid enhance the efficacy of anti-PD-1 based immunotherapy in hepatocellular carcinoma
Xin Song, Xiyao Chen, Boxiang Zhang, Xingrong Zheng, Chan Xie

- EP0825 Qi - Zhu Anti - Cancer Prescription Inhibits Angiogenesis and Tumor Growth of Hepatocellular Carcinoma by Regulating Autophagy of Vascular Endothelial Cells through the PI3K/AKT Pathway
Aaron Yih
- EP0826 Neuraminidase 1 deletion inhibited the development of hepatocellular carcinoma through Wnt/ β -catenin Signal Pathway: Therapeutic effects of celastrol
Shujun Jiang, Yanliang Zhang, Shiran Mei, Huiqin Hu, Aoyi Wang
- EP0827 HBV-DEPDC5 Integration as a Prognostic Biomarker and Potential Oncogenic Driver in HBV-Related Hepatocellular Carcinoma
YUDE CHU, CHAUTING YEH
- EP0828 FOXM1 regulates intrahepatic cholangiocarcinoma proliferation, migration, and apoptosis through the TGF β 1/Smad3-YAP/TAZ-BBC3 axis
Tongshu Wang, Min Zhou, Hongxin Piao
- EP0829 DHAQ upregulates Keap1 ubiquitination via SYVN1 to promote ferroptosis in hepatocellular carcinoma
Yulang Jiang, Xin Shi, Peizhen Ma, Mingyu Sun
- EP0830 Identified new biomarkers of hepatocellular carcinoma
Yitian Sun
- EP0831 Network pharmacology analysis of KangXianYiAi formula in treating hepatocellular carcinoma
Fan E Cheng, Xiaobin Zao
- EP0832 Exploring the Role and Mechanism of Jinqiancao in Inhibiting EMT in Liver Cancer via the SNAIL Signaling Pathway
Fan E Cheng, Xiaobin E Zao
- EP0833 Research Progress on the mechanism of action of primary hepatocellular carcinoma related pathways
Xiaoxue Wang
- EP0834 MTA1 Spliced Isoform, MTA1dE4, Contributes to Early Recurrence of Hepatocellular Carcinoma via Signature Genes Linked to Metastasis
YungTsung Li, ChunJen Liu, PeiJer Chen, JiaHorng Kao, HuiLin Wu
- EP0835 Dihydroquercetin induces the apoptosis of HepG2 cells through the AKT/MDM2/p53 axis
Yuqiao Zeng, Cheng Zhang, Bing Wu, Li Wang, Pengfei Wu, Ao Shen, Likun Wang
- EP0836 Characterization of Indole-3-carboxaldehyde as a biomarker for early screening of intrahepatic cholangiocarcinoma recurrence
Yanan Yan, Jianmin Wang, Jingfeng Liu
- EP0837 Network Pharmacology Analysis and Molecular Docking Study of Tongxinluo for the Treatment of Metabolic Associated Fatty Liver Disease
Wenying Qi, Qiuyue Wang, Xin Sun, Tingyu Zhang, Shihao Zheng, Xiangyun Zou, Jia Bo, Qiyao Liu, Xiaobin Zao
- EP0838 Differential Roles of Inflammatory Cancer-Associated Fibroblasts (iCAFs) and Myofibroblasts (mCAFs) in Hepatocellular Carcinoma: Implications for Angiogenesis and Prognosis
Fansen Ji, Haoming Xia, Shizhong Yang, Jiahong Dong

- EP0839 The mechanism of Xiaoliu Granule restrains HepG2 by mediating the Rac1-PI3K / Akt
ChengYi Wan, Mei Wu, Qiqun Gu, Jian Ping
- EP0840 The Molecular Receptor NKBB Enhances the Persistence and Anti-hepatocellular Carcinoma
Activity of GPC3 CAR-T Cells
Minghao Sui, Songbo Zhao, Qiang Zhu
- EP0841 O-GlcNAcylation of METTL3 drives hepatocellular carcinoma progression by regulating the
m6A-MCM10-IGF2BP3 axis
Zhen Chen, Ni Tang
- EP0842 Network Pharmacology Analysis and Molecular Docking Study of Tongxinluo for
Hepatocellular Carcinoma Treatment
Qiuyue Wang, Wenying Qi, Shihao Zheng, Xiangyun Zou, Xiaobin Zao, Qiyao Liu
- EP0843 Primary Isolation and Culture Protocol for Liver Tumor Organoids
Wenying Qi, Yanwei Gao, Wei Luan, Qiuyue Wang, Yujie Wang, Xiangyun Zou, Xiaobin Zao
- EP0844 Vitamin B2 Metabolic Enzyme FAD Synthase Impedes Ferroptosis and Restrains Anti-tumor
Immunity in Hepatocellular Carcinoma
Jiashuo Chao, Yuan Liang, Hao Wang, Haitao Zhao, Ling Lu
- EP0845 POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in
hepatocellular carcinoma
Hao Wang, Ling Lu
- EP0846 TBX15 regulates sorafenib resistance in hepatocellular carcinoma through cGAS/STING
pathway
Hui Yuan, Zihao Kong, Mengfan Jiao, Chuanlong Zhu
- EP0847 LncRNA SOCS2-AS1 inhibits tumor progression and angiogenesis by targeting AVPR2
Liang Bao, Huahu Guo, Suxin Li, Luhao Li, Lin Li, Longfei Xie, Zhaochen Liu, Xiaowei Dang
- EP0848 Regulatory Mechanisms of Signaling Pathways in Liver Cancer Treatment with Traditional
Chinese Medicine
Shihao Zheng, Qiuyue Wang, Wenying Qi, Size Li, Wei Wang, Xiangyun Zou, Qiyao Liu,
Xiaoke Li, Jiaxin Zhang, Xiaobin Zao, Yongan YE, Peng Zhang
- EP0849 Indole Derivatives Reshape the Tumor Immune Microenvironment to Synergize with
Immunotherapy in Hepatocellular Carcinoma
Wenhan Liu
- EP0850 The Achilles' Heel of Hepatocellular Carcinoma: Ginsenoside CK as a Novel GPX4 Degradator
Promotes Ferroptosis in Hepatocellular Carcinoma
Yulang Jiang, Xin Shi, Xulin Liu, Mingyu Sun
- EP0851 Identifying Potential Immune Cell Signatures in Hepatocellular Carcinoma through Integrative
Bioinformatics and Machine-Learning Approaches
Jing Hong, Xingchen Liu, Jie Ding, Xiaofeng Zhai, Bo Pan, Jianming Zheng
- EP0852 The anti-Hepatocellular Carcinoma Activity and Their Underlying Mechanism of HuQi
Huan Chen, Xiu Hui Li
- EP0853 Nervous System in Hepatocellular Carcinoma: Correlation, Mechanisms, Therapeutic
Implications, and Future Perspectives
Wenxuan Li, Jinghao Zhang, Yueqiu Gao, Xiaoni Kong, Xuehua Sun

- EP0854 Prediction model for HBV-related hepatocellular carcinoma
Yong Lin, Jin Shui Pan
- EP0855 Atypical Presentation of Secondary Hepatic Lymphoma with Severe Hepatic Involvement: A Case Report
Dongliang Zhao, Lai Wei
- EP0856 An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver
Zongren Ding
- EP0857 The LI-RADS Evaluation for Liver Transplantation Eligibility Criteria in Patients with Hepatocellular Carcinoma: An Outcome Study of 1,059 Recipients
Yeongseok Hwang, Soobin Huh, Seonok Kim, Keewon Song, Sanghyun Choi, Jihyun Ahn, Juhyun Shim
- EP0858 Clinicopathologic significance of fibrosis patterns in HCC and cholangiocarcinoma
HungWen Tsai, Matthew Yeh, Yayun Ren, Kutbuddin Akbary, Elaine Chng, Dean Tai
- EP0859 Transformer-Based Prediction of Immunotherapy Response in Unresectable Hepatocellular Carcinoma Using Pretreatment Multi-sequence Contrast-Enhanced MRI: A Retrospective, Multicenter Study
Jialin Chen, Linbin Lu, Hongyi Yang, Xiong Chen
- EP0860 The Performance of a New HCC Surveillance Strategy Integrating PIVKA-II and GAAD Score in Patients with Chronic Liver Disease: A Prospective Single-center Study
Haiguang Xin, Simin Guo, Honglian Gui, Huijuan Zhou, Xiaolin Wang, Rongtao Lai, Weiliang Tang, Baoyan An, Shaowen Jiang, Yan Huang, Qing Xie
- EP0861 Clinical Characteristics and Risk Factors for HBV-Related Early-Onset and Non-Early-Onset Hepatocellular Carcinoma
Songlian Liu, Yaping Wang, Bo Li, Lihua Lin, Chujiing Li, Aiqi Lu, Qikai Ning, Yujuan Guan, Jianping Li
- EP0862 The combined application of AFP, PIVKA- II , and GP73 in diagnosing hepatitis B-associated hepatocellular carcinoma is consistent with liver patholog
Rui Hu, Yueqin Ni, Li Xiao
- EP0863 Rare Occurrence of Haemobilia and Haemoperitoneum Simultaneously Post Percutaneous Liver Biopsy: A Case Report
Ian Liew, Robert Lo
- EP0864 A case of xanthogranulomatous cholecystitis masquerading as gallbladder carcinoma
Lingpeng Yang
- EP0865 Prevalence of malnutrition in patients with Hepatocellular cancer – a single center prospective study
Prachi S Patil, Samiya Khan, Deepika Lakshmi Ganesan, Vanessa Almeida, Aditi Borhade, Swati Hegde, Sadaf Fatima Husain, Dhyani Mistry, Sridhar Sundaram, Aditya Kale, Shaesta Mehta, Akash Pawar, Shraddha Patkar, Mahesh Goel
- EP0866 An Unusual Liver Mass Mimicking Colorectal Cancer Liver Metastasis: Sclerosing
Lingpeng Yang

- EP0867 A Novel Strategy for Personalized Intraoperative Imaging of Liver Cancer: Extracellular Vesicle-Based NIR-II Fluorescence Probes
Zirui Bai, Jian Li
- EP0868 Stable detection of hepatocellular carcinoma using FAP+ CAFs peptide-targeted NIR-I/II fluorescence imaging: a clinically translatable approach
En Lin, Jian Li
- EP0869 Sarcopenia and Subcutaneous Adipose Tissue Index as Predictors of Hepatocellular Carcinoma Risk in Cirrhosis: Insights from a Cohort Study
Seong Hee Kang, Young Kul Jung
- EP0870 CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor microenvironment
Gongzheng Wang, Feier Ding, Jin Cui, Xinya Zhao, Ximing Wang
- EP0871 Chemotherapy for hepatocellular carcinoma associated with macrovascular invasion: a study based on the SEER database
Zhongying Shi, Jingyu Zhang, Jingfeng Liu, Jianming Wang
- EP0872 Risk factors of very early recurrence of intrahepatic cholangiocarcinoma after surgery
YU CHENGSHU, LIN KECAN, LIU HONGZHI, ZENG YONGYI
- EP0873 Personalized Neoantigen Hydrogel Vaccine Combined with PD-1 and CTLA-4 Double Blockade Elicits Antitumor Response in Liver Metastases by Activating Intratumoral
Zhixiong Cai
- EP0874 Prognostic impact of tumor size on postoperative prognosis of solitary intrahepatic cholangiocarcinoma: a multicenter retrospective analysis
Ruilin FAN, LIU Hongzhi, LIN Qizhu, HUANG Tingfeng, ZENG Yongyi
- EP0875 Revealing key genes related to stemness in hepatocellular carcinoma through bioinformatics analysis
Zeng Junbao, Wen Zhili
- EP0876 Low-dose Chemotherapy Sensitizes Cholangiocarcinoma Immunotherapy Efficacy via Mediating SPP1+ Macrophages Elimination
Liang Zhixing, Liu Shanshan, Yu Haoyuan, Ye Linsen, Yang Yang
- EP0877 Clinical efficacy of interventional therapy combined with antiviral therapy in patients with hepatitis B related liver cancer
Chen Gao
- EP0878 Interventional combined microwave ablation for primary neuroendocrine carcinoma of the liver failing systemic chemotherapy: a case report
Yang Fang, Songnan Zhang
- EP0879 RBM8A promotes proliferation and metastasis of HCC through the AKT/mTOR signaling pathway
Xiong Xiaofeng, Wen Zhili
- EP0880 Study of the Anti-cholangiocarcinoma Effect of Erianin by Inhibiting the ITGB4-FAK Pathway
Wenjing Yang
- EP0881 Clinical Value of the Prognostic Nutritional Index in Predicting the Prognosis of Advanced Liver Cancer Treated with Transarterial Chemoembolization Combined with Ablation Therapy

Wenjing Yang

- EP0882 GCR Index: A Promising Biomarker Associated with Treatment Response of Neoadjuvant Chemotherapy for Patients with Colorectal Cancer Liver Metastases
Yanjiang Yin, Bowen Xu, Zhiyu Li, Hong Zhao, Xinyu Bi, Jianqiang Cai
- EP0883 PARD3 promotes TAZ nuclear localization and promotes AREG transcription to promote hepatocellular carcinoma cell invasion, migration and epithelial mesenchymal
Haiyan Fu, Hongjuan Li, Futao Dang, Jie Zhang, Qihong Wang
- EP0884 Metastatic Carcinomatous Cirrhosis Mimicking as Regenerative Liver Nodules in a Filipino Breast Cancer patient: A Case Report
Ysaac Querubin De Ocampo, Stephanie Monreal Dizon, MariaLuisa Abesamis Tiambeng, Celina Hernando Adraneda, Ryan Tupas Barroso
- EP0885 ALBI Grade and EZ-ALBI Grade for predicting Prognosis of Combined hepatocellular-cholangiocarcinoma Patients after liver resection
Lingpeng Yang, Kunlin Chen, Wentao Wang
- EP0886 The Role of Endoscopic Ultrasound in Detection of Liver Metastasis in Pancreatic Cancer Patients
Alaa Alsawak, Ahmed Eliwa, Mohamed Talaat Mohamed, Ashraf Elbahrawy
- EP0887 Mechanistic Study of CYP2W1 Promoting the Progression of Colorectal Cancer Liver Metastasis through Cholesterol Metabolism
Hui Zhang, Jingfeng Liu
- EP0888 Deubiquitinase USP7 promotes invasion and metastasis of intrahepatic cholangiocarcinoma by stabilizing p52 and activating non-canonical NF- κ B signaling
Tao Yuan, Hao Shen, Shengyu Huang, Yuheng Hu, Chenxiang He, Jun Li
- EP0889 A novel prognostic signature for hepatocellular carcinoma based on cuproptosis-related long non-coding RNAs
Yao Liu, Zheng Zhang
- EP0890 Serum palmitoylcarnitine shows potential as a biomarker for the diagnosis of hepatocellular carcinoma - a Mendelian randomization study
Yuwei Wang
- EP0891 Multicenter Queue-Based Explainable Artificial Intelligence Model for Liver Cancer and Spatial Proteomics Feature Study
Peizhen Wen, Hui Qian
- EP0892 Comprehensive bioinformatics analysis and machine learning of SPP1 as a target in non-alcoholic fatty liver disease associated hepatocellular carcinoma
Youwen Hu, Zhili Wen
- EP0893 A migrasome-related lncRNA prognostic model to predict survival and response to immunotherapy in liver hepatocellular carcinoma
Zhaohui Liao, Zhengyuan Xie
- EP0894 Prognostic Prediction of Hepatocellular Carcinoma Patients Based on Heterogeneous Glycosylation Patterns
Fanqin Bu

- EP0895 Initial Investigation of CNOT2 Expression, Function, and Mechanism in Hepatocellular Carcinoma
Jinke Wang, Kunhe Zhang
- EP0896 The mechanism of POLE2 promotes the proliferation and invasion of hepatocellular carcinoma via regulating YAP1
Dan Li
- EP0897 A novel protein C1orf220 encoded by a LncRNA inhibits HCC development by modulating mitochondrial membrane potential
Lin Zhang, Guangzhi Jin
- EP0898 Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: a multicenter study
Qizhen Huang, Kongying Lin, Yufeng Chen, Chuandong Sun, Shuguo Zheng, Jinhong Chen, Yifan Wang, Yanming Zhou, Weiping Zhou, Yongyi Zeng
- EP0899 The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma
Xinting Pan
- EP0900 Diagnostic significance analysis of plasma VEGF after PLT count standardization in patients with primary liver cancer
Pan Xu, Wan Zhou, Xiaohao Wang
- EP0901 LncRNA FTX accelerates the progression of hepatocellular carcinoma by FTX/miR-374a-3p/HMGB1 pathway
Min Zhang, Songman Yu, Shang Gao, Haiyan Bu, Lihua Duan, Yan Huang
- EP0902 Analysis of ferroptosis genes in hepatitis B-related hepatocellular carcinoma based on bioinformatics
Yonghong Wang, Cunliang Deng
- EP0903 Expression and Clinical Value of CTH in Hepatitis B Virus-Related Hepatocellular Carcinoma
Hongyu Liu, Chao Jin, Caillian Cai, Keshan Wang, Fangpeng Ling, Bingling Fan, Xuemei Chen, Shiyu Lan, Minghua Su
- EP0904 PRMT3 drives PD-L1-mediated immune escape through activating PDHK1 in hepatocellular carcinoma
Chenhong Ding, FangZhi Yan, Xin Zhang, Weifen Xie
- EP0905 Genomic Profiling and Potential Biomarkers for Predicting Response to Immune Checkpoint Inhibitors in Advanced HBV-Related Hepatocellular Carcinoma
Feili Wei, Juan Li, Songtao Liu, Shan Guo, Xinxin Wang, Zhongjie Hu, Jushan Wu
- EP0906 Comparison of Survival and Prognosis between Alpha-fetoprotein Positive and Negative Hepatocellular Carcinoma: A SEER Population-based Study
Shenghao LI, Yanqing Ye
- EP0907 Overexpression of Microtubule-Associated Protein 4 Is a Risk Factor for Early Recurrence and Correlates with Poor Prognosis in HBV-HCC Patients
YuAn Su, YungTsung Li, HuiLin Wu, ChunJen Liu
- EP0908 G2M-checkpoint Related Immune Barrier Structure and Signature for Prognosis and Immunotherapy Response in Hepatocellular Carcinoma: Insights from Spatial Transcriptome and Machine Learning

Jingjing Tang, Shiji Wu, Junxin Wu

- EP0909 Pyroptosis-related pattern depicting tumor microenvironment and association with prognosis and efficacy in patients with hepatocellular carcinoma receiving combined molecular targeted therapy and immune checkpoint inhibitors: A multi-omics study
Yanjiang Yin, Bowen Xu, Zhiyu Li, Hong Zhao, Xinyu Bi, Jianqiang Cai
- EP0911 TREM2 induces an immunosuppressive status in intrahepatic cholangiocarcinoma through efferocytosis-mediated metabolic reprogramming
Hao Cai, Min Deng, Xinyue Zou
- EP0912 Expression of ALKBH1 in Hepatocellular Carcinoma and Its Clinical Significance
Lixia Lu
- EP0913 Singel-cell and bulk transcriptomics reveal DDX1 as a driver of cancer stemness and tumorigenesis in hepatocellular carcinoma
YAO Yang, Hongsong Chen
- EP0914 Identification of Potential Genes Mediating the Causal Relationship Between DNA Methylation in HCC and White Blood Cell Counts
Yang Qiu, Lianjun Xing, Haiyan Zhang, Xiao Yu, Lielu Pan, Dinghong Xiao, Hongyu Miao, Ruiying Wang, Nan Shen, Peimin Pu, YinLing Zhou, Zhidong Liu, Lin He
- EP0915 METTL3-mediated regulation of m6A RNA methylation in hepatocellular carcinoma
Chaojie Yu, Zhenjing Jin
- EP0916 NPLOC4 regulates cuproptosis in hepatocellular carcinoma through the FOXO3a/FDX1 axis
Jing Deng, Jing Cao, Jiao Gong, Xinhua Li, Yutian Chong
- EP0917 Clinical significance and biological role of circUGP2 expression in hepatocellular carcinoma
Longfei Xie, Suxin Li, Luhao Li, Liang Bao, Lin Li, Zhaochen Liu, Xiaowei Dang
- EP0918 LINC00892 regulates hepatocellular carcinoma through SBDS/EIF6 mediated ribosomal stress and interacting with the immune microenvironment
Xiangchun Ding, Zhang Xu
- EP0919 Mechanisms of Fatty Acid Metabolism in Promoting Hepatocellular Carcinogenesis under the Background of Hepatitis B-Related Cirrhosis
Yangqing Ma, Haina Fan, Chenghai Liu
- EP0920 ALKBH5 regulates the malignant behavior of liver cancer cells through the activation of PI3K/AKT pathway by HGF
Huimin Liu, Hongxin Piao
- EP0921 Ubiquitin-specific peptidase 18 attenuates endoplasmic reticulum stress via the PERK-eIF2 α -ATF4 axis to reduce apoptosis in hepatocellular carcinoma cells
Lin Li, Qingsong Lei, Yi Huang, Huabao Liu
- EP0922 G-quadruplexes dependent FOXA1 transcriptional brake is attenuated by DNA helicases CHD2 in liver cancer
Huiyu Yang, Enhui Zhou, Han Li, Ying Peng, Wentian Liu
- EP0923 Visualization and Targeting of Liver Cancer Stem Cell-like Cells in vivo Reveals Their Fundamental Roles in Hepatocarcinogenesis and Therapy Resistance
Lexing Yu, Ziyue Guan, Jiaojiao Tang, Chunliang Liu, Yan Ling, Hongyang Wang

- EP1052 Integrated Bioinformatic Analysis on the Mechanism of Chronic Inflammation in Hepatocellular Carcinoma Patients
Stephen Dario Syofyan, Nicholas Putra Lesmana, Josia Nathanael Wiradikarta, Juan Benedict Widjaja, Joshua Francisco Syofyan
- EP1065 Machine Learning-Driven Integration of Single-Cell Multi-Omics Reveals Hepatic Stellate Cell Plasticity as a Mediator of Chemoresistance in Hepatocellular Carcinoma
Sahnaz Vivinda Putri, Andi Nursanti Ureng, Prihantini Prihantini, Rifaldy Fajar, Tata Bannur

Liver Cancer Management

- EP0924 Quantifying increased confidence in ruling out HCC using liver function tests and quantitative MRI
YiChun Wang, Elizabeth Shumbayawonda, Jeremy WeiSong Choo, Sulaiha Binte Ithnin, GuanHuei Lee, Marianne Anastasia De Roza, KokKiong Ong, Patricia ChingYen Chia, KeeTung Tan, NgiapChuan Tan, HanChong Toh, OiFong Chong, Jason PikEu Chang, WeiLyn Yang, XinYi Yeap, Cheryl MinEn Chua, Jacelyn SiouSze Chua, Jade ShuQi Goh, YuKi Sim, Carine ChingYee Lim, Kate Halkerston, Daniel Bulte, Michael Brady, Pierce Chow
- EP0925 The m6A reader IGF2BP3 promotes LIHC progression by enhancing MCM10 stability
Lianwu Zhao
- EP0926 Advanced Hepatocellular Carcinoma was Treated Radically with Multimodality Treatment: A Case Report
Hoa Thi Nguyen, Thang Tran
- EP0927 Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis
Yuxin Liang, Deyuan Zhong, Xiaolun Huang, Qinyan Yang
- EP0928 A machine learning model based on the “6 and 12 criteria” for predicting the prognostic effect of target-immunity combined with TACE in patients with Advanced hepatocellular carcinoma
Yanjie Zhang, Man Zhao, Jianfei Shi, Lili Mi, Guang Yang, Fei Yin
- EP0929 Efficacy and Safety of Radiotherapy versus Transarterial Chemoembolisation in Combination with Lenvatinib and Camrelizumab for Hepatocellular Carcinoma with Inferior Vena Cava/Right Atrium Tumor Thrombus: A Multicenter Study
Qizhen Huang, Kongying Lin, Shaoxing Chen, Yufei Zhou, Juhui Chen, Jinsheng Hong, Yongyi Zeng
- EP0930 Screening of the beneficiaries of adjuvant chemotherapy based on the prognostic model of intrahepatic cholangiocarcinoma
Qizhu Lin
- EP0931 TLR3 Activation Enhances Abscopal Effect of Radiotherapy in HCC by Promoting Tumor Ferroptosis
Mengchao Hepatobiliary Hospital of Fujian Medical University, Hepatology Branch of Fujian Medical Association, Liman Qiu
- EP0932 The study of the characteristics of portal vein thrombosis in patients with hepatocellular carcinoma and survival rates following treatment with transarterial chemoembolization (TACE) in HRH Princess Maha Chakri Sirindhorn Medical Center
Apinya Thammongkolchai, Asawin Sudchareon
- EP0933 Clinical efficacy observation of HBV related primary liver cancer sarcopenia
Chen Gao

- EP0934 Modeling the Prediction of Spontaneous Rupture and Bleeding in Hepatocellular Carcinoma Based on Machine Learning Algorithms
Juchao Chen
- EP0935 Development and Validation of a Nomogram based on systemic inflammatory markers for overall survival in patients with synchronous colorectal liver metastasis after Transarterial Chemoembolization
Yiheng Cai, Danyang Zhao, Wei Zhang
- EP0936 Hepatic arterial infusion of gemcitabine-based chemotherapy combined with lenvatinib and PD-1 or PDL-1 improves prognosis in patients with intrahepatic cholangiocarcinoma
Zhenzhen Zhang, Boheng Zhang
- EP0937 Clinical experience of durvalumab plus tremelimumab therapy for advanced hepatocellular carcinoma in NHO Kumamoto Medical Center
Kazuhiro Sugi, Yurie Akagi, Yuya Yamamoto, Yurika Hanazono, Shuhei Kusumoto, Hirota Sasaki, Taichi Matsuyama, Masakuni Tateyama
- EP0938 Non-surgical hepatocellular carcinoma treated by radioembolization with personalized dosimetry. French multicenter real-life study after matching with other therapeutic modalities.
Xavier Adhoute, Louis Carmarans, Claude Somma, Olivier Durieux, Alexia Gonzalez, Guillaume Penaranda, Marc Bourliere, Albert Tran, Rene Gerolami, Floriane Sellier, Patrick Chevallier, Paul Castellani, Olivia Pietri, Margaux Caviezel, David Taieb, Rodolphe Anty
- EP0939 Personalized Accurate Prediction for Tumor Progression in Unresectable Hepatocellular Carcinoma after TACE-A Machine Learning Based Predictive Model
Wen Li Lu, Run Sun, Nan Nan Zhang, Xiao Lin Tang, Wen Rui Zhao, Yu Cui Qin, Tao Li
- EP0940 Development and validation of a machine learning-based nomogram for predicting the model of early metastasis of Hepatocellular Carcinoma underwent Transarterial Chemoembolization
Nannan Zhang, Wenli Lu, Linlin Sun, Rui Sun, Qingzhong Ke, Wanhua Ren, Tao Li
- EP0941 Stereotactic Body Radiotherapy for intrahepatic lesions of hepatocellular carcinoma
Hideo Yoshida, Koji Uchino, Hiroyoshi Taniguchi
- EP0942 Radiation Pneumonitis Following Resin-Based Yttrium-90 Selective Internal Radiation Therapy – A Single Institution Retrospective Study
Kaina Chen, Aaron Tong, Aaron Tong, Pierce Chow
- EP0943 A Retrospective Study on the Outcomes of Lenvatinib and Percutaneous Microwave Ablation Therapy in Intermediate-Stage Hepatocellular Carcinoma
ARIANE ESCOBAR JOSE-BALUYOT, DIANA ALCANTARA PAYAWAL
- EP0944 Ablation remains superior to TACE and SIRT for very early HCC (BCLC 0) but not early (BCLC A) or intermediate (BCLC B) stage disease
Oliver Moore, Golo Ahlenstiel
- EP0945 Efficacy of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Randomized Controlled Trial
Yi Zhang, Xianbo Wang
- EP0946 HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway
Kuiyuan Huang, Ziyang Liu, Zhanglian Xie, Xiaoyong Zhang

- EP0947 Scutellarein suppresses hepatocellular carcinoma growth via targeting FXRD5
Qian Li, Yating Gao, Zhili Huang, Rongjie Zhang, Wenlan Zheng, Xiaoxiao Yu, Longshan Ji, Xin Zhang, Yunfeng Guan, Yueqiu Gao, Man Li
- EP0948 The therapeutic effect of Scutellaria barbata on hepatocellular carcinoma: validation based on the effective compound luteolin
Rongjie Zhang, Qian Li, Xiaoxiao Yu, Yating Gao, Longshan Ji, Zhili Huang, Xin Zhang, Yueqiu Gao, Man Li
- EP0949 The effect of XPD on PTEN gene expression and cell proliferation in Hep3B liver cancer cells
Tengzheng Li
- EP0950 4'-hydroxywogonin suppresses hepatocellular carcinoma progression via inhibiting AXL/PI3K/AKT signaling pathway
ChiYuan Chen, ChinChuan Chen, ChauTing Yeh, TongHong Wang
- EP0951 Hsa-miR-6721-5p targets GPX4 to regulate ferroptosis of liver cancer cells
Zhengqiang Wu, Zhili Wen
- EP0952 Prognostic and Predictive Value of Transcription Factors Panel for Digestive System
Guoxu Fang
- EP0953 The roles and mechanisms of transcriptional activation of Linc01910 via 3D chromatin reprogramming and its interaction with EZH2 in the liver metastasis of pancreatic cancer
Wang Fen Fen, Wen Zhi Li
- EP0954 Influence of Different TKIs on Hepatic Stiffness and Prognosis in Advanced HCC
LU YINYING
- EP0955 Global, regional, and national liver cancer attributable to smoking and alcohol use burden, 1990-2021: analysis for the Global Burden of Disease 2021 Study
Chenyi Liu, Mingqin Lu, Chao Cai, Shu Li, Shiwen Wu, Jiawen Chen
- EP0956 Pentfluridol Induces Hepatocellular Carcinoma Cell Apoptosis by Increasing Reactive Oxygen Species
Chen Qiu, Zhenjing Jin
- EP0957 Mechanistic Study of ACP5-Mediated Tumor Infiltration of Treg in Hepatocellular Carcinoma Based on Single-Cell Transcriptome Sequencing
Lei Qiao
- EP0958 Anatomic versus non-anatomic resection for early-stage intrahepatic cholangiocarcinoma
Liu Hongzhi
- EP0959 Impact of surgical margin width on long term outcomes for intrahepatic cholangiocarcinoma
Liu Hongzhi
- EP0960 Clinical efficacy of laparoscopic hepatectomy for intrahepatic cholangiocarcinoma
Luo Liu Ping, Li Jian Wei
- EP0961 Proteomics-driven noninvasive screening of circulating serumproteinpanelsfortheearly diagnosis of hepatocellular carcinoma
Xiaohua Xing, Xiaolong Liu
- EP0962 Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy

Xiaohua Xing, Xiaolong Liu

- EP0963 Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma
Jianxing Zeng
- EP0964 Efficacy of Radiofrequency Ablation Guided by Contrast-enhanced Ultrasound in the Treatment of Liver Cancer: A Meta- analysis
Ziting Peng, Tongdong Shi
- EP0965 Dynamic Muscle Atrophy predicts outcomes in Unresectable Hepatocellular Carcinoma patients treated with first-line Lenvatinib
Yuan Hung Kuo
- EP0966 Radiofrequency ablation for peribiliary hepatocellular carcinoma: propensity score matching analysis
Jin Cui, Gongzheng Wang, Feier Ding, Ximing Wang, Xinya Zhao
- EP0967 The Impact of PD-1 Inhibitors on Prognosis in Unresectable Hepatocellular Carcinoma Treated with TACE and Lenvatinib: A Retrospective Study
Zongren Ding, Yongyi Zeng
- EP0968 Advances in Targeting Tumor-Associated Macrophages
Ke Dong Xu, Zhili Wen
- EP0969 Biodegradable MnO₂-based Gene-engineered Nanocomposites for Chemodynamic Therapy and Enhanced Antitumor Immunity
Yiru Wang, Yaning Wu, Aixian Zheng
- EP0970 Human Serum Albumin as the Carrier to Fabricate STING-activating Peptide Nanovaccine for Antitumor Immunotherapy
Zhaoyu Ning, Yaning Wu, Aixian Zheng
- EP0971 Identification of Key Genes and Pathways in Lenvatinib Resistance in Hepatocellular
Ming Yang, ZhaoYue Wang, RiGa Su, Jun Zhou, Lai Wei
- EP0972 Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma
Guoxu Fang
- EP0973 Analysis of the Impact of Hepatitis B Virus Reactivation on Systemic Therapy and Prognosis in Elderly uHCC Patients
Liang Zhipeng, Chen Xiong, Lu Yinying
- EP0974 Janus Silica Nanoparticle Based Tumor Microenvironment Modulator for Restoring Tumor Sensitivity to PD-L1 Immune Checkpoint Blockade Therapy
Xinyi Lin, Xiaolong Liu, Yongyi Zeng
- EP0975 Online Risk Scores for Pre- and Postoperative Prediction of Early Recurrence in Hepatocellular Carcinoma Patients Undergoing Conversion Liver Resection After Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors Therapy

Kongying Lin, Hongzhi Liu, Jianwei Liu, Xiaodong Zhu, Yangxun Pan, Shunli Shen, Wei Zhang, Renan Jin, Chuangye Han, Jie Chen, Xiaoyun Zhang, Binyong Liang, Yaodong Zhang, Jian Ma, Nanya Wang, Dongxiao Li, Rui Xiong, Zhongchao Li, Jingdong Li, Zhibo Zhang, Jinhong Chen, Yufeng Chen, Lu Zheng, Lei Zhao, Tao Yin, Deyu Li, Lei Zhang, Xiangcheng Li, Zhiyong Huang, Tianfu Wen, Yajin Chen, Tao Peng, Xiao Liang, Tianqiang Song, Ming Kuang, Li Xu, Kui Wang, Huichuan Sun, Yongyi Zeng

- EP0976 Spatial Gene Expression Analysis of Liver Cancer Tissues Resected After Atezolizumab Plus Bevacizumab Combination Therapy: A Focus on Sinusoidal Immunity
Katsuya Nagaoka, Masaya Onishi, Tashinori Toyota, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Kentaro Tanaka, Takayuki Tokunaga, Etsuko Iio, Yoko Yoshimaru, Takehisa Watanabe, Hiroko Setoyama, Yasuhito Tanaka
- EP0977 Aberrant Activation of PI3K/AKT/HIF-1 α Pathway Promotes Glycolysis and Lenvatinib Resistance in Hepatocellular Carcinoma
Jinfeng Wang, Fei Yin, Jianfei Shi, Lili Mi, Ning Li, Man Zhao, Guangjie Han, Xin Han, Xiaoling Duan
- EP0978 The immunosuppressive role of NQO1+ macrophages in hepatocellular carcinoma
Linnan Song, Yuhao Wang, Libo Tang
- EP0979 Survival analysis of patients with advanced hepatocellular carcinoma and esophagogastric variceal hemorrhage after targeted immunotherapy
Jing Liang, Ran Ran Duan, Hui Feng Li, Xu Zhang
- EP0980 Treatment Response and Prognostic Risk Factors for Six-Month Mortality in Hepatocellular Carcinoma Patients Treated with Lenvatinib
Franzeska Anna Widinartasari, Didik Indiarso, Hesti Triwahyu Hutami, Hery Djagat Purnomo
- EP0981 Chitinase 3-Like Protein-1 Can be Used to Predict the Prognosis of Hepatocellular Carcinoma Patients Receiving Immunotherapy.
MengYuan Hu, ZhenLuo Jiang, Xue Li, XiaoYu Qian, ShuHui Nie, You Zhao, LiLi Shen, YunSong Qian, LiYun Fu
- EP0982 Low-level viremia weakens prognosis in patients with hepatitis B-associated advanced hepatocellular carcinoma
Jin Lei, Zhipeng Liang, Shi Zuo, Haiyang Li, Yinying Lu
- EP0983 Enhanced Antitumor Immunity through T Cell Activation with Optimized Tandem Double-OX40L mRNAs
Zhuoya Deng, Zherui Liu
- EP0984 Immune System Development-related Signature Predicts Prognosis and Sorafenib-treatment Resistance of Hepatocellular Carcinoma by Integrating Machine Learning and single-cell analyses
Shiji Wu, Jingjing Tang, Junxin Wu
- EP0985 Research progress of TACE combined with immunotherapy and targeted therapy in the treatment of hepatocellular carcinoma
Chuanhong Li
- EP0986 Tumor response at the time of discontinuation of atezolizumab plus bevacizumab (Ate+Beva) predict progression free survival of patients who stopped Ate+Beva therapy.
SANGYOUN HWANG, Jungwoo Im, HYUNJUN KIM, KIJUNG JEON, Beomjin Shim

- EP0987 Bladder Hypocontractility Induced by Camrelizumab Treatment for Hepatocellular Carcinoma: A Case of and Literature Review
Linhui Hu, Yong Fan, PanPan Zhang, Yan Geng, Zhuoli Zhang
- EP0988 Case report: Adrenal crisis induced by immune checkpoint inhibitors in a patient with hepatitis B associated hepatocellular carcinoma
Yue Guo, Qiang Zhu, Hua Wan Ren, Fei Fei Li
- EP0989 Construction of CD8+ T Cell-Associated Risk Model in Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA-Seq Data
Yong Sheng Shi, Xin Tong Zhang, Kai Liu, Xiao Lin Tang, Li Niu, Wen Rui Zhao, Hao Wu, Fan Lu, Wen Tao Zhang, Yu Cui Qin, Tao Li
- EP0990 Depth of radiographic response as an independent prognostic factor for patients with initially unresectable hepatocellular carcinoma receiving hepatectomy following targeted therapy plus immunotherapy
Bin Xu, Luna Wang, Ziyi Wang, Tian He, Xiaodong Zhu, Yinghao Shen, Jian Zhou, Jia Fan, Huichun Sun, Cheng Huang
- EP0991 Patients with Lower Lymphocyte Counts and Treated Combined with Tyrosine Kinase Inhibitors Lead to More Severe Immune-related Adverse Events in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors
Hongge Yang, Sihan Liu
- EP0992 Efficacy of Nivolumab + Lenvatinib therapy in Patients with Recurrent Hepatocellular
Jatinkumar Veljibhai Dhanani, Shweta Jatinkumar Dhanani
- EP0993 Undetectable hepatitis B virus DNA in hepatocellular carcinoma: virus reactivation and prognostic analysis after systemic therapy - a retrospective multi-center study
Jin Lei, Zhipeng Liang, Haiyang Li, Shi Zuo, Yinying Lu
- EP0994 Patients with HBV reactivation in advanced liver cancer have a poorer prognosis
Jin Lei, Zhipeng Liang, Huimin Chen, Shi Zuo, Haiyang Li, Yinying Lu
- EP0995 Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC
Jin Lei, Zhipeng Liang, Haiyang Li, Shi Zuo, Yinying Lu
- EP0996 Purvalanol A Exerts Anti-hepatocellular Carcinoma Activity by Activating the P53 Pathway
Yuan Yang, Yongfeng Yang, Yuxiang Gong, Anyin Yang
- EP0997 Is antiviral therapy necessary for HBV DNA negative HBV related HCC patients?
Jin Lei, Zhipeng Liang, Huimin Chen, Haiyang Li, Yinying Lu
- EP0998 DEXAGNP: Dual-Antigen/PD-L1-Blocked Dendritic Exosome Vaccine Elicits Potent Anti-Tumor Immunity in Hepatocellular Carcinoma
Shumin Luo, Fang Xu, PengPeng Lu, Yiyue Wang, Weihua Li
- EP1063 Sorafenib plus transarterial chemoembolization versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial
Yan Zhao, Wei Bai, Rong Ding, Nan You, Lin Zheng, Lei Li, Jianbin Wu, Peng Zhang, Wukui Huang, Hui Zhang, Yongjin Zhang, Diwen Zhu, Haiping Li, Dongdong Xia, Jie Yuan, Zhanxin Yin, Guohong Han

Liver Surgery and Transplantation

- EP0999 Hepatic epithelioid angiomyolipoma: a case report

Huang Xiao Mei

- EP1000 PTX3 promotes M1 macrophage polarization and exacerbates hepatic ischemia-reperfusion injury by upregulating the JAK/STAT pathway
Lijian Luo, Jinzhen Cai
- EP1001 Cirrhotic cardiomyopathy is associated with cardiovascular events after liver transplantation.
Lixia Ma, Jing Zhang
- EP1002 Antiviral Therapy in a Patient with HCV-associated Liver Cirrhosis and Subsequent Liver Transplantation
Sona Sargsyan, Violeta Sargsyan, Victoria Manukyan, Hayk Harutyunyan, Arayik Voskanyan, Vahe Yurii Azatyan, Hayrapet Barseghyan, Sergey Voskanyan, Alexey Sherba,
- EP1003 Bibliometric analysis of hepatic resection haemodynamics based on web of science
Wang Hezhao
- EP1004 Liver venous deprivation versus portal vein embolization alone prior to major hepatectomy: a systematic review and meta-analysis
Lingpeng Yang, Kunlin Chen, Wentao Wang
- EP1005 Post-hepatectomy liver failure: A case of recovery with supportive management
YING WEI, KOK PUN CHEN, LYN WEI YANG
- EP1006 The Impact of Resection Margin Width on the Prognosis of Solitary Intrahepatic Cholangiocarcinoma
Liu Hongzhi
- EP1007 The Application of Machine Learning Algorithms in the Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
Liu Hongzhi
- EP1008 Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method
Liu Hongzhi
- EP1009 Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma
Liu Hongzhi
- EP1010 Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis
Liu Hongzhi
- EP1011 A multicenter retrospective study on the clinical value of lymph node dissection during radical resection of intrahepatic cholangiocarcinoma
Liu Hongzhi
- EP1012 Total hepatic arteriotomy
Hongbin Zhu, Lijuan Chen, Xiaobing Wu
- EP1013 Exophytic Hepatocellular Carcinoma: A Potential Contraindication for Laparoscopic
Kongying Lin, Bin Huang, Yongkang Diao, Tinghao Chen, Xianming Wang, Weimin Gu, Zhong Chen, Yingjian Liang, Hangdong Jia, Hong Wang, Jiahao Xu, Mingda Wang, TimothyM Pawlik, Feng Shen, Tian Yang, Yongyi Zeng

- EP1014 Integrated analysis of hepatocellular carcinoma reveals disparate subtype of prognosis significance
Fengle Jiang, Jianmin Wang, Jingfeng Liu
- EP1015 Emphysematous esophago-gastro-duodenitis with hepatic portal venous gas
PoYu Huang, HanSiong Toh
- EP1016 The Impact of Microscopic Tumor Infiltration along the Bile Duct on Surgical Resection in Hilar Cholangiocarcinoma
Taifeng Zhu, Xiangde Shi, Chao Liu
- EP1017 Myosteatosi is associated with worse clinical outcomes in liver transplantation recipients: a systematic review and meta-analysis
Lingpeng Yang, Kunlin Chen, Wentao Wang
- EP1018 High-potency Nucleos(t)ide Analogues Alone or Plus Immunoglobulin for HBV Prophylaxis after Liver Transplantation: A Meta-analysis
LiPing Sheng, JunChang Zhang, ZhiQiang Zhong, XueHan Sheng, Jing Ren, GuiQiang
- EP1019 Bioelectrical Impedance Analysis for Preoperative Volemia Assessment in Living Donor Hepatectomy
SukWon Suh, Yooshin Choi
- EP1020 Massive Refractory Ascites after Pediatric Liver Transplantation: A Case Report and Literature Review
Jing Xiao Zhang, Jing Xiao Zhang, Tianjiin First Center Hospital
- EP1021 A case of refractory autoimmune hemolytic anemia after liver transplantation
Mengyue Zhu, Xingqiang Wang, Qingjun Guo, Xiaoye Sun
- EP1022 Successful treatment of post-transplant ribavirin-refractory persistent hepatitis E virus infection using ledipasvir/sofosbuvir plus ribavirin
Chen Hong, Fan Tie Yan, Li Jun, Wang Jing Yue, Wang Lin
- EP1023 Efficacy and safety of tyrosine kinase inhibitors combined with bevacizumab in the backline treatment of recurrent hepatocellular carcinoma patients after liver transplantation : A Case Series Study
Jin Lei, Zhipeng Liang, Haiyang Li, Shi Zuo, Yinying Lu
- EP1024 Postoperative Recovery in Liver Disease: The Role of Caregiver Perception, Knowledge, and Attitude
Lintong Hottua Simbolon, Hepri Ardianson Purba, Yesika Simbolon, Rosinta Hotmaida Pebrianti Purba, Ester Marnita Purba
- EP1025 AN EVALUATION OF LONG-TERM FASTING EFFECTS ON PREOPERATIVE AND POSTOPERATIVE OUTCOMES IN LIVER SURGERY
Rosinta Hotmaida Pebrianti Purba, Helen Try Juniasti, Yesika Simbolon
- EP1069 Risk Factors for First-year Hospital Readmission after Liver Transplantation in Viet Nam
Anh Van Nguyen Thi, Thanh Van Le

New Technology

- EP1026 Landscape and identification of immune-related genes in gastrointestinal tumors through integration of gene ontology fingerprint and multidimensional analysis
Honglian Huang, Yanling Qi, Zeyu Zhang, Ziyi Wei, Shiyang Cheng, Ying Wang, Xiaoyan

- EP1027 Preliminary application of the integrated risk prediction platform in clinical diagnosis and treatment of hepatic carcinoma
Liu Hongzhi
- EP1028 A precise surgical planning system for hepatectomy coupled with liver tissue in the hepato-portal vein territories
Siming Zheng, Mengna Zhang, Chengbin Peng, Yuting Hong, Guofeng Zhu, Bin Zhang, Xuanlei Ren, Jiyun Zhu, Jianbo Zheng, Zehao Yu, Yufei Chen, Yingan Zhao, Yongyi Zeng
- EP1029 Machine Learning-based Models for Prediction of Intra-abdominal Infection in Liver Cancer Patients
Jiaran Sun, Linlin Yan, Ruifeng Yang
- EP1030 Construction of an Early Prediction Model for Hotspot Mutations in Chinese Wilson's Disease Population Based on Machine Learning and Correlation Analysis between Genotype and Clinical Phenotype
Mingming Li
- EP1031 Research on Prediction Model of Liver Cirrhosis in Chinese Wilson's Disease Patients Based on Machine Learning
Mingming Li
- EP1032 A Systematic Review of Deep Learning Applications in Liver Lesion Detection and
YunLong Yao, Xi Zhang, Fei ChenYu, LiuJie Zhu
- EP1033 The Application of Artificial Intelligence in Liver Disease Diagnosis: Opportunities and
YunLong Yao, Xi Zhang, ChenYu Fei, LiuJie Zhu
- EP1034 Applications and Challenges of Natural Language Processing in Liver Disease Research
Xi Zhang, YunLong Yao, ChenYu Fei, LiuJie Zhu
- EP1035 Impact of liver biopsy size on fibrosis evaluation using second harmonic generation/two-photon excitation fluorescence microscopy
Daniel T Field, Yayun Ren, Elaine Chng, Dean Tai, Kutbuddin Akbary, Nikolai V Naoumov, David E Kleiner, Jonathan A Fallowfield, Timothy J Kendall, Arun J Sanyal
- EP1036 Research on the Application of Artificial Intelligence Data Processing Techniques in the Clinical Diagnosis of Fever of Unknown Origin
Pengfei Wu, Bing Wu, Cheng Zhang, Li Wang, Yuqiao Zeng , Ao Shen, Likun Wang
- EP1037 Integrated Machine Learning and Single-Cell RNA Sequencing Analysis Revealed Prognostic signature for Hepatocellular Carcinoma Based on Natural Killer Cell related Genes
Jiaran Sun, Shuo Li
- EP1038 Efficacy and safety of CA280 cytokine adsorption column in the treatment of chronic and acute liver failure
HE YAN YAN
- EP1039 Development of a highly sensitive rapid antigen test for Hepatitis B core-related antigen (HBcrAg)
Naoki Yamamoto, Kentaro Yamakawa, PaulFranck Adeyissimi AdjouMoumouni, Kazuyoshi Miyamoto, Atsushi Kaneko, Tomonao Ouki, Shintaro Yagi, Katsumi Aoyagi
- EP1040 Construction and Validation of CD86/TNFRSF14 Immune Prognostic Model Associated with HAIC Treatment Efficacy in Hepatocellular Carcinoma

Guangjie Han, Jianfei Shi, Lili Mi, Jinfeng Wang, Fei Yin

EP1041 Progress of circulating free DNA in hepatocellular carcinoma
Xinhao Gao

EP1042 Liver steatosis screening using a low-cost portable tomographic device: Preliminary results from an ongoing study evaluating the generalizability of electrical impedance tomography in a racially/ethnically-diverse cohort.
Christopher Rettenmeier, Krystalyn Edwards-Calma, Unhee Lim, Russell Chan, James Li, Zackary Kon, Megan Buras, Zidan Yu, Loic LeMarchand, Victor Andrew Stenger, Sandi

EP1043 The Novel Navigation System to Improve the Accuracy and Efficacy of Liver Cancer Ablation
KAI-WEN Huang, Jia-Yi Huang

EP1046 Prediction the risk of liver steatosis in overweight and obese patients
Guzal Ilgisovna Ahmadullina, Irina Alekseevna Kurnikova, Anastaciya Sergeevna Zhuravleva, Elena Ivanovna Kukhareva, Natalia Olegovna Danilina

深圳康泰生物制品股份有限公司

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.


深圳康泰生物制品股份有限公司（股票代码:300601）在人用疫苗领域深耕30余年，目前已成为中国500强上市企业。2008年与北京民海生物科技有限公司实施品牌重组，重组后的康泰生物集团充分发挥了“南康泰、北民海”集团化经营协同效应，努力打造“中国新、全球新”的疫苗产品。公司在研疫苗30余项，占全世界疫苗生产品种的60%以上，可有效预防20多种因细菌或病毒引起的疾病，已经成为当前中国研发品种数量、疫苗申报专利数量最多的疫苗企业之一。



冻干人用狂犬病疫苗（人二倍体细胞）



13价肺炎球菌多糖结合疫苗(TT/DT)



无细胞百白破b型流感嗜血杆菌联合疫苗



10μg、20μg和60μg
重组乙型肝炎疫苗（酿酒酵母）



冻干b型流感嗜血杆菌结合疫苗



水痘减毒活疫苗



23价肺炎球菌多糖疫苗

创造更好的疫苗

造福人类健康

· 新舒沐® (Pradefovir Mesylate Tablets) ·

Achieving A Greater HBsAg Level Decrease Among Various Nucleos(t)ide analogues (NAs)



HBsAg Level Decrease from Baseline
24% GREATER

The PDF group demonstrated a 24% GREATER HBsAg level decrease compared to the TDF group
-0.68 lg vs -0.55 lg, $P=0.029$



Proportion of patients with HBsAg level decreased to ≤ 1000 IU/mL

26% HIGHER

The PDF group exhibited a 26% HIGHER proportion of patients whose HBsAg level reduced to ≤ 1000 IU/mL compared to the TDF group

36.6% vs 29.0%, $P=0.027$

Data Source: 96-Week Data from the Phase 3 Clinical Study of PDF

PDF: Pradefovir Mesylate

TDF: Tenofovir Disoproxil Fumarate

- 全人群应用（各年龄组均有大规模使用经验，证实安全可靠）
- 使用adr亚型；针对中国人研制
- 哺乳动物细胞表达，接近天然产物



华北制药金坦生物技术股份有限公司是华北制药旗下的一家高科技生物技术制药企业，主要从事重组蛋白药物及疫苗的研发、生产和销售。拥有国际先进的自动化、密闭化生产设施，能够快速实现原核、真核微生物及哺乳动物细胞载体表达的重组生物技术产品由中试到产业化规模的转化。在国内生物医药领域拥有较高的知名度，荣获多项国家、省、市级荣誉称号，入选国务院“科改示范企业”，是科技部“863”成果产业化基地、国家级绿色工厂、社会责任突出贡献企业，获得中国医药最具成长力品牌。



人类健康至上 质量永远第一



研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

Journal of Clinical and Translational
Hepatology 2020 vol.
8 | 1-8

Fibrosis reduction was more observable when patients with baseline Ishak F3 and F4 were treated with FZHY.qFibrosis analysis confirmed the efficacy of fibrosis reduction in all 3 zones compared to placebo in the regressive group, and the evaluation of zonal fibrosis and development of a correlation for each liver disease etiology may be crucial in assessing antifibrotic agents.

美国II期临床研究

百洋制药
BAHEAL PHARMA

中华肝脏病杂志

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

降低乙肝肝硬化肝癌发生风险

扶正化瘀片治疗慢性丙型肝炎肝纤维化

美国II期临床研究

扶正化瘀片治疗慢性丙型肝炎肝纤维化

美国II期临床研究

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。



扶正化瘀片治疗慢性丙型肝炎肝纤维化

美国II期临床研究

用证据展示中药力量

Demonstrating The Efficacy Of Traditional Chinese Medicine Through Evidence

逆转肝纤维化·肝硬化
Reversing Liver Fibrosis/Cirrhosis

严谨·循证·指南推荐
Rigorous, Evidence - Based, Guideline-Recommended

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

研究由美国加州大学圣迭戈医学院肝病与肝移植中心
任Hassanein教授主持，5家美方医院参与。

降低乙肝肝硬化肝癌发生风险

全面护肝 重焕生机 LIVER CARE VITAL REPAIR



水飞蓟宾胶囊 (水林佳)
SILIBININ CAPSULES(SHUILINJIA)



Siemens Healthineers Drives Innovation to Shape the Liver Cancer Care Continuum

A comprehensive portfolio including a wide spectrum of therapy solutions along the entire liver cancer patient pathway

Screening & Early Detection



Biomarkers



Ultrasound



AI image analysis

Diagnosis & Therapy Decision



CT



MR



Digital Solutions

Treatment Planning & Delivery



Surgery



Cryoablation



Embolization & 90Y

Follow-up & Survivorship



Radiation Therapy



PET/CT



SPECT/CT



Visit us at

<https://www.siemens-healthineers.cn/clinical-specialities/oncology/cancer-types/liver-cancer>

*For reference of the professionals attending this conference only.



思美泰®适用于治疗
肝硬化前和肝硬化所致肝内胆汁淤积
妊娠期肝内胆汁淤积

注射用丁二磺酸腺苷蛋氨酸



思美泰® 针剂简明处方信息

本品为处方药，请索取详细处方资料。

【通用名称】注射用丁二磺酸腺苷蛋氨酸【适应症】肝硬化前和肝硬化所致肝内胆汁淤积；妊娠期肝内胆汁淤积。【规格】按 $C_{15}H_{23}N_6O_5S_2$ 计，500mg【用法用量】初始：针剂，500-1000mg/d，肌肉或静脉注射，两周。维持：片剂，1000-2000mg/d，口服。其他详见说明书。【主要不良反应】已证明腺苷蛋氨酸既不改变习惯，也无成瘾性。腺苷蛋氨酸治疗期间最常出现的不良反应为头痛、腹泻和恶心。其他详见说明书。【禁忌】对本品活性成分或任一辅料过敏者。腺苷蛋氨酸禁用于有影响蛋氨酸循环和 / 或引起高胱氨酸尿和 / 或高同型半胱氨酸血症的遗传缺陷的患者。其他详见说明书。【注意事项】请远离热源。针剂：注射用冻干粉针须在临用前用所附溶剂溶解，静脉注射必须非常缓慢；不应与碱性溶液或含钙溶液混合。片剂：必须整片吞服，不得嚼碎；建议在两餐之间服用；有血氨增高的肝硬化前和肝硬化患者，在口服腺苷蛋氨酸后，应监测血氨水平。自杀 / 自杀观念（具有抑郁综合征的患者）及肾功能障碍患者使用应谨慎；服用腺苷蛋氨酸的患者，高半胱氨酸免疫测定法可能测出错误的高半胱氨酸水平。其他详见说明书。【药物相互作用】报告过服用腺苷蛋氨酸和氯米帕明的患者出现血清素综合征。同时给予腺苷蛋氨酸和选择性 5-羟色胺再摄取抑制剂（SSRIs）、三环抗抑郁剂（包括氯米帕明）以及含有色氨酸基团的药品和植物源性营养补充剂时，应谨慎。（见【注意事项】）【贮藏】密闭，在 25℃ 以下保存。【包装】玻璃瓶装，每盒由 5 支粉针及 5 支注射用溶剂组成。【有效期】30 个月。【批准文号】药品批准文号：国药准字 HJ20171084，国药准字 HJ20171069【生产企业】企业名称：DELPHARM SAINT REMY 生产地址：RUE DE L'ISLE, SAINT REMY SUR AVRE, 28380, FRANCE 法国 分包装厂：上海雅培制药有限公司 分包装地址：上海市奉贤区海湾镇五四公路 1288 号【境内联系机构】公司名称：雅培贸易（上海）有限公司 公司地址：上海市南京西路 388 号仙乐斯广场 32 楼 电话号码：021-23204200

其他禁忌和不良反应详见说明书 本广告仅供医学药学专业人士阅读
沪药广审（文）第 250723-43720 号

CHN2263698-3(v3.0) 有效期至：2027年1月22日

丁二磺酸腺苷蛋氨酸肠溶片



思美泰® 片剂简明处方信息

本品为处方药，请索取详细处方资料。

【通用名称】丁二磺酸腺苷蛋氨酸肠溶片【适应症】肝硬化前和肝硬化所致肝内胆汁淤积；妊娠期肝内胆汁淤积。【规格】0.5g（以腺苷蛋氨酸计）。【用法用量】初始：针剂，500-1000mg/d，肌肉或静脉注射，两周。维持：片剂，1000-2000mg/d，口服。其他详见说明书。【主要不良反应】已证明腺苷蛋氨酸既不改变习惯，也无成瘾性。腺苷蛋氨酸治疗期间最常出现的不良反应为头痛、腹泻和恶心。其他详见说明书。【禁忌】对本品活性成分或任一辅料过敏者。腺苷蛋氨酸禁用于有影响蛋氨酸循环和 / 或引起高胱氨酸尿和 / 或高同型半胱氨酸血症的遗传缺陷的患者。其他详见说明书。【注意事项】请远离热源。针剂：注射用冻干粉针须在临用前用所附溶剂溶解，静脉注射必须非常缓慢；不应与碱性溶液或含钙溶液混合。片剂：必须整片吞服，不得嚼碎；建议在两餐之间服用；有血氨增高的肝硬化前和肝硬化患者，在口服腺苷蛋氨酸后，应监测血氨水平。自杀 / 自杀观念（具有抑郁综合征的患者）及肾功能障碍患者使用应谨慎；服用腺苷蛋氨酸的患者，高半胱氨酸免疫测定法可能测出错误的高半胱氨酸水平。其他详见说明书。【药物相互作用】报告过服用腺苷蛋氨酸和氯米帕明的患者出现血清素综合征。同时给予腺苷蛋氨酸和选择性 5-羟色胺再摄取抑制剂（SSRIs）、三环抗抑郁剂（包括氯米帕明）以及含有色氨酸基团的药品和植物源性营养补充剂时，应谨慎。（见【注意事项】）【贮藏】密闭，在 25℃ 以下保存。【包装】铝塑包装，10 片 / 盒。【有效期】片剂：36 个月【批准文号】药品批准文号：国药准字 HJ20150629【生产企业】企业名称：ABBVIE S.R.L. 生产地址：S.R.148, PONTINA KM 52, SNC CAMPOVERDE DI APRILIA 04011 APRILIA ITALY 意大利【境内联系机构】名称：雅培贸易（上海）有限公司 地址：上海市南京西路 388 号仙乐斯广场 32 楼 联系方式：021-23204200

杭州浩博医药有限公司

公司简介：

ABOUT US

浩博医药是一家面向全球、临床阶段的创新型生物制药公司，致力于变革乙肝治愈疗法、引领寡核苷酸技术创新，凭借自主知识产权的Med-Oligo™ ASO平台和高效靶向递送技术，聚焦变革性ASO疗法，应用于病毒性感染、代谢性疾病、遗传性疾病和免疫性疾病等领域，改善患者生活。

公司愿景：

OUR VISION

改善患者生活品质 铸就美好未来

公司使命：

OUR MISSION

融合前沿的寡核苷酸技术与高效精准的靶向递送推动变革性治疗 满足临床需求



核心价值观：

CORE VALUES

Aspiration

抱负

Unity

团结

Sincerity

真诚

Precision

严谨

Excellence

卓越


Responsibility

责任

平台技术：

TECHNOLOGY PLATFORMS

Med-Oligo™ ASO 平台



我们基于自主研发且拥有独立知识产权的Med-Oligo™ ASO平台，结合新型偶联技术的靶向递送系统，正在打造多元化的研发管线；以实现慢性乙肝功能性治愈为起点，研发变革性治疗方案拓展至其他疾病，解决尚未被满足的临床需求。

关于核心药物AHB-137：

ABOUT AHB-137

AHB-137是具有潜力成为慢性乙型肝炎功能性治愈基石的非偶联型的反义寡核苷酸（ASO），是浩博医药自主研发平台Med-Oligo™下首个进入临床试验的创新药物，其优秀的IIa期临床数据在2024年度美肝会（AASLD™）上获得广泛关注。目前，AHB-137正在同步开展一项国际多中心的I期临床试验以及三项在中国开展的II期临床试验。通过全球化布局，加速实现功能性治愈乙肝的目标。

全程肝预·精细化管理新里程

罗氏诊断肝病一体化解决方案

乙肝五项
Anti-HCV
HCV Duo

高敏核酸
HBV DNA
HCV RNA

AFP
PIVKA-II
hs-ctnt
NT-proBNP

PCT
IL-6
凝血功能

乙肝/丙肝

PIVKA-II

GAAD

肝硬化/肝癌

肝癌


风险人群筛查诊断
治疗决策

观察随访
风险评估

监测诊断

预后治疗

Meeting Invitation



Orphan Symposium at APASL 2025:

New Development in Wilson's Disease Management – APASL/AASLD Guidelines and Clinical Experience Sharing

肝豆状核变性治疗新进展-国际及亚太地区指南与临床经验分享

Meeting Room 405,
China National Convention Center, Beijing, China

Chairman:

Dr. JI-DONG JIA (China) 贾继东

Speakers:

Dr. WEI ZHANG (China) 张伟

Dr. ROBERT G. GISH (United States)

Friday
28th Mar 2025
12:00–13:00

Visit us at **Orphanal Booth #408-309** – where innovation meets rare disease care.

Xiamen Amoytop Biotech Co., Ltd. (Amoytop Biotech) established in 1996, is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions to major diseases (such as viral hepatitis and malignant tumors) and immunotherapy.

Keeping the global market in mind, Amoytop Biotech makes every effort to exploring international markets based on the domestic market. Up to now, Amoytop Biotech has marketed its products in more than 10 countries and regions of Southeast Asia, South America, Middle East and CIS. Through technical innovation, scientific management and product industrialization, Amoytop Biotech aims to be a leading international biopharmaceutical company in China.



First-Line Drug for CHB Patients to Achieve Functional Cure

As the first Class-I new drug of biologics in China, Pegbing® is committed to benefiting chronic viral hepatitis patients by providing them with long-term immunotherapy solutions.

The phase I-III clinical trials of Pegbing® had involved more than 2000 patients totally in 50 domestic top medical centers of 24 provinces. Until now, its phase III clinical trial in chronic hepatitis C (CHC) is the first genotyping clinical study for CHC treatment in China, as well as the largest patient size; and its phase III clinical trial in chronic hepatitis B (CHB) has the largest patient size among the registry clinical studies of peginterferon for CHB treatment in the world.



Exclusive international patent Y-shape PEG structure improves drug stability

Lower incidence of neutralizing antibody brings higher possibility to achieve SVR

Selective pegylation at high activity site results in higher antiviral activity



The First 40kD Y-shape Branched PEG Modified Interferon Alfa-2b in the World



The First Pegylated Interferon with Independent Intellectual Property Right in China



2 International Patents for Drug Structure

Covering more than 30 countries including China, the United States, Japan, Europe (21 countries) etc.



WeChat



Website



LinkedIn

Add: No.330 Wengjiao Road, Haicang, Xiamen, Fujian, P.R. China 361028

Website: www.amoytop.com

Tel: 86 592-6889105/106 Fax: 86 592-6889110

E-mail: International@amoytop.com



We look forward to welcoming you to two Gilead-sponsored satellite symposia

Friday 28 March 2025

China guideline: For viral hepatitis elimination

16:45–17:45 CST | Function Hall B

We'll be exploring China's guidelines and strategic roadmap for eliminating Hepatitis B and C, with a focus on evolving clinical practices and expanding treatment access.



Prof. Lai Wei
Beijing, Chair



Prof. Peng Hu
Chongqing



Prof. Liang Peng
Guangzhou



Saturday 29 March 2025

Ride the tide: The future of viral hepatitis is now

12:15–13:15 CST | Plenary Hall A

Together we will explore the impact of innovation on treatment outcomes for patients with viral hepatitis.



Prof. Jidong Jia
Beijing, Chair



Prof. Yuemin Nan
Shijiazhuang



Prof. Yasuhito Tanaka
Kumamoto



Dr. Chari Cohen
Doylestown